PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Legge, A				Legge, A			Hospital criticised for not obtaining proper consent	BRITISH MEDICAL JOURNAL			English	News Item																		Samuels MP, 1996, PEDIATRICS, V98, P1154	1	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1291	1291		10.1136/bmj.320.7245.1291	http://dx.doi.org/10.1136/bmj.320.7245.1291			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807604	Green Published			2022-12-28	WOS:000087077400006
J	Aronson, RB; Precht, WF; Macintyre, IG; Murdoch, TJT				Aronson, RB; Precht, WF; Macintyre, IG; Murdoch, TJT			Ecosystems - Coral bleach-out in Belize	NATURE			English	Article							REEF		Dauphin Isl Sea Lab, Dauphin Island, AL 36528 USA; PBS&J, Miami, FL 33172 USA; Smithsonian Inst, Museum Natl Hist Nat, Dept Paleobiol, Washington, DC 20560 USA	Dauphin Island Sea Lab; Smithsonian Institution; Smithsonian National Museum of Natural History	Aronson, RB (corresponding author), Dauphin Isl Sea Lab, 1-1 Bienville Blvd, Dauphin Island, AL 36528 USA.			Murdoch, Thaddeus/0000-0002-1297-1694; Aronson, Richard/0000-0003-0383-3844				Aronson RB, 1997, PALEOBIOLOGY, V23, P326, DOI 10.1017/S0094837300019710; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; Glynn PW, 1990, GLOBAL ECOLOGICAL CO, P55; Hansen J, 1999, J GEOPHYS RES-ATMOS, V104, P30997, DOI 10.1029/1999JD900835; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; *INT SOC REEF STUD, 1998, REEF ENCOUNTER, V24, P19; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; Macintyre I. G., 1995, ATOLL RES B, V430, P1, DOI DOI 10.5479/si.00775630.430.1; McField MD, 1999, B MAR SCI, V64, P155; Mumby PJ, 1999, MAR ECOL PROG SER, V190, P27, DOI 10.3354/meps190027; OLIVER J, 1985, 5TH P INT COR REEF C, V4, P201; PORTER JW, 1989, P NATL ACAD SCI USA, V86, P9342, DOI 10.1073/pnas.86.23.9342; SMITH SV, 1992, ANNU REV ECOL SYST, V23, P89, DOI 10.1146/annurev.es.23.110192.000513	14	111	123	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					36	36		10.1038/35011132	http://dx.doi.org/10.1038/35011132			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811207	Bronze			2022-12-28	WOS:000086901600039
J	Macilwain, C				Macilwain, C			NSF celebrates half a century with big plans	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					8	8		10.1038/35011225	http://dx.doi.org/10.1038/35011225			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811189	Bronze			2022-12-28	WOS:000086901600013
J	Stolk, EA; Busschbach, JJV; Caffa, M; Meuleman, EJH; Rutten, FFH				Stolk, EA; Busschbach, JJV; Caffa, M; Meuleman, EJH; Rutten, FFH			Cost utility analysis of sildenafil compared with papaverine-phentolamine injections	BRITISH MEDICAL JOURNAL			English	Article							ERECTILE DYSFUNCTION; HEALTH; THERAPY; IMPOTENCE	Objective To compare the cost effectiveness of sildenafil and papaverine-phentolamine injections for treating erectile dysfunction. Design Cost utility analysis comparing treatment with sildenafil (allowing a switch to injection therapy) and treatment with papaverine-phentolamine (no switch allowed). Costs and effects were estimated from the societal perspective, Using time trade-off, a sample of the general public (n = 169) valued health states relating to erectile dysfunction. These values were used to estimated health related quality of life by converting the clinical outcomes of a trial into quality adjusted life years (QALYSs). Participants 169 residents of Rotterdam. Main outcome measures Cost per quality adjusted life year. Results Participants thought that erectile dysfunction limits quality of life considerably: the mean utility gain attributable to sildenafil is 0.11. Overall, treatment with sildenafil gained more QALYs, but the total costs were higher. The incremental cost effectiveness ratio for the introduction of sildenafil was pound 3639 in the first year and fell in following years. Doubling the frequency of use of sildenafil almost doubled the cost per additional QALY: Conclusions Treatment with sildenafil is cost effective. When considering funding sildenafil, healthcare systems should take into account that the frequency of use affects cost effectiveness.	Erasmus Univ, Inst Med Technol Assessment, NL-3000 DR Rotterdam, Netherlands; Hosp St Antoniushove, Dept Urol, Leidschendam, Netherlands; Univ Med Ctr St Radboud, Dept Urol, Nijmegen, Netherlands	Erasmus University Rotterdam; Radboud University Nijmegen	Stolk, EA (corresponding author), Erasmus Univ, Inst Med Technol Assessment, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Busschbach, Jan/P-1584-2019	Busschbach, Jan/0000-0002-8602-0381				ALTHOF SE, 1989, J SEX MARITAL THER, V15, P121; BRAZIER J, 1995, HEALTH ECON, V4, P255, DOI 10.1002/hec.4730040402; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Dinsmore W, 1999, BRIT MED J, V318, P387, DOI 10.1136/bmj.318.7180.387; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; Drummond MF, 2015, METHODS EC EVALUATIO; *FDN PHARM STAT, 1999, WEEKLY PHARM, V134; *FDN PHARM STAT, 1999, PHARM STAT POT VIAGR, V134; FURLONG W, 1998, MULTIPLICATIVE MULTI, P5; FURLONG W, 1998, 9811 MCMAST U CTR HL, P5; Gold MR, 1996, COST EFFECTIVENESS H; Gold MR, 1996, COST EFFECTIVENESS H, P82; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; HADORN DC, 1991, SOC SCI MED, V32, P773, DOI 10.1016/0277-9536(91)90303-T; Jackson SE, 1998, UROLOGY, V51, P874, DOI 10.1016/S0090-4295(98)00141-1; Jarow JP, 1999, J UROLOGY, V162, P722, DOI 10.1097/00005392-199909010-00024; Korenman SG, 1998, AM J MED, V105, P135, DOI 10.1016/S0002-9343(98)00191-0; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; MAYNARD A, 1991, ECON J, V101, P1277, DOI 10.2307/2234443; *MED EXC, 1998, DIAGN TREATM ER DYSF; Meuleman E J, 1998, Ned Tijdschr Geneeskd, V142, P2337; Mulhall JP, 1999, J UROLOGY, V162, P1291, DOI 10.1016/S0022-5347(05)68269-9; NIJEHOLT AAB, 1998, NED TIJDSCHR GENEES, V142, P2332; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; STOLK EA, 1999, COST UTILITY VIAGRA, P65; STOLK EA, 1999, COST UTILITY VIAGRA; WILLIAMS A, 1994, EC QALYS MED ETHICS	28	39	39	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1165	1168		10.1136/bmj.320.7243.1165	http://dx.doi.org/10.1136/bmj.320.7243.1165			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310MW	10784537	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086832800013
J	Schon, JH; Kloc, C; Haddon, RC; Batlogg, B				Schon, JH; Kloc, C; Haddon, RC; Batlogg, B			RETRACTED: A superconducting field-effect switch (Retracted Article. See vol 298, pg 961, 2002)	SCIENCE			English	Article; Retracted Publication							C-60; TRANSISTORS; CRYSTALS	We report here on a novel realization of a field-effect device that allows switching between insulating and superconducting states, which is the widest possible variation of electrical properties of a material. We chose C(60) as the active material because of its Low surface state density and observed superconductivity in alkali metal-doped C(60). We induced three electrons per C(60) molecule in the topmost molecular Layer of a crystal with the field-effect device, creating a superconducting switch operating up to 11 kelvin. An insulator was thereby transformed into a superconductor. This technique offers new opportunities for the study of superconductivity as a function of carrier concentration.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Univ Kentucky, Dept Phys, Lexington, KY 40506 USA; Univ Kentucky, Ctr Adv Mat, Lexington, KY 40506 USA	Alcatel-Lucent; Lucent Technologies; AT&T; University of Kentucky; University of Kentucky; University of Kentucky	Schon, JH (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Kloc, Christian/A-2255-2011					ATALLA MM, 1959, BELL SYST TECH J, V28, P749; DRESSELHAUS MS, 1994, PHYSICAL PROPERTIES, V4, P571; FRANKEVICH E, 1993, CHEM PHYS LETT, V214, P39, DOI 10.1016/0009-2614(93)85452-T; GLOVER RE, 1960, PHYS REV LETT, V5, P248, DOI 10.1103/PhysRevLett.5.248; HADDON RC, 1995, APPL PHYS LETT, V67, P121, DOI 10.1063/1.115503; Hebard AF, 1996, PHYS REV B, V54, P14052, DOI 10.1103/PhysRevB.54.14052; HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0; Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9; Lilienfeld J.E., 1926, U.S. Patent, Patent No. [1745175A, 1745175]; MANNHART J, 1993, APPL PHYS LETT, V62, P630, DOI 10.1063/1.108877; MANNHART J, 1993, J ALLOY COMPD, V195, P519, DOI 10.1016/0925-8388(93)90791-K; Ramirez A. P., 1994, Superconductivity Review, V1, P1; SCHLUTER M, 1992, PHYS REV LETT, V68, P526, DOI 10.1103/PhysRevLett.68.526; Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022; Schon JH, 1998, PHYS REV B, V58, P12952, DOI 10.1103/PhysRevB.58.12952; SZE SM, 1981, PHYSICS SEMICONDUCTO; VARMA CM, 1991, SCIENCE, V254, P989, DOI 10.1126/science.254.5034.989; Yildirim T, 1996, PHYS REV LETT, V77, P167, DOI 10.1103/PhysRevLett.77.167	18	135	139	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					656	658		10.1126/science.288.5466.656	http://dx.doi.org/10.1126/science.288.5466.656			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784445				2022-12-28	WOS:000086727100039
J	Cincotta, RP; Wisnewski, J; Engelman, R				Cincotta, RP; Wisnewski, J; Engelman, R			Human population in the biodiversity hotspots	NATURE			English	Article								Biologists have identified 25 areas, called biodiversity hotspots, that are especially rich in endemic species and particularly threatened by human activities. The human population dynamics of these areas, however, are not well quantified. Here we report estimates of key demographic variables for each hotspot, and for three extensive tropical forest areas(1) that are less immediately threatened. We estimate that in 1995 more than 1.1 billion people, nearly 20% of world population, were living within the hotspots, an area covering about 12% of Earth's terrestrial surface. We estimate that the population growth rate in the hotspots (1995-2000) is 1.8% yr(-1), substantially higher than the population growth rate of the world as a whole (1.3% yr(-1)) and above that of the developing countries (1.6% yr(-1)). These results suggest that substantial human-induced environmental changes are likely to continue in the hotspots and that demographic change remains an important factor in global biodiversity conservation. The results also underline the potential conservation significance of the continuing worldwide declines in human fertility and of policies and programs that influence human migration.	Populat Act Int, Res Dept, Washington, DC 20036 USA		Cincotta, RP (corresponding author), Populat Act Int, Res Dept, 1300 19th St NW,2nd Floor, Washington, DC 20036 USA.	cincotta@popact.org						Mittermeier R.A., 1988, P145; Mittermeier R. A., 1999, CHELONIAN CONSERV BI; Mittermeier RA, 1998, CONSERV BIOL, V12, P516, DOI 10.1046/j.1523-1739.1998.012003516.x; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Myers N, 1988, Environmentalist, V8, P187, DOI 10.1007/BF02240252; Myers N, 1990, Environmentalist, V10, P243, DOI 10.1007/BF02239720; MYERS N, 1994, POPULATION COMPLEX R, P117; NEWMAN JL, 1984, POPULATION PATTERNS; Repetto R, 1994, 2 INDIA REVISITED PO; STEDMANEDWARDS P, 1997, ROOT CAUSES BIODIVER; TOBLER W, 1995, 956 U CAL NAT CTR GE; *UN POP DIV, 1998, WORLD POP PROSP 1998	12	639	690	10	286	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 27	2000	404	6781					990	992		10.1038/35010105	http://dx.doi.org/10.1038/35010105			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801126				2022-12-28	WOS:000086762000054
J	Stanley, HE				Stanley, HE			Non-equilibrium physics - Freezing by heating	NATURE			English	Editorial Material							COLLOIDS		Boston Univ, Dept Phys, Ctr Polymer Studies, Boston, MA 02215 USA	Boston University	Stanley, HE (corresponding author), Boston Univ, Dept Phys, Ctr Polymer Studies, 590 Commonwealth Ave, Boston, MA 02215 USA.							Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223; Helbing D, 2000, PHYS REV LETT, V84, P1240, DOI 10.1103/PhysRevLett.84.1240; Helbing D., 2000, TRAFFIC GRANULAR FLO; Horsthemke W., 1984, NOISE INDUCED TRANSI; Laughlin RB, 2000, P NATL ACAD SCI USA, V97, P32, DOI 10.1073/pnas.97.1.32; Nicolis G, 1977, SELF ORG NONEQUILIBR; Reimann P, 1996, PHYS LETT A, V215, P26, DOI 10.1016/0375-9601(96)00222-8; Rudhardt D, 1998, PHYS REV LETT, V81, P1330, DOI 10.1103/PhysRevLett.81.1330; Wei QH, 1998, PHYS REV LETT, V81, P2606, DOI 10.1103/PhysRevLett.81.2606	9	18	19	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					718	719		10.1038/35008188	http://dx.doi.org/10.1038/35008188			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783872				2022-12-28	WOS:000086523600035
J	Dries, DL; Stevenson, LW				Dries, DL; Stevenson, LW			Brain natriuretic peptide as bridge to therapy for heart failure	LANCET			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; DIASTOLIC DYSFUNCTION; COMPENSATION; PRESSURE		Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dries, DL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA.							BURNETT JC, 1989, J HUM HYPERTENS, V3, P41; BURNETT JC, 1990, CIRCULATION, V82, P1523, DOI 10.1161/01.CIR.82.4.1523; EDWARDS BS, 1988, CIRC RES, V62, P191, DOI 10.1161/01.RES.62.2.191; Murdoch DR, 1999, AM HEART J, V138, P1126, DOI 10.1016/S0002-8703(99)70079-7; Selvais PL, 1998, EUR J CLIN INVEST, V28, P636; STEVENSON LW, 1990, AM J CARDIOL, V66, P1348, DOI 10.1016/0002-9149(90)91166-4; Tsutamoto T, 1997, CIRCULATION, V96, P509; Tsutamoto T, 1999, EUR HEART J, V20, P1799, DOI 10.1053/euhj.1999.1746; TSUTAMOTO T, 1989, AM HEART J, V117, P599, DOI 10.1016/0002-8703(89)90734-5; TSUTAMOTO T, 1992, JPN CIRC J, V56, P489, DOI 10.1253/jcj.56.489; WADA A, 1994, CIRCULATION, V89, P2232, DOI 10.1161/01.CIR.89.5.2232; Weinfeld MS, 1999, AM HEART J, V138, P285, DOI 10.1016/S0002-8703(99)70113-4; Yamamoto K, 1996, HYPERTENSION, V28, P988, DOI 10.1161/01.HYP.28.6.988; Yu CM, 1996, EUR HEART J, V17, P1694	14	14	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1112	1113		10.1016/S0140-6736(00)02053-5	http://dx.doi.org/10.1016/S0140-6736(00)02053-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791367				2022-12-28	WOS:000086380900002
J	Burge, PS; Calverley, PMA; Jones, PW; Spencer, S; Anderson, JA; Maslen, TK				Burge, PS; Calverley, PMA; Jones, PW; Spencer, S; Anderson, JA; Maslen, TK		ISOLDE study investigators	Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; RESPIRATORY QUESTIONNAIRE; INHALED BUDESONIDE; GLOBAL BURDEN; LUNG HEALTH; THERAPY; MILD; BRONCHODILATOR; MORTALITY; SMOKING	Objectives To determine the effect of long term inhaled corticosteroids on lung function, exacerbations, and health status in patients with moderate to severe chronic obstructive pulmonary disease. Design Double blind, placebo controlled study: Setting Eighteen UK hospitals. Participants 751 men and women aged between 40 and 75 years with mean forced expiratory volume in one second (FEV1) 50% of predicted normal. Interventions Inhaled fluticasone propionate 500 mu g twice daily from a metered dose inhaler or identical placebo. Main outcome measures Efficacy measures: rate of decline in FEV1 after the bronchodilator and in health status, frequency of exacerbations, respiratory withdrawals. Safety measures: morning serum cortisol concentration, incidence of adverse events. Results There was no significant difference in the annual rate of decline in FEV1 (P = 0.16). Mean FEV1 after bronchodilator remained significantly higher throughout the study with fluticasone propionate compared vith placebo (P < 0.001). Median exacerbation rate was reduced by 25% from 1.32 a year on placebo to 0.99 a year on with fluticasone propionate (P = 0.026). Health status deteriorated by 3.2 units a year on placebo and 2.0 units a year on fluticasone propionate (P = 0.0043). Withdrawals because of respiratory disease not related to malignancy were higher in the placebo group (25% v 19%, P = 0.034). Conclusions Fluticasone propionate 500 mu g twice daily did not affect the rate of decline in FEV1 but did produce a small ina ease in FEV1. Patients on fluticasone propionate had fewer exacerbations and a slower decline in health status. These improvements in clinical outcomes support the use of this treatment in patients with moderate to severe chronic obstructive pulmonary disease.	Birmingham Heartlands Hosp, Dept Resp Med, Birmingham B9 5SS, W Midlands, England; Aintree Univ Hosp NHS Fdn Trust, Dept Med, Liverpool L9 7AL, Merseyside, England; Univ London St Georges Hosp, Sch Med, Dept Med Physiol, London SW17 0RE, England; Glaxo Wellcome Res & Dev Ltd, Uxbridge UB11 1BT, Middx, England	Heart of England NHS Foundation Trust; University of Birmingham; Aintree University Hospitals NHS Foundation Trust; University of Liverpool; St Georges University London; GlaxoSmithKline	Burge, PS (corresponding author), Birmingham Heartlands Hosp, Dept Resp Med, Birmingham B9 5SS, W Midlands, England.	burgeps@aol.com	Spencer, Sally/AAD-5653-2020; Spencer, Sally/D-6963-2013	Spencer, Sally/0000-0001-6330-7200; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; BRYK AS, HIERARCHICAL LINEAR, P92; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216, DOI 10.7326/0003-4819-114-3-216; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215, DOI 10.1164/ajrccm/143.6.1215; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GRUNSVEN PMJ, 1999, THORAX, V54, P7; Jarad NA, 1999, RESP MED, V93, P161, DOI 10.1016/S0954-6111(99)90001-X; JONES DJM, 1995, AM J RESP CRIT CARE, V152, P538; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Li JTC, 1999, J ALLERGY CLIN IMMUN, V103, P1062, DOI 10.1016/S0091-6749(99)70180-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Osman LM, 1997, THORAX, V52, P67; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; POSTMA DS, 1988, EUR RESPIR J, V1, P22; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; THOM TJ, 1989, AM REV RESPIR DIS, V140, pS27, DOI 10.1164/ajrccm/140.3_Pt_2.S27; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3	24	1046	1095	1	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2000	320	7245					1297	1303		10.1136/bmj.320.7245.1297	http://dx.doi.org/10.1136/bmj.320.7245.1297			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807619	Green Submitted, Green Accepted, Green Published, Bronze			2022-12-28	WOS:000087077400020
J	Savage, COS; Harper, L; Cockwell, P; Adu, D; Howie, AJ				Savage, COS; Harper, L; Cockwell, P; Adu, D; Howie, AJ			ABC of arterial and vascular disease - Vasculitis	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Birmingham B15 2TT, W Midlands, England; Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England	University of Birmingham; University of Birmingham	Savage, COS (corresponding author), Univ Birmingham, Birmingham B15 2TT, W Midlands, England.			Cockwell, Paul/0000-0003-1975-266X					0	55	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1325	1328		10.1136/bmj.320.7245.1325	http://dx.doi.org/10.1136/bmj.320.7245.1325			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807632	Green Published			2022-12-28	WOS:000087077400031
J	Chandalia, M; Garg, A; Lutjohann, D; von Bergmann, K; Grundy, SM; Brinkley, LJ				Chandalia, M; Garg, A; Lutjohann, D; von Bergmann, K; Grundy, SM; Brinkley, LJ			Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOUNSATURATED-FAT DIET; FECAL STEROID-EXCRETION; HIGH-CARBOHYDRATE DIET; 7 COUNTRIES; GUAR GUM; OAT-BRAN; CHOLESTEROL CONCENTRATIONS; PLASMA-LIPOPROTEINS; INSULIN SENSITIVITY; SERUM-CHOLESTEROL	Background: The effect of increasing the intake of dietary fiber on glycemic control in patients with type 2 diabetes mellitus is controversial. Methods: In a randomized, crossover study, we assigned 13 patients with type 2 diabetes mellitus to follow two diets, each for six weeks: a diet containing moderate amounts of fiber (total, 24 g; 8 g of soluble fiber and 16 g of insoluble fiber), as recommended by the American Diabetes Association (ADA), and a high-fiber diet (total, 50 g; 25 g of soluble fiber and 25 g of insoluble fiber) containing foods not fortified with fiber (unfortified foods). Both diets, prepared in a research kitchen, had the same macronutrient and energy content. We compared the effects of the two diets on glycemic control and plasma lipid concentrations. Results: Compliance with the diets was excellent. During the sixth week of the high-fiber diet, as compared with the sixth week of the ADA diet, mean daily preprandial plasma glucose concentrations were 13 mg per deciliter (0.7 mmol per liter) lower (95 percent confidence interval, 1 to 24 mg per deciliter [0.1 to 1.3 mmol per liter]; P = 0.04) and mean daily urinary glucose excretion was 1.3 g lower (median difference, 0.23 g; 95 percent confidence interval, 0.03 to 1.83; P = 0.008). The high-fiber diet also lowered the area under the curve for 24-hour plasma glucose and insulin concentrations, which were measured every two hours, by 10 percent (P = 0.02) and 12 percent (P = 0.05), respectively. The high-fiber diet reduced plasma total cholesterol concentrations by 6.7 percent (P = 0.02), triglyceride concentrations by 10.2 percent (P = 0.02), and very-low-density lipoprotein cholesterol concentrations by 12.5 percent (P = 0.01). Conclusions: A high intake of dietary fiber, particularly of the soluble type, above the level recommended by the ADA, improves glycemic control, decreases hyperinsulinemia, and lowers plasma lipid concentrations in patients with type 2 diabetes. (N Engl J Med 2000;342:1392-8.) (C)2000, Massachusetts Medical Society.	Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Dept Vet Affairs Med Ctr, Dallas, TX USA; Rhein Friedrich Wilhelms Univ, Dept Clin Pharmacol, Bonn, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Bonn	Garg, A (corresponding author), Univ Texas, SW Med Ctr, Ctr Human Nutr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL029252, R01HL029252] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00633] Funding Source: Medline; NHLBI NIH HHS [HL-29252] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM ZD, 1988, AM J CLIN NUTR, V47, P67; [Anonymous], 1987, Diabetes Care, V10, P126; ARO A, 1981, DIABETOLOGIA, V21, P29, DOI 10.1007/BF03216219; Brown L, 1999, AM J CLIN NUTR, V69, P30; CAMPBELL LV, 1994, DIABETES CARE, V17, P177, DOI 10.2337/diacare.17.3.177; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P288; CUMMINGS JH, 1979, BRIT J NUTR, V41, P477, DOI 10.1079/BJN19790062; CZUBAYKO F, 1991, J LIPID RES, V32, P1861; *DEP AGR, 1976, AGR HDB, V8; GARG A, 1992, DIABETES, V41, P1278, DOI 10.2337/diabetes.41.10.1278; GARG A, 1994, JAMA-J AM MED ASSOC, V271, P1421, DOI 10.1001/jama.271.18.1421; GARG A, 1988, NEW ENGL J MED, V319, P829, DOI 10.1056/NEJM198809293191304; HAGANDER B, 1988, AM J CLIN NUTR, V47, P852, DOI 10.1093/ajcn/47.5.852; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HILLMAN LC, 1985, AM J CLIN NUTR, V42, P207, DOI 10.1093/ajcn/42.2.207; HOLLENBECK CB, 1986, AM J CLIN NUTR, V43, P16, DOI 10.1093/ajcn/43.1.16; HOLMAN RR, 1987, DIABETES CARE, V10, P68, DOI 10.2337/diacare.10.1.68; JENKINS DJA, 1975, LANCET, V1, P1116, DOI 10.1016/S0140-6736(75)92503-9; JONES B, 1989, DESIGN ANAL CROSSOVE; KARLSTROM B, 1984, DIABETOLOGIA, V26, P272, DOI 10.1007/BF00283649; KAY RM, 1977, AM J CLIN NUTR, V30, P171, DOI 10.1093/ajcn/30.2.171; KESANIEMI YA, 1990, AM J CLIN NUTR, V51, P1007, DOI 10.1093/ajcn/51.6.1007; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; KIEHM TG, 1976, AM J CLIN NUTR, V29, P895, DOI 10.1093/ajcn/29.8.895; KIRBY RW, 1981, AM J CLIN NUTR, V34, P824, DOI 10.1093/ajcn/34.5.824; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; LERMANGARBER I, 1994, DIABETES CARE, V17, P311, DOI 10.2337/diacare.17.4.311; LUTJOHANN D, 1993, J LIPID RES, V34, P1039; MANHIRE A, 1981, J HUM NUTR, V35, P99; MENOTTI A, 1989, ANN MED, V21, P175, DOI 10.3109/07853898909149929; *NAT HLTH NUTR EX, 1998, NCHS CD ROM SER, V11; NESTLE M, 1995, AM J CLIN NUTR, V61, p1313S, DOI 10.1093/ajcn/61.6.1313S; NUTTALL FQ, 1993, DIABETES, V42, P503, DOI 10.2337/diabetes.42.4.503; ODEA K, 1989, J AM DIET ASSOC, V89, P1076; PARILLO M, 1992, METABOLISM, V41, P1373, DOI 10.1016/0026-0495(92)90111-M; Pick ME, 1996, J AM DIET ASSOC, V96, P1254, DOI 10.1016/S0002-8223(96)00329-X; *PUBL HLTH SERV, 1982, MAN LBA OP LIP RES C; RASMUSSEN OW, 1993, DIABETES CARE, V16, P1565, DOI 10.2337/diacare.16.12.1565; RICCARDI G, 1984, DIABETOLOGIA, V26, P116, DOI 10.1007/BF00281117; RIVELLESE A, 1980, LANCET, V2, P447; RIVELLESE AA, 1990, DIABETES CARE, V13, P446, DOI 10.2337/diacare.13.4.446; SCHAKEL SF, 1993, CRC HDB DIETARY FIBE, P567; SIMPSON HCR, 1981, LANCET, V1, P1; UUSITUPA M, 1989, AM J CLIN NUTR, V49, P345, DOI 10.1093/ajcn/49.2.345; WALTERS RL, 1975, BRIT MED J, V2, P536, DOI 10.1136/bmj.2.5970.536; YALOW RS, 1960, J CLIN INVEST, V39, P1157, DOI 10.1172/JCI104130; ZHANG JX, 1992, AM J CLIN NUTR, V56, P99, DOI 10.1093/ajcn/56.1.99; 2000, DIABETES CARE, V23, pS43	48	614	653	5	96	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1392	1398		10.1056/NEJM200005113421903	http://dx.doi.org/10.1056/NEJM200005113421903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312JR	10805824				2022-12-28	WOS:000086940600003
J	Rabitz, H; de Vivie-Riedle, R; Motzkus, M; Kompa, K				Rabitz, H; de Vivie-Riedle, R; Motzkus, M; Kompa, K			Chemistry - Whither the future of controlling quantum phenomena?	SCIENCE			English	Review							LASER-PULSES; FEEDBACK; DYNAMICS; SYSTEMS; SPECTROSCOPY; MOLECULES	This review puts into perspective the present state and prospects for controlling phenomena in atoms and molecules. The topics considered include the nature of physical and chemical control objectives, the development of possible ii quantum control rules of thumb, the theoretical design of controls and their Laboratory tory realization, quantum learning and feedback control in the laboratory, bulk media influences, and the ability to utilize coherent quantum manipulation as a means for extracting microscopic information. The preview of the field presented here suggests that important advances in the control of molecules and the capability of Learning about molecular interactions may be reached through the application of emerging theoretical concepts and laboratory technologies.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Max Planck Inst Quantenopt, D-85748 Garching, Germany	Princeton University; Max Planck Society	Rabitz, H (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.		de Vivie-Riedle, Regina/T-6445-2017	de Vivie-Riedle, Regina/0000-0002-7877-5979				Assion A, 1998, SCIENCE, V282, P919, DOI 10.1126/science.282.5390.919; Bardeen CJ, 1997, CHEM PHYS LETT, V280, P151, DOI 10.1016/S0009-2614(97)01081-6; BRUMER P, 1989, CHEM PHYS, V139, P221, DOI 10.1016/0301-0104(89)90013-X; BRUMER P, 1986, CHEM PHYS LETT, V126, P541, DOI 10.1016/S0009-2614(86)80171-3; Gaspard P., 1997, ADV CHEM PHYS, V101; JUDSON RS, 1992, PHYS REV LETT, V68, P1500, DOI 10.1103/PhysRevLett.68.1500; KAWASHIMA H, 1995, ANNU REV PHYS CHEM, V46, P627, DOI 10.1146/annurev.pc.46.100195.003211; KIEFER JH, 1988, J PHYS CHEM-US, V92, P677, DOI 10.1021/j100314a021; Maas DJ, 1997, CHEM PHYS LETT, V270, P45, DOI 10.1016/S0009-2614(97)00323-0; Mabuchi H, 1999, APPL PHYS B-LASERS O, V68, P1095, DOI 10.1007/s003400050751; Manz J, 1998, CHEM PHYS LETT, V290, P415, DOI 10.1016/S0009-2614(98)00472-2; Meshulach D, 1998, NATURE, V396, P239, DOI 10.1038/24329; PEIRCE AP, 1988, PHYS REV A, V37, P4950, DOI 10.1103/PhysRevA.37.4950; Plass R, 1998, PHYS REV LETT, V81, P4891, DOI 10.1103/PhysRevLett.81.4891; POTTER ED, 1992, NATURE, V355, P66, DOI 10.1038/355066a0; Rose-Petruck C, 1999, NATURE, V398, P310, DOI 10.1038/18631; SCHERER NF, 1991, J CHEM PHYS, V95, P1487, DOI 10.1063/1.461064; SEIDL ET, 1988, J CHEM PHYS, V88, P7043, DOI 10.1063/1.454353; SHI SH, 1988, J CHEM PHYS, V88, P6870, DOI 10.1063/1.454384; Shnitman A, 1996, PHYS REV LETT, V76, P2886, DOI 10.1103/PhysRevLett.76.2886; Tannor DJ, 1999, FARADAY DISCUSS, V113, P365, DOI 10.1039/a902103e; TOTH GJ, 1994, J CHEM PHYS, V101, P3715, DOI 10.1063/1.467555; TULL JX, 1997, ADV MAGN OPT RES, V20, P1; WARREN WS, 1993, SCIENCE, V259, P1581, DOI 10.1126/science.259.5101.1581; Weinacht TC, 1999, NATURE, V397, P233, DOI 10.1038/16654; WEINER AM, 1995, PROG QUANT ELECTRON, V19, P161, DOI 10.1016/0079-6727(94)00013-O; Williams C. P., 1998, EXPLORATIONS QUANTUM; WISEMAN HM, 1995, MOD PHYS LETT B, V9, P629, DOI 10.1142/S0217984995000590; Zhu WS, 1999, J CHEM PHYS, V111, P472, DOI 10.1063/1.479328	29	972	1004	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					824	828		10.1126/science.288.5467.824	http://dx.doi.org/10.1126/science.288.5467.824			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10796997				2022-12-28	WOS:000086869600027
J	Blobe, GC; Schiemann, WP; Lodish, HF				Blobe, GC; Schiemann, WP; Lodish, HF			Mechanisms of disease: Role of transforming growth factor beta in human disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEREDITARY HEMORRHAGIC TELANGIECTASIA; TGF-BETA; BREAST-CANCER; TUMOR-SUPPRESSOR; TRANSGENIC MICE; IN-VIVO; MICROSATELLITE INSTABILITY; GROWTH-FACTOR-BETA-1 GENE; COLORECTAL CANCERS; ENDOTHELIAL-CELLS		Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu	Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NATIONAL CANCER INSTITUTE [F32CA073161, R01CA063260] Funding Source: NIH RePORTER; NCI NIH HHS [CA73161-01, CA63260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; ANSCHER MS, 1993, NEW ENGL J MED, V328, P1592, DOI 10.1056/NEJM199306033282203; Arai T, 1998, CANCER LETT, V122, P157, DOI 10.1016/S0304-3835(97)00384-4; Awad MR, 1998, TRANSPLANTATION, V66, P1014, DOI 10.1097/00007890-199810270-00009; Bayer EM, 1998, J HEPATOL, V28, P803, DOI 10.1016/S0168-8278(98)80230-4; Beck LS, 1998, J PHARM SCI-US, V87, P1379, DOI 10.1021/js9800883; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Campistol JM, 1999, KIDNEY INT, V56, P714, DOI 10.1046/j.1523-1755.1999.00597.x; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; Charpin JM, 1998, TRANSPLANTATION, V65, P752, DOI 10.1097/00007890-199803150-00027; Comerci JT, 1997, CLIN CANCER RES, V3, P157; Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P2225; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Gallione CJ, 1998, HUM MUTAT, V11, P286, DOI 10.1002/(SICI)1098-1004(1998)11:4<286::AID-HUMU6>3.0.CO;2-B; Grady WM, 1999, CANCER RES, V59, P320; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1995, NAT MED, V1, P1067, DOI 10.1038/nm1095-1067; Grainger DJ, 1996, NAT MED, V2, P381, DOI 10.1038/nm0496-381; Grainger DJ, 1999, HUM MOL GENET, V8, P93, DOI 10.1093/hmg/8.1.93; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; IVANOVIC V, 1995, NAT MED, V1, P282, DOI 10.1038/nm0495-282; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; KOPP A, 1995, CANCER RES, V55, P4512; Kopp JB, 1996, LAB INVEST, V74, P991; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li BG, 1999, HYPERTENSION, V33, P271, DOI 10.1161/01.HYP.33.1.271; Li CG, 1999, INT J CANCER, V84, P155, DOI 10.1002/(SICI)1097-0215(19990420)84:2<155::AID-IJC11>3.0.CO;2-S; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lidral AC, 1998, AM J HUM GENET, V63, P557, DOI 10.1086/301956; Liem LM, 1999, TRANSPLANTATION, V67, P59, DOI 10.1097/00007890-199901150-00009; Lin CY, 1998, AM J NEPHROL, V18, P513, DOI 10.1159/000013397; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; MACHARA Y, 1999, J CLIN ONCOL, V17, P607; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; McCaffrey TA, 1999, J MOL CELL CARDIOL, V31, P1627, DOI 10.1006/jmcc.1999.0999; McCaffrey TA, 1997, J CLIN INVEST, V100, P2182, DOI 10.1172/JCI119754; MCDONALD CC, 1995, BRIT MED J, V311, P977; Murawaki Y, 1998, J GASTROEN HEPATOL, V13, P680, DOI 10.1111/j.1440-1746.1998.tb00713.x; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nakamura M, 1998, BRIT J CANCER, V78, P1373, DOI 10.1038/bjc.1998.687; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Noble NA, 1997, SEMIN NEPHROL, V17, P455; NORGAARD P, 1995, CANCER TREAT REV, V21, P367, DOI 10.1016/0305-7372(95)90038-1; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Picon A, 1998, CANCER EPIDEM BIOMAR, V7, P497; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Potten CS, 1997, BRIT J CANCER, V75, P1454, DOI 10.1038/bjc.1997.249; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; ROBSON MC, 1999, P 3 JOINT M EUR TISS; Romitti PA, 1999, TERATOLOGY, V59, P39, DOI 10.1002/(SICI)1096-9926(199901)59:1<39::AID-TERA9>3.0.CO;2-7; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Shim KS, 1999, CANCER-AM CANCER SOC, V85, P554, DOI 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sinha S, 1998, MATRIX BIOL, V17, P529, DOI 10.1016/S0945-053X(98)90106-8; SONIS ST, 1994, CANCER RES, V54, P1135; SPORN MB, 1993, J CLIN INVEST, V92, P2565, DOI 10.1172/JCI116868; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tsai JF, 1997, BRIT J CANCER, V76, P244, DOI 10.1038/bjc.1997.369; Tsushima H, 1999, J HEPATOL, V30, P1, DOI 10.1016/S0168-8278(99)80001-4; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Vogel G, 1999, SCIENCE, V286, P665, DOI 10.1126/science.286.5440.665; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	93	2002	2157	0	109	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2000	342	18					1350	1358		10.1056/NEJM200005043421807	http://dx.doi.org/10.1056/NEJM200005043421807			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RE	10793168				2022-12-28	WOS:000086782400007
J	Pratt, DS; Kaplan, MM				Pratt, DS; Kaplan, MM			Primary care: Evaluation of abnormal liver-enzyme results in asymptomatic patients.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GLUTAMYL-TRANSFERASE TRANSPEPTIDASE; BLOOD-DONORS; NONALCOHOLIC STEATOHEPATITIS; AMINOTRANSFERASE LEVELS; AUTOIMMUNE HEPATITIS; SERUM; DISEASE; ELEVATION		New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center	Pratt, DS (corresponding author), New England Med Ctr, Box 217,750 Washington St, Boston, MA 02111 USA.							Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Bardella MT, 1999, HEPATOLOGY, V29, P654, DOI 10.1002/hep.510290318; COHEN JA, 1979, DIGEST DIS SCI, V24, P835, DOI 10.1007/BF01324898; CZAJA AJ, 1984, SEMIN LIVER DIS, V4, P1, DOI 10.1055/s-2008-1040641; Daniel S, 1999, AM J GASTROENTEROL, V94, P3010, DOI 10.1111/j.1572-0241.1999.01451.x; Das A, 1998, GASTROENTEROLOGY, V114, pA9; DIEHL AM, 1988, GASTROENTEROLOGY, V95, P1056, DOI 10.1016/0016-5085(88)90183-7; DIEHL AM, 1984, GASTROENTEROLOGY, V86, P632; ERIKSSON S, 1986, ACTA MED SCAND, V220, P83; GOLDBERG DM, 1975, DIGESTION, V12, P232, DOI 10.1159/000197682; Hasegawa T, 1997, GASTROENTEROLOGY, V112, pA1278; HULTCRANTZ R, 1986, SCAND J GASTROENTERO, V21, P109, DOI 10.3109/00365528609034632; KATKOV WN, 1991, ANN INTERN MED, V115, P882, DOI 10.7326/0003-4819-115-11-882; Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406; KUNDROTAS LW, 1993, DIGEST DIS SCI, V38, P2145, DOI 10.1007/BF01299887; Laurin J, 1996, HEPATOLOGY, V23, P1464; Lavine JE, 1998, GASTROENTEROLOGY, V114, pA1284, DOI 10.1016/S0016-5085(98)85214-1; Maddrey WC., 1999, SCHIFFS DIS LIVER, P205; MANNS MP, 1999, SCHIFFS DIS LIVER, V2, P919; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; MOUSSAVIAN SN, 1985, DIGEST DIS SCI, V30, P211; ORREGO H, 1985, ALCOHOL CLIN EXP RES, V9, P10, DOI 10.1111/j.1530-0277.1985.tb05038.x; Piton A, 1998, HEPATOLOGY, V27, P1213, DOI 10.1002/hep.510270505; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; ROSALKI SB, 1971, LANCET, V2, P376; Schiff ER, 1999, SEMIN LIVER DIS, V19, P3; Sorbi D, 1999, AM J GASTROENTEROL, V94, P1018; Sorbi D, 1999, HEPATOLOGY, V30, p477A; WOLF PL, 1978, ARCH PATHOL LAB MED, V102, P497	30	716	756	1	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1266	1271		10.1056/NEJM200004273421707	http://dx.doi.org/10.1056/NEJM200004273421707			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10781624				2022-12-28	WOS:000086660600007
J	Laurance, WF; Delamonica, P; Laurance, SG; Vasconcelos, HL; Lovejoy, TE				Laurance, WF; Delamonica, P; Laurance, SG; Vasconcelos, HL; Lovejoy, TE			Conservation - Rainforest fragmentation kills big trees	NATURE			English	Article							FOREST		INPA, Biol Dynam Forest Fragments Project, BR-69011970 Manaus, Amazonas, Brazil; Smithsonian Inst, Washington, DC 20560 USA	Institute Nacional de Pesquisas da Amazonia; Smithsonian Institution	Laurance, WF (corresponding author), INPA, Biol Dynam Forest Fragments Project, CP 478, BR-69011970 Manaus, Amazonas, Brazil.	wfl@inpag.gov.br	Laurance, Susan/G-6021-2011; Laurance, William F/B-2709-2012; Vasconcelos, Heraldo L/C-3353-2013	Laurance, Susan/0000-0002-2831-2933; Laurance, William F/0000-0003-4430-9408; Vasconcelos, Heraldo L/0000-0001-6969-7131				Chambers JQ, 1998, NATURE, V391, P135, DOI 10.1038/34325; Clark DB, 1996, FOREST ECOL MANAG, V80, P235, DOI 10.1016/0378-1127(95)03607-5; CONDIT R, 1995, ECOL MONOGR, V65, P419, DOI 10.2307/2963497; KAPOS V, 1989, J TROP ECOL, V5, P173, DOI 10.1017/S0266467400003448; Laurance W, 1998, SCIENCE, V282, p1611a; Laurance WF, 1998, ECOLOGY, V79, P2032, DOI 10.1890/0012-9658(1998)079[2032:RFFATD]2.0.CO;2; Laurance WF, 1997, SCIENCE, V278, P1117, DOI 10.1126/science.278.5340.1117; Leighton M., 1986, AAAS (American Association for the Advancement of Science) Selected Symposium, V101, P75; Mesquita RCG, 1999, BIOL CONSERV, V91, P129, DOI 10.1016/S0006-3207(99)00086-5; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; PUTZ FE, 1984, ECOLOGY, V65, P1713, DOI 10.2307/1937767; RICHARDS P. W., 1998, TROPICAL RAIN FOREST	12	443	462	3	93	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 20	2000	404	6780					836	836		10.1038/35009032	http://dx.doi.org/10.1038/35009032			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786782	Bronze			2022-12-28	WOS:000086625000034
J	Furberg, CD; Wright, JT; Davis, BR; Cutler, JA; Alderman, M; Black, H; Cushman, W; Grimm, R; Haywood, LJ; Leenen, F; Oparil, S; Perry, HM; Probstfield, J; Whelton, P; Payne, G; Nwachuku, C; Gordon, D; Proschan, M; Frommer, P; Einhorn, P; Hawkins, M; Ford, C; Pressel, S; Piller, L; Lusk, C; Bettencourt, J; Kimmel, B; Geraci, T; Walsh, S; Rahman, M; Juratovac, A; Pospisil, R; Brennan, K; Carroll, L; Sullivan, S; Barone, G; Christian, R; Feldman, S; Lucente, T; Lewis, CE; Jenkins, K; McDowell, P; Johnson, J; Kingry, C; Letterer, R; Margolis, K; Holland, L; Jaeger-Fox, B; Williamson, J; Louis, G; Ragusa, P; Williard, A; Ferguson, RS; Tanner, J; Eckfeldt, J; Crow, R; Pelosi, J				Furberg, CD; Wright, JT; Davis, BR; Cutler, JA; Alderman, M; Black, H; Cushman, W; Grimm, R; Haywood, LJ; Leenen, F; Oparil, S; Perry, HM; Probstfield, J; Whelton, P; Payne, G; Nwachuku, C; Gordon, D; Proschan, M; Frommer, P; Einhorn, P; Hawkins, M; Ford, C; Pressel, S; Piller, L; Lusk, C; Bettencourt, J; Kimmel, B; Geraci, T; Walsh, S; Rahman, M; Juratovac, A; Pospisil, R; Brennan, K; Carroll, L; Sullivan, S; Barone, G; Christian, R; Feldman, S; Lucente, T; Lewis, CE; Jenkins, K; McDowell, P; Johnson, J; Kingry, C; Letterer, R; Margolis, K; Holland, L; Jaeger-Fox, B; Williamson, J; Louis, G; Ragusa, P; Williard, A; Ferguson, RS; Tanner, J; Eckfeldt, J; Crow, R; Pelosi, J		ALLHAT Officers; Coordinators ALLHAT Collaborators	Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR MASS; THERAPY; FAILURE	Context Hypertension is associated with a significantly increased risk of morbidity and mortality. Only diuretics and beta-blockers have been shown to reduce this risk in long-term clinical trials: Whether newer antihypertensive agents reduce the incidence of cardiovascular disease (CVD) is unknown. Objective To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril. Design Randomized, double-blind, active-controlled clinical trial, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, initiated in February 1994. In January 2000, after an interim analysis, an independent data review committee recommended discontinuing the doxazosin treatment arm based on comparisons with chlorthalidone. Therefore, outcomes data presented herein reflect follow-up through December 1999. Setting A total of 625 centers in the United States and Canada. Participants A total of 24335 patients (aged greater than or equal to 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor who received either doxazosin or chlorthialidone. Interventions Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15268), or doxazosin, 2 to 8 mg/d (n = 9067), for a planned follow-up of 4 to 8 years. Main Outcome Measures The primary outcome measure was fatal CHD or nonfatal myocardial infarction.(MI), analyzed by intent to treat; secondary outcome measures included all-cause mortality, stroke, and combined CVD (CHD death, nonfatal MI, stroke, angina, coronary revascularization, congestive heart failure [CHF], and peripheral arterial disease); com pared by the chlorthalidone group vs the doxazosin group. Results Median follow-up was 3.3 years. A total of 365 patients in the doxazosin group and 608 in the chlorthalidone group had fatal CHD or nonfatal MI, with no difference in risk between the groups (relative risk [RR], 1.03; 95 % confidence interval [CI], 0.90-1.17; P = .71). Total mortality did not differ between the doxazosin and chlorthalidone arms (4-year rates, 9.62 % and 9.08 %, respectively; RR, 1.03; 95 % CI, 0.90-1.15; P = .56.) The doxazosin arm, compared with the chlorthalidone arm, had a higher risk of stroke (RR, 1.19; 95 % CI, 1.01-1.40; P = .04) and combined CVD (4-year rates, 25.45% vs 21.76 %; RR, 1.25; 95 % CI, 1.17-1.33; P < .001). Considered separately, CHF risk was doubled (4-year rates, 8.13 % vs 4.45 %; RR, 2.04; 95 % CI, 1.79-2.32; P < .001); RRs for angina, coronary revascularization, and peripheral arterial disease were 1.16 (P < .001), 1.15 (P = .05), and 1.07 (P = .50), respectively. Conclusion Our data indicate that compared with doxazosin, chlorthalidone yields essentially equal risk of CHD death/nonfatal MI but significantly reduces the risk of combined CVD events, particularly CHF, in high-risk hypertensive patients.	Univ Texas, Sch Publ Hlth, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Davis, BR (corresponding author), Univ Texas, Sch Publ Hlth, 1200 Herman Pressler St, Houston, TX 77030 USA.		Nace, David A/D-2638-2014					American Heart Association, 2000, HEART STROK STAT UPD; Black HR, 1997, ARCH INTERN MED, V157, P2413; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; DAVIS BR, 1990, COMMUN STAT THEORY, V19, P3571, DOI 10.1080/03610929008830398; Gottdiener JS, 1997, CIRCULATION, V95, P2007, DOI 10.1161/01.CIR.95.8.2007; Grimm RH, 1996, AM J HYPERTENS, V9, P445, DOI 10.1016/0895-7061(95)00439-4; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Hypertension Detection and Follow-Up Program Cooperative Group, 1984, HYPERTENSION S1, V6; IBSEN H, 1978, SCAND J CLIN LAB INV, V38, P425, DOI 10.3109/00365517809108446; Jennison C, 2000, GROUP SEQUENTIAL MET; Klein JP., 2003, SURVIVAL ANAL TECHNI; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEENEN FHH, 1987, AM J MED, V82, P969, DOI 10.1016/0002-9343(87)90160-4; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Li K, 1997, LIFE SCI, V60, P1305, DOI 10.1016/S0024-3205(96)00650-9; LIEBSON PR, 1995, CIRCULATION, V91, P698, DOI 10.1161/01.CIR.91.3.698; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; White M, 1999, AM J HYPERTENS, V12, P151, DOI 10.1016/S0895-7061(98)00220-9; Wilson PWF, 1999, CLIN CARDIOL, V22, pV1	23	1074	1103	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2000	283	15					1967	1975						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303RC	10789664				2022-12-28	WOS:000086436600031
J	Horton, B				Horton, B			Universities encourage industrialists to come back to their roots	NATURE			English	Article																			0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					793	794						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783896				2022-12-28	WOS:000086523600059
J	Halliday, DM; Conway, BA; Farmer, SF; Shahani, U; Russell, AJC; Rosenberg, JR				Halliday, DM; Conway, BA; Farmer, SF; Shahani, U; Russell, AJC; Rosenberg, JR			Coherence between low-frequency activation of the motor cortex and tremor in patients with essential tremor	LANCET			English	Article							ELECTROMYOGRAMS; OSCILLATIONS; CEREBELLAR; DISORDERS; TASK	Background In healthy people, rhythmic activation of the motor cortex in the 15-30 Hz frequency range accompanies and contributes to voluntarily-generate postural contractions of contralateral muscle. In patients with Parkinson's disease, an abnormal low-frequency activation of the motor areas of the cortex occurs and has been directly linked to the characteristic 3-6 Hz rest tremor of this disease. We therefore investigated whether the motor cortex is involved in the transmission of the rhythmic motor drive responsible for generating essential tremor. Methods Non-invasive recordings of activity from the hand area of the motor cortex were made from six patients with essential tremor by magnetoencephalography. The recordings were made simultaneously with the electromyogram recorded from contralateral finger muscles during periods of postural tremor. A statistical spectral analysis was done to determine at which frequencies the two signals were correlated. Findings Spectral analysis of the electromyogram signals showed a significant low-frequency component at the frequency of the tremor bursts. However, there was no coherence between magnetoencephalogram and electromyogram recordings at the tremor frequency, indicating that no correlation existed between the tremor signal and low-frequency activity recorded from the primary motor cortex in individuals with essential tremor. Coherence at frequencies higher than the tremor frequency was similar to that in healthy individuals performing voluntary postural contractions. Interpretation The absence of significant coherence between the magnetoencephalogram and electromyogram at tremor frequencies suggests that in essential tremor the tremor is imposed on the active muscle through descending pathways other than those originating in the primary motor cortex. These findings challenge the model widely used to explain the efficacy of neurosurgical treatment of essential tremor, are in contrast to those of previous studies of parkinsonian rest tremor, and highlight an important difference in the pathophysiology of essential and parkinsonian tremor.	Univ Strathclyde, Bioengn Unit, Glasgow G4 0NW, Lanark, Scotland; St Marys Hosp, Dept Neurol, London, England; UCL Natl Hosp Neurol & Neurosurg, Dept Neurol, London WC1N 3BG, England; So Gen Hosp NHS Trust, Dept Neurophysiol, Wellcome Biomagnetism Unit, Glasgow, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Neurosci, Glasgow, Lanark, Scotland	University of Strathclyde; Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Glasgow	Conway, BA (corresponding author), Univ Strathclyde, Bioengn Unit, Glasgow G4 0NW, Lanark, Scotland.	b.a.conway@strath.ac.uk	Shahani, Uma/V-9096-2019; Conway, Bernard/A-9625-2016; Farmer, Simon F/D-1969-2012; Halliday, David M/A-3848-2009	Shahani, Uma/0000-0003-2597-9334; Conway, Bernard/0000-0002-0069-0131; Farmer, Simon F/0000-0001-5193-8195; Halliday, David M/0000-0001-9957-0983				Baker SN, 1997, J PHYSIOL-LONDON, V501, P225, DOI 10.1111/j.1469-7793.1997.225bo.x; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; Bucher SF, 1997, ANN NEUROL, V41, P32, DOI 10.1002/ana.410410108; COLEBATCH JG, 1990, LANCET, V336, P1028, DOI 10.1016/0140-6736(90)92489-5; Conway BA, 1995, J PHYSIOL-LONDON, V489, P917, DOI 10.1113/jphysiol.1995.sp021104; DUBINSKY R, 1987, ANN NEUROL, V22, P118; DUPUIS MJM, 1989, MOVEMENT DISORD, V4, P183, DOI 10.1002/mds.870040210; Elble RJ, 1990, TREMOR; FARMER SF, 1993, J PHYSIOL-LONDON, V470, P127, DOI 10.1113/jphysiol.1993.sp019851; Halliday DM, 1995, PROG BIOPHYS MOL BIO, V64, P237, DOI 10.1016/S0079-6107(96)00009-0; Halliday DM, 1997, J PHYSIOL-LONDON, V501P, pP38; Halliday DM, 1998, NEUROSCI LETT, V241, P5, DOI 10.1016/S0304-3940(97)00964-6; Hari R, 1999, NEUROREPORT, V10, pR1; Hua SE, 1998, J NEUROL NEUROSUR PS, V64, P273, DOI 10.1136/jnnp.64.2.273; Koller W, 1996, EUR J NEUROL, V3, P507, DOI 10.1111/j.1468-1331.1996.tb00265.x; LAMARRE Y, 1984, MOVEMENT DISORDERS T, P183; LEE RG, 1987, MOVEMENT DISORD, V2, P423; LLINAS R, 1984, MOVEMENT DISORDERS T, P165, DOI DOI 10.1007/978-1-349-06757-2_10; Strick PL, 1998, NOVART FDN SYMP, V218, P64; STRICK PL, 1998, NOVART FDN SYMP, V218, P104; Volkmann J, 1996, NEUROLOGY, V46, P1359, DOI 10.1212/WNL.46.5.1359; WILLS AJ, 1994, ANN NEUROL, V36, P636, DOI 10.1002/ana.410360413	22	70	72	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1149	1153		10.1016/S0140-6736(00)02064-X	http://dx.doi.org/10.1016/S0140-6736(00)02064-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791378				2022-12-28	WOS:000086380900013
J	Halliwell, B				Halliwell, B			The antioxidant paradox	LANCET			English	Editorial Material							VITAMIN-C; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; DNA; SUPPLEMENTATION; COPPER		Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 119260, Singapore	National University of Singapore	Halliwell, B (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 119260, Singapore.	bchbh@nus.edu.sg	Halliwell, Barry/C-8318-2009	Halliwell, Barry/0000-0002-3560-7123				Beatty E., 1999, P NUTR SOC, V58, P44; Benzie IFF, 1999, METHOD ENZYMOL, V299, P15; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; Deng XS, 1998, FREE RADICAL RES, V28, P323, DOI 10.3109/10715769809069284; Fraga CG, 1996, MUTAT RES-FUND MOL M, V351, P199, DOI 10.1016/0027-5107(95)00251-0; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hampton MB, 1998, BIOFACTORS, V8, P1, DOI 10.1002/biof.5520080101; Kang SA, 1998, FREE RADICAL RES, V28, P93, DOI 10.3109/10715769809097880; MAIORINO M, 1993, FEBS LETT, V330, P174, DOI 10.1016/0014-5793(93)80267-X; Makjanic J, 1999, NUCL INSTRUM METH B, V158, P356, DOI 10.1016/S0168-583X(99)00526-1; Niu XW, 1999, ARTERIOSCL THROM VAS, V19, P1708, DOI 10.1161/01.ATV.19.7.1708; Oberle S, 1998, CIRC RES, V82, P1016, DOI 10.1161/01.RES.82.9.1016; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; Prieme H, 1997, AM J CLIN NUTR, V65, P503, DOI 10.1093/ajcn/65.2.503; Rehman A, 1999, BIOCHEM BIOPH RES CO, V262, P828, DOI 10.1006/bbrc.1999.1235; Rehman A, 1998, BIOCHEM BIOPH RES CO, V246, P293, DOI 10.1006/bbrc.1998.8592; RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279; Rowe PM, 1996, LANCET, V347, P249, DOI 10.1016/S0140-6736(96)90413-4; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; SMITH C, 1992, BIOCHEM J, V286, P901, DOI 10.1042/bj2860901; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Suh JK, 1999, P NATL ACAD SCI USA, V96, P2687, DOI 10.1073/pnas.96.6.2687; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; SWAIN JA, 1994, FEBS LETT, V342, P49, DOI 10.1016/0014-5793(94)80582-2; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5	26	430	451	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1179	1180		10.1016/S0140-6736(00)02075-4	http://dx.doi.org/10.1016/S0140-6736(00)02075-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791396				2022-12-28	WOS:000086380900040
J	Hanebuth, T; Stattegger, K; Grootes, PM				Hanebuth, T; Stattegger, K; Grootes, PM			Rapid flooding of the Sunda Shelf: A late-glacial sea-level record	SCIENCE			English	Article							LABOR AMS FACILITY; YOUNGER DRYAS; CORALS; TAHITI; AGES; CALIBRATION; BARBADOS; OCEAN; GISP2; RISE	The increase in sea Level from the last glacial maximum has been derived from a siliciclastic system on the tectonically stable Sunda Shelf in Southeast Asia. The time from 21 to 14 thousand calendar years before the present has been poorly covered in other records. The record generally confirms sea-level reconstructions from coral reefs. The rise of sea level during meltwater pulse 1A was as much as 16 meters within 300 years (14.6 to 14.3 thousand years ago).	Univ Kiel, Inst Geosci, D-24118 Kiel, Germany	University of Kiel	Hanebuth, T (corresponding author), Univ Kiel, Inst Geosci, Olshaussenstr 40, D-24118 Kiel, Germany.		Grootes, Pieter M/F-4952-2011	Grootes, Pieter/0000-0003-4265-3168				BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; Bard E, 1998, RADIOCARBON, V40, P1085, DOI 10.1017/S0033822200019135; BLANCHON P, 1995, GEOLOGY, V23, P4, DOI 10.1130/0091-7613(1995)023<0004:RDDTLD>2.3.CO;2; CHAPPELL J, 1991, NATURE, V349, P147, DOI 10.1038/349147a0; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; Gastaldo R.A., 1993, GEOLOGICAL SOC AM SP, p[286, 107]; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HANEBUTH T, IN PRESS MAR GEOL; HANEBUTH T, 1998, HESIS U KIEL KIEL; Harris PT, 1999, SEDIMENT GEOL, V125, P235; MITROVICA JX, 1991, J GEOPHYS RES-SOL EA, V96, P20053, DOI 10.1029/91JB01284; Montaggioni LF, 1997, GEOLOGY, V25, P555, DOI 10.1130/0091-7613(1997)025<0555:CRORGO>2.3.CO;2; Nadeau MJ, 1997, NUCL INSTRUM METH B, V123, P22, DOI 10.1016/S0168-583X(96)00730-6; Nadeau MJ, 1998, RADIOCARBON, V40, P239; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; PIRAZZOLI PA, 1991, WORLD ATLAS HOLOCENE, P117; SCHIMANSKI A, 1999, THESIS U KIEL KIEL; SINANDJUNTAK TO, 1996, GEOLOGY SOC SPECIAL, V106, P185; Stattegger K., 1997, BERICHTE REPORTS GEO, V86, P211; Stuiver M, 1995, QUATERNARY RES, V44, P341, DOI 10.1006/qres.1995.1079; STUIVER M, 1998, RADIOCARBON, V40, P1401; Tjia H.D., 1996, GEOLOGICAL SOC SPECI, V106, P291; Tjia HD, 1980, Z GEOMORPHOL, V24, P405; Tomlinson P.B., 2016, BOT MANGROVES, DOI [10.1017/CBO9781139946575, DOI 10.1017/CBO9781139946575]; ZHAO Q, 1995, WESTPAC PALEOCEANOGR	27	623	689	3	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1033	1035		10.1126/science.288.5468.1033	http://dx.doi.org/10.1126/science.288.5468.1033			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807570				2022-12-28	WOS:000086988400032
J	Shearman, LP; Sriram, S; Weaver, DR; Maywood, ES; Chaves, I; Zheng, BH; Kume, K; Lee, CC; van der Horst, GTJ; Hastings, MH; Reppert, SM				Shearman, LP; Sriram, S; Weaver, DR; Maywood, ES; Chaves, I; Zheng, BH; Kume, K; Lee, CC; van der Horst, GTJ; Hastings, MH; Reppert, SM			Interacting molecular loops in the mammalian circadian clock	SCIENCE			English	Article							RAT SUPRACHIASMATIC NUCLEUS; PERIOD HOMOLOGS; GENE CLOCK; TIMELESS; EXPRESSION; PROTEIN; RHYTHMS; TRANSCRIPTION; OSCILLATION; NEURONS	We show that, in the mouse, the core mechanism for the master circadian clock consists of interacting positive and negative transcription and translation feedback Loops. Analysis of Clock/Clock mutant mice, homozygous period2(Brdm1) mutants, and Cryptochrome-deficient mice reveals substantially altered Small rhythms, consistent with a dominant role of PERIOD2 in the positive regulation of the Bmal1 Loop. In vitro analysis of CRYPTOCHROME inhibition of CLOCK: BMAL1-mediated transcription shows that the inhibition is through direct protein:protein interactions, independent of the PERIOD and TIMELESS proteins. PERIOD2 is a positive regulator of the Bmal1 Loop, and CRYPTOCHROMES are the negative regulators of the Period and Cryptochrome cycles.	Massachusetts Gen Hosp, Massachusetts Gen Hosp Children, Lab Dev Chronobiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Erasmus Univ, Dept Cell Biol & Genet, Ctr Med Genet, NL-3000 DR Rotterdam, Netherlands; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Cambridge; Erasmus University Rotterdam; Baylor College of Medicine	Reppert, SM (corresponding author), Massachusetts Gen Hosp, Massachusetts Gen Hosp Children, Lab Dev Chronobiol, Boston, MA 02114 USA.	reppert@helix.mgh.harvard.edu	Jansen, Heiko T./A-5770-2008; van der Horst, Gijsbertus TJ/E-3661-2015; Chaves, Ines/L-3074-2015	Jansen, Heiko T./0000-0003-0178-396X; van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Kume, Kazuhiko/0000-0003-4232-1657; Weaver, David/0000-0001-7941-6719; Hastings, Michael Harvey/0000-0001-8576-6651	NHLBI NIH HHS [HL07901] Funding Source: Medline; NICHD NIH HHS [R37 HD14427] Funding Source: Medline; NINDS NIH HHS [R01 NS39303] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Glossop NRJ, 1999, SCIENCE, V286, P766, DOI 10.1126/science.286.5440.766; Gotter A. L., UNPUB; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hastings M H, 1999, J Neurosci, V19, pRC11; Herzog ED, 1998, NAT NEUROSCI, V1, P708, DOI 10.1038/3708; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Honma S, 1998, NEUROSCI LETT, V250, P157, DOI 10.1016/S0304-3940(98)00464-9; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KLEIN DC, 1991, SUPRACHLASMATIC NUCL; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Liu C, 2000, NEURON, V25, P123, DOI 10.1016/S0896-6273(00)80876-4; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; OLSHI K, 1998, BIOCHEM BIOPH RES CO, V253, P199; OLSHI K, 2000, BIOCHEM BIOPH RES CO, V268, P164; Ripperger JA, 2000, GENE DEV, V14, P679; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X; SHEARMAN LP, UNPUB; Silver R, 1999, NEUROREPORT, V10, P3165, DOI 10.1097/00001756-199910190-00008; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VIELHABER E, IN PRESS MOL CELL BI; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Weaver DR, 1998, J BIOL RHYTHM, V13, P100, DOI 10.1177/074873098128999952; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Yu WJ, 1999, BIOCHEM BIOPH RES CO, V260, P760, DOI 10.1006/bbrc.1999.0970; ZHENG B, UNPUB; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	44	1054	1098	1	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	2000	288	5468					1013	1019		10.1126/science.288.5468.1013	http://dx.doi.org/10.1126/science.288.5468.1013			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807566				2022-12-28	WOS:000086988400028
J	Wight, D; Henderson, M; Raab, G; Abraham, C; Buston, K; Scott, S; Hart, G				Wight, D; Henderson, M; Raab, G; Abraham, C; Buston, K; Scott, S; Hart, G			Extent of regretted sexual intercourse among young teenagers in Scotland: a cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article									MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; Napier Univ, Sch Math & Phys Sci, Edinburgh EH10 5DT, Midlothian, Scotland; Univ Sussex, Sch Social Sci, Brighton BN1 9QN, England; Univ Durham, Dept Sociol & Social Policy, Durham, England	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; Edinburgh Napier University; University of Sussex; Durham University	Wight, D (corresponding author), MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.		Hart, Graham J/C-1591-2008; Henderson, Marion Mackay/AAS-2759-2021; Abraham, Charles/C-7130-2012; Henderson, Marion/M-2136-2019; Henderson, Marion/G-3310-2019	Henderson, Marion/0000-0001-7582-9516; Henderson, Marion/0000-0001-7582-9516; Abraham, Charles/0000-0002-0901-1975; Hart, Graham/0000-0001-9676-6577; Buston, Katie/0000-0003-4162-8868				Dickson N, 1998, BRIT MED J, V316, P29, DOI 10.1136/bmj.316.7124.29; Johnson AM, 1994, SEXUAL ATTITUDES LIF; RICHARD R, 1996, J BEHAV DECIS MAKING, V3, P263; *SAS I, 1996, SAS LOG PROC SAS STA; WIGHT D, 1997, HLTH ED, V2, P52	5	62	62	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1243	1244		10.1136/bmj.320.7244.1243	http://dx.doi.org/10.1136/bmj.320.7244.1243			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	313CF	10797033	Green Accepted, Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086981400018
J	Jehl, X; Sanquer, M; Calemczuk, R; Mailly, D				Jehl, X; Sanquer, M; Calemczuk, R; Mailly, D			Detection of doubled shot noise in short normal-metal/superconductor junctions	NATURE			English	Article							METAL-SUPERCONDUCTOR JUNCTIONS; QUASI-PARTICLES; SUPPRESSION; SCATTERING; REENTRANCE; CONTACTS; CHARGE	Shot noise refers to the fluctuations in electrical current through a device arising from the discrete nature of the charge-carrying particles. Recent experiments have exploited the fact that the shot noise is proportional to the charge of the carriers to establish fractional quantization of quasiparticles in the fractional quantum Hall effect(1,2). By a similar argument, it is expected that when a superconducting reservoir emits Cooper pairs, (which have a charge twice that of an electron) into a short normal-metal wire, the shot noise should be double that obtained for a normal-metal reservoir(3,4). Although the charge of Cooper pairs has been well established by flux quantization and tunnel experiments(5), doubling of their shot noise has not yet been observed. Here we report a shot-noise experiment using a short diffusive normal-metal superconductor contact, in which we confirm the predicted noise behaviour for double charges. The measurements, taken over a large range of bias current, establish that phase coherence is not required to observe the effect.	CEA Grenoble, SPSMS, DRFMC, F-38054 Grenoble, France; CNRS, LMM, F-92225 Bagneux, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Sanquer, M (corresponding author), CEA Grenoble, SPSMS, DRFMC, F-38054 Grenoble, France.	msanquer@cea.fr	sanquer, marc/A-7786-2010					Al'tshuler BL, 1987, SOV SCI REV A, V9, P223; Altshuler B. L., 1985, Electron-electron interactions in disordered systems, P1; Anantram MP, 1996, PHYS REV B, V53, P16390, DOI 10.1103/PhysRevB.53.16390; ANDREEV AF, 1964, SOV PHYS JETP-USSR, V19, P1228; ARTEMENKO SN, 1979, SOLID STATE COMMUN, V30, P771, DOI 10.1016/0038-1098(79)90044-9; BEENAKKER CWJ, 1992, PHYS REV B, V46, P1889, DOI 10.1103/PhysRevB.46.1889; BLANTER YM, 1999, CONDMAT9910158; Courtois H, 1999, J LOW TEMP PHYS, V116, P187, DOI 10.1023/A:1021885617107; DEJONG MJM, 1994, PHYS REV B, V49, P16070, DOI 10.1103/PhysRevB.49.16070; Deutscher G., 1969, Superconductivity, vol.2, P1005; Dieleman P, 1997, PHYS REV LETT, V79, P3486, DOI 10.1103/PhysRevLett.79.3486; Gramespacher T, 2000, PHYS REV B, V61, P8125, DOI 10.1103/PhysRevB.61.8125; Henny M, 1999, PHYS REV B, V59, P2871, DOI 10.1103/PhysRevB.59.2871; HOSS T, 1999, CONDMAT9901129; Jehl X, 1999, REV SCI INSTRUM, V70, P2711, DOI 10.1063/1.1149833; Jehl X, 1999, PHYS REV LETT, V83, P1660, DOI 10.1103/PhysRevLett.83.1660; Khlus V. A., 1987, Soviet Physics - JETP, V66, P1243; Kozhevnikov AA, 2000, J LOW TEMP PHYS, V118, P671, DOI 10.1023/A:1004695412712; LAFARGE P, 1993, NATURE, V365, P422, DOI 10.1038/365422a0; Lesovik GB, 1999, PHYS REV B, V60, P11935, DOI 10.1103/PhysRevB.60.11935; Martin T, 1996, PHYS LETT A, V220, P137, DOI 10.1016/0375-9601(96)00484-7; MUZYKANTSKII BA, 1994, PHYS REV B, V50, P3982, DOI 10.1103/PhysRevB.50.3982; NAGAEV KE, 1995, PHYS REV B, V52, P4740, DOI 10.1103/PhysRevB.52.4740; NAGAEV KE, 1992, PHYS LETT A, V169, P103, DOI 10.1016/0375-9601(92)90814-3; Petrashov VT, 1998, JETP LETT+, V67, P513, DOI 10.1134/1.567691; Pothier H, 1997, PHYS REV LETT, V79, P3490, DOI 10.1103/PhysRevLett.79.3490; Reznikov M, 1999, NATURE, V399, P238, DOI 10.1038/20384; Saminadayar L, 1997, PHYS REV LETT, V79, P2526, DOI 10.1103/PhysRevLett.79.2526; Schottky W, 1918, ANN PHYS-BERLIN, V57, P541; Steinbach AH, 1996, PHYS REV LETT, V76, P3806, DOI 10.1103/PhysRevLett.76.3806; TORRES J, 1999, CONDMAT9906012	31	137	139	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	2000	405	6782					50	53		10.1038/35011012	http://dx.doi.org/10.1038/35011012			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811213				2022-12-28	WOS:000086901600046
J	Nickeleit, V; Klimkait, T; Binet, IF; Dalquen, P; Del Zenero, V; Thiel, G; Mihatsch, MJ; Hirsch, HH				Nickeleit, V; Klimkait, T; Binet, IF; Dalquen, P; Del Zenero, V; Thiel, G; Mihatsch, MJ; Hirsch, HH			Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANT; JC-VIRUS INFECTIONS; HEMORRHAGIC CYSTITIS; PREVALENCE	Background: Reactivation of polyomavirus type BK (BK virus) is increasingly recognized as a cause of severe renal-allograft dysfunction. Currently, patients at risk for nephropathy due to infection with the BK virus are identified by the presence of cells containing viral inclusion bodies ("decoy cells'') in the urine or by biopsy of allograft tissue. Methods: In a retrospective analysis, we performed polymerase-chain-reaction assays for BK virus DNA in plasma samples from 9 renal-allograft recipients with BK virus nephropathy; 41 renal-allograft recipients who did not have signs of nephropathy, 16 of whom had decoy cells in the urine; and as immunocompromised controls, 17 patients who had human immunodeficiency virus type 1 (HIV-1) infection (stage C3 according to the classification of the Centers for Disease Control and Prevention) and who had not undergone transplantation. Results: In all nine patients with BK virus nephropathy, BK virus DNA was detected in the plasma at the time of the initial histologic diagnosis (a mean [+/-SD] of 46+/-28 weeks after transplantation) and during the course of histologically diagnosed, persistent BK virus disease. In three of the six patients with nephropathy who were studied serially after transplantation, BK virus DNA was initially undetectable but was detected 16 to 33 weeks before nephropathy became clinically evident and was confirmed by biopsy. Tests for BK virus DNA in plasma became negative and the nephropathy resolved after the doses of immunosuppressive drugs were decreased in two patients and after removal of the renal allograft in three patients. BK virus DNA was found in the plasma of only 2 of the 41 renal-allograft recipients who had no signs of nephropathy and in none of the patients with HIV-1 infection. Conclusions: Testing for BK virus DNA in plasma from renal-allograft recipients with use of the polymerase chain reaction is a sensitive and specific method for identifying viral nephropathy. (N Engl J Med 2000;342:1309-15.) (C) 2000, Massachusetts Medical Society.	Univ Basel, Inst Pathol, Basel, Switzerland; Univ Basel, Inst Med Microbiol, Basel, Switzerland; Univ Basel, Dept Internal Med, Div Nephrol, Basel, Switzerland	University of Basel; University of Basel; University of Basel	Hirsch, HH (corresponding author), Univ Basel Hosp, Dept Internal Med, Petersgraben 4, CH-4031 Basel, Switzerland.		Klimkait, Thomas/A-1057-2008	Klimkait, Thomas/0000-0003-4945-6511; Hirsch, Hans H./0000-0003-0883-0423				ANDREWS CA, 1988, J INFECT DIS, V158, P176, DOI 10.1093/infdis/158.1.176; ARTHUR RR, 1988, J INFECT DIS, V158, P563, DOI 10.1093/infdis/158.3.563; Binet I, 1999, TRANSPLANTATION, V67, P918, DOI 10.1097/00007890-199903270-00022; Bogdanovic G, 1996, BONE MARROW TRANSPL, V17, P573; Boubenider S, 1999, J NEPHROL, V12, P24; CHESTERS PM, 1983, J INFECT DIS, V147, P676, DOI 10.1093/infdis/147.4.676; COLEMAN DV, 1980, J INFECT DIS, V142, P1, DOI 10.1093/infdis/142.1.1; COTTLERFOX M, 1989, BONE MARROW TRANSPL, V4, P279; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; GARDNER SD, 1984, J CLIN PATHOL, V37, P578, DOI 10.1136/jcp.37.5.578; Hirsch Hans H., 1998, Clin Microbiol Infect, V4, P577, DOI 10.1111/j.1469-0691.1998.tb00040.x; Hogan T F, 1983, Prog Clin Biol Res, V105, P311; HOGAN TF, 1980, ANN INTERN MED, V92, P373, DOI 10.7326/0003-4819-92-3-373; Holman RC, 1998, NEUROEPIDEMIOLOGY, V17, P303, DOI 10.1159/000026184; Mackenzie E F, 1978, Proc Eur Dial Transplant Assoc, V15, P352; MARKOWITZ RB, 1993, J INFECT DIS, V167, P13, DOI 10.1093/infdis/167.1.13; Mathur VS, 1997, AM J KIDNEY DIS, V29, P754; Nickeleit V, 1999, J AM SOC NEPHROL, V10, P1080; PADGETT BL, 1971, LANCET, V1, P1257; Randhawa PS, 1999, TRANSPLANTATION, V67, P103, DOI 10.1097/00007890-199901150-00018; SHAH KV, 1973, J INFECT DIS, V128, P784, DOI 10.1093/infdis/128.6.784; Shah KV, 1996, FIELDS VIROLOGY, P2027; STILMANT MM, 1987, ACTA CYTOL, V31, P625; SUNDSFJORD A, 1994, J INFECT DIS, V169, P485, DOI 10.1093/infdis/169.3.485	24	394	416	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2000	342	18					1309	1315		10.1056/NEJM200005043421802	http://dx.doi.org/10.1056/NEJM200005043421802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RE	10793163				2022-12-28	WOS:000086782400002
J	Han, SSW; Fischer, I				Han, SSW; Fischer, I			Neural stem cells and gene therapy: Prospects for repairing the injured spinal card	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRECURSORS		Hahnemann Univ, Sch Med, Philadelphia, PA 19102 USA	Drexel University	Han, SSW (corresponding author), Hahnemann Univ, Sch Med, Philadelphia, PA 19102 USA.		Fischer, Itzhak/D-1080-2012	Fischer, Itzhak/0000-0003-3187-8740				Kalyani AJ, 1998, J NEUROSCI, V18, P7856; Liu Y, 1999, J NEUROSCI, V19, P4370; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; MURRAY M, 2000, IN PRESS NERVE REGEN; Rao MS, 1999, ANAT RECORD, V257, P137; Studer L, 1998, NAT NEUROSCI, V1, P290, DOI 10.1038/1105; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Svendsen CN, 1999, BRAIN PATHOL, V9, P499, DOI 10.1111/j.1750-3639.1999.tb00538.x; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029	9	15	19	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2300	2301		10.1001/jama.283.17.2300	http://dx.doi.org/10.1001/jama.283.17.2300			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807395	hybrid			2022-12-28	WOS:000086671600043
J	van der Gaag, MS; Ubbink, JB; Sillanaukee, P; Nikkari, S; Hendriks, HFJ				van der Gaag, MS; Ubbink, JB; Sillanaukee, P; Nikkari, S; Hendriks, HFJ			Effect of consumption of red wine, spirits, and beer on serum homocysteine	LANCET			English	Article							CORONARY HEART-DISEASE	Serum homocysteine increases after moderate consumption of red wine and spirits, but not after moderate consumption of beer. Vitamin B-6 in beer seems to prevent the alcohol-induced rise in serum homocysteine.	TNO, Nutr & Food Res Inst, Dept Nutr Physiol, NL-3700 AJ Zeist, Netherlands; Univ Pretoria, Dept Chem Pathol, ZA-0002 Pretoria, South Africa; Tampere Univ, Sch Med, FIN-33101 Tampere, Finland	Netherlands Organization Applied Science Research; University of Pretoria; Tampere University	Hendriks, HFJ (corresponding author), TNO, Nutr & Food Res Inst, Dept Nutr Physiol, POB 360, NL-3700 AJ Zeist, Netherlands.		Hendriks, Henk/AAU-5987-2021					Dudman NPB, 1999, LANCET, V354, P2072, DOI 10.1016/S0140-6736(99)03383-8; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; van der Gaag MS, 1999, ATHEROSCLEROSIS, V147, P405, DOI 10.1016/S0021-9150(99)00243-9; Verhoef P, 1998, CURR OPIN LIPIDOL, V9, P17, DOI 10.1097/00041433-199802000-00005	5	125	129	3	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1522	1522		10.1016/S0140-6736(00)02172-3	http://dx.doi.org/10.1016/S0140-6736(00)02172-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801179				2022-12-28	WOS:000086830100019
J	Wies, I; Brunner, S; Henninger, J; Herkel, J; Kanzler, S; zum Buchenfelde, KHM; Lohse, AW				Wies, I; Brunner, S; Henninger, J; Herkel, J; Kanzler, S; zum Buchenfelde, KHM; Lohse, AW			Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis	LANCET			English	Article							GLUTATHIONE-S-TRANSFERASE; CHRONIC ACTIVE HEPATITIS; SOLUBLE LIVER ANTIGEN; T-CELL VACCINATION; AUTOANTIGEN; DISEASES; SUBGROUP	Background Autoantibodies are a hallmark of autoimmune hepatitis, but most are not disease specific. Autoantibodies to soluble liver antigen (SLA) and to liver and pancreas antigen (LP) have been described as disease specific, occurring in about 30% of all patients with autoimmune hepatitis, but no standardised assays are available. Methods We tested 2000 serum samples from patients with various liver diseases and controls for SLA autoantibodies by inhibition ELISA. Serum samples positive for SLA antibodies were used for immunoscreening of cDNA expression libraries. Identified clones were tested against a panel of serum samples positive for SLA and LP autoantibodies and control serum samples, and the epitope mapped by deletion mutants and exonuclease digestion. Findings SLA and LP autoantibodies were identical. Of 2000 serum samples screened, 35 were positive for SLA autoantibodies. These positive samples came from patients with autoimmune hepatitis; three from patients with an overlap syndrome (primary biliary cirrhosis and secondary autoimmune hepatitis). Expression cloning and absorption experiments identified a 422 aminoacid protein present in two splice variants as the sole target antigen. Aminoacids 371-409 were critical for immune recognition. Interpretation The identified cDNA encodes the primary target antigen of SLA/LP autoantibodies. The SLA/LP antigen has a previously unknown aminoacid sequence, and presumably codes for an unindentified enzyme, suggested to be UGA-suppressor tRNA-associated protein. SLA/LP autoantibodies are disease specific and recognise a dominant epitope, suggesting a specific antigen-driven immune response. Identification of the SLA/LP target antigen will allow establishment of a reliable, widely available diagnostic assay. Furthermore, its role in the pathogenesis of autoimmune hepatitis can now be studied.	Johannes Gutenberg Univ Mainz, Dept Med, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Lohse, AW (corresponding author), Johannes Gutenberg Univ Mainz, Dept Med, D-55101 Mainz, Germany.	lohse@mail.uni-mainz.de		Herkel, Johannes/0000-0001-9055-9999				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9; Berg PA, 1981, VERH DTSCH GES INN M, V87, P921; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; COHEN IR, 1983, IMMUNOL TODAY, V4, P227, DOI 10.1016/0167-5699(83)90032-4; CZAJA AJ, 1998, AUTOIMMUNE LIVER DIS, P499; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Herkel J, 1997, J AUTOIMMUN, V10, P137, DOI 10.1006/jaut.1997.0125; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; Kanzler S, 1999, J HEPATOL, V31, P635, DOI 10.1016/S0168-8278(99)80342-0; Klein R, 1999, GASTROENTEROLOGY, V116, P1015, DOI 10.1016/S0016-5085(99)70095-8; Krawitt EL, 1996, NEW ENGL J MED, V334, P897, DOI 10.1056/NEJM199604043341406; Lohse A.W., 1994, AUTOIMMUNE DIS MODEL, P191; Lohse AW, 1998, HEPATOLOGY, V27, P1536, DOI 10.1002/hep.510270611; Lohse AW, 1999, HEPATOLOGY, V29, P1078, DOI 10.1002/hep.510290409; LOHSE AW, 1995, Z GASTROENTEROL, V33, P527; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; MANNS M, 1989, J HEPATOL, V9, P272, DOI 10.1016/0168-8278(89)90063-9; MANNS M, 1987, LANCET, V1, P292; STECHEMESSER E, 1987, LANCET, V1, P683; STECHEMESSER E, 1993, HEPATOLOGY, V18, P1; TEUFEL M, 1983, EUR J PEDIATR, V140, P30, DOI 10.1007/BF00661901; VANDEWATER J, 1988, J EXP MED, V167, P1791, DOI 10.1084/jem.167.6.1791; WAECHTER B, 1997, J HEPATOL, V11, P232; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; Wesierska-Gadek J, 1998, GASTROENTEROLOGY, V114, P329, DOI 10.1016/S0016-5085(98)70485-8; ZUMBUSCHENFELDE KHM, 1995, NEW ENGL J MED, V333, P1004, DOI 10.1056/NEJM199510123331512	27	214	238	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2000	355	9214					1510	1515		10.1016/S0140-6736(00)02166-8	http://dx.doi.org/10.1016/S0140-6736(00)02166-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801173				2022-12-28	WOS:000086830100013
J	Yamazaki, S; Numano, R; Abe, M; Hida, A; Takahashi, R; Ueda, M; Block, GD; Sakaki, Y; Menaker, M; Tei, H				Yamazaki, S; Numano, R; Abe, M; Hida, A; Takahashi, R; Ueda, M; Block, GD; Sakaki, Y; Menaker, M; Tei, H			Resetting central and peripheral circadian oscillators in transgenic rats	SCIENCE			English	Article							GENE-EXPRESSION; RHYTHMS; PERIOD; CLOCK; DROSOPHILA	In multicellular organisms, circadian oscillators are organized into multitissue systems which function as biological clocks that regulate the activities of the organism in relation to environmental cycles and provide an internal temporal framework. To investigate the organization of a mammalian circadian system, we constructed a transgenic rat Line in which luciferase is rhythmically expressed under the control of the mouse Per1 promoter. Light emission from cultured suprachiasmatic nuclei (SCN) of these rats was invariably and robustly rhythmic and persisted for up to 32 days in vitro. Liver, Lung, and skeletal muscle also expressed circadian rhythms, which damped after two to seven cycles in vitro. In response to advances and delays of the environmental Light cycle, the circadian rhythm of light emission from the SCN shifted more rapidly than did the rhythm of locomotor behavior or the rhythms in peripheral tissues. We hypothesize that a self-sustained circadian pacemaker in the SCN entrains circadian oscillators in the periphery to maintain adaptive phase control, which is temporarily Lost following Large, abrupt shifts in the environmental Light cycle.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan; YS New Technol Inst, Ishibashi, Tochigi 3290500, Japan; Univ Virginia, NSF Ctr Biol Timing, Charlottesville, VA 22903 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA	University of Tokyo; National Science Foundation (NSF); University of Virginia; University of Virginia	Menaker, M (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X	NIMH NIH HHS [R01 MH056647, MH56647] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056647] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andrews R V, 1971, Gegenbaurs Morphol Jahrb, V117, P89; Aschoff J., 1981, BIOL RHYTHMS, P311; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Best JD, 1999, J NEUROSCI, V19, P828; Geusz ME, 1997, CURR BIOL, V7, P758, DOI 10.1016/S0960-9822(06)00334-4; HALBERG F, 1960, COLD SPRING HARB SYM, V25, P289, DOI 10.1101/SQB.1960.025.01.031; HOCHI S-I, 1990, Animal Biotechnology, V1, P175, DOI 10.1080/10495399009525739; HONMA K, 1989, BIOL RHYTHMS; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; MENAKER M, 1996, CIRCADIAN ORG OSCILL, P39; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; TAKAMURE M, 1991, PHYSIOL BEHAV, V50, P443, DOI 10.1016/0031-9384(91)90092-3; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Ueyama T, 1999, NAT NEUROSCI, V2, P1051, DOI 10.1038/15973; US Congress. Office of Technology Assessment, 1991, OTABA463 US C; YAMAZAKI S, UNPUB; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	20	1372	1415	4	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					682	685		10.1126/science.288.5466.682	http://dx.doi.org/10.1126/science.288.5466.682			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784453				2022-12-28	WOS:000086727100047
J	Ball, P				Ball, P			Meet the spin doctors . . .	NATURE			English	Article							INJECTION; COHERENCE											AKIBA N, IN PRESS J APPL PHYS; Cowburn RP, 2000, SCIENCE, V287, P1466, DOI 10.1126/science.287.5457.1466; Fiederling R, 1999, NATURE, V402, P787, DOI 10.1038/45502; Gupta JA, 1999, PHYS REV B, V59, P10421, DOI 10.1103/PhysRevB.59.R10421; Hallstein S, 1997, PHYS REV B, V56, pR7076, DOI 10.1103/PhysRevB.56.R7076; Hammar PR, 1999, PHYS REV LETT, V83, P203, DOI 10.1103/PhysRevLett.83.203; Kikkawa JM, 1999, NATURE, V397, P139, DOI 10.1038/16420; Kikkawa JM, 1997, SCIENCE, V277, P1284, DOI 10.1126/science.277.5330.1284; Kikkawa JM, 2000, SCIENCE, V287, P473, DOI 10.1126/science.287.5452.473; Ohno H, 1996, APPL PHYS LETT, V69, P363, DOI 10.1063/1.118061; Ohno Y, 1999, NATURE, V402, P790, DOI 10.1038/45509	11	154	158	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					918	920		10.1038/35010132	http://dx.doi.org/10.1038/35010132			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801097				2022-12-28	WOS:000086762000015
J	Carmi, R; Polturak, E; Koren, G; Auerbach, A				Carmi, R; Polturak, E; Koren, G; Auerbach, A			Spontaneous macroscopic magnetization at the superconducting transition temperature of YBa2Cu3O7-delta	NATURE			English	Article							TIME-REVERSAL-SYMMETRY; HIGH-TC SUPERCONDUCTORS; C SUPERCONDUCTORS; JUNCTIONS; STATES; BI2SR2CACU2O8; ORDER	A noteworthy feature of the high-temperature superconductors is the unconventional symmetry of the superconducting order parameter. Several experiments(1-3) have established that the order parameter has a four-fold d(x2-y2) symmetry under rotation of the lattice (the order parameter of conventional superconductors is, in contrast, isotropic). An intriguing and much debated possibility is that, in certain cases, an additional imaginary component might be present, having an isotropic s-wave(4-6) or d(xy) symmetry(7-1)0. A consequence of a complex order parameter of the form d(x2-y2) + id(xy) is that it would break both reflection (parity, P) symmetry and time-reversal (T) symmetry, a clear signature of which would be the spontaneous appearance of a macroscopic magnetization at the superconducting transition temperature. Broken T symmetry has been reported(5,11), but searches for the effects of combined P and T symmetry breaking have so far yielded null results(12-15). Here we report the observation of a weak (similar to 10(-5) gauss) magnetic field that appears spontaneously at the superconducting transition temperature of epitaxial thin films of YBa2Cu3O7-delta. The magnetic signal originates near the edges of the samples. One interpretation for this observation is that the order parameter carries an intrinsic angular momentum, related to the breaking of P and T symmetries, but other possibilities cannot yet be excluded.	Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Polturak, E (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.			Auerbach, Assa/0000-0002-4497-9009				Covington M, 1997, PHYS REV LETT, V79, P277, DOI 10.1103/PhysRevLett.79.277; Fogelstrom M, 1997, PHYS REV LETT, V79, P281, DOI 10.1103/PhysRevLett.79.281; HALPERIN BI, 1989, PHYS REV B, V40, P8726, DOI 10.1103/PhysRevB.40.8726; Kawamura H, 1997, PHYS REV LETT, V78, P1556, DOI 10.1103/PhysRevLett.78.1556; KIEFL RF, 1990, PHYS REV LETT, V64, P2082, DOI 10.1103/PhysRevLett.64.2082; Kirtley JR, 1999, SCIENCE, V285, P1373, DOI 10.1126/science.285.5432.1373; KIRTLEY JR, 1995, PHYS REV B, V51, P12057, DOI 10.1103/PhysRevB.51.12057; Krishana K, 1997, SCIENCE, V277, P83, DOI 10.1126/science.277.5322.83; Krupke R, 1999, PHYS REV LETT, V83, P4634, DOI 10.1103/PhysRevLett.83.4634; Laughlin RB, 1998, PHYS REV LETT, V80, P5188, DOI 10.1103/PhysRevLett.80.5188; MATHAI A, 1995, PHYS REV LETT, V74, P4523, DOI 10.1103/PhysRevLett.74.4523; PEARL J, 1964, APPL PHYS LETT, V5, P65, DOI 10.1063/1.1754056; SALKOLA MI, 1998, PHYS REV B, V58, P5952; SHEN ZX, 1993, PHYS REV LETT, V70, P1553, DOI 10.1103/PhysRevLett.70.1553; Sigrist M, 1998, PROG THEOR PHYS, V99, P899, DOI 10.1143/PTP.99.899; SIGRIST M, 1992, J PHYS SOC JPN, V61, P4283, DOI 10.1143/JPSJ.61.4283; SPIELMAN S, 1992, PHYS REV LETT, V68, P3472, DOI 10.1103/PhysRevLett.68.3472; Tsuei CC, 1996, SCIENCE, V271, P329, DOI 10.1126/science.271.5247.329; WOLLMAN DA, 1995, PHYS REV LETT, V74, P797, DOI 10.1103/PhysRevLett.74.797	19	43	43	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					853	855		10.1038/35009062	http://dx.doi.org/10.1038/35009062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786787				2022-12-28	WOS:000086625000039
J	Reysenbach, AL; Banta, AB; Boone, DR; Cary, SC; Luther, GW				Reysenbach, AL; Banta, AB; Boone, DR; Cary, SC; Luther, GW			Biogeochemistry - Microbial essentials at hydrothermal vents	NATURE			English	Article							DIVERSITY		Portland State Univ, Dept Environm Biol, Portland, OR 97201 USA; Univ Delaware, Coll Marine Studies, Lewes, DE 19958 USA	Portland State University; University of Delaware	Reysenbach, AL (corresponding author), Portland State Univ, Dept Environm Biol, Portland, OR 97201 USA.		Luther, George/A-6384-2008	Luther, George/0000-0002-0780-885X; Banta, Amy/0000-0002-1843-5059; Cary, Stephen/0000-0002-2876-2387				ARAGNO M, 1990, PROKARYOTES, P3917; Blochl E, 1997, EXTREMOPHILES, V1, P14; DEVEREUX R, 1990, J BACTERIOL, V172, P3609, DOI 10.1128/jb.172.7.3609-3619.1990; Doolittle RF, 1998, NATURE, V392, P339, DOI 10.1038/32789; Hugenholtz P, 1998, J BACTERIOL, V180, P366, DOI 10.1128/JB.180.2.366-376.1998; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; Reysenbach AL, 1999, BIOL BULL, V196, P367, DOI 10.2307/1542972; REYSENBACH AL, 1994, APPL ENVIRON MICROB, V60, P2133; Strous M, 1999, NATURE, V400, P446, DOI 10.1038/22749; WARD DM, 1992, ADV MICROB ECOL, V12, P219; Yamamoto H, 1998, APPL ENVIRON MICROB, V64, P1680	11	81	85	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					835	835		10.1038/35009029	http://dx.doi.org/10.1038/35009029			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786781				2022-12-28	WOS:000086625000033
J	Sharma, J; Angelucci, A; Sur, M				Sharma, J; Angelucci, A; Sur, M			Induction of visual orientation modules in auditory cortex	NATURE			English	Article							CORRELATED NEURONAL-ACTIVITY; HORIZONTAL CONNECTIONS; RETINAL PROJECTIONS; PREFERENCE MAPS; SIMPLE CELLS; CAT; FERRET; THALAMUS; DEPRIVATION; SELECTIVITY	Modules of neurons sharing a common property are a basic organizational feature of mammalian sensory cortex. Primary visual cortex (V1) is characterized by orientation modules-groups of cells that share a preferred stimulus orientation-which are organized into a highly ordered orientation map. Here we show that in ferrets in which retinal projections are routed into the auditory pathway, visually responsive neurons in 'rewired' primary auditory cortex are also organized into orientation modules. The orientation tuning of neurons within these modules is comparable to the tuning of cells in V1 but the orientation map is less orderly. Horizontal connections in rewired cortex are more patchy and periodic than connections in normal auditory cortex, but less so than connections in V1. These data show that afferent activity has a profound influence on diverse components of cortical circuitry, including thalamocortical and local intracortical connections, which are involved in the generation of orientation tuning, and long-range horizontal connections, which are important in creating an orientation map.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sur, M (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.							ANDERSEN RA, 1980, J COMP NEUROL, V194, P663, DOI 10.1002/cne.901940312; Angelucci A, 1998, J COMP NEUROL, V400, P417, DOI 10.1002/(SICI)1096-9861(19981026)400:3<417::AID-CNE10>3.0.CO;2-O; Angelucci A, 1996, J NEUROSCI METH, V65, P101, DOI 10.1016/0165-0270(95)00155-7; Angelucci A, 1997, J NEUROSCI, V17, P2040; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; Bonhoeffer T., 1996, BRAIN MAPPING METHOD; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; CROWLEY, 1999, NATURE NEUROSCI, V2, P1125; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Gao WJ, 1999, J NEUROSCI, V19, P7940; GILBERT CD, 1989, J NEUROSCI, V9, P2432; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; Goodhill GJ, 1997, TRENDS NEUROSCI, V20, P375; HOPKINS B, 1954, ANN BOT-LONDON, V18, P213, DOI 10.1093/oxfordjournals.aob.a083391; IMIG TJ, 1980, J COMP NEUROL, V192, P293, DOI 10.1002/cne.901920208; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KIM DS, 1994, NATURE, V370, P370, DOI 10.1038/370370a0; KOWALSKI N, 1995, J NEUROPHYSIOL, V73, P1513, DOI 10.1152/jn.1995.73.4.1513; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; MATSUBARA JA, 1988, J COMP NEUROL, V268, P38, DOI 10.1002/cne.902680105; Oppenheim A. V., 1975, DIGITAL SIGNAL PROCE; PALLAS SL, 1993, J COMP NEUROL, V337, P317, DOI 10.1002/cne.903370212; Rao SC, 1997, J COMP NEUROL, V387, P358; ROE AW, 1990, SCIENCE, V250, P818, DOI 10.1126/science.2237432; ROE AW, 1993, J COMP NEUROL, V334, P263, DOI 10.1002/cne.903340208; ROE AW, 1992, J NEUROSCI, V12, P3651; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; Schmidt KE, 1997, J NEUROSCI, V17, P5480; Sengpiel F, 1999, NAT NEUROSCI, V2, P727, DOI 10.1038/11192; Sharma J., 1995, Society for Neuroscience Abstracts, V21, P392; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SOMERS DC, 1995, J NEUROSCI, V15, P5448; Sur M, 1999, J NEUROBIOL, V41, P33, DOI 10.1002/(SICI)1097-4695(199910)41:1<33::AID-NEU6>3.0.CO;2-1; SUR M, 1988, SCIENCE, V242, P1437, DOI 10.1126/science.2462279; TOLHURST DJ, 1981, PROC R SOC SER B-BIO, V213, P183, DOI 10.1098/rspb.1981.0061; von Melchner L, 2000, NATURE, V404, P871, DOI 10.1038/35009102; WALLACE MN, 1991, EXP BRAIN RES, V86, P527; Weliky M, 1997, NATURE, V386, P680, DOI 10.1038/386680a0; WORGOTTER F, 1987, BIOL CYBERN, V57, P349, DOI 10.1007/BF00354980; Yuste R, 1999, J NEUROBIOL, V41, P1, DOI 10.1002/(SICI)1097-4695(199910)41:1<1::AID-NEU1>3.0.CO;2-2	44	239	245	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					841	847		10.1038/35009043	http://dx.doi.org/10.1038/35009043			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786784				2022-12-28	WOS:000086625000036
J	Annane, D; Sanquer, S; Sebille, V; Faye, A; Djuranovic, D; Raphael, JC; Gajdos, P; Bellissant, E				Annane, D; Sanquer, S; Sebille, V; Faye, A; Djuranovic, D; Raphael, JC; Gajdos, P; Bellissant, E			Compartmentalised inducible nitric-oxide synthase activity in septic shock	LANCET			English	Article							MURINE MACROPHAGES; LIPOTEICHOIC ACID; HUMAN NEUTROPHILS; EXPRESSION; ENDOTOXIN; INDUCTION; FAILURE; SEPSIS; PHYSIOLOGY; INHIBITOR	Background Previous experimental studies support a role for inducible nitric-oxide synthase (iNOS) in the pathogenesis of severe sepsis. The aim of the study was to characterise iNOS activity in different tissues in patients with septic shock. Methods 13 consecutive patients with septic shock caused by cellulitis were enrolled. Skin, muscle, fat, and artery samples were obtained from normal, inflamed, and putrescent areas to measure iNOS activity, and concentrations of tumour necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL-1 beta), In two patients, iNOS activity was also assessed in peripheral blood mononuclear cells (PRMC) incubated with microorganisms causing the sepsis, or in macrophages isolated from suppurating peritoneal fluid incubated with IL-1 beta. Findings: Compared with normal and inflamed areas, iNOS activity was increased in putrescent areas for muscle (71-fold [95% CI 20-259] vs normal areas, 69-fold [19-246] vs inflamed areas; p<0.01 for each) and for fat (68-fold [23-199] and 49-fold [18-137], respectively; p<0.01), but not for shin. Compared with normal areas, putrescent areas of arteries showed increased iNOS expression (1280-fold [598-3153]; p<0.01). Compared with normal areas, TNF alpha and IL-1 beta were increased in putrescent areas of arteries (223-fold and 41-fold, respectively; p<0.01 for each). PBMCs and tissue macrophages expressed iNOS. Plasma nitrite/nitrate concentrations inversely correlated with mean arterial pressure and systemic vascular resistance. Interpretation: In human septic shock we found that iNOS activity is compartmentalised at the very site of infection and parallels expression of TNF alpha and IL-1 beta. PBMCs and tissue macrophages can be a cellular source for iNOS.	Assistance Publ Hop Paris, Hop Raymond Poincare, Fac Med Paris Ouest, Serv Reanimat Med, Garches, France; AP HP, Hop Henri Mondor, Fac Med Creteil, Toxicol Lab, Creteil, France; Fac Med St Peres, INSERM 490, Paris, France; Univ Rennes 1, Fac Med, Lab Pharmacol Expt & Clin, Rennes, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Rennes	Annane, D (corresponding author), Assistance Publ Hop Paris, Hop Raymond Poincare, Fac Med Paris Ouest, Serv Reanimat Med, 104 Blvd Raymond Poincare, Garches, France.	djillali.annane@rpc.ap-hop-paris.fr	Annane, Djillali/R-7947-2019; Sebille, Veronique/I-3309-2015	Sebille, Veronique/0000-0002-0780-7742				BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; BRADY AJB, 1992, AM J PHYSIOL, V263, pH1963, DOI 10.1152/ajpheart.1992.263.6.H1963; COBB JP, 1992, J EXP MED, V176, P1175, DOI 10.1084/jem.176.4.1175; CUNHA FQ, 1994, IMMUNOLOGY, V81, P211; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; DEKIMPE SJ, 1995, BRIT J PHARMACOL, V114, P1317; English BK, 1996, J INFECT DIS, V174, P1348, DOI 10.1093/infdis/174.6.1348; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; Kobayashi A, 1998, CHEST, V113, P1632, DOI 10.1378/chest.113.6.1632; LASZLO F, 1995, EUR J PHARMACOL, V283, P47, DOI 10.1016/0014-2999(95)00281-O; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOSHAGE H, 1995, CLIN CHEM, V41, P892; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; Orman KL, 1998, J INFECT DIS, V178, P1649, DOI 10.1086/314526; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; SCHNEIDER F, 1994, AM J PHYSIOL, V266, pH191, DOI 10.1152/ajpheart.1994.266.1.H191; SCHOEDON G, 1995, CLIN INFECT DIS, V21, pS152, DOI 10.1093/clinids/21.Supplement_2.S152; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; Wheeler MA, 1997, J CLIN INVEST, V99, P110, DOI 10.1172/JCI119121; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48	30	125	127	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1143	1148		10.1016/S0140-6736(00)02063-8	http://dx.doi.org/10.1016/S0140-6736(00)02063-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791377				2022-12-28	WOS:000086380900012
J	Peek, GJ; Morcos, S; Cooper, G				Peek, GJ; Morcos, S; Cooper, G			Regular review - The pleural cavity	BRITISH MEDICAL JOURNAL			English	Review							ABRAMS NEEDLE-BIOPSY; PERSISTENT AIR-LEAK; SPONTANEOUS PNEUMOTHORAX; PARAPNEUMONIC EFFUSIONS; PLEURODESIS; MANAGEMENT; EXPERIENCE; THORACOSCOPY; DIAGNOSIS; EFFICACY		No Gen Hosp, Dept Cardiothorac Surg, Sheffield S5 7AN, S Yorkshire, England; No Gen Hosp, Dept Radiol, Sheffield, S Yorkshire, England	Northern General Hospital; Northern General Hospital	Peek, GJ (corresponding author), Univ Leicester, Glenfield Gen Hosp, Div Cardiac Surg, Leicester LE3 9QP, Leics, England.		Peek, Giles/I-1530-2019	peek, giles/0000-0002-1313-6498				ALFAGEME I, 1994, CHEST, V106, P347, DOI 10.1378/chest.106.2.347; *AM COLL SURG, 1993, ADV TRAUMA LIFE SUPP; Athanassiadi K, 1998, WORLD J SURG, V22, P803, DOI 10.1007/s002689900473; BECKER HP, 1991, LANGENBECK ARCH CHIR, V376, P295; BOUTIN C, 1993, CANCER, V72, P389, DOI 10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V; Cagirici U, 1998, SCAND CARDIOVASC J, V32, P75; Cassina PC, 1999, J THORAC CARDIOV SUR, V117, P234, DOI 10.1016/S0022-5223(99)70417-4; Chee CBE, 1998, RESP MED, V92, P757, DOI 10.1016/S0954-6111(98)90008-7; Chin NK, 1997, CHEST, V111, P275, DOI 10.1378/chest.111.2.275; DEKKER A, 1978, AM J CLIN PATHOL, V70, P855; GRAHAM ANJ, 1992, THORAX, V47, P461, DOI 10.1136/thx.47.6.461; HART GJ, 1983, BRIT J DIS CHEST, V77, P164, DOI 10.1016/0007-0971(83)90023-2; Hyde J, 1997, BRIT MED J, V314, P914, DOI 10.1136/bmj.314.7085.914; Jain SK, 1998, J CARDIOVASC SURG, V39, P107; JAY SJ, 1986, POSTGRAD MED, V80, P181, DOI 10.1080/00325481.1986.11699567; JAY SJ, 1986, POSTGRAD MED, V80, P164, DOI 10.1080/00325481.1986.11699566; KIRSCH CM, 1995, CHEST, V108, P982, DOI 10.1378/chest.108.4.982; LARSEN K, 1982, SCAND J THORAC CARD, V16, P197, DOI 10.3109/14017438209101810; Light RW, 1998, CLIN CHEST MED, V19, P373, DOI 10.1016/S0272-5231(05)70084-8; LIGHT RW, 1973, ARCH INTERN MED, V132, P854, DOI 10.1001/archinte.132.6.854; McLean AN, 1998, CHEST, V114, P150, DOI 10.1378/chest.114.1.150; MCLOUD TC, 1991, AM J ROENTGENOL, V156, P1145, DOI 10.2214/ajr.156.6.2028857; MILLER AC, 1993, BRIT MED J, V307, P114, DOI 10.1136/bmj.307.6896.114; MILLER AC, 1993, BRIT MED J, V307, P308; Noppen M, 1997, ACTA CLIN BELG, V52, P258, DOI 10.1080/17843286.1997.11718587; Passlick B, 1998, ANN THORAC SURG, V65, P324, DOI 10.1016/S0003-4975(97)01128-4; PEEK GJ, 1995, INJURY, V26, P425, DOI 10.1016/0020-1383(95)00055-E; PETROU M, 1995, CANCER, V75, P801, DOI 10.1002/1097-0142(19950201)75:3<801::AID-CNCR2820750309>3.0.CO;2-H; RodriguezPanadero F, 1997, EUR RESPIR J, V10, P1648, DOI 10.1183/09031936.97.10071648; SALYER WR, 1975, CHEST, V67, P536, DOI 10.1378/chest.67.5.536; VARKEY B, 1921, POSTRAD MED, V80, P213; WALLACE WA, 1995, BRIT MED J, V311, P374, DOI 10.1136/bmj.311.7001.374; WALLER DA, 1993, ANN ROY COLL SURG, V75, P237; Waller DA, 1999, ANN ROY COLL SURG, V81, P387; WANG NS, 1985, CLIN CHEST MED, V6, P3; 1991, GLENNS THORACIC CARD; 1990, LASTS ANATOMY	37	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1318	1321		10.1136/bmj.320.7245.1318	http://dx.doi.org/10.1136/bmj.320.7245.1318			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807628	Green Published			2022-12-28	WOS:000087077400029
J	Seamark, CJ; Hutchinson, M				Seamark, CJ; Hutchinson, M			Controversy in primary care - Should asymptomatic haemochromatosis be treated? Treatment call be onerous for patient and doctor	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEREDITARY HEMOCHROMATOSIS; GENE; MANAGEMENT; DIAGNOSIS		Honiton Grp Practice, Honiton EX14 2NY, Devon, England		Seamark, CJ (corresponding author), Honiton Grp Practice, Honiton EX14 2NY, Devon, England.	daseamark@msn.com						Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Davis JG, 1998, ANN INTERN MED, V129, P905, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00014; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Gill M, 1998, BMJ-BRIT MED J, V316, P570, DOI 10.1136/bmj.316.7131.570; Goldwurm S, 1997, GUT, V41, P855, DOI 10.1136/gut.41.6.855; Haddow JE, 1999, BRIT MED J, V319, P531, DOI 10.1136/bmj.319.7209.531; McDonnell SM, 1998, ANN INTERN MED, V129, P962, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00007; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; Olynyk JK, 1999, LIVER, V19, P73, DOI 10.1111/j.1478-3231.1999.tb00014.x; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; Robson KJH, 1997, GUT, V41, P841	13	24	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2000	320	7245					1314	1316		10.1136/bmj.320.7245.1314	http://dx.doi.org/10.1136/bmj.320.7245.1314			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807626	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000087077400026
J	Connolly, SJ; Kerr, CR; Gent, M; Roberts, RS; Yusuf, S; Gillis, AM; Sami, MH; Talajic, M; Tang, ASL; Klein, GJ; Lau, C; Newman, DM				Connolly, SJ; Kerr, CR; Gent, M; Roberts, RS; Yusuf, S; Gillis, AM; Sami, MH; Talajic, M; Tang, ASL; Klein, GJ; Lau, C; Newman, DM		Canadian Trial of Physl Pacing Inv	Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICK-SINUS SYNDROME; DUAL-CHAMBER; RANDOMIZED TRIAL; ATRIAL; LIFE	Background: Evidence suggests that physiologic pacing (dual-chamber or atrial) may be superior to single-chamber (ventricular) pacing because it is associated with lower risks of atrial fibrillation, stroke, and death. These benefits have not been evaluated in a large, randomized, controlled trial. Methods: At 32 Canadian centers, patients without chronic atrial fibrillation who were scheduled for a first implantation of a pacemaker to treat symptomatic bradycardia were eligible for enrollment. We randomly assigned patients to receive either a ventricular pacemaker or a physiologic pacemaker and followed them for an average of three years. The primary outcome was stroke or death due to cardiovascular causes. Secondary outcomes were death from any cause, atrial fibrillation, and hospitalization for heart failure. Results: A total of 1474 patients were randomly assigned to receive a ventricular pacemaker and 1094 to receive a physiologic pacemaker. The annual rate of stroke or death due to cardiovascular causes was 5.5 percent with ventricular pacing, as compared with 4.9 percent with physiologic pacing (reduction in relative risk, 9.4 percent; 95 percent confidence interval, -10.5 to 25.7 percent [the negative value indicates an increase in risk]; P = 0.33). The annual rate of atrial fibrillation was significantly lower among the patients in the physiologic-pacing group (5.3 percent) than among those in the ventricular-pacing group (6.6 percent), for a reduction in relative risk of 18.0 percent (95 percent confidence interval, 0.3 to 32.6 percent; P = 0.05). The effect on the rate of atrial fibrillation was not apparent until two years after implantation. The observed annual rates of death from all causes and of hospitalization for heart failure were lower among the patients with a physiologic pacemaker than among those with a ventricular pacemaker, but not significantly so (annual rates of death, 6.6 percent with ventricular pacing and 6.3 percent with physiologic pacing; annual rates of hospitalization for heart failure, 3.5 percent and 3.1 percent, respectively). There were significantly more perioperative complications with physiologic pacing than with ventricular pacing (9.0 percent vs. 3.8 percent, P < 0.001). Conclusions: Physiologic pacing provides little benefit over ventricular pacing for the prevention of stroke or death due to cardiovascular causes. (N Engl J Med 2000;342:1385-91.) (C)2000, Massachusetts Medical Society.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Inst Cardiol Montreal, Montreal, PQ, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	McMaster University; McMaster University; University of British Columbia; University of Calgary; McGill University; Universite de Montreal; Institut de Cardiologie de Montreal; University of Ottawa; Western University (University of Western Ontario); University of Toronto	Connolly, SJ (corresponding author), Hamilton Hlth Sci, Gen Site,McMaster Clin Rm 501,237 Barton St E, Hamilton, ON L8L 2X2, Canada.	connostu@hhsc.ca	Tang, Anthony S/E-6203-2014; Klein, George/G-3313-2011	Talajic, Mario/0000-0001-8469-4748; Yusuf, Salim/0000-0003-4776-5601				ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; Connolly SJ, 1996, CIRCULATION, V94, P578, DOI 10.1161/01.CIR.94.3.578; COX DR, 1972, J R STAT SOC B, V34, P187; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRISTENSSON BE, 1985, PACE, V8, P73, DOI 10.1111/j.1540-8159.1985.tb05726.x; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; LINDEEDELSTAM C, 1992, PACE, V15, P905, DOI 10.1111/j.1540-8159.1992.tb03081.x; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MENOZZI C, 1990, PACE, V13, P1816, DOI 10.1111/j.1540-8159.1990.tb06896.x; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; Wharton JM, 1998, CIRCULATION, V98, P494	14	504	531	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1385	1391		10.1056/NEJM200005113421902	http://dx.doi.org/10.1056/NEJM200005113421902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312JR	10805823	Bronze			2022-12-28	WOS:000086940600002
J	Coltice, N; Albarede, F; Gillet, P				Coltice, N; Albarede, F; Gillet, P			K-40-Ar-40 constraints on recycling continental crust into the mantle	SCIENCE			English	Article							SILICATE MELTS; OCEANIC-CRUST; DEEP MANTLE; MEAN-LIFE; EARTH; SEDIMENT; GROWTH; LEAD; ND; SUBDUCTION	Extraction of potassium into magmas and outgassing of argon during melting constrain the relative amounts of potassium in the crust with respect to those of argon in the atmosphere. No more than 30% of the modern mass of the continents was subducted back into the mantle during Earth's history. It is estimated that 50 to 70% of the subducted sediments are reincorporated into the deep continental crust. A consequence of the limited exchange between the continental crust and the upper mantle is that the chemistry of the upper mantle is driven by exchange of material with the deep mantle.	Ecole Normale Super Lyon, Lab Sci Terre, F-69364 Lyon 7, France	Ecole Normale Superieure de Lyon (ENS de LYON)	Coltice, N (corresponding author), Ecole Normale Super Lyon, Lab Sci Terre, F-69364 Lyon 7, France.		Albarede, Francis/A-8871-2011	Albarede, Francis/0000-0003-1994-1428; Coltice, Nicolas/0000-0001-5444-414X				ALBAREDE F, 1989, TECTONOPHYSICS, V161, P299, DOI 10.1016/0040-1951(89)90160-1; Allegre C.J., 1986, EARTH PLANET SC LETT, V81, P127; Allegre CJ, 1996, GEOPHYS RES LETT, V23, P3555, DOI 10.1029/96GL03373; BAPTISTE PJ, 1991, EARTH PLANET SC LETT, V106, P17; Brooker RA, 1998, CHEM GEOL, V147, P185, DOI 10.1016/S0009-2541(97)00181-2; Burnard P, 1997, SCIENCE, V276, P568, DOI 10.1126/science.276.5312.568; Chamorro-Perez E, 1998, NATURE, V393, P352, DOI 10.1038/30706; CHRISTENSEN UR, 1994, J GEOPHYS RES-SOL EA, V99, P19867, DOI 10.1029/93JB03403; Coltice N, 1999, EARTH PLANET SC LETT, V174, P125, DOI 10.1016/S0012-821X(99)00258-7; CRAIG H, 1975, EARTH PLANET SC LETT, V26, P125, DOI 10.1016/0012-821X(75)90079-5; DEPAOLO DJ, 1983, GEOPHYS RES LETT, V10, P705, DOI 10.1029/GL010i008p00705; Elliott T, 1999, EARTH PLANET SC LETT, V169, P129, DOI 10.1016/S0012-821X(99)00077-1; GALER SJG, 1985, NATURE, V316, P778, DOI 10.1038/316778a0; HIYAGON H, 1986, GEOCHIM COSMOCHIM AC, V50, P2945; HOFMANN AW, 1988, EARTH PLANET SC LETT, V90, P297, DOI 10.1016/0012-821X(88)90132-X; JAMBON A, 1994, REV MINERAL, V30, P379; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; Mooney WD, 1998, J GEOPHYS RES-SOL EA, V103, P727, DOI 10.1029/97JB02122; Nataf HC, 1996, PHYS EARTH PLANET IN, V95, P101, DOI 10.1016/0031-9201(95)03105-7; OXBURGH ER, 1986, NATURE, V324, P632, DOI 10.1038/324632a0; PATCHETT J, 1984, GEOPHYS RES LETT, V11, P151, DOI 10.1029/GL011i002p00151; Plank T, 1998, CHEM GEOL, V145, P325, DOI 10.1016/S0009-2541(97)00150-2; Rea DK, 1996, EARTH PLANET SC LETT, V140, P1, DOI 10.1016/0012-821X(96)00036-2; REYMER A, 1984, TECTONICS, V3, P63, DOI 10.1029/TC003i001p00063; RUDNICK RL, 1995, REV GEOPHYS, V33, P267, DOI 10.1029/95RG01302; Sarda P, 1999, SCIENCE, V283, P666, DOI 10.1126/science.283.5402.666; SCHUBERT G, 1989, EARTH PLANET SC LETT, V92, P234, DOI 10.1016/0012-821X(89)90049-6; SCHWARTZ.DW, 1973, GEOCHIM COSMOCHIM AC, V37, P2479, DOI 10.1016/0016-7037(73)90293-7; SCLATER JG, 1980, REV GEOPHYS, V18, P269, DOI 10.1029/RG018i001p00269; Shaw D. M., 1986, NATURE LOWER CONTINE, V24, P257; Taylor S.R., 1985, CONTINENTAL CRUST IT; TUREKIAN KK, 1959, GEOCHIM COSMOCHIM AC, V17, P37, DOI 10.1016/0016-7037(59)90077-8; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; VONHUENE R, 1991, REV GEOPHYS, V29, P279, DOI 10.1029/91RG00969; WEAVER BL, 1984, NATURE, V310, P575, DOI 10.1038/310575a0; Wedepohl K. H., 1994, MINERAL MAG, V58, P959, DOI [10.1180/minmag.1994.58A.2.234, DOI 10.1180/MINMAG.1994.58A.2.234]	37	39	41	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					845	847		10.1126/science.288.5467.845	http://dx.doi.org/10.1126/science.288.5467.845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797003				2022-12-28	WOS:000086869600033
J	Casarett, D; Karlawish, JHT; Sugarman, J				Casarett, D; Karlawish, JHT; Sugarman, J			Determining when quality improvement initiatives should be considered research - Proposed criteria and potential implications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-SERVICES RESEARCH; NUCHAL-TRANSLUCENCY; SATISFACTION; DELIVERY; CONDUCT; PROJECT; CARE	Quality improvement initiatives have become a major force in shaping health care, These initiatives are diverse but share a common goal of generating knowledge that will guide improvements in health care, Although quality improvement occupies an uncertain territory between clinical care and research, this difference is extremely important, If a quality improvement initiative is research, federal regulations require a variety of procedures that must be followed to protect the human subjects involved. Conversely, if the same initiative is not research, the regulations outlining these procedures are not applicable. This article proposes 2 criteria to determine whether a quality improvement initiative should be reviewed as research, Such an initiative should be reviewed and regulated as research if (1) the majority of patients involved are not expected to benefit directly from the knowledge to be gained or (2) if additional risks or burdens are imposed to make the results generalizable. Implementation of these criteria offers the possibility that the rights and interests of those who participate in quality improvement initiatives will be protected.	Univ Penn, Ctr Bioeth, Inst Aging, Philadelphia, PA 19104 USA; Univ Penn, Div Geriatr, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; Alzheimers Dis Ctr, Philadelphia, PA USA; Duke Univ, Dept Med, Durham, NC USA; Duke Univ, Dept Philosophy, Durham, NC USA; Duke Univ, Ctr Study Med Eth & Humanities, Durham, NC USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Duke University; Duke University; Duke University	Casarett, D (corresponding author), Univ Penn, Ctr Bioeth, Inst Aging, 3615 Chestnut St, Philadelphia, PA 19104 USA.			Sugarman, Jeremy/0000-0001-7022-8332				[Anonymous], 1986, HIST THEORY INFORM C; Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; BRETT A, 1991, JAMA-J AM MED ASSOC, V265, P1854, DOI 10.1001/jama.265.14.1854; Caputo RP, 1997, AM J CARDIOL, V79, P1159, DOI 10.1016/S0002-9149(97)00074-X; Choo V, 1998, LANCET, V352, P337, DOI 10.1016/S0140-6736(05)60461-8; Davidson F, 1997, JAMA-J AM MED ASSOC, V277, P927; FREEDMAN B, 1992, CLIN RES, V40, P653; Garvican L, 1998, BRIT MED J, V316, P976, DOI 10.1136/bmj.316.7136.976; GOLDBERG HI, 1990, MED CARE, V28, P822, DOI 10.1097/00005650-199009000-00011; Langley Gj., 1996, IMPROVEMENT GUIDE PR; LYNN J, 1994, CLIN RES, V42, P3; MOORE FD, 1969, EXPT HUMAN SUBJECTS; Nelson EC, 1998, ANN INTERN MED, V128, P460, DOI 10.7326/0003-4819-128-6-199803150-00007; Parmet JL, 1998, ANESTH ANALG, V87, P661, DOI 10.1097/00000539-199809000-00032; Schmittdiel J, 1997, JAMA-J AM MED ASSOC, V278, P1596, DOI 10.1001/jama.278.19.1596; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Truog RD, 1999, NEW ENGL J MED, V340, P804, DOI 10.1056/NEJM199903113401013; Venn-Treloar J, 1998, BRIT MED J, V316, P1027	18	149	149	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2275	2280		10.1001/jama.283.17.2275	http://dx.doi.org/10.1001/jama.283.17.2275			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807388				2022-12-28	WOS:000086671600036
J	Bull, C; Yates, R; Sarkar, D; Deanfield, J; de Leval, M				Bull, C; Yates, R; Sarkar, D; Deanfield, J; de Leval, M			Scientific, ethical, and logistical considerations in introducing a new operation: a retrospective cohort study from paediatric cardiac surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ARTERIAL SWITCH OPERATION; INTACT VENTRICULAR SEPTUM; GREAT-ARTERIES; SIMPLE TRANSPOSITION; ANATOMIC CORRECTION	Objective To review the initial impact on mortality of infants with congenital heart disease of a new surgical technique that is now taken for granted. Design Retrospective cohort study. Setting A tertiary paediatric cardiology centre. Subjects 325 consecutive neonates with simple transposition of the great arteries admitted before, during, and after the preferred management changed from the Senning operation to the arterial switch (1978-98); and 100 consecutive neonates requiring a different neonatal open heart operation that did not change in that period. Main outcome measures Mortality before and early after operation reconstructed sequentially as the series evolved and retrospectively once the series was complete; actuarial survival associated with the different treatment strategies. Results For both the transposition and the comparison group, early mortality in 1998 was lower than in 1978. During that period, however, there was a phase temporally related to the adoption of the switch operation in which early mortality for transposition increased. Actuarial survival of recent patients with "intention to treat" with arterial switch is superior to those with intention to treat with the Senning operation, as predicted when the switch operation was first adopted. Conclusions A period of increased hazard for individual patients may occur when a specialist community, a particular unit, and an individual surgeon are all learning a new technique concurrently. Obtaining informed consent during this time of uncertainty is helped by clarity about the objectives of treatment and availability of relet ant local and international data.	Great Ormond St Hosp Sick Children, Cardiothorac Unit, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Bull, C (corresponding author), Great Ormond St Hosp Sick Children, Cardiothorac Unit, Great Ormond St, London WC1N 3JH, England.	C.Bull@gosh-tr.nthames.nhs.uk		Deanfield, John/0000-0001-8806-6052				Bonnet D, 1996, HEART, V76, P274, DOI 10.1136/hrt.76.3.274; CASTANEDA AR, 1984, ANN THORAC SURG, V38, P438, DOI 10.1016/S0003-4975(10)64181-1; CASTANEDA AR, 1988, J THORAC CARDIOV SUR, V95, P14; DEANFIELD J, 1988, J THORAC CARDIOV SUR, V96, P569; DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; Hasan A, 2000, BRIT MED J, V320, P171, DOI 10.1136/bmj.320.7228.171; Jatene A D, 1975, Arq Bras Cardiol, V28, P461; JATENE AD, 1981, PAEDIAT CARDIOLOGY, V3, P218; KANTER KR, 1985, J THORAC CARDIOV SUR, V90, P690; KIRKLIN JW, 1992, CIRCULATION, V86, P1501, DOI 10.1161/01.CIR.86.5.1501; Lilford RJ, 2000, BRIT MED J, V320, P43, DOI 10.1136/bmj.320.7226.43; MACARTNEY FJ, 1987, PAEDIAT CARDIOLOGY, P421; QUAEGEBEUR JM, 1986, J THORAC CARDIOV SUR, V92, P361; Sarkar D, 1999, CIRCULATION, V100, P176; SIDI D, 1987, CIRCULATION, V75, P429, DOI 10.1161/01.CIR.75.2.429; WARD CJB, 1995, CIRCULATION, V91, P2948, DOI 10.1161/01.CIR.91.12.2948; WERNOVSKY G, 1988, CIRCULATION, V77, P1333, DOI 10.1161/01.CIR.77.6.1333; YACOUB M, 1980, CIRCULATION, V62, P190	18	50	50	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	2000	320	7243					1168	1173		10.1136/bmj.320.7243.1168	http://dx.doi.org/10.1136/bmj.320.7243.1168			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784538	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086832800014
J	Creutzberg, CL; van Putten, WLJ; Koper, PCM; Lybeert, MLM; Jobsen, JJ; Warlam-Rodenhuis, CC; De Winter, KAJ; Lutgens, LCHW; van den Bergh, ACM; van de Steen-Banasik, E; Beerman, H; van Lent, M				Creutzberg, CL; van Putten, WLJ; Koper, PCM; Lybeert, MLM; Jobsen, JJ; Warlam-Rodenhuis, CC; De Winter, KAJ; Lutgens, LCHW; van den Bergh, ACM; van de Steen-Banasik, E; Beerman, H; van Lent, M		PORTEC Study Grp	Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial	LANCET			English	Article							GYNECOLOGIC-ONCOLOGY-GROUP; PROGNOSTIC FACTORS; CLINICAL STAGE; ADJUVANT RADIOTHERAPY; EXTERNAL IRRADIATION; VAGINAL IRRADIATION; TREATMENT FAILURE; RISK-FACTORS; CANCER; ADENOCARCINOMA	Background Postoperative radiotherapy for international Federation of Gynaecology and Obstetrics (FIGO) stage-1 endometrial carcinoma is a subject of controversy due to the low relapse rate and the lack of data from randomised trials. We did a multicentre prospective randomised trial to find whether postoperative pelvic radiotherapy improves locoregional control and survival for patients with stage-1 endometrial carcinoma. Methods Patients with stage-1 endometrial carcinoma (grade 1 with deep [greater than or equal to 50%] myometrial invasion, grade 2 with any invasion, or grade 3 with superficial [<50%] invasion) were enrolled, After total abdominal hysterectomy and bilateral salpingo-oophorectomy, without lymphadenectomy, 715 patients from 19 radiation oncology centres were randomised to pelvic radiotherapy (46 Gy) or no further treatment. The primary study endpoints were locoregional recurrence and death, with treatment-related morbidity and survival after relapse as secondary endpoints. Findings Analysis was done according to the intention-to-treat principle. Of the 715 patients, 714 could be evaluated. The median duration of follow-up was 52 months. 5-year actuarial locoregional recurrence rates were 4% in the radiotherapy group and 14% in the control group (p<0.001). Actuarial 5-year overall survival rates were similar in the two groups: 81% (radiotherapy) and 85% (controls), p=0.31. Endometrial-cancer-related death rates were 9% in the radiotherapy group and 6% in the control group (p=0.37). Treatment-related complications occurred in 25% of radiotherapy patients, and in 6% of the controls (p<0.0001). Two-thirds of the complications were grade 1. Grade 3-4 complications were seen in eight patients, of which seven were in the radiotherapy group (2%). 2-year survival after vaginal recurrence was 79%, in contrast to 21% after pelvic recurrence or distant metastases. Survival after relapse was significantly (p=0.02) better for patients in the control group. Multivariate analysis showed that for locoregional recurrence, radiotherapy and age below 60 years were significant favourable prognostic factors. Interpretation Postoperative radiotherapy in stage-1 endometrial carcinoma reduces locoregional recurrence but has no impact on overall survival, Radiotherapy increases treatment-related morbidity. Postoperative radiotherapy is not indicated in patients with stage-1 endometrial carcinoma below 60 years and patients with grade-2 tumours with superficial invasion.	Univ Rotterdam Hosp, Dr Daniel den Hoed Canc Ctr, Dept Radiat Oncol, NL-3075 EA Rotterdam, Netherlands; Univ Rotterdam Hosp, Dr Daniel den Hoed Canc Ctr, Dept Biostat, NL-3075 EA Rotterdam, Netherlands; Univ Rotterdam Hosp, Dr Daniel den Hoed Canc Ctr, Dept Gynaecol Oncol, NL-3075 EA Rotterdam, Netherlands; Univ Rotterdam Hosp, Dr Daniel den Hoed Canc Ctr, Dept Pathol, NL-3075 EA Rotterdam, Netherlands; Catharina Hosp, Dept Radiat Oncol, Eindhoven, Netherlands; Med Spectrum Twente, Dept Radiat Oncol, Enschede, Netherlands; Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands; Dr Bernard Verbeeten Inst, Tilburg, Netherlands; Radiotherapy Inst Limburg, Heerlen, Netherlands; Univ Groningen Hosp, Dept Radiat Oncol, Groningen, Netherlands; Radiotherapy Inst Arnhem, Arnhem, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Catharina Hospital; Medical Spectrum Twente; Utrecht University; Utrecht University Medical Center; Instituut Verbeeten; University of Groningen	Creutzberg, CL (corresponding author), Univ Rotterdam Hosp, Dr Daniel den Hoed Canc Ctr, Dept Radiat Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands.		Creutzberg, Carien L/E-2253-2018	Creutzberg, Carien L/0000-0002-7008-4321; Beerman, Henk/0000-0002-3661-4608				AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Ackerman I, 1996, GYNECOL ONCOL, V60, P177, DOI 10.1006/gyno.1996.0022; BOND WH, 1985, CLIN RADIOL, V36, P619, DOI 10.1016/S0009-9260(85)80247-6; BRADY LW, 1986, INT J RADIAT ONCOL, V12, P549, DOI 10.1016/0360-3016(86)90062-3; BURKE TW, 1990, OBSTET GYNECOL, V75, P96; CAREY MS, 1995, GYNECOL ONCOL, V57, P138, DOI 10.1006/gyno.1995.1115; CHASSAGNE D, 1993, RADIOTHER ONCOL, V26, P183; CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8; CURRAN WJ, 1988, INT J RADIAT ONCOL, V15, P803, DOI 10.1016/0360-3016(88)90110-1; DISAIA PJ, 1985, AM J OBSTET GYNECOL, V151, P1009, DOI 10.1016/0002-9378(85)90371-0; Fanning J, 1996, OBSTET GYNECOL, V87, P1041, DOI 10.1016/0029-7844(96)00055-5; GREVEN KM, 1991, INT J RADIAT ONCOL, V21, P919, DOI 10.1016/0360-3016(91)90730-R; Greven KM, 1997, CURR PROB CANCER, V21, P71, DOI 10.1016/S0147-0272(97)80002-5; GRIGSBY PW, 1992, INT J RADIAT ONCOL, V22, P905, DOI 10.1016/0360-3016(92)90786-H; HOEKSTRA CJM, 1993, RADIOTHER ONCOL, V27, P164, DOI 10.1016/0167-8140(93)90137-W; Irwin C, 1998, GYNECOL ONCOL, V70, P247, DOI 10.1006/gyno.1998.5064; KUCERA H, 1990, GYNECOL ONCOL, V38, P99, DOI 10.1016/0090-8258(90)90018-G; LEWANDOWSKI G, 1990, GYNECOL ONCOL, V36, P401, DOI 10.1016/0090-8258(90)90151-A; Lybeert MLM, 1998, EUR J CANCER, V34, P586, DOI 10.1016/S0959-8049(97)10087-9; MANDELL LR, 1985, INT J RADIAT ONCOL, V11, P1103, DOI 10.1016/0360-3016(85)90056-2; MEERWALDT JH, 1990, INT J RADIAT ONCOL, V18, P299, DOI 10.1016/0360-3016(90)90093-Y; Mohan DS, 1998, GYNECOL ONCOL, V70, P165, DOI 10.1006/gyno.1998.5098; MORROW CP, 1991, GYNECOL ONCOL, V40, P55, DOI 10.1016/0090-8258(91)90086-K; NORI D, 1987, INT J RADIAT ONCOL, V13, P489, DOI 10.1016/0360-3016(87)90062-9; Orr JW, 1998, GYNECOL ONCOL, V71, P335, DOI 10.1006/gyno.1998.5296; PODCZASKI E, 1992, GYNECOL ONCOL, V47, P323, DOI 10.1016/0090-8258(92)90134-5; POTISH RA, 1990, INT J RADIAT ONCOL, V18, P1005, DOI 10.1016/0360-3016(90)90434-L; Poulsen HK, 1996, INT J GYNECOL CANCER, V6, P38, DOI 10.1046/j.1525-1438.1996.06010038.x; POULSEN MG, 1987, INT J RADIAT ONCOL, V13, P1043, DOI 10.1016/0360-3016(87)90043-5; POULSEN MG, 1988, INT J RADIAT ONCOL, V15, P809, DOI 10.1016/0360-3016(88)90111-3; Quinn MA, 1996, INT J GYNECOL CANCER, V6, P102; REDDY S, 1985, INT J RADIAT ONCOL, V11, P127; Rose PG, 1996, NEW ENGL J MED, V335, P640, DOI 10.1056/NEJM199608293350907; SALAZAR OM, 1977, INT J RADIAT ONCOL, V2, P1101, DOI 10.1016/0360-3016(77)90116-X; SEARS JD, 1994, CANCER, V74, P1303, DOI 10.1002/1097-0142(19940815)74:4<1303::AID-CNCR2820740420>3.0.CO;2-G; SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x; SILVERBERG SG, 1992, TUMORS UTERINE CORPU, P54; Taylor RR, 1999, GYNECOL ONCOL, V74, P3, DOI 10.1006/gyno.1999.5422; Trimble EL, 1998, GYNECOL ONCOL, V71, P340, DOI 10.1006/gyno.1998.5254; VISSER O, 1998, INCIDENCE CANC NETHE, P43; Zaino RJ, 1996, CANCER-AM CANCER SOC, V77, P1115, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1115::AID-CNCR17>3.0.CO;2-4; 1995, OVERLEDENEN NAAR DOO	42	1323	1357	2	36	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1404	1411		10.1016/S0140-6736(00)02139-5	http://dx.doi.org/10.1016/S0140-6736(00)02139-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791524				2022-12-28	WOS:000086829800011
J	Zeidler, M; Sellar, RJ; Collie, DA; Knight, R; Stewart, G; Macleod, MA; Ironside, JW; Cousens, S; Colchester, AFC; Hadley, DM; Will, RG				Zeidler, M; Sellar, RJ; Collie, DA; Knight, R; Stewart, G; Macleod, MA; Ironside, JW; Cousens, S; Colchester, AFC; Hadley, DM; Will, RG			The pulvinar sign on magnetic resonance imaging in variant Creutzfetdt-Jakob disease	LANCET			English	Article							TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; FATAL FAMILIAL INSOMNIA; CEREBROSPINAL-FLUID; MRI; FEATURES; PROTEIN; BRAIN	Background There is a need for an accurate non-invasive diagnostic test for variant Creutzfeldt-Jakob disease (vCJD), We investigated the sensitivity and specificity of bilateral pulvinar high signal on magnetic resonance imaging (MRI) for the diagnosis of vCJD. Methods MRI from patients with vCJD and controls (patients with suspected CJD) were analysed. Scans were reviewed on two separate occasions by two neuroradiologists and scored for the distribution of changes, and likely final diagnosis. Scans from vCJD cases were reassessed to reach a consensus on all abnormalities. Findings We analysed 36 patients and 57 controls. vCJD patients were correctly identified based on bilateral pulvinar high signal in 29 of 36 and 32 of 36 cases on the first assessment by the two radiologists, and 32 of 36 and 31 of 36 on their second assessment. Bilateral increased pulvinar signal was identified in one of 57 and one of 57 controls on the first assessment and two of 57 and three of 57 controls on the second assessment. These reported changes in controls were graded as minimal/equivocal in six of seven patients and moderate in one (<0.5% of all control assessments). 80% of the assessments in vCJD cases were graded as moderate or substantial. On consensus review, 28 of 36 cases and none of 57 controls had prominent bilateral pulvinar signal-sensitivity 78% (95% CI 60-90%) and specificity 100% (95% CI 94-100%), Other common MRI features of vCJD were medial thalamic and periaqueductal grey matter high signal, and the notable absence of cerebral atrophy. Pulvinar high signal correlated with histological gliosis. Interpretation In the appropriate clinical context the MRI identification of bilaterally increased pulvinar signal is a useful non-invasive test for the diagnosis of vCJD.	Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EX4 2XU, Midlothian, Scotland; Western Gen Hosp, Dept Neuroradiol, Edinburgh EX4 2XU, Midlothian, Scotland; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; So Gen Hosp, Inst Neurol Sci, Dept Neuroradiol, Glasgow G51 4TF, Lanark, Scotland; Univ Kent, Elect Engn Lab, Kent Inst Med & Hlth Sci, Canterbury, Kent, England	University of Edinburgh; University of Edinburgh; University of London; London School of Hygiene & Tropical Medicine; University of Glasgow; University of Kent	Zeidler, M (corresponding author), Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Crewe Rd, Edinburgh EX4 2XU, Midlothian, Scotland.			Ironside, James/0000-0001-5869-2108				Canciani B, 1999, J NEUROPATH EXP NEUR, V58, P560, DOI 10.1097/00005072-199905000-00214; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Coulthard A, 1999, BRIT J RADIOL, V72, P742, DOI 10.1259/bjr.72.860.10624339; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; CUSMAI R, 1994, NEUROPEDIATRICS, V25, P44, DOI 10.1055/s-2008-1071582; de Silva R, 1998, BRIT MED J, V316, P593, DOI 10.1136/bmj.316.7131.593; deVillemeur TB, 1996, TRANSMISSIBLE SUBACUTE SPONGIFORM ENCEPHALOPATHIES: PRION DISEASES, P451; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; GOODBRAND IA, 1995, NEUROSCI LETT, V183, P127, DOI 10.1016/0304-3940(94)11131-2; HAHN JS, 1994, PEDIATR NEUROL, V10, P255, DOI 10.1016/0887-8994(94)90035-3; HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; Ironside JW, 1996, COLD SPRING HARB SYM, V61, P523; Johnson RT, 1998, NEW ENGL J MED, V339, P1994, DOI 10.1056/NEJM199812313392707; Salonen O, 1997, NEURORADIOLOGY, V39, P537, DOI 10.1007/s002340050463; Santos JMG, 1996, NEURORADIOLOGY, V38, P226, DOI 10.1007/s002340050235; SELLAR RJ, 1997, NEURORADIOLOGY, V39, pS53; Seno H, 1992, No To Shinkei, V44, P177; Steinhoff BJ, 1996, ARCH NEUROL-CHICAGO, V53, P162, DOI 10.1001/archneur.1996.00550020074017; Tabrizi SJ, 1996, LANCET, V347, P945, DOI 10.1016/S0140-6736(96)91419-1; Urbach H, 1998, NEURORADIOLOGY, V40, P65, DOI 10.1007/s002340050542; WILL RG, 1999, PSYCHIAT B, V23, P264; World Health Organization, 1998, REP WHO CONS GLOB SU; Yoshimura N, 1992, Rinsho Shinkeigaku, V32, P327; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6; Zeidler M, 1996, BRIT MED J, V312, P844; Zerr I, 1998, ANN NEUROL, V43, P32, DOI 10.1002/ana.410430109; Zerr I, 1998, NEUROLOGY, V51, P1398, DOI 10.1212/WNL.51.5.1398	29	231	235	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1412	1418		10.1016/S0140-6736(00)02140-1	http://dx.doi.org/10.1016/S0140-6736(00)02140-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791525				2022-12-28	WOS:000086829800012
J	Martin, MW; Grazhdankin, DV; Bowring, SA; Evans, DAD; Fedonkin, MA; Kirschvink, JL				Martin, MW; Grazhdankin, DV; Bowring, SA; Evans, DAD; Fedonkin, MA; Kirschvink, JL			Age of Neoproterozoic bilatarian body and trace fossils, White Sea, Russia: Implications for metazoan evolution	SCIENCE			English	Article							EARLY ANIMAL EVOLUTION; NORTHWESTERN CANADA; CHEMOSTRATIGRAPHY; BIOSTRATIGRAPHY; STRATIGRAPHY; STRATA; EARTH	A uranium-lead zircon age for a volcanic ash interstratified with fossil-bearing, shallow marine siliciclastic rocks in the Zimnie Gory section of the White Sea region indicates that a diverse assemblage of body and trace fossils occurred before 555.3 +/- 0.3 million years ago. This age is a minimum for the oldest well-documented triploblastic bilaterian Kimberella. It also makes co-occurring trace fossils the oldest that are reliably dated. This determination of age implies that there is no simple relation between Ediacaran diversity and the carbon isotopic composition of Neoproterozoic seawater.	MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Inst Paleontol, Moscow 117868, Russia; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	Massachusetts Institute of Technology (MIT); California Institute of Technology	Martin, MW (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.	mwm@mit.edu	Grazhdankin, Dima/J-4378-2019; Grazhdankin, Dmitriy/A-4060-2008	Grazhdankin, Dima/0000-0003-0797-1347; Grazhdankin, Dmitriy/0000-0003-0797-1347; Evans, David/0000-0001-8952-5273				Bartley JK, 1998, GEOL MAG, V135, P473, DOI 10.1017/S0016756898008772; Benus AP., 1988, GEOLOGICAL SURVEY B, P8; COMPSTON W, 1995, J GEOL SOC LONDON, V152, P599, DOI 10.1144/gsjgs.152.4.0599; Crimes TP, 1999, GEOL MAG, V136, P633, DOI 10.1017/S0016756899003179; Dalziel IWD, 1997, GEOL SOC AM BULL, V109, P16, DOI 10.1130/0016-7606(1997)109<0016:ONPGAT>2.3.CO;2; Erwin DH, 1999, AM ZOOL, V39, P617; Fedonkin M.A., 1981, BELOMORSKAYA BIOTA V; Fedonkin MA, 1997, NATURE, V388, P868, DOI 10.1038/42242; GEHLING JG, 1996, THESIS U CALIF, P222; GRAZHDANKIN D, UNPUB; GROTZINGER JP, 1995, SCIENCE, V270, P598, DOI 10.1126/science.270.5236.598; HAGADORN JW, 2000, J PALEONTOL, V74, P554; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; HOFFMAN PF, 1991, SCIENCE, V252, P1409, DOI 10.1126/science.252.5011.1409; HOFMANN HJ, 1990, GEOLOGY, V18, P1199, DOI 10.1130/0091-7613(1990)018<1199:ERFIBI>2.3.CO;2; JENKINS RJF, 1995, PRECAMBRIAN RES, V73, P51, DOI 10.1016/0301-9268(94)00071-X; Jensen S, 1998, NATURE, V393, P567, DOI 10.1038/31215; KAUFMAN AJ, 1995, PRECAMBRIAN RES, V73, P27, DOI 10.1016/0301-9268(94)00070-8; Kirschvink J. L., 1992, PROTEROZOIC BIOSPHER, P51; KNOLL AH, 1992, NATURE, V356, P673, DOI 10.1038/356673a0; KNOLL AH, 1999, SCIENCE, V284, P2129, DOI DOI 10.1126/SCIENCE.284.5423.2129; Macnaughton RB, 1999, PALAIOS, V14, P97, DOI 10.2307/3515367; NARBONNE GM, 1994, GEOL SOC AM BULL, V106, P1281, DOI 10.1130/0016-7606(1994)106<1281:ICABOT>2.3.CO;2; NARBONNE GM, 1987, CAN J EARTH SCI, V24, P1277, DOI 10.1139/e87-124; Nedin C, 1998, ALCHERINGA, V22, P315, DOI 10.1080/03115519808619329; Pelechaty SM, 1996, GEOL SOC AM BULL, V108, P992, DOI 10.1130/0016-7606(1996)108<0992:EOCCFI>2.3.CO;2; Pell S. D., 1993, Transactions Royal Society of South Australia, V117, P153; Runnegar B.N., 1992, P999; Saylor BZ, 1998, J SEDIMENT RES, V68, P1223, DOI 10.2110/jsr.68.1223; Seilacher A, 1999, PALAIOS, V14, P86, DOI 10.2307/3515363; Sprigg R. C., 1947, Transactions of the Royal Society of South Australia, V71, P212; Waggoner B, 1999, PALEOBIOLOGY, V25, P440, DOI 10.1017/S0094837300020315; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318	33	292	317	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	2000	288	5467					841	845		10.1126/science.288.5467.841	http://dx.doi.org/10.1126/science.288.5467.841			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797002				2022-12-28	WOS:000086869600032
J	Tzfati, Y; Fulton, TB; Roy, J; Blackburn, EH				Tzfati, Y; Fulton, TB; Roy, J; Blackburn, EH			Template boundary in a yeast telomerase specified by RNA structure	SCIENCE			English	Article							NORMAL HUMAN-CELLS; REVERSE-TRANSCRIPTASE; SECONDARY STRUCTURE; LIFE-SPAN; IN-VITRO; IDENTIFICATION; ELONGATION; RECONSTITUTION; MUTATIONS; DOMAIN	The telomerase ribonucleoprotein has a phylogenetically divergent RNA subunit, which contains a short template for telomeric DNA synthesis. To understand how telomerase RNA participates in mechanistic aspects of telomere synthesis, we studied a conserved secondary structure adjacent to the template. Disruption of this structure caused DNA synthesis to proceed beyond the normal template boundary, resulting in altered telomere sequences, telomere shortening, and cellular growth defects. Compensatory mutations restored normal telomerase function. Thus, the RNA structure, rather than its sequence, specifies the template boundary. This study reveals a specific function for an RNA structure in the enzymatic action of telomerase.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	telomer@itsa.ucsf.edu		Tzfati, Yehuda/0000-0001-7720-435X	NATIONAL CANCER INSTITUTE [T32CA009270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026259, R37GM026259] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09270] Funding Source: Medline; NIGMS NIH HHS [GM26259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AnsariLari MA, 1996, BIOTECHNIQUES, V21, P34; AUTEXIER C, 1995, GENE DEV, V9, P2227, DOI 10.1101/gad.9.18.2227; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Blackburn E. H., 1999, RNA WORLD, P609; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Fulton TB, 1998, MOL CELL BIOL, V18, P4961, DOI 10.1128/MCB.18.9.4961; Greene EC, 1998, MOL CELL BIOL, V18, P1544, DOI 10.1128/MCB.18.3.1544; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Harrison GP, 1998, NUCLEIC ACIDS RES, V26, P3433, DOI 10.1093/nar/26.14.3433; HENDERSON E, 1995, TELOMERES, P11; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Roy J, 1998, GENE DEV, V12, P3286, DOI 10.1101/gad.12.20.3286; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Tesmer VM, 1999, MOL CELL BIOL, V19, P6207; TZFATI Y, UNPUB; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Weilbaecher RG, 1999, CURR OPIN CHEM BIOL, V3, P573, DOI 10.1016/S1367-5931(99)00011-3; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	26	115	116	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	2000	288	5467					863	867		10.1126/science.288.5467.863	http://dx.doi.org/10.1126/science.288.5467.863			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797010				2022-12-28	WOS:000086869600040
J	Margolis, LH; Foss, RD; Tolbert, WG				Margolis, LH; Foss, RD; Tolbert, WG			Alcohol and motor vehicle-related deaths of children as passengers, pedestrians, and bicyclists	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context The overall percentage of motor vehicle deaths associated with alcohol consumption declined between 1991 and 1996, but the risk of death due to alcohol-related crashes for children warrants analysis. Objective To examine the association between alcohol use by drivers and mortality of children who were passengers, pedestrians, and bicyclists. Design and Setting Analysis of data from the Fatality Analysis Reporting System, a nationwide US registry of motor vehicle deaths, for 1991-1996. Subjects A total of 16 676 children younger than 16 years who were passengers, pedestrians, or bicyclists and whose death was due to a motor vehicle crash. Main Outcome Measure Alcohol use by drivers involved in crashes in which children died, assessed by age and sex of the child and driver and type of crash. Results A total of 3310 deaths (19.9%) involved alcohol-related crashes. The percentage declined from 21.6% in 1991 to 17.8% in 1996. Considering only crashes in which the alcohol-use status of the child's driver was relevant, the decline was less marked, from 18.8% in 1991 to 15.1% in 1995, with an increase to 16.4% in 1996, Among crashes involving alcohol, the child's own driver had been drinking in 66.3% of cases, varying from 58.0% to 70.7% over time. Drivers younger than the legal drinking age of 21 years who had been drinking alcohol accounted for 30.3% of alcohol-related passenger deaths among children. Conclusion While the overall percentage of alcohol-related motor vehicle deaths for children declined between 1991 and 1996, experiences for passengers, pedestrians, and bicyclists differ. Selected characteristics of children and drivers that elevate the risk of an alcohol-related motor vehicle death point to the need for further policy and clinical interventions.	Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA; Univ N Carolina, Highway Safety Res Ctr, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Margolis, LH (corresponding author), Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC 27599 USA.		Foss, Robert/W-1750-2019	Foss, Robert/0000-0002-1150-5763	PHS HHS [R01-CCR402444-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DiFranza JR, 1996, PEDIATRICS, V97, P560; FELL JC, 1994, MMWR-MORBID MORTAL W, V43, P861; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Grant BF, 2000, AM J PUBLIC HEALTH, V90, P112, DOI 10.2105/AJPH.90.1.112; Grossman M., 1994, J RES ADOLESC, V4, P347, DOI [10.1207/s15327795jra0402_9, DOI 10.1146/ANNUREVCLINPSY-032816-045128]; KLEIN TM, 1986, 807090 DOT HS; MARGOLIS LH, 1986, PEDIATRICS, V77, P870; *NAT CTR INJ PREV, 1997, MMWR-MORBID MORTAL W, V46, P101; *NAT CTR INJ PREV, 1997, MMWR-MORBID MORTAL W, V46, P1130; *NAT HIGHW TRAFF S, 1997, 808540 DOT HS; *NAT HIGHW TRAFF S, 1995, FAT AN REP SYST COD; *NAT HIGHW TRAFF S, 1992, TRAFF SAF FACTS 1991; *US CENS BUR, 1998, NAT POP EST 1990S MO; 1993, MMWR MORB MORTAL WKL, V42, P905	14	32	33	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2245	2248		10.1001/jama.283.17.2245	http://dx.doi.org/10.1001/jama.283.17.2245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807382	Bronze			2022-12-28	WOS:000086671600030
J	Dalesio, O; van Tinteren, H; Clarke, M; Peto, R; Schroder, FH; Dechering, I; Evans, V; Godwin, J; Blumenstein, BA; Crawford, ED; Denis, L; Hall, R; Hill, C; Iversen, P; Shipley, WU; Soloway, M; Sylvester, R				Dalesio, O; van Tinteren, H; Clarke, M; Peto, R; Schroder, FH; Dechering, I; Evans, V; Godwin, J; Blumenstein, BA; Crawford, ED; Denis, L; Hall, R; Hill, C; Iversen, P; Shipley, WU; Soloway, M; Sylvester, R		Prostate Canc Trialists Collaborat	Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials	LANCET			English	Article							PLUS CYPROTERONE-ACETATE; FINAL ANALYSIS; BILATERAL ORCHIECTOMY; METASTATIC CARCINOMA; MULTICENTER TRIAL; COMBINATION; NILUTAMIDE; FLUTAMIDE; CASTRATION; METAANALYSIS	Background In advanced prostate cancer, androgen suppression (AS) by surgery or drugs controls testicular hormone secretion, and the further addition of an antiandrogen such as nitutamide, flutamide, or cyproterone acetate is referred to as maximum androgen blockade (MAB), The aim of this overview was to compare the effects on the duration of survival of MAB and of AS alone. Methods The collaborative meta-analysis of 27 randomised trials involved central reanalysis of the data on each of 8275 men (98% of those ever randomised in trials of MAB vs AS) with metastatic (88%) or locally advanced (12%) prostate cancer. Half were over 70 years of age, and follow-up was typically for about 5 years. Findings 5932 (72%) men have died; of the deaths for which causes were provided, about 80% were attributed to prostate cancer. 5-year survival was 25.4% with MAB versus 23.6% with AS alone, a non-significant gain of 1.8% (SE 1.3; logrank 2p=0.11). There was no significant heterogeneity in the treatment effect (MAB vs AS) with respect to age or disease stage. The results for cyproterone acetate, which accounted for only a fifth of the evidence, appeared slightly unfavourable to MAB (5-year survival 15.4% MAB vs 18.1% AS alone; difference -2.8% [SE 2.4]; logrank 2p=0.04 adverse), whereas those for nilutamide and flutamide appeared slightly favourable (5-year survival 27.6% MAB vs 24.7% AS alone; difference 2.9% [SE 1.3]; logrank 2p=0.005). Non-prostate-cancer deaths (although not clearly significantly affected by treatment) accounted for some of the apparently adverse effects of cyproterone acetate. Interpretation In advanced prostate cancer, addition of an antiandrogen to AS improved the 5-year survival by about 2% or 3% (depending on whether the analysis includes or excludes the cyproterone acetate trials), but the range of uncertainty as to the true size of this benefit runs from about 0% to about 5%.	Netherlands Canc Inst, Biometr Dept, PCTCG Secretariat, NL-1066 CX Amsterdam, Netherlands; Univ Oxford, Clin Trial Serv Unit, Oxford, England; Univ Oxford, Epidemiol Studies Unit, Oxford, England; Erasmus Univ, Rotterdam, Netherlands; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Colorado, Denver, CO 80202 USA; Middelheim Gen Hosp, Antwerp, Belgium; Freeman Rd Hosp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Inst Gustave Roussy, Villejuif, France; Rigshosp, DK-2100 Copenhagen, Denmark; Massachusetts Gen Hosp, Boston, MA 02114 USA; Univ Miami, Miami, FL 33152 USA; Eortc Data Ctr, Brussels, Belgium	Netherlands Cancer Institute; University of Oxford; University of Oxford; Erasmus University Rotterdam; Fred Hutchinson Cancer Center; University of Colorado System; University of Colorado Denver; Newcastle Freeman Hospital; Newcastle University - UK; UNICANCER; Gustave Roussy; Rigshospitalet; University of Copenhagen; Harvard University; Massachusetts General Hospital; University of Miami; European Organisation for Research & Treatment of Cancer	Dalesio, O (corresponding author), Netherlands Canc Inst, Biometr Dept, PCTCG Secretariat, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Correale, Pierpaolo/K-1640-2016	Correale, Pierpaolo/0000-0003-2154-6734; Evans, Vaughan/0000-0002-2366-2301				ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; BELAND G, 1990, CANCER-AM CANCER SOC, V66, P1074; BERTAGNA C, 1994, BRIT J UROL, V73, P396, DOI 10.1111/j.1464-410X.1994.tb07603.x; Blumenstein B A, 1995, Urol Oncol, V1, P95, DOI 10.1016/1078-1439(95)00026-E; BOCCARDO F, 1993, EUR J CANCER, V29A, P1088, DOI 10.1016/S0959-8049(05)80293-X; Bono AV, 1998, UROL INT, V60, P18, DOI 10.1159/000056541; Brisset J M, 1987, Prog Clin Biol Res, V243A, P411; Clarke M, 1998, LANCET, V351, P1451; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1990, P AN M AM SOC CLIN, V9, pA523; DALESIO O, 1995, LANCET, V346, P265; de Voogt HJ, 1998, EUR UROL, V33, P152, DOI 10.1159/000019547; DELAERE KP, 1987, P EUR CANC C, V4, P68; Denis LJ, 1998, EUR UROL, V33, P144, DOI 10.1159/000019546; Dijkman GA, 1997, J UROLOGY, V158, P160, DOI 10.1097/00005392-199707000-00051; DISILVERIO F, 1990, EUR UROL, V18, P54; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Ferrari P, 1996, UROL INT, V56, P13, DOI 10.1159/000282863; FOURCADE RO, 1993, P 3 INT S REC ADV UR, P102; IVERSEN P, 1993, CANCER-AM CANCER SOC, V72, P3851, DOI 10.1002/1097-0142(19931215)72:12+<3851::AID-CNCR2820721717>3.0.CO;2-X; JORGENSEN T, 1993, EUR UROL, V24, P466; KLOSTERHALFEN H, 1987, UROLOGE A, V18, P234; KNONAGEL H, 1989, HELV CHIR ACTA, V56, P343; KUHN JM, 1989, NEW ENGL J MED, V321, P413, DOI 10.1056/NEJM198908173210701; LABRIE F, 1995, LANCET, V346, P1030, DOI 10.1016/S0140-6736(95)91710-1; LEDUC A, 1990, EUR UROL S1, V18, pS385; Morote J, 1995, Actas Urol Esp, V19, P604; NAMER M, 1990, J STEROID BIOCHEM, V37, P909, DOI 10.1016/0960-0760(90)90442-N; Navratil H, 1987, Prog Clin Biol Res, V243A, P401; QUARTEY P, 1995, LANCET, V346, P1031; RANA A, 1995, EUR J CANCER, V31A, P871, DOI 10.1016/0959-8049(95)00233-2; ROBINSON MRG, 1995, EUR UROL, V28, P273; SANDER S, 1982, SCAND J UROL NEPHROL, V16, P193, DOI 10.3109/00365598209179752; SCHULZE H, 1988, UROL INT, V43, P193, DOI 10.1159/000281336; THEIB M, 1996, UROLOGE A, pS41; Thorpe SC, 1996, EUR UROL, V29, P47; TYRRELL CJ, 1993, CANCER, V72, P3878, DOI 10.1002/1097-0142(19931215)72:12+<3878::AID-CNCR2820721723>3.0.CO;2-L; VANTINTEREN H, 1993, CANCER-AM CANCER SOC, V72, P3847, DOI 10.1002/1097-0142(19931215)72:12+<3847::AID-CNCR2820721716>3.0.CO;2-J; WAXMAN J, 1995, LANCET, V346, P1030; WILLIAMS G, 1990, BRIT J UROL, V65, P504, DOI 10.1111/j.1464-410X.1990.tb14796.x; YAMANAKA H, 1990, PROG CLIN BIOL RES, V357, P135; Zalcberg JR, 1996, BRIT J UROL, V77, P865, DOI 10.1046/j.1464-410X.1996.01517.x	43	606	619	0	45	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1491	1498						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801170				2022-12-28	WOS:000086830100010
J	Aureli, P; Fiorucci, GC; Caroli, D; Marchiaro, G; Novara, O; Leone, L; Salmaso, S				Aureli, P; Fiorucci, GC; Caroli, D; Marchiaro, G; Novara, O; Leone, L; Salmaso, S			An outbreak of febrile gastroenteritis associated with corn contaminated by Listeria monocytogenes.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIOFILMS; EPIDEMIC	Background: On May 21, 1997, numerous cases of febrile gastrointestinal illness were reported among the students and staff of two primary schools in northern Italy, all of whom had eaten at cafeterias served by the same caterer. Methods: We interviewed people who ate at the cafeterias about symptoms and foods consumed on May 20. There were no samples of foods left at the cafeterias, but we tested routine samples taken on May 20 by the caterer and environmental specimens at the catering plant. The hospitalized patients were tested for common enteropathogens and toxins. Results: Of the 2189 persons interviewed (82 percent of those exposed), 1566 (72 percent) reported symptoms; of these, 292 (19 percent) were hospitalized. Among samples obtained from hospitalized patients, all but two of the stool specimens and all blood specimens were negative for common enteropathogens. Listeria monocytogenes was isolated from one blood specimen and from 123 of the 141 stool specimens. Consumption of a cold salad of corn and tuna was associated with the development of symptoms (relative risk, 6.19; 95 percent confidence interval, 4.81 to 7.98; P<0.001). L. monocytogenes was isolated from the caterer's sample of the salad and from environmental specimens collected from the catering plant. All listeria isolates were serotype 4b and were found to be identical on DNA analysis. Experimental contamination of sterile samples of the implicated foods showed that L. monocytogenes grew on corn when kept for at least 10 hours at 25 degrees C. Conclusions: Food-borne infection with L. monocytogenes can cause febrile illness with gastroenteritis in immunocompetent persons. (N Engl J Med 2000;342:1236-41.) (C) 2000, Massachusetts Medical Society.	Ist Super Sanita, Lab Alimenti, Reparto Microbiol Alimenti, I-00161 Rome, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, Reparto Malattie Infett, I-00161 Rome, Italy; Osped Regina Margherita Santa Anna, Azienda Osped Maternoinfantile, Dipartimento Patol Clin, Turin, Italy; Azienda Reg Protez Ambientale, Dipartimento Subprov Torino, Turin, Italy; Osped San Giovanni Battista, Microbiol Lab, Turin, Italy; Osped San Croce, Lab Patol Clin, Moncalieri, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); A.O.U. Citta della Salute e della Scienza di Torino; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Aureli, P (corresponding author), Ist Super Sanita, Lab Alimenti, Reparto Microbiol Alimenti, Viale Regina Elena 299, I-00161 Rome, Italy.							Arizcun C, 1998, J FOOD PROTECT, V61, P731, DOI 10.4315/0362-028X-61.6.731; BUCHANAN RL, 1990, J FOOD PROTECT, V53, P370, DOI 10.4315/0362-028X-53.5.370; BUCHANAN RL, 1992, FOOD MICROBIOL, V9, P279, DOI 10.1016/0740-0020(92)80037-5; BULA CJ, 1995, CLIN INFECT DIS, V20, P66, DOI 10.1093/clinids/20.1.66; Dalton CB, 1997, NEW ENGL J MED, V336, P100, DOI 10.1056/NEJM199701093360204; FARBER JM, 1991, MICROBIOL REV, V55, P476, DOI 10.1128/MMBR.55.3.476-511.1991; FARBER JM, 1991, MICROBIOL REV, V55, P752; *FDA, 1984, BACT AN MAN S; Franciosa G, 1998, EUR J EPIDEMIOL, V14, P205, DOI 10.1023/A:1007448210169; GOLDEN DA, 1990, INT J FOOD MICROBIOL, V10, P143, DOI 10.1016/0168-1605(90)90062-A; Goulet V, 1998, J INFECT DIS, V177, P155, DOI 10.1086/513814; Heitmann M, 1997, PEDIATR INFECT DIS J, V16, P827, DOI 10.1097/00006454-199708000-00025; HO JL, 1986, ARCH INTERN MED, V146, P520, DOI 10.1001/archinte.146.3.520; KACZMARSKI EB, 1989, LANCET, V1, P549; Matushek MG, 1997, J CLIN MICROBIOL, V35, P536; MCLAUCHLIN J, 1991, BRIT MED J, V303, P773, DOI 10.1136/bmj.303.6805.773; MCLAUCHLIN J, 1990, INT J FOOD MICROBIOL, V10, P255, DOI 10.1016/0168-1605(90)90073-E; MCLAUCHLIN J, 1995, P 12 INT S PROBL LIS, P365; Miettinen MK, 1999, J CLIN MICROBIOL, V37, P2358, DOI 10.1128/JCM.37.7.2358-2360.1999; *MIN SAN, 1997, B EP, V15; PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046; RIEDO FX, 1994, J INFECT DIS, V170, P693, DOI 10.1093/infdis/170.3.693; Salamina G, 1996, EPIDEMIOL INFECT, V117, P429, DOI 10.1017/S0950268800059082; SCHWARTZ B, 1989, J INFECT DIS, V159, P680, DOI 10.1093/infdis/159.4.680; STELMA GN, 1987, J CLIN MICROBIOL, V25, P2085, DOI 10.1128/JCM.25.11.2085-2089.1987; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; *WHO ICMSF, 1982, WHOICMSF M HAZ AN CR; ZOTTOLA EA, 1994, INT J FOOD MICROBIOL, V23, P125, DOI 10.1016/0168-1605(94)90047-7	28	279	296	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1236	1241		10.1056/NEJM200004273421702	http://dx.doi.org/10.1056/NEJM200004273421702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10781619				2022-12-28	WOS:000086660600002
J	Silvestrini, M; Vernieri, F; Pasqualetti, P; Matteis, M; Passarelli, F; Troisi, E; Caltagirone, C				Silvestrini, M; Vernieri, F; Pasqualetti, P; Matteis, M; Passarelli, F; Troisi, E; Caltagirone, C			Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBROVASCULAR REACTIVITY; TRANSCRANIAL DOPPLER; BLOOD-FLOW; ENDARTERECTOMY; OCCLUSIONS; HEMODYNAMICS	Context Standards for treating patients with asymptomatic carotid artery stenosis have been difficult to establish because of the lack of evidence for factors influencing these patients' prognoses. However, preliminary evidence suggests that an alteration in. cerebral hemodynamic function may play a relevant role in the occurrence of stroke in patients with carotid artery disease. Objective To investigate the relationship between cerebrovascular reactivity to hypercapnia and cerebrovascular events in patients with severe unilateral asymptomatic carotid artery stenosis. Design and Setting Prospective, blinded longitudinal study conducted in an outpatient neurovascular department in Italy between June 1996 and April 1998, with a median follow-up of 28.5 months. Patients Ninety-four patients with asymptomatic carotid artery stenosis of at least 70% (74 men; mean age, 71 years). Main Outcome measures Subsequent occurrence of cerebral ischemic events (transient ischemic attack or stroke) or death, analyzed by cerebrovascular reactivity to hypercapnia (measured by transcranial Doppler ultrasonography and calculated by the breath-holding index values in the middle cerebral arteries). Results The overall annual rate for all ischemic events was 7.9%. Seventeen patients (18%) had ischemic events, all but 1 of which were ipsilateral to the carotid artery stenosis. Among factors considered, only lower breath-holding index values in the middle cerebral artery ipsilateral to carotid artery stenosis were significantly associated with the risk of an event (hazard ratio, 0.09; 95% confidence interval, 0.02-0.38; P=.001, by multivariate analysis). Based on data from previously studied healthy subjects, the cutoff of the breath-holding index for distinguishing between impaired and normal cerebrovascular reactivity was determined to be 0.69. Using this cutoff, the annual ipsilateral ischemic event risk was 4.1% in patients with normal and 13.9% in those with impaired breath-holding index values. Conclusions These results suggest a link between impaired cerebrovascular reactivity and the risk of ischemic events ipsilateral to severe asymptomatic carotid stenosis.	Univ Roma Tor Vergata, Osped S Eugenio, Neurol Clin, I-00144 Rome, Italy; IRCCS S Lucia, Rome, Italy; Osped Fatebenefratelli, Dipartimento Neurosci, AFaR CRCCS, Isola Tiberina, Italy	Sant'Eugenio Hospital; University of Rome Tor Vergata; IRCCS Santa Lucia	Silvestrini, M (corresponding author), Univ Roma Tor Vergata, Osped S Eugenio, Neurol Clin, P Umanesimo 10, I-00144 Rome, Italy.		Caltagirone, Carlo/B-4930-2013; Pasqualetti, Patrizio/D-4496-2013; Silvestrini, Mauro/AAB-3838-2019	Pasqualetti, Patrizio/0000-0001-5560-1979; troisi, elio/0000-0002-5171-0243				AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Barnett HJM, 1996, NEUROLOGY, V46, P603, DOI 10.1212/WNL.46.3.603; BARTELS E, 1996, NEUROSONOLOGY, P83; Biller J, 1998, STROKE, V29, P554, DOI 10.1161/01.STR.29.2.554; Chaturvedi S, 1998, NEUROLOGY, V50, P610, DOI 10.1212/WNL.50.3.610; DAHL A, 1992, STROKE, V23, P15, DOI 10.1161/01.STR.23.1.15; DEBRAY JM, 1995, CEREBROVASC DIS, V5, P414, DOI 10.1159/000107895; Derdeyn CP, 1999, NEUROLOGY, V53, P251, DOI 10.1212/WNL.53.2.251; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GITELMAN DR, 1991, J CEREBR BLOOD F MET, V11, P1036, DOI 10.1038/jcbfm.1991.172; GORTLER M, 1994, J NEUROL, V241, P301, DOI 10.1007/BF00868437; Grubb RL, 1998, JAMA-J AM MED ASSOC, V280, P1055, DOI 10.1001/jama.280.12.1055; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Gur AY, 1996, STROKE, V27, P2188, DOI 10.1161/01.STR.27.12.2188; HEDERA P, 1995, EUR NEUROL, V35, P212, DOI 10.1159/000117130; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; KLEISER B, 1992, STROKE, V23, P171, DOI 10.1161/01.STR.23.2.171; KUWABARA Y, 1995, STROKE, V26, P1825, DOI 10.1161/01.STR.26.10.1825; Lanska DJ, 1997, NEUROLOGY, V48, P1481, DOI 10.1212/WNL.48.6.1481; MARKUS HS, 1992, STROKE, V23, P668, DOI 10.1161/01.STR.23.5.668; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; POWERS WJ, 1991, ANN NEUROL, V29, P231, DOI 10.1002/ana.410290302; ROTHWELL PM, 1995, LANCET, V345, P209; Silvestrini M, 1999, ACTA NEUROL SCAND, V99, P187, DOI 10.1111/j.1600-0404.1999.tb07342.x; Silvestrini M, 1996, J CEREBR BLOOD F MET, V16, P746, DOI 10.1097/00004647-199607000-00027; Silvestrini M, 1996, STROKE, V27, P1970, DOI 10.1161/01.STR.27.11.1970; TOOLE JF, 1995, JAMA-J AM MED ASSOC, V274, P1505; Totaro R, 1999, CEREBROVASC DIS, V9, P142, DOI 10.1159/000015943; Vernieri F, 1999, STROKE, V30, P593, DOI 10.1161/01.STR.30.3.593; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; Warlow C, 1996, CEREBROVASC DIS, V6, P7, DOI 10.1159/000108066; WIDDER B, 1994, STROKE, V25, P1963, DOI 10.1161/01.STR.25.10.1963; World Health Organization, 1985, DIAB MELL REP WHO ST; Yamauchi H, 1996, J NEUROL NEUROSUR PS, V61, P18, DOI 10.1136/jnnp.61.1.18; YONAS H, 1993, J NEUROSURG, V79, P483, DOI 10.3171/jns.1993.79.4.0483	35	398	410	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2122	2127		10.1001/jama.283.16.2122	http://dx.doi.org/10.1001/jama.283.16.2122			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791504				2022-12-28	WOS:000086542800028
J	Willinger, M; Ko, CW; Hoffman, HJ; Kessler, RC; Corwin, MJ				Willinger, M; Ko, CW; Hoffman, HJ; Kessler, RC; Corwin, MJ			Factors associated with caregivers' choice of infant sleep position, 1994-1998 - The National Infant Sleep Position Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEATH-SYNDROME; RECEPTOR-BINDING; ARCUATE NUCLEUS; RISK; PREVALENCE; ENVIRONMENT; DECLINE	Context The success and simplicity of the 1994 national "Back to Sleep" campaign to reduce sudden infant death syndrome provides an opportunity to study which elements determine whether a behavior will change in the desired direction in response to a public health intervention. Objective To examine sociodemographic characteristics, motivation, and message exposure to ascertain which factors influenced a caregiver's choice of infant sleep position after implementation of the campaign. Design Annual nationally representative telephone surveys conducted between 1994 and 1998. Setting The 48 contiguous United States. Participants Nighttime caregivers of infants born within the 7 months prior to interview between 1994 and 1998. Approximately 1000 interviews were conducted each year. Main Outcome Measures The position the infant was usually placed in for sleep, sleep position recommendations received from specific sources, and reasons reported for position choice. Results Between 1994 and 1998, prone placement declined from 44% to 17% among white infants and from 53% to 32% among black infants. Supine placement increased from 27% to 58% among white infants and from 17% to 31% among black infants. During this period, reports of supine recommendations from at least 1 source doubled from 38% to 79%. From 1995 to 1998, 86% of caregivers who placed the infant prone reported receiving only nonprone recommendations. Infant comfort was given as a reason for prone placement by 82% of these caregivers. In multivariate analysis, physician recommendation of "supine not prone" had the strongest influence and was associated with decreased prone placement (odds ratio [OR], 0.25 [95% confidence interval {CI}, 0.16-0.39]) and increased supine placement (OR, 3.37 [95% CI, 2.38-4.76]). Recommendations from all 4 sources (the physician, neonatal nurse, reading materials, and radio/television) further increased the probability of supine placement (OR, 6.01 [95% CI, 4.57-7.90]). Other factors independently associated with increased prone and decreased supine placement included maternal black race, parity of more than 1, and living in a southern or mid-Atlantic state. Conclusions According to our study, as of 1998, approximately one fifth of infants were still placed prone, and only half were placed supine. Recommendations of supine placement during infancy by physicians at well-baby checks and by neonatal nursery staff and print and broadcast media have increased the proportion of infants placed supine. Caregiver beliefs regarding perceived advantages of prone sleeping should be addressed to attain further reduction in prone placement.	NICHHD, Ctr Res Mothers & Children, Pregnancy & Perinatol Branch, Bethesda, MD 20892 USA; Natl Inst Deafness & Other Commun Disorders, Epidemiol Stat & Data Syst Branch, Bethesda, MD USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat, Boston, MA 02118 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Harvard University; Harvard Medical School; Boston Medical Center; Boston University	Willinger, M (corresponding author), NICHHD, Ctr Res Mothers & Children, Pregnancy & Perinatol Branch, Execut Bldg,Room 4B03,6100 Execut Blvd,MSC 7510, Bethesda, MD 20892 USA.	mw75q@nih.gov		Corwin, Michael/0000-0002-6591-209X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD029067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000051] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-2-9067] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1990, SAS STAT US GUID VER; Brenner RA, 1998, JAMA-J AM MED ASSOC, V280, P341, DOI 10.1001/jama.280.4.341; CHIODINI BA, 1993, J PEDIATR-US, V123, P686, DOI 10.1016/S0022-3476(05)80841-8; DWYER T, 1995, JAMA-J AM MED ASSOC, V273, P783, DOI 10.1001/jama.273.10.783; ELDERS JM, 1994, JAMA-J AM MED ASSOC, V272, P1646, DOI 10.1001/jama.272.21.1646; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; Franco P, 1998, J PEDIATR-US, V132, P240, DOI 10.1016/S0022-3476(98)70438-X; Hiley CMH, 1996, BRIT MED J, V312, P1397, DOI 10.1136/bmj.312.7043.1397a; HOSMER DW, 1989, APPL LOGISTIC REGRES; HOYERT DL, 1999, NATL VITAL STAT REP, V47, P88; Hunt L, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.1.e11; KATTWINKEL J, 1994, PEDIATRICS, V93, P820; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; Kattwinkel J, 1996, PEDIATRICS, V98, P1216; KEMP JS, 1993, J PEDIATR-US, V122, P874, DOI 10.1016/S0022-3476(09)90010-5; KINNEY HC, 1995, SCIENCE, V269, P1446, DOI 10.1126/science.7660131; Lesko SM, 1998, JAMA-J AM MED ASSOC, V280, P336, DOI 10.1001/jama.280.4.336; MITCHELL EA, 1994, ARCH DIS CHILD, V70, P291, DOI 10.1136/adc.70.4.291; Panigrahy A, 1997, J NEUROPATH EXP NEUR, V56, P1253, DOI 10.1097/00005072-199711000-00010; Platt MJ, 1996, ARCH DIS CHILD, V75, P527, DOI 10.1136/adc.75.6.527; PONSONBY AL, 1994, PREV MED, V23, P402, DOI 10.1006/pmed.1994.1055; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; Ponsonby AL, 1997, PEDIATRICS, V99, pE31, DOI 10.1542/peds.99.1.e3; PONSONBY AL, 1995, ARCH DIS CHILD, V72, P204, DOI 10.1136/adc.72.3.204; SCHECHTMAN VL, 1992, PEDIATR RES, V31, P606, DOI 10.1203/00006450-199206000-00014; SCHECHTMAN VL, 1992, PEDIATRICS, V89, P865; Schechtman VL, 1996, PEDIATR RES, V40, P571, DOI 10.1203/00006450-199610000-00010; Skadberg BT, 1997, ARCH DIS CHILD, V76, P320, DOI 10.1136/adc.76.4.320; Ventura S J, 1998, Mon Vital Stat Rep, V46, P1; Wennergren G, 1997, ACTA PAEDIATR, V86, P963, DOI 10.1111/j.1651-2227.1997.tb15180.x; Williams SM, 1996, INT J EPIDEMIOL, V25, P366, DOI 10.1093/ije/25.2.366; Willinger M, 1998, JAMA-J AM MED ASSOC, V280, P329, DOI 10.1001/jama.280.4.329	32	143	144	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2135	2142		10.1001/jama.283.16.2135	http://dx.doi.org/10.1001/jama.283.16.2135			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791506	Bronze			2022-12-28	WOS:000086542800030
J	Razavi, B; O'Toole, J; Schilling, M; Razavi, M				Razavi, B; O'Toole, J; Schilling, M; Razavi, M			Cryptococcal meningitis, an endocrine emergency?	LANCET			English	Article							CUSHINGS-SYNDROME; OPPORTUNISTIC INFECTIONS		Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Razavi, B (corresponding author), Univ Iowa, Dept Med, Iowa City, IA 52242 USA.			Schilling, Margo/0000-0001-9684-9866				Bakker RC, 1998, J ENDOCRINOL INVEST, V21, P329, DOI 10.1007/BF03350337; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; GRAHAM BS, 1984, ANN INTERN MED, V101, P334, DOI 10.7326/0003-4819-101-3-334; ORTH DN, 1995, NEW ENGL J MED, V332, P791, DOI 10.1056/NEJM199503233321207	4	9	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1426	1426		10.1016/S0140-6736(00)02142-5	http://dx.doi.org/10.1016/S0140-6736(00)02142-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791527				2022-12-28	WOS:000086829800014
J	Strick, TR; Croquette, V; Bensimon, D				Strick, TR; Croquette, V; Bensimon, D			Single-molecule analysis of DNA uncoiling by a type II topoisomerase	NATURE			English	Article							STEADY-STATE ANALYSIS; SUPERCOILED DNA; ATP HYDROLYSIS; DROSOPHILA-MELANOGASTER; DOUBLE HELIX; MECHANISM; ELASTICITY; TRANSPORT; TOPOLOGY	Type II DNA topoisomerases are ubiquitous ATP-dependent enzymes capable of transporting a DNA through a transient double-strand break in a second DNA segment(1). This enables them to untangle DNA(2-6) and relax the interwound supercoils (plectonemes) that arise in twisted DNA(7). In vivo, they are responsible for untangling replicated chromosomes and their absence at mitosis or meiosis ultimately causes cell death(8,9). Here we describe a micromanipulation experiment in which we follow in real time a single Drosophila melanogaster topoisomerase II acting on a linear DNA molecule which is mechanically stretched and supercoiled(10-13). By monitoring the DNA's extension in the presence of ATP, we directly observe the relaxation of two supercoils during a single catalytic turnover. By controlling the force pulling on the molecule, we determine the variation of the reaction rate with the applied stress. Finally, in the absence of ATP, we observe the clamping of a DNA crossover by a single topoisomerase on at least two different timescales (configurations). These results show that single molecule experiments are a powerful new tool for the study of topoisomerases.	Univ Paris 06, Ecole Normale Super, Lab Phys Stat, CNRS,UMR 8550, F-75231 Paris 05, France; Univ Paris 07, F-75231 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Strick, TR (corresponding author), Univ Paris 06, Ecole Normale Super, Lab Phys Stat, CNRS,UMR 8550, 24 Rue Lhomond, F-75231 Paris 05, France.		Strick, Terence R/J-1886-2012; Bensimon, David/E-7768-2015	Bensimon, David/0000-0003-1971-9907; Strick, Terence/0000-0003-1744-3679; Croquette, Vincent/0000-0003-1400-0039				Allemand JF, 1998, P NATL ACAD SCI USA, V95, P14152, DOI 10.1073/pnas.95.24.14152; Bouchiat C, 1998, PHYS REV LETT, V80, P1556, DOI 10.1103/PhysRevLett.80.1556; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; HSIEH T, 1983, J BIOL CHEM, V258, P8413; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Landau L., 1967, THEORY ELASTICITY; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; Moroz JD, 1997, P NATL ACAD SCI USA, V94, P14418, DOI 10.1073/pnas.94.26.14418; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROCA J, 1993, J BIOL CHEM, V268, P14250; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; Strick TR, 1998, P NATL ACAD SCI USA, V95, P10579, DOI 10.1073/pnas.95.18.10579; Strick TR, 1998, BIOPHYS J, V74, P2016, DOI 10.1016/S0006-3495(98)77908-1; Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	25	275	283	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					901	904		10.1038/35009144	http://dx.doi.org/10.1038/35009144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786800				2022-12-28	WOS:000086625000052
J	Rittenour, TM; Brigham-Grette, J; Mann, ME				Rittenour, TM; Brigham-Grette, J; Mann, ME			El Nino-like climate teleconnections in New England during the late Pleistocene	SCIENCE			English	Article							SOUTHERN OSCILLATION; NORTHERN-HEMISPHERE; SURFACE-TEMPERATURE; VARVED SEDIMENTS; TIME-SERIES; VARIABILITY; ENSO; PACIFIC; RECONSTRUCTION; MODULATION	A glacial varve chronology from New England spanning the 4000-year period from 17,500 to 13,500 calendar years before the present was analyzed for evidence of climate variability during the late Pleistocene. The chronology shows a distinct interannual (3 to 5 years) band of enhanced variability suggestive of El Nino-Southern Oscillation (ENSO) teleconnections into North America during the Late Pleistocene, when the Laurentide ice sheet was near its maximum extent and climatic boundary conditions were different than those of today. This interannual variability largely disappears by the young end of the 4000-year chronology, with only the highest frequency components (roughly 3-year period) persisting. This record provides evidence of ENSO-Like climate variability during near-peak glacial conditions.	Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA; Univ Virginia, Dept Environm Sci, Charlottesville, VA 22903 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Virginia	Rittenour, TM (corresponding author), Univ Nebraska, Dept Geosci, Lincoln, NE 68588 USA.	tammyr@unlserve.unl.edu	Mann, Michael E/B-8472-2017	Mann, Michael E/0000-0003-3067-296X; Rittenour, Tammy/0000-0003-1925-0395				ANTEVS E, 1992, AM GEOGR SOC RES SER, V11, P1; Antevs E, 1928, AM GEOG SOC RES SER, V17, P1; ASHLEY GM, 1975, GLACIOFLUVIAL GLACIO, P304; Baranyi T, 1998, GEOPHYS RES LETT, V25, P2269, DOI 10.1029/98GL01798; Clement AC, 1999, PALEOCEANOGRAPHY, V14, P441, DOI 10.1029/1999PA900013; Cole JE, 1998, GEOPHYS RES LETT, V25, P4529, DOI 10.1029/1998GL900145; Cook ER, 1998, HOLOCENE, V8, P9, DOI 10.1191/095968398677793725; COOK ER, 1995, HOLOCENE, V5, P229, DOI 10.1177/095968369500500211; DeVries TJ, 1997, SCIENCE, V276, P965, DOI 10.1126/science.276.5314.965; DUNBAR RB, 1994, PALEOCEANOGRAPHY, V9, P291, DOI 10.1029/93PA03501; Gagan MK, 1998, SCIENCE, V279, P1014, DOI 10.1126/science.279.5353.1014; GHIL M, 1991, NATURE, V350, P324, DOI 10.1038/350324a0; Goddard L, 1997, J GEOPHYS RES-OCEANS, V102, P10423, DOI 10.1029/97JC00463; Godsey HS, 1999, CAN J EARTH SCI, V36, P533, DOI 10.1139/e99-005; GRAHAM NE, 1988, SCIENCE, V240, P1293, DOI 10.1126/science.240.4857.1293; HALPERT MS, 1992, J CLIMATE, V5, P577, DOI 10.1175/1520-0442(1992)005<0577:STPAWT>2.0.CO;2; Hardy DR, 1996, J PALEOLIMNOL, V16, P227; Hughen KA, 2000, HOLOCENE, V10, P9, DOI 10.1191/095968300676746202; Hurrell JW, 1996, GEOPHYS RES LETT, V23, P665, DOI 10.1029/96GL00459; Knutson TR, 1997, J CLIMATE, V10, P138, DOI 10.1175/1520-0442(1997)010<0138:SEIAGC>2.0.CO;2; LIU Z, 1999, PAGES NEWSLETTER, V7, P16; Mann ME, 1996, CLIMATIC CHANGE, V33, P409, DOI 10.1007/BF00142586; MANN ME, 1994, J GEOPHYS RES-ATMOS, V99, P25819, DOI 10.1029/94JD02396; MANN ME, IN PRESS EL NINO SO; PARK J, 1987, J GEOPHYS RES-SOLID, V92, P12675, DOI 10.1029/JB092iB12p12675; RIDGE JC, 1990, GEOL SOC AM BULL, V102, P889, DOI 10.1130/0016-7606(1990)102<0889:REOANE>2.3.CO;2; Ridge JC, 1999, GEOGR PHYS QUATERN, V53, P79, DOI 10.7202/004864ar; Rittenour T.M., 1999, THESIS U MASSACHUSET; Rodbell DT, 1999, SCIENCE, V283, P516, DOI 10.1126/science.283.5401.516; Sandweiss DH, 1996, SCIENCE, V273, P1531, DOI 10.1126/science.273.5281.1531; SHULMEISTER J, 1995, HOLOCENE, V5, P10, DOI 10.1177/095968369500500102; Stahle DW, 1998, B AM METEOROL SOC, V79, P2137, DOI 10.1175/1520-0477(1998)079<2137:EDROTS>2.0.CO;2; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Trenberth KE, 1997, GEOPHYS RES LETT, V24, P3057, DOI 10.1029/97GL03092; TRENBERTH KE, 1990, B AM METEOROL SOC, V71, P988, DOI 10.1175/1520-0477(1990)071<0988:ROICCI>2.0.CO;2; VEROSUB KL, 1979, GEOPHYS RES LETT, V6, P245, DOI 10.1029/GL006i004p00245; Wang B, 1996, J CLIMATE, V9, P1586, DOI 10.1175/1520-0442(1996)009<1586:TSOTSO>2.0.CO;2; YIN JH, IN PRESS J CLIM; ZEBIAK SE, 1987, MON WEATHER REV, V115, P2262, DOI 10.1175/1520-0493(1987)115<2262:AMENO>2.0.CO;2; ZEBIAK SE, 1991, GREENHOUSE GAS INDUC, P457; Zhang Y, 1997, J CLIMATE, V10, P1004, DOI 10.1175/1520-0442(1997)010<1004:ELIV>2.0.CO;2	41	65	88	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	2000	288	5468					1039	1042		10.1126/science.288.5468.1039	http://dx.doi.org/10.1126/science.288.5468.1039			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807572				2022-12-28	WOS:000086988400034
J	Gasse, C; Derby, LE; Vasilakis, C; Jick, H				Gasse, C; Derby, LE; Vasilakis, C; Jick, H			Risk of suicide among users of calcium channel blockers: population based, nested case-control study	BRITISH MEDICAL JOURNAL			English	Article									Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA	Boston University	Gasse, C (corresponding author), Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA.			Jick, Hershel/0000-0003-4270-5992	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bergman U, 1998, BRIT MED J, V317, P1076; DERBY LE, 1992, J CLIN PSYCHOPHARM, V12, P235; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Lindberg G, 1998, BMJ-BRIT MED J, V316, P741, DOI 10.1136/bmj.316.7133.741	4	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1251	1251		10.1136/bmj.320.7244.1251	http://dx.doi.org/10.1136/bmj.320.7244.1251			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797037	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086981400022
J	Hestmark, G				Hestmark, G			Oeconomia Naturae L.	NATURE			English	Editorial Material									Univ Oslo, Dept Biol, N-0316 Oslo, Norway	University of Oslo	Hestmark, G (corresponding author), Univ Oslo, Dept Biol, N-0316 Oslo, Norway.								0	4	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					19	19		10.1038/35011237	http://dx.doi.org/10.1038/35011237			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811198	Bronze			2022-12-28	WOS:000086901600027
J	Cavazzana-Calvo, M; Hacein-Bey, S; Basile, CD; Gross, F; Yvon, E; Nusbaum, P; Selz, F; Hue, C; Certain, S; Casanova, JL; Bousso, P; Le Deist, F; Fischer, A				Cavazzana-Calvo, M; Hacein-Bey, S; Basile, CD; Gross, F; Yvon, E; Nusbaum, P; Selz, F; Hue, C; Certain, S; Casanova, JL; Bousso, P; Le Deist, F; Fischer, A			Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; RECEPTOR-GAMMA CHAIN; BONE-MARROW; LYMPHOCYTES; EXPRESSION; DIFFERENTIATION; CULTURES; IL-15	Severe combined immunodeficiency-X1 (SCID-X1) is an X-linked inherited disorder characterized by an early block in T and natural killer (NK) Lymphocyte differentiation. This block is caused by mutations of the gene encoding the gamma c cytokine receptor subunit of interleukin-2, -4, -7, -9, and -15 receptors, which participates in the delivery of growth, survival, and differentiation signals to early Lymphoid progenitors. After preclinical studies, a gene therapy trial for SCID-X1 was initiated, based on the use of complementary DNA containing a defective gamma c Moloney retrovirus-derived Vector and ex vivo infection of CD34(+) cells. After a 10-month follow-up period, gamma c transgene-expressing T and NK cells were detected in two patients. T, B, and NK cell counts and function, including antigen-specific responses, were comparable to those of age-matched controls. Thus, gene therapy was able to provide full correction of disease phenotype and, hence, clinical benefit.	Hop Necker Enfants Malad, INSERM, U429, F-75743 Paris 15, France; Hop Necker Enfants Malad, Gene Therapy Lab, F-75743 Paris, France; Hop Necker Enfants Malad, Cell Therapy Lab, F-75743 Paris 15, France; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75743 Paris 15, France; Inst Pasteur, INSERM, U277, F-75730 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Fischer, A (corresponding author), Hop Necker Enfants Malad, INSERM, U429, 149 Rue Sevres, F-75743 Paris 15, France.		Casanova, Jean-Laurent/I-3418-2017; BOUSSO, Philippe/M-6547-2014; de Saint Basile, Genevieve/G-9731-2017	BOUSSO, Philippe/0000-0002-6362-561X; Casanova, Jean-Laurent/0000-0002-7782-4169; de Saint Basile, Genevieve/0000-0002-1913-5269; DOGNIAUX, Stephanie/0000-0003-3309-1204; Cavazzana, Marina/0000-0002-0264-0891				BASSIN RH, 1970, INT J CANCER, V6, P95, DOI 10.1002/ijc.2910060114; Bordignon C, 1998, NAT MED, V4, P19, DOI 10.1038/nm0198-019; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Bousso P, 2000, P NATL ACAD SCI USA, V97, P274, DOI 10.1073/pnas.97.1.274; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Candotti F, 1996, BLOOD, V87, P3097, DOI 10.1182/blood.V87.8.3097.bloodjournal8783097; CavazzanaCalvo M, 1996, BLOOD, V88, P3901, DOI 10.1182/blood.V88.10.3901.bloodjournal88103901; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Hacein-Bey S, 1998, BLOOD, V92, P4090, DOI 10.1182/blood.V92.11.4090.423a03_4090_4097; HaceinBey S, 1996, BLOOD, V87, P3108, DOI 10.1182/blood.V87.8.3108.bloodjournal8783108; HANNENBERG H, 1996, NAT MED, V2, P876; Hoogerbrugge PM, 1996, GENE THER, V3, P179; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Leonard WJ, 1996, ANNU REV MED, V47, P229; Lo M, 1999, BLOOD, V94, P3027, DOI 10.1182/blood.V94.9.3027.421k11_3027_3036; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PRINTZ M, 1995, GENE THER, V2, P143; Robbins PB, 1998, P NATL ACAD SCI USA, V95, P10182, DOI 10.1073/pnas.95.17.10182; Soudais C, 2000, BLOOD, V95, P3071, DOI 10.1182/blood.V95.10.3071.010k06_3071_3077; Stephan V, 1996, NEW ENGL J MED, V335, P1563, DOI 10.1056/NEJM199611213352104; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; Taylor N, 1996, BLOOD, V87, P3103, DOI 10.1182/blood.V87.8.3103.bloodjournal8783103; Whitwam T, 1998, BLOOD, V92, P1565, DOI 10.1182/blood.V92.5.1565.417k12_1565_1575	26	1909	2040	2	252	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					669	672		10.1126/science.288.5466.669	http://dx.doi.org/10.1126/science.288.5466.669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784449				2022-12-28	WOS:000086727100043
J	Cramer, P; Bushnell, DA; Fu, JH; Gnatt, AL; Maier-Davis, B; Thompson, NE; Burgess, RR; Edwards, AM; David, PR; Kornberg, RD				Cramer, P; Bushnell, DA; Fu, JH; Gnatt, AL; Maier-Davis, B; Thompson, NE; Burgess, RR; Edwards, AM; David, PR; Kornberg, RD			Architecture of RNA polymerase II and implications for the transcription mechanism	SCIENCE			English	Article							ELONGATION-FACTOR TFIIS; START SITE SELECTION; VIRUS X-PROTEIN; CRYSTAL-STRUCTURE; ZINC RIBBON; ESCHERICHIA-COLI; DNA-POLYMERASE; PREINITIATION COMPLEX; ANGSTROM RESOLUTION; TERNARY COMPLEX	A backbone model of a 10-subunit yeast RNA polymerase II has been derived from x-ray diffraction data extending to 3 angstroms resolution. All 10 subunits exhibit a high degree of identity with the corresponding human proteins, and 9 of the 10 subunits are conserved among the three eukaryotic RNA polymerases I, II, and III. Notable features of the model include a pair of jaws, formed by subunits Rpb1, Rpb5, and Rpb9, that appear to grip DNA downstream of the active center. A clamp on the DNA nearer the active center, formed by Rpb1, Rpb2, and Rpb6, may be Locked in the closed position by RNA, accounting for the great stability of transcribing complexes. A pore in the protein complex beneath the active center may allow entry of substrates for polymerization and exit of the transcript during proofreading and passage through pause sites in the DNA.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	Stanford University; University of Wisconsin System; University of Wisconsin Madison; University of Toronto	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu		Burgess, Richard/0000-0001-9545-3165; Edwards, Aled/0000-0002-4782-6016	NIGMS NIH HHS [GM49985] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BUSHNELL DB, UNPUB; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Conaway RC, 1997, PROG NUCLEIC ACID RE, V56, P327, DOI 10.1016/S0079-6603(08)61009-0; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)80223-H; del Rio-Portilla F, 1999, NAT STRUCT BIOL, V6, P1039; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EDWARDS AH, UNPUB; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1994, NAT STRUCT BIOL, V1, P195, DOI 10.1038/nsb0394-195; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; FURTERGRAVES EM, 1994, NUCLEIC ACIDS RES, V22, P4932, DOI 10.1093/nar/22.23.4932; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; GNATT AL, UNPUB; Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Ishihama A, 1981, Adv Biophys, V14, P1; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; Kayukawa K, 1999, GENE, V234, P139, DOI 10.1016/S0378-1119(99)00164-X; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; Krapp S, 1998, NAT STRUCT BIOL, V5, P110, DOI 10.1038/nsb0298-110; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Miyao T, 1998, P NATL ACAD SCI USA, V95, P15281, DOI 10.1073/pnas.95.26.15281; Miyao T, 1998, MOL GEN GENET, V259, P123, DOI 10.1007/s004380050796; Morin PE, 1996, P NATL ACAD SCI USA, V93, P10604, DOI 10.1073/pnas.93.20.10604; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; Powell W, 1996, J BIOL CHEM, V271, P22301, DOI 10.1074/jbc.271.37.22301; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Rubbi L, 1999, J BIOL CHEM, V274, P31485, DOI 10.1074/jbc.274.44.31485; SENTENAC A, 1992, MONOGR COLD SPRING H, V22; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TODONE F, UNPUB; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; Woychik NA, 1998, COLD SPRING HARB SYM, V63, P311, DOI 10.1101/sqb.1998.63.311; Yoon H, 1998, BIOCHEMISTRY-US, V37, P12104, DOI 10.1021/bi980924n; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhang GY, 1998, SCIENCE, V281, P262, DOI 10.1126/science.281.5374.262; Zhu WL, 1996, NAT STRUCT BIOL, V3, P122, DOI 10.1038/nsb0296-122	81	447	466	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2000	288	5466					640	649		10.1126/science.288.5466.640	http://dx.doi.org/10.1126/science.288.5466.640			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784442	Green Published			2022-12-28	WOS:000086727100036
J	de Bernardis, P; Ade, PAR; Bock, JJ; Bond, JR; Borrill, J; Boscaleri, A; Coble, K; Crill, BP; De Gasperis, G; Farese, PC; Ferreira, PG; Ganga, K; Giacometti, M; Hivon, E; Hristov, VV; Iacoangeli, A; Jaffe, AH; Lange, AE; Martinis, L; Masi, S; Mason, PV; Mauskopf, PD; Melchiorri, A; Miglio, L; Montroy, T; Netterfield, CB; Pascale, E; Piacentini, F; Pogosyan, D; Prunet, S; Rao, S; Romeo, G; Ruhl, JE; Scaramuzzi, F; Sforna, D; Vittorio, N				de Bernardis, P; Ade, PAR; Bock, JJ; Bond, JR; Borrill, J; Boscaleri, A; Coble, K; Crill, BP; De Gasperis, G; Farese, PC; Ferreira, PG; Ganga, K; Giacometti, M; Hivon, E; Hristov, VV; Iacoangeli, A; Jaffe, AH; Lange, AE; Martinis, L; Masi, S; Mason, PV; Mauskopf, PD; Melchiorri, A; Miglio, L; Montroy, T; Netterfield, CB; Pascale, E; Piacentini, F; Pogosyan, D; Prunet, S; Rao, S; Romeo, G; Ruhl, JE; Scaramuzzi, F; Sforna, D; Vittorio, N			A flat Universe from high-resolution maps of the cosmic microwave background radiation	NATURE			English	Article							ANISOTROPY; SUPERNOVAE; EMISSION	The blackbody radiation left over from the Big Bang has been transformed by the expansion of the Universe into the nearly isotropic 2.73 K cosmic microwave background. Tiny inhomogeneities in the early Universe left their imprint on the microwave background in the form of small anisotropies in its temperature. These anisotropies contain information about basic cosmological parameters, particularly the total energy density and curvature of the Universe. Here we report the first images of resolved structure in the microwave background anisotropies over a significant part of the sky. Maps at four frequencies clearly distinguish the microwave background from foreground emission. We compute the angular power spectrum of the microwave background, and rnd a peak at Legendre multipole I-peak = (197 +/- 6), with an amplitude Delta T-200 = (69 +/- 8) mu K. This is consistent with that expected for cold dark matter models in a flat (euclidean) Universe, as favoured by standard inflationary models.	Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy; Queen Mary Univ London, Dept Phys, London E1 4NS, England; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Toronto, CITA, Toronto, ON M5S 3H8, Canada; LBNL, NERSC, Berkeley, CA 94720 USA; CNR, IROE, I-50127 Florence, Italy; Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; CALTECH, Pasadena, CA 91125 USA; Univ Roma Tor Vergata, Dipartimento Fis, I-00133 Rome, Italy; Univ Oxford, Oxford OX1 3RH, England; Coll France, PCC, F-75231 Paris 05, France; Univ Calif Berkeley, Ctr Particle Astrophys, Berkeley, CA 94720 USA; ENEA, Ctr Ric Frascati, I-00044 Frascati, Italy; Cardiff Univ, Dept Phys & Astron, Cardiff CF2 3YB, S Glam, Wales; Univ Massachusetts, Dept Phys & Astron, Amherst, MA 01003 USA; Univ Toronto, Dept Phys & Astron, Toronto, ON M5S 3H8, Canada; Ist Nazl Geofis, I-00143 Rome, Italy	Sapienza University Rome; University of London; Queen Mary University London; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Toronto; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Consiglio Nazionale delle Ricerche (CNR); University of California System; University of California Santa Barbara; California Institute of Technology; University of Rome Tor Vergata; University of Oxford; UDICE-French Research Universities; PSL Research University Paris; College de France; University of California System; University of California Berkeley; Italian National Agency New Technical Energy & Sustainable Economics Development; Cardiff University; University of Massachusetts System; University of Massachusetts Amherst; University of Toronto; Istituto Nazionale Geofisica e Vulcanologia (INGV)	de Bernardis, P (corresponding author), Univ Roma La Sapienza, Dipartimento Fis, P A Moro 2, I-00185 Rome, Italy.	debernardis@roma1.infn.it	Jaffe, Andrew/D-3526-2009; Ruhl, John/HHS-2212-2022; Melchiorri, Alessandro/AAD-1715-2020; de Gasperis, Giancarlo/Q-6532-2019; Piacentini, Francesco/E-7234-2010; Pascale, Enzo/A-3665-2012; de Gasperis, Giancarlo/C-8534-2012; Piacentini, Francesco/ABD-3434-2020; Hivon, Eric/C-4298-2014	Ruhl, John/0000-0001-5875-4751; Melchiorri, Alessandro/0000-0001-5326-6003; Piacentini, Francesco/0000-0002-5444-9327; Pascale, Enzo/0000-0002-3242-8154; de Gasperis, Giancarlo/0000-0003-2899-2171; Piacentini, Francesco/0000-0002-5444-9327; Hivon, Eric/0000-0003-1880-2733; ROMEO, Giovanni/0000-0002-5535-7803; Mauskopf, Philip/0000-0001-6397-5516; Masi, Silvia/0000-0001-5105-1439; de Bernardis, Paolo/0000-0001-6547-6446; Ade, Peter/0000-0002-5127-0401; Prunet, Simon/0000-0002-1755-4582				BAKER JC, 1999, ASTROPH9904415; BAKER JC, UNPUB MON NOT R ASTR; Bock JJ, 1998, P SOC PHOTO-OPT INS, V3357, P297, DOI 10.1117/12.317365; Bond JR, 1999, COMPUT SCI ENG, V1, P12; Bond JR, 1997, MON NOT R ASTRON SOC, V291, pL33; Borrill J, 1999, AIP CONF PROC, V476, P277; BORRILL J, 1999, P 5 EUR SGI CRAY MPP; Borrill J., 1999, ASTROPH9911389; CHEUNG LH, 1980, ASTROPHYS J, V240, P74, DOI 10.1086/158208; Coble K, 1999, ASTROPHYS J, V519, pL5, DOI 10.1086/312093; de Bernardis P., 1999, New Astronomy Reviews, V43, P289, DOI 10.1016/S1387-6473(99)00022-6; Delabrouille J, 1998, MON NOT R ASTRON SOC, V298, P445, DOI 10.1046/j.1365-8711.1998.01646.x; Efstathiou G, 1999, MON NOT R ASTRON SOC, V304, P75, DOI 10.1046/j.1365-8711.1999.02274.x; GORSKI KM, P MPA ESO C EUR SO O; Hinshaw G, 1996, ASTROPHYS J, V464, pL17, DOI 10.1086/310074; Hu W, 1997, NATURE, V386, P37, DOI 10.1038/386037a0; Kogut A, 1999, ASTR SOC P, V181, P91; KOGUT A, 1993, ASTROPHYS J, V419, P1, DOI 10.1086/173453; LEITCH EM, 1998, ASTROPH9807312; LEITCH EM, UNPUB ASTROPHYS J; Lewis A., 1999, ASTROPH9911177; Masi S, 1998, CRYOGENICS, V38, P319, DOI 10.1016/S0011-2275(97)00174-4; Masi S, 1999, CRYOGENICS, V39, P217, DOI 10.1016/S0011-2275(99)00018-1; MAUSKOPF P, UNPUB ASTROPHYS J; Mauskopf PD, 1997, APPL OPTICS, V36, P765, DOI 10.1364/AO.36.000765; MAUSKOPF PD, 1999, ASTROPH9911444; MELCHIORNI A, 1999, ASTROPH9911445; MELCHIORNI A, UNPUB ASTROPHYS J; MILLER AD, UNPUB ASTROPHYS J; MILLER AD, 1999, ASTROPH9906421; Netterfield CB, 1997, ASTROPHYS J, V474, P47, DOI 10.1086/303438; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; PETERSON JB, 1999, ASTROPH9910503; PRUNET S, 2000, P C EN DENS UN; SACHS RK, 1967, ASTROPHYS J, V147, P73, DOI 10.1086/148982; Schlegel DJ, 1998, ASTROPHYS J, V500, P525, DOI 10.1086/305772; Scott PF, 1996, ASTROPHYS J, V461, pL1, DOI 10.1086/310000; SELJAK U, 1996, ASTROPHYS J, V437, P469; Tegmark M, 1997, PHYS REV D, V56, P4514, DOI 10.1103/PhysRevD.56.4514; Toffolatti L, 1998, MON NOT R ASTRON SOC, V297, P117, DOI 10.1046/j.1365-8711.1998.01458.x; Torbet E, 1999, ASTROPHYS J, V521, pL79, DOI 10.1086/312197; Weinberg S., 1972, GRAVITATION COSMOLOG; WILSON GW, 1999, ASTROPH9902047; WILSON GW, UNPUB ASTROPHYS J; WRIGHT AE, 1994, ASTROPHYS J SUPPL S, V91, P111, DOI 10.1086/191939; WRIGHT EL, 1994, ASTROPHYS J, V420, P1, DOI 10.1086/173537	47	2236	2240	2	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 27	2000	404	6781					955	959		10.1038/35010035	http://dx.doi.org/10.1038/35010035			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801117	Green Submitted			2022-12-28	WOS:000086762000045
J	Hu, W				Hu, W			Ringing in the new cosmology	NATURE			English	Editorial Material									Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Hu, W (corresponding author), Inst Adv Study, Sch Nat Sci, Olden Lane, Princeton, NJ 08540 USA.							Bahcall NA, 1999, SCIENCE, V284, P1481, DOI 10.1126/science.284.5419.1481; de Bernardis P, 2000, NATURE, V404, P955, DOI 10.1038/35010035; Fukugita M, 1998, ASTROPHYS J, V503, P518, DOI 10.1086/306025; Hu W, 1997, NATURE, V386, P37, DOI 10.1038/386037a0; MAUSKOPF PD, IN PRESS ASTROPHYS J; Miller AD, 1999, ASTROPHYS J, V524, pL1, DOI 10.1086/312293; PEEBLES PJE, 1970, ASTROPHYS J, V162, P815, DOI 10.1086/150713; Smoot G.F., 1992, APJ, V396, pL1	8	20	20	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					939	940		10.1038/35010242	http://dx.doi.org/10.1038/35010242			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801106				2022-12-28	WOS:000086762000034
J	Ober, CK				Ober, CK			Polymer science - Shape persistence of synthetic polymers	SCIENCE			English	Editorial Material							POLYELECTROLYTE		Cornell Univ, Dept Mat Sci, Ithaca, NY 14853 USA	Cornell University	Ober, CK (corresponding author), Cornell Univ, Dept Mat Sci, 327 Bard Hall, Ithaca, NY 14853 USA.		Ober, Christopher/AAI-1568-2019	Ober, Christopher/0000-0002-3805-3314				Brodowski G, 1996, MACROMOLECULES, V29, P6962, DOI 10.1021/ma960256i; Chen JT, 1996, SCIENCE, V273, P343, DOI 10.1126/science.273.5273.343; Gerle M, 1999, MACROMOLECULES, V32, P2629, DOI 10.1021/ma9816463; HERMANN W, 1997, MACROMOLECULES, V30, P4966; *MAX PLANCK I POL, 2000, SHAP PERS MACR CHEM; Philippova OE, 1998, MACROMOLECULES, V31, P1168, DOI 10.1021/ma970597b; Schluter AD, 2000, ANGEW CHEM INT EDIT, V39, P864, DOI 10.1002/(SICI)1521-3773(20000303)39:5<864::AID-ANIE864>3.0.CO;2-E; Smolenyak P, 1999, J AM CHEM SOC, V121, P8628, DOI 10.1021/ja991498b; WEGNER G, 1969, Z NATURFORSCH PT B, VB 24, P824; Wegner G, 2000, ACTA MATER, V48, P253, DOI 10.1016/S1359-6454(99)00298-0	10	38	38	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					448	449		10.1126/science.288.5465.448	http://dx.doi.org/10.1126/science.288.5465.448			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10798980				2022-12-28	WOS:000086626000024
J	Spurgeon, D				Spurgeon, D			Ontario joins the genomics goldrush	NATURE			English	News Item																		2000, NATURE, V404, P8	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					692	692		10.1038/35008215	http://dx.doi.org/10.1038/35008215			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10809625	Bronze			2022-12-28	WOS:000086523600006
J	Ward, C				Ward, C			Regenesis - Transcript of the last cybercast from Fox-Warner reporter Daniel Lundgren.	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					708	708		10.1038/35008162	http://dx.doi.org/10.1038/35008162			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783866	Bronze			2022-12-28	WOS:000086523600027
J	Barry, CA; Bradley, CP; Britten, N; Stevenson, FA; Barber, N				Barry, CA; Bradley, CP; Britten, N; Stevenson, FA; Barber, N			Patients' unvoiced agendas in general practice consultations: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							DOCTORS	Objective To investigate patients' agendas before consultation and to assess which aspects of agendas are voiced in the consultation and the effects; of unvoiced agendas on outcomes. Design Qualitative study. Setting 20 general practices in south east England and the West Midlands. Participants 35 patients consulting 20 general practitioners in appointment and emergency surgeries. Results Patients' agendas are complex and multifarious. Only four of 35 patients voiced all their agendas in consultation. Agenda items most commonly voiced were symptoms and requests for diagnoses and prescriptions. The most common unvoiced agenda items were: worries about possible diagnosis and what die future holds; patients' ideas about what is wrong; side effects; not wanting a prescription; and information relating to social contest. Agenda items that were not raised in the consultation often led to specific problem outcomes (for example, major misunderstandings), unwanted prescriptions, non-use of prescriptions, and non-adherence to treatment. In all of the 14 consultations with problem outcomes at least one of the problems was related to an unvoiced agenda item. Conclusion Patients have many needs and when these are not voiced they can not be addressed. Some of the poor outcomes in the case studies were related to unvoiced agenda items. This suggests that when patients and their needs are more fully articulated in the consultation better health care may be effected. Steps should be taken in both daily clinical practice and research to encourage the voicing of patients' agendas.	Kings Coll London, Guys Kings & St Thomass Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England; Univ Coll Cork, Dept Gen Practice, Cork, Ireland; Univ London, Sch Pharm, London WC1N 1AX, England	University of London; King's College London; University College Cork; University of London; University College London; University of London School of Pharmacy	Barry, CA (corresponding author), Brunel Univ, Dept Human Sci, Ctr Study Hlth Sickness & Disablement, Uxbridge UB8 3PH, Middx, England.	christine.barry@brunel.ac.uk	Stevenson, Fiona/AAJ-2727-2021; González-Gay, Miguel A./B-2306-2008; Hajeer, Ali/L-4189-2019	Stevenson, Fiona/0000-0003-2139-2309; González-Gay, Miguel A./0000-0002-7924-7406; Hajeer, Ali/0000-0003-2727-9964; Bradley, Colin/0000-0002-3595-9567				Barry CA, 1999, QUAL HEALTH RES, V9, P26, DOI 10.1177/104973299129121677; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; Britten N, 2000, BMJ-BRIT MED J, V320, P484, DOI 10.1136/bmj.320.7233.484; CAMPION PD, 1992, FAM PRACT, V9, P181, DOI 10.1093/fampra/9.2.181; FRANKEL R, 1989, COMMUNICATING MED PA; HENBEST RJ, 1989, FAM PRACT, V6, P249, DOI 10.1093/fampra/6.4.249; LAZARUS E S, 1988, Medical Anthropology Quarterly, V2, P34, DOI 10.1525/maq.1988.2.1.02a00030; LEVENSTEIN JH, 1986, FAM PRACT, V3, P24, DOI 10.1093/fampra/3.1.24; Mason J, 1998, QUALITATIVE RES; Mishler EG, 1984, DISCOURSE MED DIALEC; *ROYAL PHARM SOC, 1997, COMPL CONC ACH SHAR; SALMON P, 1994, SOC SCI MED, V38, P585, DOI 10.1016/0277-9536(94)90255-0; Stevenson FA, 2000, SOC SCI MED, V50, P829, DOI 10.1016/S0277-9536(99)00376-7; Stewart M A, 1979, J R Coll Gen Pract, V29, P77; Stimson G. V., 1975, GOING SEE DOCTOR CON; WEBB S, 1994, BRIT J GEN PRACT, V44, P165; Winefield HR, 1995, FAM PRACT, V12, P402, DOI 10.1093/fampra/12.4.402	17	351	362	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1246	1250		10.1136/bmj.320.7244.1246	http://dx.doi.org/10.1136/bmj.320.7244.1246			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	313CF	10797036	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000086981400021
J	Baker, D				Baker, D			A surprising simplicity to protein folding	NATURE			English	Article							SINGLE-DOMAIN PROTEINS; TRANSITION-STATE; LATTICE MODELS; CONTACT ORDER; DYNAMICS; SIMULATIONS; LANDSCAPE; SEQUENCES; PATHWAYS; KINETICS	The polypeptide chains that make up proteins have thousands of atoms and hence millions of possible inter-atomic interactions. It might be supposed that the resulting complexity would make prediction of protein structure and protein-folding mechanisms nearly impossible. But the fundamental physics underlying folding may be much simpler than this complexity would lead us to expect: folding rates and mechanisms appear to be largely determined by the topology of the native (folded) state, and new methods have shown great promise in predicting protein-folding mechanisms and the three-dimensional structures of proteins.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Baker, D (corresponding author), Univ Washington, Dept Biochem, J567 Hlth Sci Bldg,Box 357350, Seattle, WA 98195 USA.		Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217				ABKEVICH VI, 1994, BIOCHEMISTRY-US, V33, P10026, DOI 10.1021/bi00199a029; Alm E, 1999, P NATL ACAD SCI USA, V96, P11305, DOI 10.1073/pnas.96.20.11305; Alm E, 1999, CURR OPIN STRUC BIOL, V9, P189, DOI 10.1016/S0959-440X(99)80027-X; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Burton RE, 1998, BIOCHEMISTRY-US, V37, P5337, DOI 10.1021/bi980245c; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; Chiti F, 1999, NAT STRUCT BIOL, V6, P1005; Debe DA, 1999, J MOL BIOL, V294, P619, DOI 10.1006/jmbi.1999.3278; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Galzitskaya OV, 1999, P NATL ACAD SCI USA, V96, P11299, DOI 10.1073/pnas.96.20.11299; GO N, 1983, ANNU REV BIOPHYS BIO, V12, P183, DOI 10.1146/annurev.bb.12.060183.001151; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; Kim DE, 1998, P NATL ACAD SCI USA, V95, P4982, DOI 10.1073/pnas.95.9.4982; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Li AJ, 1996, J MOL BIOL, V257, P412, DOI 10.1006/jmbi.1996.0172; LopezHernandez E, 1996, FOLD DES, V1, P43, DOI 10.1016/S1359-0278(96)00011-9; Martinez JC, 1999, NAT STRUCT BIOL, V6, P1010; Micheletti C, 1999, PHYS REV LETT, V82, P3372, DOI 10.1103/PhysRevLett.82.3372; Moult J, 1999, PROTEINS, P2; Munoz V, 1999, P NATL ACAD SCI USA, V96, P11311, DOI 10.1073/pnas.96.20.11311; Murzin AG, 1999, PROTEINS, P88; Onuchic JN, 2000, ADV PROTEIN CHEM, V53, P87; Orengo CA, 1999, PROTEINS, P149; Ortiz AR, 1999, PROTEINS, P177; Pande VS, 1998, CURR OPIN STRUC BIOL, V8, P68, DOI 10.1016/S0959-440X(98)80012-2; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; Portman JJ, 1998, PHYS REV LETT, V81, P5237, DOI 10.1103/PhysRevLett.81.5237; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; Riddle DS, 1999, NAT STRUCT BIOL, V6, P1016; Riddle DS, 1997, NAT STRUCT BIOL, V4, P805, DOI 10.1038/nsb1097-805; Samudrala R, 1999, PROTEINS, P194; Shakhnovich EI, 1998, FOLD DES, V3, pR108, DOI 10.1016/S1359-0278(98)00056-X; Shea JE, 1999, P NATL ACAD SCI USA, V96, P12512, DOI 10.1073/pnas.96.22.12512; Sheinerman FB, 1997, PROTEINS, V29, P193, DOI 10.1002/(SICI)1097-0134(199710)29:2<193::AID-PROT7>3.0.CO;2-E; Simons KT, 1999, PROTEINS, P171; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Thirumalai D, 1998, FOLD DES, V3, pR112, DOI 10.1016/S1359-0278(98)00057-1; Villegas V, 1998, J MOL BIOL, V283, P1027, DOI 10.1006/jmbi.1998.2158; Weigelt J, 1999, STRUCT FOLD DES, V7, P681, DOI 10.1016/S0969-2126(99)80089-6	44	606	631	3	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	2000	405	6782					39	42		10.1038/35011000	http://dx.doi.org/10.1038/35011000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811210				2022-12-28	WOS:000086901600043
J	Kniffen, DA				Kniffen, DA			Instrument's ability to do the job is NASA's priority	NATURE			English	Letter									NASA, Off Space Sci, Res Program Management Div, Washington, DC 20546 USA	National Aeronautics & Space Administration (NASA)	Kniffen, DA (corresponding author), NASA, Off Space Sci, Res Program Management Div, Washington, DC 20546 USA.							Macilwain C, 2000, NATURE, V403, P587	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					14	14		10.1038/35011154	http://dx.doi.org/10.1038/35011154			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811195	Bronze			2022-12-28	WOS:000086901600018
J	Snow, V; Lascher, S; Mottur-Pilson, C				Snow, V; Lascher, S; Mottur-Pilson, C		Amer Coll Phys Amer Soc Internal M	Pharmacologic treatment of acute major depression and dysthymia	ANNALS OF INTERNAL MEDICINE			English	Article							RECURRENT		Amer Coll Physicians, Amer Soc Internal Med, Educ Div, Sci Policy Dept,Customer Serv, Philadelphia, PA 19106 USA	American College of Physicians	Snow, V (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, Educ Div, Sci Policy Dept,Customer Serv, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							*DEPR GUID PAN, 1993, AHCPR PUBL; Glass RM, 1999, JAMA-J AM MED ASSOC, V281, P83, DOI 10.1001/jama.281.1.83; Medical Economics, 1998, MED EC; MULROW CD, 1999, AHCPR PUBLICATION; Reynolds CF, 1999, JAMA-J AM MED ASSOC, V281, P39, DOI 10.1001/jama.281.1.39; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897	6	96	98	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					738	742		10.7326/0003-4819-132-9-200005020-00010	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308VT	10787369				2022-12-28	WOS:000086734100009
J	Herxheimer, A; McPherson, A; Miller, R; Shepperd, S; Yaphe, J; Ziebland, S				Herxheimer, A; McPherson, A; Miller, R; Shepperd, S; Yaphe, J; Ziebland, S			Database of patients' experiences (DIPEx): a multi-media approach to sharing experiences and information	LANCET			English	Article							OUTCOMES; INVOLVEMENT; CRITERIA; QUALITY; CARE	The Database of Individual Patients' Experience of illness (DIPEx) is a multimedia website and CD-ROM that links patients' experiences with evidence-based information about treatments and the illness itself and with a range of other resources that may be useful, including support groups and links to other websites. DIPEx aims to identify the questions that matter to people when they are ill and it has potential for informing patients, educating health care professionals, and providing a patient-centred perspective to researchers and those who manage health services.	Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Imperial Canc Res Fund,Gen Practice Res Grp, Oxford OX3 7LF, England	University of Oxford	Ziebland, S (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, Imperial Canc Res Fund,Gen Practice Res Grp, Old Rd, Oxford OX3 7LF, England.	sue.ziebland@dphpc.ox.ac.uk	Yaphe, John/B-8034-2010	Yaphe, John/0000-0002-3131-9984; Shepperd, Sasha/0000-0001-6384-8322; Ziebland, Sue/0000-0002-6496-4859				ALDISS B, 1999, FEAST FINISHED; BAYLEY J, 1998, IRIS MURDOCH; BRODY DS, 1989, J GEN INTERN MED, V4, P506, DOI 10.1007/BF02599549; Charnock D, 1999, J EPIDEMIOL COMMUN H, V53, P105, DOI 10.1136/jech.53.2.105; COULTER A, 1998, INFORMING PATIENTS A; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; GANN B, 1994, DISSEMINATION INFORM; Glaser B.G., 1965, AWARENESS DYING; Gray JAM, 1998, BRIT MED J, V317, P1500; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HANLEY B, 1999, RES DEV NHS CAN YOU; Hood CA, 1998, BRIT MED J, V316, P1009, DOI 10.1136/bmj.316.7136.1009; Hurwitz, 1998, NARRATIVE BASED MED; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kim P, 1999, BMJ-BRIT MED J, V318, P647, DOI 10.1136/bmj.318.7184.647; Kjellgren KI, 1997, SCAND J PRIM HEALTH, V15, P188, DOI 10.3109/02813439709035026; Kleinman A., 1988, ILLNESS NARRATIVES; LEYDON G, IN PRESS BMJ; Mandell H, 1987, DOCTORS GET SICK; Marshall MN, 1996, FAM PRACT, V13, P522, DOI 10.1093/fampra/13.6.522; McCrum R., 1998, MY YEAR OFF REDISCOV; McLellan F, 1998, LANCET, V352, P39; MEADE CD, 1991, PATIENT EDUC COUNS, V17, P153, DOI 10.1016/0738-3991(91)90017-Y; MEREDITH P, 1995, BRIT MED J, V311, P4, DOI 10.1136/bmj.311.6996.4; Mishler E. G., 1991, RES INTERVIEWING; MORGAN M, 1988, SOCIOL HEALTH ILL, V10, P561, DOI 10.1111/1467-9566.ep10837256; MORSE J, 2000, RESEARCH, V10, P3; Picardie R., 1998, I SAY GOODBYE; Tuckett D, 1985, M EXP APPR SHAR ID M	30	88	89	1	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2000	355	9214					1540	1543		10.1016/S0140-6736(00)02174-7	http://dx.doi.org/10.1016/S0140-6736(00)02174-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801187				2022-12-28	WOS:000086830100041
J	Wenzel, T; Jaranson, J; Sibitz, I; Kastrup, M				Wenzel, T; Jaranson, J; Sibitz, I; Kastrup, M			Torture and the scientific community	LANCET			English	Editorial Material							BONE-SCINTIGRAPHY		World Psychiat Assoc, Sect Psychol Consequences Torture & Persecut, A-1160 Vienna, Austria; Univ Hosp Vienna, Dept Psychiat, Vienna, Austria; Rehabil Ctr Torture Survivors, Copenhagen, Denmark	University Hospital Vienna	Wenzel, T (corresponding author), World Psychiat Assoc, Sect Psychol Consequences Torture & Persecut, A-1160 Vienna, Austria.			Wenzel, Thomas/0000-0003-3990-1773				*IRCT, IN PRESS TORTURE; LOK V, 1991, LANCET, V337, P846, DOI 10.1016/0140-6736(91)92548-G; Salinsky M, 1998, LANCET, V352, P1854, DOI 10.1016/S0140-6736(05)79918-9; Tunca M, 1998, LANCET, V352, P1859, DOI 10.1016/S0140-6736(05)79928-1; YUKSEL S, 1989, LANCET, V2, P866	5	2	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1550	1550		10.1016/S0140-6736(05)74598-0	http://dx.doi.org/10.1016/S0140-6736(05)74598-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801191				2022-12-28	WOS:000086830100045
J	Gao, YJ; Ferguson, DO; Xie, W; Manis, JP; Sekiguchi, J; Frank, KM; Chaudhuri, J; Horner, J; DePinho, RA; Alt, FW				Gao, YJ; Ferguson, DO; Xie, W; Manis, JP; Sekiguchi, J; Frank, KM; Chaudhuri, J; Horner, J; DePinho, RA; Alt, FW			Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development	NATURE			English	Article							STRAND BREAK REPAIR; V(D)J RECOMBINATION; TRANSLOCATIONS; TRANSPOSITION; CELLS; RAG1; MICE	XRCC4 is a non-homologous end-joining protein employed in DNA double strand break repair and in V(D)J recombination(1,2). In mice, XRCC4-deficiency causes a pleiotropic phenotype, which includes embryonic lethality and massive neuronal apoptosis 2. When DNA damage is not repaired, activation of the cell cycle checkpoint protein p53 can lead to apoptosis(3). Here we show that p53-deficiency rescues several aspects of the XRCC4-deficient phenotype, including embryonic lethality, neuronal apoptosis, and impaired cellular proliferation. However, there was no significant rescue of impaired V(D)J recombination or lymphocyte development. Although p53-deficiency allowed postnatal survival of XRCC4-deficient mice, they routinely succumbed to pro-B-cell lymphomas which had chromosomal translocations linking amplified c-myc oncogene and IgH locus sequences. Moreover, even XRCC4-deficient embryonic fibroblasts exhibited marked genomic instability including chromosomal translocations. Our findings support a crucial role for the non-homologous end-joining pathway as a caretaker of the mammalian genome, a role required both for normal development and for suppression of tumours.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Alt, FW (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.	alt@rascal.med.harvard.edu		Sekiguchi, JoAnn/0000-0002-7178-4258; DePinho, Ronald/0000-0002-5625-577X				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bieche I, 1998, INT J CANCER, V78, P661, DOI 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.3.CO;2-9; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; Di JA, 1996, J EXP MED, V183, P1923, DOI 10.1084/jem.183.4.1923; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658	25	479	488	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	2000	404	6780					897	900		10.1038/35009138	http://dx.doi.org/10.1038/35009138			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786799				2022-12-28	WOS:000086625000051
J	Ihinger, PD; Zink, SI				Ihinger, PD; Zink, SI			Determination of relative growth rates of natural quartz crystals	NATURE			English	Article							LONG-VALLEY; MINERALS; WATER; CATHODOLUMINESCENCE; SPECTROSCOPY; PHENOCRYSTS; MANTLE	Although the theory describing crystal growth in the geological environment is well established(1-3), there are few quantitative studies that delimit the absolute time involved in the growth of natural crystals(4-6). The actual mechanisms responsible for the variation in size and shape of individual crystal faces are, in fact, not well understood. Here we describe a micro-infrared spectroscopic study of a single, gem-quality quartz crystal that allows us to measure the size, shape and relative growth rate of each of the crystal faces that are active throughout its growth history. We demonstrate that the abundances of hydrogen-bearing impurities can serve as 'speedometers' to monitor the growth rate of advancing crystal faces. Our technique can be applied to crystals from a variety of geological environments to determine their growth histories. Within the electronics industry, the technique might facilitate the production of defect-free synthetic crystals required for high-quality resonators and, ultimately, might allow determination of the absolute time involved in geological processes such as the crystallization of magmas, fluid flow in metamorphism and the sealing of open cracks in earthquake rupture zones.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	Yale University	Ihinger, PD (corresponding author), Yale Univ, Dept Geol & Geophys, POB 6666, New Haven, CT 06520 USA.							AINES RD, 1984, J GEOPHYS RES, V89, P4059, DOI 10.1029/JB089iB06p04059; BELL DR, 1992, SCIENCE, V255, P1391, DOI 10.1126/science.255.5050.1391; CHRISTENSEN JN, 1993, CONTRIB MINERAL PETR, V113, P100, DOI 10.1007/BF00320834; DODD DM, 1967, AM MINERAL, V52, P149; DOWTY E, 1976, AM MINERAL, V61, P460; Frondel C., 1962, SYSTEM MINERALOGY SI, P77; GRIGGS DT, 1965, SCIENCE, V147, P292, DOI 10.1126/science.147.3655.292; Kats A., 1962, PHILIPS RES REP, V17, P133; KIRKPATRICK RJ, 1975, AM MINERAL, V60, P798; KRONENBERG AK, 1994, REV MINERAL, V29, P123; KRONENBERG AK, 1986, J GEOPHYS RES-SOLID, V91, P2723, DOI 10.1029/JB091iB12p12723; Mackwell S., 1985, GEOPHYS MONOGR SER, V31, P141; Martin JJ, 1996, PROCEEDINGS OF THE 1996 IEEE INTERNATIONAL FREQUENCY CONTROL SYMPOSIUM (50TH ANNIVERSARY), P126, DOI 10.1109/FREQ.1996.559831; MARTIN JJ, 1983, J CRYST GROWTH, V62, P203, DOI 10.1016/0022-0248(83)90026-X; NAKAMOTO K, 1955, J AM CHEM SOC, V77, P6480, DOI 10.1021/ja01629a013; ONASCH CM, 1995, GEOLOGY, V23, P1103, DOI 10.1130/0091-7613(1995)023<1103:DPOOIA>2.3.CO;2; PAQUETTE J, 1995, GEOCHIM COSMOCHIM AC, V59, P735, DOI 10.1016/0016-7037(95)00004-J; PATERSON MS, 1986, PHYS CHEM MINER, V13, P245, DOI 10.1007/BF00308276; RAMSEYER K, 1988, MINERAL MAG, V52, P669, DOI 10.1180/minmag.1988.052.368.11; REEDER RJ, 1989, SEDIMENT GEOL, V65, P239, DOI 10.1016/0037-0738(89)90026-2; Reid MR, 1997, EARTH PLANET SC LETT, V150, P27, DOI 10.1016/S0012-821X(97)00077-0; ROSSMAN GR, 1988, REV MINERAL, V18, P193; ROVETTA MR, 1989, J GEOPHYS RES-SOLID, V94, P5840, DOI 10.1029/JB094iB05p05840; SMYTH JR, 1987, AM MINERAL, V72, P1051; Sunagawa I, 1987, MORPHOLOGY CRYSTALS, P509; SUNAGAWA I, 1987, GEOCHEMISTRY MINERAL, P683; TULLIS J, 1979, B MINERAL, V102, P110, DOI 10.3406/bulmi.1979.7263; VANCE D, 1990, EARTH PLANET SC LETT, V97, P227, DOI 10.1016/0012-821X(90)90044-X; Watson EB, 1995, AM MINERAL, V80, P1179; Watt GR, 1997, GEOCHIM COSMOCHIM AC, V61, P4337, DOI 10.1016/S0016-7037(97)00248-2; [No title captured]	31	45	46	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					865	869		10.1038/35009091	http://dx.doi.org/10.1038/35009091			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786791				2022-12-28	WOS:000086625000043
J	Eng, PJ; Trainor, TP; Brown, GE; Waychunas, GA; Newville, M; Sutton, SR; Rivers, ML				Eng, PJ; Trainor, TP; Brown, GE; Waychunas, GA; Newville, M; Sutton, SR; Rivers, ML			Structure of the hydrated alpha-Al2O3 (0001) surface	SCIENCE			English	Article							METAL-OXIDE SURFACES; ELECTRONIC-STRUCTURE; ALUMINA SURFACES; WATER; ADSORPTION; AL2O3; H2O; SPECTROSCOPY; SORPTION; CO(II)	The physical and chemical properties of the hydrated alpha-Al2O3 (0001) surface are important for understanding the reactivity of natural and synthetic aluminum-containing oxides. The structure of this surface was determined in the presence of water vapor at 300 kelvin by crystal truncation rod diffraction at a third-generation synchrotron x-ray source. The fully hydrated surface is oxygen terminated, with a 53% contracted double Al Layer directly below. The structure is an intermediate between alpha-Al2O3 and gamma-Al(OH)(3), a fully hydroxylated form of alumina. A semiordered oxygen Layer about 2.3 angstroms above the terminal oxygen Layer is interpreted as adsorbed water. The clean alpha-Al2O3 (0001) surface, in contrast, is AL terminated and significantly relaxed relative to the bulk structure. These differences explain the different reactivities of the clean and hydroxylated surfaces.	Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL 60637 USA; Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA; Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Chicago	Eng, PJ (corresponding author), Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL 60637 USA.		Eng, Peter/ABA-8842-2021; Newville, Matthew G/B-3372-2009; Newville, Matthew/GNP-3282-2022	Eng, Peter/0000-0002-8072-3203; Newville, Matthew G/0000-0001-6938-1014; 				Ahn J, 1997, SURF SCI, V388, P121, DOI 10.1016/S0039-6028(97)00383-X; Bargar JR, 1997, J COLLOID INTERF SCI, V185, P473, DOI 10.1006/jcis.1996.4574; Brown GE, 1999, CHEM REV, V99, P77, DOI 10.1021/cr980011z; BROWN ID, 1985, ACTA CRYSTALLOGR B, V41, P244, DOI 10.1107/S0108768185002063; CHEN JG, 1986, J CHEM PHYS, V84, P5906, DOI 10.1063/1.449902; COUSTET V, 1994, SURF SCI, V307, P1161, DOI 10.1016/0039-6028(94)91557-1; Di Felice R, 1999, PHYS REV B, V60, pR16287, DOI 10.1103/PhysRevB.60.R16287; DYER C, 1993, SPECTROCHIM ACTA A, V49, P691, DOI 10.1016/0584-8539(93)80092-O; Elam JW, 1998, J PHYS CHEM B, V102, P7008, DOI 10.1021/jp981070j; Fenter P, 2000, GEOCHIM COSMOCHIM AC, V64, P1221, DOI 10.1016/S0016-7037(99)00403-2; FITTS J, UNPUB; Gates B.C., 1992, CATALYTIC CHEM; GAUTIER M, 1994, J AM CERAM SOC, V77, P323, DOI 10.1111/j.1151-2916.1994.tb06999.x; GODIN TJ, 1994, PHYS REV B, V49, P7691, DOI 10.1103/PhysRevB.49.7691; GUENARD P, 1997, SURF REV LETT, V5, P321; Hass KC, 1998, SCIENCE, V282, P265, DOI 10.1126/science.282.5387.265; HIERNSTRA T, 1999, LANGMUIR, V15, P5942; ISHIZAWA N, 1980, ACTA CRYSTALLOGR B, V36, P228, DOI 10.1107/S0567740880002981; Kelber JA, 2000, SURF SCI, V446, P76, DOI 10.1016/S0039-6028(99)01089-4; KIRFEL A, 1990, ACTA CRYSTALLOGR A, V46, P271, DOI 10.1107/S0108767389012596; KNOZINGER H, 1978, CATAL REV, V17, P31, DOI 10.1080/03602457808080878; Laiti E, 1998, LANGMUIR, V14, P825, DOI 10.1021/la970383n; LEE DH, 1995, MATER LETT, V23, P241, DOI 10.1016/0167-577X(95)00039-9; Liu P, 1998, SURF SCI, V417, P53, DOI 10.1016/S0039-6028(98)00661-X; MANASSIDIS I, 1993, SURF SCI LETT, V285, P517; Nelson CE, 1998, SURF SCI, V416, P341, DOI 10.1016/S0039-6028(98)00439-7; Pauling L., 1960, NATURE CHEM BOND, P547; Puchin VE, 1997, SURF SCI, V370, P190, DOI 10.1016/S0039-6028(96)00971-5; Renaud G, 1998, SURF SCI REP, V32, P1, DOI 10.1016/S0167-5729(98)00005-3; Robinson I. K., 1991, HDB SYNCHROTRON RAD, V3, P221; ROBINSON IK, 1992, REP PROG PHYS, V55, P599, DOI 10.1088/0034-4885/55/5/002; Sverjensky DA, 1996, GEOCHIM COSMOCHIM AC, V60, P3773, DOI 10.1016/0016-7037(96)00207-4; THIEL PA, 1987, SURF SCI REP, V7, P211, DOI 10.1016/0167-5729(87)90001-X; Toofan J, 1998, SURF SCI, V401, P162, DOI 10.1016/S0039-6028(97)01031-5; Towle SN, 1999, J COLLOID INTERF SCI, V217, P312, DOI 10.1006/jcis.1999.6351; Verdozzi C, 1999, PHYS REV LETT, V82, P799, DOI 10.1103/PhysRevLett.82.799; Wefers K, 1987, 19 ALC LAB ALC CTR; Wittbrodt JM, 1998, J PHYS CHEM B, V102, P6539, DOI 10.1021/jp981516w; YAN BD, 1987, IEEE T COMPON HYBR, V10, P247	39	455	455	10	227	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1029	1033		10.1126/science.288.5468.1029	http://dx.doi.org/10.1126/science.288.5468.1029			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807569	Green Submitted			2022-12-28	WOS:000086988400031
J	Ostro, SJ; Hudson, RS; Nolan, MC; Margot, JL; Scheeres, DJ; Campbell, DB; Magri, C; Giorgini, JD; Yeomans, DK				Ostro, SJ; Hudson, RS; Nolan, MC; Margot, JL; Scheeres, DJ; Campbell, DB; Magri, C; Giorgini, JD; Yeomans, DK			Radar observations of asteroid 216 Kleopatra	SCIENCE			English	Article							SHAPE; COLLISIONS; TOUTATIS	Radar observations of the main-belt, M-class asteroid 216 Kleopatra reveal a dumbbell-shaped object with overall dimensions of 217 kilometers by 94 kilometers by 81 kilometers (+/-25%). The asteroid's surface properties are consistent with a regolith having a metallic composition and a porosity comparable to that of Lunar soil. Kleopatra's shape is probably the outcome of an exotic sequence of collisional events, and much of its interior may have an unconsolidated rubble-pile structure.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Washington State Univ, Sch Elect Engn & Comp Sci, Pullman, WA 99164 USA; Arecibo Observ, Arecibo, PR 00612 USA; Univ Michigan, Dept Aerosp Engn, Ann Arbor, MI 48109 USA; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Univ Maine, Farmington, ME 04938 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Washington State University; National Aeronautics & Space Administration (NASA); University of Michigan System; University of Michigan; Cornell University; University of Maine System; University of Maine Farmington; University of Maine Orono	Ostro, SJ (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.		Margot, Jean-Luc/A-6154-2012; Nolan, Michael C/H-4980-2012	Margot, Jean-Luc/0000-0001-9798-1797; Nolan, Michael C/0000-0001-8316-0680; SCHEERES, DANIEL/0000-0003-0558-3842				ANDREWS AK, 1995, OPT LETT, V20, P2327, DOI 10.1364/OL.20.002327; Asphaug E, 1998, NATURE, V393, P437, DOI 10.1038/30911; CARRIER WD, 1973, P LUNAR PLANET SCI C, V4, P2403; Chapman CR, 1999, ICARUS, V140, P28, DOI 10.1006/icar.1999.6119; Davis D.R., 1979, ASTER 528; Dunham D.W., 1981, OCCULTATION NEWSL, V2, P139; DUNHAM DW, 1992, SKY TELESCOPE, V83, P73; FARINELLA P, 1982, ICARUS, V52, P409, DOI 10.1016/0019-1035(82)90003-3; Harmon JK, 1999, J GEOPHYS RES-PLANET, V104, P14065, DOI 10.1029/1998JE900042; HARTMANN WK, 1978, ICARUS, V36, P353, DOI 10.1016/0019-1035(78)90114-8; HARTMANN WK, 1979, ASTEROIDS, P466; HUDSON RS, 1995, SCIENCE, V270, P84, DOI 10.1126/science.270.5233.84; HUDSON RS, 1994, SCIENCE, V263, P940, DOI 10.1126/science.263.5149.940; LEINHARDT ZM, IN PRESS ICARUS; MAGNUSSON P, 1990, ICARUS, V85, P229, DOI 10.1016/0019-1035(90)90113-N; Magri C, 1999, ICARUS, V140, P379, DOI 10.1006/icar.1999.6130; MARCHIS D, 1999, 7308 IAU SMITHS ASTR; McKay D.S., 1989, ASTEROIDS, VII, P617; MITCHELL DL, 1995, ICARUS, V118, P105, DOI 10.1006/icar.1995.1180; Mitchell DL, 1996, ICARUS, V124, P113, DOI 10.1006/icar.1996.0193; OSTRO SJ, 1991, SCIENCE, V252, P1399, DOI 10.1126/science.252.5011.1399; SCALTRITI F, 1978, ICARUS, V34, P425; Scheeres DJ, 1998, ICARUS, V132, P53, DOI 10.1006/icar.1997.5870; SIMPSON RA, 1982, IEEE T ANTENN PROPAG, V30, P438, DOI 10.1109/TAP.1982.1142803; Strahler A. N., 1971, EARTH SCI; THOLEN DJ, 1980, SKY TELESCOPE, V60, P203; ZAPPALA V, 1983, ICARUS, V53, P458, DOI 10.1016/0019-1035(83)90210-5; [No title captured]	28	147	149	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					836	839		10.1126/science.288.5467.836	http://dx.doi.org/10.1126/science.288.5467.836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797000				2022-12-28	WOS:000086869600030
J	Zhou, ZH; Dougherty, M; Jakana, J; He, J; Rixon, FJ; Chiu, W				Zhou, ZH; Dougherty, M; Jakana, J; He, J; Rixon, FJ; Chiu, W			Seeing the herpesvirus capsid at 8.5 angstrom	SCIENCE			English	Article							SIMPLEX-VIRUS TYPE-1; ELECTRON CRYOMICROSCOPY; PROTEIN; PARTICLES; TRIPLEX; DNA; RECONSTRUCTION; VISUALIZATION; MATURATION; SCAFFOLD	Human herpesviruses are large and structurally complex viruses that cause a variety of diseases. The three-dimensional structure of the herpesvirus capsid has been determined at 8.5 angstrom resolution by electron cryomicroscopy. More than 30 putative alpha helices were identified in the four proteins that make up the 0.2 billion-dalton shell. Some of these helices are located at domains that undergo conformational changes during capsid assembly and DNA packaging. The unique spatial arrangement of the heterotrimer at the local threefold positions accounts for the asymmetric interactions with adjacent capsid components and the unusual co-dependent folding of its subunits.	Baylor Coll Med, Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA; Baylor Coll Med, Grad Program Struct & Computat Biol & Mol Biophys, Houston, TX 77030 USA; Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland	Baylor College of Medicine; University of Texas System; Baylor College of Medicine; University of Glasgow	Chiu, W (corresponding author), Baylor Coll Med, Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA.		Zhou, Z Hong/HDN-0747-2022					ARVIN AM, 1996, FIELDS VIROLOGY, V2, P2547; BATTERSON W, 1983, J VIROL, V45, P397, DOI 10.1128/JVI.45.1.397-407.1983; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; BRITT WJ, 1996, FIELDS VIROLOGY, V2, P2493; Conway JF, 1997, NATURE, V386, P91, DOI 10.1038/386091a0; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; Desai P, 1999, VIROLOGY, V261, P357, DOI 10.1006/viro.1999.9877; FIELDS BN, 1996, FIELDS VIROLOGY, V2; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; HARRISON SC, 1996, VIROLOGY, V1, P59; Kirkitadze MD, 1998, J VIROL, V72, P10066, DOI 10.1128/JVI.72.12.10066-10072.1998; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; NEWCOMB WW, 1994, J VIROL, V68, P433, DOI 10.1128/JVI.68.1.433-440.1994; NEWCOMB WW, 1993, J MOL BIOL, V232, P499, DOI 10.1006/jmbi.1993.1406; RICKINSON A, 1996, FIELDS VIROLOGY, V2, P2397; RIXON FJ, UNPUB; ROIZMAN B, 1996, FIELDS VIROLOGY, V2, P2231; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; Saad A, 1999, J VIROL, V73, P6821, DOI 10.1128/JVI.73.8.6821-6830.1999; SCHULZ TF, 1998, HUMAN TUMOR VIRUSES, P87; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; STEVEN AC, 1997, STRUCTURAL BIOL VIRU, P312; Thuman-Commike PA, 1999, BIOPHYS J, V76, P2249, DOI 10.1016/S0006-3495(99)77381-9; Trus BL, 1996, J MOL BIOL, V263, P447, DOI 10.1016/S0022-2836(96)80018-0; TRUS BL, 1997, NAT STRUCT BIOL, V4, P411; WHITLEY RJ, 1996, FIELDS VIROLOGY, V2, P2297; Wingfield PT, 1997, J VIROL, V71, P8955, DOI 10.1128/JVI.71.12.8955-8961.1997; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; Zhou ZH, 1999, J VIROL, V73, P3210, DOI 10.1128/JVI.73.4.3210-3218.1999; Zhou ZH, 1998, BIOPHYS J, V74, P576, DOI 10.1016/S0006-3495(98)77816-6; Zhou ZH, 1996, J STRUCT BIOL, V116, P216, DOI 10.1006/jsbi.1996.0033; Zhou ZH, 1998, P NATL ACAD SCI USA, V95, P2778, DOI 10.1073/pnas.95.6.2778; ZHOU ZH, 1995, NAT STRUCT BIOL, V2, P1026, DOI 10.1038/nsb1195-1026; ZHOU ZH, 1994, J MOL BIOL, V242, P456, DOI 10.1006/jmbi.1994.1594	35	254	266	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					877	880		10.1126/science.288.5467.877	http://dx.doi.org/10.1126/science.288.5467.877			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797014				2022-12-28	WOS:000086869600044
J	Darling, KF; Wade, CM; Stewart, IA; Kroon, D; Dingle, R; Brown, AJL				Darling, KF; Wade, CM; Stewart, IA; Kroon, D; Dingle, R; Brown, AJL			Molecular evidence for genetic mixing of Arctic and Antarctic subpolar populations of planktonic foraminifers	NATURE			English	Article							CRYPTIC SPECIATION; FOSSIL RECORD; EVOLUTION; TEMPERATURE; RATES; SEA; PHYLOGENY; SEQUENCES; BINDIN; OCEAN	Bipolarity, the presence of a species in the high latitudes separated by a gap in distribution across the tropics, is a well-known pattern of global species distribution. But the question of whether bipolar species have evolved independently at the poles since the establishment of the cold-water provinces 16-8 million years ago, or if genes have been transferred across the tropics since that time, has not been addressed. Here we examine genetic variation in the small subunit ribosomal RNA gene of three bipolar planktonic foraminiferal morphospecies. We identify at least one identical genotype in all three morphospecies in both the Arctic and Antarctic subpolar provinces, indicating that trans-tropical gene flow must have occurred. Our genetic analysis also reveals that foraminiferal morphospecies can consist of a complex of genetic types. Such occurrences of genetically distinct populations within one morphospecies may affect the use of planktonic foraminifers as a palaeoceanographic proxy for climate change and necessitate a reassessment of the species concept for the group.	Univ Edinburgh, Dept Geol & Geophys, Edinburgh EH9 3JW, Midlothian, Scotland; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Nottingham, Inst Genet, Nottingham NG7 2UH, England; British Antarctic Survey, Cambridge CB3 0ET, England	University of Edinburgh; University of Edinburgh; University of Nottingham; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey	Darling, KF (corresponding author), Univ Edinburgh, Dept Geol & Geophys, Edinburgh EH9 3JW, Midlothian, Scotland.		Brown, Andrew Leigh/ABF-8269-2020; Leigh Brown, Andrew/F-3802-2010	Brown, Andrew Leigh/0000-0002-5700-3128; Leigh Brown, Andrew/0000-0002-5700-3128; Wade, Christopher/0000-0002-1269-9694				[Anonymous], 1861, ORIGIN SPECIES MEANS; Be A.W.H., 1977, OCEANIC MICROPALEONT; Biermann CH, 1998, MOL BIOL EVOL, V15, P1761, DOI 10.1093/oxfordjournals.molbev.a025902; BIJMA J, 1990, J FORAMIN RES, V20, P117, DOI 10.2113/gsjfr.20.2.117; BRUMMER GJA, 1988, PLANKTONIC FORAMINIF, P293; *CLIMAP PROJ MEMB, 1981, GEOLOGICAL SOC AM MA; Coyne JA, 1998, PHILOS T ROY SOC B, V353, P287, DOI 10.1098/rstb.1998.0210; CRAME JA, 1993, J BIOGEOGR, V20, P145, DOI 10.2307/2845668; Darling KF, 1999, PALEOCEANOGRAPHY, V14, P3, DOI 10.1029/1998PA900002; Darling KF, 1996, J FORAMIN RES, V26, P324, DOI 10.2113/gsjfr.26.4.324; Darling KF, 1997, MAR MICROPALEONTOL, V30, P251, DOI 10.1016/S0377-8398(96)00057-6; de Vargas C, 1998, MOL PHYLOGENET EVOL, V9, P463, DOI 10.1006/mpev.1998.0491; de Vargas C, 1999, P NATL ACAD SCI USA, V96, P2864, DOI 10.1073/pnas.96.6.2864; deVargas C, 1997, J MOL EVOL, V45, P285, DOI 10.1007/PL00006232; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GUILDERSON TP, 1994, SCIENCE, V263, P663, DOI 10.1126/science.263.5147.663; Hilbrecht H, 1997, MAR MICROPALEONTOL, V31, P31, DOI 10.1016/S0377-8398(96)00054-0; Hooker JD, 1847, BOT ANTARCTIC VOYAGE; Huber BT, 1997, PALEOBIOLOGY, V23, P33, DOI 10.1017/S0094837300016638; Kennett J.P., 1983, NEOGENE PLANKTONIC F; KENNETT JP, 1985, GEOL SOC AM MEM, V163, P197; KNOWLTON N, 1993, ANNU REV ECOL SYST, V24, P189, DOI 10.1146/annurev.es.24.110193.001201; LINDBERG DR, 1991, PALEOBIOLOGY, V17, P308, DOI 10.1017/S0094837300010629; McIntyre A, 1989, PALEOCEANOGRAPHY, V4, P19, DOI 10.1029/PA004i001p00019; Metz EC, 1996, MOL BIOL EVOL, V13, P397, DOI 10.1093/oxfordjournals.molbev.a025598; Mix AC, 1996, SOUTH ATLANTIC, P503; PALUMBI SR, 1994, ANNU REV ECOL SYST, V25, P547, DOI 10.1146/annurev.es.25.110194.002555; Pawlowski J, 1997, MOL BIOL EVOL, V14, P498, DOI 10.1093/oxfordjournals.molbev.a025786; Ross James Clark, 1847, VOYAGE DISCOVERY RES; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671; Spezzaferri Silvia, 1994, Palaeontographia Italica, V81, P1; STUTE M, 1995, SCIENCE, V269, P379, DOI 10.1126/science.269.5222.379; SWOFFORD DL, 1998, PAUP PHYLOGENETIC AN; TAPPAN H, 1988, J PALEONTOL, V62, P695; Tregenza T, 1999, NATURE, V400, P311, DOI 10.1038/22419; Wolff T, 1998, GEOLOGY, V26, P675, DOI 10.1130/0091-7613(1998)026<0675:OIVCKT>2.3.CO;2; ZHAO M, 1995, PALEOCEANOGRAPHY, V10, P661, DOI 10.1029/94PA03354	40	262	284	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					43	47		10.1038/35011002	http://dx.doi.org/10.1038/35011002			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811211				2022-12-28	WOS:000086901600044
J	Knowles, MT				Knowles, MT			How metrics could have saved UK car industry	NATURE			English	Letter											Knowles, MT (corresponding author), 11 Powlett Court, Bath BA2 6QJ, Avon, England.							2000, NATURE, V404, P27	1	0	0	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					13	14		10.1038/35011152	http://dx.doi.org/10.1038/35011152			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811194	Bronze			2022-12-28	WOS:000086901600017
J	Yu, H				Yu, H			Humankind still has need of dragon slayers.	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					21	21		10.1038/35011126	http://dx.doi.org/10.1038/35011126			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811199	Bronze			2022-12-28	WOS:000086901600028
J	George, JN				George, JN			Platelets	LANCET			English	Article							THROMBOTIC THROMBOCYTOPENIC PURPURA; HEMOLYTIC-UREMIC SYNDROME; EDTA-DEPENDENT PSEUDOTHROMBOCYTOPENIA; FACTOR-CLEAVING PROTEASE; PLASMA-EXCHANGE; ESSENTIAL THROMBOCYTHEMIA; HIGH-RISK; ANTIBODIES; MANAGEMENT; CHILDHOOD	Platelets, derived from megakaryocte cytoplasm, have a critical role in normal haemostasis, and in thrombotic disorders. The development of megakaryocytes is controlled by thrombopoietin, which binds to c-mpl on the surface of platelets and megakaryocytes. Platelet membrane glycoproteins mediate binding to subendothelial tissue and aggregation into haemostatic plugs. Thrombocytopenia and disorders of platelet function cause petechiae and mucocutaneous bleeding. Drugs causing specific inhibition of platelet function are important in the treatment of cardiovascular and cerebrovascular disease.	Univ Oklahoma, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	George, JN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Hematol Oncol Sect, POB 26901, Oklahoma City, OK 73190 USA.	Jim-George@OUHSC.edu						AMOROSI EL, 1966, MEDICINE, V45, P139, DOI 10.1097/00005792-196603000-00003; ASTER RH, 1966, J CLIN INVEST, V45, P645, DOI 10.1172/JCI105380; Bahner I, 1997, BLOOD, V90, P1787, DOI 10.1182/blood.V90.5.1787; Behnke O, 1998, EUR J HAEMATOL, V60, P3; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; Berkowitz SD, 1998, J AM COLL CARDIOL, V32, P311, DOI 10.1016/S0735-1097(98)00252-6; BIZZARO N, 1995, AM J HEMATOL, V50, P103, DOI 10.1002/ajh.2830500206; Blickstein D, 1997, BLOOD, V90, P2768, DOI 10.1182/blood.V90.7.2768.2768_2768_2771; BoltonMaggs PHB, 1997, LANCET, V350, P620, DOI 10.1016/S0140-6736(97)04143-3; Burgess JK, 1998, BLOOD, V92, P2366, DOI 10.1182/blood.V92.7.2366.2366_2366_2373; BURROWS RF, 1993, NEW ENGL J MED, V329, P1463, DOI 10.1056/NEJM199311113292005; Clark WF, 1999, ANN INTERN MED, V131, P453, DOI 10.7326/0003-4819-131-6-199909210-00011; CORTELAZZO S, 1995, NEW ENGL J MED, V332, P1132, DOI 10.1056/NEJM199504273321704; Dang CT, 1999, BLOOD, V93, P1264, DOI 10.1182/blood.V93.4.1264.404k16_1264_1270; Fiorin F, 1998, AM J CLIN PATHOL, V110, P178; Francois B, 1997, AM J MED, V103, P114, DOI 10.1016/S0002-9343(97)00136-8; Frederiksen H, 1999, BLOOD, V94, P909, DOI 10.1182/blood.V94.3.909.415k02_909_913; Furlan M, 1998, NEW ENGL J MED, V339, P1578, DOI 10.1056/NEJM199811263392202; Gentilini G, 1998, BLOOD, V92, P2359, DOI 10.1182/blood.V92.7.2359.2359_2359_2365; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1991, NEW ENGL J MED, V324, P27, DOI 10.1056/NEJM199101033240106; George JN, 1998, J CLIN APHERESIS, V13, P120, DOI 10.1002/(SICI)1098-1101(1998)13:3<120::AID-JCA5>3.0.CO;2-E; GEORGE JN, 1990, BLOOD, V75, P1383; George JN, 1998, ANN INTERN MED, V129, P886, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00009; GEORGE JN, 1990, BLOOD, V76, P859; GOTTSCHALL JL, 1994, AM J HEMATOL, V47, P283, DOI 10.1002/ajh.2830470407; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Ihara K, 1999, P NATL ACAD SCI USA, V96, P3132, DOI 10.1073/pnas.96.6.3132; KANESHIRO MM, 1969, NEW ENGL J MED, V281, P1039, DOI 10.1056/NEJM196911062811904; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Lescale KB, 1996, AM J OBSTET GYNECOL, V174, P1014, DOI 10.1016/S0002-9378(96)70342-3; Lilleyman JS, 1999, BRIT J HAEMATOL, V105, P871, DOI 10.1046/j.1365-2141.1999.14094195.x; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; MARTIN JN, 1995, AM J OBSTET GYNECOL, V172, P1107, DOI 10.1016/0002-9378(95)91470-6; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; NAJEAN Y, 1995, SEMIN THROMB HEMOST, V21, P294, DOI 10.1055/s-2007-1000650; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Ruggeri M, 1998, BRIT J HAEMATOL, V103, P772; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Santoso S, 1999, BLOOD, V93, P2449, DOI 10.1182/blood.V93.8.2449.408k34_2449_2453; Sharis PJ, 1998, ANN INTERN MED, V129, P394, DOI 10.7326/0003-4819-129-5-199809010-00009; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Shiozaki H, 2000, BLOOD, V95, P2187; SHUMAK KH, 1995, ANN INTERN MED, V122, P569, DOI 10.7326/0003-4819-122-8-199504150-00002; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203; Valat AS, 1998, BRIT J HAEMATOL, V103, P397, DOI 10.1046/j.1365-2141.1998.01006.x; Vesely S, 2000, J PEDIAT HEMATOL ONC, V22, P55, DOI 10.1097/00043426-200001000-00011; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1; [No title captured]	51	359	380	0	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2000	355	9214					1531	1539		10.1016/S0140-6736(00)02175-9	http://dx.doi.org/10.1016/S0140-6736(00)02175-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801186				2022-12-28	WOS:000086830100040
J	Kouwenhoven, LP; Venema, LC				Kouwenhoven, LP; Venema, LC			Nanotechnology - Heat flow through nanobridges	NATURE			English	Editorial Material							CONDUCTANCE		Delft Univ Technol, Dept Appl Phys, NL-2600 GA Delft, Netherlands	Delft University of Technology	Kouwenhoven, LP (corresponding author), Delft Univ Technol, Dept Appl Phys, POB 5046, NL-2600 GA Delft, Netherlands.			Venema, Liesbeth/0000-0002-5896-1766				Frank S, 1998, SCIENCE, V280, P1744, DOI 10.1126/science.280.5370.1744; Imry Y, 1999, REV MOD PHYS, V71, pS306, DOI 10.1103/RevModPhys.71.S306; MULLER CJ, 1992, PHYS REV LETT, V69, P140, DOI 10.1103/PhysRevLett.69.140; Schwab K, 2000, NATURE, V404, P974, DOI 10.1038/35010065; VANHOUTEN H, 1996, PHYS TODAY      0722; VANWEES BJ, 1988, PHYS REV LETT, V60, P848, DOI 10.1103/PhysRevLett.60.848; [No title captured]	7	4	4	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					943	944		10.1038/35010251	http://dx.doi.org/10.1038/35010251			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801108				2022-12-28	WOS:000086762000036
J	Matsuda, T; Bebenek, K; Masutani, C; Hanaoka, F; Kunkel, TA				Matsuda, T; Bebenek, K; Masutani, C; Hanaoka, F; Kunkel, TA			Low fidelity DNA synthesis by human DNA polymerase-eta	NATURE			English	Article							PIGMENTOSUM VARIANT CELLS; ESCHERICHIA-COLI; HYPERMUTABILITY; PHOTOPRODUCTS; MUTAGENESIS; REPLICATION; MUTATION	A superfamily of DNA polymerases that bypass lesions in DNA has been described(1-4). Some family members are described as error-prone because mutations that inactivate the polymerase reduce damage-induced mutagenesis. In contrast, mutations in the skin cancer susceptibility gene XPV5,6, which encodes DNA polymerase (pol)-eta, lead to increased ultraviolet-induced mutagenesis(7-11). This, and the fact that pol-eta primarily inserts adenines during efficient bypass of thymine-thymine dimers in vitro(8,12,13), has led to the description of pol-eta as error-free. However, here we show that human pol-eta copies undamaged DNA with much lower fidelity than any other template-dependent DNA polymerase studied. Pol-eta lacks an intrinsic proofreading exonuclease activity and, depending on the mismatch, makes one base substitution error for every 18 to 380 nucleotides synthesized. This very low fidelity indicates a relaxed requirement for correct base pairing geometry and indicates that the function of pol-eta may be tightly controlled to prevent potentially mutagenic DNA synthesis.	NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; RIKEN, Wako, Saitama 3510198, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Osaka University; Japan Science & Technology Agency (JST); RIKEN	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.		Masutani, Chikahide/I-6160-2014; Kunkel, Thomas/D-5088-2019	Masutani, Chikahide/0000-0002-8600-8227; Kunkel, Thomas/0000-0002-9900-1788				Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Clairmont CA, 1999, P NATL ACAD SCI USA, V96, P9580, DOI 10.1073/pnas.96.17.9580; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; KANG XL, 1992, GENETICS, V130, P285; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; KUNKEL TA, IN PRESS ANN REV BIO, V69; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; McDonald JP, 1997, GENETICS, V147, P1557; MYHR BC, 1979, MUTAT RES, V62, P341, DOI 10.1016/0027-5107(79)90089-7; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191	28	312	334	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					1011	1013		10.1038/35010014	http://dx.doi.org/10.1038/35010014			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801132				2022-12-28	WOS:000086762000060
J	Pockley, P				Pockley, P			Clean-up strategy at Australian nuclear site called into question	NATURE			English	News Item																			0	4	4	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					797	797		10.1038/35009207	http://dx.doi.org/10.1038/35009207			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786760	Bronze			2022-12-28	WOS:000086625000003
J	Wadman, M				Wadman, M			US geneticists encouraged to play by the book	NATURE			English	News Item																		[Anonymous], 2000, NATURE, V404, P114	1	5	5	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					530	530		10.1038/35007210	http://dx.doi.org/10.1038/35007210			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10787343	Bronze			2022-12-28	WOS:000086400100005
J	Stansby, G				Stansby, G			Women, pregnancy, and varicose veins	LANCET			English	Editorial Material							PREVALENCE; POPULATION		Freeman Rd Hosp, No Vasc Ctr, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK	Stansby, G (corresponding author), Freeman Rd Hosp, No Vasc Ctr, High Heaton, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.			Stansby, Gerard/0000-0001-5539-3049				CALLAM MJ, 1994, BRIT J SURG, V81, P167, DOI 10.1002/bjs.1800810204; Canonico S, 1998, ANGIOLOGY, V49, P129, DOI 10.1177/000331979804900205; Cordts PR, 1996, J VASC SURG, V24, P763, DOI 10.1016/S0741-5214(96)70010-1; DINDELLI M, 1993, ANGIOLOGY, V44, P361, DOI 10.1177/000331979304400504; Evans CJ, 1998, J VASC SURG, V28, P767, DOI 10.1016/S0741-5214(98)70051-5; Mashiah A, 1999, CARDIOVASC SURG, V7, P327, DOI 10.1016/S0967-2109(98)00132-X; Smith JJ, 1999, J VASC SURG, V30, P710, DOI 10.1016/S0741-5214(99)70110-2; Sparey C, 1999, EUR J VASC ENDOVASC, V18, P294, DOI 10.1053/ejvs.1999.0870; Sparey C, 1999, BRIT J OBSTET GYNAEC, V106, P557, DOI 10.1111/j.1471-0528.1999.tb08324.x	9	30	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2000	355	9210					1117	1118		10.1016/S0140-6736(00)02057-2	http://dx.doi.org/10.1016/S0140-6736(00)02057-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791371				2022-12-28	WOS:000086380900006
J	Garcia-Castro, MI; Vielmetter, E; Bronner-Fraser, M				Garcia-Castro, MI; Vielmetter, E; Bronner-Fraser, M			N-cadherin, a cell adhesion molecule involved in establishment of embryonic left-right asymmetry	SCIENCE			English	Article							CHICK EMBRYOGENESIS; VERTEBRATE HEART; PRIMITIVE-STREAK; PATHWAY; PITX2; EXPRESSION; PROTEIN; SIGNALS; MOUSE; FGF8	Within the bilaterally symmetric vertebrate body plan, many organs develop asymmetrically, Here, it is demonstrated that a cell adhesion molecule, N-cadherin, is one of the earliest proteins to be asymmetrically expressed in the chicken embryo and that its activity is required during gastrulation for proper establishment of the Left-right axis. Blocking N-cadherin function randomizes heart Looping and alters the expression of Snail and Pitx2, Later components of the molecular cascade thar regulate left-right asymmetry. However, the expression of other components of this cascade (Nodal and Lefty) was unchanged after blocking N-cadherin function, suggesting the existence of parallel pathways in the establishment of Left-right morphogenesis. Here, the results suggest that N-cadherin-mediated cell adhesion events are required for establishment of left-right asymmetry.	CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA	California Institute of Technology	Garcia-Castro, MI (corresponding author), CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA.			Bronner, Marianne/0000-0003-4274-1862; Garcia-Castro, Martin I./0000-0001-5128-0004	NICHD NIH HHS [HD 15527] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; DEHAAN RL, 1963, EXP CELL RES, V29, P544, DOI 10.1016/S0014-4827(63)80016-6; DEHAAN RL, 1966, CONTRIB EMBRYOL, V263, P111; DEHAAN RL, 1965, ORGANOGENESIS, P377; Esteban CR, 1999, NATURE, V401, P243, DOI 10.1038/45738; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GARCIAMARTINEZ V, 1993, DEV BIOL, V159, P706, DOI 10.1006/dbio.1993.1276; GARCIAMARTINEZ V, 1993, J EXP ZOOL, V267, P431, DOI 10.1002/jez.1402670409; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARA K, 1978, MILESTONE HALF CENTU, pCH7; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HATTA K, 1985, P NATL ACAD SCI USA, V82, P2789, DOI 10.1073/pnas.82.9.2789; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Hensen V., 1876, Z ANAT ENTW GESCH, V1, P353; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; King T, 1999, CURR BIOL, V9, pR18, DOI 10.1016/S0960-9822(99)80036-0; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; LEPORI N G, 1969, Monitore Zoologico Italiano, V3, P33; Levin M, 1999, DEVELOPMENT, V126, P4703; Levin M, 1998, DEV BIOL, V203, P90, DOI 10.1006/dbio.1998.9024; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Linask KK, 1997, DEV BIOL, V185, P148, DOI 10.1006/dbio.1997.8570; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Nakagawa S, 1997, DEV GROWTH DIFFER, V39, P451; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; ROSENQUIST GC, 1970, DEV BIOL, V22, P461, DOI 10.1016/0012-1606(70)90163-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Sefton M, 1998, DEVELOPMENT, V125, P3111; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Wetzel R., 1929, Archiv fuer Entwicklungsmechanik Berlin, V119, P188; YOKOUCHIY, 1999, CELL, V98, P573; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Yost HJ, 1999, CURR OPIN GENET DEV, V9, P422	41	117	121	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1047	1051		10.1126/science.288.5468.1047	http://dx.doi.org/10.1126/science.288.5468.1047			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807574				2022-12-28	WOS:000086988400036
J	Mills, JL				Mills, JL			Fortification of foods with folic acid - How much is enough?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEURAL-TUBE DEFECTS; COBALAMIN DEFICIENCY; PERNICIOUS-ANEMIA; FOLATE; PREVENTION; SUPPLEMENTATION		NICHHD, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mills, JL (corresponding author), NICHHD, Bethesda, MD 20892 USA.			Mills, James/0000-0003-4496-332X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD002502] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002502] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], 1999, Pediatrics, V104, P325, DOI 10.1542/peds.104.2.325; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; *BUR CENS, 1998, US POP EST AG SEX RA; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P325; Christen WG, 2000, ARCH INTERN MED, V160, P422, DOI 10.1001/archinte.160.4.422; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Daly S, 1997, LANCET, V350, P1666, DOI 10.1016/S0140-6736(97)07247-4; *FOOD DRUG ADM, 1996, FED REGISTER, V61, P8786; *FOOD NUTR BOARD I, 1998, DIET REF TAK THIAM R; HALE RW, 1998, COMMUNICATION   0428; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Lawrence JM, 1999, LANCET, V354, P915, DOI 10.1016/S0140-6736(99)03227-4; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; *MRC VIT STUD RES, 1997, LANCET, V338, P131; Oakley GP, 1999, NEW ENGL J MED, V341, P1546, DOI 10.1056/NEJM199911113412012; Parry T E, 1987, Baillieres Clin Haematol, V1, P315, DOI 10.1016/S0950-3536(87)80005-7; Rader JI, 1999, FOOD TESTING ANAL, V5, P14; SAVAGE D, 1983, AM J MED, V74, P765, DOI 10.1016/0002-9343(83)91064-1; Savage D.G., 1995, FOLATE HLTH DIS, V1st, P237; SAVAGE DG, 1995, BAILLIERE CLIN HAEM, V8, P657, DOI 10.1016/S0950-3536(05)80225-2; SHOJANIA AM, 1980, CAN MED ASSOC J, V123, P1127; SINOW RM, 1987, ARCH INTERN MED, V147, P1828, DOI 10.1001/archinte.147.10.1828; U. S. Food and Drug Administration, 1993, FED REGISTER, V58, P53305; *US FDA, 1996, FED REGISTER, V61, P8781; Watkins ML, 1999, NEW ENGL J MED, V341, P923; 1947, N ENGL J MED, V237, P713; 1980, FED REG, V45, P69043	28	75	77	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1442	1445		10.1056/NEJM200005113421911	http://dx.doi.org/10.1056/NEJM200005113421911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312JR	10805832				2022-12-28	WOS:000086940600011
J	Kobayashi, S; Saito, N; Horiuchi, H; Iorio, R; Takaoka, K				Kobayashi, S; Saito, N; Horiuchi, H; Iorio, R; Takaoka, K			Poor bone quality or hip structure as risk factors affecting survival of total-hip arthroplasty	LANCET			English	Article							LOW-FRICTION ARTHROPLASTY; SOCKET	Background The principal long-term complication after total hip arthroplasty (THA) has been aseptic fixation failure. Many hip prostheses and operative techniques have been developed to improve outcomes, but few measures have been taken to cope with poor bone quality or hip structure. We assessed risk factors for aseptic fixation failure after THA. Methods We assessed, by multivariate analysis, survival of 405 primary Charnley THAs to identify risk factors for aseptic fixation failures. We also investigated risk factors for development of rapid polyethylene wear (penetration depth of the femoral head into the socket polyethylene greater than or equal to 2 mm/year). Findings In the entire series of 405 THAs, with use of radiographic fixation failure or revision for a loose socket as the endpoint, development of rapid polyethylene wear and the preoperative diagnosis of atrophic osteoarthrosis (defined by scarce osteophyte formation) were identified as risk factors for socket loosening (p less than or equal to 0.02). A medullary canal with an unfavourable geometry (a stovepipe canal, Noble's canal-flare index <3.0) was the only risk factor for femoral fixation failure (p less than or equal to 6.7 x 10(3)). The only variable related to development of rapid polyethylene wear was the type of steel used in the femoral prosthesis-Ortron 90 prostheses significantly lowered the rate of development of rapid wear from 12.7% to 0.4%. In the 248 THAs in which these femoral prostheses were used, socket survival was affected only by the preoperative diagnosis of atrophic osteoarthrosis (for radiographic fixation failure and revision, p=4.0 x 10(-5) and p=0.042, respectively). Interpretation in THA, the critical risk factors are poor bone quality, which manifests as atrophic osteoarthrosis, for socket survival and poor bone structure for femoral-prosthesis survival. To ensure longer durability of THAs, these factors should be assessed further and efforts, especially biological initiatives, should be made to resolve them.	Shinshu Univ, Sch Med, Dept Orthopaed Surg, Matsumoto, Nagano 3908621, Japan; Lahey Clin, Dept Orthopaed Surg, Burlington, MA USA	Shinshu University; Lahey Hospital & Medical Center	Kobayashi, S (corresponding author), Shinshu Univ, Sch Med, Dept Orthopaed Surg, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.							BARNETT E, 1960, Clin Radiol, V11, P166, DOI 10.1016/S0009-9260(60)80012-8; Bombelli R, 1983, OSTEOARTHRITIS HIP C, P98; Callaghan J.J.W., 1998, ADULT HIP, V1st; CHARNLEY J, 1975, CLIN ORTHOP RELAT R, P170; Charnley J., 1979, LOW FRICTION ARTHROP; Dorey F, 1986, J Arthroplasty, V1, P63, DOI 10.1016/S0883-5403(86)80010-9; Eftekhar NS, 1993, TOTAL HIP ARTHROPLAS; Engh CA, 1997, J BONE JOINT SURG AM, V79A, P177, DOI 10.2106/00004623-199702000-00003; Gustilo R B, 1982, Hip, P27; HODGKINSON JP, 1988, CLIN ORTHOP RELAT R, P105; Joshi RP, 1998, J BONE JOINT SURG BR, V80B, P585, DOI 10.1302/0301-620X.80B4.7361; KOBAYASHI S, 1994, CLIN ORTHOP RELAT R, P84; KOBAYASHI S, 1990, J BONE JOINT SURG BR, V72, P439, DOI 10.1302/0301-620X.72B3.2341444; KOBAYASHI S, 1993, ARCH ORTHOP TRAUM SU, V112, P56, DOI 10.1007/BF00420254; KOBAYASHI S, 1994, CLIN ORTHOP RELAT R, P73; Kobayashi S, 1992, J Arthroplasty, V7 Suppl, P327, DOI 10.1016/S0883-5403(07)80021-0; Kobayashi S, 1997, J BONE JOINT SURG AM, V79A, P1618, DOI 10.2106/00004623-199711000-00002; NOBLE PC, 1988, CLIN ORTHOP RELAT R, P148; Ritter MA, 1999, J BONE JOINT SURG BR, V81B, P982, DOI 10.1302/0301-620X.81B6.9634; Schmalzried TP, 1999, J BONE JOINT SURG AM, V81A, P115, DOI 10.2106/00004623-199901000-00016; SCHULTE KR, 1993, J BONE JOINT SURG AM, V75A, P961, DOI 10.2106/00004623-199307000-00002; SHARP IK, 1961, J BONE JOINT SURG BR, V43, P268, DOI 10.1302/0301-620X.43B2.268; Smith SW, 1998, J BONE JOINT SURG AM, V80A, P1632, DOI 10.2106/00004623-199811000-00010; Wroblewski BM, 1999, J BONE JOINT SURG BR, V81B, P427, DOI 10.1302/0301-620X.81B3.9521	24	103	111	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1499	1504		10.1016/S0140-6736(00)02164-4	http://dx.doi.org/10.1016/S0140-6736(00)02164-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801171				2022-12-28	WOS:000086830100011
J	McFarlane, IG				McFarlane, IG			Lessons about antibodies in autoimmune hepatitis	LANCET			English	Editorial Material							SOLUBLE LIVER ANTIGEN; AUTOANTIBODIES		Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	McFarlane, IG (corresponding author), Kings Coll Hosp London, Inst Liver Studies, Denmark Hill, London SE5 9RS, England.							Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9; Czaja AJ, 1999, GASTROENTEROLOGY, V117, P645, DOI 10.1016/S0016-5085(99)70458-0; CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1522, DOI 10.1016/0016-5085(93)90160-E; Kanzler S, 1999, J HEPATOL, V31, P635, DOI 10.1016/S0168-8278(99)80342-0; MANNS M, 1987, LANCET, V1, P292; McFarlane IG, 1999, BIOMED PHARMACOTHER, V53, P255, DOI 10.1016/S0753-3322(99)80096-1; Strettell MDJ, 1997, GASTROENTEROLOGY, V112, P2028, DOI 10.1053/gast.1997.v112.pm9178696; Wesierska-Gadek J, 1998, GASTROENTEROLOGY, V114, P329, DOI 10.1016/S0016-5085(98)70485-8	8	19	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1475	1476		10.1016/S0140-6736(00)02156-5	http://dx.doi.org/10.1016/S0140-6736(00)02156-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801163				2022-12-28	WOS:000086830100003
J	Loder, N				Loder, N			Director of Wellcome centre resigns over damning report	NATURE			English	News Item																		Loder N, 2000, NATURE, V403, P695, DOI 10.1038/35001747; 2000, NATURE, V403, P353	2	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					696	696		10.1038/35008235	http://dx.doi.org/10.1038/35008235			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10809626	Bronze			2022-12-28	WOS:000086523600013
J	Crown, J; O'Leary, M				Crown, J; O'Leary, M			The taxanes: an update	LANCET			English	Article							METASTATIC BREAST-CANCER; PHASE-II TRIAL; INITIAL CHEMOTHERAPY; OVARIAN-CANCER; PACLITAXEL; CISPLATIN; DOXORUBICIN; DOCETAXEL; INFUSION; WOMEN	The taxanes are anticancer cytotoxics that stabilise cellular microtubules. Two members, paclitaxel and docetaxel have substantial activity. One or both agents are widely accepted as evidence-based components of therapy for advanced breast, lung, and ovarian carcinomas. Paclitaxel has recently been approved in the USA for the adjuvant treatment of early stage node-positive breast carcinoma.	St Vincents Univ Hosp, Dublin 4, Ireland	University College Dublin; Saint Vincent's University Hospital	Crown, J (corresponding author), St Vincents Univ Hosp, Dublin 4, Ireland.		Crown, John/AAL-3367-2020					Baselga J, 1998, CANCER RES, V58, P2825; BELANI CP, 1998, P ASCO, V17, pC455; Bishop JF, 1999, J CLIN ONCOL, V17, P2355, DOI 10.1200/JCO.1999.17.8.2355; Buzdar AU, 1999, J CLIN ONCOL, V17, P3412, DOI 10.1200/JCO.1999.17.11.3412; Crown J, 1999, EUR J CANCER, V35, pS232, DOI 10.1016/S0959-8049(99)81330-6; Crown J, 1999, SEMIN ONCOL, V26, P33; DANCEY J, 1999, P AN M AM SOC CLIN, V18, pA491; EISENHAUER EA, 1994, J CLIN ONCOL, V12, P2654, DOI 10.1200/JCO.1994.12.12.2654; FRANK V, 1999, P ASCO, V18, pC460; GATZEMEIER U, 1998, P AN M AM SOC CLIN, V17, pA454; GEORGOULIAS V, 1999, P AN M AM SOC CLIN, V18, pA461; Giaccone G, 1998, J CLIN ONCOL, V16, P2133, DOI 10.1200/JCO.1998.16.6.2133; GIANNI L, 1995, J CLIN ONCOL, V13, P2688, DOI 10.1200/JCO.1995.13.11.2688; HARPER P, 1999, P ASCO, V18, pC356; HARVEY J, 1997, P ASCO, V16, P601; HENDERSON IC, 1998, P AN M AM SOC CLIN, V17, pA101; HOLMES FA, 1998, P AN M AM SOC CLIN, V17, pA110; Hudis CA, 1996, J CLIN ONCOL, V14, P58, DOI 10.1200/JCO.1996.14.1.58; Huinink WTB, 1997, J CLIN ONCOL, V15, P2183, DOI 10.1200/JCO.1997.15.6.2183; KELLY K, 1999, P AN M AM SOC CLIN, V18, pA461; KIM K, 1998, P ASCO, V17, pA461; McCaffrey JA, 1997, J CLIN ONCOL, V15, P1853, DOI 10.1200/JCO.1997.15.5.1853; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Monnier A, 1998, ANN ONCOL, V9, P12; Muggia FM, 2000, J CLIN ONCOL, V18, P106, DOI 10.1200/JCO.2000.18.1.106; Nabholtz JM, 1996, J CLIN ONCOL, V14, P1858, DOI 10.1200/JCO.1996.14.6.1858; Nabholtz JM, 1999, J CLIN ONCOL, V17, P1413, DOI 10.1200/JCO.1999.17.5.1413; Nabholtz JM, 1999, P AN M AM SOC CLIN, V18, p127a; Norton L, 1999, P AN M AM SOC CLIN, V18, p127a; Ozols RF, 1999, P AN M AM SOC CLIN, V18, p356a; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; PERETZ T, 1995, EJC SUPPL, V31, pS75; Petrylak DP, 1999, J CLIN ONCOL, V17, P958, DOI 10.1200/JCO.1999.17.3.958; Pluzzanska A, 1999, EUR J CANCER, V35, pS314, DOI 10.1016/S0959-8049(99)81676-1; REICHMAN BS, 1993, J CLIN ONCOL, V11, P1943, DOI 10.1200/JCO.1993.11.10.1943; Roszkowski K, 1999, EUR J CANCER, V35, pS246, DOI 10.1016/S0959-8049(99)81396-3; SHEPHERD R, 1999, P ASCO, V18, pA463; SLEDGE GW, 1997, P AN M AM SOC CLIN, V16, pA1; Smith RE, 1999, J CLIN ONCOL, V17, P3403, DOI 10.1200/JCO.1999.17.11.3403; STUART G, 1998, P AN M AM SOC CLIN, V17, pA361; Thatcher N, 1998, ANN ONCOL, V9, P1; Wasserheit C, 1996, J CLIN ONCOL, V14, P1993, DOI 10.1200/JCO.1996.14.7.1993; WINER E, 1998, P AN M AM SOC CLIN, V17, pA101	43	308	319	2	29	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2000	355	9210					1176	1178		10.1016/S0140-6736(00)02074-2	http://dx.doi.org/10.1016/S0140-6736(00)02074-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791395				2022-12-28	WOS:000086380900039
J	Liaw, LCT; Nayar, DM; Pedler, SJ; Coulthard, MG				Liaw, LCT; Nayar, DM; Pedler, SJ; Coulthard, MG			Home collection of urine for culture from infants by three methods: survey of parents' preferences and bacterial contamination rates	BRITISH MEDICAL JOURNAL			English	Article							TRACT INFECTION; EARLY-CHILDHOOD		Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Coulthard, MG (corresponding author), Royal Victoria Infirm, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.							HARDY JD, 1976, BRIT J UROL, V48, P279, DOI 10.1111/j.1464-410X.1976.tb03021.x; JADRESIC L, 1993, BRIT MED J, V307, P761, DOI 10.1136/bmj.307.6907.761; KASS EH, 1956, T ASSOC AM PHYSICIAN, V69, P56; Macfarlane PI, 1999, LANCET, V354, P571, DOI 10.1016/S0140-6736(99)02270-9; Vernon S, 1997, BRIT J GEN PRACT, V47, P297	5	54	55	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1312	1313		10.1136/bmj.320.7245.1312	http://dx.doi.org/10.1136/bmj.320.7245.1312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807624	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000087077400024
J	Gabunia, L; Vekua, A; Lordkipanidze, D; Swisher, CC; Ferring, R; Justus, A; Nioradze, M; Tvalchrelidze, M; Anton, SC; Bosinski, G; Joris, O; de Lumley, MA; Majsuradze, G; Mouskhelishvili, A				Gabunia, L; Vekua, A; Lordkipanidze, D; Swisher, CC; Ferring, R; Justus, A; Nioradze, M; Tvalchrelidze, M; Anton, SC; Bosinski, G; Joris, O; de Lumley, MA; Majsuradze, G; Mouskhelishvili, A			Earliest Pleistocene hominid cranial remains from Dmanisi, Republic of Georgia: Taxonomy, geological setting, and age	SCIENCE			English	Article							STONE TOOLS; AFFINITIES; HOMO	Archaeological excavations at the site of Dmanisi in the Republic of Georgia have uncovered two partial early Pleistocene hominid crania. The new fossils consist of a relatively complete cranium and a second relatively complete calvaria from the same site and stratigraphic unit that yielded a hominid mandible in 1991. In contrast with the uncertain taxonomic affinity of the mandible. the new fossils are comparable in size and morphology with Homo ergaster from Koobi Fora, Kenya. Paleontological, archaeological, geochronological, and paleomagnetic data from Dmanisi all indicate an earliest Pleistocene age of about 1.7 million years ago, supporting correlation of the new specimens with the Koobi Fora fossils. The Dmanisi fossils, in contrast with Pleistocene hominids from Western Europe and Eastern Asia, show clear African affinity and may represent the species that first migrated out of Africa.	Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Republ Georgia Natl Acad Sci, GE-380007 Tbilisi, Georgia; Republ Georgia State Museum, Dept Geol & Paleontol, GE-380007 Tbilisi, Georgia; Univ N Texas, Dept Geog, Denton, TX 76203 USA; Romisch German Zent Museum, Mainz, Germany; Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA; CNRS, Lab Museum Natl Hist Nat, Paris, France	Berkeley Geochronolgy Center; National Academy of Sciences of Georgia; University of North Texas System; University of North Texas Denton; State University System of Florida; University of Florida; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN)	Swisher, CC (corresponding author), Berkeley Geochronol Ctr, 2455 Ridge Rd, Berkeley, CA 94709 USA.	geonathist@ip.osgf.ge; cswish@bgc.org	Lordkipanidze, David/AAH-6472-2020	Joris, Olaf/0000-0002-6360-5096				Aguirre E., 1997, PLEISTOCENE BOUNDARY, P114; Anton SC, 1997, AM J PHYS ANTHROPOL, V102, P497, DOI 10.1002/(SICI)1096-8644(199704)102:4<497::AID-AJPA6>3.0.CO;2-P; ANTON SC, 2000, C P INT ASS STUD HUM, P97; Arsuaga JL, 1999, J HUM EVOL, V37, P431, DOI 10.1006/jhev.1999.0309; ASFAW B, 1992, NATURE, V360, P732, DOI 10.1038/360732a0; Bar-Yosef O., 1998, EARLY HUMAN BEHAV GL, P221; Bartstra G.-J, 1985, MODERN QUATERNARY RE, V9, P99; BARYOSEF O, IN PRESS DMAN C VOL; Berggren W. A., 1995, GEOCHRONOLOGY TIME S, P129, DOI DOI 10.2110/PEC.95.04.0129; BOSINSKI G, 1995, EARLIEST OCCUPATION, P263; Brauer G, 1996, J HUM EVOL, V30, P445, DOI 10.1006/jhev.1996.0037; BRAUER G, 1996, JB RGZM, V42, P183; DEAN D, 1995, NATURE, V373, P472, DOI 10.1038/373472a0; DZAPARIDZE V, 1989, JB ROM GERM ZENTRALM, V36, P67; GABUNIA L, 1995, NATURE, V373, P509, DOI 10.1038/373509a0; Gabunia L, 2000, J HUM EVOL, V38, P785, DOI 10.1006/jhev.1999.0383; GABUNIA L, 1992, ANTHROPOLOGIE, V99, P29; GABUNIA L, 1988, NEWSL GEORGIAN ACAD, V14, P344; GABUNIA L, 1992, JAHR RGZM, V39, P185; GABUNIA L, 1999, ARCHAEOL KORRESPOND, V29, P299; GILE LH, 1966, SOIL SCI, V101, P347, DOI 10.1097/00010694-196605000-00001; HUANG WP, 1995, NATURE, V378, P275; JUSTUS A, 1998, DMANISI, V1, P140; KLEIN RG, 1999, HUMAN CAREER HUMAN B, P1; Leonard WR, 1999, AM J PHYS ANTHROPOL, P182; Leonard WR, 2000, ON THE MOVE: HOW AND WHY ANIMALS TRAVEL IN GROUPS, P628; Lieberman DE, 1996, J HUM EVOL, V30, P97, DOI 10.1006/jhev.1996.0008; MAJSURADZE G, 1996, JB RGZM, V42, P25; Movius H.L., 1948, T AM PHILOS SOC, V38, P329; Renne PR, 1998, CHEM GEOL, V145, P117, DOI 10.1016/S0009-2541(97)00159-9; Rosas A, 1998, AM J PHYS ANTHROPOL, V107, P145, DOI 10.1002/(SICI)1096-8644(199810)107:2<145::AID-AJPA2>3.3.CO;2-8; RUBINSTEJN MM, 1972, MEZD KOL PROB GRAN M, P162; SAUNDERS JJ, NATL SCI MUSEUM MONO, V14, P215; Schick K.D., 1993, EVOL ANTHR ISSUES NE, V2, P22, DOI DOI 10.1002/EVAN.1360020105; Schmincke H.-U., 1995, JB ROMISCH GER ZENT, V42, P75; SEMAH F, 1992, J HUM EVOL, V23, P439, DOI 10.1016/0047-2484(92)90092-N; Semaw S, 1997, NATURE, V385, P333, DOI 10.1038/385333a0; SOLOGASVILI DZ, 1995, JB RGZM, V42, P51; SWISHER CC, 1994, SCIENCE, V263, P1118, DOI 10.1126/science.8108729; SWISHER CC, 1996, ANNM PAL SOC NEW ORL; TATTERSALL I, 1999, DOSS SCI, V1, P70; Vekua A., 1995, JB R MISCH GERMANISC, V42, P77; WALKER A, NARIOKOTOME HOMO ERE, P63; Weidenreich F., 1943, Palaeontologia Sinica, VD 10, P1; Wood B., 1991, HOMINID CRANIAL REMA, V4; YAMEI H, 2000, SCIENCE, V287, P1621	46	426	449	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	2000	288	5468					1019	1025		10.1126/science.288.5468.1019	http://dx.doi.org/10.1126/science.288.5468.1019			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	313EY	10807567				2022-12-28	WOS:000086988400029
J	Graps, AL; Grun, E; Svedhem, H; Kruger, H; Horanyi, M; Heck, A; Lammers, S				Graps, AL; Grun, E; Svedhem, H; Kruger, H; Horanyi, M; Heck, A; Lammers, S			Io as a source of the jovian dust streams	NATURE			English	Article							COMET SHOEMAKER-LEVY-9; GOSSAMER RING; JUPITER; MAGNETOSPHERE; EJECTION	Streams of dust emerging from the direction of Jupiter were discovered in 1992 during the flyby of the Ulysses spacecraft(1,2), but their precise origin within the jovian system remained unclear(2). Further data(3-5) collected by the Galileo spacecraft, which has been orbiting Jupiter since December 1995, identified the possible sources of dust as Jupiter's main ring(6), its gossamer ring(7), comet Shoemaker-Levy 9 (ref. 8) and Io. All but Jupiter's gossamer ring and Io have since been ruled out(4,9-14). Here we find that the dominant source of the jovian dust streams is Io, on the basis of periodicities in the dust impact signal. Io's volcanoes, rather than impact ejecta, are the dust sources.	Max Planck Inst Kernphys, D-69117 Heidelberg, Germany; European Space Res & Technol Ctr, NL-2200 AG Noordwijk, Netherlands; Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA	Max Planck Society; European Space Agency; University of Colorado System; University of Colorado Boulder	Graps, AL (corresponding author), Max Planck Inst Kernphys, Saupfercheckweg 1, D-69117 Heidelberg, Germany.			Graps, Amara/0000-0003-1758-2943				CARR TD, 1983, PHYSICS JOVIAN MAGNE, P248; GRUEN E, 1993, NATURE, V362, P428; Grun E, 1998, J GEOPHYS RES-PLANET, V103, P20011, DOI 10.1029/98JE00228; GRUN E, 1994, GEOPHYS RES LETT, V21, P1035, DOI 10.1029/94GL00701; GRUN E, 1992, SCIENCE, V257, P1550, DOI 10.1126/science.11538054; Grun E, 1996, SCIENCE, V274, P399, DOI 10.1126/science.274.5286.399; Grun E, 1996, NATURE, V381, P395, DOI 10.1038/381395a0; HAMILTON DP, 1993, NATURE, V364, P695, DOI 10.1038/364695a0; Horanyi M, 1997, GEOPHYS RES LETT, V24, P2175, DOI 10.1029/97GL01539; HORANYI M, 1993, NATURE, V363, P144, DOI 10.1038/363144a0; HORANYI M, 1993, J GEOPHYS RES-SPACE, V98, P21245, DOI 10.1029/93JA02588; IP WH, 1996, GEOPHYS RES LETT, V24, P3671; JOHNSON TV, 1980, GEOPHYS RES LETT, V7, P305, DOI 10.1029/GL007i005p00305; Kruger H, 1999, NATURE, V399, P558, DOI 10.1038/21136; MARAVILLA D, 1995, ASTROPHYS J, V438, P968, DOI 10.1086/175138; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McGrath MA, 1997, SCIENCE, V278, P237, DOI 10.1126/science.278.5336.237; SCARGLE JD, 1982, ASTROPHYS J, V263, P835, DOI 10.1086/160554; SEKANINA Z, 1994, ASTRON ASTROPHYS, V289, P607; SHOWALTER MR, 1985, NATURE, V316, P526, DOI 10.1038/316526a0; SHOWALTER MR, 1987, ICARUS, V69, P458, DOI 10.1016/0019-1035(87)90018-2; Spencer JR, 1996, ANNU REV EARTH PL SC, V24, P125, DOI 10.1146/annurev.earth.24.1.125; Zook HA, 1996, SCIENCE, V274, P1501, DOI 10.1126/science.274.5292.1501	23	79	80	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					48	50		10.1038/35011008	http://dx.doi.org/10.1038/35011008			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811212				2022-12-28	WOS:000086901600045
J	Wee, CC; McCarthy, EP; David, RB; Phillips, RS				Wee, CC; McCarthy, EP; David, RB; Phillips, RS			Screening for cervical and breast cancer: Is obesity an unrecognized barrier to preventive care?	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	22nd Annual Meeting of the Society-of-General-Internal-Medicine	APR 29-MAY 01, 1999	SAN FRANCISCO, CA	Soc Gen Internal Med		cervix neoplasms; breast neoplasms; obesity; mammography; vaginal smears	BODY-WEIGHT; WHITE WOMEN; ATTITUDES; DISEASE; OVERWEIGHT; PHYSICIAN; PROFESSIONALS; CONSEQUENCES; MAMMOGRAPHY; STAGE	Background: Compared with thinner women, obese women have higher mortality rates for breast and cervical cancer. In addition, obesity leads to adverse social and psychological consequences. Whether obesity limits access to screening for breast and cervical cancer is unclear. Objective: To examine the relation between obesity and screening with Papanicolaou (Pap) smears and mammography. Design: Population-based survey. Setting: United States. Participants: 11 435 women who responded to the "Year 2000 Supplement" of the 1994 National Health Interview Survey. Measurements: Screening with Pap smears and mammography was assessed by questionnaire. Results: In women 18 to 75 years of age who had not previously undergone hysterectomy (n = 8394), fewer overweight women (78%) and obese women (78%) than normal-weight women (84%) had had Pap smears in the previous 3 years (P < 0.001). After adjustment for sociodemographic information, insurance and access to care, illness burden, and provider specialty, rate differences for screening with Pap smears were still seen among overweight (-3.5% [95% CI, -5.9% to -1.1%]) and obese women (-5.3% [CI, -8.0% to -2.6%]). In women 50 to 75 years of age (n = 3502), fewer overweight women (64%) and obese women (62%) than normal-weight women (68%) had had mammography in the previous Z years (P < 0.002). After adjustment, rate differences were -2.8% (CI, -6.7% to 0.9%) for overweight women and -5.4% (CI, -10.8% to -0.1 %) for obese women. Conclusions: Overweight and obese women were less likely to be screened for cervical and breast cancer with Pap smears and mammography, even after adjustment for other known barriers to care. Because overweight and obese women have higher mortality rates for cervical and breast cancer, they should be targeted for increased screening.	Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Harvard Med Sch, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Wee, CC (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Harvard Med Sch, 330 Brookline Ave,Libby 330, Boston, MA 02215 USA.	cweekuo@caregroup.harvard.edu			AHRQ HHS [1 F32 HS00137-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [F32HS000137] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAMS CH, 1993, WOMEN HEALTH, V20, P45, DOI 10.1300/J013v20n02_04; ALLAN JD, 1993, RES NURS HEALTH, V16, P323, DOI 10.1002/nur.4770160503; ALLISON DB, 1999, JAMA-J AM MED ASSOC, V282, P1583; CADE J, 1991, BRIT J GEN PRACT, V41, P147; Caldwell MB, 1997, INT J EAT DISORDER, V22, P127, DOI 10.1002/(SICI)1098-108X(199709)22:2&lt;127::AID-EAT2&gt;3.0.CO;2-H; DAWSON DA, 1988, AM J PUBLIC HEALTH, V78, P1326, DOI 10.2105/AJPH.78.10.1326; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; Fontaine KR, 1998, ARCH FAM MED, V7, P381, DOI 10.1001/archfami.7.4.381; FRANK A, 1993, JAMA-J AM MED ASSOC, V269, P2132, DOI 10.1001/jama.269.16.2132; GARFINKEL L, 1985, ANN INTERN MED, V103, P1034, DOI 10.7326/0003-4819-103-6-1034; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; INGRAM D, 1989, CANCER, V64, P1049, DOI 10.1002/1097-0142(19890901)64:5&lt;1049::AID-CNCR2820640515&gt;3.0.CO;2-M; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Kiefe CI, 1998, J GEN INTERN MED, V13, P357, DOI 10.1046/j.1525-1497.1998.00115.x; KOCH GG, 1975, INT STAT REV, V43, P59, DOI 10.2307/1402660; LUBITZ RM, 1995, AM J MED, V98, P491, DOI 10.1016/S0002-9343(99)80350-7; LURIE N, 1993, NEW ENGL J MED, V329, P478, DOI 10.1056/NEJM199308123290707; MILLER TM, 1980, J AM DIET ASSOC, V77, P561; *NAT CTR HLTH STAT, 1994, CD ROM SER, V10; National Center for Health Statistics, 1996, HLTH PEOPL 2000 REV; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; PRICE JH, 1987, AM J PREV MED, V3, P339; Reeves MJ, 1996, CANCER, V77, P301, DOI 10.1002/(SICI)1097-0142(19960115)77:2<301::AID-CNCR12>3.0.CO;2-5; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; SHAH BV, 1992, SUDAAN USERS MANUAL; STEVENS J, 1994, AM J PUBLIC HEALTH, V84, P1322, DOI 10.2105/AJPH.84.8.1322; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VERREAULT R, 1989, AM J EPIDEMIOL, V129, P260, DOI 10.1093/oxfordjournals.aje.a115131; WADDEN TA, 1985, ANN INTERN MED, V103, P1062, DOI 10.7326/0003-4819-103-6-1062; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; YOUNG LM, 1985, J HEALTH SOC BEHAV, V26, P233, DOI 10.2307/2136755	35	217	217	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					697	+		10.7326/0003-4819-132-9-200005020-00003	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	308VT	10787362				2022-12-28	WOS:000086734100002
J	Broos, P; Fourneau, I				Broos, P; Fourneau, I			Host factors that affect outcome of total hip arthroplasty	LANCET			English	Editorial Material									Univ Hosp Gasthuisberg, Dept Traumatol, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven	Broos, P (corresponding author), Univ Hosp Gasthuisberg, Dept Traumatol, B-3000 Louvain, Belgium.							BOONEN S, 1996, AM J ORTHOPSYCHIAT, V25, P19; Broos PLO, 1999, ACTA CHIR BELG, V99, P190; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; WEINBERGER M, 1986, Arthritis and Rheumatism, V29, pS155; Young NL, 1998, CAN J SURG, V41, P188	5	18	18	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2000	355	9214					1479	1480		10.1016/S0140-6736(00)02159-0	http://dx.doi.org/10.1016/S0140-6736(00)02159-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310LR	10801166				2022-12-28	WOS:000086830100006
J	Cox, T; Lachmann, R; Hollak, C; Aerts, J; van Weely, S; Hrebicek, M; Platt, F; Butters, T; Dwek, R; Moyses, C; Gow, I; Elstein, D; Zimran, A				Cox, T; Lachmann, R; Hollak, C; Aerts, J; van Weely, S; Hrebicek, M; Platt, F; Butters, T; Dwek, R; Moyses, C; Gow, I; Elstein, D; Zimran, A			Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis	LANCET			English	Article							PLASMA CHITOTRIOSIDASE ACTIVITY; REPLACEMENT THERAPY; GLYCOLIPID BIOSYNTHESIS; LYSOSOMAL STORAGE; MICE; GLUCOCEREBROSIDASE; IMIGLUCERASE; INHIBITOR; FEATURES	Background Current treatment for Gaucher's disease involves administration of intravenous glucocerebrosidase to degrade glucocerebroside stored in lysosomes. Lowering the rate of biosynthesis of glucocerebroside should decrease accummulation of this substrate. We investigated the safety and efficacy of OGT 918 (N-butyldeoxynojirimycin), an inhibitor of glucosyltransferase, as a novel oral treatment for non-neuronopathic Gaucher's disease. Methods We recruited, into a 1-year open-label study, 28 adults (seven with previous splenectomies) from four national Gaucher's referral clinics, who were unable or unwilling to receive enzyme treatment. We measured liver and spleen volume by computed tomography or magnetic resonance imaging at baseline and at months 6 and 12, and biochemical and haematological variables monthly, including chitotriosidase activity (a sensitive marker of Gaucher's disease activity). Patients were started on 100 mg oral OGT 918 three times daily, Findings Baseline liver volumes were 1.1-2.7 times normal and spleen volumes 5.1-24.8 times normal. At 12 months, mean liver and spleen Volumes were significantly lowered by 12% (95% CI 7.8-16.4) and 19% (14.3-23.7), respectively (each p<0001). Haematological variables improved slightly, Mean organ volume and blood counts improved continually between 6 months and 12 months of treatment. Mean chitotriosidase concentrations fell by 16.4% over 12 months (p<0.001). Six patients withdrew because of gastrointestinal complaints (two), personal reasons (two), or severe preexisting disease (two). The most frequent adverse effect was diarrhoea, which occurred in 79% of patients shortly after the start of treatment. Interpretation Decrease of substrate formation by OGT 918 improves key clinical features of non-neuronopathic Gaucher's disease. The strategy justifies further trials in this and other glycosphingolipid storage disorders.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Inst Inherited Metab Disorders, Prague, Czech Republic; Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford, England; Oxford GlycoSci, Abingdon Sci Pk, Oxon, England; Shaare Zedek Med Ctr, Jerusalem, Israel	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Amsterdam; Academic Medical Center Amsterdam; University of Oxford; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Cox, T (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England.		Platt, Frances/G-1004-2010; Hrebicek, Martin/M-2019-2017; Aerts, Johannes/A-1028-2009	Hrebicek, Martin/0000-0003-0628-8917; Aerts, Johannes/0000-0001-8168-2565; Platt, Frances/0000-0001-7614-0403; Lachmann, Robin/0000-0002-2618-2581				Aerts JMFG, 1997, BAILLIERE CLIN HAEM, V10, P691, DOI 10.1016/S0950-3536(97)80034-0; Andersson U, 2000, BIOCHEM PHARMACOL, V59, P821, DOI 10.1016/S0006-2952(99)00384-6; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; Beutler E., 1995, METABOLIC MOL BASES, P2641; BRADY RO, 1978, METABOLIC BASIS INHE, P731; CONZELMANN E, 1984, DEV NEUROSCI-BASEL, V6, P58, DOI 10.1159/000112332; Cox TM, 1997, BAILLIERE CLIN HAEM, V10, P657, DOI 10.1016/S0950-3536(97)80033-9; Elstein D, 1998, QJM-MON J ASSOC PHYS, V91, P483, DOI 10.1093/qjmed/91.7.483; FISCHL MA, 1994, J ACQ IMMUN DEF SYND, V7, P139; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Jeyakumar M, 1999, P NATL ACAD SCI USA, V96, P6388, DOI 10.1073/pnas.96.11.6388; KATTLOVE HE, 1969, BLOOD-J HEMATOL, V33, P379, DOI 10.1182/blood.V33.2.379.379; PLATT FM, 1994, J BIOL CHEM, V269, P27108; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; TIERNEY M, 1995, J ACQ IMMUN DEF SYND, V10, P549, DOI 10.1097/00042560-199510050-00008; ZIMRAN A, 1995, LANCET, V345, P1479, DOI 10.1016/S0140-6736(95)91038-7; ZIMRAN A, 1992, MEDICINE, V71, P337, DOI 10.1097/00005792-199211000-00002	22	595	634	1	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2000	355	9214					1481	1485		10.1016/S0140-6736(00)02161-9	http://dx.doi.org/10.1016/S0140-6736(00)02161-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801168				2022-12-28	WOS:000086830100008
J	Canfield, DE; Habicht, KS; Thamdrup, B				Canfield, DE; Habicht, KS; Thamdrup, B			The Archean sulfur cycle and the early history of atmospheric oxygen	SCIENCE			English	Article							BACTERIAL SULFATE REDUCTION; COASTAL MARINE BASIN; ISOTOPE FRACTIONATION; IRON-FORMATIONS; SEDIMENTS; CARBON; OCEANS; MODELS; RISE	The isotope record of sedimentary sulfides can help resolve the history of oxygen accumulation into the atmosphere. We measured sulfur isotopic fractionation during microbial sulfate reduction up to 88 degrees C and show how sulfate reduction rate influences the preservation of biological fractionations in sediments. The sedimentary sulfur isotope record suggests Low concentrations of seawater sulfate and atmospheric oxygen in the early Archean (3.4 to 2.8 billion years ago). The accumulation of oxygen and sulfate began later, in the early Proterozoic (2.5 to 0.54 billion years ago).	Odense Univ, SDU, Danish Ctr Earth Syst Sci, DK-5230 Odense M, Denmark; Odense Univ, SDU, Inst Biol, DK-5230 Odense, Denmark	University of Southern Denmark; University of Southern Denmark	Canfield, DE (corresponding author), Odense Univ, SDU, Danish Ctr Earth Syst Sci, Campusvej 55, DK-5230 Odense M, Denmark.		Canfield, Don/C-1735-2012; Thamdrup, Bo/F-3889-2016	Canfield, Don/0000-0001-7602-8366; Thamdrup, Bo/0000-0002-1221-7077				BERKNER LV, 1965, J ATMOS SCI, V22, P225, DOI 10.1175/1520-0469(1965)022<0225:OTOARO>2.0.CO;2; BIRKLUND PW, 1974, PEDOLOGY WEATHERING; Bottcher ME, 1999, ARCH MICROBIOL, V172, P125, DOI 10.1007/s002030050749; BOUDREAU BP, 1984, GEOCHIM COSMOCHIM AC, V48, P2503, DOI 10.1016/0016-7037(84)90301-6; Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; CAMERON EM, 1982, NATURE, V296, P145, DOI 10.1038/296145a0; CAMERON EM, 1987, CHEM GEOL, V65, P341, DOI 10.1016/0168-9622(87)90013-3; Canfield DE, 1999, AM J SCI, V299, P697, DOI 10.2475/ajs.299.7-9.697; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; CHAMBERS LA, 1975, CAN J MICROBIOL, V21, P1602, DOI 10.1139/m75-234; CHANTON JP, 1987, GEOCHIM COSMOCHIM AC, V51, P1201, DOI 10.1016/0016-7037(87)90212-2; CORLISS JB, 1979, SCIENCE, V203, P1073, DOI 10.1126/science.203.4385.1073; DeRonde CEJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4025, DOI 10.1016/S0016-7037(97)00205-6; GARRELS RM, 1974, SEA, P303; GOODWIN AM, 1976, ECON GEOL, V71, P870, DOI 10.2113/gsecongeo.71.5.870; Habicht KS, 1997, GEOCHIM COSMOCHIM AC, V61, P5351, DOI 10.1016/S0016-7037(97)00311-6; Habicht KS, 1996, NATURE, V382, P342, DOI 10.1038/382342a0; HARRISON AG, 1958, T FARADAY SOC, V54, P84, DOI 10.1039/tf9585400084; Hayes JM., 1983, EARTHS EARLIEST BIOS, P291; HOLLAND HD, 1995, EARLY LIFE EARTH, P237; Holland HD., 1999, GEOCHEM NEWS, V100, P20; Kakegawa T, 1998, GEOCHIM COSMOCHIM AC, V62, P3205, DOI 10.1016/S0016-7037(98)00229-4; KAPLAN IR, 1964, J GEN MICROBIOL, V34, P195, DOI 10.1099/00221287-34-2-195; KLUMP JV, 1987, GEOCHIM COSMOCHIM AC, V51, P1161, DOI 10.1016/0016-7037(87)90209-2; Knoblauch C, 1999, APPL ENVIRON MICROB, V65, P4230; Knoll A. H, 1992, ORIGIN EARLY EVOLUTI, P53; KNOLL AH, 1998, ISOTOPE PALEOBIOLOGY, P212; Middelburg JJ, 1997, DEEP-SEA RES PT I, V44, P327, DOI 10.1016/S0967-0637(96)00101-X; OHMOTO H, 1993, SCIENCE, V262, P555, DOI 10.1126/science.11539502; OHMOTO H, 1987, NATURE, V328, P244, DOI 10.1038/328244a0; OHMOTO H, 1997, GEOCHEM NEWS, V93, P12; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; PETER JM, 1992, GEOCHIM COSMOCHIM AC, V56, P1025; Rabouille C, 1998, LIMNOL OCEANOGR, V43, P420, DOI 10.4319/lo.1998.43.3.0420; Rasmussen B, 1999, GEOLOGY, V27, P115, DOI 10.1130/0091-7613(1999)027<0115:RSOTAA>2.3.CO;2; Roychoudhury AN, 1998, APPL GEOCHEM, V13, P269, DOI 10.1016/S0883-2927(97)00064-4; SCHLESINGER WH, 1990, NATURE, V348, P232, DOI 10.1038/348232a0; STACKEBRANDT DA, 1995, SULFATE REDUCING BAC, P49; THODE HG, 1983, PRECAMBRIAN RES, V20, P337, DOI 10.1016/0301-9268(83)90080-3; WESTRICH JT, 1988, GEOMICROBIOL J, V6, P99, DOI 10.1080/01490458809377828; WILLIAMSON MA, 1994, GEOCHIM COSMOCHIM AC, V58, P5443, DOI 10.1016/0016-7037(94)90241-0	41	313	344	1	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					658	661		10.1126/science.288.5466.658	http://dx.doi.org/10.1126/science.288.5466.658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784446				2022-12-28	WOS:000086727100040
J	Bezryadin, A; Lau, CN; Tinkham, M				Bezryadin, A; Lau, CN; Tinkham, M			Quantum suppression of superconductivity in ultrathin nanowires	NATURE			English	Article							WIRES; LOCALIZATION; FLUCTUATIONS; DISSIPATION; TRANSITIONS; JUNCTIONS; SYSTEM	It is of fundamental importance to establish whether there is a limit to how thin a superconducting wire can be, while retaining its superconducting character-and if there is a limit, to determine what sets it. This issue may also be of practical importance in defining the limit to miniaturization of superconducting electronic circuits. At high temperatures, the resistance of linear superconductors is caused by excitations called thermally activated phase slips(1-4). Quantum tunnelling of phase slips is another possible source of resistance that is still being debated(5-8). It has been theoretically predicted(8) that such quantum phase slips can destroy superconductivity in very narrow wires. Here we report resistance measurements on ultrathin ( less than or similar to 10 nm) nanowires produced by coating carbon nanotubes with a superconducting Mo-Ge alloy. We rnd that nanowires can be superconducting or insulating depending on the ratio of their normal-state resistance (R-N) to the quantum resistance for Cooper pairs (R-q). If R-N < R-q, quantum tunnelling of phase slips is prohibited by strong damping, and so the wires stay superconducting. In contrast, we observe an insulating state for R-N > R-q, which we explain in terms of proliferation of quantum phase slips and a corresponding localization of Cooper pairs.	Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University	Bezryadin, A (corresponding author), Harvard Univ, Dept Phys, Cambridge, MA 02138 USA.		Bezryadin, Alexey/H-1815-2016	Bezryadin, Alexey/0000-0002-4822-6960; Lau, Chun Ning/0000-0003-2159-6723				Averin DV, 1999, NATURE, V398, P748, DOI 10.1038/19622; Bezryadin A, 1997, APPL PHYS LETT, V71, P1273, DOI 10.1063/1.119871; BULGADAEV SA, 1984, JETP LETT+, V39, P315; CALDEIRA AO, 1981, PHYS REV LETT, V46, P211, DOI 10.1103/PhysRevLett.46.211; DUAN JM, 1995, PHYS REV LETT, V74, P5128, DOI 10.1103/PhysRevLett.74.5128; GIORDANO N, 1988, PHYS REV LETT, V61, P2137, DOI 10.1103/PhysRevLett.61.2137; Goldman AM, 1998, PHYS TODAY, V51, P39, DOI 10.1063/1.882069; GRAYBEAL JM, 1984, PHYS REV B, V29, P4167, DOI 10.1103/PhysRevB.29.4167; IVLEV BI, 1984, ADV PHYS, V33, P47, DOI 10.1080/00018738400101641; LANGER JS, 1967, PHYS REV, V164, P498, DOI 10.1103/PhysRev.164.498; LIKHAREV KK, 1985, J LOW TEMP PHYS, V59, P347, DOI 10.1007/BF00683782; MCCUMBER DE, 1970, PHYS REV B-SOLID ST, V1, P1054, DOI 10.1103/PhysRevB.1.1054; MOOIJ JE, 1985, PHYS REV LETT, V55, P114, DOI 10.1103/PhysRevLett.55.114; Oreg Y, 1999, PHYS REV LETT, V83, P191, DOI 10.1103/PhysRevLett.83.191; Penttila JS, 1999, PHYS REV LETT, V82, P1004, DOI 10.1103/PhysRevLett.82.1004; SCHMID A, 1983, PHYS REV LETT, V51, P1506, DOI 10.1103/PhysRevLett.51.1506; SCHON G, 1990, PHYS REP, V198, P237, DOI 10.1016/0370-1573(90)90156-V; Tinkham M., 1996, INTRO SUPERCONDUCTIV, P288; VANRUN AJ, 1987, JPN J APPL PHYS 1, V26, P1765, DOI 10.7567/JJAPS.26S3.1765; Zaikin AD, 1998, USP FIZ NAUK+, V168, P244, DOI 10.3367/UFNr.0168.199802aj.0244; Zaikin AD, 1997, PHYS REV LETT, V78, P1552, DOI 10.1103/PhysRevLett.78.1552	21	540	551	3	153	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					971	974		10.1038/35010060	http://dx.doi.org/10.1038/35010060			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801120	Green Submitted			2022-12-28	WOS:000086762000048
J	Parker, RA; Kennedy, DW				Parker, RA; Kennedy, DW			A 48-year-old man with recurrent sinusitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NASAL POLYPS; COMMON COLD; SURGERY; ASTHMA; RHINOSINUSITIS; ADULTS		Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA	Harvard University; Beth Israel Deaconess Medical Center; University of Pennsylvania	Parker, RA (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							Adkins TN, 1998, ANN ALLERG ASTHMA IM, V81, P181, DOI 10.1016/S1081-1206(10)62807-4; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BARANIUK JN, 1994, SINUSITIS PATHOPHYSI, P1939; Bhattacharyya T, 1997, ARCH OTOLARYNGOL, V123, P1189; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214; DZCZEKLIK A, 1999, J ALLERGY CLIN IMMUN, V104, P5; Gable CB, 1994, PHARMACOEPIDEM DR S, V3, P337; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; Gliklich RE, 1997, OTOLARYNG HEAD NECK, V117, P12, DOI 10.1016/S0194-5998(97)70199-2; Gluck U, 1996, AM J RHINOL, V10, P55, DOI 10.2500/105065896781795193; Greisner WA, 1996, ALLERGY ASTHMA PROC, V17, P283, DOI 10.2500/108854196778662192; Gwaltney J M Jr, 1999, Can Respir J, V6 Suppl A, p46A; Gwaltney J M Jr, 1995, Ann Otol Rhinol Laryngol Suppl, V167, P22; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, IN PRESS CLIN INFECT; Halpern Georges M., 1996, P323; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; Holmes TH., 1950, NOSE EXPT STUDY REAC, V1st; Jones NS, 1997, CLIN OTOLARYNGOL, V22, P47, DOI 10.1046/j.1365-2273.1997.00862.x; Kaluskar S K, 1997, Ear Nose Throat J, V76, P884; Kane KJ, 1997, AM J RHINOL, V11, P361, DOI 10.2500/105065897781286034; Keles N, 1999, AM J RHINOL, V13, P185, DOI 10.2500/105065899781389731; Kennedy DW, 1998, LARYNGOSCOPE, V108, P502, DOI 10.1097/00005537-199804000-00008; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; KENNEDY DW, 1992, LARYNGOSCOPE, V102, P118; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; LEVINE HL, 1990, LARYNGOSCOPE, V100, P79; Nadel DM, 1999, AM J RHINOL, V13, P87, DOI 10.2500/105065899782106742; Nadel DM, 1998, AM J RHINOL, V12, P233, DOI 10.2500/105065898781390000; *NAT DIS THER IND, 1994, PLYM M, P963; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Porter JP, 1999, AM J RHINOL, V13, P203, DOI 10.2500/105065899781389696; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; Senior BA, 1999, OTOLARYNG HEAD NECK, V121, P66, DOI 10.1016/S0194-5998(99)70127-0; Senior BA, 1998, LARYNGOSCOPE, V108, P151, DOI 10.1097/00005537-199802000-00001; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; Slavin RG, 1997, JAMA-J AM MED ASSOC, V278, P1849, DOI 10.1001/jama.278.22.1849; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P534, DOI 10.1016/0091-6749(92)90180-A; STANKIEWICZ JA, 1989, LARYNGOSCOPE, V99, P686; Stewart MG, 1999, AM J RHINOL, V13, P161, DOI 10.2500/105065899781389704; SZCZEKLIK A, 1986, DRUGS, V32, P148, DOI 10.2165/00003495-198600324-00011; Taccariello Michelle, 1999, Rhinology (Utrecht), V37, P29; THALER ER, 1994, AM J RHINOL, V8, P237, DOI 10.2500/105065894782537361; Vleming M, 1990, AM J RHINOL, V4, P13; WILLIAMS JW, 1995, JAMA-J AM MED ASSOC, V273, P1015, DOI 10.1001/jama.273.13.1015; Yoshida Steven H., 1996, P367; YOUSEM DM, 1991, J OTOLARYNGOL, V20, P419; ZURLO JJ, 1992, AM J MED, V93, P157, DOI 10.1016/0002-9343(92)90045-D	49	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2143	2150		10.1001/jama.283.16.2143	http://dx.doi.org/10.1001/jama.283.16.2143			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791507				2022-12-28	WOS:000086542800031
J	Yeomans, D				Yeomans, D			Small bodies of the solar system	NATURE			English	Article							253-MATHILDE; FLYBY		CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Yeomans, D (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.							Beech M, 1999, MON NOT R ASTRON SOC, V310, P168, DOI 10.1046/j.1365-8711.1999.02948.x; BELTON MJS, 1995, NATURE, V374, P785, DOI 10.1038/374785a0; BUS SJ, 1989, ICARUS, V77, P223, DOI 10.1016/0019-1035(89)90087-0; BUS SJ, 1991, SCIENCE, V251, P774, DOI 10.1126/science.251.4995.774; Harris A.W., 1996, LUNAR PLANET SCI, V27, P493; Housen KR, 1999, NATURE, V402, P155, DOI 10.1038/45985; LEWIS JS, 1996, MINING SKY; Magri C, 1999, ICARUS, V140, P379, DOI 10.1006/icar.1999.6130; MARSDEN BG, 1992, 5585 IAU; Merline WJ, 1999, NATURE, V401, P565, DOI 10.1038/44089; Ostro SJ, 1999, SCIENCE, V285, P557, DOI 10.1126/science.285.5427.557; SEKANINA Z, 1996, 6495 IAU; Stern SA, 1996, ASTRON J, V112, P1203, DOI 10.1086/118091; Veverka J, 1999, SCIENCE, V285, P562, DOI 10.1126/science.285.5427.562; Veverka J, 1997, SCIENCE, V278, P2109, DOI 10.1126/science.278.5346.2109; WEISSMAN PR, 1986, NATURE, V320, P242, DOI 10.1038/320242a0; Weissman PR, 1997, ASTROPHYS J, V488, pL133, DOI 10.1086/310940; WHIPPLE FL, 1950, ASTROPHYS J, V111, P375, DOI 10.1086/145272; WHIPPLE FL, 1951, ASTROPHYS J, V113, P464, DOI 10.1086/145416; Yeomans DK, 1999, SCIENCE, V285, P560, DOI 10.1126/science.285.5427.560; Yeomans DK, 1997, SCIENCE, V278, P2106, DOI 10.1126/science.278.5346.2106; Zolensky ME, 1999, SCIENCE, V285, P1377, DOI 10.1126/science.285.5432.1377; [No title captured]	23	14	15	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					829	832		10.1038/35009193	http://dx.doi.org/10.1038/35009193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786778				2022-12-28	WOS:000086625000030
J	Bukau, B; Deuerling, E; Pfund, C; Craig, EA				Bukau, B; Deuerling, E; Pfund, C; Craig, EA			Getting newly synthesized proteins into shape	CELL			English	Review							NASCENT POLYPEPTIDE-CHAINS; FOLDING IN-VIVO; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; TRIGGER FACTOR		Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Freiburg	Craig, EA (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.			Bukau, Bernd/0000-0003-0521-7199				Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Houry WA, 1999, NATURE, V402, P147, DOI 10.1038/45977; Kim S, 1998, P NATL ACAD SCI USA, V95, P12860, DOI 10.1073/pnas.95.22.12860; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nicola AV, 1999, NAT CELL BIOL, V1, P341, DOI 10.1038/14032; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809	16	334	351	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 14	2000	101	2					119	122		10.1016/S0092-8674(00)80806-5	http://dx.doi.org/10.1016/S0092-8674(00)80806-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	305DP	10786831	Bronze, Green Published			2022-12-28	WOS:000086524400002
J	Iwasaki, H; Williams, SB; Kitayama, Y; Ishiura, M; Golden, SS; Kondo, T				Iwasaki, H; Williams, SB; Kitayama, Y; Ishiura, M; Golden, SS; Kondo, T			A KaiC-interacting sensory histidine kinase, SasA, necessary to sustain robust circadian oscillation in cyanobacteria	CELL			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; CLONING; RHYTHMS; BIOLUMINESCENCE; LUCIFERASE; PHOSPHATE; PROTEINS; FRAGMENT; BACTERIA	Both regulated expression of the clock genes kaiA, kaiB, and kaiC and interactions among the Kai proteins are proposed to be important for circadian function in the cyanobacterium Synechococcus sp, strain PCC 7942. We have identified the histidine kinase SasA as a KaiC-interacting protein. SasA contains a KaiB-like sensory domain, which appears sufficient for interaction with KaiC. Disruption of the sasA gene lowered kaiBC expression and dramatically reduced amplitude of the kai expression rhythms while shortening the period. Accordingly, sasA disruption attenuated circadian expression patterns of all tested genes, some of which became arrhythmic. Continuous sasA overexpression eliminated circadian rhythms, whereas temporal overexpression changed the phase of kaiBC expression rhythm. Thus, SasA is a close associate of the cyanobacterial clock that is necessary to sustain robust circadian rhythms.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Nagoya University; Texas A&M University System; Texas A&M University College Station	Kondo, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan.	kondo@bio.nagoya-u.ac.jp		Iwasaki, Hideo/0000-0002-3754-4955	NIGMS NIH HHS [F32 GM19644] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019644] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1993, MOL MICROBIOL, V8, P81, DOI 10.1111/j.1365-2958.1993.tb01205.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSSON CR, 2000, IN PRESS METHODS ENZ; AOKI S, 1995, J BACTERIOL, V177, P5606, DOI 10.1128/jb.177.19.5606-5611.1995; BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; GOLDEN SS, 1986, EMBO J, V5, P2789, DOI 10.1002/j.1460-2075.1986.tb04569.x; HIRSCH PR, 1986, GENE, V48, P203, DOI 10.1016/0378-1119(86)90078-8; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 1999, EMBO J, V18, P1137, DOI 10.1093/emboj/18.5.1137; Katayama M, 1999, J BACTERIOL, V181, P3516, DOI 10.1128/JB.181.11.3516-3524.1999; Kim SK, 1996, MOL MICROBIOL, V22, P135, DOI 10.1111/j.1365-2958.1996.tb02663.x; KONDO T, 1994, J BACTERIOL, V176, P1881, DOI 10.1128/jb.176.7.1881-1885.1994; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; Kutsuna S, 1998, J BACTERIOL, V180, P2167, DOI 10.1128/JB.180.8.2167-2174.1998; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; Mizuno T, 1996, DNA Res, V3, P407, DOI 10.1093/dnares/3.6.407; NAGAYA M, 1993, GENE, V131, P119; Nishiwaki T, 2000, P NATL ACAD SCI USA, V97, P495, DOI 10.1073/pnas.97.1.495; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; SCANLAN DJ, 1992, PLANT MOL BIOL, V19, P877, DOI 10.1007/BF00027085; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Tsinoremas NF, 1996, EMBO J, V15, P2488, DOI 10.1002/j.1460-2075.1996.tb00606.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Yan OY, 1998, P NATL ACAD SCI USA, V95, P8660, DOI 10.1073/pnas.95.15.8660	35	194	214	3	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 14	2000	101	2					223	233		10.1016/S0092-8674(00)80832-6	http://dx.doi.org/10.1016/S0092-8674(00)80832-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	305DP	10786837	Bronze			2022-12-28	WOS:000086524400008
J	Schubert, U; Anton, LC; Gibbs, J; Norbury, CC; Yewdell, JW; Bennink, JR				Schubert, U; Anton, LC; Gibbs, J; Norbury, CC; Yewdell, JW; Bennink, JR			Rapid degradation of a large fraction of newly synthesized proteins by proteasomes	NATURE			English	Article							MHC CLASS-I; CHYMOTRYPSIN-LIKE ACTIVITY; MOLECULES; PEPTIDES; INHIBITION; CHAINS; CELLS	MHC class I molecules function to present peptides eight to ten residues long to the immune system. These peptides originate primarily from a cytosolic pool of proteins through the actions of proteasomes(1), and are transported into the endoplasmic reticulum, where they assemble with nascent class I molecules(2). Most peptides are generated from proteins that are apparently metabolically stable. To explain this, we previously proposed that peptides arise from proteasomal degradation of defective ribosomal products (DRiPs). DRiPs are polypeptides that never attain native structure owing to errors in translation or post-translational processes necessary for proper protein folding(3). Here we show, first, that DRiPs constitute upwards of 30% of newly synthesized proteins as determined in a variety of cell types; second, that at least some DRiPs represent ubiquitinated proteins; and last, that ubiquitinated DRiPs are formed from human immunodeficiency virus Gag polyprotein, a long-lived viral protein that serves as a source of antigenic peptides.	NIAID, Viral Dis Lab, Bethesda, MD 20892 USA; Univ Hamburg, Heinrich Pette Inst, Hamburg, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Heinrich Pette Institute; University of Hamburg	Yewdell, JW (corresponding author), NIAID, Viral Dis Lab, Bethesda, MD 20892 USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012; Antón, Luis C/C-4740-2013	Antón, Luis C/0000-0001-9665-011X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000653, ZIAAI000658, Z01AI000658, Z01AI000653] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Alberts B., 1994, MOL BIOL CELL; Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ENGELHARD VH, 1994, ANNU REV IMMUNOL, V12, P181, DOI 10.1146/annurev.iy.12.040194.001145; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; RAMMENSEE HG, 1997, MHC LIGANDS PEPTIDE; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; STEINMAN RM, 1998, FUNDAMENTAL IMMUNOLO, P547; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wojcik C, 1996, EUR J CELL BIOL, V71, P311; Yewdell JW, 1996, J IMMUNOL, V157, P1823	18	1161	1200	1	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					770	774		10.1038/35008096	http://dx.doi.org/10.1038/35008096			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783891				2022-12-28	WOS:000086523600054
J	Carson, AJ; Best, S; Warlow, C; Sharpe, M				Carson, AJ; Best, S; Warlow, C; Sharpe, M			Suicidal ideation among outpatients at general neurology clinics: prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Carson, AJ (corresponding author), Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland.	A.Carson@ed.ac.uk		sharpe, michael/0000-0002-6474-9980				Carson AJ, 2000, J NEUROL NEUROSUR PS, V68, P202, DOI 10.1136/jnnp.68.2.202; DIEKSTRA RFW, 1993, ACTA PSYCHIAT SCAND, V87, P9, DOI 10.1111/j.1600-0447.1993.tb05368.x; Feinstein A, 1997, BRIT MED J, V315, P691, DOI 10.1136/bmj.315.7110.691; PAYKEL ES, 1974, BRIT J PSYCHIAT, V124, P460, DOI 10.1192/bjp.124.5.460; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749	5	33	33	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2000	320	7245					1311	1312		10.1136/bmj.320.7245.1311	http://dx.doi.org/10.1136/bmj.320.7245.1311			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807623	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000087077400023
J	Payne, D				Payne, D			Ireland's junior doctors to strike	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1227	1227						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797027				2022-12-28	WOS:000086981400012
J	Sackett, DL				Sackett, DL			The sins of expertness and a proposal for redemption	BRITISH MEDICAL JOURNAL			English	Editorial Material									Trout Res & Educ Ctr Irish Lake, Markdale, ON, Canada		Sackett, DL (corresponding author), Trout Res & Educ Ctr Irish Lake, Markdale, ON, Canada.								0	41	46	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1283	1283		10.1136/bmj.320.7244.1283	http://dx.doi.org/10.1136/bmj.320.7244.1283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797065	Green Published			2022-12-28	WOS:000086981400060
J	Craig, JV; Lancaster, GA; Williamson, PR; Smyth, RL				Craig, JV; Lancaster, GA; Williamson, PR; Smyth, RL			Temperature measured at the axilla compared with rectum in children and young people: systematic review	BRITISH MEDICAL JOURNAL			English	Article							INFANTS; FEVER; THERMOMETER; GUIDELINES; TERM	Objective To evaluate the agreement between temperature measured at the axilla and rectum in children and young people. Design A systematic review of studies comparing temperature measured at the axilla (test site) with temperature measured at the rectum (reference site) using the same type of measuring device at both sites in each patient. Devices were mercury or electronic thermometers or indwelling thermocouple probes. Studies reviewed 40 studies including 5528 children and young people from birth to Is years. Data extraction Difference in temperature readings at the axilla and rectum. Results 20 studies (n = 3201 (58%) participants) had sufficient data to be included in a meta-analysis. There was significant residual heterogeneity in both mean differences and sample standard deviations within the groups using different devices and within age groups. The pooled (random effects) mean temperature difference (rectal minus axillary temperature) for mercury thermometers was 0.25 degrees C (95% limits of agreement -0.15 degrees C to 0.65 degrees C) and for electronic thermometers was 0.85 degrees C (-0.19 degrees C to 1.90 degrees C). The pooled (random effects) mean temperature difference (rectal minus axillary; temperature) for neonates was 0.17 degrees C (-0.15 degrees C to 0.50 degrees C) and for older children and young people was 0.92 degrees C (-0.15 degrees C to 1.98 degrees C). Conclusions The difference between temperature readings at the axilla and rectum using either mercury or electronic thermometers shelved wide variation across studies. This has implications for clinical situations where temperature needs to be measured with precision.	Alder Hey Childrens Hosp, Inst Child Hlth, Liverpool L12 2AP, Merseyside, England; Univ Liverpool, Dept Math Sci, Liverpool L69 3BX, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; University of Liverpool	Smyth, RL (corresponding author), Alder Hey Childrens Hosp, Inst Child Hlth, Liverpool L12 2AP, Merseyside, England.		Williamson, Paula R/B-6425-2016	Williamson, Paula R/0000-0001-9802-6636; Craig, Jean/0000-0003-2296-6773				AKINBAMI F O, 1991, African Journal of Medicine and Medical Sciences, V20, P49; ANAGNOSTAKIS D, 1993, CLIN PEDIATR, V32, P268, DOI 10.1177/000992289303200503; Barrus D H, 1983, Pediatr Nurs, V9, P424; BISSONNETTE B, 1989, ANESTH ANALG, V69, P192; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRITTON GR, 1980, J OBSTET GYNECOL MAR, P84; BROWN RD, 1992, CLIN PEDIATR, V31, P523; BUNTAIN WL, 1977, J LOUISIANA ST MED S, V129, P5; *COCHR METH WORK G, 1996, COCHR LIB; Cusson RM, 1997, NURS RES, V46, P202, DOI 10.1097/00006199-199707000-00004; DAVIES SP, 1986, J ADV NURS, V11, P535, DOI 10.1111/j.1365-2648.1986.tb01285.x; Davis K, 1993, Pediatr Nurs, V19, P267; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EOFF MJ, 1981, AM J NURS, V81, P1010, DOI 10.2307/3424734; EOFF MJF, 1974, NURS RES, V23, P457; ERICKSON RS, 1994, HEART LUNG, V23, P181; GOEHNER E, 1990, UNPUB COMP ACCURACY; Haddock B, 1986, Neonatal Netw, V5, P36; Haddock B J, 1996, Pediatr Nurs, V22, P121; HOLTZ JB, 1989, NURS RES, V38, P85; HOLTZ JB, 1991, SCH INQ NURS PRACT, V5, P113; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JIRAPAET V, 1999, CENT C INT COUNC NUR; JONES RJ, 1993, ARCH DIS CHILD, V69, P437, DOI 10.1136/adc.69.4.437; KEELEY D, 1992, BRIT MED J, V304, P931, DOI 10.1136/bmj.304.6832.931; Keeling E B, 1992, Matern Child Nurs J, V20, P124; KHAN M N, 1990, Indian Pediatrics, V27, P807; KRESCH MJ, 1984, J PEDIATR-US, V104, P596, DOI 10.1016/S0022-3476(84)80558-2; KUNNEL MT, 1988, NURS RES, V37, P162; Leon J E, 1990, Can J Anaesth, V37, pS98; Martyn K K, 1988, Nurse Pract, V13, P31; MAYFIELD SR, 1984, J PEDIATR-US, V104, P271, DOI 10.1016/S0022-3476(84)81011-2; Morley C J, 1992, Midwives Chron, V105, P26; MORLEY CJ, 1992, ARCH DIS CHILD, V67, P122, DOI 10.1136/adc.67.1.122; MUMA BK, 1991, ANN EMERG MED, V20, P41, DOI 10.1016/S0196-0644(05)81116-3; OGREN JM, 1990, AM J DIS CHILD, V144, P109, DOI 10.1001/archpedi.1990.02150250121048; Ovali F, 1997, J Perinatol, V17, P419; PITUCH K, 1981, LANCET          0704, P43; Pontious S, 1994, J Pediatr Nurs, V9, P114; Roll C, 1998, Z GEBURTSH NEONATOL, V202, P207; SCHIFFMAN RF, 1982, NURS RES, V31, P274; SCHMITT BD, 1980, AM J DIS CHILD, V134, P176, DOI 10.1001/archpedi.1980.02130140050015; Shann F, 1996, ARCH PEDIAT ADOL MED, V150, P74, DOI 10.1001/archpedi.1996.02170260078013; Thomas V, 1994, J Emerg Nurs, V20, P505; TRELOAR D, 1988, ANN EMERG MED, V17, P435; Weiss M E, 1994, J Obstet Gynecol Neonatal Nurs, V23, P798, DOI 10.1111/j.1552-6909.1994.tb01955.x; Weiss M E, 1994, Neonatal Netw, V13, P35; WEISSE ME, 1991, PEDIATR INFECT DIS J, V10, P541, DOI 10.1097/00006454-199107000-00013; YETMAN RJ, 1993, J PEDIATR-US, V122, P769, DOI 10.1016/S0022-3476(06)80024-7; Zengeya ST, 1996, EUR J PEDIATR, V155, P1005, DOI 10.1007/s004310050522	51	155	160	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1174	1178		10.1136/bmj.320.7243.1174	http://dx.doi.org/10.1136/bmj.320.7243.1174			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310MW	10784539	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086832800017
J	Lynch, JW; Smith, GD; Kaplan, GA; House, JS				Lynch, JW; Smith, GD; Kaplan, GA; House, JS			Income inequality and mortality: importance to health of individual income, psychosocial environment, or material conditions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; MULTILEVEL ANALYSIS; LIFE EXPECTANCY; SOCIAL COHESION; EPIDEMIOLOGY; DETERMINANTS; NATIONS		Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Social Res, Survey Res Ctr, Ann Arbor, MI 48109 USA; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Bristol	Lynch, JW (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 109 Observ St, Ann Arbor, MI 48109 USA.	jwlynch@sph.umich.edu	Davey Smith, George/A-7407-2013; Lynch, John W/A-4797-2008; Kaplan, George/AAJ-2398-2020	Davey Smith, George/0000-0002-1407-8314; Lynch, John W/0000-0003-2781-7902; 				Backlund E, 1996, ANN EPIDEMIOL, V6, P12, DOI 10.1016/1047-2797(95)00090-9; CHARLTON J, 1994, HLTH ADULT BRITAIN 1; Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; DIENER E, 1995, J PERS SOC PSYCHOL, V69, P851, DOI 10.1037/0022-3514.69.5.851; Diez-Roux AV, 1998, AM J PUBLIC HEALTH, V88, P216, DOI 10.2105/AJPH.88.2.216; Ecob R, 1999, SOC SCI MED, V48, P693, DOI 10.1016/S0277-9536(98)00385-2; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; Goodman A., 1994, RICHER POORER CHANGI; GOUGH I, 1994, INT J HEALTH SERV, V24, P715, DOI 10.2190/KHAM-M986-W67T-56B7; Gravelle H, 1998, BMJ-BRIT MED J, V316, P382, DOI 10.1136/bmj.316.7128.382; Judge K, 1998, SOC SCI MED, V46, P567, DOI 10.1016/S0277-9536(97)00204-9; JUDGE K, 1995, BRIT MED J, V311, P1282, DOI 10.1136/bmj.311.7015.1282; KABIR M, 1996, HLTH POVERTY DEV IND; Kaplan GA, 1996, BRIT MED J, V312, P999; Kawachi I, 1997, AM J PUBLIC HEALTH, V87, P1491, DOI 10.2105/AJPH.87.9.1491; Kennedy BP, 1996, BRIT MED J, V312, P1004, DOI 10.1136/bmj.312.7037.1004; Kennedy BP, 1998, BRIT MED J, V317, P917; Koopman JS, 1999, AM J PUBLIC HEALTH, V89, P1170, DOI 10.2105/AJPH.89.8.1170; Lynch J W, 1997, J Health Psychol, V2, P297, DOI 10.1177/135910539700200303; Lynch JW, 1997, SOC SCI MED, V44, P809, DOI 10.1016/S0277-9536(96)00191-8; Lynch JW, 1998, AM J PUBLIC HEALTH, V88, P1074, DOI 10.2105/AJPH.88.7.1074; LYNCH JW, IN PRESS J EPIDEMIOL; LYNCH JW, IN PRESS SOC SCI MED; LYNCH JW, IN PRESS SOCIAL EPID; Muntaner C, 1999, INT J HEALTH SERV, V29, P699, DOI 10.2190/HNC9-BEFF-7UWL-92Y2; Muntaner C, 1999, INT J HEALTH SERV, V29, P59, DOI 10.2190/G8QW-TT09-67PL-QTNC; Newman K. S., 1999, NO SHAME MY GAME WOR; Ross NA, 2000, BRIT MED J, V320, P898, DOI 10.1136/bmj.320.7239.898; Sapolsky R.M., 1999, HORMONES HLTH BEHAV, P18, DOI DOI 10.1017/CBO9780511623462.002; Smith GD, 1996, BRIT MED J, V312, P987; Smith GD, 1996, BRIT MED J, V313, P1584, DOI 10.1136/bmj.313.7072.1584; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith TW, 1997, SOC SCI RES, V26, P170, DOI 10.1006/ssre.1997.0592; Soobader MJ, 1999, SOC SCI MED, V48, P733, DOI 10.1016/S0277-9536(98)00401-8; Stanistreet D, 1999, J PUBLIC HEALTH MED, V21, P205, DOI 10.1093/pubmed/21.2.205; Szreter S., 1999, RENEWAL, V7, P30; Szwarcwald CL, 1999, AM J PUBLIC HEALTH, V89, P845, DOI 10.2105/AJPH.89.6.845; WAINWRIGHT D, 1996, CRITICAL SOCIAL POLI, V49, P67; Waitzman NJ, 1998, MILBANK Q, V76, P341, DOI 10.1111/1468-0009.00095; *WHO, 1999, WHO STAT DAT; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilkinson RG, 1997, BRIT MED J, V314, P591, DOI 10.1136/bmj.314.7080.591; Wolfson M, 1999, BRIT MED J, V319, P953, DOI 10.1136/bmj.319.7215.953; Woolcock M, 1998, THEOR SOC, V27, P151, DOI 10.1023/A:1006884930135; *WORLD BANK, 1997, WORLD BANK DEV IND C; World Bank, 1996, IMPR WOM HLTH IND	48	884	909	1	153	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	2000	320	7243					1200	1204		10.1136/bmj.320.7243.1200	http://dx.doi.org/10.1136/bmj.320.7243.1200			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310MW	10784551	Green Published			2022-12-28	WOS:000086832800025
J	Silove, D; Ekblad, S; Mollica, R				Silove, D; Ekblad, S; Mollica, R			The rights of the severely mentally ill in post-conflict societies	LANCET			English	Editorial Material							TRAUMA		Univ New S Wales, Sch Psychiat, Psychiat Res & Teaching Unit, Sydney, NSW, Australia; Karolinska Inst, Dept Publ Hlth Sci, Div Psychosocial Factors & Hlth, Stockholm, Sweden; Harvard Univ, Sch Med, Harvard Program Refugee Trauma, Boston, MA USA	University of New South Wales Sydney; Karolinska Institutet; Harvard University; Harvard Medical School	Silove, D (corresponding author), Univ New S Wales, Sch Psychiat, Psychiat Res & Teaching Unit, Sydney, NSW, Australia.		Ekblad, Solvig/B-6389-2009					Mollica RF, 1999, JAMA-J AM MED ASSOC, V282, P433, DOI 10.1001/jama.282.5.433; Silove D, 1999, J NERV MENT DIS, V187, P200, DOI 10.1097/00005053-199904000-00002; Summerfield D, 1999, SOC SCI MED, V48, P1449, DOI 10.1016/S0277-9536(98)00450-X	3	48	49	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1548	1549		10.1016/S0140-6736(00)02177-2	http://dx.doi.org/10.1016/S0140-6736(00)02177-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310LR	10801189				2022-12-28	WOS:000086830100043
J	Manabe, M; Barrett, PM; Isaji, S				Manabe, M; Barrett, PM; Isaji, S			Palaeontology - A refugium for relicts?	NATURE			English	Article									Museum Nat Sci, Dept Geol, Shinjuku Ku, Tokyo 1690073, Japan; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Chiba Prefectural Museum Nat Hist, Chiba 2600682, Japan	University of Oxford	Manabe, M (corresponding author), Museum Nat Sci, Dept Geol, Shinjuku Ku, 3-23-1 Hyakunin Cho, Tokyo 1690073, Japan.	paul.barrett@zoo.ox.ac.uk	Barrett, Paul M/A-2648-2010	Barrett, Paul M/0000-0003-0412-3000; Manabe, Makoto/0000-0003-2490-6125				BAKKER RT, 1978, NATURE, V274, P661, DOI 10.1038/274661a0; Evans Susan E., 1998, Bulletin of the New Mexico Museum of Natural History and Science, V14, P183; Luo ZX, 1999, NATURE, V400, P23, DOI 10.1038/21790; MAEDA SHIRO, 1961, JOUR COLL ARTS AND SCI CHIBA UNIV, V3, P369; Makovicky Peter J., 1998, American Museum Novitates, V3240, P1; Manabe M, 1999, J PALEONTOL, V73, P1176, DOI 10.1017/S002233600003105X; Manabe M., 1995, 6 S MES TERR EC BIOT, P179; NORMAN DB, IN PRESS SPEC PAP PA; Sereno PC, 1999, SCIENCE, V284, P2137, DOI 10.1126/science.284.5423.2137; Setoguchi T., 1999, P 7 ANN M CHIN SOC V, P117; Xu X, 1999, NATURE, V399, P350, DOI 10.1038/20670; Xu Xing, 1998, Vertebrata Palasiatica, V36, P147; Zhao XJ, 1998, NATURE, V394, P234, DOI 10.1038/28300	13	41	50	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 27	2000	404	6781					953	953		10.1038/35010199	http://dx.doi.org/10.1038/35010199			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801116	Bronze			2022-12-28	WOS:000086762000044
J	Hutter, JC; Kuehnert, MJ; Wallis, RR; Lucas, DD; Sen, S; Jarvis, WR				Hutter, JC; Kuehnert, MJ; Wallis, RR; Lucas, DD; Sen, S; Jarvis, WR			Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIALYSIS CENTER; CELLULOSE; INTOXICATION; OXIDATION; MEMBRANES	Context A recent event in which 7 patients at 1 hospital developed decreased vision and hearing, conjunctivitis, headache, and other severe neurologic symptoms 7 to 24 hours after hemodialysis drew attention to the issue of the long-term integrity of dialysis machines and materials. Objective To determine the cause of the adverse reactions that occurred during this event. Design, Patients, and Setting Retrospective cohort study of all 9 patients who received hemodialysis at hospital A on September 18, 1996, the day of the outbreak. A case-patient was defined as any hospital A patient with acute onset of decreased vision and hearing and conjunctivitis after dialysis on that day. Non-case-patients were all others who underwent dialysis at hospital A on that day but did not develop adverse reactions. in an attempt to reproduce the conditions of the event, cellulose acetate dialysis membranes of various ages were retrieved from other sources and tested for physical and chemical degradation, and degradation products were identified, characterized, and injected intravenously into rabbits. Main Outcome Measures Clinical signs and symptoms, time to resolution of symptoms, mortality, and dialyzer type and age, for case- vs non-case-patients. Results Seven of the 9 patients met the case definition. In addition to diminished vision and hearing, conjunctivitis, and headache, some case-patients had blood leak alarm activation (n=6), confusion/lethargy (n=5), corneal opacification (n=4), cardiac arrest (n=2), or other neurologic signs and symptoms. One case-patient died during hospitalization after the event; 5 of 7 case-patients died within 13 months. Resolution of signs and symptoms varied but persisted more than 3 years or until death in 3 of the 6 patients who survived hospitalization. All case-patients but no non-case-patients were exposed to 11.5-year-old cellulose acetate dialyzers (all of these dialyzers were discarded by the hospital before our investigation). Laboratory investigation of field-retrieved 0- to 13.6-year-old dialyzers of similar type indicated significant chemical degradation in the older membranes. In vivo injection of extracts of membrane degradation products produced iritis and hemorrhages in rabbits' eyes. Conclusions Severe patient injury was associated with exposure to aged cellulose acetate membranes of dialyzers, allowing cellulose acetate degradation products to enter the blood. Clinicians should be aware that aged cellulose acetate membranes may cause severe adverse reactions.	US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20852 USA; Ctr Dis Control & Prevent, Hosp Infect Program, Natl Ctr Infect Dis, Atlanta, GA USA	US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA	Hutter, JC (corresponding author), US FDA, Ctr Devices & Radiol Hlth, 12725 Twinbrook Pkwy,HFZ 150, Rockville, MD 20852 USA.							ARNOW PM, 1994, ANN INTERN MED, V121, P339, DOI 10.7326/0003-4819-121-5-199409010-00005; *ASTM, 1983, STAND METH TEST CELL; Brandrup J., 1989, POLYM HDB, V3rd ed.; BURWEN DR, 1995, KIDNEY INT, V48, P469, DOI 10.1038/ki.1995.315; CHURCHILL DN, 1988, NEPHRON, V50, P325, DOI 10.1159/000185197; DAKA JN, 1994, 20 ANN M SOC BIOM AP; DAUGIRDAS JT, 1988, KIDNEY INT S24, V33, pS37; DEAN AG, 1990, EPI INFO VERSION 6 W; Favero MS, 1996, HOSP EPIDEMIOLOGY IN, P693; FUJIWARA N, 1994, DESALINATION, V96, P431, DOI 10.1016/0011-9164(94)85192-1; GLATER J, 1983, DESALINATION, V46, P389, DOI 10.1016/0011-9164(83)87181-1; GORDON SM, 1990, AM J NEPHROL, V10, P123, DOI 10.1159/000168066; GORDON SM, 1990, KIDNEY INT, V37, P110, DOI 10.1038/ki.1990.15; HENDERSON LW, 1993, YB NEPHROLOGY, P210; KESSLER LG, 1996, NOTICE MANUFACTURERS; KROSCHWITZ J, 1985, ENCY POLYM SCI ENG; KUMANO A, 1994, DESALINATION, V96, P451, DOI 10.1016/0011-9164(94)85194-8; MCCRAY SB, 1991, J MEMBRANE SCI, V59, P305; MURPHY AP, 1991, DESALINATION, V85, P45, DOI 10.1016/0011-9164(91)85145-K; OBA T, 1984, ARTIF ORGANS, V8, P429, DOI 10.1111/j.1525-1594.1984.tb04319.x; PEGUES DA, 1992, KIDNEY INT, V42, P1232, DOI 10.1038/ki.1992.409; PEGUES DA, 1992, J AM SOC NEPHROL, V3, P1002; Perry RH., 1984, PERRYS CHEM ENG HDB; PHILIPP B, 1984, PURE APPL CHEM, V56, P391, DOI 10.1351/pac198456030391; RANBY RG, 1959, J POLYM SCI, V36, P561; VOS KD, 1966, J APPL POLYM SCI, V10, P825, DOI 10.1002/app.1966.070100515; YIN L, 1997, NOTICE MANUFACTURERS	27	32	32	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2128	2134		10.1001/jama.283.16.2128	http://dx.doi.org/10.1001/jama.283.16.2128			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791505				2022-12-28	WOS:000086542800029
J	Angetter, DC				Angetter, DC		Senate Project Univ Vienna	Anatomical science at University of Vienna 1938-45	LANCET			English	Review							PURE SCIENCE; FICTION		Univ Vienna, Dept Hist Med, A-1090 Vienna, Austria	University of Vienna	Angetter, DC (corresponding author), Univ Vienna, Dept Hist Med, Wahringerstr 24, A-1090 Vienna, Austria.							ERNST E, 1995, ANN INTERN MED, V122, P789, DOI 10.7326/0003-4819-122-10-199505150-00009; FABREGUET M, 1994, THESIS PARIS; HOLUBAR K, 2000, NIH S MED RES END 20; HYRTL J, 1996, ANATOMIE WIENER U, V6; LANGBEIN H, 1980, WIDERSTAND NATIONSOZ; Le Chene Evelyn, 1971, MAUTHAUSEN HIST DEAT; Malina P, 1997, WIEN KLIN WOCHENSCHR, V109, P935; Malina P, 1998, WIEN KLIN WOCHENSCHR, V110, P193; MARSALEK H, 1980, GESHC KONZENTRATIONS; NEUGEBAUER WM, 1996, JB VEREINS GESCH STA; PERNKOPF E, 1937, LEHRBUCH ATLAS RAGIO; PERNKOPF E, 1938, WIEN KLIN WOCHENSCHR, V511, P545; RABITSCH G, 1970, STUDIEN GESCH KONZ 1, V1, P50; RABITSCH G, 1967, THESIS WIEN; SCHUTZ W, 2000, NIH S MED RES END 20; SEIDELMAN WE, 1996, HIPPOCRATES BETRAYED; SENEFELDER L, 1905, GESCH STADT WIEN, V2, P1057; UIBLEIN P, 1981, HIST MITT, V23, P171; WEISSMANN G, 1985, HOSP PRACT, V15, P152; Williams D J, 1988, J Biocommun, V15, P2; Williams D.J, 1986, ACT P 30 INT C HIST, P524	21	50	50	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1454	1457		10.1016/S0140-6736(00)02151-6	http://dx.doi.org/10.1016/S0140-6736(00)02151-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791540				2022-12-28	WOS:000086829800041
J	Chabanov, AA; Stoytchev, M; Genack, AZ				Chabanov, AA; Stoytchev, M; Genack, AZ			Statistical signatures of photon localization	NATURE			English	Article							PROBABILITY-DISTRIBUTION; ANDERSON LOCALIZATION; INTENSITY CORRELATION; DISORDERED MEDIUM; WAVE-GUIDES; TRANSMISSION; ABSORPTION; RESISTANCE; DIFFUSION; TRANSPORT	The realization that electron localization in disordered systems(1) (Anderson localization) is ultimately a wave phenomenon(2,3) has led to the suggestion that photons could be similarly localized by disorder 3. This conjecture attracted wide interest because the differences between photons and electrons-in their interactions, spin statistics, and methods of injection and detection-may open a new realm of optical and microwave phenomena, and allow a detailed study of the Anderson localization transition undisturbed by the Coulomb interaction. To date, claims of three-dimensional photon localization have been based on observations of the exponential decay of the electromagnetic wave(4-8) as it propagates through the disordered medium. But these reports have come under close scrutiny because of the possibility that the decay observed may be due to residual absorption(9-11), and because absorption itself may suppress localization 3. Here we show that the extent of photon localization can be determined by a different approach-measurement of the relative size of fluctuations of certain transmission quantities. The variance of relative fluctuations accurately reflects the extent of localization, even in the presence of absorption. Using this approach, we demonstrate photon localization in both weakly and strongly scattering quasi-one-dimensional dielectric samples and in periodic metallic wire meshes containing metallic scatterers, while ruling it out in three-dimensional mixtures of aluminium spheres.	CUNY Queens Coll, Dept Phys, Flushing, NY 11367 USA	City University of New York (CUNY) System; Queens College NY (CUNY)	Chabanov, AA (corresponding author), CUNY Queens Coll, Dept Phys, Flushing, NY 11367 USA.		Chabanov, Andrey/B-5627-2009	Chabanov, Andrey/0000-0002-5886-4333				ANDERSON PW, 1958, PHYS REV, V109, P1492, DOI 10.1103/PhysRev.109.1492; ARYA K, 1986, PHYS REV LETT, V57, P2725, DOI 10.1103/PhysRevLett.57.2725; Brouwer PW, 1998, PHYS REV B, V57, P10526, DOI 10.1103/PhysRevB.57.10526; CONDAT CA, 1987, PHYS REV LETT, V58, P226, DOI 10.1103/PhysRevLett.58.226; GARCIA N, 1993, PHYS LETT A, V176, P458, DOI 10.1016/0375-9601(93)90479-J; GARCIA N, 1989, PHYS REV LETT, V63, P1678, DOI 10.1103/PhysRevLett.63.1678; GARCIA N, 1992, PHYS REV B, V46, P14475, DOI 10.1103/PhysRevB.46.14475; GARCIA N, 1991, PHYS REV LETT, V66, P1850, DOI 10.1103/PhysRevLett.66.1850; GENACK AZ, 1991, PHYS REV LETT, V66, P2064, DOI 10.1103/PhysRevLett.66.2064; Ioffe A. F., 1960, PROG SEMICOND, V4, P237; JOHN S, 1984, PHYS REV LETT, V53, P2169, DOI 10.1103/PhysRevLett.53.2169; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; KOGAN E, 1995, PHYS REV B, V52, pR3813, DOI 10.1103/PhysRevB.52.R3813; LAGENDIJK A, 1989, PHYS LETT A, V136, P81, DOI 10.1016/0375-9601(89)90683-X; LANDAUER R, 1970, PHILOS MAG, V21, P863, DOI 10.1080/14786437008238472; Scheffold F, 1999, NATURE, V398, P206, DOI 10.1038/18347; SHAPIRO B, 1987, PHILOS MAG B, V56, P1031, DOI 10.1080/13642818708215341; SIGALAS MM, 1995, PHYS REV B, V52, P11744, DOI 10.1103/PhysRevB.52.11744; Stoytchev M, 1997, PHYS REV LETT, V79, P309, DOI 10.1103/PhysRevLett.79.309; Stoytchev M, 1999, OPT LETT, V24, P262, DOI 10.1364/OL.24.000262; Stoytchev M, 1997, PHYS REV B, V55, pR8617, DOI 10.1103/PhysRevB.55.R8617; THOULESS DJ, 1977, PHYS REV LETT, V39, P1167, DOI 10.1103/PhysRevLett.39.1167; van Rossum MCW, 1999, REV MOD PHYS, V71, P313, DOI 10.1103/RevModPhys.71.313; vanLangen SA, 1996, PHYS REV E, V53, pR1344, DOI 10.1103/PhysRevE.53.R1344; Vlasov YA, 1999, PHYS REV B, V60, P1555, DOI 10.1103/PhysRevB.60.1555; WEAVER RL, 1993, PHYS REV B, V47, P1077, DOI 10.1103/PhysRevB.47.1077; Wiersma DS, 1997, NATURE, V390, P671, DOI 10.1038/37757; Wiersma DS, 1999, NATURE, V398, P207, DOI 10.1038/18350; YOSEFIN M, 1994, EUROPHYS LETT, V25, P675, DOI 10.1209/0295-5075/25/9/007	30	462	467	1	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					850	853		10.1038/35009055	http://dx.doi.org/10.1038/35009055			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786786	Green Submitted			2022-12-28	WOS:000086625000038
J	Bailis, JM; Roeder, GS				Bailis, JM; Roeder, GS			Pachytene exit controlled by reversal of Mek1-dependent phosphorylation	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; CHECKPOINT GENES; CELL-CYCLE; DNA-DAMAGE; PROTEIN PHOSPHATASE; CHROMOSOME SYNAPSIS; SHUTTLE VECTORS; YEAST; MEIOSIS	During yeast meiosis, a checkpoint prevents exit from pachytene in response to defects in meiotic recombination and chromosome synapsis. This pachytene checkpoint requires two meiotic chromosomal proteins, Red1 and Mek1; Mek1 is a kinase that phosphorylates Red1. In mutants that undergo checkpoint-mediated pachytene arrest, Mek1 is active and Red1 remains phosphorylated. Activation of Mek1 requires the initiation of meiotic recombination and certain DNA damage checkpoint proteins. Mek1 kinase activity and checkpoint-induced pachytene arrest are counteracted by protein phosphatase type 1 (Glc7). Glc7 coimmunoprecipitates with Red1,colocalizes with Red1 on chromosomes, and dephosphorylates Red1 in vitro. We speculate that phosphorylated Red1 prevents exit from pachytene and that completion of meiotic recombination triggers Glc7-dependent dephosphorylation of Red1.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Roeder, GS (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.	shirleen.roeder@yale.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Bailis JM, 1998, GENE DEV, V12, P3551, DOI 10.1101/gad.12.22.3551; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bloecher A, 1999, GENE DEV, V13, P517, DOI 10.1101/gad.13.5.517; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; de los Santos T, 1999, J BIOL CHEM, V274, P1783, DOI 10.1074/jbc.274.3.1783; ESPOSITO RE, 1974, P NATL ACAD SCI USA, V71, P3172, DOI 10.1073/pnas.71.8.3172; Grushcow JM, 1999, GENETICS, V153, P607; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hepworth SR, 1998, MOL CELL BIOL, V18, P5750, DOI 10.1128/MCB.18.10.5750; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Kondo T, 1999, MOL CELL BIOL, V19, P1136; LEEM SH, 1992, NUCLEIC ACIDS RES, V20, P449, DOI 10.1093/nar/20.3.449; Leu JY, 1999, MOL CELL, V4, P805, DOI 10.1016/S1097-2765(00)80390-1; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Lydall D, 1997, MOL GEN GENET, V256, P638, DOI 10.1007/s004380050612; Ramaswamy NT, 1998, GENETICS, V149, P57; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1991, GENE DEV, V5, P2392, DOI 10.1101/gad.5.12b.2392; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; San-Segundo PA, 1999, CELL, V97, P313, DOI 10.1016/S0092-8674(00)80741-2; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; Sherman F., 1986, METHODS YEAST GENETI; SHUSTER EO, 1989, GENETICS, V123, P29; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; Tarsounas M, 1999, J CELL SCI, V112, P423; Tu JL, 1996, MOL CELL BIOL, V16, P4199; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; Xu LH, 1997, GENE DEV, V11, P106, DOI 10.1101/gad.11.1.106; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	47	71	75	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 14	2000	101	2					211	221		10.1016/S0092-8674(00)80831-4	http://dx.doi.org/10.1016/S0092-8674(00)80831-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	305DP	10786836	Bronze			2022-12-28	WOS:000086524400007
J	Scheufler, C; Brinker, A; Bourenkov, G; Pegoraro, S; Moroder, L; Bartunik, H; Hartl, FU; Moarefi, I				Scheufler, C; Brinker, A; Bourenkov, G; Pegoraro, S; Moroder, L; Bartunik, H; Hartl, FU; Moarefi, I			Structure of TPR domain-peptide complexes: Critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine	CELL			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONE; HSP90; BINDING; IDENTIFICATION; HOP; CRYSTALLOGRAPHY; INTERACTS; CLONING	The adaptor protein Hop mediates the association of the molecular chaperones Hsp70 and Hsp90. The TPR1 domain of Hop specifically recognizes the C-terminal heptapeptide of Hsp70 while the TPR2A domain binds the C-terminal pentapeptide of Hsp90. Both sequences end with the motif EEVD. The crystal structures of the TPR-peptide complexes show the peptides in an extended conformation, spanning a groove in the TPR domains. Peptide binding is mediated by electrostatic interactions with the EEVD motif, with the C-terminal aspartate acting as a two-carboxylate anchor, and by hydrophobic interactions with residues upstream of EEVD. The hydrophobic contacts with the peptide are critical for specificity. These results explain how TPR domains participate in the ordered assembly of Hsp70-Hsp90 multichaperone complexes.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Max Planck Res Unit Struct Mol Biol, D-22603 Hamburg, Germany	Max Planck Society; Max Planck Society	Moarefi, I (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.		Bourenkov, Gleb P/C-7794-2017; Hartl, F. Ulrich/Y-8206-2019	Bourenkov, Gleb P/0000-0002-2617-5920; Scheufler, Clemens/0000-0002-3693-3529; Moroder, Luis/0000-0001-9570-5713				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Dolinski KJ, 1998, MOL CELL BIOL, V18, P7344, DOI 10.1128/MCB.18.12.7344; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HONORE B, 1992, J BIOL CHEM, V267, P8485; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kordes E, 1998, GENOMICS, V52, P90, DOI 10.1006/geno.1998.5385; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Marsh JA, 1998, MOL CELL BIOL, V18, P7353, DOI 10.1128/MCB.18.12.7353; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murthy AE, 1996, DNA CELL BIOL, V15, P727, DOI 10.1089/dna.1996.15.727; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Smith DF, 1998, PHARMACOL REV, V50, P493; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Su GF, 1999, GENOMICS, V55, P157, DOI 10.1006/geno.1998.5633; Tsukahara F, 1996, J BIOCHEM-TOKYO, V120, P820; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; ZHANG P, 1992, Journal of Dairy Science, V75, P106	50	987	1020	0	74	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 14	2000	101	2					199	210		10.1016/S0092-8674(00)80830-2	http://dx.doi.org/10.1016/S0092-8674(00)80830-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	305DP	10786835	Bronze			2022-12-28	WOS:000086524400006
J	Schiermeier, Q; Hellerer, U				Schiermeier, Q; Hellerer, U			German parliament agrees on limits to bioethics inquiry	NATURE			English	News Item																		1999, NATURE, V402, P331	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					692	692		10.1038/35008213	http://dx.doi.org/10.1038/35008213			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10809624	Bronze			2022-12-28	WOS:000086523600005
J	Tojima, Y; Fujimoto, A; Delhase, M; Chen, Y; Hatakeyama, S; Nakayama, K; Kaneko, Y; Nimura, Y; Motoyama, N; Ikeda, K; Karin, M; Nakanishi, M				Tojima, Y; Fujimoto, A; Delhase, M; Chen, Y; Hatakeyama, S; Nakayama, K; Kaneko, Y; Nimura, Y; Motoyama, N; Ikeda, K; Karin, M; Nakanishi, M			NAK is an I kappa B kinase-activating kinase	NATURE			English	Article							TRANSCRIPTION FACTOR; ALPHA PROTEOLYSIS; CELL-DEATH; C-EPSILON; PHOSPHORYLATION; SIGNAL; APOPTOSIS; PATHWAYS; JNK; IKK	Phosphorylation of I kappa B by the I kappa B kinase (IKK) complex is a critical step leading to IkB degradation and activation of transcription factor NF-kappa B-1. The IKK complex contains two catalytic subunits, IKK alpha and IKK beta, the latter being indispensable for NF-kappa B activation by pro-inflammatory cytokines(2-7). Although IKK is activated by phosphorylation of the IKK beta activation loop(8), the physiological IKK kinases that mediate responses to extracellular stimuli remain obscure(1,9). Here we describe an IKK-related kinase, named NAK (NF-kappa B-activating kinase), that can activate IKK through direct phosphorylation. NAK induces I kappa B degradation and NF-kappa B activity through IKKb. Endogenous NAK is activated by phorbol ester tumour promoters and growth factors, whereas catalytically inactive NAK specifically inhibits activation of NF-kappa B by protein kinase C-epsilon (PKC epsilon). Thus, NAK is an IKK kinase that may mediate IKK and NF-kappa B activation in response to growth factors that stimulate PKC epsilon activity.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Nagoya Univ, Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 4668550, Japan; Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA; Kyusyu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Higashi Ku, Fukuoka 8128582, Japan; Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya University; University of California System; University of California San Diego; Japan Science & Technology Agency (JST); Nagoya City University	Nakanishi, M (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan.		Delhase, Mireille/ABE-5256-2021	Delhase, Mireille/0000-0003-2312-1051				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NNISHIZUKA Y, 1992, SCIENCE, V258, P607; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	30	304	317	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					778	782		10.1038/35008109	http://dx.doi.org/10.1038/35008109			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783893				2022-12-28	WOS:000086523600056
J	McEvoy, AW; Kitchen, ND; Thomas, DGT				McEvoy, AW; Kitchen, ND; Thomas, DGT			Lesson of the week - Intracerebral haemorrhage in young adults: the emerging importance of drug misuse	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTRA-CRANICAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; AMPHETAMINE ABUSE; COCAINE ABUSE; COMPLICATIONS; VASCULITIS; PREVALENCE; ECSTASY; PATIENT; MDMA		UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Univ Dept Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	McEvoy, AW (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Inst Neurol, Univ Dept Neurosurg, London WC1N 3BG, England.	a.mcevoy@ion.ucl.ac.uk						Aggarwal SK, 1996, NEUROLOGY, V46, P1741, DOI 10.1212/WNL.46.6.1741; BENOWITZ NL, 1992, CIBA F SYMP, V166, P125; BRUST JCM, 1977, NEW YORK STATE J MED, V77, P1473; CAHILL DW, 1981, NEUROLOGY, V31, P1058, DOI 10.1212/WNL.31.8.1058-a; CAPLAN L, 1988, NEUROLOGY, V38, P624, DOI 10.1212/WNL.38.4.624; CITRON BP, 1970, NEW ENGL J MED, V283, P1003, DOI 10.1056/NEJM197011052831901; DELANEY P, 1980, NEUROLOGY, V30, P1125, DOI 10.1212/WNL.30.10.1125; Fessler RD, 1997, SURG NEUROL, V47, P339, DOI 10.1016/S0090-3019(96)00431-4; GERICKE OL, 1945, JAMA-J AM MED ASSOC, V128, P1098, DOI 10.1001/jama.1945.92860320004011b; GLEDHILL JA, 1993, J NEUROL NEUROSUR PS, V56, P1036, DOI 10.1136/jnnp.56.9.1036; HARRINGTON H, 1983, ARCH NEUROL-CHICAGO, V40, P503, DOI 10.1001/archneur.1983.04210070043012; HENRY JA, 1992, BRIT MED J, V305, P5, DOI 10.1136/bmj.305.6844.5; KLONER RA, 1992, CIRCULATION, V85, P407, DOI 10.1161/01.CIR.85.2.407; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LICHTENFELD PJ, 1984, ARCH NEUROL-CHICAGO, V41, P223, DOI 10.1001/archneur.1984.04050140125041; LUKES SA, 1983, ARCH NEUROL-CHICAGO, V40, P60, DOI 10.1001/archneur.1983.04050010080027; MANGIARDI JR, 1988, ACTA NEUROL SCAND, V77, P177, DOI 10.1111/j.1600-0404.1988.tb05891.x; MARGOLIS MT, 1971, NEURORADIOLOGY, V2, P179, DOI 10.1007/BF00335049; MCNAGNY SE, 1992, JAMA-J AM MED ASSOC, V267, P1106, DOI 10.1001/jama.267.8.1106; Nolte KB, 1996, NEUROLOGY, V46, P1291, DOI 10.1212/WNL.46.5.1291; OVESIKU NM, 1993, NEUROSURGERY, V32, P518; PEROUTKA SJ, 1987, NEW ENGL J MED, V317, P1542; RUMBAUGH CL, 1971, RADIOLOGY, V101, P335, DOI 10.1148/101.2.335; SALANOVA V, 1984, POSTGRAD MED J, V60, P429, DOI 10.1136/pgmj.60.704.429; SANCHEZ J, 1995, J EPIDEMIOL COMMUN H, V49, P54, DOI 10.1136/jech.49.1.54; *SECR STAT HLTH, 1992, HLTH NAT; SELMI F, 1995, BRIT J NEUROSURG, V9, P93; Shibata S, 1991, Neurol Med Chir (Tokyo), V31, P49, DOI 10.2176/nmc.31.49; SIMPSON R K JR, 1990, British Journal of Neurosurgery, V4, P27, DOI 10.3109/02688699009000678; SQUIRES NF, 1995, J PUBLIC HEALTH MED, V17, P103; TOFFOL GJ, 1987, ARCH NEUROL-CHICAGO, V44, P483, DOI 10.1001/archneur.1987.00520170013014; TOGNA G, 1985, HAEMOSTASIS, V15, P100; YARNELL PR, 1977, HEADACHE, V17, P69	33	49	49	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2000	320	7245					1322	1324		10.1136/bmj.320.7245.1322	http://dx.doi.org/10.1136/bmj.320.7245.1322			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807629	Green Published			2022-12-28	WOS:000087077400030
J	Cole, TJ; Bellizzi, MC; Flegal, KM; Dietz, WH				Cole, TJ; Bellizzi, MC; Flegal, KM; Dietz, WH			Establishing a standard definition for child overweight and obesity worldwide: international survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX; CARDIOVASCULAR RISK; YOUNG-ADULTS; ADOLESCENTS	Objective To develop an internationally acceptable definition of child overweight and obesity, specifying the measurement, the reference population, and the age and sex specific cut off points. Design International survey of six large nationally representative cross sectional growth studies. Setting Brazil, Great Britain, Hong Kong, the Netherlands, Singapore, and the United States. Subjects 97 876 males and 94 851 females from birth to 25 years of age. Main outcome measure Body mass index (weight/height(2)). Results For each of the surveys, centile curves were drawn that at age 18 years passed through the widely used cut off points of 25 and 30 kg/m(2) for adult overweight and obesity. The resulting curves were averaged to provide age and sex specific cut off points from 2-18 years. Conclusions The proposed cut off points, which are less arbitrary and more internationally based than current alternatives, should help to provide internationally comparable prevalence rates of overweight and obesity in children.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; Int Obes Task Force Secretariat, London NW1 2NS, England; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA 30341 USA	University of London; University College London; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA	Cole, TJ (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, 30 Guilford St, London WC1N 1EH, England.	tim.cole@ich.ucl.ac.uk	lehmann, jennifer/AAB-8110-2019; Flegal, Katherine M/A-4608-2013; Cole, Tim J/B-7883-2008	Cole, Tim J/0000-0001-5711-8200; Flegal, Katherine/0000-0002-0838-469X	Medical Research Council [G9827821(62595), G9827821] Funding Source: Medline; MRC [G9827821] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; Bellizzi MC, 1999, AM J CLIN NUTR, V70, p173S; BERENSON GS, 1993, ANN NY ACAD SCI, V699, P93, DOI 10.1111/j.1749-6632.1993.tb18840.x; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4&lt;407::AID-SIM742&gt;3.0.CO;2-L; DAMATO M, 1999, INT BIOM SOC IT REG; Dietz WH, 1998, J PEDIATR-US, V132, P191; FLEGAL KM, 1993, CRIT REV FOOD SCI, V33, P307, DOI 10.1080/10408399309527625; Mahoney LT, 1996, J AM COLL CARDIOL, V27, P277, DOI 10.1016/0735-1097(95)00461-0; Malina RM, 1999, AM J CLIN NUTR, V70, p131S; Power C, 1997, INT J OBESITY, V21, P507, DOI 10.1038/sj.ijo.0800454; ROLLANDCACHERA MF, 1982, AM J CLIN NUTR, V36, P178, DOI 10.1093/ajcn/36.1.178; *WHO, 1998, WHO CONS GEN 3 5 JAN; *WHO, 1995, PHYS STAT US NT ANTH	15	11234	11730	29	977	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 6	2000	320	7244					1240	1243		10.1136/bmj.320.7244.1240	http://dx.doi.org/10.1136/bmj.320.7244.1240			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797032	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000086981400017
J	Bickell, NA; Chassin, MR				Bickell, NA; Chassin, MR			Determining the quality of breast cancer care: Do tumor registries measure up?	ANNALS OF INTERNAL MEDICINE			English	Article						registries; breast neoplasms; quality of health care; health services research	CONSERVING SURGERY; RADIATION-THERAPY; COMPLETENESS	Background: Hospital tumor registries, which provide data that inform health services research and cancer control policies, may be a source of information about quality of cancer care. However, the accuracy of data from such registries is unknown. Objective: To determine the accuracy of tumor registry data by comparing it with data collected from numerous sources for a breast cancer quality improvement project. Design: Retrospective cohort study. Setting: Three teaching hospitals with tumor registries in the New York metropolitan area that had participated in the quality improvement project. Patients: All women with newly diagnosed primary breast cancer (stage I or stage ii) who were surgically treated at the study hospitals between 1 November 1994 and 31 August 1996. Measurements: Sensitivity and specificity were calculated, and data from the quality improvement project were used as the gold standard. Results: The tumor registries and the quality improvement project had similar information on tumor stage and surgery type. Sensitivity ranged from 0.91 to 0.96, and specificity ranged from 0.93 to 0.97. When both sources were used to calculate quality measures, the overall rate of radiation therapy after breast-conserving surgery was 80% in the quality improvement project and 48% in the tumor registries (sensitivity, 0.58; specificity, 0.94). For receipt of adjuvant systemic treatment, the rate was 78% in the quality improvement project and 22% in the tumor registries (sensitivity, 0.27; specificity, 0.97). Conclusions: Data from tumor registries provide accurate measures for hospital-based surgical treatments but not for outpatient treatments. Unverified tumor registry data should not be used to measure quality of care.	Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Bickell, NA (corresponding author), Mt Sinai Sch Med, Dept Hlth Policy, Box 1077,1 Gustave L Levy Pl, New York, NY 10029 USA.							ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; [Anonymous], 1992, Lancet, V339, P1; Bickell N A, 1998, Qual Manag Health Care, V6, P63; BICKELL NA, IN PRESS ANN SURG; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; CHASSIN MR, 1991, JAMA-J AM MED ASSOC, V266, P3472, DOI 10.1001/jama.266.24.3472; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; Guadagnoli E, 1998, CANCER-AM CANCER SOC, V83, P302, DOI 10.1002/(SICI)1097-0142(19980715)83:2<302::AID-CNCR14>3.3.CO;2-C; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; Harvei S, 1996, EUR J CANCER, V32A, P104, DOI 10.1016/0959-8049(95)00501-3; HAWKINS MM, 1992, BRIT J CANCER, V66, P408, DOI 10.1038/bjc.1992.279; Hewitt M, 1999, ENSURING QUALITY CAN; Hillner BE, 1996, BREAST CANCER RES TR, V40, P75, DOI 10.1007/BF01806004; Hillner BE, 1997, J CLIN ONCOL, V15, P1401, DOI 10.1200/JCO.1997.15.4.1401; JAKLEVIC MC, 1999, MODERN HEALTHCAR JAN, V18, P14; Klawansky S, 1991, Int J Technol Assess Health Care, V7, P134; LAPHAM R, 1992, BRIT J CANCER, V66, P552, DOI 10.1038/bjc.1992.312; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; Lazovich D, 1997, ARCH SURG-CHICAGO, V132, P418; LEEFELDSTEIN A, 1994, JAMA-J AM MED ASSOC, V271, P1163, DOI 10.1001/jama.271.15.1163; MUKHERJEE AK, 1991, PUBLIC HEALTH, V105, P69, DOI 10.1016/S0033-3506(05)80319-1; Newcomer LN, 1998, HEALTH AFFAIR, V17, P32, DOI 10.1377/hlthaff.17.4.32; Sennett C, 1998, HEALTH AFFAIR, V17, P36, DOI 10.1377/hlthaff.17.4.36; Young WW, 1996, MED CARE, V34, P1003, DOI 10.1097/00005650-199610000-00003; ZIPPIN C, 1995, CANCER, V76, P2343, DOI 10.1002/1097-0142(19951201)76:11<2343::AID-CNCR2820761124>3.0.CO;2-#	27	82	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					705	+		10.7326/0003-4819-132-9-200005020-00004	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308VT	10787363				2022-12-28	WOS:000086734100003
J	Rothman, DJ				Rothman, DJ			Medical professionalism - Focusing on the real issues.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Rothman, DJ (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.							*AAFP FDN CORP MEM, 1995, B AM ACAD FAM PHYSIC, V10, P4; *AM SOC NEPHR, 1999, 32 ANN M AM SOC NEPH; Casalino LP, 1999, NEW ENGL J MED, V341, P1147, DOI 10.1056/NEJM199910073411511; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; Cleary PD, 1997, JAMA-J AM MED ASSOC, V278, P1608, DOI 10.1001/jama.278.19.1608; DERBYSHIRE RC, 1983, LAW HUMAN BEHAV, V7, P193, DOI 10.1007/BF01044523; Eichenwald Kurt, 1999, N Y Times Web, pA16; Kassirer JP, 1997, NEW ENGL J MED, V336, P1666, DOI 10.1056/NEJM199706053362308; Ludmerer KM, 1999, JAMA-J AM MED ASSOC, V282, P881, DOI 10.1001/jama.282.9.881; Pellegrino ED, 1999, JAMA-J AM MED ASSOC, V282, P984, DOI 10.1001/jama.282.10.984; Rodwin M. A., 1993, MED MONEY MORALS PHY; Sullivan WM, 1999, HASTINGS CENT REP, V29, P7, DOI 10.2307/3528344; Swick HM, 1999, JAMA-J AM MED ASSOC, V282, P830, DOI 10.1001/jama.282.9.830; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; Wynia MK, 1999, NEW ENGL J MED, V341, P1612, DOI 10.1056/NEJM199911183412112	15	133	138	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1284	1286		10.1056/NEJM200004273421711	http://dx.doi.org/10.1056/NEJM200004273421711			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10787328				2022-12-28	WOS:000086660600011
J	Field, J; Shreeves, G; Sumner, S; Casiraghi, M				Field, J; Shreeves, G; Sumner, S; Casiraghi, M			Insurance-based advantage to helpers in a tropical hover wasp	NATURE			English	Article							GROUP MEMBERS; EUSOCIALITY; EVOLUTION	The origin and maintenance of eusociality is a central problem in evolutionary biology(1,2). Eusocial groups contain individuals that forfeit their own reproduction in order to help others reproduce. In facultatively eusocial taxa, offspring can choose whether to found new nests or become helpers in their natal groups. In many facultatively eusocial insects, offspring need continuous care during development, but adult carers have life expectancies shorter than the developmental period(3-7). When a lone foundress dies, her partly reared brood are usually doomed. Here, we show that helpers in a tropical hover wasp (Liostenogaster flavolineata) have an insurance-based advantage over lone foundresses because after a helper dies, most of the brood that she has partly reared will be brought to maturity by surviving nest-mates. After some of the helpers are experimentally removed from a multi-female nest, the reduced group is left with more brood than it would normally rear. We found that larger, more valuable extra brood were reared through to maturity, but not smaller, less valuable brood. Smaller brood may be sacrificed to feed larger brood, and reduced groups probably benefited from increased short-term helper recruitment. Rearing extra brood did not increase adult mortality or brood development time.	UCL, Dept Biol, London NW1 2HE, England	University of London; University College London	Field, J (corresponding author), UCL, Dept Biol, Wolfson House,4 Stephenson Way, London NW1 2HE, England.	jeremy.field@ucl.ac.uk	Sumner, Seirian/E-6611-2011; Casiraghi, Maurizio/E-7273-2011	Casiraghi, Maurizio/0000-0002-2733-2094; Sumner, Seirian/0000-0003-0213-2018				Crawley M.J., 1993, GLIM ECOLOGISTS; Field J, 1999, ANIM BEHAV, V57, P633, DOI 10.1006/anbe.1999.0995; Field J, 1999, BEHAV ECOL SOCIOBIOL, V45, P378, DOI 10.1007/s002650050574; Field J, 1998, P ROY SOC B-BIOL SCI, V265, P973, DOI 10.1098/rspb.1998.0386; GADAGKAR R, 1990, PHILOS T ROY SOC B, V329, P17, DOI 10.1098/rstb.1990.0146; GERVET J, 1964, ANN SCI NAT ZOOL, V6, P601; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HATCHWELL BJ, 1990, BEHAV ECOL SOCIOBIOL, V27, P199; Hatchwell BJ, 1996, P ROY SOC B-BIOL SCI, V263, P83, DOI 10.1098/rspb.1996.0014; Kukuk PF, 1998, NATURWISSENSCHAFTEN, V85, P445, DOI 10.1007/s001140050528; MEAD F, 1994, J ETHOL, V12, P43, DOI 10.1007/BF02350079; NONACS P, 1993, BEHAV PROCESS, V30, P47, DOI 10.1016/0376-6357(93)90011-F; Queller David C., 1996, P218; QUELLER DC, 1994, P ROY SOC B-BIOL SCI, V256, P105, DOI 10.1098/rspb.1994.0056; QUELLER DC, 1989, P NATL ACAD SCI USA, V86, P3224, DOI 10.1073/pnas.86.9.3224; Reeve H.K., 1991, P99; Reeve HK, 1997, BEHAV ECOL, V8, P75, DOI 10.1093/beheco/8.1.75; SCHMIDHEMPEL P, 1998, PARASITES SOCIAL INS; STRASSMANN JE, 1989, WESTV STUD, P81; Szathmary E, 1995, MAJOR TRANSITIONS EV; Turillazzi S., 1991, P74; [No title captured]	22	87	90	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					869	871		10.1038/35009097	http://dx.doi.org/10.1038/35009097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786792				2022-12-28	WOS:000086625000044
J	von Melchner, L; Pallas, SL; Sur, M				von Melchner, L; Pallas, SL; Sur, M			Visual behaviour mediated by retinal projections directed to the auditory pathway	NATURE			English	Article							CROSS-MODAL PLASTICITY; CEREBRAL-CORTEX; SPECIFICATION; THALAMUS; ORGANIZATION; MECHANISMS; KITTENS; FERRETS; HUMANS; DEAF	An unresolved issue in cortical development concerns the relative contributions of intrinsic and extrinsic factors to the functional specification of different cortical areas(1-4). Ferrets in which retinal projections are redirected neonatally to the auditory thalamus(5) have visually responsive cells in auditory thalamus and cortex, form a retinotopic map in auditory cortex and have visual receptive field properties in auditory cortex that are typical of cells in visual cortex(5-8.) Here we report that this cross-modal projection and its representation in auditory cortex can mediate visual behaviour. When light stimuli are presented in the portion of the visual field that is 'seen' only by this projection, 'rewired' ferrets respond as though they perceive the stimuli to be visual rather than auditory. Thus the perceptual modality of a neocortical region is instructed to a significant extent by its extrinsic inputs. In addition, gratings of different spatial frequencies can be discriminated by the rewired pathway, although the grating acuity is lower than that of the normal visual pathway.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sur, M (corresponding author), Merck KGaA, Dept CNS Res, D-64293 Darmstadt, Germany.		Pallas, Sarah L/W-1860-2019	Pallas, Sarah L/0000-0002-1760-7437				Angelucci A, 1998, J COMP NEUROL, V400, P417, DOI 10.1002/(SICI)1096-9861(19981026)400:3<417::AID-CNE10>3.0.CO;2-O; Boring E.G., 1950, HIST EXPT PSYCHOL; DOBSON V, 1978, VISION RES, V18, P1469, DOI 10.1016/0042-6989(78)90001-9; Gao WJ, 1999, J NEUROSCI, V19, P7940; HELD R, 1989, COGNITION, V33, P139, DOI 10.1016/0010-0277(89)90008-5; Kujala T, 1997, PSYCHOPHYSIOLOGY, V34, P213, DOI 10.1111/j.1469-8986.1997.tb02134.x; Levitt P, 1997, ANNU REV NEUROSCI, V20, P1, DOI 10.1146/annurev.neuro.20.1.1; MITCHELL DE, 1991, PHILOS T R SOC B, V333, P51, DOI 10.1098/rstb.1991.0060; MITCHELL DE, 1989, CAN J PSYCHOL, V43, P141, DOI 10.1037/h0084215; NEVILLE HJ, 1983, BRAIN RES, V266, P127, DOI 10.1016/0006-8993(83)91314-8; Neville HJ, 1998, P NATL ACAD SCI USA, V95, P922, DOI 10.1073/pnas.95.3.922; Pallas SL, 1999, P NATL ACAD SCI USA, V96, P8751, DOI 10.1073/pnas.96.15.8751; PALLAS SL, 1993, J COMP NEUROL, V337, P317, DOI 10.1002/cne.903370212; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; ROE AW, 1990, SCIENCE, V250, P818, DOI 10.1126/science.2237432; ROE AW, 1993, J COMP NEUROL, V334, P263, DOI 10.1002/cne.903340208; ROE AW, 1992, J NEUROSCI, V12, P3651; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Sharma J, 2000, NATURE, V404, P841, DOI 10.1038/35009043; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; Sur M, 1999, J NEUROBIOL, V41, P33, DOI 10.1002/(SICI)1097-4695(199910)41:1<33::AID-NEU6>3.0.CO;2-1; SUR M, 1988, SCIENCE, V242, P1437, DOI 10.1126/science.2462279; SUR M, 1990, TRENDS NEUROSCI, V13, P227, DOI 10.1016/0166-2236(90)90165-7; ZAHS KR, 1985, J COMP NEUROL, V241, P210, DOI 10.1002/cne.902410208	25	232	236	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					871	876		10.1038/35009102	http://dx.doi.org/10.1038/35009102			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786793				2022-12-28	WOS:000086625000045
J	Smaglik, P				Smaglik, P			Varmus tells Congress to grasp thorny policy issues	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					530	530		10.1038/35007207	http://dx.doi.org/10.1038/35007207			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10787344	Bronze			2022-12-28	WOS:000086400100006
J	Nagatani, A				Nagatani, A			Plant biology - Lighting up the nucleus	SCIENCE			English	Editorial Material							PHYTOCHROME-B; SIGNAL-TRANSDUCTION; PROTEIN; ARABIDOPSIS; PIF3		Kyoto Univ, Grad Sch Sci, Dept Bot, Kyoto 6068502, Japan	Kyoto University	Nagatani, A (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Bot, Kyoto 6068502, Japan.							Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; Deng XW, 1999, SEMIN CELL DEV BIOL, V10, P121, DOI 10.1006/scdb.1999.0287; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Halliday KJ, 1999, P NATL ACAD SCI USA, V96, P5832, DOI 10.1073/pnas.96.10.5832; Kircher S, 1999, PLANT CELL, V11, P1445, DOI 10.1105/tpc.11.8.1445; Martinez-Garcia JF, 2000, SCIENCE, V288, P859, DOI 10.1126/science.288.5467.859; Neff MM, 2000, GENE DEV, V14, P257; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Ni M, 1999, NATURE, V400, P781, DOI 10.1038/23500; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Yamaguchi R, 1999, J CELL BIOL, V145, P437, DOI 10.1083/jcb.145.3.437; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	13	6	6	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					821	822		10.1126/science.288.5467.821	http://dx.doi.org/10.1126/science.288.5467.821			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10809652				2022-12-28	WOS:000086869600025
J	Scott, EC				Scott, EC			Not (just) in Kansas anymore	SCIENCE			English	Article									Natl Ctr Sci Educ, El Cerrito, CA 94530 USA		Scott, EC (corresponding author), Natl Ctr Sci Educ, 925 Kearny St, El Cerrito, CA 94530 USA.			Scott, Eugenie Carol/0000-0003-3795-8207					0	10	10	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					813	+		10.1126/science.288.5467.813	http://dx.doi.org/10.1126/science.288.5467.813			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10809650				2022-12-28	WOS:000086869600020
J	Giraldo, O; Brock, SL; Marquez, M; Suib, SL; Hillhouse, H; Tsapatsis, M				Giraldo, O; Brock, SL; Marquez, M; Suib, SL; Hillhouse, H; Tsapatsis, M			Materials - Spontaneous formation of inorganic helices	NATURE			English	Article							MOLECULAR-SIEVES; SILICA		Univ Connecticut, Dept Chem, Storrs, CT 06269 USA; Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA; Univ Connecticut, Inst Mat Sci, Storrs, CT 06269 USA; Univ Massachusetts, Dept Chem Engn, Goessmann Lab 159, Amherst, MA 01003 USA	University of Connecticut; University of Connecticut; University of Connecticut; University of Massachusetts System; University of Massachusetts Amherst	Giraldo, O (corresponding author), Univ Connecticut, Dept Chem, Storrs, CT 06269 USA.		Brock, Stephanie/AAS-5974-2021; Tsapatsis, Michael/AAA-2527-2019	Giraldo Osorio, Oscar Hernan/0000-0002-9213-6348; Brock, Stephanie/0000-0002-0439-302X				Antal T, 1999, PHYS REV LETT, V83, P2880, DOI 10.1103/PhysRevLett.83.2880; Bruinsma PJ, 1997, CHEM MATER, V9, P2507, DOI 10.1021/cm970282a; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; denExter MJ, 1996, STUD SURF SCI CATAL, V102, P413; Gier TE, 1998, NATURE, V395, P154, DOI 10.1038/25960; Jones CW, 1998, NATURE, V393, P52, DOI 10.1038/29959; RAIMONDI ME, 1997, J CHEM SOC CHEM COMM, V19, P1843; Rowan AE, 1998, ANGEW CHEM INT EDIT, V37, P63, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<63::AID-ANIE63>3.0.CO;2-4; SHEN YF, 1993, SCIENCE, V260, P511, DOI 10.1126/science.260.5107.511; SOGHOMONIAN V, 1993, SCIENCE, V259, P1596, DOI 10.1126/science.259.5101.1596; Trau M, 1997, NATURE, V390, P674, DOI 10.1038/37764; WU CG, 1994, SCIENCE, V264, P1757, DOI 10.1126/science.264.5166.1757	12	79	80	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					38	38		10.1038/35011139	http://dx.doi.org/10.1038/35011139			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811209	Bronze			2022-12-28	WOS:000086901600041
J	Groisman, A; Steinberg, V				Groisman, A; Steinberg, V			Elastic turbulence in a polymer solution flow	NATURE			English	Article							TAYLOR-COUETTE FLOW; INSTABILITIES; TRANSITION	Turbulence is a ubiquitous phenomenon that is not fully understood. It is known that the flow of a simple, newtonian fluid is likely to be turbulent when the Reynolds number is large (typically when the velocity is high, the viscosity is low and the size of the tank is large(1,2)). In contrast, viscoelastic fluids(3) such as solutions of flexible long-chain polymers have nonlinear mechanical properties and therefore may be expected to behave differently. Here we observe experimentally that the flow of a sufficiently elastic polymer solution can become irregular even at low velocity, high viscosity and in a small tank. The fluid motion is excited in a broad range of spatial and temporal scales, and we observe an increase in the flow resistance by a factor of about twenty. Although the Reynolds number may be arbitrarily low, the observed flow has all the main features of developed turbulence. A comparable state of turbulent flow for a newtonian fluid in a pipe would have a Reynolds number as high as 10(5) (refs 1, 2). The low Reynolds number or 'elastic' turbulence that we observe is accompanied by significant stretching of the polymer molecules, resulting in an increase in the elastic stresses of up to two orders of magnitude.	Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Groisman, A (corresponding author), Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel.		Steinberg, Victor/B-3205-2009					Bird R.B., 1987, FLUID MECH-SOV RES, V1; BYARS JA, 1994, J FLUID MECH, V271, P173, DOI 10.1017/S0022112094001734; Giesekus H., 1968, Rheologica Acta, V7, P127, DOI 10.1007/BF01982375; Groisman A, 1998, PHYS FLUIDS, V10, P2451, DOI 10.1063/1.869764; Landau L.D., 1987, PHYS TODAY, V6; LARSON RG, 1990, J FLUID MECH, V218, P573, DOI 10.1017/S0022112090001124; LARSON RG, 1992, RHEOL ACTA, V31, P213, DOI 10.1007/BF00366504; MAGDA JJ, 1988, J NON-NEWTON FLUID, V30, P1, DOI 10.1016/0377-0257(88)80014-4; MULLER SJ, 1989, RHEOL ACTA, V28, P499, DOI 10.1007/BF01332920; Shaqfeh ESG, 1996, ANNU REV FLUID MECH, V28, P129, DOI 10.1146/annurev.fl.28.010196.001021; TIRTAATMADJA V, 1993, J RHEOL, V37, P1081, DOI 10.1122/1.550372; TRITTON DT, 1988, PHYSICAL FLUID DYNAM; WEISSENBERG K, 1947, NATURE, V159, P310, DOI 10.1038/159310a0	13	568	580	9	144	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					53	55		10.1038/35011019	http://dx.doi.org/10.1038/35011019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811214	Green Submitted			2022-12-28	WOS:000086901600047
J	Larson, RG				Larson, RG			Fluid dynamics - Turbulence without inertia	NATURE			English	Editorial Material							FLOW; INSTABILITIES		Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Larson, RG (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.							BYARS JA, 1994, J FLUID MECH, V271, P173, DOI 10.1017/S0022112094001734; Cladis P E, 1992, SOLITONS LIQUID CRYS, P111; Groisman A, 2000, NATURE, V405, P53, DOI 10.1038/35011019; KALIKA DS, 1987, J RHEOL, V31, P815, DOI 10.1122/1.549942; Khayat RE, 1999, J FLUID MECH, V400, P33, DOI 10.1017/S0022112099006412; Landau L.D., 1987, PHYS TODAY, V6; LARSON RG, 1990, J FLUID MECH, V218, P573, DOI 10.1017/S0022112090001124; PETRIE CJS, 1976, AICHE J, V22, P209, DOI 10.1002/aic.690220202; PHANTHIEN N, 1983, J NON-NEWTON FLUID, V13, P325, DOI 10.1016/0377-0257(83)80027-5; Taylor GI, 1923, PHILOS T R SOC LOND, V223, P289, DOI 10.1098/rsta.1923.0008; WEISSENBERG K, 1947, NATURE, V159, P310, DOI 10.1038/159310a0	12	63	65	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					27	28		10.1038/35011172	http://dx.doi.org/10.1038/35011172			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811202	Green Published			2022-12-28	WOS:000086901600031
J	Buys, CHCM				Buys, CHCM			Telomeres, telomerase, and cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Groningen, NL-9713 AW Groningen, Netherlands	University of Groningen	Buys, CHCM (corresponding author), Univ Groningen, NL-9713 AW Groningen, Netherlands.							Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Remes K, 2000, BRIT J CANCER, V82, P601, DOI 10.1054/bjoc.1999.0970; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	5	50	60	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1282	1283		10.1056/NEJM200004273421710	http://dx.doi.org/10.1056/NEJM200004273421710			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10781627	Green Published			2022-12-28	WOS:000086660600010
J	Messenger, S				Messenger, S			Identification of molecular-cloud material in interplanetary dust particles	NATURE			English	Article							ISOTOPIC COMPOSITION; CARBON; METEORITES; ORIGIN; WATER	Interplanetary dust particles (IDPs) collected in the Earth's stratosphere and meteorites are fragments of comets and asteroids. These are 'primitive' meteorites in part because they have preserved materials which predate the formation of the Solar System. The most primitive (least altered) meteorites contain a few parts per million of micrometre-sized dust which formed in the atmospheres of giant stars(1). Some meteorites(2) have elevated D/H and N-15/N-14 ratios that are attributed to surviving interstellar organic molecules which have probably been strongly diluted and altered by parent-body processes(2). Most IDPs are chemically, mineralogically, and texturally primitive in comparison to meteorites(3,4). Here I show that H and N isotopic anomalies among fragile 'cluster' IDPs are far larger, more common, and less equilibrated than those previously observed in other IDPs or meteorites. In some cases, the D/H ratios that we measure reach the values of interstellar molecules, suggesting that molecular-cloud material has survived intact. These observations indicate that cluster IDPs are the most primitive class of Solar System materials currently available for laboratory analysis.	Washington Univ, Dept Phys, McDonnell Ctr Space Sci, St Louis, MO 63130 USA	Washington University (WUSTL)	Messenger, S (corresponding author), Washington Univ, Dept Phys, McDonnell Ctr Space Sci, St Louis, MO 63130 USA.	dbunny@howdy.wustl.edu						ADAMS NG, 1981, ASTROPHYS J, V247, pL123, DOI 10.1086/183604; Alexander CMO, 1998, METEORIT PLANET SCI, V33, P603, DOI 10.1111/j.1945-5100.1998.tb01667.x; Bockelee-Morvan D, 1998, ICARUS, V133, P147, DOI 10.1006/icar.1998.5916; BRADLEY JP, 1987, METEORITES EARLY SOL, P861; Brownlee D.E., 1995, LUNAR PLANET SCI, P183; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; FLYNN GJ, 1993, METEORITICS, V28, P349; FRAUNDORF P, 1982, J GEOPHYS RES, V87, pA403, DOI 10.1029/JB087iS01p0A403; GUAN Y, 1997, LUNAR PLANET SCI, V28, P489; GUAN Y, 1998, LUNAR PLANET SCI, V29; KELLER LP, 1997, LUNAR PLANET SCI, V28; LANGER WD, 1984, ASTROPHYS J, V277, P581, DOI 10.1086/161730; MCKEEGAN KD, 1985, GEOCHIM COSMOCHIM AC, V49, P1971, DOI 10.1016/0016-7037(85)90091-2; MCKEEGAN KD, 1987, THESIS WASHINGTON U; MCKEEGAN KD, 1987, LUNAR PLANET SCI, V18, P627; Meier R, 1998, SCIENCE, V279, P1707, DOI 10.1126/science.279.5357.1707; MESSENGER S, 1998, LUNAR PLANET SCI, V29; MESSENGER S, 1997, AIP C P, V402, P545; Millar TJ, 1998, FARADAY DISCUSS, V109, P15, DOI 10.1039/a800127h; Sandford S. A., 1987, Fundamentals of Cosmic Physics, V12, P1; STADERMANN FJ, 1991, THESIS U HEIDELBERG; THOMAS KL, 1993, GEOCHIM COSMOCHIM AC, V57, P1551, DOI 10.1016/0016-7037(93)90012-L; TIELENS AGG, 1998, AIP C P, V402, P523; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147; ZINNER E, 1989, GEOCHIM COSMOCHIM AC, V53, P3273, DOI 10.1016/0016-7037(89)90107-5	25	282	282	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 27	2000	404	6781					968	971		10.1038/35010053	http://dx.doi.org/10.1038/35010053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801119				2022-12-28	WOS:000086762000047
J	Reinisch, KM; Nibert, M; Harrison, SC				Reinisch, KM; Nibert, M; Harrison, SC			Structure of the reovirus core at 3.6 angstrom resolution	NATURE			English	Article							DOUBLE-STRANDED-RNA; PARTICLES; DNA; CRYSTALLOGRAPHY; CONFORMATION; ORGANIZATION; PROTEINS; PACKING; TYPE-3; GENOME	The reovirus core is an assembly with a relative molecular mass of 52 million that synthesizes, modifies and exports viral messenger RNA. Analysis of its structure by X-ray crystallography shows that there are alternative, specific and completely nonequivalent contacts made by several surfaces of two of its proteins; that the RNA capping and export apparatus is a hollow cylinder, which probably sequesters its substrate to ensure completion of the capping reactions; that the genomic double-stranded RNA is coiled into concentric layers within the particle; and that there is a protein shell that appears to be common to all groups of double-stranded RNA viruses.	Harvard Univ, Fairchild Bldg,7 Divin Ave, Cambridge, MA 02138 USA; Howard Hughes Med Inst, Cambridge, MA 02138 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Inst Mol Virol, Madison, WI 53706 USA	Harvard University; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Harrison, SC (corresponding author), Harvard Univ, Fairchild Bldg,7 Divin Ave, Cambridge, MA 02138 USA.	harrison@crystal.harvard.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOOY FP, 1991, CELL, V64, P1007, DOI 10.1016/0092-8674(91)90324-R; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; CARSON M, 1996, MACROMOLECULAR ENZYM, P493; Cerritelli ME, 1997, CELL, V91, P271, DOI 10.1016/S0092-8674(00)80409-2; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; COOMBS KM, 1990, J MOL BIOL, V215, P1, DOI 10.1016/S0022-2836(05)80089-0; Dryden KA, 1998, VIROLOGY, V245, P33, DOI 10.1006/viro.1998.9146; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; EARNSHAW WC, 1978, CELL, V14, P559, DOI 10.1016/0092-8674(78)90242-8; EARNSHAW WC, 1977, NATURE, V268, P598, DOI 10.1038/268598a0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fields B.N., 1996, FIELDS VIROLOGY, P1553; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; Gouet P, 1999, CELL, V97, P481, DOI 10.1016/S0092-8674(00)80758-8; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HARRISON SC, 1983, J MOL BIOL, V171, P577, DOI 10.1016/0022-2836(83)90045-1; Harrison SJ, 1999, VIROLOGY, V258, P54, DOI 10.1006/viro.1999.9707; HARVEY JD, 1981, VIROLOGY, V112, P240, DOI 10.1016/0042-6822(81)90629-2; Hill CL, 1999, NAT STRUCT BIOL, V6, P565, DOI 10.1038/9347; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; Hu GH, 1999, P NATL ACAD SCI USA, V96, P7149, DOI 10.1073/pnas.96.13.7149; Jacobson DH, 1996, ACTA CRYSTALLOGR D, V52, P693, DOI 10.1107/S0907444996001060; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LABBE M, 1991, J VIROL, V65, P2946; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; Luongo CL, 2000, J BIOL CHEM, V275, P2804, DOI 10.1074/jbc.275.4.2804; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOSS SR, 1994, VIRUS RES, V32, P401, DOI 10.1016/0168-1702(94)90088-4; NIBERT ML, 1996, FIELDS VIROLOGY, P1557; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; Shaw AL, 1996, STRUCTURE, V4, P957, DOI 10.1016/S0969-2126(96)00102-5; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; XU PT, 1993, VIROLOGY, V197, P726, DOI 10.1006/viro.1993.1648; Zhang H, 1999, J VIROL, V73, P1624, DOI 10.1128/JVI.73.2.1624-1629.1999	46	358	391	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 27	2000	404	6781					960	967		10.1038/35010041	http://dx.doi.org/10.1038/35010041			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801118				2022-12-28	WOS:000086762000046
J	Tang, MJ; Pham, P; Shen, X; Taylor, JS; O'Donnell, M; Woodgate, R; Goodman, MF				Tang, MJ; Pham, P; Shen, X; Taylor, JS; O'Donnell, M; Woodgate, R; Goodman, MF			Roles of E-coli DNA polymerases IV and V in lesion-targeted and untargeted SOS mutagenesis	NATURE			English	Article							SINGLE-STRANDED VECTOR; ESCHERICHIA-COLI; RECA PROTEIN; CIS-SYN; ULTRAVIOLET-LIGHT; MOUSE HOMOLOGS; REPLICATION; MUTATION; BYPASS; PHOTOPRODUCTS	The expression of the Escherichia coli DNA polymerases pol V (UmuD'(2) C complex)(1,2) and pol IV (DinB)(3) increases in response to DNA damage(4). The induction of pol V is accompanied by a substantial increase in mutations targeted at DNA template lesions in a process called SOS-induced error-prone repair(4). Here we show that the common DNA template lesions, TT (6-4) photoproducts, TT cis-syn photodimers and abasic sites, are efficiently bypassed within 30 seconds by pol V in the presence of activated RecA protein (RecA*), single-stranded binding protein (SSB) and pol III's processivity beta,gamma-complex. There is no detectable bypass by either pol IV or pol III on this time scale. A mutagenic 'signature' for pol V is its incorporation of guanine opposite the 3'-thymine of a TT (6-4) photoproduct, in agreement with mutational spectra. In contrast, pol III and pol IV incorporate adenine almost exclusively. When copying undamaged DNA, pol V exhibits low fidelity with error rates of around 10(-3) to 10(-4), with pol IV being 5- to 10-fold more accurate. The effects of RecA protein on pol V, and beta,gamma-complex on pol IV, cause a 15,000- and 3,000-fold increase in DNA synthesis efficiency, respectively. However, both polymerases exhibit low processivity, adding 6 to 8 nucleotides before dissociating. Lesion bypass by pol V does not require beta,gamma-complex in the presence of non-hydrolysable ATP gamma S, indicating that an intact RecA filament may be required for translesion synthesis.	Univ So Calif, Dept Biol Sci & Chem, Los Angeles, CA 90089 USA; Washington Univ, Dept Chem, St Louis, MO 63130 USA; Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA; NICHHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA	University of Southern California; Washington University (WUSTL); Rockefeller University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci & Chem, Univ Pk, Los Angeles, CA 90089 USA.		Taylor, John-Stephen/AAA-3218-2020	Taylor, John-Stephen/0000-0002-8615-7257; Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bambara RA, 1995, METHOD ENZYMOL, V262, P270; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; Bruck I, 1996, J BIOL CHEM, V271, P10767, DOI 10.1074/jbc.271.18.10767; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Fijalkowska IJ, 1997, J BACTERIOL, V179, P7435, DOI 10.1128/jb.179.23.7435-7445.1997; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Jing YQ, 1998, NUCLEIC ACIDS RES, V26, P3845, DOI 10.1093/nar/26.16.3845; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; KNIPPERS R, 1970, NATURE, V228, P1050, DOI 10.1038/2281050a0; LAWRENCE CW, 1990, MOL GEN GENET, V222, P166, DOI 10.1007/BF00283040; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; Radman M, 1999, NATURE, V401, P866, DOI 10.1038/44738; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; Rangarajan S, 1999, P NATL ACAD SCI USA, V96, P9224, DOI 10.1073/pnas.96.16.9224; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Smith CA, 1996, BIOCHEMISTRY-US, V35, P4146, DOI 10.1021/bi951975c; Sommer S, 1998, MOL MICROBIOL, V28, P281, DOI 10.1046/j.1365-2958.1998.00803.x; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7	30	367	387	1	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					1014	1018		10.1038/35010020	http://dx.doi.org/10.1038/35010020			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801133				2022-12-28	WOS:000086762000061
J	Ainsworth, SB; Beresford, MW; Milligan, DWA; Shaw, NJ; Matthews, JNS; Fenton, AC; Platt, MPW				Ainsworth, SB; Beresford, MW; Milligan, DWA; Shaw, NJ; Matthews, JNS; Fenton, AC; Platt, MPW			Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial	LANCET			English	Article							ARTIFICIAL SURFACTANT; NATURAL SURFACTANT; PRETERM RABBITS; INFANTS; BIRTH; DEFICIENCY; BABIES; LAMBS; SCORE	Background Exogenous surfactant preparations vary in their constitution and biophysical properties. Synthetic and animal-derived preparations lower the rate of death compared with controls. No significant differences in mortality or important long-term clinical outcomes have been shown between them in randomised trials, We did a randomised controlled trial to compare pumactant, a synthetic surfactant, with poractant alfa, an animal-derived surfactant, both of which are widely used in the UK. Methods We enrolled 212 neonates born between 25 weeks' and 29 weeks and 6 days' gestation who were intubated for presumed surfactant deficiency and were free from life-threatening malformations, We randomly assigned 105 neonates poractant alfa, and 107 pumactant. The primary outcome was duration of high-dependency care and mortality was a secondary outcome. Analysis was by intention to treat. Findings Outcome data were analysed for 199 babies. The trial was stopped on the recommendation of the data and safety monitoring committee because mortality assumed a greater importance than the primary outcome, Predischarge mortality differed significantly between groups, in favour of poractant alfa (14.1 vs 31.0%, p=0.006; odds ratio 0.37 [95% CI 0.18-0.76). This difference was sustained after adjustment for centre, gestation, birthweight, sex, plurality, and use of antenatal steroids, Interpretation Mortality was unexpectedly lower among neonates who received poractant alfa than among those who received pumactant, and was independent of all the variables we investigated. Stopping the trial early may have widened the difference between the treatment groups.	Royal Victoria Infirm, Newcastle Neonatal Serv, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Liverpool Womens Hosp, Neonatal Unit, Liverpool, Merseyside, England; Univ Newcastle Upon Tyne, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; University of Liverpool; Newcastle University - UK	Milligan, DWA (corresponding author), Royal Victoria Infirm, Newcastle Neonatal Serv, Ward 35 Leazes Wing, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.		Beresford, Michael William/AAB-5261-2021; Matthews, John N S/H-7502-2013; Platt, Martin Ward/D-4008-2014	Beresford, Michael William/0000-0002-5400-9911; Matthews, John N S/0000-0003-2559-037X; Platt, Martin Ward/0000-0003-0536-5749				Arnold C, 1996, PEDIATRICS, V97, P1; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Bjorklund LJ, 1997, PEDIATR RES, V42, P348; COCKBURN F, 1993, LANCET, V342, P193; CORCORAN JD, 1994, ARCH DIS CHILD-FETAL, V71, pF165, DOI 10.1136/fn.71.3.F165; Creuwels LAJM, 1997, LUNG, V175, P1, DOI 10.1007/PL00007554; Halliday HL, 1996, DRUGS, V51, P226, DOI 10.2165/00003495-199651020-00004; HORBAR JD, 1993, J PEDIATR-US, V123, P757, DOI 10.1016/S0022-3476(05)80856-X; Hudak ML, 1997, PEDIATRICS, V100, P39, DOI 10.1542/peds.100.1.39; IKEGAMI M, 1992, AM REV RESPIR DIS, V145, P1005, DOI 10.1164/ajrccm/145.5.1005; JOBE AH, 1993, AM J OBSTET GYNECOL, V168, P508, DOI 10.1016/0002-9378(93)90483-Y; LEVENE MI, 1981, ARCH DIS CHILD, V56, P900, DOI 10.1136/adc.56.12.900; Maier RF, 1997, ARCH DIS CHILD-FETAL, V76, pF146, DOI 10.1136/fn.76.3.F146; MILNER AD, 1983, ARCH DIS CHILD, V58, P458, DOI 10.1136/adc.58.6.458; MORLEY C, 1980, ARCH DIS CHILD, V55, P758, DOI 10.1136/adc.55.10.758; MORLEY CJ, 1987, BRIT MED J, V294, P991; MORLEY CJ, 1988, EARLY HUM DEV, V17, P41, DOI 10.1016/S0378-3782(88)80056-2; MORLEY CJ, 1981, LANCET, V1, P65; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PICKERING J, 1993, ARCH DIS CHILD-FETAL, V68, P539; *REP JOINT WORK PA, 1999, EARLY HUM DEV, V46, P239; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; RIDER ED, 1993, AM REV RESPIR DIS, V147, P669, DOI 10.1164/ajrccm/147.3.669; SEIDNER SR, 1995, AM J RESP CRIT CARE, V152, P113, DOI 10.1164/ajrccm.152.1.7599809; SOLL RF, 1999, COCHRANE REV; SOLL RF, 1999, COCHRANE LIB; SPEER CP, 1995, ARCH DIS CHILD-FETAL, V72, pF8, DOI 10.1136/fn.72.1.F8; STENSON BJ, 1994, ARCH DIS CHILD, V70, P19; Takahashi Akio, 1994, Acta Paediatrica Japonica, V36, P613; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; WILKINSON A, 1985, LANCET, V2, P287	32	75	77	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1387	1392		10.1016/S0140-6736(00)02136-X	http://dx.doi.org/10.1016/S0140-6736(00)02136-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791521				2022-12-28	WOS:000086829800008
J	Lacorre, P; Goutenoire, F; Bohnke, O; Retoux, R; Laligant, Y				Lacorre, P; Goutenoire, F; Bohnke, O; Retoux, R; Laligant, Y			Designing fast oxide-ion conductors based on La2Mo2O9	NATURE			English	Article								The ability of solid oxides to conduct oxide ions has been known for more than a century, and fast oxide-ion conductors (or oxide electrolytes) are now being used for applications ranging from oxide fuel cells to oxygen pumping devices(1,2). To be technologically viable, these oxide electrolytes must exhibit high oxide-ion mobility at low operating temperatures. Because of the size and interaction of oxygen ions with the cationic network, high mobility can only be achieved with classes of materials with suitable structural features. So far, high mobility has been observed in only a small number of structural families, such as fluorite(3-5), perovskites(6,7), intergrowth perovskite/Bi2O2 layers(8,9) and pyrochlores(10,11). Here we report a family of solid oxides based on the parent compound(12) La2Mo2O9 (with a different crystal structure from all known oxide electrolytes) which exhibits fast oxide-ion conducting properties. Like other ionic conductors(2,13), this material undergoes a structural transition around 580 degrees C resulting in an increase of conduction by almost two orders of magnitude. Its conductivity is about 6 x 10(-2) S cm(-1) at 800 degrees C, which is comparable to that of stabilized zirconia, the most widely used oxide electrolyte. The structural similarity of La2Mo2O9 with beta-SnWO4 (ref. 14) suggests a structural model for the origin of the oxide-ion conduction. More generally, substitution of a cation that has a lone pair of electrons by a different cation that does not have a lone pair-and which has a higher oxidation state-could be used as an original way to design other oxide-ion conductors.	Univ Maine, Lab Fluorures, UPRESA CNRS 6010, F-72085 Le Mans 9, France	Le Mans Universite	Lacorre, P (corresponding author), Univ Maine, Lab Fluorures, UPRESA CNRS 6010, Ave Olivier Messiaen, F-72085 Le Mans 9, France.		Ravella, Uay Krishna/E-6353-2010					ABRAHAM F, 1990, SOLID STATE IONICS, V40-1, P934, DOI 10.1016/0167-2738(90)90157-M; ABRAHAM F, 1988, SOLID STATE IONICS, V28, P529, DOI 10.1016/S0167-2738(88)80096-1; Boivin JC, 1998, CHEM MATER, V10, P2870, DOI 10.1021/cm980236q; FENG M, 1994, EUR J SOL STATE INOR, V31, P663; Fournier J., 1970, B SOC CHIM FR II-CH, V12, P4277, DOI 10.1002/chin.197401058; GOUTENOIRE F, UNPUB CHEM MAT; HARWIG HA, 1978, J SOLID STATE CHEM, V26, P265, DOI 10.1016/0022-4596(78)90161-5; ISHIHARA T, 1994, J AM CHEM SOC, V116, P3801, DOI 10.1021/ja00088a016; JEITSCHKO W, 1972, ACTA CRYSTALLOGR B, V28, P3174, DOI 10.1107/S056774087200768X; Kendall KR, 1995, SOLID STATE IONICS, V82, P215, DOI 10.1016/0167-2738(95)00207-4; KRAMERS SA, 1995, SOLID STATE IONICS, V82, P15, DOI 10.1016/0167-2738(95)00156-Z; Kuang WX, 1998, J MATER CHEM, V8, P19, DOI 10.1039/a706525f; Lacorre P, 1997, J SOLID STATE CHEM, V132, P443, DOI 10.1006/jssc.1997.7535; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Steele B.H.C., 1989, HIGH CONDUCTIVITY SO, P402; Subbarao EC, 1981, ADV CERAM, V1, P1; Takahashi T., 1973, J APPL ELECTROCHEM, V3, P65; Tuller HL, 1997, SOLID STATE IONICS, V94, P63, DOI 10.1016/S0167-2738(96)00585-1; WAGNER JB, 1957, J CHEM PHYS, V26, P1597, DOI 10.1063/1.1743590; Wells AF, 1987, STRUCTURAL INORGANIC, P1187	20	608	633	9	297	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					856	858		10.1038/35009069	http://dx.doi.org/10.1038/35009069			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786788				2022-12-28	WOS:000086625000040
J	Phan, TD; Kistler, LM; Klecker, B; Haerendel, G; Paschmann, G; Sonnerup, BUO; Baumjohann, W; Bavassano-Cattaneo, MB; Carlson, CW; Dilellis, AM; Fornacon, KH; Frank, LA; Fujimoto, M; Georgescu, E; Kokubun, S; Moebius, E; Mukai, T; Oieroset, M; Paterson, WR; Reme, H				Phan, TD; Kistler, LM; Klecker, B; Haerendel, G; Paschmann, G; Sonnerup, BUO; Baumjohann, W; Bavassano-Cattaneo, MB; Carlson, CW; Dilellis, AM; Fornacon, KH; Frank, LA; Fujimoto, M; Georgescu, E; Kokubun, S; Moebius, E; Mukai, T; Oieroset, M; Paterson, WR; Reme, H			Extended magnetic reconnection at the Earth's magnetopause from detection of bi-directional jets	NATURE			English	Article							FIELD	Magnetic reconnection is a process that converts magnetic energy into bi-directional plasma jets; it is believed to be the dominant process by which solar-wind energy enters the Earth's magnetosphere(1,2). This energy is subsequently dissipated by magnetic storms and aurorae(3,4). Previous single-spacecraft observations(5-7) revealed only single jets at the magnetopause-while the existence of a counter-streaming jet was implicitly assumed, no experimental confirmation was available. Here we report in situ two-spacecraft observations of bi-directional jets at the magnetopause, finding evidence for a stable and extended reconnection line; the latter implies substantial entry of the solar wind into the magnetosphere. We conclude that reconnection is determined by large-scale interactions between the solar wind and the magnetosphere, rather than by local conditions at the magnetopause.	Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA; Univ New Hampshire, Ctr Space Sci, Durham, NH 03824 USA; Max Planck Inst Extraterr Phys, D-85740 Garching, Germany; Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; CNR, IFSI, I-00133 Rome, Italy; Tech Univ Braunschweig, D-38106 Braunschweig, Germany; Univ Iowa, Dept Phys & Astron, Iowa City, IA 52242 USA; Tokyo Inst Technol, Dept Earth & Planetary Sci, Meguro Ku, Tokyo 152, Japan; Inst Space Sci, Bucharest 76900, Romania; Nagoya Univ, Solar Terr Environm Lab, Aichi 442, Japan; Inst Space & Astronaut Sci, Kanagawa 229, Japan; Univ Toulouse 3, Ctr Etud Spatiale Rayonnements, F-31029 Toulouse, France	University of California System; University of California Berkeley; University System Of New Hampshire; University of New Hampshire; Max Planck Society; Dartmouth College; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); Braunschweig University of Technology; University of Iowa; Tokyo Institute of Technology; Institute of Space Science; Nagoya University; Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Phan, TD (corresponding author), Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA.		Baumjohann, Wolfgang/A-1012-2010; Paterson, William/F-5684-2012	Baumjohann, Wolfgang/0000-0001-6271-0110; Moebius, Eberhard/0000-0002-2745-6978				AKASOFU SI, 1981, SPACE SCI REV, V28, P121, DOI 10.1007/BF00218810; AXFORD WI, 1961, CAN J PHYS, V39, P1433, DOI 10.1139/p61-172; BERCHEM J, 1995, GEOPHYS MONOGR SER, V90, P205; Burke WJ, 1999, J GEOPHYS RES-SPACE, V104, P9989, DOI 10.1029/1999JA900031; Cowley S. W. H., 1984, GEOPHYS MONOGR SER, V30, P375, DOI DOI 10.1029/GM030P0375; COWLEY SWH, 1984, ESA SP, V217, P483; CROOKER NU, 1979, J GEOPHYS RES-SPACE, V84, P951, DOI 10.1029/JA084iA03p00951; DUNGEY JW, 1961, PHYS REV LETT, V6, P47, DOI 10.1103/PhysRevLett.6.47; FAIRFIELD DH, 1966, J GEOPHYS RES, V71, P155, DOI 10.1029/JZ071i001p00155; GONZALEZ WD, 1974, J GEOPHYS RES, V79, P4186, DOI 10.1029/JA079i028p04186; GOSLING JT, 1986, J GEOPHYS RES, V91, P3029, DOI 10.1029/JA091iA03p03029; LINDQVIST PA, 1990, J GEOPHYS RES-SPACE, V95, P17137, DOI 10.1029/JA095iA10p17137; Nagai T, 1998, J GEOPHYS RES-SPACE, V103, P4419, DOI 10.1029/97JA02190; PASCHMANN G, 1979, NATURE, V282, P243, DOI 10.1038/282243a0; PASCHMANN G, 1986, J GEOPHYS RES, V91, P1099, DOI 10.1029/JA091iA10p11099; SONNERUP BU, 1974, J GEOPHYS RES, V79, P1546, DOI 10.1029/JA079i010p01546; SONNERUP BUO, 1981, J GEOPHYS RES-SPACE, V86, P49, DOI 10.1029/JA086iA12p10049	17	192	193	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					848	850		10.1038/35009050	http://dx.doi.org/10.1038/35009050			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786785				2022-12-28	WOS:000086625000037
J	Formiga, F; Mascaro, J; Chivite, D; Pujol, R				Formiga, F; Mascaro, J; Chivite, D; Pujol, R			Reversible dementia due to two coexisting diseases	LANCET			English	Article									Bellvitge Hosp, Geriatr Unit, Barcelona 08907, Spain; CSU Bellvitge, Internal Med Serv, Geriatr Unit, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Formiga, F (corresponding author), Bellvitge Hosp, Geriatr Unit, C Feixa Llarga S-N, Barcelona 08907, Spain.		Pujol-Farriols, Ramon/O-5567-2019; formiga, Francesc/ABD-7976-2020	formiga, Francesc/0000-0002-3587-298X; Chivite, David/0000-0002-8855-4758				COX J, 1988, J AM GERIATR SOC, V36, P650, DOI 10.1111/j.1532-5415.1988.tb06166.x; FRIEDLAND RP, 1989, JAMA-J AM MED ASSOC, V262, P2577, DOI 10.1001/jama.262.18.2577; SIER HC, 1988, J AM GERIATR SOC, V36, P157; van Crevel H, 1999, J NEUROL, V246, P73, DOI 10.1007/s004150050311; Zahrani AA, 1997, LANCET, V349, P1233, DOI 10.1016/S0140-6736(96)06176-4	5	10	10	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2000	355	9210					1154	1154		10.1016/S0140-6736(00)02065-1	http://dx.doi.org/10.1016/S0140-6736(00)02065-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	302TC	10791379				2022-12-28	WOS:000086380900014
J	Dickinson, K; Bunn, F; Wentz, R; Edwards, P; Roberts, I				Dickinson, K; Bunn, F; Wentz, R; Edwards, P; Roberts, I			Size and quality of randomised controlled trials in head injury: review of published studies	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To assess whether trials in head injury are large enough to avoid moderate random errors and designed to avoid moderate biases. Design All randomised controlled trials on the treatment and rehabilitation of patients with head injury published before December 1998 were surveyed. Trials were identified from electronic databases, by hand searching journals and conference proceedings, and by contacting researchers. Data were extracted on the number of participants, quality of concealment of allocation, use of blinding, loss to follow up, and types of participants, interventions, and outcome measures. Results 279 reports were identified, containing information on 208 separate trials. The average number of participants per trial was 82, with no evidence of increasing size over time. The total number of randomised participants in the 203 trials in which size was reported was 16 613. No trials were large enough to detect reliably a 5% absolute I-eduction in the risk of death or disability and only 4% were large enough to detect an absolute reduction of 10%. Concealment of allocation was adequate in 22 and inadequate or unclear in 25 of the 47 (23%) in which it was reported. Of 126 trials assessing disability, 111 reported the number of patients followed up, and average loss to follow up was 19%. Of trials measuring disability, 26 (21%) reported that outcome assessors were blinded. Conclusions Randomised trials in head injury are too small and poorly designed to detect or refute reliably moderate but clinically important benefits or hazards of treatment Limited funding for injury research and unfamiliarity with issues of consent may have been important obstacles.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, Cochrane Injuries Grp, London WC1N 1EH, England	University of London; London School of Hygiene & Tropical Medicine; University College London	Roberts, I (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, Child Hlth Monitoring Unit, Cochrane Injuries Grp, 30 Guilford St, London WC1N 1EH, England.	ian.roberts@ich.ucl.ac.uk	Bunn, Frances/I-8108-2015	Bunn, Frances/0000-0002-5885-918X; Edwards, Phil/0000-0003-4431-8822				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], INV HLTH RES DEV; Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5; *DEP HLTH HUM SERV, 1995, FED REGISTER, V60, P49086; Kunz R, 1998, BRIT MED J, V317, P1185, DOI 10.1136/bmj.317.7167.1185; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; *ROYAL COLL SURG E, 1999, REP WORK PART MAN PA; Sandercock P, 1997, LANCET, V349, P1569; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Smith R, 1997, BRIT MED J, V314, P1059, DOI 10.1136/bmj.314.7087.1059; Teasdale GM, 1991, J NEUROTRAUM, V8, P88; *WORLD BANK, 1999, GLOB ROAD SAF PARTN; Yates D, 1999, J ACCID EMERG MED, V16, P83	16	98	101	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2000	320	7245					1308	1311		10.1136/bmj.320.7245.1308	http://dx.doi.org/10.1136/bmj.320.7245.1308			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807622	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000087077400022
J	Dowell, SF; Kupronis, BA; Zell, ER; Shay, DK				Dowell, SF; Kupronis, BA; Zell, ER; Shay, DK			Mortality from pneumonia in children in the United States, 1939 through 1996	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	37th Annual Meeting of the Infectious-Diseases-Society-of-America	NOV 18-21, 1999	PHILADELPHIA, PA	Infect Dis Soc Amer			US CHILDREN; DISEASE; MANAGEMENT; INFECTIONS; REDUCTION; INFLUENZA; MEDICAID; CARE	Background and Methods: Pneumonia remains an important cause of childhood deaths throughout the world, but in developed countries, the mortality rate is decreasing. We reviewed death records for children in the United States from 1939 through 1996. A plot of the annual rates of change in the number of deaths from pneumonia was used to generate hypotheses about the influence of various events and interventions. We used data from the National Hospital Discharge Survey, the Medicaid program, and published reports to test these hypotheses. Results: During the 58-year study period, the number of children who died from pneumonia declined by 97 percent, from 24,637 in 1939 to 800 in 1996. During the same period, the rate of mortality from other causes declined by 82 percent. There were steep declines in the mortality rates for pneumonia from 1944 to 1950, although the rate increased among older children in 1957, and there were sustained declines in all age groups from 1966 to 1982. From 1966 to 1982, the mortality declined by an average of 13.0 percent annually, and these decreases coincided with increases in the proportion of poor children covered by Medicaid, increases in rates of hospitalization for pneumonia, a narrowing of the gap between the mortality rate for black children and the rate for white children, and a convergence between the mortality rate in the South and the rates in the other three census regions. Conclusions: Since 1939, the rate of mortality from pneumonia in children in the United States has declined markedly. We hypothesize that the steep declines in the late 1940s are attributable to the use of penicillin, that the peak in 1957 was due to the influenza A pandemic, and that the sustained decline from 1966 through 1982 may be attributable in part to improved access to medical care for poor children. (N Engl J Med 2000;342:1399-407.) (C)2000, Massachusetts Medical Society.	Natl Ctr Infect Dis, Resp Dis Branch, Atlanta, GA USA; Natl Ctr Infect Dis, Biostat & Informat Management Branch, Div Bacterial & Mycot Dis, Atlanta, GA USA; Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Res & Enter Viruses Branch, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Dowell, SF (corresponding author), Ctr Dis Control & Prevent, Mailstop C-23,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	sfd2@cdc.gov		Kupronis, Benjamin/0000-0001-6437-4843; Shay, David/0000-0001-9619-4820				AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BANG AT, 1994, B WORLD HEALTH ORGAN, V72, P897; BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; Berkelhamer J E, 1982, Adv Pediatr, V29, P211; Berman S, 1998, PEDIATRICS, V101, P944; Black S, 1997, PEDIATR ANN, V26, P355, DOI 10.3928/0090-4481-19970601-04; COLLINS SD, 1951, PUBLIC HEALTH REP, V66, P1487, DOI 10.2307/4587915; Cox NJ, 1998, INFECT DIS CLIN N AM, V12, P27, DOI 10.1016/S0891-5520(05)70406-2; Davis K, 1978, HLTH WAR POVERTY 10; DUFIFN J, 1993, CAMBRIDGE WORLD HIST, P938; FAUST MM, 1964, VIT STAT SPEC REP SE, V51; FAUST MM, 1965, VIT STAT SPEC REP SE, V51; FAUVEAU V, 1992, B WORLD HEALTH ORGAN, V70, P109; FINKE W, 1952, AMA AM J DIS CHILD, V83, P755, DOI 10.1001/archpedi.1952.02040100053004; FOTZ AM, 1975, MED CARE, V13, P630; GRAHAM GG, 1985, PEDIATRICS, V75, P117; HETZEL AM, 1997, DHHS PUBL PHS, P1; HUANG NN, 1980, CLIN CHEST MED, V1, P385; Iglehart JK, 1999, NEW ENGL J MED, V340, P403, DOI 10.1056/NEJM199902043400525; Kayhty H, 1996, EMERG INFECT DIS, V2, P289, DOI 10.3201/eid0204.9604; KILGORE PE, 1995, JAMA-J AM MED ASSOC, V274, P1143, DOI 10.1001/jama.274.14.1143; King JC, 1998, J INFECT DIS, V177, P1394, DOI 10.1086/517822; KLEBBA AJ, 1980, MON VITAL STAT REP, V28; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; MALDONADO YA, 1997, PRINCIPLES PRACTICE, P1254; MARKOWITZ LE, 1991, REV INFECT DIS, V13, pS555; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; *NAT CTR HLTH STAT, 1975, VIT HLTH STAT, V2; NELSON JD, 1983, PEDIATR INFECT DIS J, V2, P394, DOI 10.1097/00006454-198309000-00017; Newacheck PW, 1998, JAMA-J AM MED ASSOC, V280, P1789, DOI 10.1001/jama.280.20.1789; OBERG CN, 1990, J SCHOOL HEALTH, V60, P493, DOI 10.1111/j.1746-1561.1990.tb05888.x; PANDEY MR, 1991, LANCET, V338, P993, DOI 10.1016/0140-6736(91)91847-N; ROGHMANN KJ, 1971, NEW ENGL J MED, V285, P1053, DOI 10.1056/NEJM197111042851904; SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S; SERFLING RE, 1967, AM J EPIDEMIOL, V86, P433, DOI 10.1093/oxfordjournals.aje.a120753; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; 1993, MMWR MORB MORTAL WKL, V42, P70	37	53	59	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1399	1407		10.1056/NEJM200005113421904	http://dx.doi.org/10.1056/NEJM200005113421904			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	312JR	10805825				2022-12-28	WOS:000086940600004
J	Wootton, R; Bloomer, SE; Corbett, R; Eedy, DJ; Hicks, N; Lotery, HE; Mathews, C; Paisley, J; Steele, K; Loane, MA				Wootton, R; Bloomer, SE; Corbett, R; Eedy, DJ; Hicks, N; Lotery, HE; Mathews, C; Paisley, J; Steele, K; Loane, MA			Multicentre randomised control trial comparing real time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSTIC-ACCURACY; NORTHERN-IRELAND; TELECONSULTATIONS; PATIENT	Objectives Comparison of real time teledermatology with outpatient dermatology in terms of clinical outcomes, cost-benefits, and patient reattendance. Design Randomised controlled trial with a minimum follow up of three months. Setting Four health centres (two urban, two rural) and two regional hospitals. Subjects 204 general practice patients requiring referral to dermatology services; 102 were randomised to teledermatology consultation and. 102 to traditional outpatient consultation. Main outcome measures Reported clinical outcome of initial consultation, primary care and outpatient reattendance data, and cost-benefit analysis of both methods of delivering care. Results No major differences were found in the reported clinical outcomes of teledermatology and conventional dermatology. Of patients randomised to teledermatology, 55 (54%) were managed within primary care and 47 (46%) required at least one hospital appointment. Of patients randomised to the conventional hospital outpatient consultation, 46 (45%) required at least one further hospital appointment, 15 (15%) required general practice review and 30 (39%) no follow up visits. Clinical records showed that 42 (41%) patients seen by teledermatology attended subsequent hospital appointments compared with 41 (40%) patients seen conventionally. The net societal cost of the initial consultation was pound 132.10 pet patient for teledermatology and pound 48.73 for conventional consultation. Sensitivity analysis revealed that if each health centre had allocated one morning session a week to teledermatology and the average round trip to hospital had been 78 km instead of 26 km, the costs of the two methods of care would have been equal. Conclusions Real time teledermatology was clinically feasible but not cost effective compared with conventional dermatological outpatient care. However, if the equipment were purchased at current prices and the travelling distances greater, teledermatology would be a cost effective alternative to conventional care.	Royal Hosp Trust, Inst Telemed & Telecare, Belfast BT12 6BA, Antrim, North Ireland; Portadown Hlth Ctr, Orchard Family Practice, Portadown BT62 3BU, Armagh, North Ireland; Queens Univ Belfast, Dept Med, Belfast BT9 7HR, Antrim, North Ireland; Craigavon Area Hosp Grp, Dept Dermatol, Craigavon BT63 5QQ, Armagh, North Ireland; The Surg, Dromara BT25 2AT, Down, North Ireland; Queens Univ Belfast, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland	Queens University Belfast; Queens University Belfast	Wootton, R (corresponding author), Univ Queensland, Royal Brisbane Hosp, Ctr Online Hlth, Brisbane, Qld 4029, Australia.		Wootton, Richard/F-7609-2014	Wootton, Richard/0000-0002-2666-3596; Loane, Maria/0000-0002-1206-3637				Altman D.G., 1991, PRACTICAL STAT MED R; *DEP HLTH, 1994, PERS SOC SERV STAT E; Gilmour E, 1998, BRIT J DERMATOL, V139, P81; Lesher JL, 1998, J AM ACAD DERMATOL, V38, P27, DOI 10.1016/S0190-9622(98)70534-1; Loane MA, 1998, J TELEMED TELECARE, V4, P36, DOI 10.1258/1357633981931254; Loane MA, 1999, J TELEMED TELECARE, V5, P1, DOI 10.1258/1357633991932414; Loane MA, 1998, J TELEMED TELECARE, V4, P95, DOI 10.1258/1357633981932028; Lowitt MH, 1998, ARCH DERMATOL, V134, P471, DOI 10.1001/archderm.134.4.471; Oakley AMM, 1997, NEW ZEAL MED J, V110, P51; Phillips CM, 1997, J AM ACAD DERMATOL, V37, P398, DOI 10.1016/S0190-9622(97)70139-7; Royal College of General Practitioners Office of Population Consensus & Survey. Department of Health, 1995, MORB STAT GEN PRACT; RYAN T, 1993, DERMATOLOGY SERVICE; VIERHOUT WPM, 1995, LANCET, V346, P990, DOI 10.1016/S0140-6736(95)91686-5	13	187	190	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1252	1256		10.1136/bmj.320.7244.1252	http://dx.doi.org/10.1136/bmj.320.7244.1252			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797038	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086981400023
J	Martinez-Garcia, JF; Huq, E; Quail, PH				Martinez-Garcia, JF; Huq, E; Quail, PH			Direct targeting of light signals to a promoter element-bound transcription factor	SCIENCE			English	Article							DISRUPTS CIRCADIAN-RHYTHMS; LOOP-HELIX PROTEIN; PHYTOCHROME-A; GENE-EXPRESSION; G-BOX; CONSTITUTIVE EXPRESSION; ARABIDOPSIS-THALIANA; BZIP PROTEIN; TRANSDUCTION; SPECIFICITY	Light signals perceived by the phytochrome family of sensory photoreceptors are transduced to photoresponsive genes by an unknown mechanism. Here, we show that the basic helix-loop-helix transcription factor PIF3 binds specifically to a G-box DNA-sequence motif present in various Light-regulated gene promoters, and that phytochrome B binds reversibly to G-box-bound PIF3 specifically upon light-triggered conversion of the photoreceptor to its biologically active conformer. We suggest that the phytochromes may function as integral Light-switchable components of transcriptional regulator complexes, permitting continuous and immediate sensing of changes in this environmental signal directly at target gene promoters.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; ARS, USDA, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.		Martinez-Garcia, Jaime F/H-6868-2015	Martinez-Garcia, Jaime F/0000-0003-1516-0341; Huq, Enamul/0000-0001-7692-5139				Ahmad M, 1996, PLANT J, V10, P1103, DOI 10.1046/j.1365-313X.1996.10061103.x; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; ARGNELLOASTORGA G, 1998, ANNU REV PLANT PHYS, V49, P525; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Canton FR, 1999, PLANT PHYSIOL, V121, P1207, DOI 10.1104/pp.121.4.1207; Chattopadhyay S, 1998, PLANT CELL, V10, P673, DOI 10.1105/tpc.10.5.673; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; Deng XW, 1999, SEMIN CELL DEV BIOL, V10, P121, DOI 10.1006/scdb.1999.0287; DONALD RGK, 1990, EMBO J, V9, P1717, DOI 10.1002/j.1460-2075.1990.tb08295.x; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; Hoecker U, 1999, SCIENCE, V284, P496, DOI 10.1126/science.284.5413.496; Hudson M, 1999, GENE DEV, V13, P2017, DOI 10.1101/gad.13.15.2017; Ishige F, 1999, PLANT J, V18, P443, DOI 10.1046/j.1365-313X.1999.00456.x; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Kircher S, 1999, PLANT CELL, V11, P1445, DOI 10.1105/tpc.11.8.1445; Littlewood TD., 1998, HELIX LOOP HELIX TRA; MARTINEZGARCIA JF, UNPUB; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Ni M, 1999, NATURE, V400, P781, DOI 10.1038/23500; Niu XP, 1999, PLANT MOL BIOL, V41, P1, DOI 10.1023/A:1006206011502; Oyama T, 1997, GENE DEV, V11, P2983, DOI 10.1101/gad.11.22.2983; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Puente P, 1996, EMBO J, V15, P3732, DOI 10.1002/j.1460-2075.1996.tb00743.x; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; QUAIL PH, 1995, T R SOC LONDON, V353, P1399; Schafer E, 1997, PLANT CELL ENVIRON, V20, P722, DOI 10.1046/j.1365-3040.1997.d01-98.x; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; Soh MS, 1998, PLANT J, V16, P411, DOI 10.1046/j.1365-313x.1998.00307.x; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Wagner D, 1997, PLANT CELL, V9, P731, DOI 10.1105/tpc.9.5.731; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Whitelam GC, 1998, PHILOS T ROY SOC B, V353, P1445, DOI 10.1098/rstb.1998.0300; WILLIAMS ME, 1992, PLANT CELL, V4, P485, DOI 10.1105/tpc.4.4.485; Yamaguchi R, 1999, J CELL BIOL, V145, P437, DOI 10.1083/jcb.145.3.437	43	486	537	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					859	863		10.1126/science.288.5467.859	http://dx.doi.org/10.1126/science.288.5467.859			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797009				2022-12-28	WOS:000086869600039
J	O'Neill, WW; Serruys, P; Knudtson, M; van Es, GA; Timmis, GC; van der Zwaan, C; Kleiman, J; Gong, JJ; Roecker, EB; Dreiling, R; Alexander, J; Anders, R				O'Neill, WW; Serruys, P; Knudtson, M; van Es, GA; Timmis, GC; van der Zwaan, C; Kleiman, J; Gong, JJ; Roecker, EB; Dreiling, R; Alexander, J; Anders, R		EXCITE Trial Investigators	Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBACUTE STENT THROMBOSIS; RANDOMIZED TRIAL; ARTERY DISEASE; ULTRASOUND GUIDANCE; BALLOON ANGIOPLASTY; ANTICOAGULATION; COMPLICATIONS; IMPLANTATION; INTERVENTION; MULTICENTER	Background: When administered intravenously at the time of percutaneous coronary revascularization, glycoprotein IIb/IIIa receptor antagonists decrease the incidence of death and nonfatal myocardial infarction and the need for urgent revascularization. We hypothesized that long-term administration of oral glycoprotein IIb/IIIa antagonists, which block the aggregation of platelets, might stabilize intravascular plaque and prevent additional ischemic cardiac events. Methods: We conducted a prospective, double-blind trial in which 7232 patients were randomly assigned to receive 20 mg of oral xemilofiban or placebo 30 to 90 minutes before undergoing percutaneous coronary revascularization, with maintenance doses of 10 or 20 mg of xemilofiban or placebo administered three times daily for up to 182 days. There were two primary composite end points: one was death, nonfatal myocardial infarction, or urgent revascularization at 182 days, and the other was death or nonfatal myocardial infarction at 182 days. Results: Death, myocardial infarction, or urgent revascularization occurred within 182 days in 324 patients who received placebo (Kaplan-Meier cumulative event rate, 13.5 percent), 332 who received 10 mg of xemilofiban (13.9 percent, P=0.82 for the comparison with placebo), and 306 who received 20 mg of xemilofiban (12.7 percent, P=0.36 for the comparison with placebo). The incidence of death or myocardial infarction was also similar in all three groups. Clinically significant hemorrhagic complications and thrombocytopenia were infrequent. Conclusions: The administration of the glycoprotein IIb/IIIa antagonist xemilofiban before percutaneous coronary revascularization and for up to six months thereafter does not significantly reduce the incidence of important clinical end points. (N Engl J Med 2000;342:1316-24.) (C) 2000, Massachusetts Medical Society.	William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48073 USA; Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands; Foothills Hosp, Calgary, AB T2N 2T9, Canada; Cardialysis, Rotterdam, Netherlands; Searle, Skokie, IL USA; Univ Wisconsin, Madison, WI USA; Corvallis Clin, Corvallis, OR USA	Beaumont Health; Erasmus University Rotterdam; Erasmus MC; University of Calgary; Cardialysis; University of Wisconsin System; University of Wisconsin Madison	O'Neill, WW (corresponding author), William Beaumont Hosp, Div Cardiol, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.							Adgey AAJ, 1998, EUR HEART J, V19, pD10; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; Antman Elliott M., 1998, HARRISONS PRINCIPLES, P1352; Antoniucci D, 1998, AM HEART J, V135, P510, DOI 10.1016/S0002-8703(98)70329-1; Ault KA, 1999, J AM COLL CARDIOL, V33, P634, DOI 10.1016/S0735-1097(98)00635-4; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; *CAPTURE INV, 1997, LANCET, V350, P744; Carrozza, 1995, J Thromb Thrombolysis, V1, P289, DOI 10.1007/BF01060739; COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; Dangas G, 1999, AM HEART J, V138, P49, DOI 10.1016/S0002-8703(99)70245-0; ELLIS SG, 1988, CIRCULATION, V77, P372, DOI 10.1161/01.CIR.77.2.372; FernandezAviles F, 1996, J AM COLL CARDIOL, V27, P22, DOI 10.1016/0735-1097(95)00440-8; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FUSTER V, 1987, PROG CARDIOVASC DIS, V29, P325, DOI 10.1016/0033-0620(87)90001-6; GANGNON R, 1999, CONTROL CLIN TRIALS, V20, pS35; Hanrath P, 1997, CIRCULATION, V96, P1445; Hasdai D, 1996, J AM COLL CARDIOL, V28, P361, DOI 10.1016/0735-1097(96)00136-2; HAUDE M, 1993, AM HEART J, V126, P15, DOI 10.1016/S0002-8703(07)80005-6; Karrillon GJ, 1996, CIRCULATION, V94, P1519, DOI 10.1161/01.CIR.94.7.1519; Kereiakes DJ, 1998, CIRCULATION, V98, P1268, DOI 10.1161/01.CIR.98.13.1268; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Mak KH, 1996, J AM COLL CARDIOL, V27, P494, DOI 10.1016/0735-1097(95)00466-1; Mark DB, 1996, CIRCULATION, V94, P629, DOI 10.1161/01.CIR.94.4.629; Moussa I, 1997, J AM COLL CARDIOL, V29, P6, DOI 10.1016/S0735-1097(96)00452-4; O'Neill WW, 1999, J INTERV CARDIOL, V12, P109, DOI 10.1111/j.1540-8183.1999.tb00219.x; Peter K, 1998, BLOOD, V92, P3240, DOI 10.1182/blood.V92.9.3240.421k21_3240_3249; *PLAT REC INH ISCH, 1998, NEW ENGL J MED, V339, P415; PLOW EF, 1987, BIOCHEM PHARMACOL, V36, P4035, DOI 10.1016/0006-2952(87)90558-2; Ruygrok PN, 1996, CIRCULATION, V94, P882, DOI 10.1161/01.CIR.94.5.882; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Simoons ML, 1997, LANCET, V349, P1429; Steiner B, 1998, CIRCULATION, V98, P561; Steinhubl SR, 1999, JAMA-J AM MED ASSOC, V281, P806, DOI 10.1001/jama.281.9.806; TCHENG JE, 1995, CIRCULATION, V91, P2151, DOI 10.1161/01.CIR.91.8.2151; Tcheng JE, 1997, LANCET, V349, P1422; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, JAMA-J AM MED ASSOC, V278, P479, DOI 10.1001/jama.278.6.479; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Topol EJ, 1997, NEW ENGL J MED, V336, P1689	44	157	159	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2000	342	18					1316	1324		10.1056/NEJM200005043421803	http://dx.doi.org/10.1056/NEJM200005043421803			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RE	10793164				2022-12-28	WOS:000086782400003
J	Boyd, J; Sonoda, Y; Federici, MG; Bogomolniy, F; Rhei, E; Maresco, DL; Saigo, PE; Almadrones, LA; Barakat, RR; Brown, CL; Chi, DS; Curtin, JP; Poynor, EA; Hoskins, WJ				Boyd, J; Sonoda, Y; Federici, MG; Bogomolniy, F; Rhei, E; Maresco, DL; Saigo, PE; Almadrones, LA; Barakat, RR; Brown, CL; Chi, DS; Curtin, JP; Poynor, EA; Hoskins, WJ			Clinicopathologic features of BRCA-linked and sporadic ovarian cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASHKENAZI-JEWISH INDIVIDUALS; GERM-LINE MUTATIONS; TRANSCRIPTIONAL ACTIVATION; GENETIC-HETEROGENEITY; CARRIER FREQUENCY; SEQUENCE-ANALYSIS; FAMILY HISTORY; DNA-DAMAGE; BREAST; HEREDITARY	Context Most hereditary ovarian cancers are associated with germline mutations in BRCA1 or BRCA2. Attempts to define the clinical significance of BRCA mutation status in ovarian cancer have produced conflicting results, especially regarding survival. Objective To determine whether hereditary ovarian cancers have distinct clinical and pathological features compared with sporadic (nonhereditary) ovarian cancers. Design and Setting Retrospective cohort study of a consecutive series of 933 ovarian cancers diagnosed and treated at our institution, which is a comprehensive cancer center as designated by the National Cancer Institute, over a 12-year period (December 1986 to August 1998). Patients The study was restricted to patients of Jewish origin because of the ease of BRCA1 and BRCA2 genotyping in this ethnic group. From the 189 patients who identified themselves as Jewish, 88 hereditary cases were identified with the presence of a germline founder mutation in BRCA1 or BRCA2, The remaining 101 cases from the same series not associated with a BRCA mutation and 2 additional groups (Gynecologic Oncology Group protocols 52 and 111) with ovarian cancer from clinical trials (for the survival analysis) were included for comparison. Main Outcome Measures Age at diagnosis, surgical stage, histologic cell type and grade, and surgical outcome; and response to chemotherapy and survival for advanced-stage (III and IV) cases. Results Hereditary cancers were rarely diagnosed before age 40 years and were common after age 60 years, with mean age at diagnosis being significantly younger for BRCA1- vs BRCA2-linked patients (54 vs 62 years; P=.04). Histology, grade, stage, and success of cytoreductive surgery were similar for hereditary and sporadic cases. The hereditary group had a longer disease-free interval following primary chemotherapy in comparison with the nonhereditary group, with a median time to recurrence of 14 months and 7 months, respectively (P<.001). Those with hereditary cancers had improved survival compared with the nonhereditary group (P=.004). For stage III cancers, BRCA mutation status was an independent prognostic variable (P=.03). Conclusions Although BRCA-associated hereditary ovarian cancers in this population have surgical and pathological characteristics similar to those of sporadic cancers, advanced-stage hereditary cancer patients survive longer than nonhereditary cancer patients, Age penetrance is greater for BRCA1-linked than for BRCA2-linked cancers in this population.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Boyd, J (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Box 201,1275 York Ave, New York, NY 10021 USA.	boydj@mskcc.org		Curtin, John/0000-0002-9370-5119; Boyd, Jeff/0000-0002-3517-7637	NCI NIH HHS [R01-CA71840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aida H, 1998, CLIN CANCER RES, V4, P235; Beller U, 1997, GYNECOL ONCOL, V67, P123, DOI 10.1006/gyno.1997.4844; BEWTRA C, 1992, INT J GYNECOL PATHOL, V11, P180, DOI 10.1097/00004347-199207000-00003; Boyd J, 1998, ONCOLOGY-NY, V12, P399; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; FRIEDLANDER ML, 1991, SEMIN ONCOL, V18, P205; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LevyLahad E, 1997, AM J HUM GENET, V60, P1059; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NAROD S, 1994, LANCET, V343, P236, DOI 10.1016/S0140-6736(94)91021-9; NAROD SA, 1994, CANCER-AM CANCER SOC, V74, P2341, DOI 10.1002/1097-0142(19941015)74:8<2341::AID-CNCR2820740819>3.0.CO;2-Z; NAROD SA, 1995, AM J HUM GENET, V56, P254; Oddoux C, 1996, NAT GENET, V14, P188, DOI 10.1038/ng1096-188; OMURA GA, 1989, J CLIN ONCOL, V7, P457, DOI 10.1200/JCO.1989.7.4.457; Ozols Robert F., 1997, P919; Pharoah PDP, 1999, CANCER RES, V59, P868; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; Randall TC, 1998, GYNECOL ONCOL, V70, P432, DOI 10.1006/gyno.1998.5081; Rhei E, 1998, CANCER RES, V58, P3193; Roa BB, 1996, NAT GENET, V14, P185, DOI 10.1038/ng1096-185; Robson M, 1999, JNCI-J NATL CANCER I, V91, P2112, DOI 10.1093/jnci/91.24.2112; Robson ME, 1997, LANCET, V350, P117, DOI 10.1016/S0140-6736(05)61821-1; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; ShattuckEidens D, 1997, JAMA-J AM MED ASSOC, V278, P1242, DOI 10.1001/jama.278.15.1242; STRAUSS W, 1998, CURRENT PROTOCOLS MO, V1; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; Tapper J, 1998, CANCER RES, V58, P2715; van der Heijden O, 1998, MOL CARCINOGEN, V23, P243, DOI 10.1002/(SICI)1098-2744(199812)23:4<243::AID-MC7>3.0.CO;2-E; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8; Zweemer RP, 1998, AM J OBSTET GYNECOL, V178, P85, DOI 10.1016/S0002-9378(98)70632-5	41	410	425	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2260	2265		10.1001/jama.283.17.2260	http://dx.doi.org/10.1001/jama.283.17.2260			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807385	Bronze			2022-12-28	WOS:000086671600033
J	Brancati, FL; Kao, WHL; Folsom, AR; Watson, RL; Szklo, M				Brancati, FL; Kao, WHL; Folsom, AR; Watson, RL; Szklo, M			Incident type 2 diabetes mellitus in African American and white adults - The atherosclerosis risk in communities study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPAIRED GLUCOSE-TOLERANCE; ENZYMATIC DETERMINATION; SOCIOECONOMIC-STATUS; ALCOHOL-USE; PREVALENCE; BLACKS; CHOLESTEROL; REAGENT; HEALTH; RACE	Context Although the excess prevalence of type 2 diabetes mellitus in African Americans is well established, few studies have compared incident diabetes in African American and white persons. Objectives To compare risk of incident diabetes in African American vs white adults and to identify explanatory factors for racial disparities. Design Prospective cohort study using baseline data collected from 1986 to 1989 from the ongoing Atherosclerosis Risk in Communities (ARIC) Study, with 9 years of follow-up. Setting and Participants A total of 2646 African American and 9461 white adults aged 45 to 64 years without diabetes at baseline, sampled from 4 US communities. Main Outcome Measures Incident type 2 diabetes, ascertained by self-report of physician diagnosis, use of diabetes medications, or fasting glucose level of at least 7.0 mmol/L (126 mg/dL), compared among white and African American subjects and by presence of potentially modifiable risk factors. Results Diabetes incidence per 1000 person-years was about 2.4-fold greater in African American women (25.1 [95% confidence interval {CI}, 22.4-28.1] vs 10.4 [95% CI, 9.4-11.4]) and about 1.5-fold greater in men (23.4 [95% CI, 19.9-27.2] vs 15.9 [95% CI, 14.6-17.2]) than in their white counterparts (P<.001). Results from proportional hazards regression models indicated that racial differences in potentially modifiable risk factors, particularly adiposity, accounted for 47.8% of the excess risk in African American women but accounted for little excess risk in African American men. Compared with their white counterparts, African American men and women had higher blood pressures before diabetes onset (diastolic blood pressure difference=5.6 mm Hg in women and 8.4 mm Hg in men; P=.005). Conclusions Our data indicate that compared with their white counterparts, middle-aged African Americans are at greater risk of developing type 2 diabetes and have higher blood pressure prior to development of diabetes. In women, almost 50% of this excess risk might be related to potentially modifiable factors.	Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA; Univ Mississippi, Med Ctr, Dept Prevent Med, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA	Johns Hopkins University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of Mississippi; University of Mississippi Medical Center; University of Mississippi; University of Mississippi Medical Center	Brancati, FL (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.	fbrancat@jhmi.edu		Szklo, Moyses/0000-0001-9433-6266	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055018, N01HC055016, N01HC055015] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01 HC55016, N01 HC55018, N01 HC55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1995, DIABETES AM; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BONHAM GS, 1985, AM J CLIN NUTR, V41, P776, DOI 10.1093/ajcn/41.4.776; Brancati FL, 1996, ANN EPIDEMIOL, V6, P67, DOI 10.1016/1047-2797(95)00095-X; BRESLOW NE, 1990, IARC PUBLICATION, V32, P76; Burke JP, 1999, ARCH INTERN MED, V159, P1450, DOI 10.1001/archinte.159.13.1450; COWIE CC, 1993, AM J EPIDEMIOL, V137, P719, DOI 10.1093/oxfordjournals.aje.a116732; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gavin JR, 1999, DIABETES CARE, V22, pS5; Gress TW, 2000, NEW ENGL J MED, V342, P905, DOI 10.1056/NEJM200003303421301; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; Kaufman JS, 1997, EPIDEMIOLOGY, V8, P621, DOI 10.1097/00001648-199710000-00002; Kenny S. J., 1995, DIABETES AM, P47; Lei HH, 1999, DIABETES, V48, P1868, DOI 10.2337/diabetes.48.9.1868; LIPTON RB, 1993, AM J EPIDEMIOL, V138, P826, DOI 10.1093/oxfordjournals.aje.a116786; MCPHILLIPS JB, 1990, AM J EPIDEMIOL, V131, P443, DOI 10.1093/oxfordjournals.aje.a115519; MELTON LJ, 1983, DIABETES CARE, V6, P75, DOI 10.2337/diacare.6.1.75; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165; OBRIEN TR, 1989, JAMA-J AM MED ASSOC, V262, P1485, DOI 10.1001/jama.262.11.1485; Pavlik Valory N., 1996, Ethnicity and Disease, V6, P213; Ray NF, 1998, DIABETES CARE, V21, P296; Resnick HE, 1998, DIABETES CARE, V21, P1828, DOI 10.2337/diacare.21.11.1828; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; Schmidt MI, 1996, DIABETES CARE, V19, P414, DOI 10.2337/diacare.19.5.414; SHATEN BJ, 1993, DIABETES CARE, V16, P1331, DOI 10.2337/diacare.16.10.1331; SIEDEL J, 1983, CLIN CHEM, V29, P1075; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stern MP, 1996, ANN INTERN MED, V124, P110, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00006; TULL ES, 1995, DIABETES AM, P613; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *UK PROSP DIAB STU, 1999, BMJ-BRIT MED J, V318, P291; WARNICK GR, 1982, CLIN CHEM, V28, P1574; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184	36	385	386	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2253	2259		10.1001/jama.283.17.2253	http://dx.doi.org/10.1001/jama.283.17.2253			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807384	Bronze			2022-12-28	WOS:000086671600032
J	Grady, D; Wenger, NK; Herrington, D; Khan, S; Furberg, C; Hunninghake, D; Vittinghoff, E; Hulley, S				Grady, D; Wenger, NK; Herrington, D; Khan, S; Furberg, C; Hunninghake, D; Vittinghoff, E; Hulley, S		Heart Estrogen Progestin Replacem	Postmenopausal hormone therapy increases risk for venous thromboembolic disease - The heart and estrogen/progestin replacement study	ANNALS OF INTERNAL MEDICINE			English	Article						estrogen replacement therapy; venous thrombosis; thrombophlebitis; thromboembolism; progestin	ORAL-CONTRACEPTIVES; PULMONARY-EMBOLISM; VASCULAR-DISEASE; RANDOMIZED TRIAL; BREAST-CANCER; WOMEN; ESTROGEN; THROMBOSIS; PREVENTION; POPULATION	Background: Oral contraceptive use increases risk for venous thromboembolism, but data on the effect of postmenopausal hormone therapy are limited. Objective: To determine the effect of therapy with estrogen plus progestin on risk for venous thromboembolic events in postmenopausal women. Design: Randomized, double-blind, placebo-controlled trial. Setting: 20 clinical centers in the United States. Participants: 2763 postmenopausal women younger than 80 years of age (mean age, 67 years) who had coronary heart disease but no previous Venous thromboembolism and had not had a hysterectomy. Intervention: Conjugated equine estrogens, 0.625 mg, plus medroxyprogesterone acetate, 2.5 mg, in one tablet (n = 1380) or placebo that was identical in appearance (n = 1383). Measurements: Documented deep venous thrombosis or pulmonary embolism. Results: During an average of 4.1 years of follow-up, 34 women in the hormone therapy group and 13 in the placebo group experienced Venous thromboembolic events (relative hazard, 2.7 [95% CI, 1.4 to 5.0] [P = 0.003]; excess risk, 3.9 per 1000 woman-years [CI, 1.4 to 6.4 per 1000 woman-years]; number needed to treat for harm, 256 [CI, 157 to 692]). In multivariate analysis, the risk for venous thromboembolism was increased among women who had lower-extremity fractures (relative hazard, 18.1 [CI, 5.4 to 60.4]) or cancer (relative hazard, 3.9 [Cl, 1.6 to 9.4]) and for 90 days after inpatient surgery (relative hazard, 4.9 [CI, 2.4 to 9.8]) or nonsurgical hospitalization (relative hazard, 5.7 [Ct, 3.0 to 10.8]). Risk was decreased with aspirin (relative hazard, 0.5 [CI, 0.2 to 0.8]) or statin use (relative hazard, 0.5 [CI, 0.2 to 0.9]). Conclusions: Postmenopausal therapy with estrogen plus progestin increases risk for venous thromboembolism in women with coronary heart disease. This risk should be considered when the risks and benefits of therapy are being weighed.	Univ Calif San Francisco, San Francisco, CA 94105 USA; Emory Univ, Sch Med, Atlanta, GA USA; Wake Forest Univ, Sch Med, Winston Salem, NC USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Minnesota, Minneapolis, MN USA	University of California System; University of California San Francisco; Emory University; Wake Forest University; Cedars Sinai Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Grady, D (corresponding author), Univ Calif San Francisco, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.	bhudson@mail.acponline.org						[Anonymous], 1997, ARCH INTERN MED, V157, P1237; [Anonymous], 1974, NEW ENGL J MED, V290, P15; Carr BR, 1997, CONTRACEPTION, V55, P267, DOI 10.1016/S0010-7824(97)00029-2; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; Grady D, 1997, JAMA-J AM MED ASSOC, V278, P477, DOI 10.1001/jama.1997.03550060053030; Grady D, 1998, CONTROL CLIN TRIALS, V19, P314, DOI 10.1016/S0197-2456(98)00010-5; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; MAYER J, 1992, ANN HEMATOL, V64, P196, DOI 10.1007/BF01696223; Meilahn E N, 1992, Ann Epidemiol, V2, P445; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POULTER NR, 1995, LANCET, V346, P1575; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; Wilkes HC, 1996, BRIT MED J, V312, P473	28	555	563	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					689	+		10.7326/0003-4819-132-9-200005020-00002	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308VT	10787361				2022-12-28	WOS:000086734100001
J	Bauchner, H; Wise, PH				Bauchner, H; Wise, PH			Antibiotics without prescription: "bacterial or medical resistance"?	LANCET			English	Editorial Material									Boston Univ, Boston Med Ctr, Sch Med, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Boston Med Ctr, Sch Med, Dept Publ Hlth, Boston, MA 02118 USA	Boston Medical Center; Boston University; Boston Medical Center; Boston University	Bauchner, H (corresponding author), Boston Univ, Boston Med Ctr, Sch Med, Dept Pediat, Boston, MA 02118 USA.			Bauchner, Howard/0000-0002-8368-9805				BAUCHNER H, 2000, PED AC SOC M MAY BOS, pA173; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Holman H, 2000, BRIT MED J, V320, P526, DOI 10.1136/bmj.320.7234.526; Lee AJ, 1997, MED CARE, V35, P1173, DOI 10.1097/00005650-199712000-00002; Reeves DS, 1999, J ANTIMICROB CHEMOTH, V44, P163, DOI 10.1093/jac/44.2.163; Watson RL, 1999, PEDIATRICS, V104, P1251, DOI 10.1542/peds.104.6.1251; Wood MJ, 1999, J ANTIMICROB CHEMOTH, V44, P149, DOI 10.1093/jac/44.2.149	7	23	23	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1480	1480		10.1016/S0140-6736(00)02160-7	http://dx.doi.org/10.1016/S0140-6736(00)02160-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801167				2022-12-28	WOS:000086830100007
J	Holdstock, D; Waterston, L				Holdstock, D; Waterston, L			Nuclear weapons, a continuing threat to health	LANCET			English	Editorial Material							RADIATION; WORKERS; CANCER	32 000 nuclear weapons, with a destructive force equivalent to several thousand megatons of conventional explosive, are still deployed. The risk of nuclear war by accident may have increased and new threats include war between newly declared nuclear-weapon-states and the construction by terrorist groups of crude but effective devices. Health workers have drawn attention in the past to the likely major health consequences of the use of nuclear weapons. An opportunity for their global elimination under a nuclear weapons convention arises with the current review conference in New York of the nuclear Non-Proliferation Treaty-a crucial event for efforts to bring about a world free of nuclear weapons.	Medact, London N19 4DJ, England		Holdstock, D (corresponding author), Medact, 601 Holloway Rd, London N19 4DJ, England.	info@medact.org						ALLBRIGHT D, 1997, PLUTONIUM HIGHLY ENR; [Anonymous], 1977, EFFECTS NUCL WEAPONS; Barnaby F, 1997, Med Confl Surviv, V13, P195, DOI 10.1080/13623699708409339; BITHELL JF, 1994, BRIT MED J, V309, P501, DOI 10.1136/bmj.309.6953.501; CHIVIAN E, 1981, LAST AID MED DIMENSI; Clarke R. H., 1996, Journal of Radiological Protection, V16, P91, DOI 10.1088/0952-4746/16/2/005; COCHRAN TB, 1998, NUCL WEAPONS ROAD ZE, P157; *COMM MED ASP RAD, 1996, 4 REP INC CANC LEUK; *COMM MED ASP RAD, 1986, 1 REP IMPL NEW DAT R; Datan Merav, 1999, SECURITY SURVIVAL CA; DEVRIES P, 1997, MORUROA US; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; Draper GJ, 1997, BRIT MED J, V315, P1181, DOI 10.1136/bmj.315.7117.1181; FETTER S, 1998, NUCL WEAPONS ROAD ZE, P71; Forrow L, 1998, NEW ENGL J MED, V338, P1326, DOI 10.1056/NEJM199804303381824; Forrow L, 1998, JAMA-J AM MED ASSOC, V280, P456, DOI 10.1001/jama.280.5.456; GODLEE F, 1992, BRIT MED J, V304, P299, DOI 10.1136/bmj.304.6822.299; Gorbachev M., 1987, PERESTROIKA NEW THIN, P154; *INT PHYS PREV NUC, 1996, CRUD NUCL WEAP PROL; International Court of Justice (ICJ), 1996, ADVISORY OPINION INT; *JOINT NORW RUSS E, 1997, SOURC CONTR CONT TEC; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; Lord BI, 1998, BRIT J CANCER, V78, P301, DOI 10.1038/bjc.1998.491; Lown B, 1998, JAMA-J AM MED ASSOC, V280, P467, DOI 10.1001/jama.280.5.467; MACKENZIE D, 1996, MED CONFL SURV, V12, P202; MAKHIJANI A, 1995, NUCL WASTELANDS; MARK JC, 1990, REACTOR GRADE PLUTON; *NCI, 1997, STUD EST THYR DOS I1; Norris RS, 2000, B ATOM SCI, V56, P79, DOI 10.2968/056002019; *OFF TECHN ASS, 1980, C US EFF NUCL WAR; Omar RZ, 1999, BRIT J CANCER, V79, P1288, DOI 10.1038/sj.bjc.6690207; PITTOCK AB, 1985, ENV CONSEQUENCES NUC; ROFF SR, 1997, MED CONFL SURVIV S1, V13, P1; ROTBLAT J, 1981, NUCL RAD WARFARE; ROTBLAT J, 1983, EFFECTS NUCL WAR HLT, P26; SMITH J, 1981, BMJ-BRIT MED J, V283, P844, DOI 10.1136/bmj.283.6295.844; SMITH J, 1981, BRIT MED J, V283, P963, DOI 10.1136/bmj.283.6297.963; SMITH J, 1981, BRIT MED J, V283, P771, DOI 10.1136/bmj.283.6294.771; SMITH J, 1981, BMJ-BRIT MED J, V2583, P907; *SPEC STUD SECT, 1962, NEW ENGL J MED, V266, P1126; STEPHENS W, 1990, JAMA-J AM MED ASSOC, V264, P585; Sumner D., 1994, RAD RISKS EVALUATION; *WHO, 1987, 3628 WHO WHA MAN GRO	43	9	10	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2000	355	9214					1544	1547		10.1016/S0140-6736(00)02176-0	http://dx.doi.org/10.1016/S0140-6736(00)02176-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801188				2022-12-28	WOS:000086830100042
J	Nadruz, W; Carvalheira, JBC; Brenelli, SL				Nadruz, W; Carvalheira, JBC; Brenelli, SL			A man with chronic facial swelling	LANCET			English	Article							ANGIOEDEMA		State Univ Campinas, Sch Med Sci, Dept Internal Med, BR-13081970 Campinas, SP, Brazil	Universidade Estadual de Campinas	Nadruz, W (corresponding author), State Univ Campinas, Sch Med Sci, Dept Internal Med, BR-13081970 Campinas, SP, Brazil.		Nadruz, Wilson/I-3643-2013; Carvalheira, Jose Barreto Campello/E-8562-2013; Carvalheira, Jose B/H-8405-2012	Nadruz, Wilson/0000-0002-0003-5102; Carvalheira, Jose Barreto Campello/0000-0002-0136-0943; 				COHEN MD, 1982, J RHEUMATOL, V9, P325; HUSTON DP, 1992, MED CLIN N AM, V76, P805, DOI 10.1016/S0025-7125(16)30327-3; INVERNIZZI F, 1986, RES CLIN LAB, V16, P269; Khan NA, 1996, J LARYNGOL OTOL, V110, P578, DOI 10.1017/S0022215100134310; MARGO CE, 1992, AM J OPHTHALMOL, V113, P691, DOI 10.1016/S0002-9394(14)74796-8	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1516	1516		10.1016/S0140-6736(00)02167-X	http://dx.doi.org/10.1016/S0140-6736(00)02167-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801174				2022-12-28	WOS:000086830100014
J	Dawson, VL				Dawson, VL			Neurobiology - Of flies and mice	SCIENCE			English	Editorial Material							PARKINSONS-DISEASE		Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA	Johns Hopkins University	Dawson, VL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, 600 N Wolfe St Carnegie 214, Baltimore, MD 21287 USA.		Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970				Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mizuno Y, 1999, BIOMED PHARMACOTHER, V53, P109, DOI 10.1016/S0753-3322(99)80075-4; Orr HT, 2000, CELL, V101, P1, DOI 10.1016/S0092-8674(00)80617-0; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432	9	13	14	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					631	632		10.1126/science.288.5466.631	http://dx.doi.org/10.1126/science.288.5466.631			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10799001				2022-12-28	WOS:000086727100033
J	Gullison, RE; Rice, RE; Blundell, AG				Gullison, RE; Rice, RE; Blundell, AG			'Marketing' species conservation	NATURE			English	Editorial Material									Univ British Columbia, Ctr Biodivers, Vancouver, BC V6T 1Z4, Canada; Conservat Int, Ctr Appl Biodivers Sci, Washington, DC 20037 USA; US EPA, Natl Ctr Environm Assessment, Washington, DC 20460 USA	University of British Columbia; Conservation International; United States Environmental Protection Agency	Gullison, RE (corresponding author), Univ British Columbia, Ctr Biodivers, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.							Bowles IA, 1998, SCIENCE, V280, P1899, DOI 10.1126/science.280.5371.1899; Lamb FB., 1966, MAHOGANY TROPICAL AM; PEARCE D, 2000, 9915 CSERGE GEC U CO; RODAN BD, 1992, ENVIRON CONSERV, V19, P331, DOI 10.1017/S0376892900031453; SCHWARTZMAN S, 1997, GLOBAL DEFORESTATION	5	21	23	0	6	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					923	924		10.1038/35010151	http://dx.doi.org/10.1038/35010151			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801103				2022-12-28	WOS:000086762000021
J	Seo, JS; Whang, D; Lee, H; Jun, SI; Oh, J; Jeon, YJ; Kim, K				Seo, JS; Whang, D; Lee, H; Jun, SI; Oh, J; Jeon, YJ; Kim, K			A homochiral metal-organic porous material for enantioselective separation and catalysis	NATURE			English	Article							HYDROGEN-BONDED NETWORKS; FRAMEWORK; SOLIDS; CHEMISTRY; CHANNELS; ANALOGS	Inorganic zeolites are used for many practical applications that exploit the microporosity intrinsic to their crystal structures. Organic analogues, which are assembled from modular organic building blocks linked through non-covalent interactions, are of interest for similar applications. These range from catalysis, separation and sensor technology to optoelectronics(1-3), with enantioselective separation and catalysis being especially important for the chemical and pharmaceutical industries. The modular construction of these analogues allows flexible and rational design, as both the architecture and chemical functionality of the micropores can, in principle, be precisely controlled. Porous organic solids with large voids and high framework stability have been produced(14,15), and investigations into the range of accessible pore functionalities have been initiated(7,11,12,16-23). For example, catalytically active organic zeolite analogues are known(13,22,23), as are chiral metal-organic open-framework materials. However, the latter are only available as racemic mixtures(24,25), or lack the degree of framework stability or void space that is required for practical applications(26,27). Here we report the synthesis of a homochiral metal-organic porous material that allows the enantioselective inclusion of metal complexes in its pores and catalyses a transesterification reaction in an enantioselective manner. Our synthesis strategy, which uses enantiopure metal-organic clusters as secondary building blocks(14), should be readily applicable to chemically modified cluster components and thus provide access to a wide range of porous organic materials suitable for enantioselective separation and catalysis.	Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Smart Supramol, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Dept Chem, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Kim, K (corresponding author), Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Smart Supramol, San 31 Hyojadong, Pohang 790784, South Korea.		Kim, Kimoon/B-7181-2008; Whang, Dongmok/C-7016-2013; Seo, Jeong-Sun/J-2763-2012	Lee, Hyoyoung/0000-0002-8031-0791; Whang, Dongmok/0000-0001-9449-0597				ABRAHAMS BF, 1994, NATURE, V369, P727, DOI 10.1038/369727a0; Aoyama Y, 1996, J AM CHEM SOC, V118, P5562, DOI 10.1021/ja953600k; Aoyama Y, 1998, TOP CURR CHEM, V198, P131; Biradha K, 1999, ANGEW CHEM INT EDIT, V38, P492, DOI 10.1002/(SICI)1521-3773(19990215)38:4<492::AID-ANIE492>3.0.CO;2-#; Brunet P, 1997, J AM CHEM SOC, V119, P2737, DOI 10.1021/ja963905e; Chui SSY, 1999, SCIENCE, V283, P1148, DOI 10.1126/science.283.5405.1148; DECURTINS S, 1994, J AM CHEM SOC, V116, P9521, DOI 10.1021/ja00100a016; Endo K, 1997, J AM CHEM SOC, V119, P4117, DOI 10.1021/ja964198s; FUJITA M, 1994, J AM CHEM SOC, V116, P1151, DOI 10.1021/ja00082a055; Gardner GB, 1996, J AM CHEM SOC, V118, P6946, DOI 10.1021/ja960595r; GARDNER GB, 1995, NATURE, V374, P792, DOI 10.1038/374792a0; HATHAWAY BJ, 1987, COMPREHENSIVE COORDI, V2, P439; Heo J, 1999, ANGEW CHEM INT EDIT, V38, P641, DOI 10.1002/(SICI)1521-3773(19990301)38:5<641::AID-ANIE641>3.0.CO;2-O; Janiak C, 1997, ANGEW CHEM INT EDIT, V36, P1431, DOI 10.1002/anie.199714311; Kiang YH, 1999, J AM CHEM SOC, V121, P8204, DOI 10.1021/ja991100b; Kitagawa S, 1998, B CHEM SOC JPN, V71, P1739, DOI 10.1246/bcsj.71.1739; Kondo M, 1997, ANGEW CHEM INT EDIT, V36, P1725, DOI 10.1002/anie.199717251; Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248; Li HL, 1998, J AM CHEM SOC, V120, P2186, DOI 10.1021/ja974172g; Lin KJ, 1999, ANGEW CHEM INT EDIT, V38, P2730, DOI 10.1002/(SICI)1521-3773(19990917)38:18<2730::AID-ANIE2730>3.3.CO;2-0; NORMAN RE, 1987, J CHEM SOC DALTON, P2905, DOI 10.1039/dt9870002905; Ranford JD, 1998, ANGEW CHEM INT EDIT, V37, P1114, DOI 10.1002/(SICI)1521-3773(19980504)37:8<1114::AID-ANIE1114>3.0.CO;2-E; Reineke TM, 1999, J AM CHEM SOC, V121, P1651, DOI 10.1021/ja983577d; Russell VA, 1997, SCIENCE, V276, P575, DOI 10.1126/science.276.5312.575; Sawaki T, 1999, J AM CHEM SOC, V121, P4793, DOI 10.1021/ja9900407; SUBRAMANIAN S, 1995, ANGEW CHEM INT EDIT, V34, P2127, DOI 10.1002/anie.199521271; Yaghi OM, 1998, ACCOUNTS CHEM RES, V31, P474, DOI 10.1021/ar970151f; YAGHI OM, 1995, NATURE, V378, P703, DOI 10.1038/378703a0	28	3627	3726	39	1628	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					982	986		10.1038/35010088	http://dx.doi.org/10.1038/35010088			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801124				2022-12-28	WOS:000086762000052
J	Delbanco, T; Hartman, EE				Delbanco, T; Hartman, EE			A 69-year-old man with anger and angina, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Williams RB, 1999, JAMA-J AM MED ASSOC, V282, P763, DOI 10.1001/jama.282.8.763	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2151	2151		10.1001/jama.283.16.2151	http://dx.doi.org/10.1001/jama.283.16.2151			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791508				2022-12-28	WOS:000086542800032
J	Lugg, DJ				Lugg, DJ			Antarctic medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CELL-MEDIATED-IMMUNITY; BLOOD-PRESSURE; EXPEDITION		Australian Antarctic Div, Kingston, Tas 7050, Australia	Australian Antarctic Division	Lugg, DJ (corresponding author), Australian Antarctic Div, Channel Highway, Kingston, Tas 7050, Australia.	des.lugg@antdiv.gov.au						Cattermole TJ, 1999, INJURY, V30, P491, DOI 10.1016/S0020-1383(99)00139-4; Cattermole TJ, 1999, AVIAT SPACE ENVIR MD, V70, P135; COOK FA, 1990, 1 ANTARCTIC NIGHT 18; Cugini P, 1997, AVIAT SPACE ENVIR MD, V68, P795; DEAKIN C, 1992, ANARE RES NOTES, V84, P1; EDHOLM OG, 1973, POLAR HUMAN BIOL; Farrace S, 1999, PHYSIOL BEHAV, V66, P613, DOI 10.1016/S0031-9384(98)00341-2; Gunderson E., 1974, ANTARCT RES SER, V22, P1; Ikegawa M, 1998, AVIAT SPACE ENVIR MD, V69, P452; JENNINGS GL, 1991, ANN MED, V23, P313, DOI 10.3109/07853899109148066; LEVINSON JM, 1998, SAFE PASSAGE QUESTIO; Lloyd RM, 1973, POLAR HUMAN BIOL, P71; LUGG DJ, 1998, PROBLEMS COLD WORK, P224; Lugg DJ., 1973, POLAR HUMAN BIOL, P93; LUGG DJ, 1997, P ANARE JUB SCI S JU; Lugg DJ, 1993, ANTARCTIC DIVISION, P12; MULLER HK, 1995, IMMUNOL CELL BIOL, V73, P316, DOI 10.1038/icb.1995.48; Palinkas LA, 1996, J NERV MENT DIS, V184, P530, DOI 10.1097/00005053-199609000-00003; PARDOE R, 1965, Med J Aust, V1, P344; Pitson GA, 1996, EUR J APPL PHYSIOL O, V72, P231, DOI 10.1007/BF00838644; PODKOLINSKI MT, 1979, MED J AUSTRALIA, V2, P275, DOI 10.5694/j.1326-5377.1979.tb125705.x; Reed H L, 1995, Arctic Med Res, V54 Suppl 2, P9; REED HL, 1990, J CLIN ENDOCR METAB, V70, P965, DOI 10.1210/jcem-70-4-965; ROBERTSTHOMSON PJ, 1985, J CLIN LAB IMMUNOL, V17, P115; SAVOUREY G, 1993, CR ACAD SCI III-VIE, V316, P607; Savourey G, 1996, EUR J APPL PHYSIOL O, V73, P237, DOI 10.1007/BF02425482; Sawhney RC, 1998, INT J BIOMETEOROL, V42, P51, DOI 10.1007/s004840050083; *SCAR, 1999, SCAR B, V135, P1; Sullivan P, 1991, Arctic Med Res, VSuppl, P502; SULLIVAN P, 1995, 25 INT C ENV SYST SA; Taylor A J, 1998, Int J Circumpolar Health, V57, P56; Tingate TR, 1997, IMMUNOL CELL BIOL, V75, P275, DOI 10.1038/icb.1997.42; WILLIAMS DL, 1986, J CLIN LAB IMMUNOL, V20, P43; Wood J, 1999, ENVIRON BEHAV, V31, P299, DOI 10.1177/00139169921972128; Yonei T, 1999, BONE, V24, P145, DOI 10.1016/S8756-3282(98)00162-8; Zerath E, 1999, EUR J APPL PHYSIOL, V79, P141, DOI 10.1007/s004210050487; [No title captured]	38	18	18	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2082	2084		10.1001/jama.283.16.2082	http://dx.doi.org/10.1001/jama.283.16.2082			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791487				2022-12-28	WOS:000086542800002
J	Moffatt, HK				Moffatt, HK			Euler's disk and its finite-time singularity - Air viscosity makes the rolling speed of a disk go up as its energy goes down.	NATURE			English	Article									Isaac Newton Inst Math Sci, Cambridge CB3 0EH, England	University of Cambridge	Moffatt, HK (corresponding author), Isaac Newton Inst Math Sci, 20 Clarkson Rd, Cambridge CB3 0EH, England.							Euler L, 1765, THEORIA MOTUS CORPOR; PARS LA, 1965, TREATISE ANAL DYNAMI	2	59	62	17	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					833	834		10.1038/35009017	http://dx.doi.org/10.1038/35009017			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786779				2022-12-28	WOS:000086625000031
J	Tans, SJ; Dekker, C				Tans, SJ; Dekker, C			Molecular transistors - Potential modulations along carbon nanotubes	NATURE			English	Article							SINGLE-WALL		Delft Univ Technol, Dept Appl Phys, NL-2628 CJ Delft, Netherlands; Delft Univ Technol, DIMES, NL-2628 CJ Delft, Netherlands	Delft University of Technology; Delft University of Technology	Tans, SJ (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.		Tans, Sander/AAS-2901-2020	Dekker, Cees/0000-0001-6273-071X				Ando T, 1998, J PHYS SOC JPN, V67, P1704, DOI 10.1143/JPSJ.67.1704; Antonov RD, 1999, PHYS REV LETT, V83, P3274, DOI 10.1103/PhysRevLett.83.3274; Bezryadin A, 1998, PHYS REV LETT, V80, P4036, DOI 10.1103/PhysRevLett.80.4036; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; McEuen PL, 1999, PHYS REV LETT, V83, P5098, DOI 10.1103/PhysRevLett.83.5098; Soh HT, 1999, APPL PHYS LETT, V75, P627, DOI 10.1063/1.124462; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	9	163	166	2	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					834	835		10.1038/35009026	http://dx.doi.org/10.1038/35009026			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786780				2022-12-28	WOS:000086625000032
J	Kitzman, H; Olds, DL; Sidora, K; Henderson, CR; Hanks, C; Cole, R; Luckey, DW; Bondy, J; Cole, K; Glazner, J				Kitzman, H; Olds, DL; Sidora, K; Henderson, CR; Hanks, C; Cole, R; Luckey, DW; Bondy, J; Cole, K; Glazner, J			Enduring effects of nurse home visitation on maternal life course - A 3-year follow-up of a randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTISOCIAL-BEHAVIOR; PROGRAM; WOMEN	Context A home visitation program using nurses to improve maternal and child outcomes had favorable results in a randomized trial with a primarily white, semirural population, Many of the short-term findings have been replicated with urban blacks, but whether the program will continue to demonstrate effectiveness after its conclusion is uncertain. Objective To determine the effectiveness of a prenatal and infancy home visitation program on the maternal life course of women in an urban environment 3 years after the program ended. Design and Setting Th ree-year follow-up of a randomized controlled trial of women seen consecutively between June 1990 and August 1991 at an obstetrical clinic in Memphis, Tenn, who were enrolled in a visitation program for 2 years after the birth of their first child. Participants A cohort of 743 women who were primarily black, were pregnant for less than 29 weeks, had no previous live births, and had at least 2 sociodemographic risk factors (unmarried, <12 years of education, or unemployed). Intervention An average of 7 (range, 0-18) home visits during pregnancy and 26 (range, 0-71) from birth to the child's second birthday. Main Outcome Measures Rate of subsequent pregnancy, mean interval between first and second birth, and mean number of months of welfare use. Results Compared with the control group, women who received home visits by nurses had fewer subsequent pregnancies (1.15 vs 1.34; P=.03), fewer closely spaced subsequent pregnancies (0.22 vs 0.32; P=.03), longer intervals between the birth of the first and second child (30.25 vs 26.60 months; P=.004), and fewer months of using Aid to Families with Dependent Children (32.55 vs 36.19; P=.01) and food stamps (41.57 vs 45.04; P=.005). Compared with the effect of the program while the program was in operation, the effect after it ended was essentially equal for Aid to Families with Dependent Children, greater for food stamps, greater for rates of closely spaced subsequent pregnancies, and smaller for rates of subsequent pregnancy overall. Conclusions We found enduring effects of a home visitation program on the lives of black women living in an urban setting. While these results were smaller in magnitude than those achieved in a previous trial with white women living in a semirural setting, the direction of the effects was consistent across the 2 studies.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80218 USA; Univ Rochester, Sch Nursing, Rochester, NY USA; Univ Rochester, Dept Pediat, Rochester, NY USA; Univ Rochester, Dept Psychiat, Rochester, NY USA; Univ Colorado, Dept Prevent Med & Biometr, Denver, CO 80202 USA; Cornell Univ, Dept Human Dev, New York, NY USA; Baylor Univ, Sch Nursing, Houston, TX 77030 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Rochester; University of Rochester; University of Rochester; University of Colorado System; University of Colorado Denver; Cornell University; Baylor University	Olds, DL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, 1825 Marion St,Suite 200, Denver, CO 80218 USA.			Kitzman, Harriet/0000-0001-9470-7979	NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001382] Funding Source: NIH RePORTER; NIMH NIH HHS [1-K05-MH01382-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AZ DEP EC SEC, 1997, HLTH FAM AR EV REP 1; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BRADY A, 1998, MASSACHUSETTS HLTH F; Duggan AK, 1999, FUTURE CHILD, V9, P66, DOI 10.2307/1602722; FURSTENBERG F, 1987, ADOLESCENT MOTHERS L; Gomby DS, 1999, FUTURE CHILD, V9, P4, DOI 10.2307/1602719; HENDERSON CR, 1982, BIOMETRICS, V38, P623, DOI 10.2307/2530044; KALLAN JE, 1997, SOC BIOL, V44, P3; Kitzman H, 1997, JAMA-J AM MED ASSOC, V278, P644, DOI 10.1001/jama.278.8.644; Maynard R, 1993, BREAKING CYCLE POVER; Nam CB, 1983, SOCIOECONOMIC APPROA; Olds D, 1997, J COMMUNITY PSYCHOL, V25, P9; Olds D, 1998, J COMMUNITY PSYCHOL, V26, P65; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; OLDS D, 1999, LONG TERM EFFECTS HO; OLDS DL, 1993, MED CARE, V31, P155, DOI 10.1097/00005650-199302000-00006; OLDS DL, 1988, AM J PUBLIC HEALTH, V78, P1436, DOI 10.2105/AJPH.78.11.1436; OLDS DL, 1994, PEDIATRICS, V93, P89; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; OLDS DL, 1986, PRENATAL EARLY INFAN; PEARLIN LI, 1967, J HLTH SOCIAL BEHAV, V19, P2; QUINT JC, 1997, NEW CHANCE FINAL REP; RAWLINGS JS, 1995, NEW ENGL J MED, V332, P69, DOI 10.1056/NEJM199501123320201; Shipley WC, 1940, J PSYCHOL, V9, P371, DOI 10.1080/00223980.1940.9917704; SOARES JF, 1983, COMMUN STAT-THEOR M, V12, P2017, DOI 10.1080/03610928308828586; St Pierre RG, 1999, FUTURE CHILD, V9, P134; STEBBINS H, 1998, IMPROVING SERVICES C; STPIERRE RG, 1995, NATL EVALUATION EVEN; TYGART CE, 1991, YOUTH SOC, V22, P5235; Ware JE, 1985, REFINEMENTS MEASUREM; Wilson R., 1987, TRULY DISADVANTAGED	31	143	145	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2000	283	15					1983	1989		10.1001/jama.283.15.1983	http://dx.doi.org/10.1001/jama.283.15.1983			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303RC	10789666	Bronze			2022-12-28	WOS:000086436600033
J	Zennou, V; Petit, C; Guetard, D; Nerhbass, U; Montagnier, L; Charneau, P				Zennou, V; Petit, C; Guetard, D; Nerhbass, U; Montagnier, L; Charneau, P			HIV-1 genome nuclear import is mediated by a central DNA flap	CELL			English	Article							TYPE-1 PREINTEGRATION COMPLEXES; VIRAL MATRIX PROTEIN; NONDIVIDING CELLS; MACROPHAGE INFECTION; LOCALIZATION SIGNAL; POLYPURINE TRACT; VIRUS-DNA; REPLICATION; PHOSPHORYLATION; INTEGRATION	HIV-1 and other lentiviruses have the unique property among retroviruses to replicate in nondividing cells. This property relies on the use of a nuclear import pathway enabling the viral DNA to cross the nuclear membrane of the host cell. In HIV-1 reverse transcription, a central strand displacement event consecutive to central initiation and termination of plus strand synthesis creates a plus strand overlap: the central DNA flap. We show here that the central DNA flap acts as a cia-determinant of HIV-1 DNA nuclear import. Wildtype viral linear DNA is almost entirely imported into the nucleus where it integrates or circularizes. In contrast, mutant viral DNA, which lacks the DNA flap, accumulates in infected cells as unintegrated linear DNA, at the vicinity of the nuclear membrane. Consistently, HIV-1 vectors devoid of DNA flap exhibit a strong defect of nuclear import, which can be corrected to wild-type levels by reinsertion of the DNA flap sequence.	Inst Pasteur, Unite Oncol Virale, F-75724 Paris 15, France; Inst Pasteur, Unite Biol Cellulaire Noyau, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Charneau, P (corresponding author), Inst Pasteur, Unite Oncol Virale, 25-28 Rue Dr Roux, F-75724 Paris 15, France.		CHARNEAU, Pierre/M-1565-2017	CHARNEAU, Pierre/0000-0003-1184-5773				BARBOSA P, 1994, AIDS RES HUM RETROV, V10, P53, DOI 10.1089/aid.1994.10.53; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; EMERMAN M, 1994, NATURE, V369, P108, DOI 10.1038/369108a0; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Freed EO, 1997, CELL, V88, P171, DOI 10.1016/S0092-8674(00)81836-X; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; FREED EO, 1994, NATURE, V369, P107, DOI 10.1038/369107b0; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gallop MA, 1997, CURR OPIN CHEM BIOL, V1, P94, DOI 10.1016/S1367-5931(97)80114-7; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Hagstrom JE, 1997, J CELL SCI, V110, P2323; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HARRIS JD, 1981, VIROLOGY, V113, P573, DOI 10.1016/0042-6822(81)90185-9; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUNGNES O, 1992, VIROLOGY, V190, P440, DOI 10.1016/0042-6822(92)91230-R; KARAGEORGOS L, 1993, AIDS RES HUM RETROV, V9, P817, DOI 10.1089/aid.1993.9.817; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Stetor SR, 1999, BIOCHEMISTRY-US, V38, P3656, DOI 10.1021/bi982764l; THORMAR H, 1963, VIROLOGY, V19, P273, DOI 10.1016/0042-6822(63)90064-3; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; Whittaker GR, 1998, VIROLOGY, V246, P1, DOI 10.1006/viro.1998.9165; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564	32	667	762	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 14	2000	101	2					173	185		10.1016/S0092-8674(00)80828-4	http://dx.doi.org/10.1016/S0092-8674(00)80828-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	305DP	10786833	Bronze			2022-12-28	WOS:000086524400004
J	Trieloff, M; Kunz, J; Clague, DA; Harrison, D; Allegre, CJ				Trieloff, M; Kunz, J; Clague, DA; Harrison, D; Allegre, CJ			The nature of pristine noble gases in mantle plumes	SCIENCE			English	Article							LOIHI SEAMOUNT; EARTHS MANTLE; ISOTOPIC VARIATIONS; POPPING ROCK; SOLAR ARGON; HELIUM; HAWAII; NEON; SYSTEMATICS; COMPONENT	High-precision noble gas data show that the Hawaiian and Icelandic mantle plume sources contain uniquely primitive neon that is composed of moderately nucleogenic neon-21 and a primordial component indistinguishable from the meteoritic occurrence of solar neon. This suggests that Earth's solar-type rare gas inventory was acquired during accretion from small planetesimals previously irradiated by solar wind from the early sun. However, nonradiogenic argon, krypton, and xenon isotopes derived from the mantle display nonsolar compositions and indicate an atmosphere-like fingerprint that is not due to recent subduction.	Univ Paris 07, Inst Phys Globe Paris, Lab Geochim & Cosmochim, F-75252 Paris 05, France; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Univ Manchester, Dept Earth Sci, Manchester M13 9PL, Lancs, England	UDICE-French Research Universities; Universite Paris Cite; Monterey Bay Aquarium Research Institute; University of Manchester	Trieloff, M (corresponding author), Univ Heidelberg, Inst Mineral, Neuenheimer Feld 236, D-69120 Heidelberg, Germany.							Allegre C.J., 1986, EARTH PLANET SC LETT, V81, P127; BENKERT JP, 1993, J GEOPHYS RES-PLANET, V98, P13147, DOI 10.1029/93JE01460; BLACK DC, 1972, GEOCHIM COSMOCHIM AC, V36, P347, DOI 10.1016/0016-7037(72)90028-2; Burnard P, 1997, SCIENCE, V276, P568, DOI 10.1126/science.276.5312.568; CLAGUE DA, 1988, J PETROL, V29, P1161, DOI 10.1093/petrology/29.6.1161; Goswami J. N., 1983, Journal of Geophysical Research, V88, P755, DOI 10.1029/JB088iS02p0A755; GOSWAMI JN, 1979, ICARUS, V10, P510; Harper CL, 1996, SCIENCE, V273, P1814, DOI 10.1126/science.273.5283.1814; Harrison D, 1999, EARTH PLANET SC LETT, V171, P199, DOI 10.1016/S0012-821X(99)00143-0; Hilton DR, 1998, CHEM GEOL, V149, P173, DOI 10.1016/S0009-2541(98)00044-8; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; HONDA M, 1991, NATURE, V349, P149, DOI 10.1038/349149a0; HUMAYUN M, 1995, GEOCHIM COSMOCHIM AC, V59, P2131, DOI 10.1016/0016-7037(95)00132-8; Kunz J, 1998, SCIENCE, V280, P877, DOI 10.1126/science.280.5365.877; Kunz J, 1999, NATURE, V399, P649, DOI 10.1038/21352; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P388, DOI 10.1016/0012-821X(83)90154-1; MAZOR E, 1970, GEOCHIM COSMOCHIM AC, V34, P781, DOI 10.1016/0016-7037(70)90031-1; Moreira M, 1998, SCIENCE, V279, P1178, DOI 10.1126/science.279.5354.1178; Niedermann S, 1997, GEOCHIM COSMOCHIM AC, V61, P2697, DOI 10.1016/S0016-7037(97)00102-6; OZIMA M, 1993, GEOCHEM J, V27, P185, DOI 10.2343/geochemj.27.185; OZIMA M, 1994, REV GEOPHYS, V32, P405, DOI 10.1029/94RG01875; Ozima M., 1983, NOBLE GAS GEOCHEMIST; PATTERSON DB, 1990, GEOPHYS RES LETT, V17, P705, DOI 10.1029/GL017i006p00705; Pepin RO, 1998, NATURE, V394, P664, DOI 10.1038/29272; PEPIN RO, 1991, ICARUS, V92, P2, DOI 10.1016/0019-1035(91)90036-S; PORCELLI D, 1995, GEOCHIM COSMOCHIM AC, V59, P4921, DOI 10.1016/0016-7037(95)00336-3; POREDA RJ, 1992, EARTH PLANET SC LETT, V113, P129, DOI 10.1016/0012-821X(92)90215-H; ROEDDER E, 1983, EARTH PLANET SC LETT, V66, P407; SARDA P, 1988, EARTH PLANET SC LETT, V91, P73, DOI 10.1016/0012-821X(88)90152-5; Scherer P, 2000, METEORIT PLANET SCI, V35, P145, DOI 10.1111/j.1945-5100.2000.tb01981.x; TURNER G, 1989, J GEOL SOC LONDON, V146, P147, DOI 10.1144/gsjgs.146.1.0147; Valbracht PJ, 1997, EARTH PLANET SC LETT, V150, P399, DOI 10.1016/S0012-821X(97)00094-0	32	232	242	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1036	1038		10.1126/science.288.5468.1036	http://dx.doi.org/10.1126/science.288.5468.1036			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807571				2022-12-28	WOS:000086988400033
J	Badr, MS; Zahn, BR				Badr, MS; Zahn, BR			Upper-airway resistance syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Vet Affairs Med Ctr, Detroit, MI 48201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Badr, MS (corresponding author), Vet Affairs Med Ctr, Detroit, MI 48201 USA.		badr, M.Safwan/L-5445-2014						0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1408	1408		10.1056/NEJM200005113421905	http://dx.doi.org/10.1056/NEJM200005113421905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312JR	10805826				2022-12-28	WOS:000086940600005
J	Rahel, FJ				Rahel, FJ			Homogenization of fish faunas across the United States	SCIENCE			English	Article							BIOLOGICAL INVASIONS; FRESH-WATER	Fish faunas across the continental United States have become more similar through time because of widespread introductions of a group of cosmopolitan species intended to enhance food and sport fisheries. On average, pairs of states have 15.4 more species in common now than before European settlement of North America. The 89 pairs of states that formerly had no species in common now share an average of 25.2 species. Introductions have played a Larger role than extirpations in homogenizing fish faunas. Western and New England states have received the most introductions, which is a reflection of the small number of native fishes in these areas considered desirable gamefish by settlers.	Univ Wyoming, Dept Zool & Physiol, Laramie, WY 82071 USA	University of Wyoming	Rahel, FJ (corresponding author), Univ Wyoming, Dept Zool & Physiol, Laramie, WY 82071 USA.		Ebersole, Joseph L/A-8371-2009					COURTENAY W R JR, 1990, Journal of the World Aquaculture Society, V21, P145, DOI 10.1111/j.1749-7345.1990.tb01017.x; Courtenay WR., 1996, BIODIVERSITY MANAGED, P239; Fuller PL, 1999, SPECIAL PUBLICATION, V27; Krebs C.J., 2014, ECOLOGICAL METHODOLO; LEE DS, 1980, PUBLICATION N CAROLI, P407; LEVER C, 1996, NATURALIZED FISH WOR; LITVAK MK, 1993, FISHERIES, V18, P6, DOI 10.1577/1548-8446(1993)018<0006:EOFBUI>2.0.CO;2; McKinney ML, 1999, TRENDS ECOL EVOL, V14, P450, DOI 10.1016/S0169-5347(99)01679-1; McMahon TE, 1996, FISHERIES, V21, P6, DOI 10.1577/1548-8446(1996)021<0006:WANP>2.0.CO;2; Minckley W.L., 1987, P93; Moyle PB, 1996, BIOL CONSERV, V78, P149, DOI 10.1016/0006-3207(96)00024-9; Rahel FJ, 1997, FISHERIES, V22, P8; Ricciardi A, 2000, TRENDS ECOL EVOL, V15, P62, DOI 10.1016/S0169-5347(99)01745-0; Vander Zanden MJ, 1999, NATURE, V401, P464, DOI 10.1038/46762; Vitousek PM, 1996, AM SCI, V84, P468; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494	16	515	537	3	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					854	856		10.1126/science.288.5467.854	http://dx.doi.org/10.1126/science.288.5467.854			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797007				2022-12-28	WOS:000086869600037
J	Conaway, JW; Conaway, RC				Conaway, JW; Conaway, RC			Structural biology - Light at the end of the channel	SCIENCE			English	Editorial Material							RNA-POLYMERASE-II		Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation	Conaway, JW (corresponding author), Oklahoma Med Res Fdn, Program Mol & Cell Biol, Howard Hughes Med Inst, 825 NE 13th St, Oklahoma City, OK 73104 USA.	conawayj@omrf.ouhsc.edu		Conaway, Joan/0000-0002-2786-0663				Conaway RC, 1997, PROG NUCLEIC ACID RE, V56, P327, DOI 10.1016/S0079-6603(08)61009-0; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Kornberg Roger D., 1999, Trends in Cell Biology, V9, pM46, DOI 10.1016/S0962-8924(99)01679-7; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Poglitsch CL, 1999, CELL, V98, P791, DOI 10.1016/S0092-8674(00)81513-5; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	9	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2000	288	5466					632	633		10.1126/science.288.5466.632	http://dx.doi.org/10.1126/science.288.5466.632			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10799002				2022-12-28	WOS:000086727100034
J	Cederstrom, B; Cahn, RN; Danielsson, M; Lundqvist, M; Nygren, DR				Cederstrom, B; Cahn, RN; Danielsson, M; Lundqvist, M; Nygren, DR			Focusing hard X-rays with old LPs	NATURE			English	Article							REFRACTIVE LENS		Royal Inst Technol, Dept Phys, SE-10405 Stockholm, Sweden; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Phys, Berkeley, CA 94720 USA	Royal Institute of Technology; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Cederstrom, B (corresponding author), Royal Inst Technol, Dept Phys, SE-10405 Stockholm, Sweden.			Danielsson, Mats/0000-0002-3039-9791				Lengeler B, 1998, J APPL PHYS, V84, P5855, DOI 10.1063/1.368899; MICHETTE AG, 1991, NATURE, V353, P510; Snigirev A, 1996, NATURE, V384, P49, DOI 10.1038/384049a0; SUEHIRO S, 1991, NATURE, V352, P385, DOI 10.1038/352385c0; YANG BX, 1993, NUCL INSTRUM METH A, V328, P578, DOI 10.1016/0168-9002(93)90678-B	5	70	76	0	12	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					951	951		10.1038/35010190	http://dx.doi.org/10.1038/35010190			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801113	Bronze			2022-12-28	WOS:000086762000041
J	Shah, R				Shah, R			Short-sighted move to close the 12-m telescope	NATURE			English	Letter									Univ Virginia, Dept Astron, Charlottesville, VA 22903 USA	University of Virginia	Shah, R (corresponding author), Univ Virginia, Dept Astron, 530 McCormick Rd, Charlottesville, VA 22903 USA.								0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					921	921		10.1038/35010141	http://dx.doi.org/10.1038/35010141			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801099	Bronze			2022-12-28	WOS:000086762000017
J	Hwang, SW				Hwang, SW			Mortality among men using homeless shelters in Toronto, Ontario	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	22nd Annual Meeting of the Society-of-General-Internal-Medicine	APR 29-MAY 01, 1999	SAN FRANCISCO, CALIFORNIA	Soc Gen Internal Med			NEW-YORK-CITY; HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; HEALTH-STATUS; LOS-ANGELES; INNER-CITY; TUBERCULOSIS INFECTION; DEATH CERTIFICATES; ADULT MORTALITY; URBAN HOMELESS	Context Homeless persons in US cities have high mortality rates. However, few comparison data exist for death rates among homeless persons in other developed countries. Objectives To compare mortality rates among men using homeless shelters and the general population in Toronto, Ontario, and to determine whether mortality rates differ significantly among men using homeless shelters in Canadian and US cities. Design Cohort study conducted from 1995 through 1997, with a mean follow-up of 2.6 years. Participants Men aged 18 years or older who used homeless shelters in Toronto in 1995 (n=8933). Main Outcome Measure Mortality rate ratios comparing age-specific mortality rates among men using homeless shelters in Toronto with those of men in the general population of Toronto and of men using homeless shelters in New York, NY; Boston, Mass; and Philadelphia, Pa. Results Men using homeless shelters in Toronto were more likely to die than men in the city's general population. Mortality rate ratios were 8.3 (95% confidence interval [CI], 4.4-15.6) for men aged 18 to 24 years, 3.7 (95% CI, 3.0-4.6) for men aged 25 to 44 years, and 2.3 (95% CI, 1.8-3.0) for men aged 45 to 64 years. In most cases, however, the risk of death was significantly lower for men using homeless shelters in Toronto than for those in US cities. For men aged 25 to 44 years using homeless shelters, mortality rate ratios were 0.52 (95% CI, 0.41-0.65) for Toronto compared with Boston and 0.61 (95% CI, 0.44-0.85) for Toronto compared with New York City. For men aged 35 to 54 years using homeless shelters, the mortality rate ratio was 0.42 (95% CI, 0.27-0.66) for Toronto compared with Philadelphia. Conclusions Mortality rates among men who use homeless shelters in Toronto, while higher than in the general population of Toronto, are much lower than mortality rates observed among men using homeless shelters in 3 major US cities. Further study is needed to identify the reasons for this disparity.	Univ Toronto, St Michaels Hosp, Inner City Hlth Res Unit, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Hwang, SW (corresponding author), Univ Toronto, St Michaels Hosp, Inner City Hlth Res Unit, 30 Bond St,Shuter Wing 2-026, Toronto, ON M5B 1W8, Canada.		Hwang, Stephen W./D-2297-2011; Hwang, Stephen W./GVR-7773-2022	Hwang, Stephen W./0000-0002-1276-1101; 				ALLEN DM, 1994, AIDS, V8, P1593, DOI 10.1097/00002030-199411000-00011; ALSTROM CH, 1975, BRIT J ADDICT, V70, P245; Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305; Barrow SM, 1999, AM J PUBLIC HEALTH, V89, P529, DOI 10.2105/AJPH.89.4.529; BASSUK EL, 1984, AM J PSYCHIAT, V141, P1546; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BRICKNER PW, 1986, ANN INTERN MED, V104, P405, DOI 10.7326/0003-4819-104-3-405; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUCHER HC, 1995, AM J PUBLIC HEALTH, V85, P1231, DOI 10.2105/AJPH.85.9.1231; BURT MR, 1989, AM HOMELESS NUMBERS; Chiasson MA, 1999, J ACQ IMMUN DEF SYND, V21, P59, DOI 10.1097/00126334-199905010-00008; *COMM HOM ASS PLAN, 1991, MMWR-MORBID MORTAL W, V40, P865; CONCATO J, 1994, ARCH INTERN MED, V154, P2069, DOI 10.1001/archinte.154.18.2069; ELVY A, 1985, HLTH CARE HOMELESS P, P223; FEIN O, 1995, J GEN INTERN MED, V10, P577, DOI 10.1007/BF02640369; FERENCHICK GS, 1991, AM J MED SCI, V301, P379, DOI 10.1097/00000441-199106000-00004; Fingerhut LA, 1998, JAMA-J AM MED ASSOC, V280, P423, DOI 10.1001/jama.280.5.423; FISCHER PJ, 1991, AM PSYCHOL, V46, P1115, DOI 10.1037/0003-066X.46.11.1115; FOLSOM AR, 1987, AM J EPIDEMIOL, V125, P1012, DOI 10.1093/oxfordjournals.aje.a114617; Fox JA., 1999, HOMICIDE TRENDS US; Gelberg L, 1997, AM J PUBLIC HEALTH, V87, P217, DOI 10.2105/AJPH.87.2.217; GELBERG L, 1993, MED CARE, V31, P757, DOI 10.1097/00005650-199309000-00001; GELBERG L, 1990, ARCH INTERN MED, V150, P2325, DOI 10.1001/archinte.150.11.2325; GELBERG L, 1992, J GEN INTERN MED, V7, P601, DOI 10.1007/BF02599198; Geronimus AT, 1996, NEW ENGL J MED, V335, P1552, DOI 10.1056/NEJM199611213352102; Gorey KM, 1997, AM J PUBLIC HEALTH, V87, P1156, DOI 10.2105/AJPH.87.7.1156; HALMAN MH, 1998, P 151 ANN M AM PSYCH; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; HIBBS JR, 1994, NEW ENGL J MED, V331, P304, DOI 10.1056/NEJM199408043310506; Hwang SW, 1997, ANN INTERN MED, V126, P625, DOI 10.7326/0003-4819-126-8-199704150-00007; Hwang SW, 1998, ARCH INTERN MED, V158, P1454, DOI 10.1001/archinte.158.13.1454; Katz SJ, 1996, AM J PUBLIC HEALTH, V86, P520, DOI 10.2105/AJPH.86.4.520; Kessler RC, 1997, NEW ENGL J MED, V336, P551, DOI 10.1056/NEJM199702203360806; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1085; KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1011; Kuhn R, 1998, AM J COMMUN PSYCHOL, V26, P207, DOI 10.1023/A:1022176402357; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; McDonough P, 1997, AM J PUBLIC HEALTH, V87, P1476, DOI 10.2105/AJPH.87.9.1476; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; PADGETT D, 1990, MED CARE, V28, P805, DOI 10.1097/00005650-199009000-00010; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; ROBERTSON MJ, 1986, AM J PUBLIC HEALTH, V76, P561, DOI 10.2105/AJPH.76.5.561; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P178; Singh GK, 1996, AM J PUBLIC HEALTH, V86, P560, DOI 10.2105/AJPH.86.4.560; Stark LR, 1992, HOMELESSNESS PREVENT, P151; *STAT CAN, 1999, CAN STAT AG STAND MO; SUSSER E, 1989, ARCH GEN PSYCHIAT, V46, P845; TANAKA M, 1991, INT J BIOMETEOROL, V34, P242, DOI 10.1007/BF01041837; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 1987, MMWR MORB MORTAL WKL, V36, P297; 1991, MMWR MORB MORTAL WKL, V40, P877	53	268	269	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2152	2157		10.1001/jama.283.16.2152	http://dx.doi.org/10.1001/jama.283.16.2152			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	305MA	10791509	Bronze			2022-12-28	WOS:000086542800033
J	Scheetz, A; Fry, ME				Scheetz, A; Fry, ME			The stories	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2000	283	15					1934	1934		10.1001/jama.283.15.1934	http://dx.doi.org/10.1001/jama.283.15.1934			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303RC	10789647				2022-12-28	WOS:000086436600001
J	Mook, HA; Dai, PC; Dogan, F; Hunt, RD				Mook, HA; Dai, PC; Dogan, F; Hunt, RD			One-dimensional nature of the magnetic fluctuations in YBa2Cu3O6.6	NATURE			English	Article							NEUTRON-SCATTERING; HUBBARD-MODEL; SUPERCONDUCTORS	There is increasing evidence that inhomogeneous distributions of charge and spin-so-called 'striped phases'-play an important role in determining the properties of the high-temperature superconductors. For example, recent neutron-scattering measurements on the YBa2Cu3O7-x family of materials show both spin and charge fluctuations that are consistent with the striped-phase picture. But the fluctuations associated with a striped phase are expected to be one-dimensional, whereas the magnetic fluctuations observed to date appear to display two-dimensional symmetry. We show here that this apparent two-dimensionality results from measurements on twinned crystals, and that similar measurements on substantially detwinned crystals of YBa2Cu3O6.6 reveal the one-dimensional character of the magnetic fluctuations, thus greatly strengthening the striped-phase interpretation. Moreover, our results also suggest that superconductivity originates in charge stripes that extend along the b crystal axis, where the superfluid density is found to be substantially larger than for the a direction.	Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA; Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Washington; University of Washington Seattle	Mook, HA (corresponding author), Oak Ridge Natl Lab, Oak Ridge, TN 37831 USA.	ham@ornl.gov	Dai, Pengcheng/C-9171-2012	Dai, Pengcheng/0000-0002-6088-3170				BASOV DN, 1995, PHYS REV LETT, V74, P598, DOI 10.1103/PhysRevLett.74.598; Brinckmann J, 1999, PHYS REV LETT, V82, P2915, DOI 10.1103/PhysRevLett.82.2915; CHEONG SW, 1991, PHYS REV LETT, V67, P1791, DOI 10.1103/PhysRevLett.67.1791; Dai PC, 1998, PHYS REV LETT, V80, P1738, DOI 10.1103/PhysRevLett.80.1738; EMERY VJ, 1994, PHYSICA C, V235, P189, DOI 10.1016/0921-4534(94)91345-5; Emery VJ, 1997, PHYS REV B, V56, P6120, DOI 10.1103/PhysRevB.56.6120; FONG HF, 1995, PHYS REV LETT, V75, P316, DOI 10.1103/PhysRevLett.75.316; Hardy W. N., 1996, Proceedings of the 10th Anniversary HTS Workshop on Physics, Materials and Applications, P223; KAO YJ, 1999, CONDMAT9908302; KIVELSON SA, 1994, STRONGLY CORRELATED ELECTRONIC MATERIALS - THE LOS ALAMOS SYMPOSIUM, 1993, P619; LINDEMER TB, 1989, J AM CERAM SOC, V72, P1775, DOI 10.1111/j.1151-2916.1989.tb05978.x; MASON TE, 1992, PHYS REV LETT, V68, P1414, DOI 10.1103/PhysRevLett.68.1414; MOOK HA, 1993, PHYS REV LETT, V70, P3490, DOI 10.1103/PhysRevLett.70.3490; Mook HA, 1999, NATURE, V401, P145, DOI 10.1038/43629; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; NORMAN MR, 1999, CONDMAT9912203; POILBLANC D, 1989, PHYS REV B, V39, P9749, DOI 10.1103/PhysRevB.39.9749; RANQUADA JM, 1998, PHYSICA B, V241; ROSSATMIGNOD J, 1991, PHYSICA C, V185, P86, DOI 10.1016/0921-4534(91)91955-4; SCHULZ HJ, 1989, J PHYS-PARIS, V50, P2833, DOI 10.1051/jphys:0198900500180283300; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; Wakimoto S, 2000, PHYS REV B, V61, P3699, DOI 10.1103/PhysRevB.61.3699; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391	24	212	215	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	2000	404	6779					729	731		10.1038/35008005	http://dx.doi.org/10.1038/35008005			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783878	Green Submitted			2022-12-28	WOS:000086523600041
J	Reits, EAJ; Vos, JC; Gromme, M; Neefjes, J				Reits, EAJ; Vos, JC; Gromme, M; Neefjes, J			The major substrates for TAP in vivo are derived from newly synthesized proteins	NATURE			English	Article							MHC CLASS-I; LATERAL MOBILITY; MEMBRANES; TRANSPORT; TRANSLOCATION; FLUORESCENCE; MOLECULES; SUBUNIT; DOMAIN; CELLS	The transporter associated with antigen processing (TAP) is a member of the family of ABC transporters that translocate a large variety of substrates across membranes(1). TAP transports peptides from the cytosol into the endoplasmic reticulum for binding to MHC class I molecules and for subsequent presentation to the immune system(2). Here we follow the lateral mobility of TAP in living cells. TAP's mobility increases when it is inactive and decreases when it translocates peptides. Because TAP activity is dependent on substrate, the mobility of TAP is used to monitor the intracellular peptide content in vivo. Comparison of the diffusion rates in peptide-free and peptide-saturated cells indicates that normally about one-third of all TAP molecules actively translocate peptides. However, during an acute influenza infection TAP becomes fully employed owing to the production and degradation of viral proteins. Furthermore, TAP activity depends on continuing protein translation. This implies that MHC class I molecules mainly sample peptides that originate from newly synthesized proteins, to ensure rapid presentation to the immune system.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Neefjes, J (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jneefjes@nki.nl	Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211; Vos, J. Chris/0000-0003-3737-9942				Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; DELEIJ L, 1985, CANCER RES, V45, P6024; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gromme M, 1997, EUR J IMMUNOL, V27, P898, DOI 10.1002/eji.1830270415; Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326; HAYDEN FG, 1990, ANTIVIR RES, V14, P25, DOI 10.1016/0166-3542(90)90063-D; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JOVIN TM, 1989, METHOD ENZYMOL, V172, P471; KRUG RM, 1989, INFLUENZA VIRUSES, P89; KWON G, 1994, CELL SIGNAL, V6, P663, DOI 10.1016/0898-6568(94)90049-3; Lehner PJ, 1998, CURR BIOL, V8, pR605, DOI 10.1016/S0960-9822(98)70387-2; LIVNEH E, 1986, J CELL BIOL, V103, P327, DOI 10.1083/jcb.103.2.327; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Neisig A, 1996, J IMMUNOL, V156, P3196; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; SCHLESSINGER J, 1976, P NATL ACAD SCI USA, V73, P2409, DOI 10.1073/pnas.73.7.2409; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; STAM NJ, 1986, J IMMUNOL, V137, P2299; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611	29	324	327	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	2000	404	6779					774	778		10.1038/35008103	http://dx.doi.org/10.1038/35008103			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783892				2022-12-28	WOS:000086523600055
J	Babiker, A; Darby, S; De Angelis, D; Kwart, D; Porter, K; Beral, V; Darbyshire, J; Day, N; Gill, N; Coutinho, R; Prins, M; van Benthem, B; Coutinho, R; Dabis, F; Marimoutou, C; Ruiz, I; Tusell, J; Altisent, C; Evatt, B; Jaffe, H; Kirk, O; Pedersen, C; Rosenberg, P; Goedert, J; Biggar, R; Melbye, M; Brettie, R; Downs, A; Hamouda, O; Touloumi, G; Karafoulidou, A; Katsarou, O; Donfield, S; Gomperts, E; Hilgartner, M; Hoots, K; Schoenbaum, E; Beral, V; Zangerle, R; Del Amo, J; Pezzotti, P; Rezza, G; Hutchinson, S; Day, N; De Angelis, D; Gore, S; Kingsley, L; Schrager, L; Rosenberg, P; Goedert, J; Melnick, S; Koblin, B; Eskild, A; Bruun, J; Sannes, M; Evans, B; Lepri, AC; Sabin, C; Buchbinder, S; Vittinghoff, E; Moss, A; Osmond, D; Winkelstein, W; Goldberg, D; Boufassa, F; Meyer, L; Egger, M; Francioli, P; Rickenbach, M; Cooper, D; Tindall, B; Sharkey, T; Vizzard, J; Kaldor, J; Cunningham, P; Vanhems, P; Vizzard, J; Kaldor, J; Learmont, J; Farewell, V; Berglund, O; Mosley, J; Operskalski, E; van den Berg, M; Metzger, D; Tobin, D; Woody, G; Rusnak, J; Hendrix, C; Garner, R; Hawkes, C; Renzullo, P; Garland, F; Darby, S; Ewart, D; Giangrande, P; Lee, C; Phillips, A; Spooner, R; Wilde, J; Winter, M; Babiker, A; Darbyshire, J; Evans, B; Gill, N; Johnson, A; Phillips, A; Porter, K; Lorenzo, JI; Schechter, M				Babiker, A; Darby, S; De Angelis, D; Kwart, D; Porter, K; Beral, V; Darbyshire, J; Day, N; Gill, N; Coutinho, R; Prins, M; van Benthem, B; Coutinho, R; Dabis, F; Marimoutou, C; Ruiz, I; Tusell, J; Altisent, C; Evatt, B; Jaffe, H; Kirk, O; Pedersen, C; Rosenberg, P; Goedert, J; Biggar, R; Melbye, M; Brettie, R; Downs, A; Hamouda, O; Touloumi, G; Karafoulidou, A; Katsarou, O; Donfield, S; Gomperts, E; Hilgartner, M; Hoots, K; Schoenbaum, E; Beral, V; Zangerle, R; Del Amo, J; Pezzotti, P; Rezza, G; Hutchinson, S; Day, N; De Angelis, D; Gore, S; Kingsley, L; Schrager, L; Rosenberg, P; Goedert, J; Melnick, S; Koblin, B; Eskild, A; Bruun, J; Sannes, M; Evans, B; Lepri, AC; Sabin, C; Buchbinder, S; Vittinghoff, E; Moss, A; Osmond, D; Winkelstein, W; Goldberg, D; Boufassa, F; Meyer, L; Egger, M; Francioli, P; Rickenbach, M; Cooper, D; Tindall, B; Sharkey, T; Vizzard, J; Kaldor, J; Cunningham, P; Vanhems, P; Vizzard, J; Kaldor, J; Learmont, J; Farewell, V; Berglund, O; Mosley, J; Operskalski, E; van den Berg, M; Metzger, D; Tobin, D; Woody, G; Rusnak, J; Hendrix, C; Garner, R; Hawkes, C; Renzullo, P; Garland, F; Darby, S; Ewart, D; Giangrande, P; Lee, C; Phillips, A; Spooner, R; Wilde, J; Winter, M; Babiker, A; Darbyshire, J; Evans, B; Gill, N; Johnson, A; Phillips, A; Porter, K; Lorenzo, JI; Schechter, M		Collaborative Grp AIDS Incubation	Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTING DRUG-USERS; HOMOSEXUAL MEN; HEPATITIS-C; DISEASE PROGRESSION; TYPE-1 INFECTION; NATURAL-HISTORY; AGE; HEMOPHILIA; SURVIVAL	Background We used data from Europe, North America, and Australia to assess the effect of exposure category on the AIDS incubation period and HIV-1 survival and whether the effect of age at seroconversion varies with exposure category and with time since seroconversion. Methods 38 studies of HIV-1-infected individuals whose dates of seroconversion could be reliably estimated were included in the analysis. Individual data on 13 030 HIV-1-infected individuals from 15 countries were collated, checked, and analysed centrally. We calculated estimates of mortality and AIDS incidence rates and estimated the proportions of individuals surviving and developing AIDS at each year after seroconversion from the numbers of observed deaths or cases of AIDS and the corresponding person-years at risk. Analyses were adjusted for age at seroconversion, time since seroconversion, and other factors as appropriate. Findings Mortality and AIDS incidence increased strongly with time since seroconversion and age at seroconversion. Median survival varied from 12.5 years (95% CI 12.1-12.9) for those aged 15-24 years at seroconversion to 7.9 years (7.4-8.5) for those aged 45-54 years at seroconversion, whereas for development of AIDS the corresponding values were 11.0 years (10.7-11.7) and 7.7 years (7.1-8.6). There was no appreciable effect of exposure category on survival. For AIDS incidence, the exposure category effect that we noted was explained by the high incidence of Kaposi's sarcoma in those infected through sex between men. We estimated that among people aged 25-29 years at seroconversion 90% (89-91) and 60% (57-62) survived to 5 years and 10 years, respectively, after seroconversion, whereas 13% (12-15) and 46% (44-49), respectively, developed AIDS (excluding Kaposi's sarcoma). Interpretation Before widespread use of highly-active antiretroviral therapy (before 1996), time since seroconversion and age at seroconversion were the major determinants of survival and development of AIDS in Europe, North America, and Australia.	Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford OX2 6HE, England; Amsterdam Cohort Study Drug Users, Amsterdam, Netherlands; Amsterdam Cohort Study Homosexual Men, Amsterdam, Netherlands; Barcelona Haemophillia Cohort, Barcelona, Spain; Ctr Dis Control & Prevent, Atlanta, GA USA; Copenhagen Cohort, Copenhagen, Denmark; Aquitaine Cohort, Aquitaine, France; Edinburgh City Hosp Cohort, Edinburgh, Midlothian, Scotland; European Ctr Epidemiol Monitoring AIDS, St Maurice, France; HERO Study, Birmingham, AL USA; Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford, England; Innsbruck AIDS Study, Innsbruck, Austria; Inst Salud Carlos III, Madrid, Spain; MRC BIAS, Edinburgh, Midlothian, Scotland; MRC, Biostat Unit, Cambridge CB2 2BW, England; NCI, Bethesda, MD 20892 USA; New York Blood Ctr, New York Prospect AIDS Study, New York, NY 10021 USA; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; Royal Free Hosp, Sch Med, London, England; San Francisco City Clin Cohort, San Francisco, CA USA; San Francisco Gen Hosp Cohort, San Francisco, CA USA; San Francisco Mens Hlth Study, San Francisco, CA USA; Scottish Ctr Infect & Environm Hlth, Glasgow, Lanark, Scotland; Swiss HIV Cohort Study, Lausanne, Switzerland; Sydney AIDS Prospect Study, Sydney, NSW, Australia; Sydney Primary HIV Infect Cohort, Sydney, NSW, Australia; Sydney Primary HIV Infect Working Party, Sydney, NSW, Australia; Sydney Red Cross Cohort, Sydney, NSW, Australia; Toronto Sexual Hlth Study, Toronto, ON, Canada; Univ Utrecht Hosp, Utrecht, Netherlands; Univ Penn, Risk Assessment Project, Philadelphia, PA 19104 USA; USAF, HIV Nat Hist Study, Washington, DC 20330 USA; USA, Data Syst Cohort, Washington, DC 20310 USA; USN, HIV Cohort, Washington, DC 20350 USA; Valencia Haemophilia Cohort, Valencia, Spain; Vancouver Lymphadenopathy AIDS Study, Vancouver, BC, Canada	Radcliffe Infirmary; University of Oxford; Centers for Disease Control & Prevention - USA; University of Oxford; Instituto de Salud Carlos III; MRC Biostatistics Unit; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York Blood Center; Public Health England; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; San Francisco General Hospital Medical Center; Utrecht University; Utrecht University Medical Center; University of Pennsylvania; United States Department of Defense; United States Air Force; United States Department of Defense; United States Navy	Beral, V (corresponding author), Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.		PEZZOTTI, PATRIZIO/C-6480-2016; DEL AMO VALERO, JULIA/M-7020-2015; Metzger, David/D-9499-2012; Sabin, Caroline/C-2464-2008; Kaldor, John M/D-4545-2011; Phillips, Andrew N/B-4427-2008; kirk, ole/ABB-4746-2021; DABIS, FRANCOIS/S-9298-2019; rezza, giovanni/D-4393-2016; Schechter, Mauro/AAG-7445-2020; Hendrix, Craig W/G-4182-2014	PEZZOTTI, PATRIZIO/0000-0002-0805-2927; DEL AMO VALERO, JULIA/0000-0002-3104-540X; Sabin, Caroline/0000-0001-5173-2760; Phillips, Andrew N/0000-0003-2384-4807; DABIS, FRANCOIS/0000-0002-1614-8857; rezza, giovanni/0000-0003-0268-6790; Hendrix, Craig W/0000-0002-5696-8665; Porter, Kholoud/0000-0002-9226-6206; Johnson, Anne/0000-0003-1330-7100				Altisent C, 1996, NEW ENGL J MED, V334, P1065, DOI 10.1056/NEJM199604183341616; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Beral V, 1998, AIDS, V12, P659; BIRD G, 1994, AIDS, V8, P911; Brettle RP, 1996, AIDS, V10, P419, DOI 10.1097/00002030-199604000-00011; Carre N, 1996, AIDS, V10, P77, DOI 10.1097/00002030-199601000-00011; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; Darby SC, 1996, LANCET, V347, P1573, DOI 10.1016/S0140-6736(96)91073-9; Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HESSOL NA, 1994, AM J EPIDEMIOL, V139, P1077, DOI 10.1093/oxfordjournals.aje.a116951; LONGINI IM, 1991, J ACQ IMMUN DEF SYND, V4, P1141; MARIOTTO AB, 1992, AM J EPIDEMIOL, V135, P428, DOI 10.1093/oxfordjournals.aje.a116303; *OFF POP CENS SURV, 1990, SER DH1, V24; OPERSKALSKI EA, 1995, J INFECT DIS, V172, P648, DOI 10.1093/infdis/172.3.648; Pehrson P, 1997, AIDS, V11, P1007, DOI 10.1097/00002030-199708000-00009; PHILLIPS AN, 1991, J ACQ IMMUN DEF SYND, V4, P970; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; SCHRADER EK, 1993, AIDS, V7, P1009; Touloumi G, 1998, AIDS, V12, P1691, DOI 10.1097/00002030-199813000-00018; VEUGELERS PJ, 1994, AM J EPIDEMIOL, V140, P747, DOI 10.1093/oxfordjournals.aje.a117322; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014; 1993, LANCET, V341, P441	26	329	339	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1131	1137						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791375				2022-12-28	WOS:000086380900010
J	Batchelor, T				Batchelor, T			Temozolomide for malignant brain tumours	LANCET			English	Editorial Material							GLIOMA; TRIAL		Massachusetts Gen Hosp, Brain Tumor Ctr, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Batchelor, T (corresponding author), Massachusetts Gen Hosp, Brain Tumor Ctr, Boston, MA 02114 USA.							Bower M, 1997, CANCER CHEMOTH PHARM, V40, P484, DOI 10.1007/s002800050691; Brock CS, 1998, CANCER RES, V58, P4363; *CENTR BRAIN TUM R, 1997, ANN REP; Friedman HS, 1998, J CLIN ONCOL, V16, P3851, DOI 10.1200/JCO.1998.16.12.3851; HARRAS E, 1996, CANC RATES RISKS; Newlands ES, 1996, EUR J CANCER, V32A, P2236, DOI 10.1016/S0959-8049(96)00258-4; Newlands ES, 1997, CANCER TREAT REV, V23, P35, DOI 10.1016/S0305-7372(97)90019-0; Schold SC, 2000, NEURO-ONCOLOGY, V2, P34, DOI 10.1093/neuonc/2.1.34; Wedge SR, 1996, BRIT J CANCER, V73, P1049, DOI 10.1038/bjc.1996.203; YUNG A, 1999, P AN M AM SOC CLIN, V18, pA139; Yung WKA, 1999, J CLIN ONCOL, V17, P2762, DOI 10.1200/JCO.1999.17.9.2762	11	24	25	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1115	1116		10.1016/S0140-6736(00)02055-9	http://dx.doi.org/10.1016/S0140-6736(00)02055-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791369				2022-12-28	WOS:000086380900004
J	Byford, S; Torgerson, DJ; Raftery, J				Byford, S; Torgerson, DJ; Raftery, J			Economic note - Cost of illness studies	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE		Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; Hlth Serv Management Ctr, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England	University of York - UK; University of Birmingham	Byford, S (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.		Torgerson, David/L-4566-2019; Byford, Sarah/D-1699-2010	Torgerson, David/0000-0002-1667-4275; Byford, Sarah/0000-0001-7084-1495				AMENT A, 1993, HEALTH POLICY, V26, P29, DOI 10.1016/0168-8510(93)90076-2; BEHRENS C, 1988, HEALTH POLICY, V10, P137, DOI 10.1016/0168-8510(88)90002-4; Murray C.J, 1994, GLOBAL COMP ASSESSME; RICE DP, 1994, LANCET, V344, P1519, DOI 10.1016/S0140-6736(94)90342-5; ROBINSON R, 1993, BRIT MED J, V307, P793, DOI 10.1136/bmj.307.6907.793; SHIELL A, 1987, HEALTH POLICY, V8, P317, DOI 10.1016/0168-8510(87)90007-8	6	187	192	1	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1335	1335		10.1136/bmj.320.7245.1335	http://dx.doi.org/10.1136/bmj.320.7245.1335			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807635	Green Published			2022-12-28	WOS:000087077400034
J	O'Reilly, DS				O'Reilly, DS			Thyroid function tests-time for a reassessment	BRITISH MEDICAL JOURNAL			English	Article							STIMULATING HORMONE; HYPOTHYROIDISM; DISEASE; SERUM; HYPERTHYROIDISM; ASSAY		Royal Infirm, Dept Clin Biochem & Clin Thyroid Dis, Glasgow G4 0SF, Lanark, Scotland	Royal Infirmary of Edinburgh	O'Reilly, DS (corresponding author), Royal Infirm, Dept Clin Biochem & Clin Thyroid Dis, Glasgow G4 0SF, Lanark, Scotland.							BECKETT G, 1998, CPD B CLIN BIOCH, V1, P9; BILLEWICZ WZ, 1969, Q J MED, V38, P255; CROOKS J, 1959, Q J MED, V28, P211; EKINS R, 1990, ENDOCR REV, V11, P5, DOI 10.1210/edrv-11-1-5; EVERED DC, 1973, BRIT MED J, V1, P657, DOI 10.1136/bmj.1.5854.657; GURNEY C, 1970, LANCET, V2, P1275; HALL R, 1971, BRIT MED J, V1, P582, DOI 10.1136/bmj.1.5749.582; HALL R, 1994, CLIN ENDOCRINOL, V17, P1; HEDLEY AJ, 1971, LANCET, V1, P455; KLEIN I, 1988, ARCH INTERN MED, V148, P387, DOI 10.1001/archinte.148.2.387; MCGREGOR AM, 1996, OXFORD TXB MED, P1603; MURRAY I P, 1964, Med J Aust, V1, P827; *NHS SCOTL, 1999, LAB STAT 1999; SETH J, 1984, BRIT MED J, V289, P1334, DOI 10.1136/bmj.289.6455.1334; Skinner GRB, 1997, BRIT MED J, V314, P1764, DOI 10.1136/bmj.314.7096.1764; SMALL M, 1990, CLIN ENDOCRINOL, V32, P185, DOI 10.1111/j.1365-2265.1990.tb00854.x; SPENCER C, 1987, CLIN CHEM, V33, P1391; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vanderpump MPJ, 1996, BMJ-BRIT MED J, V313, P539; WAYNE EJ, 1960, BRIT MED J, V78, P90; Weetman AP, 1997, BRIT MED J, V314, P1175, DOI 10.1136/bmj.314.7088.1175; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; WILKINSON E, 1993, CLIN CHEM, V39, P2166	24	22	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1332	1334		10.1136/bmj.320.7245.1332	http://dx.doi.org/10.1136/bmj.320.7245.1332			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807634	Green Published, Green Accepted			2022-12-28	WOS:000087077400033
J	Meibom, A; Desch, SJ; Krot, AN; Cuzzi, JN; Petaev, MI; Wilson, L; Keil, K				Meibom, A; Desch, SJ; Krot, AN; Cuzzi, JN; Petaev, MI; Wilson, L; Keil, K			Large-scale thermal events in the solar nebula: Evidence from Fe,Ni metal grains in primitive meteorites	SCIENCE			English	Article							ACCRETION DISKS; CARBONACEOUS CHONDRITES; TEMPERATURE; HISTORY	Chemical zoning patterns in some iron, nickel metal grains from CH carbonaceous chondrites imply formation at temperatures from 1370 to 1270 kelvin by condensation from a solar nebular gas cooling at a rare of similar to 0.2 kelvin per hour. This cooling rate requires a Large-scale thermal event in the nebula, in contrast to the localized, transient heating events inferred for chondrule formation. In our model, mass accretion through the protoplanetary disk caused Large-scale evaporation of precursor dust near its midplane inside of a few astronomical units. Gas convectively moved from the midplane to cooler regions above it, and the metal grains condensed in these parcels of rising gas.	Univ Hawaii Manoa, Sch Ocean & Earth Sci & Technol, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Lancaster, Inst Environm & Nat Sci, Dept Environm Sci, Lancaster LA1 4YQ, England; Univ Hawaii Manoa, Hawaii Ctr Volcanol, Honolulu, HI 96822 USA	University of Hawaii System; University of Hawaii Manoa; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Lancaster University; University of Hawaii System; University of Hawaii Manoa	Meibom, A (corresponding author), Stanford Univ, Dept Geol & Environm Sci, Bldg 320,Lomita Mall, Stanford, CA 94305 USA.			Meibom, Anders/0000-0002-4542-2819				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Bell KR, 1997, ASTROPHYS J, V486, P372, DOI 10.1086/304514; BOSS AP, 1993, ICARUS, V106, P168, DOI 10.1006/icar.1993.1164; CUZZI JN, 1996, CHONDRULES PROTOPLAN, P35; DEAN DC, 1986, METALL TRANS A, V17, P1131, DOI 10.1007/BF02665311; Grossman J.N., 1988, METEORITES EARLY SOL, P680; GROSSMAN L, 1974, GEOCHIM COSMOCHIM AC, V38, P173, DOI 10.1016/0016-7037(74)90202-6; GROSSMAN L, 1974, REV GEOPHYS, V12, P71, DOI 10.1029/RG012i001p00071; KELLY WR, 1977, GEOCHIM COSMOCHIM AC, V41, P93, DOI 10.1016/0016-7037(77)90190-9; Kippenhahn R., 1990, STELLAR STRUCTURE EV; Klahr HH, 1999, ASTROPHYS J, V514, P325, DOI 10.1086/306926; LARIMER JW, 1988, METEORITES EARLY SOL, P375; LEE MS, 1992, GEOCHIM COSMOCHIM AC, V56, P2521; LIDE DR, 1981, HDB CHEM PHYSICS; Lin D.N.C., 1985, PROTOSTARS PLANETS, VII, P981; Lofgren G., 1996, CHONDRULES PROTOPLAN, P187; MacPherson G.J., 1988, METEORITES EARLY SOL, P746; MCSWEEN HY, 1977, GEOCHIM COSMOCHIM AC, V41, P477, DOI 10.1016/0016-7037(77)90286-1; Meibom A, 1999, J GEOPHYS RES-PLANET, V104, P22053, DOI 10.1029/1999JE001052; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; ROZYCZKA M, 1994, ASTROPHYS J, V423, P736, DOI 10.1086/173853; SANDERS DE, 1991, SURF SCI, V254, P341, DOI 10.1016/0039-6028(91)90666-G; Scott E.R.D., 1996, CHONDRULES PROTOPLAN, P265; STOLPER E, 1986, GEOCHIM COSMOCHIM AC, V50, P1785, DOI 10.1016/0016-7037(86)90139-0; WEINBRUCH S, 1997, METEORIT PLANET SCI, V32, P138; Weisberg M. K., 1999, 24 S ANT MET 24 S ANT MET, P187; ZANDA B, 1991, LUNAR PLANET SCI, V22, P1543	27	67	68	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					839	841		10.1126/science.288.5467.839	http://dx.doi.org/10.1126/science.288.5467.839			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797001				2022-12-28	WOS:000086869600031
J	Yang, Y; Fang, SY; Jensen, JP; Weissman, AM; Ashwell, JD				Yang, Y; Fang, SY; Jensen, JP; Weissman, AM; Ashwell, JD			Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli	SCIENCE			English	Article							TUMOR-SUPPRESSOR PROTEIN; PROGRAMMED CELL-DEATH; BACULOVIRUS INHIBITOR; C-CBL; E3; FINGER; P53	To determine why proteasome inhibitors prevent thymocyte death, we examined whether proteasomes degrade anti-apoptotic molecules in cells induced to undergo apoptosis, The c-IAP1 and XIAP inhibitors of apoptosis were selectively lost in glucocorticoid- or etoposide-treated thymocytes in a proteasome-dependent manner before death. IAPs catalyzed their own ubiquitination in vitro, an activity requiring the RING domain. Overexpressed wild-type c-IAP1, but not a RING domain mutant, was spontaneously ubiquitinated and degraded, and stably expressed XIAP lacking the RING domain was relatively resistant to apoptosis-induced degradation and, correspondingly, more effective at preventing apoptosis than wild-type XIAP. Autoubiquitination and degradation of IAPs may be a key event in the apoptotic program.	NCI, Lab Immune Cell Biol, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ashwell, JD (corresponding author), NCI, Lab Immune Cell Biol, Div Basic Sci, NIH, Bethesda, MD 20892 USA.		Fang, Shengyun/H-3802-2011	Fang, Shengyun/0000-0001-7280-5463	DIVISION OF BASIC SCIENCES - NCI [Z01BC009290] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; ELBEN LJ, 1998, RESULTS PROBL CELL D, V24, P91; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Young SS, 1999, MAMM GENOME, V10, P44	23	828	859	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					874	877		10.1126/science.288.5467.874	http://dx.doi.org/10.1126/science.288.5467.874			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797013				2022-12-28	WOS:000086869600043
J	Paytan, A				Paytan, A			Earth history - Sulfate clues for the early history of atmospheric oxygen	SCIENCE			English	Editorial Material							SULFUR ISOTOPE ABUNDANCES; REDUCTION; EVOLUTION; OCEANS; CARBON; IRON		Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA	Stanford University	Paytan, A (corresponding author), Stanford Univ, Dept Geol & Environm Sci, Braun Gall,Bldg 320, Stanford, CA 94305 USA.	apaytan@pangea.stanford.edu						Aharon P, 2000, GEOCHIM COSMOCHIM AC, V64, P233, DOI 10.1016/S0016-7037(99)00292-6; BERNER RA, 1989, PALAEOGEOGR PALAEOCL, V75, P97, DOI DOI 10.1016/0031-0182(89)90186-7; BRIMBLECOMB P, 1989, SCOPE, V39; CAMERON EM, 1982, NATURE, V296, P145, DOI 10.1038/296145a0; Canfield DE, 2000, SCIENCE, V288, P658, DOI 10.1126/science.288.5466.658; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Carpenter SJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4831, DOI 10.1016/S0016-7037(97)00361-X; CHAMBERS LA, 1975, CAN J MICROBIOL, V21, P1602, DOI 10.1139/m75-234; DEMARAIS DJ, 1992, NATURE, V359, P605; GOODWIN AM, 1976, ECON GEOL, V71, P870, DOI 10.2113/gsecongeo.71.5.870; Habicht KS, 1996, NATURE, V382, P342, DOI 10.1038/382342a0; HATTORI K, 1983, NATURE, V302, P323, DOI 10.1038/302323a0; HATTORI K, 1983, SCIENCE, V221, P549, DOI 10.1126/science.221.4610.549; Hayes J.M., 1992, PROTEROZOIC BIOSPHER, P129; Holland HD., 1984, CHEM EVOLUTION ATMOS; Kakegawa T, 1998, GEOCHIM COSMOCHIM AC, V62, P3205, DOI 10.1016/S0016-7037(98)00229-4; KAPLAN IR, 1964, J GEN MICROBIOL, V34, P195, DOI 10.1099/00221287-34-2-195; KEMP ALW, 1968, GEOCHIM COSMOCHIM AC, V32, P71, DOI 10.1016/0016-7037(68)90088-4; LAMBERT IB, 1978, NATURE, V276, P808, DOI 10.1038/276808a0; LAMBERT IB, 1990, STABLE ISOTOPES FLUI, V23, P260; LASAGA AC, 1989, AM J SCI, V289, P411, DOI 10.2475/ajs.289.4.411; Miller S. L., 1974, ORIGINS LIFE EARTH; MONSTER J, 1979, GEOCHIM COSMOCHIM AC, V43, P405, DOI 10.1016/0016-7037(79)90205-9; OHMOTO H, 1993, SCIENCE, V262, P555, DOI 10.1126/science.11539502; OHMOTO H, 1987, NATURE, V328, P244, DOI 10.1038/328244a0; Ohmoto H, 1992, EARLY ORGANIC EVOLUT, P378, DOI DOI 10.1007/978-3-642-76884-2_29; SCHIDLOWSKI JM, 1983, EARTHS EARLIEST BIOS, P149; Schopf JW, 1983, EARTHS EARLIEST BIOS; SKYRING GW, 1982, PRECAMBRIAN RES, V17, P41, DOI 10.1016/0301-9268(82)90153-X; Strauss H, 1997, PALAEOGEOGR PALAEOCL, V132, P97, DOI 10.1016/S0031-0182(97)00067-9; Trudinger P.A., 1992, EARLY ORGANIC EVOLUT, P367; WALKER JCG, 1985, PRECAMBRIAN RES, V28, P205, DOI 10.1016/0301-9268(85)90031-2	32	10	10	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2000	288	5466					626	627		10.1126/science.288.5466.626	http://dx.doi.org/10.1126/science.288.5466.626			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10798999				2022-12-28	WOS:000086727100030
J	Cousineau, B; Lawrence, S; Smith, D; Belfort, M				Cousineau, B; Lawrence, S; Smith, D; Belfort, M			Retrotransposition of a bacterial group II intron	NATURE			English	Article							RIBOSOMAL-RNA; REVERSE-TRANSCRIPTASE; TRANSPOSITION; MOBILITY; RECOMBINATION; INTEGRATION; EVOLUTION; INVITRO; PIECES	Self-splicing group II introns may be the evolutionary progenitors of eukaryotic spliceosomal introns(1-7), but the route by which they invade new chromosomal sites is unknown. To address the mechanism by which group II introns are disseminated, we have studied the bacterial Ll.LtrB intron from Lactococcus lactis(8). The protein product of this intron, LtrA, possesses maturase, reverse transcriptase and endonuclease enzymatic activities(9-11). Together with the intron, LtrA forms a ribonucleoprotein (RNP) complex which mediates a process known as retrohoming(11). In retrohoming, the intron reverse splices into a cognate intronless DNA site. Integration of a DNA copy of the intron is recombinase independent but requires all three activities of LtrA(11). Here we report the first experimental demonstration of a group II intron invading ectopic chromosomal sites, which occurs by a distinct retrotransposition mechanism. This retrotransposition process is endonuclease-independent and recombinase-dependent, and is likely to involve reverse splicing of the intron RNA into cellular RNA targets. These retrotranspositions suggest a mechanism by which splicesomal introns may have become widely dispersed.	New York State Dept Hlth, Wadsworth Ctr, Mol Genet Program, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Belfort, M (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Mol Genet Program, POB 22002, Albany, NY 12201 USA.			Belfort, Marlene/0000-0002-1592-5618				AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BISWAS I, 1993, J BACTERIOL, V175, P3628, DOI 10.1128/JB.175.11.3628-3635.1993; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; Cousineau B, 1998, CELL, V94, P451, DOI 10.1016/S0092-8674(00)81586-X; Curcio MJ, 1996, CELL, V84, P9, DOI 10.1016/S0092-8674(00)80987-3; Eickbush TH, 1999, CURR BIOL, V9, pR11, DOI 10.1016/S0960-9822(99)80034-7; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; Hetzer M, 1997, NATURE, V386, P417, DOI 10.1038/386417a0; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; Matsuura M, 1997, GENE DEV, V11, P2910, DOI 10.1101/gad.11.21.2910; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Mills DA, 1997, J BACTERIOL, V179, P6107, DOI 10.1128/jb.179.19.6107-6111.1997; Mohr G, 2000, GENE DEV, V14, P559; MOHR G, 1991, NATURE, V354, P164, DOI 10.1038/354164a0; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; ROGER AJ, 1993, NATURE, V364, P289, DOI 10.1038/364289a0; ROMAN J, 1995, RNA, V1, P478; Roman J, 1999, RNA, V5, P1, DOI 10.1017/S1355838299981244; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; THOMPSON AJ, 1994, J MOL BIOL, V236, P455, DOI 10.1006/jmbi.1994.1157; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	29	111	114	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					1018	1021		10.1038/35010029	http://dx.doi.org/10.1038/35010029			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801134				2022-12-28	WOS:000086762000062
J	Levinson, P				Levinson, P			The enduring test - How long must you wait before proving your humanity?	NATURE			English	Article																			0	0	0	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					937	937		10.1038/35010187	http://dx.doi.org/10.1038/35010187			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801105	Bronze			2022-12-28	WOS:000086762000033
J	Schoonveld, WA; Wildeman, J; Fichou, D; Bobbert, PA; van Wees, BJ; Klapwijk, TM				Schoonveld, WA; Wildeman, J; Fichou, D; Bobbert, PA; van Wees, BJ; Klapwijk, TM			Coulomb-blockade transport in single-crystal organic thin-film transistors	NATURE			English	Article							FIELD-EFFECT TRANSISTORS; TUNNEL-JUNCTIONS; CHARGE-TRANSPORT; EFFECT MOBILITY; SEXITHIOPHENE; ARRAYS	Coulomb-blockade transport-whereby the Coulomb interaction between electrons can prohibit their transport around a circuit-occurs in systems in which both the tunnel resistance, R-T, between neighbouring sites is large (much greater than h/e(2)) and the charging energy, E-C (E-C = e(2)/2C, where C is the capacitance of the site), of an excess electron on a site is large compared to kT. (Here e is the charge of an electron, k is Boltzmann's constant, and h is Planck's constant.) The nature of the individual sites-metallic, superconducting, semiconducting or quantum dot-is to first order irrelevant for this phenomenon to be observed(1). Coulomb blockade has also been observed in two-dimensional arrays of normal-metal tunnel junctions(2), but the relatively large capacitances of these micrometre-sized metal islands results in a small charging energy, and so the effect can be seen only at extremely low temperatures. Here we demonstrate that organic thin-film transistors based on highly ordered molecular materials can, to first order, also be considered as an array of sites separated by tunnel resistances. And as a result of the subnanometre sizes of the sites (the individual molecules), and hence their small capacitances, the charging energy dominates at room temperature. Conductivity measurements as a function of both gate bias and temperature reveal the presence of thermally activated transport, consistent with the conventional model of Coulomb blockade.	Univ Groningen, Dept Appl Phys, NL-9747 AG Groningen, Netherlands; Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Polymer Chem, NL-9747 AG Groningen, Netherlands; CNRS, Mat Mol Lab, F-94320 Thiais, France; Eindhoven Univ Technol, Dept Phys, NL-5600 MB Eindhoven, Netherlands; Delft Univ Technol, Dept Appl Phys, Nanophys & Nanotechnol Sect, NL-2628 CJ Delft, Netherlands	University of Groningen; University of Groningen; University of Groningen; Centre National de la Recherche Scientifique (CNRS); Eindhoven University of Technology; Delft University of Technology	Schoonveld, WA (corresponding author), Univ Groningen, Dept Appl Phys, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		van, bart/U-1770-2017; Klapwijk, Teunis M/C-8431-2016; Bobbert, Peter A/L-4959-2013; Fichou, Denis/K-3540-2013	Klapwijk, Teunis M/0000-0002-9369-9548; Bobbert, Peter A/0000-0001-7780-7062; Fichou, Denis/0000-0002-5081-3806				BOBBERT PA, 1990, MACROSCOPIC QUANTUM, P119; Bouchoms IPM, 1999, SYNTHETIC MET, V104, P175, DOI 10.1016/S0379-6779(99)00050-8; Brown AR, 1997, SYNTHETIC MET, V88, P37, DOI 10.1016/S0379-6779(97)80881-8; CAMPBELL RB, 1962, ACTA CRYSTALLOGR, V15, P289, DOI 10.1107/S0365110X62000699; GEIGENMULLER U, 1989, EUROPHYS LETT, V10, P765, DOI 10.1209/0295-5075/10/8/011; GRABERT H, 1992, NATO ASI SER, pCH1; HOLSTEIN T, 1959, ANN PHYS-NEW YORK, V8, P325, DOI 10.1016/0003-4916(59)90002-8; HOROWITZ G, 1995, J PHYS III, V5, P355, DOI 10.1051/jp3:1995132; HOROWITZ G, 1995, CHEM MATER, V7, P1337, DOI 10.1021/cm00055a010; MOOIJ JE, 1990, PHYS REV LETT, V65, P645, DOI 10.1103/PhysRevLett.65.645; Nelson SF, 1998, APPL PHYS LETT, V72, P1854, DOI 10.1063/1.121205; PORZIO W, 1993, ACTA POLYM, V44, P266, DOI 10.1002/actp.1993.010440602; SCHOELER H, 1997, NATO ASI SER, pCH1; Schon JH, 1999, APPL PHYS LETT, V74, P260, DOI 10.1063/1.123274; Schoonveld WA, 1998, APPL PHYS LETT, V73, P3884, DOI 10.1063/1.122924; Silinsh E. A., 1994, ORGANIC MOL CRYSTALS; Torsi L, 1996, SCIENCE, V272, P1462, DOI 10.1126/science.272.5267.1462; Torsi L, 1998, PHYS REV B, V57, P2271, DOI 10.1103/PhysRevB.57.2271; Vissenberg MCJM, 1998, PHYS REV B, V57, P12964, DOI 10.1103/PhysRevB.57.12964; Vrijmoeth J, 1998, J APPL PHYS, V83, P3816, DOI 10.1063/1.367145; WARAGAI K, 1995, PHYS REV B, V52, P1786, DOI 10.1103/PhysRevB.52.1786	21	128	128	2	61	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					977	980		10.1038/35010073	http://dx.doi.org/10.1038/35010073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801122	Green Published			2022-12-28	WOS:000086762000050
J	Hill, SR; Mitchell, AS; Henry, DA				Hill, SR; Mitchell, AS; Henry, DA			Problems with the interpretation of pharmacoeconomic analyses - A review of submissions to the Australian pharmaceutical benefits scheme	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECONOMIC SUBMISSIONS; COST-EFFECTIVENESS; GUIDELINES; JOURNALS; QUALITY; BMJ	Context Pharmacoeconomic analyses are being used increasingly as the basis for reimbursement of the costs of new drugs. Reports of these analyses are often published in peer-reviewed journals, However, the analyses are complex and difficult to evaluate. Objective To describe the nature of problems encountered in the evaluation anti interpretation of pharmacoeconomic analyses used as a basis for reimbursement decisions, Data Sources All major submissions to the Department of Health and Aged Care (DHAC) by the pharmaceutical industry for funding made under the Australian Pharmaceutical Benefits Scheme. Specifically, the DHAC's database of submissions that were received between January 1994 and December 1997 were reviewed. Study Selection Of a total of 326 submissions, 218 had serious problems of interpretation and were included in the analysis, The nature of the serious problems reviewed were classified as estimates of comparative clinical efficacy, comparator issues, modeling issues, and calculation errors. Data Extraction Ail submissions in the DHAC's database were reviewed and data were extracted if both the DHAC evaluators and technical subcommittee considered problems to have a significant bearing on the decisions of the parent committee, Data Synthesis Of a total of 326 submissions, 218 (67%) had significant problems and 31 had more than 1 problem. Of the 249 problems identified, 154 (62%) related to uncertainty in the estimates of comparative clinical efficacy, and 71 (28.5%) related to modeling issues, which included clinical assumptions or cost estimates, used in the construction of the economic models. There were 15 instances of disagreement over the choice of comparator, and serious calculation errors were found on 9 occasions. Overall, 159 problems (64%) were considered to be avoidable. Conclusions Significant problems were identified in these pharmacoeconomic analyses. The intensive evaluation process used in the Australian Pharmaceutical Benefits Scheme allowed for identification and correction of pharmacoeconomic analysis problems, but the resources that are required may be beyond the capacity of many organizations, including peer-reviewed journals.	Univ Newcastle, Fac Med & Hlth Sci, Sch Populat Hlth Sci, Discipline Clin Pharmacol, Newcastle, NSW 2308, Australia; Dept Hlth & Aged Care, Pharmaceut Evaluat Sect, Pharmaceut Benefits Branch, Woden, ACT, Australia	University of Newcastle	Henry, DA (corresponding author), Newcastle Mater Misericordiae Hosp, Discipline Clin Pharmacol, Level 5,Clin Sci Bldg, Waratah, NSW 2298, Australia.	mddah@mail.newcastle.edu.au	Henry, David/AAU-4650-2020; Henry, David/L-3895-2017	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242				Baladi JF, 1998, HEALTH ECON, V7, P221, DOI 10.1002/(SICI)1099-1050(199805)7:3<221::AID-HEC341>3.0.CO;2-N; BATTISTA RN, 1995, INT J TECHNOL ASSESS, V11, P287, DOI 10.1017/S0266462300006905; *COMM DEP HUM SERV, 1995, GUID PHARM IND PREP; Drummond M, 1993, Int J Technol Assess Health Care, V9, P26; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; DRUMMOND MF, 1992, HEALTH AFFAIR, V11, P191, DOI 10.1377/hlthaff.11.4.191; Fayers PM, 1997, LANCET, V350, P1025, DOI 10.1016/S0140-6736(97)03053-5; FREEMANTLE N, 1994, HEALTH ECON, V3, P63, DOI 10.1002/hec.4730030202; FREEMANTLE N, 1995, BRIT MED J, V310, P955, DOI 10.1136/bmj.310.6985.955; FRIEDBERG M, 1999, JAMA-J AM MED ASSOC, V282, P1452; Gold MR, 1996, COST EFFECTIVENESS H; Henry D, 1992, Pharmacoeconomics, V1, P54, DOI 10.2165/00019053-199201010-00010; HILLMAN AL, 1995, ANN INTERN MED, V123, P61; Horwitz RI, 1996, J CLIN EPIDEMIOL, V49, P395, DOI 10.1016/0895-4356(95)00058-5; *IND COMM, 1996, 51 IND COMM; JEFFERSON T, 1995, BRIT MED J, V311, P393, DOI 10.1136/bmj.311.7001.393c; JEFFERSON T, 1995, HEALTH ECON, V4, P383, DOI 10.1002/hec.4730040504; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KESSLER DA, 1995, SCI AM           MAR, P26; Krimsky S, 1999, JAMA-J AM MED ASSOC, V282, P1474, DOI 10.1001/jama.282.15.1474; Mullins CD, 1998, CLIN THER, V20, P1194, DOI 10.1016/S0149-2918(98)80115-X; OBrien B, 1996, MED CARE, V34, pDS99; Pausjenssen AM, 1998, MED DECIS MAKING, V18, pS19, DOI 10.1177/0272989X9801800204; SCHULMAN K, 1994, JAMA-J AM MED ASSOC, V272, P154, DOI 10.1001/jama.272.2.154; SKETRIS IS, 1998, CAN J CLIN PHARM, V5, P111; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238	26	160	162	2	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2116	2121		10.1001/jama.283.16.2116	http://dx.doi.org/10.1001/jama.283.16.2116			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791503				2022-12-28	WOS:000086542800027
J	Festing, MFW; Fisher, EMC				Festing, MFW; Fisher, EMC			Mighty mice - Clarence Little's brainwave gave biomedical researchers their best friend.	NATURE			English	Editorial Material									Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; St Marys Hosp, Imperial Coll Sch Med, Dept Neurogenet, London W2 1PG, England	University of Leicester; Imperial College London	Festing, MFW (corresponding author), Univ Leicester, MRC, Toxicol Unit, Lancaster Rd, Leicester LE1 9HN, Leics, England.		Fisher, Elizabeth MC/C-2168-2008	Fisher, Elizabeth MC/0000-0003-2850-9936					0	18	19	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					815	815		10.1038/35009167	http://dx.doi.org/10.1038/35009167			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786770	Bronze			2022-12-28	WOS:000086625000024
J	Nadis, S				Nadis, S			Top physicist crosses to Boston in search of like minds	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					798	798		10.1038/35009214	http://dx.doi.org/10.1038/35009214			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786762	Bronze			2022-12-28	WOS:000086625000006
J	Nathens, AB; Jurkovich, GJ; Cummings, P; Rivara, FP; Maier, RV				Nathens, AB; Jurkovich, GJ; Cummings, P; Rivara, FP; Maier, RV			The effect of organized systems of trauma care on motor vehicle crash mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SPEED LIMIT; INSTITUTION; FATALITIES; STATES	Context Despite calls for wider national implementation of an integrated approach to trauma care, the effectiveness of this approach at a regional or state level remains unproven. Objective To determine whether implementation of an organized system of trauma care reduces mortality due to motor vehicle crashes. Design Cross-sectional time-series analysis of crash mortality data collected for 1979 through 1995 from the Fatality Analysis Reporting System. Setting All 50 US states and the District of Columbia. Subjects All front-seat passenger vehicle occupants aged 15 to 74 years. Main Outcome Measures Rates of death due to motor vehicle crashes compared before and after implementation of an organized trauma care system. Estimates are based on within-state comparisons adjusted for national trends in crash mortality. Results Ten years following initial trauma system implementation, mortality due to traffic crashes began to decline; about 15 years following trauma system implementation, mortality was reduced by 8% (95% confidence interval [CI], 3%-12%) after adjusting for secular trends in crash mortality, age, and the introduction of traffic safety laws. Implementation of primary enforcement of restraint laws and laws deterring drunk driving resulted in reductions in crash mortality of 13% (95% CI, 11%-16%)and 5% (95% CI, 3%-7%), respectively, while relaxation of state speed limits increased mortality by 7% (95% CI, 3%-10%). Conclusions Our data indicate that implementation of an organized system of trauma care reduces crash mortality. The effect does not appear for 10 years, a finding consistent with the maturation and development of trauma triage protocols, interhospital transfer agreements, organization of trauma centers, and ongoing quality assurance.	Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nathens, AB (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Box 359796,325 9th Ave, Seattle, WA 98104 USA.	anathens@u.washington.edu			PHS HHS [R49/CCR002570] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], 1976, Bull Am Coll Surg, V61, P15; BAZZOLI GJ, 1995, JAMA-J AM MED ASSOC, V273, P395; BAZZOLI GJ, 1993, INVENTORY TRAUMA SYS; CAMERON AC, 1998, REGRESSION ANAL COUN, P275; GALLAHER MM, 1989, JAMA-J AM MED ASSOC, V262, P2243; GARBER S, 1990, ACCIDENT ANAL PREV, V22, P137, DOI 10.1016/0001-4575(90)90065-S; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; GRAHAM JD, 1993, ANNU REV PUBL HEALTH, V14, P515; Ma MHM, 1999, J TRAUMA, V46, P168; MCCULLAGH P, 1989, GEN LINEAR MODELS, P39; Meislin H, 1999, J TRAUMA, V46, P457, DOI 10.1097/00005373-199903000-00020; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; *NAT HIGHW TRAFF S, 1980, FAT AN REP SYST 1979; *NAT HIGHW TRAFF S, 1997, TRAFF SAF FACTS 1997; *NAT SAF COUNC, 1985, ACC FACTS 1985 1995; Rivara FP, 1999, AM J PREV MED, V16, P30, DOI 10.1016/S0749-3797(98)00113-5; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P196; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; ZADOR P L, 1989, Journal of Public Health Policy, V10, P467, DOI 10.2307/3342519	21	328	334	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2000	283	15					1990	+		10.1001/jama.283.15.1990	http://dx.doi.org/10.1001/jama.283.15.1990			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303RC	10789667	Bronze			2022-12-28	WOS:000086436600034
J	Hanski, I; Ovaskainen, O				Hanski, I; Ovaskainen, O			The metapopulation capacity of a fragmented landscape	NATURE			English	Article							ENVIRONMENTAL STOCHASTICITY; DYNAMICS; EXTINCTION; PERSISTENCE; POPULATIONS; PATTERNS; MODEL	Ecologists and conservation biologists have used many measures of landscape structure(1-5) to predict the population dynamic consequences of habitat loss and fragmentation(6-8), but these measures are not well justified by population dynamic theory. Here we introduce a new measure for highly fragmented landscapes, termed the metapopulation capacity, which is rigorously derived from metapopulation theory and can easily be applied to real networks of habitat fragments with known areas and connectivities. Technically, metapopulation capacity is the leading eigenvalue of an appropriate 'landscape' matrix. A species is predicted to persist in a landscape if the metapopulation capacity of that landscape is greater than a threshold value determined by the properties of the species. Therefore, metapopulation capacity can conveniently be used to rank different landscapes in terms of their capacity to support viable metapopulations. We present an empirical example on multiple networks occupied by an endangered species of butterfly. Using this theory, we may also calculate how the metapopulation capacity is changed by removing habitat fragments from or adding new ones into specific spatial locations, or by changing their areas. The metapopulation capacity should rnd many applications in metapopulation ecology, landscape ecology and conservation biology.	Univ Helsinki, Dept Ecol & Systemat, FIN-00014 Helsinki, Finland	University of Helsinki	Hanski, I (corresponding author), Univ Helsinki, Dept Ecol & Systemat, POB 17,Arkadiankatu 7, FIN-00014 Helsinki, Finland.	ilkka.hanski@helsinki.fi	Ovaskainen, Otso/D-9119-2012; Ovaskainen, Otso/AGN-4838-2022	Ovaskainen, Otso/0000-0001-9750-4421; Ovaskainen, Otso/0000-0001-9750-4421				ADLER FR, 1994, THEOR POPUL BIOL, V45, P41, DOI 10.1006/tpbi.1994.1003; ANDERSON R M, 1991; BASCOMPTE J, 1994, J ANIM ECOL, V63, P256, DOI 10.2307/5544; FOLEY P, 1994, CONSERV BIOL, V8, P124, DOI 10.1046/j.1523-1739.1994.08010124.x; Freitag S, 1998, P ROY SOC B-BIOL SCI, V265, P1475, DOI 10.1098/rspb.1998.0460; Gardner R. H., 1991, QUANTITATIVE METHODS; GARDNER RH, 1993, HUMANS AS COMPONENTS OF ECOSYSTEMS, P208; Grenfell B. T., 1995, ECOLOGY INFECT DIS N; Gustafson EJ, 1996, ECOLOGY, V77, P94, DOI 10.2307/2265659; Gustafson EJ, 1998, ECOSYSTEMS, V1, P143, DOI 10.1007/s100219900011; HANSKI I, 1994, J ANIM ECOL, V63, P151, DOI 10.2307/5591; Hanski I, 1998, NATURE, V396, P41, DOI 10.1038/23876; Hanski I, 1997, SCIENCE, V275, P397, DOI 10.1126/science.275.5298.397; Hanski I, 1996, CONSERV BIOL, V10, P578, DOI 10.1046/j.1523-1739.1996.10020578.x; Hanski I., 1999, METAPOPULATION ECOLO; Hanski Ilkka, 1997, P217; Hill MF, 1999, ECOL LETT, V2, P121, DOI 10.1046/j.1461-0248.1999.22061.x; LANDE R, 1987, AM NAT, V130, P624, DOI 10.1086/284734; LANDE R, 1993, AM NAT, V142, P911, DOI 10.1086/285580; LAVOREL S, 1993, OIKOS, V67, P521, DOI 10.2307/3545364; Lawton John H., 1994, P41; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; Lindenmayer D. B., 1994, RISK EXTINCTION RANK; MAY RM, 1991, S ZOOLOGICAL SOC LON, V62, P145; NEE S, 1992, J ANIM ECOL, V61, P37, DOI 10.2307/5506; NEE S, 1994, NATURE, V367, P123, DOI 10.1038/367123b0; Pressey RL, 1996, BIOL CONSERV, V76, P259, DOI 10.1016/0006-3207(95)00120-4; Turner MG, 1989, LANDSCAPE ECOL, V3, P153, DOI 10.1007/BF00131534; With KA, 1999, CONSERV BIOL, V13, P314, DOI 10.1046/j.1523-1739.1999.013002314.x; With KA, 1997, OIKOS, V78, P151, DOI 10.2307/3545811	30	731	756	11	494	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	2000	404	6779					755	758		10.1038/35008063	http://dx.doi.org/10.1038/35008063			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783887				2022-12-28	WOS:000086523600050
J	Horton, B				Horton, B			Georgia realizes the commercial potential of science	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					794	794		10.1038/35008200	http://dx.doi.org/10.1038/35008200			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783897	Bronze			2022-12-28	WOS:000086523600060
J	Ollmann, M; Young, LM; Di Como, CJ; Karim, F; Belvin, M; Robertson, S; Whittaker, K; Demsky, M; Fisher, WW; Buchman, A; Duyk, G; Friedman, L; Prives, C; Kopczynski, C				Ollmann, M; Young, LM; Di Como, CJ; Karim, F; Belvin, M; Robertson, S; Whittaker, K; Demsky, M; Fisher, WW; Buchman, A; Duyk, G; Friedman, L; Prives, C; Kopczynski, C			Drosophila p53 is a structural and functional homolog of the tumor suppressor p53	CELL			English	Article							P53-MEDIATED TRANSCRIPTIONAL REPRESSION; DEPENDENT KINASE INHIBITOR; CELL-CYCLE CHECKPOINTS; ATAXIA-TELANGIECTASIA; CRYSTAL-STRUCTURE; APOPTOSIS; GENE; PROTEIN; DEATH; EXPRESSION	The importance of p53 in carcinogenesis stems from its central role in inducing cell cycle arrest or apoptosis in response to cellular stresses. We have identified a Drosophila homolog of p53 ("Dmp53"). Like mammalian p53, Dmp53 binds specifically to human p53 binding sites, and overexpression of Dmp53 induces apoptosis. Importantly, inhibition of Dmp53 function renders cells resistant to X ray-induced apoptosis, suggesting that Dmp53 is required for the apoptotic response to DNA damage. Unlike mammalian p53, Dmp53 appears unable to induce a G1 cell cycle block when overexpressed, and inhibition of Dmp53 activity does not affect X ray-induced cell cycle arrest. These data reveal an ancestral proapoptotic function for p53 and identify Drosophila as an ideal model system for elucidating the p53 apoptotic pathway(s) induced by DNA damage.	Exelixis Inc, San Francisco, CA 94080 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Exelixis, Inc.; Columbia University	Kopczynski, C (corresponding author), Exelixis Inc, 260 Littlefield Ave, San Francisco, CA 94080 USA.	caseyk@exelixis.com		DiComo, Charles/0000-0003-2818-9215	NCI NIH HHS [CA58316, CA777742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA058316, R01CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Agami R, 1999, NATURE, V399, P809; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Barker CM, 1997, EXP CELL RES, V232, P240, DOI 10.1006/excr.1997.3513; Barlow C, 1998, NAT GENET, V18, P298, DOI 10.1038/ng0398-298b; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Beumer TL, 1998, CELL DEATH DIFFER, V5, P669, DOI 10.1038/sj.cdd.4400396; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; BRODSKY MH, 2000, IN PRESS GENES DEV; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BUKOVSKY A, 1995, J ASSIST REPROD GEN, V12, P123, DOI 10.1007/BF02211381; Chehab NH, 2000, GENE DEV, V14, P278; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; DENOOIJ JC, 1995, SCIENCE, V270, P983, DOI 10.1126/science.270.5238.983; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Di Como CJ, 1998, ONCOGENE, V16, P2527; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; Edgar BA, 1996, SCIENCE, V274, P1646, DOI 10.1126/science.274.5293.1646; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong JG, 1999, NATURE, V399, P806; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARPER JW, 1993, CELL, V75, P805; HAY BA, 1994, DEVELOPMENT, V120, P2121; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; LEE W, 1995, NAT STRUCT BIOL, V2; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levin JM, 1997, PROTEIN ENG, V10, P771, DOI 10.1093/protein/10.7.771; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liao MJ, 1999, MOL CELL BIOL, V19, P3095; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; MIYASHITA T, 1995, CELL, V80, P293; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NICOL CJ, 1995, NAT GENET, V11, P104, DOI 10.1038/ng0995-104b; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prikhod'ko GG, 1999, J VIROL, V73, P1227; Prives C, 1999, J PATHOL, V187, P112; Quenby SM, 1999, MOL HUM REPROD, V5, P737, DOI 10.1093/molehr/5.8.737; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1997, PROTEINS, P50; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Shieh SY, 2000, GENE DEV, V14, P289; STEWART N, 1995, ONCOGENE, V10, P109; Su TT, 1998, DEV BIOL, V196, P160, DOI 10.1006/dbio.1998.8855; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VanBeneden RJ, 1997, MOL MAR BIOL BIOTECH, V6, P116; VANVACTOR D, 1999, ANATOMICAL TECHNIQUE; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WOLFF T, 1991, DEVELOPMENT, V113, P841; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113; Yin YZ, 1998, DEV BIOL, V204, P165, DOI 10.1006/dbio.1998.9074; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; YUAN ZM, 1999, NATURE, V19	94	322	333	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 31	2000	101	1					91	101		10.1016/S0092-8674(00)80626-1	http://dx.doi.org/10.1016/S0092-8674(00)80626-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778859	Bronze			2022-12-28	WOS:000086249900011
J	Smith, CM; Gavranich, J; Cotterill, A; Rodda, CP				Smith, CM; Gavranich, J; Cotterill, A; Rodda, CP			Lesson of the week - Congenital neonatal thyrotoxicosis and previous maternal radioiodine therapy	BRITISH MEDICAL JOURNAL			English	Review									Monash Univ, Monash Med Ctr, Dept Paediat, Clayton, Vic 3168, Australia; Mater Childrens Hosp, S Brisbane, Qld 4101, Australia; Ipswich Hosp, Ipswich, Qld 4305, Australia	Monash University	Rodda, CP (corresponding author), Monash Univ, Monash Med Ctr, Dept Paediat, Clayton, Vic 3168, Australia.		cotterill, andrew/B-3056-2011					Degroot LJ, 1997, THYROID, V7, P259, DOI 10.1089/thy.1997.7.259; MCKENZIE JM, 1992, THYROID, V2, P155, DOI 10.1089/thy.1992.2.155; MORTIMER RH, 1990, CLIN ENDOCRINOL, V32, P141, DOI 10.1111/j.1365-2265.1990.tb00850.x; ZAKARIJA M, 1986, J CLIN ENDOCR METAB, V62, P368, DOI 10.1210/jcem-62-2-368	4	9	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1260	1261		10.1136/bmj.320.7244.1260	http://dx.doi.org/10.1136/bmj.320.7244.1260			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797041	Green Published			2022-12-28	WOS:000086981400025
J	Nowak, MA; Sigmund, K				Nowak, MA; Sigmund, K			Social science - Shrewd investments	SCIENCE			English	Editorial Material									Princeton Univ, Inst Adv Study, Princeton, NJ 08540 USA; Univ Vienna, Inst Math, A-1090 Vienna, Austria; Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria	Institute for Advanced Study - USA; Princeton University; University of Vienna; International Institute for Applied Systems Analysis (IIASA)	Nowak, MA (corresponding author), Princeton Univ, Inst Adv Study, Princeton, NJ 08540 USA.		Nowak, Martin A/A-6977-2008					Alexander R., 1987, BIOL MORAL SYSTEMS; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Barkow J.H., 1992, ADAPTED MIND; Boyd R., 1985, CULTURE EVOLUTIONARY; Colman AM, 2013, GAME THEORY ITS APPL; Dugatkin L.A., 1997, COOPERATION ANIMALS; FEHR E, 1998, EUR ECON REV, V42, P232; Frank R. H., 1988, PASSIONS REASON; Haig D, 2000, SCIENCE, V287, P2438, DOI 10.1126/science.287.5462.2438; HAMILTON WD, 1996, NARROW ROADS GENE LA, V7; Kagel JH, 1995, HDB EXPT EC; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; Pinker S., 1997, MIND WORKS; RIDLEY M, 1997, ORIGIN VIRTUE; Trivers R. L., 1985, SOCIAL EVOLUTION; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850; Zahavi A, 1996, HANDICAP PRINCIPLE	17	33	34	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					819	820		10.1126/science.288.5467.819	http://dx.doi.org/10.1126/science.288.5467.819			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10809651				2022-12-28	WOS:000086869600023
J	Lonn, E; McKelvie, R				Lonn, E; McKelvie, R			Regular review - Drug treatment in heart failure	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LEFT-VENTRICULAR DYSFUNCTION; CONVERTING ENZYME-INHIBITORS; MYOCARDIAL-INFARCTION; VASODILATOR THERAPY; RANDOMIZED TRIALS; MORTALITY; MORBIDITY; AMIODARONE; WITHDRAWAL; ENALAPRIL		Hamilton Hlth Sci Corp, McMaster Clin, Med, Hamilton, ON L8L 2X2, Canada	McMaster University	Lonn, E (corresponding author), Hamilton Hlth Sci Corp, McMaster Clin, Med, Gen Site, Hamilton, ON L8L 2X2, Canada.	lonnern@fhs.McMaster.ca						American Heart Association, 1997, 1998 HEART STROK STA; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1989, NEW ENGL J MED, V321, P406; *AUSTR NZ HEART FA, 1997, LANCET, V349, P1349; BALL SG, 1993, LANCET, V342, P821; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Cohn JN, 1997, CIRCULATION, V96, P856, DOI 10.1161/01.cir.96.3.856; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Connolly SJ, 1997, LANCET, V350, P1417; DIBIANCO R, 1989, NEW ENGL J MED, V320, P677, DOI 10.1056/NEJM198903163201101; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; KJELSHUS J, 1995, J AM COLL CARDIOL, V25, pA282; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Lechat P, 1999, LANCET, V353, P9; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; Lechat P, 1998, CIRCULATION, V98, P1184, DOI 10.1161/01.CIR.98.12.1184; Massie BM, 1997, AM HEART J, V133, P703, DOI 10.1016/S0002-8703(97)70173-X; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Packer M, 1998, EUR HEART J, V19, pB40; Perry G, 1997, NEW ENGL J MED, V336, P525; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Poole-Wilson Philip A., 1997, P269; Remme WJ, 1997, EUR HEART J, V18, P736; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; *STUD LEFT VENTR D, 1992, NEW ENGL J MED, V327, P575; SUTTON GC, 1997, HEART FAILURE SCI PR, P617; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1998, EUR HEART J SUPPL, V19, P34	37	27	32	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	2000	320	7243					1188	1192		10.1136/bmj.320.7243.1188	http://dx.doi.org/10.1136/bmj.320.7243.1188			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784546	Green Published			2022-12-28	WOS:000086832800022
J	Mulvin, D				Mulvin, D			Malcolm John Coptcoat - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		COPTCOAT MJ, PUBLICATION LIST	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1213	1213						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784564				2022-12-28	WOS:000086832800047
J	Parsons, T; Toda, S; Stein, RS; Barka, A; Dieterich, JH				Parsons, T; Toda, S; Stein, RS; Barka, A; Dieterich, JH			Heightened odds of large earthquakes near Istanbul: An interaction-based probability calculation	SCIENCE			English	Article							NORTH-ANATOLIAN FAULT; MARMARA SEA REGION; STRESS; SEISMICITY; PREDICTION; MAGNITUDE; SPACE	We calculate the probability of strong shaking in Istanbul, an urban center of 10 million people, from the description of earthquakes on the North Anatolian fault system in the Marmara Sea during the past 500 years and test the resulting catalog against the frequency of damage in Istanbul during the preceding millennium. Departing from current practice, we include the time-dependent effect of stress transferred by the 1999 moment magnitude M = 7.4 Izmit earthquake to faults nearer to Istanbul. We find a 62 +/- 15% probability (one standard deviation) of strong shaking during the next 30 years and 32 +/- 12% during the next decade.	US Geol Survey, Menlo Park, CA 94025 USA; Univ Tokyo, Earthquake Res Inst, Tokyo 1130032, Japan; Istanbul Tech Univ, TR-80626 Istanbul, Turkey	United States Department of the Interior; United States Geological Survey; University of Tokyo; Istanbul Technical University	Parsons, T (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Park, CA 94025 USA.		Parsons, Tom E/A-3424-2008	Parsons, Tom/0000-0002-0582-4338				Aki K., 1965, B EARTHQ RES I TOKYO, V43, P237; Ambraseys NN, 1990, TERRA NOVA, V2, P167, DOI 10.1111/j.1365-3121.1990.tb00059.x; Ambraseys N.N., 1995, SEISMICITY TURKEY AD; AMBRASEYS NN, 1987, ANN GEOPHYS B-TERR P, V5, P701; AMBRASEYS NN, 1988, EARTHQ ENG STRUCT D, V17, P1, DOI 10.1002/eqe.4290170101; AMBRASEYS NN, 1991, TERRA NOVA, V3, P527, DOI 10.1111/j.1365-3121.1991.tb00188.x; Bakun WH, 1997, B SEISMOL SOC AM, V87, P1502; Barka A, 1996, B SEISMOL SOC AM, V86, P1238; DIETERICH J, 1994, J GEOPHYS RES-SOL EA, V99, P2601, DOI 10.1029/93JB02581; Dieterich JH, 1996, P NATL ACAD SCI USA, V93, P3787, DOI 10.1073/pnas.93.9.3787; FINKEL CF, 1996, BIBLIO I FRANCAIS ET, V43; Gurbuz C, 2000, TECTONOPHYSICS, V316, P1, DOI 10.1016/S0040-1951(99)00253-X; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24347, DOI 10.1029/98JB01576; Hubert-Ferrari A, 2000, NATURE, V404, P269, DOI 10.1038/35005054; ITO A, 1999, EOS S, V80, pF662; JACKSON DD, 1995, B SEISMOL SOC AM, V85, P379; Ketin I., 1969, B MIN RES EXP I, V72, P1; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; MATTHEWS MV, IN PRESS J GEOPHYS R; Nalbant SS, 1998, J GEOPHYS RES-SOL EA, V103, P24469, DOI 10.1029/98JB01491; Ogata Y, 1999, J GEOPHYS RES-SOL EA, V104, P17995, DOI 10.1029/1999JB900115; OKADA Y, 1992, B SEISMOL SOC AM, V82, P1018; Parke JR, 1999, TERRA NOVA, V11, P223; Parsons T, 1999, J GEOPHYS RES-SOL EA, V104, P20183, DOI 10.1029/1999JB900056; REASENBERG PA, 1992, SCIENCE, V255, P1687, DOI 10.1126/science.255.5052.1687; SAVAGE JC, 1991, B SEISMOL SOC AM, V81, P862; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; Stein RS, 1997, GEOPHYS J INT, V128, P594, DOI 10.1111/j.1365-246X.1997.tb05321.x; Straub C, 1997, J GEOPHYS RES-SOL EA, V102, P27587, DOI 10.1029/97JB02563; Toda S, 1998, J GEOPHYS RES-SOL EA, V103, P24543, DOI 10.1029/98JB00765; TOKSOZ MN, 1979, PURE APPL GEOPHYS, V117, P1258, DOI 10.1007/BF00876218; Wald D.J., 1999, EARTHQ SPECTRA, V15, P557, DOI [DOI 10.1193/1.1586058, 10.1193/1.1586058]; WELLS DL, 1994, B SEISMOL SOC AM, V84, P974; Wesnousky SG, 1999, B SEISMOL SOC AM, V89, P1131; *WORK GROUP CA EAR, 1990, 1053 US GEOL SURV; Working Group on California Earthquake Probabilities, 1999, 99517 US GEOL SURV; WRIGHT TJ, 1999, EOS S, V80, pF671	37	384	398	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					661	665		10.1126/science.288.5466.661	http://dx.doi.org/10.1126/science.288.5466.661			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784447	Green Submitted			2022-12-28	WOS:000086727100041
J	Kawabuchi, M; Satomi, Y; Takao, T; Shimonishi, Y; Nada, S; Nagai, K; Tarakhovsky, A; Okada, M				Kawabuchi, M; Satomi, Y; Takao, T; Shimonishi, Y; Nada, S; Nagai, K; Tarakhovsky, A; Okada, M			Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases	NATURE			English	Article							T-CELL ACTIVATION; PHOSPHORYLATED PROTEINS; CSK; SUPPRESSION; MEMBRANES; DOMAINS; RAFTS	The Src family of protein tyrosine kinases (Src-PTKs) is important in the regulation of growth and differentiation of eukaryotic cells. The activity of Src-PTKs in cells of different types is negatively controlled by Csk, which specifically phosphorylates a conserved regulatory tyrosine residue at the carboxy-terminal tail of the Src-PTKs(1-3). Csk is mainly cytoplasmic and Src-PTKs are predominantly membrane-associated. This raises a question about the mechanism of interaction between these enzymes. Here we present Cbp-a transmembrane phosphoprotein that is ubiquitously expressed and binds specifically to the SH2 domain of Csk. Cbp is involved in the membrane localization of Csk and in the Csk-mediated inhibition of c-Src. In the plasma membrane Cbp is exclusively localized in the GM1 ganglioside-enriched detergent-insoluble membrane domain, which is important in receptor-mediated signalling(4-8). These findings reveal Cbp as a new component of the regulatory mechanism controlling the activity of membrane-associated Src-PTKs.	Osaka Univ, Inst Prot Res, Div Prot Metab, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Div Organ Chem, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Div Biol Sci, Osaka 5670047, Japan; Univ Cologne, Inst Genet, Lab Lymphocyte Signalling, D-50931 Cologne, Germany	Osaka University; Osaka University; Osaka University; University of Cologne	Tarakhovsky, A (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Metab, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sasha@mac.genetik.uni-koeln.de; okadam@protein.osaka-u.ac.jp		Satomi, Yoshinori/0000-0002-8991-1040				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Harlow E, 1988, ANTIBODIES LABORATOR, P359; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; Jensen ON, 1999, METH MOL B, V112, P513; Kobayashi S, 1998, J BIOCHEM-TOKYO, V123, P624; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang YQ, 1998, IEEE T NEURAL NETWOR, V9, P83, DOI 10.1109/72.655032	21	444	469	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 27	2000	404	6781					999	1003		10.1038/35010121	http://dx.doi.org/10.1038/35010121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801129				2022-12-28	WOS:000086762000057
J	MacIlwain, C				MacIlwain, C			Budget crisis forces hard choices on US high-energy physics	NATURE			English	News Item																			0	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					909	910		10.1038/35010209	http://dx.doi.org/10.1038/35010209			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801089	Bronze			2022-12-28	WOS:000086762000003
J	Hubenstorf, M				Hubenstorf, M			Anatomical science in Vienna, 1938-45	LANCET			English	Editorial Material									Univ Toronto, Inst Hist & Philosophy Sci & Technol, Victoria Coll, Toronto, ON M5S 1K7, Canada	University of Toronto	Hubenstorf, M (corresponding author), Univ Toronto, Inst Hist & Philosophy Sci & Technol, Victoria Coll, Toronto, ON M5S 1K7, Canada.							CZECH H, 1999, H GROSS WISSENSCHAFT, P53; DIECHMANN U, 1996, BIOL HITLER, P183; ERNST E, 1995, ANN INTERN MED, V122, P789, DOI 10.7326/0003-4819-122-10-199505150-00009; GISEL A, 1988, VERTRIEBENE VERNUNFT, V2, P17; GROSS H, 1977, HDB CLIN NEUROLOGY, V30, P681; HUBENSTORF M, 1989, WILLFAHRIGE WISSENSC, V242, P258; LINGENS PM, 1977, PROFIL VIENNA   1206, P15; PLEIGER H, 1980, M ARB KRIT MED VIENN; SABLIK K, 1983, MED SOZIALREFORMER, P298; Seidelman W. E., 1999, DOKUMENTATIONSARCHIV, P15; *SEN U WIEN, 1998, UNT AN WISS WIEN 193	11	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1385	1386		10.1016/S0140-6736(00)02135-8	http://dx.doi.org/10.1016/S0140-6736(00)02135-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791520				2022-12-28	WOS:000086829800007
J	Dawson, TM				Dawson, TM			New animal models for Parkinson's disease	CELL			English	Review									Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Dawson, TM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA.							Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Grunewald T, 1999, NAT MED, V5, P1354, DOI 10.1038/70918; Kowall NW, 2000, NEUROREPORT, V11, P211, DOI 10.1097/00001756-200001170-00041; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Liberatore GT, 1999, NAT MED, V5, P1403; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mizuno Y, 1999, BIOMED PHARMACOTHER, V53, P109, DOI 10.1016/S0753-3322(99)80075-4; Orr HT, 2000, CELL, V101, P1, DOI 10.1016/S0092-8674(00)80617-0; Polymeropoulos MH, 1998, ANN NEUROL, V44, pS63, DOI 10.1002/ana.410440710; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; WAKABAYASHI K, 2000, IN PRESS ANN NEUROL	20	77	77	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 14	2000	101	2					115	118		10.1016/S0092-8674(00)80629-7	http://dx.doi.org/10.1016/S0092-8674(00)80629-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	305DP	10786830	Bronze			2022-12-28	WOS:000086524400001
J	Fishlock, TW; Oral, A; Egdell, RG; Pethica, JB				Fishlock, TW; Oral, A; Egdell, RG; Pethica, JB			Manipulation of atoms across a surface at room temperature	NATURE			English	Article							SCANNING TUNNELING MICROSCOPE; C-60 MOLECULES; SINGLE ATOMS; SCALE; TIP; STEPS; STM	Since the realization that the tips of scanning probe microscopes can interact with atoms at surfaces, there has been much interest in the possibility of building or modifying nanostructures or molecules directly from single atoms(1). Individual large molecules can be positioned on surfaces(2-4), and atoms can be transferred controllably between the sample and probe tip(5,6). The most complex structures(7-11) are produced at cryogenic temperatures by sliding atoms across a surface to chosen sites. But there are problems in manipulating atoms laterally at higher temperatures-atoms that are sufficiently well bound to a surface to be stable at higher temperatures require a stronger tip interaction to be moved. This situation differs significantly from the idealized weakly interacting tips(12,13) of scanning tunnelling or atomic force microscopes. Here we demonstrate that precise positioning of atoms on a copper surface is possible at room temperature. The triggering mechanism for the atomic motion unexpectedly depends on the tunnelling current density, rather than the electric field or proximity of tip and surface.	Univ Oxford, Dept Mat, Oxford OX1 3PH, England; Univ Oxford, Inorgan Chem Lab, Oxford OX1 3QR, England	University of Oxford; University of Oxford	Pethica, JB (corresponding author), Univ Oxford, Dept Mat, Parks Rd, Oxford OX1 3PH, England.	john.pethica@materials.ox.ac		Egdell, Russell George/0000-0002-1438-4426				AVOURIS P, 1995, ACCOUNTS CHEM RES, V28, P95, DOI 10.1021/ar00051a002; Bartels L, 1997, PHYS REV LETT, V79, P697, DOI 10.1103/PhysRevLett.79.697; BETON PH, 1995, APPL PHYS LETT, V67, P1075, DOI 10.1063/1.114469; CROMMIE MF, 1995, PHYSICA D, V83, P98, DOI 10.1016/0167-2789(94)00254-N; Cross G, 1998, PHYS REV LETT, V80, P4685, DOI 10.1103/PhysRevLett.80.4685; Cuberes MT, 1996, APPL PHYS LETT, V69, P3016, DOI 10.1063/1.116824; Dujardin G, 1998, PHYS REV LETT, V80, P3085, DOI 10.1103/PhysRevLett.80.3085; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Hansen O, 1998, PHYS REV LETT, V81, P5572, DOI 10.1103/PhysRevLett.81.5572; Jarvis SP, 1996, NATURE, V384, P247, DOI 10.1038/384247a0; Jung TA, 1996, SCIENCE, V271, P181, DOI 10.1126/science.271.5246.181; LYO IW, 1991, SCIENCE, V253, P173, DOI 10.1126/science.253.5016.173; Meyer G, 1996, APPL PHYS A-MATER, V63, P557, DOI 10.1007/BF01567211; RALLS KS, 1989, PHYS REV B, V40, P11561, DOI 10.1103/PhysRevB.40.11561; SHEN TC, 1995, SCIENCE, V268, P1590, DOI 10.1126/science.268.5217.1590; SPENCER ND, 1983, J VAC SCI TECHNOL A, V1, P1554, DOI 10.1116/1.572185; Todorov TN, 1998, PHILOS MAG B, V77, P965, DOI 10.1080/014186398259040; WALKUP RE, 1993, PHYS REV B, V48, P1858, DOI 10.1103/PhysRevB.48.1858; WHITMAN LJ, 1991, SCIENCE, V251, P1206, DOI 10.1126/science.251.4998.1206; WINTTERLIN J, 1989, PHYS REV LETT, V62, P59, DOI 10.1103/PhysRevLett.62.59	20	63	66	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	2000	404	6779					743	745		10.1038/35008030	http://dx.doi.org/10.1038/35008030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783883	Green Published			2022-12-28	WOS:000086523600046
J	van Dellen, A; Blakemore, C; Deacon, R; York, D; Hannan, AJ				van Dellen, A; Blakemore, C; Deacon, R; York, D; Hannan, AJ			Delaying the onset of Huntington's in mice	NATURE			English	Article							SIZED SPINY NEURONS; STRIATUM; DENSITY; GENE		Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; Univ Natal, Sch Med, Dept Virol, ZA-4001 Durban, South Africa	University of Oxford; University of Oxford; University of Kwazulu Natal	van Dellen, A (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.			Hannan, Anthony/0000-0001-7532-8922; Blakemore, Colin/0000-0003-2659-7899				COMERY TA, 1995, NEUROBIOL LEARN MEM, V63, P217, DOI 10.1006/nlme.1995.1025; Comery TA, 1996, NEUROBIOL LEARN MEM, V66, P93, DOI 10.1006/nlme.1996.0049; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Deckel AW, 1998, NEUROLOGY, V51, P1576, DOI 10.1212/WNL.51.6.1576; Foster TC, 1996, BRAIN RES, V736, P243, DOI 10.1016/0006-8993(96)00707-X; Georgiou N, 1999, MOVEMENT DISORD, V14, P320, DOI 10.1002/1531-8257(199903)14:2<320::AID-MDS1018>3.0.CO;2-Z; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MURPHY KPS, IN PRESS J NEUROSCI; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449	11	370	374	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					721	722		10.1038/35008142	http://dx.doi.org/10.1038/35008142			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783874				2022-12-28	WOS:000086523600037
J	Tournier, C; Hess, P; Yang, DD; Xu, J; Turner, TK; Nimnual, A; Bar-Sagi, D; Jones, SN; Flavell, RA; Davis, RJ				Tournier, C; Hess, P; Yang, DD; Xu, J; Turner, TK; Nimnual, A; Bar-Sagi, D; Jones, SN; Flavell, RA; Davis, RJ			Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway	SCIENCE			English	Article							N-TERMINAL KINASE; CELL-DEATH; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; CASPASE ACTIVATION; TNF RECEPTOR-1; PROTEIN; BCL-2; JUN; MITOCHONDRIA	The c-Jun NH2-terminal kinase (JNK) is activated when cells are exposed to ultraviolet (UV) radiation. However, the functional consequence of JNK activation in UV-irradiated cells has not been established. It is shown here that JNK is required for UV-induced apoptosis in primary murine embryonic fibroblasts. Fibroblasts with simultaneous targeted disruptions of all the functional Jnk genes were protected against UV-stimulated apoptosis. The absence of JNK caused a defect in the mitochondrial death signaling pathway, including the failure to release cytochrome c. These data indicate that mitochondria are influenced by proapoptotic signal transduction through the JNK pathway.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med,Howard Hughes Med Inst, Worcester, MA 01605 USA; Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06520 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Yale University; University of Massachusetts System; University of Massachusetts Worcester; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med,Howard Hughes Med Inst, Worcester, MA 01605 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948				Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dolbeare F, 1990, Methods Cell Biol, V33, P207; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; TOURNIER C, UNPUB; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yuan JY, 1999, NAT CELL BIOL, V1, pE44, DOI 10.1038/10037; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	1485	1539	1	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					870	874		10.1126/science.288.5467.870	http://dx.doi.org/10.1126/science.288.5467.870			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797012				2022-12-28	WOS:000086869600042
J	Inglesby, TV; Dennis, DT; Henderson, DA; Bartlett, JG; Ascher, MS; Eitzen, E; Fine, AD; Friedlander, AM; Hauer, J; Koerner, JF; Layton, M; McDade, J; Osterholm, MT; O'Toole, T; Parker, G; Perl, TM; Russell, PK; Schoch-Spana, M; Tonat, K				Inglesby, TV; Dennis, DT; Henderson, DA; Bartlett, JG; Ascher, MS; Eitzen, E; Fine, AD; Friedlander, AM; Hauer, J; Koerner, JF; Layton, M; McDade, J; Osterholm, MT; O'Toole, T; Parker, G; Perl, TM; Russell, PK; Schoch-Spana, M; Tonat, K		Working Grp Civilian Biodefense	Plague as a biological weapon - Medical and public health management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							YERSINIA-PESTIS INFECTION; EXPERIMENTAL PNEUMONIC PLAGUE; DOXYCYCLINE; CIPROFLOXACIN; MICE	Objective The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals following the use of plague as a biological weapon against a civilian population. Participants The working group included 25 representatives from major academic medical centers and research, govern ment, military, public health, and emergency management institutions and agencies. Evidence MEDLINE databases were searched from January 1966 to June 1998 for the Medical Subject Headings plague, Yersinia pestis, biological weapon, biological terrorism, biological warfare, and biowarfare, Review of the bibliographies of the references identified by this search led to subsequent identification of relevant references published prior to 1966. In addition, participants identified other unpublished references and sources. Additional MEDLINE searches were conducted through January 2000. Consensus Process The first draft of the consensus statement was a synthesis of information obtained in the formal evidence-gathering process. The working group was convened to review drafts of the document in October 1998 and May 1999. The final statement incorporates all relevant evidence obtained by the literature search in conjunction with final consensus recommendations supported by all working group members. Conclusions An aerosolized plague weapon could cause fever, cough, chest pain, and hemoptysis with signs consistent with severe pneumonia 1 to 6 days after exposure. Rapid evolution of disease would occur in the 2 to 4 days after symptom onset and would lead to septic shock with high mortality without early treatment. Early treatment and prophylaxis with streptomycin or gentamicin or the tetracycline or fluoroquinolone classes of antimicrobials would be advised.	Johns Hopkins Univ, Johns Hopkins Ctr Civilian Biodef Studies, Sch Med, Baltimore, MD 21202 USA; Johns Hopkins Univ, Johns Hopkins Ctr Civilian Biodef Studies, Sch Publ Hlth, Baltimore, MD 21202 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Ft Collins, CO USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA; Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Berkeley, CA USA; USA, Med Res Inst Infect Dis, Frederick, MD USA; Sci Applicat Int Corp, McLean, VA 22102 USA; New York City Dept Hlth, Off Communicable Dis, New York, NY 10013 USA; US Dept HHS, Off Emergency Preparedness, Rockville, MD USA; Infect Control Advisory Network Inc, Eden Prairie, MN USA	Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; California Department of Health Care Services; Science Applications International Corporation (SAIC); New York City Department of Health & Mental Hygiene	Inglesby, TV (corresponding author), Johns Hopkins Univ, Johns Hopkins Ctr Civilian Biodef Studies, Sch Med, Candler Bldg,Suite 850,111 Market Pl, Baltimore, MD 21202 USA.	tvi@jhsph.edu	Schoch-Spana, Monica/AAZ-9681-2021	Schoch-Spana, Monica/0000-0002-8397-8367; /0000-0003-3225-9968				Aleksic S., 1999, MANUAL CLIN MICROBIO, P483; Alibek Ken., 1999, BIOHAZARD; *AM HOSP FORM SERV, 2000, AHFS DRUG INF; *AM PUBL HLTH ASS, 1995, CONTR COMM DIS MAN, P353; [Anonymous], 1970, World Health Organ Tech Rep Ser, V447, P1; Barnes AM, 1992, INFECT DIS, P1285; BONACORSI SP, 1994, ANTIMICROB AGENTS CH, V38, P481, DOI 10.1128/AAC.38.3.481; BRYGOO E. R., 1958, BULL SOC PATHOL EXOT, V51, P47; BURKLE FM, 1973, CLIN PEDIATR, V12, P291, DOI 10.1177/000992287301200512; BURMEISTER RW, 1962, ANN INTERN MED, V56, P789, DOI 10.7326/0003-4819-56-5-789; BUTLER T, 1976, J INFECT DIS, V133, P493, DOI 10.1093/infdis/133.5.493; BUTLER T, 1995, PRINCIPLES PRACTICE, P2070; BUTLER T, 1991, TROPICAL MED, P408; Byrne WR, 1998, ANTIMICROB AGENTS CH, V42, P675, DOI 10.1128/AAC.42.3.675; CAMPEL G, 1998, HARRISONS PRINCIPLES, P975; Carus W. S., 1998, BIOTERRORISM BIOCRIM; *CDCP, 1997, MMWR-MORBID MORTAL W, V278, P380; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P15; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P242; *CDCP, 1999, UNPUB CRIT BIOL AG P; *CDP, 1992, MMWR-MORBID MORTAL W, V41, P737; CHERNIN E, 1989, J HIST MED ALL SCI, V44, P296, DOI 10.1093/jhmas/44.3.296; *COMM INF DIS, 1997, 1997 REDBOOK, P408; *CONS REP INT SOC, 1995, PEDIATR INFECT DIS J, V14, P1; CROOK LD, 1992, ARCH INTERN MED, V152, P1253, DOI 10.1001/archinte.152.6.1253; CZIEL A, 1997, OBSTET GYNECOL, V89, P524; Davis KJ, 1996, ARCH PATHOL LAB MED, V120, P156; Dennis David T., 1997, P21; *EXP COMM PLAG, 1959, WHO TECHN REP SER, V165; FINEGOLD MJ, 1968, J INFECT DIS, V53, P99; Frean JA, 1996, ANTIMICROB AGENTS CH, V40, P2646, DOI 10.1128/AAC.40.11.2646; Freeman BA, 1985, TXB MICROBIOLOGY, P513; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; Garner JS, 1996, INFECT CONT HOSP EP, V17, P54, DOI 10.1017/S0195941700006123; Gershon RRM, 1998, J OCCUP ENVIRON MED, V40, P497, DOI 10.1097/00043764-199805000-00014; Harris S. H., 1994, FACTORIES DEATH, p[78, 96]; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; HUGHES J, 1998, NATIONS PUBLIC HLTH; *I MED NAT RES COU, 1999, CHEM BIOL TERR RES D, P95; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Kellogg WH, 1920, AM J PUBLIC HEALTH, V10, P599, DOI 10.2105/AJPH.10.7.599; LEWIECKI EM, 1978, ROCKY MT MED J, V75, P201; LYAMUYA EF, 1992, J TROP MED HYG, V95, P335; Makarovskaia L N, 1993, Antibiot Khimioter, V38, P48; MCCRUMB FR, 1953, AM J MED, V14, P284, DOI 10.1016/0002-9343(53)90040-0; McGovern TW, 1997, MED ASPECTS CHEM BIO, P479; MEYER KF, 1961, BACTERIOL REV, V25, P249, DOI 10.1128/MMBR.25.3.249-261.1961; MORSE SA, 1994, METHOD ENZYMOL, V235, P1; NGUYEN VI, 1972, B SOC PATHOL EXOT, P769; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; Poland JD, 1998, BACTERIAL INFECT HUM, P545; RASOAMANANA B, 1989, Archives de l'Institut Pasteur de Madagascar, V56, P37; Ratsitorahina M, 2000, LANCET, V355, P111, DOI 10.1016/S0140-6736(99)05163-6; Russell P, 1996, J ANTIMICROB CHEMOTH, V37, P769, DOI 10.1093/jac/37.4.769; Russell P, 1998, J ANTIMICROB CHEMOTH, V41, P301, DOI 10.1093/jac/41.2.301; Ryzhko I. V., 1998, Antibiotiki i Khimioterapiya, V43, P24; Ryzhko I V, 1994, Antibiot Khimioter, V39, P32; SAKALA E, 1997, OBSTET GYNECOLOGY, P945; SAMOKHODKINA ED, 1992, ANTIBIOT KHIMIOTERAP, V37, P26; SCOTT JL, 1965, NEW ENGL J MED, V272, P1137, DOI 10.1056/NEJM196506032722201; SLACK P, 1989, T ROY SOC TROP MED H, V83, P461, DOI 10.1016/0035-9203(89)90247-2; SMITH MD, 1995, ANTIMICROB AGENTS CH, V39, P2153, DOI 10.1128/AAC.39.9.2153; SPECK RS, 1957, J INFECT DIS, V100, P58, DOI 10.1093/infdis/100.1.58; TITBALL RW, 1999, VACCINES, P734; WATTERBERG KL, 1989, THER DRUG MONIT, V11, P16, DOI 10.1097/00007691-198901000-00004; WELTY TK, 1985, WESTERN J MED, V142, P641; WERNER SB, 1984, JAMA-J AM MED ASSOC, V251, P929, DOI 10.1001/jama.251.7.929; *WHO, 1986, SAF MEAS US OUTBR CO; WHO Group of Consultants, 1970, HLTH ASP CHEM BIOL W, P98; Wilmoth BA, 1996, J CLIN MICROBIOL, V34, P2829, DOI 10.1128/JCM.34.11.2829-2830.1996; WONG TW, 1986, TROP DOCT, V16, P187, DOI 10.1177/004947558601600418; Wu L.-T., 1926, TREATISE PNEUMONIC P	72	688	714	2	85	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2281	2290		10.1001/jama.283.17.2281	http://dx.doi.org/10.1001/jama.283.17.2281			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807389				2022-12-28	WOS:000086671600037
J	Malik, AH; Lee, WM				Malik, AH; Lee, WM			Chronic hepatitis B virus infection: Treatment strategies for the next millennium	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; RECOMBINANT ALPHA-INTERFERON; CHRONIC VIRAL-HEPATITIS; E-ANTIGEN; LAMIVUDINE THERAPY; DOUBLE-BLIND; TRANSCRIPTIONAL ACTIVATION; PREDNISONE WITHDRAWAL; NUCLEOSIDE ANALOGS; THYMOSIN ALPHA(1)	Chronic hepatitis B Virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma worldwide. Its prevalence approaches 10% in hyperendemic areas, such as southeast Asia, China, and Africa. Although chronic HBV infection is seen less frequently in North America and Europe, an estimated 1.25 million persons in the United States are infected. In the past decade, revolutionary strides have been made toward the treatment of chronic HBV infection. Interferon-a was once the only available therapy but has recently been joined by the nucleoside analogues, the most extensively studied of which is lamivudine. Interferon therapy continues to have a role in the treatment of a carefully selected group of patients. Lamivudine therapy, which has less stringent selection criteria, suppresses HBV DNA in almost all treated patients: Seventeen percent to 33% experience loss of hepatitis B e antigen, and 53% to 56% have a histologic response. Extended lamivudine treatment leads to the development of a specific lamivudine-resistant virus with base-pair substitutions at the YMDD locus of the DNA polymerase. Newer nucleoside analogues and other immunomodulator therapies are being investigated. In the future, combination therapy with different classes of agents may yield improved response rates and delay the development of resistance.	Univ Texas, SW Med Ctr, Div Digest & Liver Dis, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lee, WM (corresponding author), Univ Texas, SW Med Ctr, Div Digest & Liver Dis, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628; Andreone P, 1996, HEPATOLOGY, V24, P774; Andreone P, 1996, LIVER, V16, P207; Atkins M, 1998, HEPATOLOGY, V28, p319A; Bartholomeusz A, 1997, INTERVIROLOGY, V40, P337, DOI 10.1159/000150566; Bloomer J, 1998, HEPATOLOGY, V28, p486A; Bloomer J., 1997, Hepatology, V26, p428A; BROOK MG, 1989, HEPATOLOGY, V10, P761, DOI 10.1002/hep.1840100502; BRUNETTO MR, 1989, HEPATOLOGY, V10, P198, DOI 10.1002/hep.1840100213; BRUNETTO MR, 1993, GASTROENTEROLOGY, V105, P845, DOI 10.1016/0016-5085(93)90903-P; CAMMACK N, 1992, BIOCHEM PHARMACOL, V43, P2059, DOI 10.1016/0006-2952(92)90162-C; CARMAN WF, 1989, LANCET, V2, P588; Chayama K, 1998, HEPATOLOGY, V27, P1711, DOI 10.1002/hep.510270634; Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906; Chien RN, 1999, HEPATOLOGY, V30, P770, DOI 10.1002/hep.510300313; Chien RN, 1998, HEPATOLOGY, V27, P1383, DOI 10.1002/hep.510270527; CHISARI FV, 1995, SPRINGER SEMIN IMMUN, V17, P261, DOI 10.1007/BF00196169; COHARD M, 1994, HEPATOLOGY, V20, P1390, DOI 10.1002/hep.1840200603; Colledge D, 1997, HEPATOLOGY, V26, P216; DECLERCQ E, 1994, NUCLEOS NUCLEOT NUCL, V13, P1271, DOI 10.1080/15257779408012151; DIBISCEGLIE AM, 1993, AM J GASTROENTEROL, V88, P1887; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; DOOLEY JS, 1986, GASTROENTEROLOGY, V90, P150, DOI 10.1016/0016-5085(86)90087-9; FATTOVICH G, 1994, J HEPATOL, V21, P361, DOI 10.1016/S0168-8278(05)80314-9; Fried MW, 1996, MED CLIN N AM, V80, P957, DOI 10.1016/S0025-7125(05)70475-2; FRIED MW, 1992, HEPATOLOGY, V16, pA127; Fu L, 1998, BIOCHEM PHARMACOL, V55, P1567, DOI 10.1016/S0006-2952(98)00050-1; Gilson R. J. C., 1996, Hepatology, V24, p281A; Gilson RJC, 1998, HEPATOLOGY, V28, p491A; Haiderali AM, 1999, HEPATOLOGY, V30, p347A; Heathcote EJ, 1998, HEPATOLOGY, V28, p317A; Heathcote J, 1998, HEPATOLOGY, V28, p318A; Heathcote J., 1998, Journal of Hepatology, V28, P43, DOI 10.1016/S0168-8278(98)80380-2; Heathcote J, 1996, HEPATOLOGY, V24, P628; Honkoop P, 1998, J VIRAL HEPATITIS, V5, P307, DOI 10.1046/j.1365-2893.1998.00121.x; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; HOOFNAGLE JH, 1981, ANN INTERN MED, V94, P744, DOI 10.7326/0003-4819-94-6-744; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; HOOFNAGLE JH, 1993, GASTROENTEROLOGY, V104, P1116, DOI 10.1016/0016-5085(93)90281-G; HOOFNAGLE JH, 1990, NEW ENGL J MED, V323, P337, DOI 10.1056/NEJM199008023230510; JEFFERS J, 1998, ANTIVIR RES, V37, pA197; Johnson MA, 1999, CLIN PHARMACOKINET, V36, P41, DOI 10.2165/00003088-199936010-00004; Josefson D, 1998, BRIT MED J, V317, P1034; Kahn J, 1999, JAMA-J AM MED ASSOC, V282, P2305, DOI 10.1001/jama.282.24.2305; KANE M, 1995, VACCINE, V13, pS47; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Kuhen KL, 1999, VIROLOGY, V254, P182, DOI 10.1006/viro.1998.9536; Kuhen KL, 1998, J VIROL, V72, P9934, DOI 10.1128/JVI.72.12.9934-9939.1998; Lacey LF, 1999, HEPATOLOGY, V30, p481A; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lai CL, 1998, HEPATOLOGY, V28, p490A; Lau GKK, 1998, HEPATOLOGY, V28, p216A; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Leung N, 1998, HEPATOLOGY, V28, p587A; LEUNG N, 1948, HEPATOLOGY, V28, pA489; Leung YK, 1998, HEPATOLOGY, V28, p216A; Liaw YF, 1998, GASTROENTEROLOGY, V114, pA1289, DOI 10.1016/S0016-5085(98)85233-5; LOK ASF, 1984, LIVER, V4, P45; Main J, 1996, J VIRAL HEPATITIS, V3, P211, DOI 10.1111/j.1365-2893.1996.tb00098.x; Mancini M, 1996, P NATL ACAD SCI USA, V93, P12496, DOI 10.1073/pnas.93.22.12496; Marques AR, 1998, J INFECT DIS, V178, P1483, DOI 10.1086/314430; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; Melegari M, 1998, HEPATOLOGY, V27, P628, DOI 10.1002/hep.510270243; MOYER LA, 1994, AM J PREV MED, V10, P45, DOI 10.1016/S0749-3797(18)30514-2; MUTCHNICK MG, 1991, HEPATOLOGY, V14, P409, DOI 10.1002/hep.1840140302; MUTCHNICK MG, 1995, GASTROENTEROLOGY, V108, pA1127; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Niesters HGM, 1998, J INFECT DIS, V177, P1382, DOI 10.1086/517819; Ono-Nita SK, 1998, HEPATOLOGY, V28, p165A; PAAR DP, 1992, 32ND INT C ANT AG CH, P264; PERRILLO R, 1995, GASTROENTEROLOGY, V109, P908, DOI 10.1016/0016-5085(95)90401-8; Perrillo R, 1999, GASTROENTEROLOGY, V116, pA1261; PERRILLO RP, 1988, ANN INTERN MED, V109, P95, DOI 10.7326/0003-4819-109-2-95; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PERRILLO RP, 1990, HEPATOLOGY, V12, P1433, DOI 10.1002/hep.1840120626; PERRILLO RP, 1986, J HEPATOL, V3, pS57, DOI 10.1016/S0168-8278(86)80101-5; PETERS M, 1989, SEMIN LIVER DIS, V9, P235, DOI 10.1055/s-2008-1040516; Pol S, 1998, HEPATOLOGY, V28, p488A; POL S, 1933, CR HEBD ACAD SCI, V316, P688; Putlitz JZ, 1998, HEPATOLOGY, V28, p590A; RENAULT PF, 1987, ARCH INTERN MED, V147, P1577, DOI 10.1001/archinte.147.9.1577; SCHALM SW, 1995, J HEPATOL, V22, P52; Schiff E, 1998, HEPATOLOGY, V28, p163A; Schiff E, 1998, HEPATOLOGY, V28, p388A; Senturk H, 1998, HEPATOLOGY, V28, p588A; Tang JH, 1998, J INFECT DIS, V178, P866, DOI 10.1086/515345; Tassopoulos NC, 1999, HEPATOLOGY, V29, P889, DOI 10.1002/hep.510290321; Taylor JL, 1998, SEMIN ONCOL, V25, P23; Tompkins WA, 1999, J INTERF CYTOK RES, V19, P817, DOI 10.1089/107999099313325; Trepo C, 1996, HEPATOLOGY, V24, P247; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662; Wolters LMM, 1998, J HEPATOL, V28, P909, DOI 10.1016/S0168-8278(98)80243-2; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; Xiong X, 1998, HEPATOLOGY, V28, p491A; Xiong XF, 1998, HEPATOLOGY, V28, P1669, DOI 10.1002/hep.510280629; 1991, MMWR MORB MORTAL WKL, V40, P1; 1999, MED LETT, V41, P113	100	126	141	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					723	731		10.7326/0003-4819-132-9-200005020-00007	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308VT	10787366				2022-12-28	WOS:000086734100006
J	Mann, RD; Pearce, GL; Dunn, N; Shakir, S				Mann, RD; Pearce, GL; Dunn, N; Shakir, S			Sedation with "non-sedating'' antihistamines: four prescription-event monitoring studies in general practice	BRITISH MEDICAL JOURNAL			English	Article							2ND-GENERATION ANTIHISTAMINES; FEXOFENADINE; LIFE	Objectives To investigate the frequency with which sedation was reported in post-marketing surveillance studies of four second generation antihistamines: loratadine, cetirizine, fexofenadine, and acrivastine. Design Prescription-event monitoring studies. Setting Prescriptions were obtained for each cohort in the immediate post-marketing period. Subjects Event data were obtained for a total of 43 363 patients. Main outcome measure Reporting of sedation or drowsiness. Results The adds ratios (adjusted for age and sex) for the incidence of sedation were 0.63 (95% confidence interval 0.36 to 1.11; P = 0.1) for fexofenadine; 2.79 (1.69 to 4.58; p < 0.0001) for acrivastine, and 3.53 (2.07 to 5.42; P < 0.0001) for cetirizine compared with loratadine. No increased risk of accident or injury it as evident with any of the four drugs. Conclusions Although the risk of sedation was low with all four drugs, fexofenadine and loratadine may be more appropriate for people working in safety critical jobs.	Univ Southampton, Southampton, Hants, England; Drug Safety Res Unit, Southampton SO31 1AA, Hants, England	University of Southampton	Mann, RD (corresponding author), Manor Cottage, Midhurst GU29 9RL, W Sussex, England.							Gonzalez MA, 1998, INT J CLIN PHARM TH, V36, P292; Mann RD, 1998, BRIT J CLIN PHARMACO, V46, P195, DOI 10.1046/j.1365-2125.1998.00774.x; MANN RD, 1984, MODERN DRUG USE, P16; Markham A, 1998, DRUGS, V55, P269, DOI 10.2165/00003495-199855020-00012; Nightingale CH, 1996, PHARMACOTHERAPY, V16, P905; Nolen TM, 1997, CLIN THER, V19, P39, DOI 10.1016/S0149-2918(97)80071-9; Pinto YM, 1999, LANCET, V353, P980, DOI 10.1016/S0140-6736(99)01009-0; Slater JW, 1999, DRUGS, V57, P31, DOI 10.2165/00003495-199957010-00004; Wilton LV, 1998, BRIT J OBSTET GYNAEC, V105, P882, DOI 10.1111/j.1471-0528.1998.tb10234.x	9	102	106	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1184	1186		10.1136/bmj.320.7243.1184	http://dx.doi.org/10.1136/bmj.320.7243.1184			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784544	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000086832800020
J	Mourits, MP; van Kempen-Harteveld, ML; Garcia, MBG; Koppeschaar, HPF; Tick, L; Terwee, CB				Mourits, MP; van Kempen-Harteveld, ML; Garcia, MBG; Koppeschaar, HPF; Tick, L; Terwee, CB			Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study	LANCET			English	Article							QUALITY-OF-LIFE; RADIATION RETINOPATHY; ORBITAL DECOMPRESSION; OPHTHALMOPATHY; DISEASE; MANAGEMENT; IRRADIATION; PREDNISONE; THERAPY	Background The best treatment (steroids, irradiation, or both) for moderately severe Graves' orbitopathy, a self-limiting disease is not known. We tested the efficacy of external beam irradiation compared with sham-irradiation. Methods In a double-blind randomised clinical trial, 30 patients with moderately severe Graves' orbitopathy had radiotherapy (20 Gy in ten fractions), and 30 were assigned sham-irradiation (ten fractions of 0 Gy). Treatment outcome was measured qualitatively by changes in major and minor criteria and quantitatively in several ophthalmic and other variables, such as eyelid aperture, proptosis, eye movements, subjective eye score, and clinical-activity score at 24 weeks. Findings The qualitative treatment outcome was successful in 18 of 30 (60%) irradiated patients versus nine of 29 (31%) sham-irradiated patients at week 24 (relative risk [RR]=1.9 [95% CI 1.0-3.6], p=0.04). This difference was caused by improvements in diplopia grade, but not by reduction of proptosis, nor of eyelid swelling. Quantitatively, elevation improved significantly in the radiotherapy group, whereas all other variables remained unchanged. The field of binocular single vision was enlarged in 11 of 17 patients after irradiation compared with two of 15 after sham-irradiation. Nevertheless, only 25% of the irradiated patients were spared from additional strabismus surgery. Interpretation In these patients with moderately severe Graves' orbitopathy, radiotherapy should be used only to treat motility impairment.	Univ Med Ctr, Donders Inst Ophthalmol, Orbital Unit, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Dept Radiotherapy, NL-3584 CX Utrecht, Netherlands; Univ Med Ctr, Dept Endocrinol, NL-3584 CX Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	Mourits, MP (corresponding author), Univ Med Ctr, Donders Inst Ophthalmol, Orbital Unit, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.			Terwee, Caroline/0000-0003-4570-2826				BAHN RS, 1987, ENDOCRIN METAB CLIN, V16, P391, DOI 10.1016/S0889-8529(18)30485-7; BARTALENA L, 1983, J CLIN ENDOCR METAB, V56, P1139, DOI 10.1210/jcem-56-6-1139; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; Bartley GB, 1996, AM J OPHTHALMOL, V121, P200, DOI 10.1016/S0002-9394(14)70585-9; Baschieri L, 1997, THYROID, V7, P579, DOI 10.1089/thy.1997.7.579; BURCH HB, 1993, ENDOCR REV, V14, P747, DOI 10.1210/er.14.6.747; DANDONA P, 1979, BRIT MED J, V1, P374, DOI 10.1136/bmj.1.6160.374; DONALDSON SS, 1973, J CLIN ENDOCR METAB, V37, P276, DOI 10.1210/jcem-37-2-276; DUKEELDER S, 1962, FDN OPHTHALMOLOGY HE, V7, P370; Gerding MN, 1998, J ENDOCRINOL INVEST, V21, P459, DOI 10.1007/BF03347327; Gerding MN, 1997, THYROID, V7, P885, DOI 10.1089/thy.1997.7.885; Gorman C A, 1991, Thyroid, V1, P353, DOI 10.1089/thy.1991.1.353; KINYOUN JL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1473; KRASSAS GE, 1995, CLIN ENDOCRINOL, V42, P571, DOI 10.1111/j.1365-2265.1995.tb02682.x; LEONE CR, 1984, OPHTHALMOLOGY, V91, P770; MEIN J, 1991, DIAGNOSIS MANAGEMENT, P86; Meinert CL, 1998, JAMA-J AM MED ASSOC, V279, P1487, DOI 10.1001/jama.279.18.1487; MOURITS MP, 1994, OPHTHALMOLOGY, V101, P1341; MOURITS MP, 1990, OPHTHALMOLOGY, V97, P636; Mourits MP, 1997, CLIN ENDOCRINOL, V47, P9, DOI 10.1046/j.1365-2265.1997.2331047.x; MOURITS MP, 1998, 6 INT S GRAV OPHTH A; OLIVOTTO IA, 1985, INT J RADIAT ONCOL, V11, P2085, DOI 10.1016/0360-3016(85)90088-4; Paridaens D, 1998, EYE, V12, P800, DOI 10.1038/eye.1998.207; PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479; PRUMMEL MF, 1989, NEW ENGL J MED, V321, P1353, DOI 10.1056/NEJM198911163212002; PRUMMEL MF, 1993, LANCET, V342, P949, DOI 10.1016/0140-6736(93)92001-A; Terwee CB, 1998, BRIT J OPHTHALMOL, V82, P773, DOI 10.1136/bjo.82.7.773; VIEBAHN M, 1991, BRIT J OPHTHALMOL, V75, P629, DOI 10.1136/bjo.75.10.629; WERNER SC, 1977, J CLIN ENDOCR METAB, V44, P204	29	182	192	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1505	1509		10.1016/S0140-6736(00)02165-6	http://dx.doi.org/10.1016/S0140-6736(00)02165-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801172				2022-12-28	WOS:000086830100012
J	Reese, DM				Reese, DM			Choice of hormonal therapy for prostate cancer	LANCET			English	Editorial Material							BICALUTAMIDE; MONOTHERAPY; CASTRATION; ANDROGEN		Univ Calif San Francisco, Mt Zion Med Ctr, Urol Oncol Program, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Reese, DM (corresponding author), Univ Calif San Francisco, Mt Zion Med Ctr, Urol Oncol Program, San Francisco, CA 94115 USA.							Bales GT, 1996, UROLOGY, V47, P38, DOI 10.1016/S0090-4295(96)80007-0; Boccardo F, 1999, J CLIN ONCOL, V17, P2027, DOI 10.1200/JCO.1999.17.7.2027; DALESIO O, 1995, LANCET, V346, P265; FOWLER JE, 1995, J UROLOGY, V154, P448, DOI 10.1016/S0022-5347(01)67071-X; Huggins C, 1941, CANCER RES, V1, P293; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; LABRIE F, 1982, CLIN INVEST MED, V5, P267; LABRIE F, 1995, LANCET, V346, P1031; QUARTEY P, 1995, LANCET, V346, P1031; Schroder FH, 2000, BRIT J CANCER, V82, P283, DOI 10.1054/bjoc.1999.0916; Tyrrell CJ, 1998, EUR UROL, V33, P447, DOI 10.1159/000019634; WAXMAN J, 1995, LANCET, V346, P1030	12	20	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1474	1475		10.1016/S0140-6736(00)02155-3	http://dx.doi.org/10.1016/S0140-6736(00)02155-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801162				2022-12-28	WOS:000086830100002
J	Toft, AD				Toft, AD			Surgery for primary hyperparathyroidism - sooner rather than later	LANCET			English	Editorial Material							PARATHYROIDECTOMY; SURVIVAL		Royal Infirm, Endocrine Unit, Edinburgh EH3 9YW, Midlothian, Scotland	Royal Infirmary of Edinburgh	Toft, AD (corresponding author), Royal Infirm, Endocrine Unit, Edinburgh EH3 9YW, Midlothian, Scotland.							CHAN AK, 1995, ANN SURG, V222, P402, DOI 10.1097/00000658-199509000-00017; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; HEDBACK G, 1991, WORLD J SURG, V15, P399, DOI 10.1007/BF01658740; Nilsson IL, 1999, SURGERY, V126, P1049, DOI 10.1067/msy.2099.101422; PALMER M, 1987, LANCET, V1, P59; Richards ML, 1999, SURGERY, V126, P1160, DOI 10.1067/msy.2099.101436; SCHOLZ DA, 1981, MAYO CLIN PROC, V56, P473; Silverberg SJ, 1999, NEW ENGL J MED, V341, P1249, DOI 10.1056/NEJM199910213411701; Wermers RA, 1998, AM J MED, V104, P115, DOI 10.1016/S0002-9343(97)00270-2	9	19	23	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1478	1479		10.1016/S0140-6736(00)02158-9	http://dx.doi.org/10.1016/S0140-6736(00)02158-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801165				2022-12-28	WOS:000086830100005
J	Brainard, MS; Doupe, AJ				Brainard, MS; Doupe, AJ			Interruption of a basal ganglia-forebrain circuit prevents plasticity of learned vocalizations	NATURE			English	Article							ADULT ZEBRA FINCHES; SONG DEVELOPMENT; VOCAL BEHAVIOR; NUCLEUS; LESIONS; MAINTENANCE; NEURONS; CANARY; SYSTEM; BRAIN	Birdsong, like speech, is a learned vocal behaviour that relies greatly on hearing; in both songbirds(1) and humans(2) the removal of auditory feedback by deafening leads to a gradual deterioration of adult vocal production. Here we investigate the neural mechanisms that contribute to the processing of auditory feedback during the maintenance of song in adult zebra finches. We show that the deleterious effects on song production that normally follow deafening can be prevented by a second insult to the nervous system-the lesion of a basal ganglia-forebrain circuit. The results suggest that the removal of auditory feedback leads to the generation of an instructive signal that actively drives nonadaptive changes in song; they also suggest that this instructive signal is generated within (or conveyed through) the basal ganglia-forebrain pathway. Our findings provide evidence that cortical-basal ganglia circuits may participate in the evaluation of sensory feedback during calibration of motor performance, and demonstrate that damage to such circuits can have little effect on previously learned behaviour while conspicuously disrupting the capacity to adaptively modify that behaviour.	Univ Calif San Francisco, Keck Ctr Integrat Neurosci, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Keck Ctr Integrat Neurosci, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Brainard, MS (corresponding author), Univ Calif San Francisco, Keck Ctr Integrat Neurosci, Dept Physiol, San Francisco, CA 94143 USA.			Brainard, Michael/0000-0002-9425-9907				AKUTAGAWA E, 1994, P NATL ACAD SCI USA, V91, P12413, DOI 10.1073/pnas.91.26.12413; ARNOLD AP, 1975, J EXP ZOOL, V191, P261, DOI 10.1002/jez.1401910212; BOTTJER SW, 1984, SCIENCE, V224, P901, DOI 10.1126/science.6719123; Bottjer SW, 1997, J NEUROBIOL, V33, P602, DOI 10.1002/(SICI)1097-4695(19971105)33:5<602::AID-NEU8>3.0.CO;2-8; Bottjer SW, 1997, BRAIN BEHAV EVOLUT, V50, P284, DOI 10.1159/000113342; COWIE R, 1992, POSTINGUALLY ACQUIRE, P1; Doupe AJ, 1997, J NEUROSCI, V17, P1147; Doupe AJ, 1999, ANNU REV NEUROSCI, V22, P567, DOI 10.1146/annurev.neuro.22.1.567; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Hessler NA, 1999, J NEUROSCI, V19, P10461; Houde JF, 1998, SCIENCE, V279, P1213, DOI 10.1126/science.279.5354.1213; JOHNSON F, 1994, DEVELOPMENT, V120, P13; KIRN JR, 1993, J NEUROSCI, V13, P1654; KLEIN D, 1994, NEUROREPORT, V5, P2295, DOI 10.1097/00001756-199411000-00022; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Konishi M., 1965, Zeitschrift fuer Tierpsychologie, V22, P770; Leonardo A, 1999, NATURE, V399, P466, DOI 10.1038/20933; MARLER P, 1970, J COMP PHYSIOL PSYCH, V71, P1, DOI 10.1037/h0029144; MORRISON RG, 1993, J NEUROBIOL, V24, P1045, DOI 10.1002/neu.480240805; Nakamura K, 1999, J NEUROPHYSIOL, V82, P1063, DOI 10.1152/jn.1999.82.2.1063; NORDEEN KW, 1993, BEHAV NEURAL BIOL, V59, P79, DOI 10.1016/0163-1047(93)91215-9; NORDEEN KW, 1992, BEHAV NEURAL BIOL, V57, P58, DOI 10.1016/0163-1047(92)90757-U; NOTTEBOHM F, 1976, J COMP NEUROL, V165, P457, DOI 10.1002/cne.901650405; SCHARFF C, 1991, J NEUROSCI, V11, P2896; SOHRABJI F, 1990, BEHAV NEURAL BIOL, V53, P51, DOI 10.1016/0163-1047(90)90797-A; Solis MM, 1999, J NEUROSCI, V19, P4559; VICARIO DS, 1991, J NEUROBIOL, V22, P63, DOI 10.1002/neu.480220107; VU ET, 1994, J NEUROSCI, V14, P6924; Williams H, 1999, J NEUROBIOL, V39, P14, DOI 10.1002/(SICI)1097-4695(199904)39:1<14::AID-NEU2>3.0.CO;2-X; Yu AC, 1996, SCIENCE, V273, P1871, DOI 10.1126/science.273.5283.1871	30	342	356	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					762	766		10.1038/35008083	http://dx.doi.org/10.1038/35008083			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783889				2022-12-28	WOS:000086523600052
J	Houlahan, JE; Findlay, CS; Schmidt, BR; Meyer, AH; Kuzmin, SL				Houlahan, JE; Findlay, CS; Schmidt, BR; Meyer, AH; Kuzmin, SL			Quantitative evidence for global amphibian population declines	NATURE			English	Article							NATURAL FLUCTUATIONS; HUMAN IMPACTS; FROG; MORTALITY; MOUNTAIN; SYNERGISM; COLORADO; FAUNA	Although there is growing concern that amphibian populations are declining globally(1-3), much of the supporting evidence is either anecdotal(4,5) or derived from short-term studies at small geographical scales(6-8). This raises questions not only about the difficulty of detecting temporal trends in populations which are notoriously variable(9,10), but also about the validity of inferring global trends from local or regional studies(11,12). Here we use data from 936 populations to assess large-scale temporal and spatial variations in amphibian population trends. On a global scale, our results indicate relatively rapid declines from the late 1950s/early 1960s to the late 1960s, followed by a reduced rate of decline to the present. Amphibian population trends during the 1960s were negative in western Europe (including the United Kingdom) and North America, but only the latter populations showed declines from the 1970s to the late 1990s. These results suggest that while large-scale trends show considerable geographical and temporal variability, amphibian populations are in fact declining-and that this decline has been happening for several decades.	Univ Ottawa, Ottawa Carleton Inst Biol, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Inst Environm, Ottawa, ON K1N 6N5, Canada; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; Swiss Fed Stat Off, Sekt Hsch & Wissensch, CH-2010 Neuchatel, Switzerland; Russian Acad Sci, Inst Ecol & Evolut, Moscow 117071, Russia	University of Ottawa; University of Ottawa; University of Zurich; Russian Academy of Sciences	Houlahan, JE (corresponding author), Univ Ottawa, Ottawa Carleton Inst Biol, 30 Marie Curie, Ottawa, ON K1N 6N5, Canada.		Schmidt, Benedikt R./B-8491-2008	Schmidt, Benedikt R./0000-0002-4023-1001				BEEBEE TJC, 1990, BIOL CONSERV, V37, P59; Berger L, 1998, P NATL ACAD SCI USA, V95, P9031, DOI 10.1073/pnas.95.15.9031; Blaustein AR, 1998, AM ZOOL, V38, P799; BLAUSTEIN AR, 1994, CONSERV BIOL, V8, P60, DOI 10.1046/j.1523-1739.1994.08010060.x; BLAUSTEIN AR, 1990, TRENDS ECOL EVOL, V5, P203, DOI 10.1016/0169-5347(90)90129-2; CAREY C, 1993, CONSERV BIOL, V7, P355, DOI 10.1046/j.1523-1739.1993.07020355.x; CORN PS, 1984, J HERPETOL, V18, P147, DOI 10.2307/1563742; CUNNINGHAM AA, 1993, VET REC, V133, P141, DOI 10.1136/vr.133.6.141; Draper N.R., 1998, APPL REGRESSION ANAL, P79; Drost CA, 1996, CONSERV BIOL, V10, P414, DOI 10.1046/j.1523-1739.1996.10020414.x; Englund G, 1999, ECOLOGY, V80, P1132, DOI 10.1890/0012-9658(1999)080[1132:TIODSC]2.0.CO;2; Green D.M., 1997, AMPHIBIANS DECLINE C, P291; HARTE J, 1989, CONSERV BIOL, V3, P149, DOI 10.1111/j.1523-1739.1989.tb00067.x; Hecnar SJ, 1996, ECOLOGY, V77, P2091, DOI 10.2307/2265703; Hecnar SJ, 1997, CONSERV BIOL, V11, P670, DOI 10.1046/j.1523-1739.1997.96096.x; Heyer W.R., 1994, MEASURING MONITORING; KIESECKER JM, 1995, P NATL ACAD SCI USA, V92, P11049, DOI 10.1073/pnas.92.24.11049; Laurance WF, 1996, CONSERV BIOL, V10, P406, DOI 10.1046/j.1523-1739.1996.10020406.x; Lips KR, 1998, CONSERV BIOL, V12, P106, DOI 10.1046/j.1523-1739.1998.96359.x; LONG LE, 1995, CONSERV BIOL, V9, P1301, DOI 10.1046/j.1523-1739.1995.951301.x; Meyer AH, 1998, P ROY SOC B-BIOL SCI, V265, P523, DOI 10.1098/rspb.1998.0326; PECHMANN JHK, 1994, HERPETOLOGICA, V50, P65; PECHMANN JHK, 1991, SCIENCE, V253, P892, DOI 10.1126/science.253.5022.892; Pounds JA, 1999, NATURE, V398, P611, DOI 10.1038/19297; Pounds JA, 1997, CONSERV BIOL, V11, P1307, DOI 10.1046/j.1523-1739.1997.95485.x; TYLER M J, 1991, Alytes (Paris), V9, P43; WAKE D B, 1991, Alytes (Paris), V9, P33; WAKE DB, 1991, SCIENCE, V253, P860, DOI 10.1126/science.253.5022.860; Wake DB, 1998, TRENDS ECOL EVOL, V13, P379, DOI 10.1016/S0169-5347(98)01428-1; WEYGOLDT P, 1989, STUD NEOTROP FAUNA E, V24, P249, DOI 10.1080/01650528909360795	30	954	1031	7	306	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					752	755		10.1038/35008052	http://dx.doi.org/10.1038/35008052			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783886				2022-12-28	WOS:000086523600049
J	Liljegren, SJ; Ditta, GS; Eshed, HY; Savidge, B; Bowman, JL; Yanofsky, MF				Liljegren, SJ; Ditta, GS; Eshed, HY; Savidge, B; Bowman, JL; Yanofsky, MF			SHATTERPROOF MADS-box genes control seed dispersal in Arabidopsis	NATURE			English	Article							FLORAL ORGAN IDENTITY; BRASSICA-NAPUS L; ECTOPIC EXPRESSION; FLOWER DEVELOPMENT; PLANT DEVELOPMENT; POD DEVELOPMENT; MESSENGER-RNA; TRANSCRIPTION; POLYGALACTURONASE; DEHISCENCE	The fruit, which mediates the maturation and dispersal of seeds, is a complex structure unique to flowering plants. Seed dispersal in plants such as Arabidopsis occurs by a process called fruit dehiscence, or pod shatter. Few studies(1-3) have focused on identifying genes that regulate this process, in spite of the agronomic value of controlling seed dispersal in crop plants such as canola(4,5). Here we show that the closely related SHATTERPROOF (SHP1) and SHATTERPROOF2 (SHP2) MADS-box genes are required for fruit dehiscence in Arabidopsis. Moreover, SHP1 and SHP2 are functionally redundant, as neither single mutant displays a novel phenotype. Our studies of shp1 shp2 fruit, and of plants constitutively expressing SHP1 and SHP2, show that these two genes control dehiscence zone differentiation and promote the lignification of adjacent cells. Our results indicate that further analysis of the molecular events underlying fruit dehiscence may allow genetic manipulation of pod shatter in crop plants.	Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	University of California System; University of California San Diego; University of California System; University of California Davis	Yanofsky, MF (corresponding author), Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.			Bowman, John/0000-0001-7347-3691; Eshed, Yuval/0000-0001-8290-0018				BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Bowman JL, 1999, CURR TOP DEV BIOL, V45, P155, DOI 10.1016/S0070-2153(08)60316-6; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; Child RD, 1998, J EXP BOT, V49, P829, DOI 10.1093/jexbot/49.322.829; COUPE SA, 1993, PLANT MOL BIOL, V23, P1223, DOI 10.1007/BF00042355; Eshed Y, 1999, CELL, V99, P199, DOI 10.1016/S0092-8674(00)81651-7; Ferrandiz C, 1999, ANNU REV BIOCHEM, V68, P321, DOI 10.1146/annurev.biochem.68.1.321; Flanagan CA, 1996, PLANT J, V10, P343, DOI 10.1046/j.1365-313X.1996.10020343.x; Gu Q, 1998, DEVELOPMENT, V125, P1509; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; Jenkins ES, 1996, J EXP BOT, V47, P111, DOI 10.1093/jxb/47.1.111; KEMPIN SA, 1995, SCIENCE, V267, P522, DOI 10.1126/science.7824951; Kempin SA, 1997, NATURE, V389, P802, DOI 10.1038/39770; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MacLeod J., 1981, Oilseed rape book., P107; MANDEL MA, 1995, PLANT CELL, V7, P1763, DOI 10.1105/tpc.7.11.1763; MEAKIN PJ, 1990, J EXP BOT, V41, P995, DOI 10.1093/jxb/41.8.995; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; Petersen M, 1996, PLANT MOL BIOL, V31, P517, DOI 10.1007/BF00042225; Purugganan MD, 1997, J MOL EVOL, V45, P392, DOI 10.1007/PL00006244; Riechmann JL, 1997, BIOL CHEM, V378, P1079; Rollins R.C., 1993, CRUCIFERAE CONTINENT; ROUNSLEY SD, 1995, PLANT CELL, V7, P1259, DOI 10.1105/tpc.7.8.1259; SAVIDGE B, 1995, PLANT CELL, V7, P721, DOI 10.1105/tpc.7.6.721; Spence J, 1996, J MICROSC-OXFORD, V181, P195, DOI 10.1046/j.1365-2818.1996.111391.x; SPENCE J, 1992, DEV SILIQUE ARABIDOP; SUNDARESAN V, 1995, GENE DEV, V9, P1797, DOI 10.1101/gad.9.14.1797; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	30	643	704	3	116	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					766	770		10.1038/35008089	http://dx.doi.org/10.1038/35008089			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783890				2022-12-28	WOS:000086523600053
J	Berger, A				Berger, A			Cell preselection is key to gene therapy success	BRITISH MEDICAL JOURNAL			English	News Item																		2000, PROC NATL ACAD SCI, V97, P5411	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1296	1296		10.1136/bmj.320.7245.1296	http://dx.doi.org/10.1136/bmj.320.7245.1296			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807617	Green Published			2022-12-28	WOS:000087077400018
J	Kovacs, JA; Masur, H				Kovacs, JA; Masur, H			Drug therapy: Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PNEUMOCYSTIS-CARINII PNEUMONIA; MYCOBACTERIUM-AVIUM COMPLEX; ACTIVE ANTIRETROVIRAL THERAPY; PLACEBO-CONTROLLED TRIAL; RANDOMIZED TRIAL; TRIMETHOPRIM-SULFAMETHOXAZOLE; ACQUIRED-IMMUNODEFICIENCY; CYTOMEGALOVIRUS RETINITIS; MAINTENANCE THERAPY; TOXOPLASMIC ENCEPHALITIS		NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Masur, H (corresponding author), NIH, Dept Crit Care Med, Ctr Clin, 10 Ctr Dr, Bethesda, MD 20892 USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				ABERG JA, 2000, P 7 C RETR OPP INF S, P123; AMPEL NM, 1999, AIDS THERAPY, P423; [Anonymous], 1995, CLIN INFECT DIS   S1, V21, pS32; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P1; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1; [Anonymous], 1997, MMWR MORB MORTAL WKL, V46, P1; BENSON CA, 1996, P 3 C RETR OPP INF W, P91; BOZZETTE SA, 1991, NEW ENGL J MED, V324, P580, DOI 10.1056/NEJM199102283240902; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; Brosgart CL, 1998, AIDS, V12, P269, DOI 10.1097/00002030-199803000-00004; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Cohn DL, 1999, CLIN INFECT DIS, V29, P125, DOI 10.1086/520141; COSTAGLIOLA D, 1998, 12 INT C AIDS GEN JU, P82; CURRIER JS, 1999, 39 INT C ANT AG CHEM, P19; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; Dunne MW, 1999, LANCET, V354, P891, DOI 10.1016/S0140-6736(98)10328-8; DWORKIN M, 1999, P 6 C RETR OPP INF C, P198; El-Sadr WM, 1999, CLIN INFECT DIS, V29, P775, DOI 10.1086/520433; El-Sadr WM, 1998, NEW ENGL J MED, V339, P1889, DOI 10.1056/NEJM199812243392604; ELSADR WM, 2000, P 7 C RETR OPP INF S, P122; Engels EA, 1999, ANN INTERN MED, V131, P256, DOI 10.7326/0003-4819-131-4-199908170-00004; FLEMING C, 2000, P 7 C RETR OPP INF S, P123; FLEXNER C, 1999, AIDS THERAPY, P785; Furrer H, 1999, NEW ENGL J MED, V340, P1301, DOI 10.1056/NEJM199904293401701; FURRER H, 2000, P 7 C RETR OPP INF S, P122; Giorgi JV, 1998, AIDS, V12, P1833, DOI 10.1097/00002030-199814000-00015; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; Gordin F, 2000, JAMA-J AM MED ASSOC, V283, P1445, DOI 10.1001/jama.283.11.1445; Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505; Gordin FM, 1999, CLIN INFECT DIS, V28, P1080, DOI 10.1086/514748; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Graham NMH, 1996, ARCH INTERN MED, V156, P889, DOI 10.1001/archinte.156.8.889; Grulich AE, 1999, J ACQ IMMUN DEF SYND, V21, pS27; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Havlir DV, 1998, CLIN INFECT DIS, V27, P1369, DOI 10.1086/515018; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006; Helweg-Larsen J, 1999, LANCET, V354, P1347, DOI 10.1016/S0140-6736(99)03320-6; JOHNSON S, 2000, P 7 C RETR OPP INF S, P127; Jones J L, 1999, MMWR CDC Surveill Summ, V48, P1; Kaplan JE, 1998, J INFECT DIS, V178, P1126, DOI 10.1086/515658; KAPLAN JE, 1999, 39 INT C ANT AG CHEM, P13; Katlama C, 1996, CLIN INFECT DIS, V22, P268, DOI 10.1093/clinids/22.2.268; KAZANJIAN P, 2000, P 7 C RETR OPP INF S, P119; Keely SP, 1997, J CLIN MICROBIOL, V35, P2745, DOI 10.1128/JCM.35.11.2745-2747.1997; Kirk O, 1999, AIDS, V13, P1647, DOI 10.1097/00002030-199909100-00007; KOLETAR SL, 2000, P 7 C RETR OPP INF S, P122; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; LEDERGERBER B, 2000, P 7 C RETR OPP INF S, P235; LEOUNG G, 1997, 37 INT C ANT AG CHEM; Lewis RA, 1997, ANN INTERN MED, V126, P264, DOI 10.7326/0003-4819-126-4-199702150-00002; Lewis RA, 1997, J INFECT DIS, V176, P50, DOI 10.1086/514039; LOPEZ JC, 1999, 39 INT C ANT AG CHEM, P19; LUNDGREN JD, 1995, CLIN INFECT DIS, V21, P106, DOI 10.1093/clinids/21.1.106; LUNDGREN JD, 1999, 39 INT C ANT AG CHEM, P91; Ma L, 1999, J INFECT DIS, V180, P1969, DOI 10.1086/315148; Macdonald JC, 1998, J INFECT DIS, V177, P1182, DOI 10.1086/515281; MARTIN D, 2000, P 7 C RETR OPP INF S, P119; Martin DF, 1999, NEW ENGL J MED, V340, P1063, DOI 10.1056/NEJM199904083401402; MASUR H, 1981, NEW ENGL J MED, V305, P1431, DOI 10.1056/NEJM198112103052402; MASUR H, 1993, NEW ENGL J MED, V329, P898, DOI 10.1056/NEJM199309163291228; McKinsey DS, 1999, CLIN INFECT DIS, V28, P1049, DOI 10.1086/514744; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; Miller V, 1999, LANCET, V353, P463, DOI 10.1016/S0140-6736(98)04954-X; MIRO JM, 2000, P 7 C RETR OPP INF S, P119; MOORE RD, 1998, P 5 C RETR OPP INF C, P113; Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014; Newell ML, 1997, AIDS, V11, P1859; Nielsen H, 1998, SCAND J INFECT DIS, V30, P597, DOI 10.1080/00365549850161160; OPRAVIL M, 1995, CLIN INFECT DIS, V20, P531, DOI 10.1093/clinids/20.3.531; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PARA MF, 1997, P 4 C RETR OPP INF W, P65; PEARSON RD, 1985, ANN INTERN MED, V103, P782, DOI 10.7326/0003-4819-103-5-782; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; PODZAMCZER D, 1995, ANN INTERN MED, V123, P175, DOI 10.7326/0003-4819-123-3-199508010-00003; PODZAMCZER D, 1995, ANN INTERN MED, V122, P755, DOI 10.7326/0003-4819-122-10-199505150-00004; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RICHARDS FO, 1995, CLIN INFECT DIS, V21, pS49, DOI 10.1093/clinids/21.Supplement_1.S49; Saag MS, 1999, CLIN INFECT DIS, V28, P291, DOI 10.1086/515110; SCHNEIDER MME, 1995, J INFECT DIS, V171, P1632, DOI 10.1093/infdis/171.6.1632; Schneider MME, 1999, LANCET, V353, P201, DOI 10.1016/S0140-6736(98)07204-3; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; Schuman P, 1997, ANN INTERN MED, V126, P689, DOI 10.7326/0003-4819-126-9-199705010-00003; Shafran SD, 1996, NEW ENGL J MED, V335, P377, DOI 10.1056/NEJM199608083350602; SIEGAL FP, 1981, NEW ENGL J MED, V305, P1439, DOI 10.1056/NEJM198112103052403; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; STEWART JA, 1995, CLIN INFECT DIS, V21, pS114, DOI 10.1093/clinids/21.Supplement_1.S114; Tasker SA, 1999, ANN INTERN MED, V131, P430, DOI 10.7326/0003-4819-131-6-199909210-00006; Tsolaki AG, 1996, J INFECT DIS, V174, P141, DOI 10.1093/infdis/174.1.141; Tural C, 1998, J INFECT DIS, V177, P1080, DOI 10.1086/517399; US Public Health Service and Infectious Diseases Society of America, 1999, MMWR-MORBID MORTAL W, V48, P1; *USPHS RIF TRIAL G, 1998, AM J RESP CRIT CAR S, V157, P7; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; Vrabec TR, 1998, OPHTHALMOLOGY, V105, P1259, DOI 10.1016/S0161-6420(98)97031-2; WARD JW, 1996, 34 ANN M INF DIS SOC, P81; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; WHEAT J, 1993, ANN INTERN MED, V118, P610, DOI 10.7326/0003-4819-118-8-199304150-00006; WHEAT J, 1999, AIDS THERAPY, P412; Whitcup SM, 1999, JAMA-J AM MED ASSOC, V282, P1633, DOI 10.1001/jama.282.17.1633; Yangco BG, 2000, ANN INTERN MED, V132, P201, DOI 10.7326/0003-4819-132-3-200002010-00005; ZURLO JJ, 1995, CLIN INFECT DIS, V20, P768, DOI 10.1093/clinids/20.4.768; 1989, MMWR MORB MORTAL S5, V38, P1; 1992, MMWR MORB MORTAL WKL, V41, P4; 1981, MMWR MORB MORTAL WKL, V30, P250	110	151	161	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1416	1429		10.1056/NEJM200005113421907	http://dx.doi.org/10.1056/NEJM200005113421907			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312JR	10805828				2022-12-28	WOS:000086940600007
J	Dubrova, YE; Plumb, M; Gutierrez, B; Boulton, E; Jeffreys, AJ				Dubrova, YE; Plumb, M; Gutierrez, B; Boulton, E; Jeffreys, AJ			Genome stability - Transgenerational mutation by radiation	NATURE			English	Article							INSTABILITY; MICE; TUMORS		Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Russian Acad Sci, NI Vavilov Inst Gen Genet, Moscow, Russia; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England	University of Leicester; Russian Academy of Sciences; Vavilov Institute of General Genetics	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.		Dubrova, Yuri/ABA-7148-2020	Dubrova, Yuri/0000-0001-5281-7539				Burruel VR, 1997, MUTAT RES-FUND MOL M, V381, P59, DOI 10.1016/S0027-5107(97)00148-6; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; Lord BI, 1998, BRIT J CANCER, V78, P301, DOI 10.1038/bjc.1998.491; Luke GA, 1997, MUTAGENESIS, V12, P147, DOI 10.1093/mutage/12.3.147; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; NOMURA T, 1983, MUTAT RES, V121, P59, DOI 10.1016/0165-7992(83)90087-8; *UNSCEAR, 1993, UNSCEAR SOURC EFF IO; VOROBTSOVA IE, 1993, MUTAT RES, V287, P207, DOI 10.1016/0027-5107(93)90013-6; ZLOATOGORA J, 1988, HUM GENET, V102, P381	13	144	153	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					37	37		10.1038/35011135	http://dx.doi.org/10.1038/35011135			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811208	Bronze			2022-12-28	WOS:000086901600040
J	Ware, LB; Matthay, MA				Ware, LB; Matthay, MA			Medical progress - The acute respiratory distress syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LUNG INJURY; END-EXPIRATORY PRESSURE; CRITICALLY ILL PATIENTS; EXTRACORPOREAL MEMBRANE-OXYGENATION; PERMEABILITY PULMONARY-EDEMA; RANDOMIZED CONTROLLED TRIAL; HIGH-DOSE CORTICOSTEROIDS; III PROCOLLAGEN PEPTIDE; INHALED NITRIC-OXIDE; QUALITY-OF-LIFE		Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Matthay, MA (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Box 0130,505 Parnassus Ave, San Francisco, CA 94143 USA.	mmatt@itsa.ucsf.edu	Ware, Lorraine/AAJ-9307-2021	Ware, Lorraine/0000-0002-9429-4702	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL108713] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL108713] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abel SJC, 1998, THORAX, V53, P292, DOI 10.1136/thx.53.4.292; ABERLE DR, 1988, RADIOLOGY, V168, P73, DOI 10.1148/radiology.168.1.3380985; Abraham E, 1999, CRIT CARE MED, V27, P1478, DOI 10.1097/00003246-199908000-00013; Abraham E, 2000, CRIT CARE MED, V28, P232, DOI 10.1097/00003246-200001000-00039; *AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; ANDERSON WR, 1992, ULTRASTRUCT PATHOL, V16, P615, DOI 10.3109/01913129209023751; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; ASHBAUGH DG, 1967, LANCET, V2, P319; BACHOFEN M, 1982, CLIN CHEST MED, V3, P35; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; BARNARD JW, 1994, J APPL PHYSIOL, V77, P774, DOI 10.1152/jappl.1994.77.2.774; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; BERNARD GR, 1987, NEW ENGL J MED, V317, P1565, DOI 10.1056/NEJM198712173172504; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Berthiaume Y, 1999, THORAX, V54, P150, DOI 10.1136/thx.54.2.150; BISHOP MJ, 1983, AM REV RESPIR DIS, V128, P998; BITTERMAN PB, 1992, AM J MED, V92, pS39, DOI 10.1016/0002-9343(92)90606-C; BONE RC, 1989, CHEST, V96, P114, DOI 10.1378/chest.96.1.114; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; CARLON GC, 1983, CHEST, V84, P551, DOI 10.1378/chest.84.5.551; Chesnutt AN, 1997, AM J RESP CRIT CARE, V156, P840, DOI 10.1164/ajrccm.156.3.9701124; CLARK JG, 1995, ANN INTERN MED, V122, P17, DOI 10.7326/0003-4819-122-1-199501010-00003; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; Dobbs LG, 1998, P NATL ACAD SCI USA, V95, P2991, DOI 10.1073/pnas.95.6.2991; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; DOYLE RL, 1995, AM J RESP CRIT CARE, V152, P1818, DOI 10.1164/ajrccm.152.6.8520742; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; ELLIOTT CG, 1987, AM REV RESPIR DIS, V135, P634; FALKE KJ, 1972, J CLIN INVEST, V51, P2315, DOI 10.1172/JCI107042; Folkesson HG, 1998, AM J PHYSIOL-LUNG C, V275, pL478, DOI 10.1152/ajplung.1998.275.3.L478; Folkesson HG, 1996, J APPL PHYSIOL, V80, P1431, DOI 10.1152/jappl.1996.80.5.1431; Fort P, 1997, CRIT CARE MED, V25, P937, DOI 10.1097/00003246-199706000-00008; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; FUKUDA Y, 1987, AM J PATHOL, V126, P171; Fulkerson WJ, 1996, ARCH INTERN MED, V156, P29, DOI 10.1001/archinte.156.1.29; Garat C, 1997, CHEST, V111, P1381, DOI 10.1378/chest.111.5.1381; GATTINONI L, 1994, JAMA-J AM MED ASSOC, V271, P1772, DOI 10.1001/jama.271.22.1772; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; GHIO AJ, 1989, AM REV RESPIR DIS, V140, P862; GHIO AJ, 1989, AM REV RESPIR DIS, V139, P1158, DOI 10.1164/ajrccm/139.5.1158; Gillis P, 1999, J CELL SCI, V112, P2049; Goodman LR, 1996, RADIOL CLIN N AM, V34, P33; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; Gunther A, 2000, AM J RESP CRIT CARE, V161, P454; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237, DOI 10.1164/ajrccm.161.1.9810007; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HEFFNER JE, 1995, AM J RESP CRIT CARE, V152, P1518, DOI 10.1164/ajrccm.152.5.7582287; HEYLAND DK, 1993, INTENS CARE MED, V19, P435, DOI 10.1007/BF01711083; Hirschl RB, 1996, JAMA-J AM MED ASSOC, V275, P383, DOI 10.1001/jama.275.5.383; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; Ingbar DH, 1998, LUNG BIOL HEALTH DIS, V116, P477; Jiang XP, 1998, AM J PHYSIOL-CELL PH, V275, pC1610, DOI 10.1152/ajpcell.1998.275.6.C1610; KIRBY RR, 1975, CHEST, V67, P156, DOI 10.1378/chest.67.2.156; KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106; Kurahashi K, 1999, J CLIN INVEST, V104, P743, DOI 10.1172/JCI7124; Lasnier JM, 1996, J APPL PHYSIOL, V81, P1723, DOI 10.1152/jappl.1996.81.4.1723; LAUFE MD, 1986, AM J MED, V80, P1022, DOI 10.1016/0002-9343(86)90659-5; LESSARD MR, 1994, ANESTHESIOLOGY, V80, P983, DOI 10.1097/00000542-199405000-00006; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; LEWIS JF, 1993, AM REV RESPIR DIS, V147, pU1065; LINDROOS PM, 1995, AM J RESP CELL MOL, V13, P455, DOI 10.1165/ajrcmb.13.4.7546776; LONG W, 1991, J PEDIATR-US, V118, P595, DOI 10.1016/S0022-3476(05)83388-8; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; MARTIN C, 1995, CHEST, V107, P196, DOI 10.1378/chest.107.1.196; Martinet Y, 1996, ARCH TOX S, V18, P127; Masclans JR, 1996, AM J RESP CRIT CARE, V154, P529, DOI 10.1164/ajrccm.154.2.8756833; Matalon S, 1996, AM J PHYSIOL-LUNG C, V271, pL1, DOI 10.1152/ajplung.1996.271.1.L1; Matthay M A, 1999, Chest, V116, p119S; MATTHAY MA, 1994, SEMIN RESP CRIT CARE, V15, P271, DOI 10.1055/s-2007-1006373; Matthay MA, 1996, AM J PHYSIOL-LUNG C, V270, pL487, DOI 10.1152/ajplung.1996.270.4.L487; MATTHAY MA, 1990, AM REV RESPIR DIS, V142, P1250, DOI 10.1164/ajrccm/142.6_Pt_1.1250; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; MCHUGH LG, 1994, AM J RESP CRIT CARE, V150, P90, DOI 10.1164/ajrccm.150.1.8025779; Meade MO, 2000, AM J RESP CRIT CARE, V161, P85, DOI 10.1164/ajrccm.161.1.9809003; MEDURI GU, 1994, CHEST, V105, P1516, DOI 10.1378/chest.105.5.1516; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MEDURI GU, 1991, CHEST, V100, P943, DOI 10.1378/chest.100.4.943; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; Modelska K, 1999, AM J RESP CRIT CARE, V160, P1450, DOI 10.1164/ajrccm.160.5.9901096; Monchi M, 1998, AM J RESP CRIT CARE, V158, P1076, DOI 10.1164/ajrccm.158.4.9802009; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MONTGOMERY AB, 1989, AM REV RESPIR DIS, V139, P1548, DOI 10.1164/ajrccm/139.6.1548; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P838; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; Mure M, 1997, CRIT CARE MED, V25, P1539, DOI 10.1097/00003246-199709000-00022; MURRAY JF, 1977, AM REV RESPIR DIS, V115, P1071; Nakos G, 2000, AM J RESP CRIT CARE, V161, P360, DOI 10.1164/ajrccm.161.2.9810037; Nelson S, 1998, J INFECT DIS, V178, P1075, DOI 10.1086/515694; Newman V, 2000, AM J RESP CRIT CARE, V161, P990, DOI 10.1164/ajrccm.161.3.9901042; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PARKER JC, 1984, J APPL PHYSIOL, V57, P1809, DOI 10.1152/jappl.1984.57.6.1809; PAYEN D, 1999, INTENS CARE MED S, V25, pS166; PEPE PE, 1984, NEW ENGL J MED, V311, P281, DOI 10.1056/NEJM198408023110502; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054; PRATT PC, 1979, AM J PATHOL, V95, P191; Prescott SM, 1999, J CLIN INVEST, V104, P1019, DOI 10.1172/JCI8506; PREWITT RM, 1981, J CLIN INVEST, V67, P409, DOI 10.1172/JCI110049; PREWITT RM, 1981, ANESTHESIOLOGY, V55, P537, DOI 10.1097/00000542-198111000-00010; Pugin J, 1996, AM J RESP CRIT CARE, V153, P1850, DOI 10.1164/ajrccm.153.6.8665045; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; RADERMACHER P, 1990, ANESTHESIOLOGY, V72, P238, DOI 10.1097/00000542-199002000-00005; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Saint S, 1998, AM J MED, V105, P515, DOI 10.1016/S0002-9343(98)00322-2; Saldias FJ, 1999, J APPL PHYSIOL, V87, P30, DOI 10.1152/jappl.1999.87.1.30; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; SCHNAPP LM, 1995, CRIT CARE MED, V23, P272, DOI 10.1097/00003246-199502000-00012; SIMMONS RS, 1987, AM REV RESPIR DIS, V135, P924, DOI 10.1164/arrd.1987.135.4.924; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; SUCHYTA MR, 1993, RESPIRATION, V60, P103; Sznajder JI, 1999, AM J RESP CRIT CARE, V160, P1441; THOMSEN GE, 1995, AM J RESP CRIT CARE, V152, P965, DOI 10.1164/ajrccm.152.3.7663811; Viget N, 1999, AM J RESP CRIT CARE, V159, pA600; VILLAR J, 1989, AM REV RESPIR DIS, V140, P814, DOI 10.1164/ajrccm/140.3.814; Wang YB, 1999, J APPL PHYSIOL, V87, P1852, DOI 10.1152/jappl.1999.87.5.1852; Ware LB, 1999, AM J RESP CRIT CARE, V159, P980, DOI 10.1164/ajrccm.159.3.9802105; WARE LB, 1999, AM J RESP CRIT SA694, V159; WARE LB, 2000, AM J RESP CRIT CARE, V161, pA380; Waters CM, 1997, AM J PHYSIOL-LUNG C, V272, pL681, DOI 10.1152/ajplung.1997.272.4.L681; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WEBSTER NR, 1988, ANAESTHESIA, V43, P923, DOI 10.1111/j.1365-2044.1988.tb05652.x; Weg JG, 1998, NEW ENGL J MED, V338, P341, DOI 10.1056/NEJM199802053380601; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047; Widdcombe JH, 2000, AM J PHYSIOL-LUNG C, V278, pL231, DOI 10.1152/ajplung.2000.278.2.L231; Wiedemann HP, 2000, JAMA-J AM MED ASSOC, V283, P1995; WIENERKRONISH JP, 1991, J CLIN INVEST, V88, P864, DOI 10.1172/JCI115388; WIENERKRONISH JP, 1988, CHEST, V93, P852, DOI 10.1378/chest.93.4.852; WRIGHT PE, 1994, CHEST, V106, P1517, DOI 10.1378/chest.106.5.1517; Yano T, 1996, AM J RESP CELL MOL, V15, P433, DOI 10.1165/ajrcmb.15.4.8879176; YU MH, 1993, CRIT CARE MED, V21, P830, DOI 10.1097/00003246-199306000-00009; ZAPOL WM, 1979, AM REV RESPIR DIS, V119, P547; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	149	3946	4199	8	196	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2000	342	18					1334	1349		10.1056/NEJM200005043421806	http://dx.doi.org/10.1056/NEJM200005043421806			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RE	10793167				2022-12-28	WOS:000086782400006
J	Cobey, J; Ayotte, B				Cobey, J; Ayotte, B			Tools to measure landmine incidents and injuries	LANCET			English	Editorial Material									Physicians Human Rights, Boston, MA 02116 USA		Cobey, J (corresponding author), Physicians Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.								0	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1549	1550		10.1016/S0140-6736(05)74597-9	http://dx.doi.org/10.1016/S0140-6736(05)74597-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801190				2022-12-28	WOS:000086830100044
J	Blazquez, MA; Weigel, D				Blazquez, MA; Weigel, D			Integration of floral inductive signals in Arabidopsis	NATURE			English	Article							FLOWERING-TIME GENES; INFLORESCENCE DEVELOPMENT; PLANT TRANSFORMATION; SHOOT DEVELOPMENT; BINARY VECTORS; EMF GENES; LEAFY; THALIANA; EXPRESSION; INITIATION	Flowering of Arabidopsis is regulated by a daylength-dependent pathway that accelerates flowering in long days and a daylength-independent pathway that ensures flowering in the absence of inductive conditions(1-3). These pathways are genetically separable, as there are mutations that delay flowering in long but not short days(4). Conversely, mutations that block synthesis of the hormone gibberellin abolish flowering in short days, but have on their own only a minor effect in long days(5). A third pathway, the autonomous pathway, probably acts by modulating the other two pathways(3). Understanding where and how these pathways are integrated is a prerequisite for understanding why similar environmental or endogenous cues can elicit opposite flowering responses in different plants(6,7). In Arabidopsis, floral induction leads ultimately to the upregulation of floral meristem-identity genes such as LEAFY(8-13), indicating that floral inductive signals are integrated upstream of LEAFY. Here we show that gibberellins activate the LEAFY promoter through cis elements that are different from those that are sufficient for the daylength response, demonstrating that the LEAFY promoter integrates environmental and endogenous signals controlling flowering time.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008; Blazquez, Miguel A/B-1495-2008	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Blazquez, Miguel A/0000-0001-5743-0448				Bechtold N, 1998, METH MOL B, V82, P259; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; Bernier G., 1981, PHYSL FLOWERING; Blazquez MA, 1998, PLANT CELL, V10, P791, DOI 10.1105/tpc.10.5.791; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Chen LJ, 1997, PLANT CELL, V9, P2011, DOI 10.1105/tpc.9.11.2011; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Hempel FD, 1997, DEVELOPMENT, V124, P3845; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; Nilsson O, 1998, GENETICS, V150, P403; Pineiro M, 1998, PLANT PHYSIOL, V117, P1, DOI 10.1104/pp.117.1.1; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; Simpson GG, 1999, ANNU REV CELL DEV BI, V15, P519, DOI 10.1146/annurev.cellbio.15.1.519; SUNG ZR, 1992, SCIENCE, V258, P1645, DOI 10.1126/science.258.5088.1645; URAO T, 1993, PLANT CELL, V5, P1529, DOI 10.1105/tpc.5.11.1529; Wang ZY, 1997, PLANT CELL, V9, P491, DOI 10.1105/tpc.9.4.491; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILSON RN, 1992, PLANT PHYSIOL, V100, P403, DOI 10.1104/pp.100.1.403; YANG CH, 1995, DEV BIOL, V169, P421, DOI 10.1006/dbio.1995.1158; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	30	354	405	4	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					889	892		10.1038/35009125	http://dx.doi.org/10.1038/35009125			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786797				2022-12-28	WOS:000086625000049
J	Beekman, M; Calis, JNM; Boot, WJ				Beekman, M; Calis, JNM; Boot, WJ			Insect behaviour - Parasitic honeybees get royal treatment	NATURE			English	Article							APIS-MELLIFERA-CAPENSIS; CASTE DIFFERENTIATION; EVOLUTION; LARVAE		Wageningen Univ Agr, Entomol Lab, NL-6700 EH Wageningen, Netherlands	Wageningen University & Research	Beekman, M (corresponding author), Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England.		Beekman, Madeleine/A-3983-2011; Beekman, Madeleine/AAF-8574-2019	Beekman, Madeleine/0000-0002-9040-3756; Beekman, Madeleine/0000-0002-9040-3756				Allsopp M, 1992, S AFR BEE J, V64, P52; BROUWERS EVM, 1984, J APICULT RES, V23, P94, DOI 10.1080/00218839.1984.11100616; CREWE RM, 1980, NATURWISSENSCHAFTEN, V67, P467, DOI 10.1007/BF00405650; Greeff JM, 1997, S AFR J SCI, V93, P306; HEPBURN HR, 1994, S AFR J SCI, V90, P247; Moritz RFA, 1996, NATURE, V384, P31, DOI 10.1038/384031a0; NONACS P, 1992, EVOLUTION, V46, P1605, DOI [10.2307/2410019, 10.1111/j.1558-5646.1992.tb01157.x]; RUTTNER F, 1977, APIDOLOGIE, V8, P281, DOI 10.1051/apido:19770305; VANHANDE.E, 1967, ANAL BIOCHEM, V19, P193, DOI 10.1016/0003-2697(67)90152-2; WIRTZ P, 1972, ENTOMOL EXP APPL, V15, P517, DOI 10.1007/BF00293616	10	53	55	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					723	723		10.1038/35008148	http://dx.doi.org/10.1038/35008148			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783876	Bronze			2022-12-28	WOS:000086523600039
J	Nishikawa, T; Edelstein, D; Du, XL; Yamagishi, S; Matsumura, T; Kaneda, Y; Yorek, MA; Beebe, D; Oates, PJ; Hammes, HP; Giardino, I; Brownlee, M				Nishikawa, T; Edelstein, D; Du, XL; Yamagishi, S; Matsumura, T; Kaneda, Y; Yorek, MA; Beebe, D; Oates, PJ; Hammes, HP; Giardino, I; Brownlee, M			Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage	NATURE			English	Article							ADVANCED GLYCATION ENDPRODUCTS; BOVINE ENDOTHELIAL-CELLS; ALDOSE REDUCTASE; IN-VITRO; KAPPA-B; ACTIVATION; OVEREXPRESSION; EXPRESSION; PROTEIN; RAT	Diabetic hyperglycaemia causes a variety of pathological changes in small vessels, arteries and peripheral nerves(1). Vascular endothelial cells are an important target of hyperglycaemic damage, but the mechanisms underlying this damage are not fully understood. Three seemingly independent biochemical pathways are involved in the pathogenesis: glucose-induced activation of protein kinase C isoforms(2); increased formation of glucose-derived advanced glycation end-products(3); and increased glucose flux through the aldose reductase pathway(4). The relevance of each of these pathways is supported by animal studies in which pathway-specific inhibitors prevent various hyperglycaemia-induced abnormalities(3,5-7). Hyperglycaemia increases the production of reactive oxygen species inside cultured bovine aortic endothelial cells(8). Here we show that this increase in reactive oxygen species is prevented by an inhibitor of electron transport chain complex II, by an uncoupler of oxidative phosphorylation, by uncoupling protein-1 and by manganese superoxide dismutase. Normalizing levels of mitochondrial reactive oxygen species with each of these agents prevents glucose-induced activation of protein kinase C, formation of advanced glycation end-products, sorbitol accumulation and NF kappa B activation.	Albert Einstein Coll Med, Diabet Res Ctr, Bronx, NY 10461 USA; Osaka Univ, Sch Med, Div Gene Therapy Sci, Suita, Osaka 5650871, Japan; Univ Iowa, Dept Internal Med, Iowa City, IA 52246 USA; Pfizer Inc, Div Cent Res, Dept Metab Dis, Groton, CT 06340 USA; Univ Giessen, Dept Med 3, D-35385 Giessen, Germany	Yeshiva University; Albert Einstein College of Medicine; Osaka University; University of Iowa; Pfizer; Justus Liebig University Giessen	Brownlee, M (corresponding author), Albert Einstein Coll Med, Diabet Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Yorek, Mark/AAC-3136-2021; Hammes, Hans-Peter/S-3719-2019	Yorek, Mark/0000-0001-7737-5554; 				BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; CASTEILLA L, 1990, P NATL ACAD SCI USA, V87, P5124, DOI 10.1073/pnas.87.13.5124; Chandra A, 1997, BBA-PROTEIN STRUCT M, V1341, P217, DOI 10.1016/S0167-4838(97)00084-8; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; Ishihara H, 1996, DIABETES, V45, P1238, DOI 10.2337/diabetes.45.9.1238; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; Knight RJ, 1996, CARDIOVASC RES, V32, P1016, DOI 10.1016/S0008-6363(96)00137-X; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Kurose I, 1997, J CLIN INVEST, V99, P867, DOI 10.1172/JCI119251; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; *NAT DIAB DAT GROU, 1994, DIAB AM; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pieper GM, 1997, J CARDIOVASC PHARM, V30, P528, DOI 10.1097/00005344-199710000-00019; Pieper GM, 1997, CARDIOVASC RES, V34, P145, DOI 10.1016/S0008-6363(96)00237-4; Saeki Y, 1998, GENE THER, V5, P1031, DOI 10.1038/sj.gt.3300711; Saeki Y, 1997, HUM GENE THER, V8, P2133, DOI 10.1089/hum.1997.8.17-2133; Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885; SIMA AAF, 1990, J CLIN INVEST, V85, P1410, DOI 10.1172/JCI114585; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Yorek MA, 1999, KIDNEY INT, V55, P215, DOI 10.1046/j.1523-1755.1999.00235.x	24	3262	3462	7	254	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					787	790		10.1038/35008121	http://dx.doi.org/10.1038/35008121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783895				2022-12-28	WOS:000086523600058
J	Elble, RJ				Elble, RJ			Origins of tremor	LANCET			English	Editorial Material									So Illinois Univ, Sch Med, Dept Neurol, Springfield, IL 62794 USA	Southern Illinois University System; Southern Illinois University	Elble, RJ (corresponding author), So Illinois Univ, Sch Med, Dept Neurol, Springfield, IL 62794 USA.							Boecker H, 1998, MOVEMENT DISORD, V13, P64; Deuschl G, 1999, ANN NEUROL, V46, P126, DOI 10.1002/1531-8249(199907)46:1<126::AID-ANA20>3.0.CO;2-3; DUPUIS MJM, 1989, MOVEMENT DISORD, V4, P183, DOI 10.1002/mds.870040210; Elble RJ, 1998, MOVEMENT DISORD, V13, P35; Elble RJ, 1996, J CLIN NEUROPHYSIOL, V13, P133, DOI 10.1097/00004691-199603000-00004; Guridi J, 1997, NEUROSURGERY, V41, P1169, DOI 10.1097/00006123-199711000-00029; GURIDI J, 1997, NEUROSURGERY, V41, P1180; Hua S, 1998, MOVEMENT DISORD, V13, P40; Hua SE, 1998, J NEUROL NEUROSUR PS, V64, P273, DOI 10.1136/jnnp.64.2.273; Hurtado JM, 1999, P NATL ACAD SCI USA, V96, P1674, DOI 10.1073/pnas.96.4.1674; Miyagi Y, 1999, J NEUROSURG, V91, P885, DOI 10.3171/jns.1999.91.5.0885; Speelman JD, 1998, MOVEMENT DISORD, V13, P103; Volkmann J, 1996, NEUROLOGY, V46, P1359, DOI 10.1212/WNL.46.5.1359	13	53	54	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2000	355	9210					1113	1114		10.1016/S0140-6736(00)02054-7	http://dx.doi.org/10.1016/S0140-6736(00)02054-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791368				2022-12-28	WOS:000086380900003
J	Loder, N				Loder, N			Giant tortoises come home	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					426	426		10.1038/35006716	http://dx.doi.org/10.1038/35006716			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10787341	Bronze			2022-12-28	WOS:000086257700009
J	Bloxham, J				Bloxham, J			Sensitivity of the geomagnetic axial dipole to thermal core-mantle interactions	NATURE			English	Article							FIELD; FREQUENCY; REVERSALS; GEODYNAMO; SYMMETRY	Since the work of William Gilbert in 1600 (ref. 1), it has been widely believed that the Earth's magnetic field, when suitably time-averaged, is that of a magnetic dipole positioned at the Earth's centre and aligned with the rotational axis. This 'geocentric axial dipole' (GAD) hypothesis has been the central model for the study of the Earth's magnetic field-it underpins almost all interpretations of palaeomagnetic data, whether for studies of palaeomagnetic secular variation, for plate tectonic reconstructions, or for studies of palaeoclimate(2). Although the GAD hypothesis appears to provide a good description of the Earth's magnetic field over at least the past 100 Myr (ref. 2), it is difficult to test the hypothesis for earlier periods, and there is some evidence that a more complicated model is required for the period before 250 Myr ago(3). Kent and Smethurst(3) suggested that this additional complexity might be because the inner core would have been smaller at that time. Here I use a numerical geodynamo model and find that reducing the size of the inner core does not significantly change the character of the magnetic field. I also consider an alternative process that could lead to the breakdown of the GAD hypothesis on this timescale, the evolution of heat-flux variations at the core-mantle boundary, induced by mantle convection. I find that a simple pattern of heat-flux variations at the core-mantle boundary, which is plausible for times before the Mesozoic era, results in a strong octupolar contribution to the field, consistent with previous findings(3).	Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Harvard University	Bloxham, J (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, 20 Oxford St, Cambridge, MA 02138 USA.	jeremy_bloxham@harvard.edu		Bloxham, Jeremy/0000-0001-8556-2675				Bloxham J, 2000, PHILOS T R SOC A, V358, P1171, DOI 10.1098/rsta.2000.0579; BLOXHAM J, 1987, NATURE, V325, P511, DOI 10.1038/325511a0; BLOXHAM J, 1985, NATURE, V317, P777, DOI 10.1038/317777a0; Buffett BA, 1996, J GEOPHYS RES-SOL EA, V101, P7989, DOI 10.1029/95JB03539; COX A, 1975, REV GEOPHYS, V13, P35, DOI 10.1029/RG013i003p00035; Cox A., 1964, B SEISMOL SOC AM, V54, P2243; EVANS ME, 1976, NATURE, V262, P676, DOI 10.1038/262676a0; GIARDINI D, 1987, NATURE, V325, P405, DOI 10.1038/325405a0; GILBERT W, 1600, MAGNETE; Glatzmaier GA, 1999, NATURE, V401, P885, DOI 10.1038/44776; GUBBINS D, 1993, PHYS EARTH PLANET IN, V75, P225, DOI 10.1016/0031-9201(93)90003-R; GUBBINS D, 1987, NATURE, V325, P509, DOI 10.1038/325509a0; HIDE R, 1967, SCIENCE, V157, P55, DOI 10.1126/science.157.3784.55; Irving E., 1956, GEOFIS PURA APPL, V33, P23, DOI DOI 10.1007/BF02629944; Kent DV, 1998, EARTH PLANET SC LETT, V160, P391, DOI 10.1016/S0012-821X(98)00099-5; Kuang WL, 1997, NATURE, V389, P371, DOI 10.1038/38712; McElhinny MW, 1996, SURV GEOPHYS, V17, P575, DOI 10.1007/BF01888979; MCELHINNY MW, 2000, PALEOMAGNETISM; Sarson GR, 1997, PHYS EARTH PLANET IN, V101, P13, DOI 10.1016/S0031-9201(96)03248-7; ZHANG K, 1993, J FLUID MECH, V250, P209, DOI 10.1017/S0022112093001430; Zhang K, 1992, GEOPHYS J INT, V108, P247, DOI 10.1111/j.1365-246X.1992.tb00853.x	21	62	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	2000	405	6782					63	65		10.1038/35011045	http://dx.doi.org/10.1038/35011045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811217				2022-12-28	WOS:000086901600050
J	Brower, RG; Matthay, MA; Morris, A; Schoenfeld, D; Thompson, BT; Wheeler, A; Wiedemann, HP; Arroliga, AC; Fisher, CJ; Komara, JJ; Perez-Trepichio, P; Parsons, PE; Wolkin, R; Welsh, C; Fulkerson, WJ; MacIntyre, N; Mallatratt, L; Sebastian, M; McConnell, R; Wilcox, C; Govert, J; Thompson, D; Clemmer, T; Davis, R; Orme, J; Weaver, L; Grissom, C; Eskelson, M; Young, M; Gooder, V; McBride, K; Lawton, C; d'Hulst, J; Peerless, JR; Smith, C; Brownlee, J; Pluss, W; Kallet, R; Luce, JM; Gottlieb, J; Elmer, M; Girod, A; Park, P; Daniel, B; Gropper, M; Abraham, E; Piedalue, F; Glodowski, J; Lockrem, J; McIntyre, R; Reid, K; Stevens, C; Kalous, D; Silverman, HJ; Shanholtz, C; Corral, W; Toews, GB; Arnoldi, D; Bartlett, RH; Dechert, R; Watts, C; Lanken, PN; Anderson, H; Finkel, B; Hanson, CW; Barton, R; Mone, M; Hudson, LD; Lee, C; Carter, G; Maier, RV; Steinberg, KP; Bernard, G; Stroud, M; Swindell, B; Stone, L; Collins, L; Mogan, S; Ancukiewicz, M; Hayden, D; Molay, F; Ringwood, N; Wenzlow, G; Kazeroonian, AS; Gail, DB; Bosken, CH; Randall, P; Waclawiw, M; Spragg, RG; Boyett, J; Kelley, J; Leeper, K; Secundy, MG; Slutsky, A; Hyers, TM; Emerson, SS; Garcia, JGN; Marini, JJ; Pingleton, SK; Shasby, MD; Sibbald, WJ				Brower, RG; Matthay, MA; Morris, A; Schoenfeld, D; Thompson, BT; Wheeler, A; Wiedemann, HP; Arroliga, AC; Fisher, CJ; Komara, JJ; Perez-Trepichio, P; Parsons, PE; Wolkin, R; Welsh, C; Fulkerson, WJ; MacIntyre, N; Mallatratt, L; Sebastian, M; McConnell, R; Wilcox, C; Govert, J; Thompson, D; Clemmer, T; Davis, R; Orme, J; Weaver, L; Grissom, C; Eskelson, M; Young, M; Gooder, V; McBride, K; Lawton, C; d'Hulst, J; Peerless, JR; Smith, C; Brownlee, J; Pluss, W; Kallet, R; Luce, JM; Gottlieb, J; Elmer, M; Girod, A; Park, P; Daniel, B; Gropper, M; Abraham, E; Piedalue, F; Glodowski, J; Lockrem, J; McIntyre, R; Reid, K; Stevens, C; Kalous, D; Silverman, HJ; Shanholtz, C; Corral, W; Toews, GB; Arnoldi, D; Bartlett, RH; Dechert, R; Watts, C; Lanken, PN; Anderson, H; Finkel, B; Hanson, CW; Barton, R; Mone, M; Hudson, LD; Lee, C; Carter, G; Maier, RV; Steinberg, KP; Bernard, G; Stroud, M; Swindell, B; Stone, L; Collins, L; Mogan, S; Ancukiewicz, M; Hayden, D; Molay, F; Ringwood, N; Wenzlow, G; Kazeroonian, AS; Gail, DB; Bosken, CH; Randall, P; Waclawiw, M; Spragg, RG; Boyett, J; Kelley, J; Leeper, K; Secundy, MG; Slutsky, A; Hyers, TM; Emerson, SS; Garcia, JGN; Marini, JJ; Pingleton, SK; Shasby, MD; Sibbald, WJ		Acute Resp Distress Syndrome Netwo	Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	International Conference of the American-Lung-Association/American-Thoracic-Society	APR   26, 1999	SAN DIEGO, CALIFORNIA	Amer Lung Assoc, Amer Thorac Soc			PRESSURE-LIMITED VENTILATION; END-EXPIRATORY PRESSURE; MECHANICAL VENTILATION; PERMISSIVE HYPERCAPNIA; AIRWAY PRESSURES; CLINICAL-TRIALS; MORTALITY; SYSTEM; ADULTS; BAROTRAUMA	Background: Traditional approaches to mechanical ventilation use tidal volumes of 10 to 15 ml per kilogram of body weight and may cause stretch-induced lung injury in patients with acute lung injury and the acute respiratory distress syndrome. We therefore conducted a trial to determine whether ventilation with lower tidal volumes would improve the clinical outcomes in these patients. Methods: Patients with acute lung injury and the acute respiratory distress syndrome were enrolled in a multicenter, randomized trial. The trial compared traditional ventilation treatment, which involved an initial tidal volume of 12 ml per kilogram of predicted body weight and an airway pressure measured after a 0.5-second pause at the end of inspiration (plateau pressure) of 50 cm of water or less, with ventilation with a lower tidal volume, which involved an initial tidal volume of 6 ml per kilogram of predicted body weight and a plateau pressure of 30 cm of water or less. The first primary outcome was death before a patient was discharged home and was breathing without assistance. The second primary outcome was the number of days without ventilator use from day 1 to day 28. Results: The trial was stopped after the enrollment of 861 patients because mortality was lower in the group treated with lower tidal volumes than in the group treated with traditional tidal volumes (31.0 percent vs. 39.8 percent, P=0.007), and the number of days without ventilator use during the first 28 days after randomization was greater in this group (mean [+/-SD], 12+/-11 vs. 10+/-11; P=0.007). The mean tidal volumes on days 1 to 3 were 6.2+/-0.8 and 11.8+/-0.8 ml per kilogram of predicted body weight (P<0.001), respectively, and the mean plateau pressures were 25+/-6 and 33+/-8 cm of water (P<0.001), respectively. Conclusions: In patients with acute lung injury and the acute respiratory distress syndrome, mechanical ventilation with a lower tidal volume than is traditionally used results in decreased mortality and increases the number of days without ventilator use. (N Engl J Med 2000;342:1301-8.) (C) 2000, Massachusetts Medical Society.	Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21287 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; LDS Hosp, Salt Lake City, UT USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Vanderbilt Univ, Nashville, TN USA; Denver Hlth Med Ctr, Denver, CO USA; Denver Vet Affairs Med Ctr, Denver, CO USA; Duke Univ, Med Ctr, Durham, NC 27706 USA; Metrohlth Med Ctr, Cleveland, OH USA; Rose Med Ctr, Denver, CO USA; San Francisco Gen Hosp, Med Ctr, San Francisco, CA 94110 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA; Univ Maryland, College Pk, MD 20742 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Utah Hosp, Salt Lake City, UT USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Johns Hopkins University; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Vanderbilt University; Denver Health Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; Duke University; MetroHealth System; San Francisco General Hospital Medical Center; Jefferson University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University System of Maryland; University of Maryland College Park; University of Michigan System; University of Michigan; University of Pennsylvania; Utah System of Higher Education; University of Utah; University of Utah Hospital; Harborview Medical Center; University of Washington; University of Washington Seattle; Harvard University	Brower, RG (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, 600 N Wolfe St, Baltimore, MD 21287 USA.		Garcia, Joe GN/E-8862-2010; Mone, Mary/F-1971-2019; Slutsky, Arthur/M-3325-2019; Arroliga, Alejandro/AAX-3933-2021	Mone, Mary/0000-0001-7176-2860; 	DIVISION OF LUNG DISEASES [N01HR046055, N01HR046054, N01HR046056] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HR 46054, N01-HR 46055, N01-HR 46056] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BLANCH L, 1994, J CRIT CARE, V9, P151, DOI 10.1016/0883-9441(94)90011-6; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Carmichael LC, 1996, J CRIT CARE, V11, P9, DOI 10.1016/S0883-9441(96)90015-5; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DEMETS DL, 1980, BIOMETRIKA, V67, P651; DOYLE RL, 1995, AM J RESP CRIT CARE, V152, P1818, DOI 10.1164/ajrccm.152.6.8520742; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; Gattinoni L, 1986, J Thorac Imaging, V1, P25, DOI 10.1097/00005382-198607000-00005; HEDLEYWHYTE J, 1966, J CLIN INVEST, V45, P1543, DOI 10.1172/JCI105461; Heitjan DF, 1999, CONTROL CLIN TRIALS, V20, P309, DOI 10.1016/S0197-2456(99)00012-4; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Knoben JE, 1993, HDB CLIN DRUG DATA, V7th; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; Marini JJ, 1996, CLIN CHEST MED, V17, P555, DOI 10.1016/S0272-5231(05)70331-2; MAUNDER RJ, 1986, JAMA-J AM MED ASSOC, V255, P2463, DOI 10.1001/jama.255.18.2463; Mergoni M, 1997, AM J RESP CRIT CARE, V156, P846, DOI 10.1164/ajrccm.156.3.9607040; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024; Pittet JF, 1997, AM J RESP CRIT CARE, V155, P1187, DOI 10.1164/ajrccm.155.4.9105054; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; SCHNAPP LM, 1995, CRIT CARE MED, V23, P272, DOI 10.1097/00003246-199502000-00012; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; SLUTSKY AS, 1994, CHEST, V106, P656; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; Weg JG, 1998, NEW ENGL J MED, V338, P341, DOI 10.1056/NEJM199802053380601; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	42	6722	6985	6	252	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2000	342	18					1301	1308		10.1056/nejm200005043421801	http://dx.doi.org/10.1056/nejm200005043421801			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RE	10793162	Bronze			2022-12-28	WOS:000086782400001
J	Khochbin, S				Khochbin, S			Persian role in flowering of Islamic science	NATURE			English	Letter									Inst Albert Bonniot, INSERM, U309, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Khochbin, S (corresponding author), Inst Albert Bonniot, INSERM, U309, F-38706 La Tronche, France.		Khochbin, Saadi/M-8090-2013	Khochbin, Saadi/0000-0002-0455-0857				Bignami GF, 2000, NATURE, V404, P227, DOI 10.1038/35005178	1	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					14	14		10.1038/35011158	http://dx.doi.org/10.1038/35011158			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811197	Bronze			2022-12-28	WOS:000086901600020
J	Patel, DD; Gooding, ME; Parrott, RE; Curtis, KM; Haynes, BF; Buckley, RH				Patel, DD; Gooding, ME; Parrott, RE; Curtis, KM; Haynes, BF; Buckley, RH			Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; T-CELLS; V(D)J RECOMBINATION; RECONSTITUTION; REGENERATION; EXPRESSION; IMMUNITY; PRODUCTS; INFANTS; CD4(+)	Background: Immune function can be restored in infants with severe combined immunodeficiency by transplantation of unfractionated bone marrow from HLA-identical donors or T-cell-depleted marrow stem cells from haploidentical donors, with whom there is a single haplotype mismatch, without the need for chemotherapy before transplantation or prophylaxis against graft-versus-host disease. The role of the thymus in this process is unknown. Methods: We analyzed the phenotypes of circulating T cells and the proliferative responses of peripheral-blood mononuclear cells to phytohemagglutinin in 83 patients with severe combined immunodeficiency who received allogeneic marrow transplants without T-cell ablation from related donors over an 18-year period. We also tested for the presence of episomes of T-cell antigen receptors (extrachromosomal DNA circles formed during intrathymic T-cell development) to assess thymus-dependent T-cell reconstitution. Results: Before and early after transplantation, the numbers of circulating T cells were low, with a predominance of mature CD45RO+ T cells (primarily resulting from the transplacental transfer of maternal cells); T-cell antigen-receptor episomes were undetectable in peripheral-blood mononuclear cells. In 73 of the infants, thymus-derived T cells expressing CD45RA and T-cell antigen-receptor episomes were detected within three to six weeks after transplantation. The mean (+/-SD) value for thymus-dependent T-cell antigen-receptor episomes peaked (at 7311+/-8652 per microgram of peripheral-blood mononuclear-cell DNA) 1 to 2 years after transplantation and declined to low levels (less than 100 episomes per microgram of DNA) within 14 years, as compared with a gradual decline from birth to the age of about 80 years in normal subjects. Conclusions: The vestigial thymus in infants with severe combined immunodeficiency is functional and can produce enough T cells after bone marrow transplantation to provide normal immune function. (N Engl J Med 2000;342:1325-32.) (C) 2000, Massachusetts Medical Society.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Human Vaccine Inst, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Patel, DD (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 3258, Durham, NC 27710 USA.	pate1003@mc.duke.edu	Buckley, Rebecca/AAB-1578-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018613, R01AI047604, R01AI047605] Funding Source: NIH RePORTER; NIAID NIH HHS [5R37AI18613, R01 AI47604, R01 AI47605] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT MJ, 1988, CLIN EXP IMMUNOL, V72, P118; Bell EB, 1998, IMMUNOL TODAY, V19, P60, DOI 10.1016/S0167-5699(97)01211-5; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; Cossarizza A, 1996, MECH AGEING DEV, V86, P173, DOI 10.1016/0047-6374(95)01691-0; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; FRIEDMAN NJ, 1991, PEDIAT ALLERG IMMUNO, V2, P111; HAYNE SBF, 1999, J CLIN INVEST, V103, P921; Haynes BF, 1999, J CLIN INVEST, V103, P453, DOI 10.1172/JCI5201; Heitger A, 1997, BLOOD, V90, P850, DOI 10.1182/blood.V90.2.850.850_850_857; HOLLANDER GA, 1994, TRANSPLANTATION, V58, P1037, DOI 10.1097/00007890-199411150-00011; HOLLANDER GA, 1995, NATURE, V373, P350, DOI 10.1038/373350a0; HONG R, 1987, BONE MARROW TRANSPL, V1, P405; Kong FK, 1999, P NATL ACAD SCI USA, V96, P1536, DOI 10.1073/pnas.96.4.1536; Livak F, 1996, MOL CELL BIOL, V16, P609; Mackall CL, 1997, IMMUNOL REV, V157, P61, DOI 10.1111/j.1600-065X.1997.tb00974.x; MACKALL CL, 1993, BLOOD, V82, P2585; Markert ML, 1999, NEW ENGL J MED, V341, P1180, DOI 10.1056/NEJM199910143411603; NEUHAUS T J, 1986, Pediatric Pathology, V5, P251; NEZELOF C, 1992, HISTOPATHOLOGY, V21, P499, DOI 10.1111/j.1365-2559.1992.tb00437.x; REISNER Y, 1983, BLOOD, V61, P341; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; ROBERTS JL, 1989, J IMMUNOL, V143, P1575; SCHIFF SE, 1987, J IMMUNOL, V138, P2088; SCHIFF SE, 1987, CLIN EXP IMMUNOL, V68, P685; TAKESHITA S, 1989, EMBO J, V8, P3261, DOI 10.1002/j.1460-2075.1989.tb08486.x; TJONNFJORD GE, 1994, BLOOD, V84, P3584	29	156	160	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2000	342	18					1325	1332		10.1056/NEJM200005043421804	http://dx.doi.org/10.1056/NEJM200005043421804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RE	10793165				2022-12-28	WOS:000086782400004
J	Reichhardt, T				Reichhardt, T			Doubts and uncertainties slow NASA's schedule	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					4	4		10.1038/35011204	http://dx.doi.org/10.1038/35011204			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811184	Bronze			2022-12-28	WOS:000086901600005
J	Thompson, SG; Barber, JA				Thompson, SG; Barber, JA			How should cost data in pragmatic randomised trials be analysed?	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; CLINICAL-TRIALS; ECONOMIC EVALUATIONS; STATISTICAL-ANALYSIS; CARE; OUTCOMES		Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Med Stat & Evaluat, London W12 0NN, England	Imperial College London	Thompson, SG (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.			Barber, Julie/0000-0001-5762-762X				Altman D.G., 1991, PRACTICAL STAT MED R; ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; Armitage P., 1987, STAT METHODS MED RES; Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; BARBER JA, IN PRESS STAT MED; Bradley JV., 1968, DISTRIBUTION FREE ST; Briggs A, 1998, J Health Serv Res Policy, V3, P233; Briggs AH, 1999, BRIT MED J, V319, P635, DOI 10.1136/bmj.319.7210.635; Coyle D, 1996, PHARMACOECONOMICS, V9, P506, DOI 10.2165/00019053-199609060-00005; Creed F, 1997, BRIT MED J, V314, P1381; Desgagne A, 1998, PHARMACOECONOMICS, V13, P487, DOI 10.2165/00019053-199813050-00002; DRUMMOND MF, 1984, CONTROL CLIN TRIALS, V5, P115, DOI 10.1016/0197-2456(84)90118-1; Drummond MF, 2015, METHODS EC EVALUATIO; Efron B., 1994, MONOGRAPHS STAT APPL; Evans K, 1999, PSYCHOL MED, V29, P19, DOI 10.1017/S003329179800765X; Fayers PM, 1997, LANCET, V350, P1025, DOI 10.1016/S0140-6736(97)03053-5; Forbes JF, 1998, LANCET, V352, P1656; Gray AM, 1997, BRIT J PSYCHIAT, V170, P47, DOI 10.1192/bjp.170.1.47; Knapp M, 1998, BRIT J PSYCHIAT, V172, P506, DOI 10.1192/bjp.172.6.506; Lambert CM, 1998, BRIT MED J, V316, P965, DOI 10.1136/bmj.316.7136.965; Moffett JK, 1999, BRIT MED J, V319, P279, DOI 10.1136/bmj.319.7205.279; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; RUTTENVANMOLKEN MPMH, 1994, HEALTH ECON, V3, P333, DOI 10.1002/hec.4730030507; Sculpher MJ, 1996, BRIT J OBSTET GYNAEC, V103, P142, DOI 10.1111/j.1471-0528.1996.tb09666.x; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; Tyrer P, 1998, BRIT MED J, V316, P106	26	578	584	0	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1197	1200		10.1136/bmj.320.7243.1197	http://dx.doi.org/10.1136/bmj.320.7243.1197			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784550	Green Published			2022-12-28	WOS:000086832800024
J	Ku, CC; Murakami, M; Sakamato, A; Kappler, J; Marrack, P				Ku, CC; Murakami, M; Sakamato, A; Kappler, J; Marrack, P			Control of homeostasis of CD8(+) memory T cells by opposing cytokines	SCIENCE			English	Article							MURINE IL-2 RECEPTOR; MONOCLONAL-ANTIBODY; IN-VIVO; MICE; EXPRESSION; INDUCTION; ANTIGEN; INTERLEUKIN-7; ACTIVATION; SUBSETS	Memory T cells maintain their numbers for long periods after antigen exposure, Here we show that CD8(+) T cells of memory phenotype divide slowly in animals. This division requires interleukin-15 and is markedly increased by inhibition of interleukin-2 (IL-2), Therefore, the numbers of CD8(+) memory T cells in animals are controlled by a balance between IL-15 and IL-2.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med Ctr, Howard Hughes Med Inst,Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Biol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80206 USA	Howard Hughes Medical Institute; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Marrack, P (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med Ctr, Howard Hughes Med Inst,Dept Med, 4200 E 9th Ave, Denver, CO 80206 USA.	marrackp@njc.org	Marrack, Philippa/AHE-6316-2022	KU, CHIA-CHI/0000-0002-5740-1505; Marrack, Philippa/0000-0003-1883-3687	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI018785, R56AI017134, R01AI017134, P01AI022295, R01AI018785, R37AI017134, R37AI018785] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-17134, AI-18785, AI-22295] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bamford RN, 1998, J IMMUNOL, V160, P4418; BARRAT F, 1995, RES IMMUNOL, V146, P23, DOI 10.1016/0923-2494(96)80237-9; Bruno L, 1996, EUR J IMMUNOL, V26, P3179, DOI 10.1002/eji.1830261251; BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; CARAYON P, 1992, J IMMUNOL METHODS, V147, P225, DOI 10.1016/S0022-1759(12)80012-3; Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976; Doherty TM, 1996, J IMMUNOL, V156, P735; Ehrhardt RO, 1997, J IMMUNOL, V158, P566; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRIFFIN JP, 1994, INFECT IMMUN, V62, P1683, DOI 10.1128/IAI.62.5.1683-1690.1994; HEUFLER C, 1993, J EXP MED, V178, P1109, DOI 10.1084/jem.178.3.1109; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Jonuleit H, 1997, J IMMUNOL, V158, P2610; Ke Y, 1998, J EXP MED, V187, P49, DOI 10.1084/jem.187.1.49; KRAMER S, 1994, EUR J IMMUNOL, V24, P2317, DOI 10.1002/eji.1830241009; KU CC, UNPUB; Kung JT, 1998, CELL IMMUNOL, V185, P158, DOI 10.1006/cimm.1998.1282; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; MALEK TR, 1984, J IMMUNOL, V133, P1976; MALEK TR, 1993, P NATL ACAD SCI USA, V90, P9125; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Miller RA, 1997, FASEB J, V11, P775, DOI 10.1096/fasebj.11.10.9271362; Moore TA, 1996, J IMMUNOL, V157, P2366; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; Murali-Krishna K, 1999, SCIENCE, V286, P1377, DOI 10.1126/science.286.5443.1377; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PICKER LJ, 1990, J IMMUNOL, V145, P3247; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Selin LK, 1996, J EXP MED, V183, P2489, DOI 10.1084/jem.183.6.2489; SIMPSON SJ, 1995, EUR J IMMUNOL, V25, P2618, DOI 10.1002/eji.1830250932; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; Swain S L, 1992, Semin Immunol, V4, P59; Swain SL, 1999, SCIENCE, V286, P1381, DOI 10.1126/science.286.5443.1381; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; TANAKA T, 1991, J IMMUNOL, V147, P2222; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Wrenshall LE, 1999, J IMMUNOL, V163, P3793; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6; Zheng LX, 1998, J IMMUNOL, V160, P763	45	690	721	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2000	288	5466					675	678		10.1126/science.288.5466.675	http://dx.doi.org/10.1126/science.288.5466.675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784451				2022-12-28	WOS:000086727100045
J	Goh, KJ; Tan, CT; Chew, NK; Tan, PSK; Kamarulzaman, A; Sarji, SA; Wong, KT; Abdullah, BJJ; Chua, KB; Lam, SK				Goh, KJ; Tan, CT; Chew, NK; Tan, PSK; Kamarulzaman, A; Sarji, SA; Wong, KT; Abdullah, BJJ; Chua, KB; Lam, SK			Clinical features of nipah virus encephalitis among pig farmers in Malaysia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORSES	Background: Between September 1998 and June 1999, there was an outbreak of severe viral encephalitis due to Nipah virus, a newly discovered paramyxovirus, in Malaysia. Methods: We studied the clinical features of the patients with Nipah virus encephalitis who were admitted to a medical center in Kuala Lumpur. The case definition was based on epidemiologic, clinical, cerebrospinal fluid, and neuroimaging findings. Results: Ninety-four patients with Nipah virus infection were seen from February to June 1999 (mean age, 37 years; ratio of male patients to female patients, 4.5 to 1). Ninety-three percent had had direct contact with pigs, usually in the two weeks before the onset of illness, suggesting that there was direct viral transmission from pigs to humans and a short incubation period. The main presenting features were fever, headache, dizziness, and vomiting. Fifty-two patients (55 percent) had a reduced level of consciousness and prominent brain-stem dysfunction. Distinctive clinical signs included segmental myoclonus, areflexia and hypotonia, hypertension, and tachycardia and thus suggest the involvement of the brain stem and the upper cervical spinal cord. The initial cerebrospinal fluid findings were abnormal in 75 percent of patients. Antibodies against Hendra virus were detected in serum or cerebrospinal fluid in 76 percent of 83 patients tested. Thirty patients (32 percent) died after rapid deterioration in their condition. An abnormal doll's-eye reflex and tachycardia were factors associated with a poor prognosis. Death was probably due to severe brain-stem involvement. Neurologic relapse occurred after initially mild disease in three patients. Fifty patients (53 percent) recovered fully, and 14 (15 percent) had persistent neurologic deficits. Conclusions: Nipah virus causes a severe, rapidly progressive encephalitis with a high mortality rate and features that suggest involvement of the brain stem. The infection is associated with recent contact with pigs. (N Engl J Med 2000;342:1229-35.) (C) 2000, Massachusetts Medical Society.	Univ Malaya, Fac Med, Dept Med, Div Neurol, Kuala Lumpur 59100, Malaysia; Univ Malaya, Dept Med, Div Infect Dis, Kuala Lumpur 59100, Malaysia; Univ Malaya, Dept Anaesthesiol & Intens Care, Kuala Lumpur 59100, Malaysia; Univ Malaya, Dept Radiol, Kuala Lumpur 59100, Malaysia; Univ Malaya, Dept Pathol, Kuala Lumpur 59100, Malaysia; Univ Malaya, Dept Med Microbiol, Kuala Lumpur 59100, Malaysia	Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya; Universiti Malaya	Tan, PSK (corresponding author), Univ Malaya, Fac Med, Dept Med, Div Neurol, Kuala Lumpur 59100, Malaysia.		LAM, SAI KIT/B-5231-2010; Goh, Khean Jin/D-1990-2010; KAMARULZAMAN, ADEEBA/B-5216-2010; Wong, Kum Thong/B-2788-2010	Goh, Khean Jin/0000-0001-5416-9627; 				[Anonymous], 1999, MMWR-MORBID MORTAL W, V48, P335; Chua KB, 1999, LANCET, V354, P1257, DOI 10.1016/S0140-6736(99)04299-3; Lee KE, 1999, ANN NEUROL, V46, P428, DOI 10.1002/1531-8249(199909)46:3<428::AID-ANA23>3.3.CO;2-9; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Paton NI, 1999, LANCET, V354, P1253, DOI 10.1016/S0140-6736(99)04379-2; SELVEY LA, 1995, MED J AUSTRALIA, V162, P642, DOI 10.5694/j.1326-5377.1995.tb126050.x; THONGCHAROEN P, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P559; 1999, MMWR MORB MORTAL WKL, V48, P339; 1999, MMWR MORB MORTAL WKL, V48, P265	9	312	333	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1229	1235		10.1056/NEJM200004273421701	http://dx.doi.org/10.1056/NEJM200004273421701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10781618	Green Submitted, Green Published			2022-12-28	WOS:000086660600001
J	Wadman, M				Wadman, M			Women and ethnic minorities needed for US skills gap ...	NATURE			English	News Item																			0	1	1	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					800	800		10.1038/35009224	http://dx.doi.org/10.1038/35009224			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786764	Bronze			2022-12-28	WOS:000086625000010
J	Greaves, JS; Holland, WS; Jenness, T; Hawarden, TG				Greaves, JS; Holland, WS; Jenness, T; Hawarden, TG			Magnetic field surrounding the starburst nucleus of the galaxy M82 from polarized dust emission	NATURE			English	Article							POLARIMETRY	Magnetic fields may play an important role in the star-formation process, especially in the central regions of 'starburst' galaxies where star formation is vigorous. But the field directions are very difficult to determine in the dense molecular gas out of which the stars form, so it has hitherto been impossible to test this hypothesis. Dust grains in interstellar clouds tend to be magnetically aligned, and it is possible to determine the alignment direction based on the polarization of optical light due to preferential extinction along the long axes of the aligned grains(1). This technique works, however, only for diffuse gas, not for the dense molecular gas. Here we report observations of polarized thermal emission from the aligned dust grains in the central region of M82, which directly traces(2) the magnetic field structure (as projected onto the plane of the sky). Organized field lines are seen around the brightest star-forming regions, while in the dusty halo the field lines form a giant magnetic bubble possibly blown out by the galaxy's 'superwind'.	Joint Astron Ctr, Hilo, HI 96720 USA		Greaves, JS (corresponding author), Joint Astron Ctr, 660 N Aohoku Pl, Hilo, HI 96720 USA.			Jenness, Tim/0000-0001-5982-167X				Alton PB, 1999, ASTRON ASTROPHYS, V343, P51; Beck R, 1996, ANNU REV ASTRON ASTR, V34, P155, DOI 10.1146/annurev.astro.34.1.155; Dowell CD, 1998, ASTROPHYS J, V504, P588, DOI 10.1086/306069; Greaves JS, 1999, ASTRON ASTROPHYS, V344, P668; GREAVES JS, IN PRESS ASP C SERIE; HILDEBRAND RH, 1995, ASTROPHYS J, V450, P663, DOI 10.1086/176173; HILDEBRAND RH, 1988, Q J ROY ASTRON SOC, V29, P327; Holland WS, 1999, MON NOT R ASTRON SOC, V303, P659, DOI 10.1046/j.1365-8711.1999.02111.x; Hough JH, 1996, ASTR SOC P, V97, P569; HUGHES DH, 1994, MON NOT R ASTRON SOC, V270, P641, DOI 10.1093/mnras/270.3.641; JONES TJ, 1988, AM ASTR SOC M AM I P, V193; LESCH H, 1993, ASTRON ASTROPHYS, V268, P58; Murray AG, 1996, ASTR SOC P, V97, P116; Neininger N, 1998, ASTRON ASTROPHYS, V339, P737; OCONNELL RW, 1995, ASTROPHYS J, V446, pL1, DOI 10.1086/187916; REUTER HP, 1994, ASTRON ASTROPHYS, V282, P724; REUTER HP, 1995, ASTRON ASTROPHYS, V293, P287; Vallee J. P., 1997, FUNDAM COSMIC PHYS, V19, P1; Wilson CD, 1999, ASTROPHYS J, V513, pL139, DOI 10.1086/311916	19	46	46	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					732	733		10.1038/35008010	http://dx.doi.org/10.1038/35008010			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783879				2022-12-28	WOS:000086523600042
J	Ranero, CR; von Huene, R				Ranero, CR; von Huene, R			Subduction erosion along the Middle America convergent margin	NATURE			English	Article							COSTA-RICA; SEDIMENT SUBDUCTION; TRENCH; ACCRETION; SEAMOUNT; PACIFIC; MODEL; ZONES	'Subduction erosion' has been invoked to explain material missing from some continents along convergent margins(1). It has been suggested that this form of tectonic erosion removes continental material at the front of the margin or along the underside of the upper (continental) plate(2-4). Frontal erosion is interpreted from disrupted topography at the base of a slope and is most evident in the wake of subducting seamounts(5,6). In contrast, structures resulting from erosion at the base of a continental plate are seldom recognized in seismic reflection images because such images typically have poor resolution at distances greater than similar to 5 km from the trench axis. Basal erosion from seamounts and ridges has been inferred(7,8), but few large subducted bodies-let alone the eroded base of the upper plate-are imaged convincingly. From seismic images we identify here two mechanisms of basal erosion: erosion by seamount tunnelling and removal of large rock lenses of a distending upper plate. Seismic cross-sections from Costa Rica to Nicaragua indicate that erosion may extend along much of the Middle America convergent margin.	GEOMAR, D-24148 Kiel, Germany	Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel	Ranero, CR (corresponding author), GEOMAR, Wischhofstr 1-3, D-24148 Kiel, Germany.		Ranero, César R/B-9165-2009	Ranero, César R/0000-0002-5204-545X				AUBOUIN J, 1982, NATURE, V297, P458, DOI 10.1038/297458a0; BALLANCE PF, 1989, TECTONICS, V8, P953, DOI 10.1029/TC008i005p00953; COLLOT JY, 1989, GEOLOGY, V17, P939; HILDE TWC, 1983, TECTONOPHYSICS, V99, P381, DOI 10.1016/0040-1951(83)90114-2; Hinz K, 1996, TECTONICS, V15, P54, DOI 10.1029/95TC02355; KIMUR AG, 1997, INIT REP ODP, V170; LALLEMAND S, 1987, GEOLOGY, V15, P1065, DOI 10.1130/0091-7613(1987)15<1065:CWMATT>2.0.CO;2; LEPICHON X, 1993, ANNU REV EARTH PL SC, V21, P307; MACKAY S, 1993, GEOPHYSICS, V58, P1148, DOI 10.1190/1.1443498; MCINTOSH K, 1993, TECTONICS, V12, P1380, DOI 10.1029/93TC01792; MURAUCHI S, 1980, INITIAL REP DEEP SEA, V56, P463; PROTTI M, 1995, SPECIAL PAPER GEOLOG, V295; RANERO CR, IN PRESS TECTONICS; RUTLAND RWR, 1971, NATURE, V233, P252, DOI 10.1038/233252a0; SCHOLL DW, 1980, GEOLOGY, V8, P564, DOI 10.1130/0091-7613(1980)8<564:SMACAT>2.0.CO;2; Scholz CH, 1997, GEOLOGY, V25, P487, DOI 10.1130/0091-7613(1997)025<0487:TEOSSO>2.3.CO;2; SHIPLEY TH, 1992, J GEOPHYS RES-SOL EA, V97, P4439, DOI 10.1029/91JB02999; Stavenhagen A.U, 1998, ZBL GEOL PALAONT, V1, P393; VONHUENE R, 1991, REV GEOPHYS, V29, P279, DOI 10.1029/91RG00969; VONHUENE R, IN PRESS TECTONICS; VROLIJK P, 1990, GEOLOGY, V18, P703, DOI 10.1130/0091-7613(1990)018<0703:OTMROS>2.3.CO;2; WALTHER CHE, IN PRESS GEOPHYS J I; WANG WB, 1994, J GEOPHYS RES-SOL EA, V99, P6789, DOI 10.1029/93JB02875; Ye S, 1996, TECTONICS, V15, P1006, DOI 10.1029/96TC00827	24	365	377	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					748	752		10.1038/35008046	http://dx.doi.org/10.1038/35008046			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783885				2022-12-28	WOS:000086523600048
J	Han, J; Craighead, HG				Han, J; Craighead, HG			Separation of long DNA molecules in a microfabricated entropic trap array	SCIENCE			English	Article							CAPILLARY ELECTROPHORESIS; MICROLITHOGRAPHIC ARRAYS; NUCLEIC-ACIDS; DEVICE	A nanofluidic channel device, consisting of many entropic traps, was designed and fabricated for the separation of Long DNA molecules. The channel comprises narrow constrictions and wider regions that cause size-dependent trapping of DNA at the onset of a constriction. This process creates electrophoretic mobility differences, thus enabling efficient separation without the use of a gel matrix or pulsed electric fields. Samples of Long DNA molecules (5000 to similar to 160,000 base pairs) were efficiently separated into bands in 15-millimeter-long channels. Multiple-channel devices operating in parallel were demonstrated. The efficiency, compactness, and ease of fabrication of the device suggest the possibility of more practical integrated DNA analysis systems.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA	Cornell University	Craighead, HG (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R44HG001597, R43HG001597] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01597] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Burke DT, 1997, GENOME RES, V7, P189, DOI 10.1101/gr.7.3.189; Burns MA, 1998, SCIENCE, V282, P484, DOI 10.1126/science.282.5388.484; Chou CF, 1999, P NATL ACAD SCI USA, V96, P13762, DOI 10.1073/pnas.96.24.13762; Chou HP, 1999, P NATL ACAD SCI USA, V96, P11, DOI 10.1073/pnas.96.1.11; Duke TAJ, 1996, ELECTROPHORESIS, V17, P1075, DOI 10.1002/elps.1150170616; GIDDINGS JC, 1991, UNIFIED SEPARATION S, P96; Han J, 1999, J VAC SCI TECHNOL A, V17, P2142, DOI 10.1116/1.581740; Han J, 1999, PHYS REV LETT, V83, P1688, DOI 10.1103/PhysRevLett.83.1688; KIM Y, 1994, ANAL CHEM, V66, P3081, DOI 10.1021/ac00091a015; KIM YS, 1995, ANAL CHEM, V67, P784, DOI 10.1021/ac00101a002; Madabhushi RS, 1997, ELECTROPHORESIS, V18, P104, DOI 10.1002/elps.1150180120; MITNIK L, 1995, SCIENCE, V267, P219, DOI 10.1126/science.7809626; SUDOR J, 1994, ANAL CHEM, V66, P2446, DOI 10.1021/ac00087a007; Turner SW, 1998, J VAC SCI TECHNOL B, V16, P3835, DOI 10.1116/1.590419; VOLKMUTH WD, 1992, NATURE, V358, P600, DOI 10.1038/358600a0; VOLKMUTH WD, 1994, PHYS REV LETT, V72, P2117, DOI 10.1103/PhysRevLett.72.2117	16	855	937	6	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1026	1029		10.1126/science.288.5468.1026	http://dx.doi.org/10.1126/science.288.5468.1026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807568				2022-12-28	WOS:000086988400030
J	Oda, E; Ohki, R; Murasawa, H; Nemoto, J; Shibue, T; Yamashita, T; Tokino, T; Taniguchi, T; Tanaka, N				Oda, E; Ohki, R; Murasawa, H; Nemoto, J; Shibue, T; Yamashita, T; Tokino, T; Taniguchi, T; Tanaka, N			Nora, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis	SCIENCE			English	Article							TRANSCRIPTION FACTOR IRF-1; P53-DEPENDENT APOPTOSIS; CYTOCHROME-C; CELL-DEATH; DEPENDENT ACTIVATION; THYMOCYTE APOPTOSIS; DNA-DAMAGE; P53; BAX; PROTEIN	A critical function of tumor suppressor p53 is the induction of apoptosis in cells exposed to noxious stresses. We report a previously unidentified pro-apoptotic gene, Nora. Expression of Nora induction in primary mouse cells exposed to x-ray irradiation was dependent on p53, Nora encodes a Bcl-2 homology 3 (BH3)-only member of the Bcl-2 family of proteins; this member contains the BH3 region but not other BH domains. When ectopically expressed, Nora underwent BH3 motif-dependent Localization to mitochondria and interacted with anti-apoptotic Bcl-2 family members, resulting in the activation of caspase-9. We also demonstrate that blocking the endogenous Nora induction results in the suppression of apoptosis. Nora may thus represent a mediator of p53-dependent apoptosis.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0608543, Japan	University of Tokyo; University of Tokyo; Sapporo Medical University	Taniguchi, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Tokino, Takashi/AAI-9887-2021; MURASAWA, Hideki/AAP-9514-2021	MURASAWA, Hideki/0000-0003-4897-1239; Tanaka, Nobuyuki/0000-0002-6373-2220				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marcellus RC, 1996, CELL GROWTH DIFFER, V7, P1643; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NEMOTO J, UNPUB; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; ODA E, UNPUB; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Sugrue MM, 1999, BIOCHEM BIOPH RES CO, V261, P123, DOI 10.1006/bbrc.1999.0984; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamano S, 1999, J VIROL, V73, P10095, DOI 10.1128/JVI.73.12.10095-10103.1999; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	1588	1679	1	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1053	1058		10.1126/science.288.5468.1053	http://dx.doi.org/10.1126/science.288.5468.1053			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807576				2022-12-28	WOS:000086988400038
J	Ramanan, N; Wang, Y				Ramanan, N; Wang, Y			A high-affinity iron permease essential for Candida albicans virulence	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT; GENE; ACQUISITION; EXPRESSION; INFECTION; CLONING; PROTEIN; GROWTH; YEAST	Microbial pathogens must compete with the iron-withholding defense systems of their host to acquire this essential nutrient. Here, two high-affinity iron permease genes, CaFTR1 and CaFTR2, were isolated. CaFTR1 expression was induced under iron-limited conditions and repressed when iron supply was sufficient, whereas the expression of CaFTR2 was regulated in a reversed manner. Mutants Lacking CaFTR1 but not CaFTR2 exhibited a severe growth defect in iron-deficient medium and were unable to establish systemic infection in mice. Thus, CaFTR1-mediated iron-uptake mechanism constitutes a virulence factor of Candida albicans and may be a target for the development of anti-Candida therapies.	Inst Mol & Cell Biol, Microbial Collect & Screening Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Wang, Y (corresponding author), Inst Mol & Cell Biol, Microbial Collect & Screening Lab, 30 Med Dr, Singapore 117609, Singapore.		Wang, Yue/AGN-6053-2022; Wang, Yue/H-2107-2011	Wang, Yue/0000-0002-1211-2822				Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Askwith C, 1997, J BIOL CHEM, V272, P401; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Cornelissen CN, 1998, MOL MICROBIOL, V27, P611, DOI 10.1046/j.1365-2958.1998.00710.x; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; Eck R, 1999, MICROBIOL-UK, V145, P2415, DOI 10.1099/00221287-145-9-2415; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; EIDE D, 1992, J BIOL CHEM, V267, P20774; Fonzi WA, 1999, J BACTERIOL, V181, P7070, DOI 10.1128/JB.181.22.7070-7079.1999; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Howard DH, 1999, CLIN MICROBIOL REV, V12, P394, DOI 10.1128/CMR.12.3.394; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; NICHOLAS DJD, 1965, METHOD ENZYMOL, V3, P1035; Richards MJ, 1999, CRIT CARE MED, V27, P887, DOI 10.1097/00003246-199905000-00020; Sanglard D, 1997, INFECT IMMUN, V65, P3539, DOI 10.1128/IAI.65.9.3539-3546.1997; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Stevens MK, 1996, INFECT IMMUN, V64, P1724, DOI 10.1128/IAI.64.5.1724-1735.1996; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D	22	248	260	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1062	1064		10.1126/science.288.5468.1062	http://dx.doi.org/10.1126/science.288.5468.1062			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807578				2022-12-28	WOS:000086988400040
J	Peppard, PE; Young, T; Palta, M; Skatrud, J				Peppard, PE; Young, T; Palta, M; Skatrud, J			Prospective study of the association between sleep-disordered breathing and hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; BLOOD-PRESSURE; SYSTEMIC HYPERTENSION; LONGITUDINAL DATA; APNEA SYNDROME; POPULATION; PREVALENCE; MEN; COMMUNITY; HYPOXIA	Background: Sleep-disordered breathing is prevalent in the general population and has been linked to chronically elevated blood pressure in cross-sectional epidemiologic studies. We performed a prospective, population-based study of the association between objectively measured sleep-disordered breathing and hypertension (defined as a laboratory-measured blood pressure of at least 140/90 mm Hg or the use of antihypertensive medications). Methods: We analyzed data on sleep-disordered breathing, blood pressure, habitus, and health history at base line and after four years of follow-up in 709 participants of the Wisconsin Sleep Cohort Study (and after eight years of follow-up in the case of 184 of these participants). Participants were assessed overnight by 18-channel polysomnography for sleep-disordered breathing, as defined by the apnea-hypopnea index (the number of episodes of apnea and hypopnea per hour of sleep). The odds ratios for the presence of hypertension at the four-year follow-up study according to the apnea-hypopnea index at base line were estimated after adjustment for base-line hypertension status, body-mass index, neck and waist circumference, age, sex, and weekly use of alcohol and cigarettes. Results: Relative to the reference category of an apnea-hypopnea index of 0 events per hour at base line, the odds ratios for the presence of hypertension at follow-up were 1.42 (95 percent confidence interval, 1.13 to 1.78) with an apnea-hypopnea index of 0.1 to 4.9 events per hour at base line as compared with none, 2.03 (95 percent confidence interval, 1.29 to 3.17) with an apnea-hypopnea index of 5.0 to 14.9 events per hour, and 2.89 (95 percent confidence interval, 1.46 to 5.64) with an apnea-hypopnea index of 15.0 or more events per hour. Conclusions: We found a dose-response association between sleep-disordered breathing at base line and the presence of hypertension four years later that was independent of known confounding factors. The findings suggest that sleep-disordered breathing is likely to be a risk factor for hypertension and consequent cardiovascular morbidity in the general population. (N Engl J Med 2000;342:1378-84.) (C)2000, Massachusetts Medical Society.	Univ Wisconsin, Sch Med, Dept Prevent Med, Madison, WI 53705 USA; Univ Wisconsin, Sch Med, Dept Biostat & Med Informat, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Peppard, PE (corresponding author), Univ Wisconsin, Sch Med, Dept Prevent Med, 502 N Walnut St, Madison, WI 53705 USA.	ppeppard@facstaff.wisc.edu	Lavu, Madhav/A-9409-2013		NCRR NIH HHS [RR03186] Funding Source: Medline; NHLBI NIH HHS [R01HL62252, P01HL42242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062252, P01HL042242] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1992, AM J HYPERTENS, V5, P207; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Arabi Y, 1999, J APPL PHYSIOL, V87, P689, DOI 10.1152/jappl.1999.87.2.689; BEARPARK H, 1995, AM J RESP CRIT CARE, V151, P1459, DOI 10.1164/ajrccm.151.5.7735600; Black HR, 1998, ARCH INTERN MED, V158, P573; CARLSON JT, 1994, AM J RESP CRIT CARE, V150, P72, DOI 10.1164/ajrccm.150.1.8025776; DAVIES RJO, 1994, CLIN SCI, V86, P417, DOI 10.1042/cs0860417; ESCOURROU P, 1990, CHEST, V98, P1362, DOI 10.1378/chest.98.6.1362; FERINISTRAMBI L, 1994, CHEST, V105, P1759, DOI 10.1378/chest.105.6.1759; FLETCHER EC, 1995, AM J MED, V98, P118, DOI 10.1016/S0002-9343(99)80395-7; GARPESTAD E, 1992, J APPL PHYSIOL, V73, P1743, DOI 10.1152/jappl.1992.73.5.1743; *GENMOD PROC, 1996, SAS STAT SOFTW CHANG; GISLASON T, 1987, ACTA MED SCAND, V222, P415; GISLASON T, 1993, CHEST, V103, P1147, DOI 10.1378/chest.103.4.1147; GRUNSTEIN R, 1993, INT J OBESITY, V17, P533; GUILLEMINAULT C, 1986, CHEST, V89, P331, DOI 10.1378/chest.89.3.331; Hedner J, 1994, SLEEP BREATH, P823; HEITJAN DF, 1994, J AM STAT ASSOC, V89, P750, DOI 10.2307/2290900; HOFFSTEIN V, 1992, CHEST, V101, P379, DOI 10.1378/chest.101.2.379; Hu FB, 1999, AM J EPIDEMIOL, V150, P806; JENNUM P, 1992, CHEST, V102, P1371, DOI 10.1378/chest.102.5.1371; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; KOSKENVUO M, 1985, LANCET, V1, P893; Kripke DF, 1997, SLEEP, V20, P65, DOI 10.1093/sleep/20.1.65; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LOHMAN TG, 1988, ANTHROPOMETRIC STAND, P1; MILLMAN RP, 1991, CHEST, V99, P861, DOI 10.1378/chest.99.4.861; Morgan BJ, 1998, SLEEP, V21, P737, DOI 10.1093/sleep/21.7.737; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; OKABE S, 1995, THORAX, V50, P28, DOI 10.1136/thx.50.1.28; OLSON LG, 1995, AM J RESP CRIT CARE, V152, P711, DOI 10.1164/ajrccm.152.2.7633731; OLSON LG, 1995, AM J RESP CRIT CARE, V152, P717, DOI 10.1164/ajrccm.152.2.7633732; Pankow W, 1997, CHEST, V112, P1253, DOI 10.1378/chest.112.5.1253; RAUSCHER H, 1992, CHEST, V102, P367, DOI 10.1378/chest.102.2.367; Rechtschaffen A, 1968, NIH PUBLICATION, V204; Rothman K., 1998, MODERN EPIDEMIOLOGY; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; SCHMIDTNOWARA WW, 1990, PROG CLIN BIOL RES, V345, P377; STRADLING JR, 1990, BRIT MED J, V300, P75, DOI 10.1136/bmj.300.6717.75; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; STROHL KP, 1994, SLEEP, V17, P614, DOI 10.1093/sleep/17.7.614; Wilcox I, 1998, THORAX, V53, pS25; Wright J, 1997, BRIT MED J, V314, P851; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; YOUNG T, 2000, SLEEP APNEA IMPLICAT, P261; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	47	3337	3533	6	138	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1378	1384		10.1056/NEJM200005113421901	http://dx.doi.org/10.1056/NEJM200005113421901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	312JR	10805822	Bronze			2022-12-28	WOS:000086940600001
J	Jones, J				Jones, J			Britain's first "virtual hospital" gets go ahead	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1227	1227						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797026				2022-12-28	WOS:000086981400011
J	van der Kleij, FGH; Zijlstra, JG				van der Kleij, FGH; Zijlstra, JG			Pneumomediastinum and severe subcutaneous emphysema.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Groningen Hosp, NL-9700 RB Groningen, Netherlands	University of Groningen	van der Kleij, FGH (corresponding author), Univ Groningen Hosp, NL-9700 RB Groningen, Netherlands.		zijlstra, jan g/E-6782-2011	zijlstra, jan g/0000-0001-9079-0795					0	6	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 4	2000	342	18					1333	1333		10.1056/NEJM200005043421805	http://dx.doi.org/10.1056/NEJM200005043421805			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	309RE	10793166				2022-12-28	WOS:000086782400005
J	Grissom, CK; Radwin, MI; Harmston, CH; Hirshberg, EL; Crowley, TJ				Grissom, CK; Radwin, MI; Harmston, CH; Hirshberg, EL; Crowley, TJ			Respiration during snow burial using an artificial air pocket	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AVALANCHE	Context Asphyxia is the most common cause of death after avalanche burial. A device that allows a person to breathe air contained in snow by diverting expired carbon dioxide (CO2) away from a 500-cm(3) artificial inspiratory air pocket may improve chances of survival in avalanche burial. Objective To determine the duration of adequate oxygenation and ventilation during burial in dense snow while breathing with vs without the artificial air pocket device. Design Field study of physiologic respiratory measures during snow burial with and without the device from December 1998 to March 1999. Study burials were terminated at the subject's request, when oxygen saturation as measured by pulse oximetry (SpO(2)) dropped to less than 84%, or after 60 minutes elapsed. Setting Mountainous outdoor site at 2385 m elevation, with an average barometric pressure of 573 mm Hg. Participants Six male and 2 female volunteers (mean age, 34.6 years; range, 28-39 years). Main Outcome Measures Burial time, SpO(2), partial pressure of end-tidal CO2 (ETCO2), partial pressure of inspiratory CO2 (PICO2), respiratory rate, and heart rate at baseline (in open atmosphere) and during snow burial while breathing with the device and without the device but with a 500-cm(3) air pocket in the snow. Results Mean burial time was 58 minutes (range, 45-60 minutes) with the device and 10 minutes (range, 5-14 minutes) without it (P=.001). A mean baseline SpO(2) of 96% (range, 90%-99%) decreased to 90% (range, 77%-96%) in those buried with the device (P=.01) and to 84% (range, 79%-92%) in the control burials (P=.02). Only 1 subject buried with the device, but 6 central subjects buried without the device, decreased SpO(2) to less than 88% (P=.005). A mean baseline ETCO2 of 32 mm Hg (range, 27-38 mm Hg) increased to 45 mm Hg (range, 32-53 mm Hg) in the burials with the device (P=.02) and to 54 mm Hg (range, 44-63 mm Hg) in the control burials (P=.02). A mean baseline Pico, of 2 mm Hg (range, 0-3 mm Hg) increased to 32 mm Hg (range, 20-44 mm Hg) in the burials with the device (P=.01) and to 44 mm Hg (range, 37-50 mm Hg) in the control burials (P=.02). Respiratory and heart rates did not change in burials with the device but significantly increased in control burials. Conclusions In our study, although hypercapnia developed, breathing with the device during snow burial considerably extended duration of adequate oxygenation compared with breathing with an air pocket in the snow. Further study will be needed to determine whether the device improves survival during avalanche burial.	Univ Utah, Latter Day St Hosp, Div Pulm, Salt Lake City, UT 84143 USA; Black Diamond Equipment Ltd, Salt Lake City, UT USA; TJ Crowley Corp, Aurora, CO USA	Utah System of Higher Education; University of Utah	Grissom, CK (corresponding author), Univ Utah, Latter Day St Hosp, Div Pulm, 8th Ave & C St, Salt Lake City, UT 84143 USA.			Radwin, Martin/0000-0002-4455-414X				ATKINS D, 1999, COLORADO AVALANCHE I; BERGER AJ, 1988, TXB RESP MED, P199; De Vito EL, 1998, AM J RESP CRIT CARE, V158, P107, DOI 10.1164/ajrccm.158.1.9709098; FALK M, 1994, NATURE, V368, P21, DOI 10.1038/368021a0; GROSSMAN MD, 1989, J TRAUMA, V29, P1705, DOI 10.1097/00005373-198912000-00021; LOCHER T, 1991, SCHWEIZ MED WSCHR, V121, P1020; MARGID J, 1998, P 1998 INT SNOW SCI; MCCLUNG D, 1993, AVALANCHE HDB, P115; NUNN JF, 1987, APPL RESP PHYSL, P226; Page CE, 1999, WILD ENVIRON MED, V10, P146, DOI 10.1580/1080-6032(1999)010[0146:ADITUS]2.3.CO;2; RADWIN MI, 1998, P 1998 INT SNOW SCI; STALSBERG H, 1989, VIRCHOWS ARCH A, V414, P415, DOI 10.1007/BF00718625; WILLIAMS K, 1995, WILDERNESS MED MANAG, P616	13	53	53	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2266	2271		10.1001/jama.283.17.2266	http://dx.doi.org/10.1001/jama.283.17.2266			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807386				2022-12-28	WOS:000086671600034
J	Scarlatis, G				Scarlatis, G			Optical prosthesis: Visions of the future	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Northwestern Univ, Sch Med, Chicago, IL 60611 USA	Northwestern University	Scarlatis, G (corresponding author), Northwestern Univ, Sch Med, Chicago, IL 60611 USA.							BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519; DEJUAN E, 1999, OPHTHALMOLOGY CLIN N, V12, P539; Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P2073; Normann RA, 1999, VISION RES, V39, P2577, DOI 10.1016/S0042-6989(99)00040-1; Peachey NS, 1999, J REHABIL RES DEV, V36, P371; Peyman G, 1998, OPHTHALMIC SURG LAS, V29, P234; Walter P, 1999, RETINA-J RET VIT DIS, V19, P546, DOI 10.1097/00006982-199911000-00012; Zrenner E, 1999, VISION RES, V39, P2555, DOI 10.1016/S0042-6989(98)00312-5	8	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2297	+		10.1001/jama.283.17.2297	http://dx.doi.org/10.1001/jama.283.17.2297			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807393	hybrid			2022-12-28	WOS:000086671600041
J	Gallopin, T; Fort, P; Eggermann, E; Cauli, B; Luppi, PH; Rossier, J; Audinat, E; Muhlethaler, M; Serafin, M				Gallopin, T; Fort, P; Eggermann, E; Cauli, B; Luppi, PH; Rossier, J; Audinat, E; Muhlethaler, M; Serafin, M			Identification of sleep-promoting neurons in vitro	NATURE			English	Article							CEREBELLAR SLICES; BASAL FOREBRAIN; IN-VITRO; RAT; INVITRO; CELLS; NUCLEUS; AROUSAL	The neurons responsible for the onset of sleep are thought to be located in the preoptic area(1-3) and more specifically, in the ventrolateral preoptic nucleus (VLPO)(4-6). Here we identify sleep-promoting neurons in vitro and show that they represent an homogeneous population of cells that must be inhibited by systems of arousal during the waking state. We rnd that two-thirds of the VLPO neurons are multipolar triangular cells that show a low-threshold spike. This proportion matches that of cells active during sleep in the same region(6). We then show, using single-cell reverse transcriptase followed by polymerase chain reaction, that these neurons probably contain g-aminobutyric acid (GABA). We also show that these neurons are inhibited by noradrenaline and acetylcholine, both of which are transmitters of wakefulness(3,7,8). As most of these cells are also inhibited by serotonin but unaffected by histamine, their overall inhibition by transmitters of wakefulness is in agreement with their relative inactivity during waking with respect to sleep(6). We propose that the reciprocal inhibitory interaction of such VLPO neurons with the noradrenergic, serotoninergic and cholinergic waking systems to which they project(5,9,10) is a key factor for promoting sleep.	Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Neurobiol Etats Sommeil & Eveil, F-69373 Lyon, France; ESPCI, CNRS, UMR 7637, Lab Neurobiol & Divers Cellulaire, F-75005 Paris, France	University of Geneva; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Muhlethaler, M (corresponding author), Ctr Med Univ Geneva, Dept Physiol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.		Audinat, Etienne/F-4789-2019; Luppi, Pierre-Hervé/C-4333-2014; FORT, Patrice/G-6851-2017	Audinat, Etienne/0000-0002-6389-422X; Luppi, Pierre-Hervé/0000-0002-0503-423X; FORT, Patrice/0000-0003-1211-8631; Cauli, Bruno/0000-0003-1471-4621; Gallopin, Thierry/0000-0002-9741-3738				Audinat E, 1996, NEUROCHEM INT, V28, P119, DOI 10.1016/0197-0186(95)00075-5; Cauli B, 1997, J NEUROSCI, V17, P3894; DODT HU, 1994, TRENDS NEUROSCI, V17, P453, DOI 10.1016/0166-2236(94)90130-9; Fort P, 1998, NEUROREPORT, V9, P61, DOI 10.1097/00001756-199801050-00013; FORT P, 1998, NEUR ABSTR, V24; GAUS SE, 1998, NEUR ABSTR, V24; Gorelova N, 1996, J NEUROPHYSIOL, V75, P695, DOI 10.1152/jn.1996.75.2.695; GRIFFITH WH, 1988, J NEUROPHYSIOL, V59, P1590, DOI 10.1152/jn.1988.59.5.1590; JONES BE, 1994, PRINCIPLES PRACTICE, P145; Kondo S, 1998, J PHYSIOL-LONDON, V509, P221, DOI 10.1111/j.1469-7793.1998.221bo.x; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P549, DOI 10.1113/jphysiol.1981.sp013763; Lu J, 1999, NEUROSCIENCE, V93, P209, DOI 10.1016/S0306-4522(99)00094-9; Luppi PH, 1999, RAPID EYE MOVEMENT SLEEP, P107; McCormick DA, 1997, ANNU REV NEUROSCI, V20, P185, DOI 10.1146/annurev.neuro.20.1.185; OSAKA T, 1995, NEUROSCI RES, V21, P323, DOI 10.1016/0168-0102(94)00871-C; OSAKA T, 1994, NEUROSCI RES, V19, P39, DOI 10.1016/0168-0102(94)90006-X; Paxinos G., 1998, RAT BRAIN STEROTAXIC; Porter JT, 1998, EUR J NEUROSCI, V10, P3617, DOI 10.1046/j.1460-9568.1998.00367.x; Porter JT, 1999, J NEUROSCI, V19, P5228; Sherin JE, 1998, J NEUROSCI, V18, P4705; Sherin JE, 1996, SCIENCE, V271, P216, DOI 10.1126/science.271.5246.216; SHIROMANI PJ, 1999, HDB BEHAV STATE CONT, P311; Steriade M., 1990, BRAINSTEM CONTROL WA; SZYMUSIAK R, 1995, SLEEP, V18, P478, DOI 10.1093/sleep/18.6.478; Szymusiak R, 1998, BRAIN RES, V803, P178, DOI 10.1016/S0006-8993(98)00631-3	27	334	347	4	42	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					992	995		10.1038/35010109	http://dx.doi.org/10.1038/35010109			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801127				2022-12-28	WOS:000086762000055
J	Stewart, AK; Schuh, AC				Stewart, AK; Schuh, AC			White cells 2: impact of understanding the molecular basis of haematological malignant disorders on clinical practice	LANCET			English	Review							ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; MINIMAL RESIDUAL DISEASE; NON-HODGKINS-LYMPHOMA; PML-RAR-ALPHA; MULTIPLE-MYELOMA; B-CELL	The molecular basis of many leukaemias is now known, allowing precise diagnosis. Treatment of chronic myeloid leukaemia is now possible by targeting of the BCR-ABL tyrosine kinase. The underlying molecular abnormalities in acute leukaemias allow the outlook for individual patients to be assessed at diagnosis and therapy tailored accordingly. Analysis of V-H genes in B-cell malignant disorders allows these to be placed in the hierarchy of B-cell development and may provide prognostically valuable information.	Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Stewart, AK (corresponding author), Princess Margaret Hosp, Dept Med Oncol, Room 5-126,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	k.stewart@utoronto.ca						BAHLER DW, 1992, P NATL ACAD SCI USA, V89, P6770, DOI 10.1073/pnas.89.15.6770; Barlogie B, 1999, BLOOD, V93, P55, DOI 10.1182/blood.V93.1.55.401k04_55_65; Bergsagel PL, 1997, CURR TOP MICROBIOL, V224, P283; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; CHAGN H, 1999, LEUKEMIA, V13, P105; CHEN Z, 1994, CANCER GENET CYTOGEN, V78, P10, DOI 10.1016/0165-4608(94)90039-6; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Cuneo A, 1999, HAEMATOLOGICA, V84, P589; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fonseca R, 1998, BRIT J HAEMATOL, V101, P296, DOI 10.1046/j.1365-2141.1998.00700.x; Frank R, 1995, ONCOGENE, V11, P2667; Golub TR, 1997, CURR TOP MICROBIOL, V220, P67; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRIBBEN JG, 1994, BLOOD, V83, P3800; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heim S, 1995, CANC CYTOGENETICS; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Hussell T, 1996, J PATHOL, V178, P122, DOI 10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D; Kapp U, 1999, J EXP MED, V189, P1939, DOI 10.1084/jem.189.12.1939; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Kuppers R, 1998, ANN ONCOL, V9, P17, DOI 10.1023/A:1008449822185; Kurzrock R, 1998, J CLIN ONCOL, V16, P1526, DOI 10.1200/JCO.1998.16.4.1526; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MILLER WH, 1993, BLOOD, V82, P1689; Mrozek K, 1997, SEMIN ONCOL, V24, P17; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rubnitz JE, 1997, J CLIN ONCOL, V15, P1150, DOI 10.1200/JCO.1997.15.3.1150; Rubnitz JE, 1996, LEUKEMIA, V10, P74; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; SEONG DC, 1995, BLOOD, V86, P2343, DOI 10.1182/blood.V86.6.2343.bloodjournal8662343; Shaughnessy J, 1999, CURR TOP MICROBIOL, V246, P199; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; STEWART AK, 1994, BLOOD, V83, P1717; Stilgenbauer S, 1998, ANN HEMATOL, V76, P101, DOI 10.1007/s002770050373; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vallisa D, 1999, AM J MED, V106, P556, DOI 10.1016/S0002-9343(99)00069-8; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Warrell RP, 1997, INT J CANCER, V70, P496, DOI 10.1002/(SICI)1097-0215(19970207)70:4<496::AID-IJC25>3.3.CO;2-P; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	58	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2000	355	9213					1447	1453		10.1016/S0140-6736(00)02150-4	http://dx.doi.org/10.1016/S0140-6736(00)02150-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791539				2022-12-28	WOS:000086829800040
J	Wong, CA; Walsh, LJ; Smith, CJP; Wisniewski, AF; Lewis, SA; Hubbard, R; Cawte, S; Green, DJ; Pringle, M; Tattersfield, AE				Wong, CA; Walsh, LJ; Smith, CJP; Wisniewski, AF; Lewis, SA; Hubbard, R; Cawte, S; Green, DJ; Pringle, M; Tattersfield, AE			Inhaled corticosteroid use and bone-mineral density in patients with asthma	LANCET			English	Article							BECLOMETHASONE DIPROPIONATE; REFERENCE RANGES; STEROID-THERAPY; WOMEN; RISK; BUDESONIDE; GLUCOCORTICOIDS; FLUTICASONE; METABOLISM; FRACTURE	Background Inhaled corticosteroids are absorbed into the systemic circulation, but the extent to which they have adverse effects on bone is uncertain. The question is important since 3% of the European population take an inhaled corticosteroid regularly and may do so for many years. Methods We studied the dose-response relation between cumulative inhaled corticosteroid dose and bone-mineral density at the lumbar spine and proximal femur in 196 adults (119 women) with asthma aged 20-40 years. Patients had taken an inhaled corticosteroid regularly for at least 6 months, and had had limited exposure to systemic steroids. Cumulative dose of inhaled corticosteroid was calculated from questionnaires and computerised and written general-practice records, and its effect on bone-mineral density was estimated by multiple regression analysis. Findings Median duration of inhaled corticosteroid treatment was 6 years (range 0.5-24), and median cumulative dose was 876 mg (87-4380), There was a negative association between cumulative dose of inhaled corticosteroid and bone-mineral density at the lumbar spine (L2-L4), femoral neck, Ward's triangle, and trochanter, both before and after adjustment for the effects of age and sex. A doubling in dose of inhaled corticosteroid was associated with a decrease in bone-mineral density at the lumbar spine of 0.16 SD (95% CI 0.04-0.28). Similar decreases were found at the femoral neck, Ward's triangle, and trochanter, Adjustment for potential confounding factors including physical activity and past oral, nasal, dermal, and parenteral corticosteroids did not weaken the associations. Interpretation This study provides evidence of a negative relation between total cumulative dose of inhaled corticosteroid and bone-mineral density in patients with asthma.	City Hosp, Div Resp Med, Nottingham NG5 1PB, England; City Hosp, Dept Radiol, Nottingham NG5 1PB, England; Queens Med Ctr, Dept Gen Practice, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham; University of Nottingham	Wong, CA (corresponding author), City Hosp, Div Resp Med, Nottingham NG5 1PB, England.							BALFOURLYNN L, 1987, PAEDIATRICIAN, V24, P237; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; Bisgaard H, 1996, EUR RESPIR J, V9, pS28; BOULET LP, 1994, J ALLERGY CLIN IMMUN, V94, P796, DOI 10.1016/0091-6749(94)90145-7; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; EASTELL R, 1991, J BONE MINER RES, V6, P207; Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283; Egan JJ, 1999, EUR RESPIR J, V13, P1267, DOI 10.1183/09031936.99.13612769; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; HANANIA NA, 1995, J ALLERGY CLIN IMMUN, V96, P571, DOI 10.1016/S0091-6749(95)70254-7; HERRALA J, 1994, BONE, V15, P621, DOI 10.1016/8756-3282(94)90309-3; Hughes JA, 1999, THORAX, V54, P223, DOI 10.1136/thx.54.3.223; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107, DOI 10.1093/oxfordjournals.aje.a116833; Lau EMC, 1998, CLIN EXP ALLERGY, V28, P1066; Luengo M, 1997, EUR RESPIR J, V10, P2110, DOI 10.1183/09031936.97.10092110; Marystone JF, 1995, AM J PUBLIC HEALTH, V85, P1693, DOI 10.2105/AJPH.85.12.1693; Mazess RB, 1997, BRIT J RADIOL, V70, P109, DOI 10.1259/bjr.70.829.9059309; Packe GE, 1996, J ROY COLL PHYS LOND, V30, P128; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Petley GW, 1996, BRIT J RADIOL, V69, P655, DOI 10.1259/0007-1285-69-823-655; RUSELL G, 1993, ARCH DIS CHILD, V69, P694; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; Truscott JG, 1997, BRIT J RADIOL, V70, P1245, DOI 10.1259/bjr.70.840.9505843; Walsh LJ, 1999, THORAX, V54, P296, DOI 10.1136/thx.54.4.296; WASNICH R, 1993, AM J MED, V95, pS6, DOI 10.1016/0002-9343(93)90374-X; Wisniewski AF, 1997, THORAX, V52, P853, DOI 10.1136/thx.52.10.853; WOLFF AH, 1991, ANN ALLERGY, V67, P117	30	247	258	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1399	1403		10.1016/S0140-6736(00)02138-3	http://dx.doi.org/10.1016/S0140-6736(00)02138-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791523				2022-12-28	WOS:000086829800010
J	Smith, O				Smith, O			Physiology - Contortions of the heart	SCIENCE			English	Editorial Material																		Kilner PJ, 2000, NATURE, V404, P759, DOI 10.1038/35008075	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					453	453		10.1126/science.288.5465.453	http://dx.doi.org/10.1126/science.288.5465.453			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10798983				2022-12-28	WOS:000086626000027
J	Hartmann, WK				Hartmann, WK			The paradigm and the pendulum - All hail the new Dark Ages.	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					817	817		10.1038/35009200	http://dx.doi.org/10.1038/35009200			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786771	Bronze			2022-12-28	WOS:000086625000025
J	Sharma, RP; Ogale, SB; Zhang, ZH; Liu, JR; Chu, WK; Veal, B; Paulikas, A; Zheng, H; Venkatesan, T				Sharma, RP; Ogale, SB; Zhang, ZH; Liu, JR; Chu, WK; Veal, B; Paulikas, A; Zheng, H; Venkatesan, T			Phase transitions in the incoherent lattice fluctuations in YBa2Cu3O7-delta	NATURE			English	Editorial Material							T-J MODEL; SPIN-GAP; DYNAMICS; SUPERCONDUCTORS; DISTORTIONS; LA2-XSRXCUO4; CRYSTALS; RANGE; HOLES	The growing body of experimental evidence(1-7) for the existence of complex textures of charges and spins in the high-temperature superconductors has drawn attention to the so-called 'stripe-phase' model(8-12) as a possible basis for the mechanism of superconductivity in these materials. Such observations have until now been restricted to systems where the texture dynamics are slow or suppressed altogether, and do not include the important case of YBa2Cu3O7-delta. It seems likely that the dynamic behaviour of stripes(12,13), which has been suggested to undergo several phase transitions as a function of temperature(12), should also be reflected in the lattice properties of the host materials, and this forms the motivation for our present experiments. Specifically, we use MeV helium ion channelling, an ultrafast real-space probe of atomic displacements (with sub-picometre resolution), to probe incoherent lattice fluctuations in YBa2Cu3O7-delta as a function of temperature and oxygen doping. We detect lattice fluctuations that are larger than the expected thermal vibration component, and which show anomalies characteristic of the phase transitions anticipated for a dynamic stripe phase. Comparison of our lattice results with single-particle-tunnelling and photoemission data highlights the importance of spin-charge separation phenomena in the copper oxide superconductors.	Univ Maryland, Ctr Superconduct Res, Dept Phys, College Pk, MD 20742 USA; Univ Houston, Texas Ctr Superconduct, Houston, TX 77204 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA	University System of Maryland; University of Maryland College Park; University of Houston System; University of Houston; United States Department of Energy (DOE); Argonne National Laboratory	Venkatesan, T (corresponding author), Univ Maryland, Ctr Superconduct Res, Dept Phys, College Pk, MD 20742 USA.		Venkatesan, Thirumalai V/E-1667-2013	Venkatesan, Thirumalai/0000-0001-9683-4584				BARRETT JH, 1971, PHYS REV B, V3, P1527, DOI 10.1103/PhysRevB.3.1527; BATLOGG B, 1994, J LOW TEMP PHYS, V95, P23, DOI 10.1007/BF00754919; Batlogg B, 1996, NATURE, V382, P20, DOI 10.1038/382020a0; Bianconi A, 1996, PHYS REV LETT, V76, P3412, DOI 10.1103/PhysRevLett.76.3412; BORSA F, 1995, PHYS REV B, V52, P7334, DOI 10.1103/PhysRevB.52.7334; CHEONG SW, 1991, PHYS REV LETT, V67, P1791, DOI 10.1103/PhysRevLett.67.1791; Dai PC, 1999, SCIENCE, V284, P1344, DOI 10.1126/science.284.5418.1344; EMERY VJ, 1990, PHYS REV LETT, V64, P475, DOI 10.1103/PhysRevLett.64.475; Emery VJ, 1997, PHYS REV B, V56, P6120, DOI 10.1103/PhysRevB.56.6120; GEMMELL DS, 1974, REV MOD PHYS, V46, P129, DOI 10.1103/RevModPhys.46.129; Hauff R, 1996, PHYS REV LETT, V77, P4620, DOI 10.1103/PhysRevLett.77.4620; HELLBERG, 1999, PHYS REV LETT, V83, P132; HOMES CC, 1993, PHYS REV LETT, V71, P1645, DOI 10.1103/PhysRevLett.71.1645; Kataev V, 1997, PHYS REV B, V55, pR3394, DOI 10.1103/PhysRevB.55.R3394; LINDHARD J, 1965, KGL DANSKE VIDENSKAB, V34, P1; Loeser AG, 1996, SCIENCE, V273, P325, DOI 10.1126/science.273.5273.325; Mook HA, 1999, NATURE, V401, P145, DOI 10.1038/43629; Noda T, 1999, SCIENCE, V286, P265, DOI 10.1126/science.286.5438.265; Salkola MI, 1996, PHYS REV LETT, V77, P155, DOI 10.1103/PhysRevLett.77.155; SCHULZ HJ, 1990, PHYS REV LETT, V64, P1445, DOI 10.1103/PhysRevLett.64.1445; Sharma RP, 1996, PHYS REV LETT, V77, P4624, DOI 10.1103/PhysRevLett.77.4624; Starykh OA, 1996, PHYS REV LETT, V77, P2558, DOI 10.1103/PhysRevLett.77.2558; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; Tranquada JM, 1996, PHYS REV B, V54, P7489, DOI 10.1103/PhysRevB.54.7489; WARREN WW, 1989, PHYS REV LETT, V62, P1193, DOI 10.1103/PhysRevLett.62.1193; White SR, 1998, PHYS REV LETT, V80, P1272, DOI 10.1103/PhysRevLett.80.1272; Zaanen J, 1996, PHYS REV B, V53, P8671, DOI 10.1103/PhysRevB.53.8671; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391	29	98	99	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					736	740		10.1038/35008018	http://dx.doi.org/10.1038/35008018			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783881				2022-12-28	WOS:000086523600044
J	Butler, D; Pockley, P				Butler, D; Pockley, P			Cereal gene bank accepts need for patents ... as Monsanto makes rice genome public	NATURE			English	News Item																		1999, NATURE, V401, P102	1	3	4	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					534	534		10.1038/35007230	http://dx.doi.org/10.1038/35007230			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10787345	hybrid			2022-12-28	WOS:000086400100013
J	Treindl, R				Treindl, R			Japan sets tissue donor guidelines	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 6	2000	404	6778					529	529		10.1038/35007205	http://dx.doi.org/10.1038/35007205			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	303BC	10787342	Bronze			2022-12-28	WOS:000086400100004
J	Tracy, RB; Hsieh, CL; Lieber, MR				Tracy, RB; Hsieh, CL; Lieber, MR			Stable RNA/DNA hybrids in the mammalian genome: Inducible intermediates in immunoglobulin class switch recombination	SCIENCE			English	Article							HEAVY-CHAIN SWITCH; REPETITIVE SEQUENCES; CIRCULAR DNA; B-CELLS; REGION; RNA; TRANSCRIPTION; ISOTYPE; SPECIFICITY; MECHANISM	Although it is well established that mammalian class switch recombination is responsible for altering the class of immunoglobulins, the mechanistic details of the process have remained unclear, Here, we show that stable RNA/DNA hybrids form at class switch sequences in the mouse genome upon cytokine-specific stimulation of class switch in primary splenic B cells. The RNA hybridized to the switch DNA is transcribed in the physiological orientation. Mice that constitutively express an Escherichia coli ribonuclease H transgene show a marked reduction in RNA/DNA hybrid formation, an impaired ability to generate serum immunoglobulin G antibodies, and significant inhibition of class switch recombination in their splenic B cells. These data provide evidence that stable RNA/DNA hybrids exist in the mammalian nuclear genome, can serve as intermediates for physiologic: processes, and are mechanistically important For efficient class switching in vivo.	Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Microbiol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Lieber, MR (corresponding author), Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Rooms 5420 & 5428, Los Angeles, CA 90089 USA.			Lieber, Michael/0000-0001-8809-0909				Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; CHU CC, 1992, P NATL ACAD SCI USA, V89, P6978, DOI 10.1073/pnas.89.15.6978; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Coligan JE., 1994, CURRENT PROTOCOLS IM; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; DANIELS GA, 1995, P NATL ACAD SCI USA, V92, P5625, DOI 10.1073/pnas.92.12.5625; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; DUNNICK W, 1980, NATURE, V286, P669, DOI 10.1038/286669a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Hein K, 1998, J EXP MED, V188, P2369, DOI 10.1084/jem.188.12.2369; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; KATAOKA T, 1981, CELL, V23, P357, DOI 10.1016/0092-8674(81)90131-8; LEPSE CL, 1994, DNA CELL BIOL, V13, P1151, DOI 10.1089/dna.1994.13.1151; LEUNG H, 1992, P NATL ACAD SCI USA, V89, P4154, DOI 10.1073/pnas.89.9.4154; LIBONATI M, 1992, MOL CELL BIOCHEM, V117, P139; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MILLS FC, 1990, NUCLEIC ACIDS RES, V18, P7305, DOI 10.1093/nar/18.24.7305; NIKAIDO T, 1981, NATURE, V292, P845, DOI 10.1038/292845a0; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Sambrook J., 1989, MOL CLONING; SCHWEDLER U, 1990, NATURE, V345, P452; SNAPPER CM, 1999, FUNDAMENTAL IMMUNOLO, P831; STANTON LW, 1982, NUCLEIC ACIDS RES, V10, P5993, DOI 10.1093/nar/10.19.5993; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; SZUREK P, 1985, J IMMUNOL, V135, P620; Tracy RB, 2000, EMBO J, V19, P1055, DOI 10.1093/emboj/19.5.1055; Wuerffel RA, 1997, J IMMUNOL, V159, P4139; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; ZHANG J, 1995, IMMUNOGLOBULIN GENES, P235	37	16	17	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1058	1061		10.1126/science.288.5468.1058	http://dx.doi.org/10.1126/science.288.5468.1058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807577				2022-12-28	WOS:000086988400039
J	Hafernik, J; Saul-Gershenz, L				Hafernik, J; Saul-Gershenz, L			Beetle larvae cooperate to mimic bees	NATURE			English	Article									San Francisco State Univ, Dept Biol, San Francisco, CA 94132 USA	California State University System; San Francisco State University	Hafernik, J (corresponding author), San Francisco State Univ, Dept Biol, 1600 Holloway Ave, San Francisco, CA 94132 USA.		Saul-Gershenz, Leslie/AAE-1523-2019	Saul-Gershenz, Leslie/0000-0002-8492-9305				[Anonymous], 1971, INSECT SOC; BORGKARLSON AK, 1990, PHYTOCHEMISTRY, V29, P1359, DOI 10.1016/0031-9422(90)80086-V; CLAUSEN CP, 1976, ANNU REV ENTOMOL, V21, P343, DOI 10.1146/annurev.en.21.010176.002015; Cooper K. W., 1955, Transactions of the American Entomological Society, V80, P119; Crespi Bernard J., 1997, P499; ERICKSON EH, 1974, ANN ENTOMOL SOC AM, V67, P903, DOI 10.1093/aesa/67.6.903; LIMNAEUS C, 1767, SYSTEMA NATURAE REGN; PINTO J D, 1970, P222; Southwood T.R.E., 1978, ECOLOGICAL METHODS, V2nd ed., DOI 10.1007/978-94-015-7291-0; Visscher PK, 1999, NATURE, V397, P400, DOI 10.1038/17047; von Frisch K., 1950, BEES THEIR VISION CH	11	25	30	2	87	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					35	36		10.1038/35011129	http://dx.doi.org/10.1038/35011129			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811206				2022-12-28	WOS:000086901600038
J	Grigsby, PW; Siegel, BA; Baker, S; Eichling, JO				Grigsby, PW; Siegel, BA; Baker, S; Eichling, JO			Radiation exposure from outpatient radioactive iodine (I-131) therapy for thyroid carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context In May 1997, the US Nuclear Regulatory Commission (NRC) revised its patient release regulations, allowing for outpatient administration of larger activities of sodium iodide I-131 than previously permitted. Objective To measure the radiation exposure to household members from patients receiving outpatient I-131 therapy for thyroid carcinoma in accordance with the new regulations, Design Consecutive case series from October 1998 to June 1999. Setting and Patients Thirty patients who received outpatient I-131 therapy following thyroidectomy for differentiated thyroid carcinoma were enrolled, along with their 65 household members and 17 household pets. Main Outcome Measure Radiation exposure to household members and 4 rooms in each home, as monitored with dosimeters for 10 days following I-131 administration. Results The patients received I-131 doses ranging from 2.8 to 5.6 GBq (mean, 4.3 GBq). The radiation dose to 65 household members ranged from 0.01 mSv to 1.09 mSv (mean, 0.24 mSv). The dose to 17 household pets ranged from 0.02 mSv to 1.11 mSv (mean, 0.37 mSv). The mean dose to the 4 rooms ranged from 0.17 mSv (kitchen) to 0.58 mSv (bedroom). Conclusion In our study, I-131 doses to household members of patients receiving outpatient I-131 therapy were well below the limit (5.0 mSv) mandated by current NRC regulations.	Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Grigsby, PW (corresponding author), Radiat Oncol Ctr, Box 8224,4939 Childrens Pl,Suite 5500, St Louis, MO 63110 USA.							CULVER CM, 1991, J NUCL MED, V32, P169; HARBERT JC, 1974, J NUCL MED, V15, P887; IBIS E, 1992, J NUCL MED, V33, P2110; JACOBSON AP, 1978, AM J PUBLIC HEALTH, V68, P225, DOI 10.2105/AJPH.68.3.225; *US NUCL REG COMM, 2000, REL PAT ADM RAD MAT; 1997, FED REG, V62, P4120	6	78	82	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2272	2274		10.1001/jama.283.17.2272	http://dx.doi.org/10.1001/jama.283.17.2272			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807387	Bronze			2022-12-28	WOS:000086671600035
J	Cernicharo, J; Noriega-Crespo, A; Cesarsky, D; Lefloch, B; Gonzalez-Alfonso, E; Najarro, F; Dartois, E; Cabrit, S				Cernicharo, J; Noriega-Crespo, A; Cesarsky, D; Lefloch, B; Gonzalez-Alfonso, E; Najarro, F; Dartois, E; Cabrit, S			Windows through the dusty disks surrounding the youngest low-mass protostellar objects	SCIENCE			English	Article							HERBIG-HARO JETS; STELLAR OBJECTS; STARS; FEATURES; FLOWS; ICES	The formation and evolution of young Low-mass stars are characterized by important processes of mass Loss and accretion occurring in the innermost regions of their placentary circumstellar disks. Because of the Large obscuration of these disks at optical and infrared wavelengths in the early protostellar stages (class 0 sources), they were previously detected only at radio wavelengths using interferometric techniques. We have detected with the Infrared Space Observatory the mid-infrared (mid-IR) emission associated with the class 0 protostar VLA1 in the HH1-HH2 region located in the Orion nebula. The emission arises in three wavelength windows (at 5.3, 6.6, and 7.5 micrometers) where the absorption due to ices and silicates has a local minimum that exposes the central part of the young protostellar system to mid-IR investigations. The mid-IR emission arises from a central source with a diameter of 4 astronomical units at an averaged temperature of similar to 700 K, deeply embedded in a dense region with a visual extinction of 80 to 100 magnitudes.	Consejo Super Invest Cient, Inst Estructura Mat, Dept Fis Mol, Madrid 28006, Spain; CALTECH, Ctr Sci, Space Infrared Telescope Facil, Pasadena, CA 91125 USA; Univ Paris 11, Inst Astrophys Spatiale, F-94500 Orsay, France; Observ Grenoble, F-38406 St Martin Dheres, France; Inst Radio Astron Millimetr, F-38406 St Martin Dheres, France; Observ Paris, Dept Etud Mat Infrarouge & Millimetr, CNRS, UMR 8540, F-75014 Paris, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Estructura de la Materia (IEM); California Institute of Technology; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Cernicharo, J (corresponding author), Consejo Super Invest Cient, Inst Estructura Mat, Dept Fis Mol, Serrano 121, Madrid 28006, Spain.	cerni@astro.iem.csic.es	Cernicharo, Jose/G-3059-2015; Appourchaux, Thierry/F-4692-2010; Najarro, Francisco/G-7288-2015; Alfonso, Eduardo González/AAA-4790-2019	Cernicharo, Jose/0000-0002-3518-2524; Najarro, Francisco/0000-0002-9124-0039; Alfonso, Eduardo González/0000-0001-5285-8517; Noriega-Crespo, Alberto/0000-0002-6296-8960; Dartois, Emmanuel/0000-0003-1197-7143				ADAMS FC, 1987, ASTROPHYS J, V312, P788, DOI 10.1086/164924; ANDRE P, 1993, ASTROPHYS J, V406, P122, DOI 10.1086/172425; Andre P., 2000, PROTOSTARS PLANETS 4, P59; Bachiller R, 1996, ANNU REV ASTRON ASTR, V34, P111, DOI 10.1146/annurev.astro.34.1.111; Cernicharo J, 1996, ASTROPHYS J, V460, pL57, DOI 10.1086/309967; CESARSKY C, 1996, ASTRON ASTROPHYS, V315, P32; Chini R, 1997, ASTRON ASTROPHYS, V325, P542; DARTOIS E, 1999, THESIS U PARIS 6; DEMYK K, COMMUNICATION; dHendecourt L, 1996, ASTRON ASTROPHYS, V315, pL365; Gerakines PA, 1996, ASTRON ASTROPHYS, V312, P289; HARO G, 1952, ASTROPHYS J, V115, P572, DOI 10.1086/145576; HERBIG GH, 1951, ASTROPHYS J, V113, P697, DOI 10.1086/145440; Hester JJ, 1998, ASTRON J, V116, P372, DOI 10.1086/300396; HUDGINS DM, 1993, ASTROPHYS J SUPPL S, V86, P713, DOI 10.1086/191796; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; LADA CJ, 1991, NATO ADV SCI I C-MAT, V342, P329; Lefloch B, 1996, ASTRON ASTROPHYS, V313, pL17; Moro-Martin A, 1999, ASTROPHYS J, V520, pL111, DOI 10.1086/312156; ODell CR, 1997, SCIENCE, V276, P1355, DOI 10.1126/science.276.5317.1355; PELLETIER G, 1992, ASTROPHYS J, V394, P117, DOI 10.1086/171565; PRAVDO SH, 1985, ASTROPHYS J, V293, pL35, DOI 10.1086/184486; REIPURTH B, 1995, REV MEX AST ASTR, V1, P43; REIPURTH B, 1993, ASTROPHYS J, V408, pL49, DOI 10.1086/186828; RODRIGUEZ L, UNPUB; Schutte WA, 1996, ASTRON ASTROPHYS, V315, pL333; SHU FH, 1994, ASTROPHYS J, V429, P797, DOI 10.1086/174364; WHITTET DCB, 1996, ASTRON ASTROPHYS, V315, P357	28	18	18	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2000	288	5466					649	652		10.1126/science.288.5466.649	http://dx.doi.org/10.1126/science.288.5466.649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784443				2022-12-28	WOS:000086727100037
J	Maddocks, S; O'Brien, R				Maddocks, S; O'Brien, R			African trypanosomiasis in Australia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Westmead Hosp, Sydney, NSW, Australia	University of Sydney	Maddocks, S (corresponding author), Westmead Hosp, Sydney, NSW, Australia.								0	6	6	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1254	1254		10.1056/NEJM200004273421705	http://dx.doi.org/10.1056/NEJM200004273421705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10781622				2022-12-28	WOS:000086660600005
J	Sobolev, AV; Hofmann, AW; Nikogosian, IK				Sobolev, AV; Hofmann, AW; Nikogosian, IK			Recycled oceanic crust observed in 'ghost plagioclase' within the source of Mauna Loa lavas	NATURE			English	Article							SCIENTIFIC DRILLING PROJECT; MELT INCLUSIONS; OXYGEN-ISOTOPE; MANTLE; OLIVINE; OPHIOLITE; ECLOGITE; BASALTS; PLUME; RIDGE	The hypothesis that mantle plumes contain recycled oceanic crust(1) is now widely accepted. Some specific source components of the Hawaiian plume have been inferred to represent recycled oceanic basalts(2), pelagic sediments(3,4) or oceanic gabbros(5). Bulk lava compositions, however, retain the specific trace-element fingerprint of the original crustal component in only a highly attenuated form. Here we report the discovery of exotic, strontium-enriched melt inclusions in Mauna Loa olivines. Their complete trace-element patterns strongly resemble those of layered gabbros found in ophiolites, which are characterized by cumulus plagioclase with very high strontium abundances(6). The major-element compositions of these melts indicate that their composition cannot be the result of the assimilation of present-day oceanic crust through which the melts have travelled. Instead, the gabbro has been transformed into a (high-pressure) eclogite by subduction and recycling, and this eclogite has then been incorporated into the Hawaiian mantle plume. The trace-element signature of the original plagioclase is present only as a 'ghost' signature, which permits specific identification of the recycled rock type. The 'ghost plagioclase' trace-element signature demonstrates that the former gabbro can retain much of its original chemical identity through the convective cycle without completely mixing with other portions of the former oceanic crust.	Max Planck Inst Chem, D-55020 Mainz, Germany; Russian Acad Sci, Vernadskii Inst Geochem, Moscow 117975, Russia; Vrije Univ Amsterdam, Dept Petrol, NL-1081 HV Amsterdam, Netherlands	Max Planck Society; Russian Academy of Sciences; Vernadsky Institute of Geochemistry & Analytical Chemistry; Vrije Universiteit Amsterdam	Sobolev, AV (corresponding author), Max Planck Inst Chem, Postfach 3060, D-55020 Mainz, Germany.		Sobolev, Alexander/AAB-4269-2021; Sobolev, Alexander/AAQ-6001-2021; Sobolev, Alexander/E-6367-2010	Sobolev, Alexander/0000-0002-1997-2032; Nikogosian, I.K./0000-0002-1270-5134				ALLEGRE CJ, 1986, NATURE, V323, P123, DOI 10.1038/323123a0; Blichert-Toft J, 1999, SCIENCE, V285, P879, DOI 10.1126/science.285.5429.879; CHRISTENSEN UR, 1994, J GEOPHYS RES-SOL EA, V99, P19867, DOI 10.1029/93JB03403; Danyushevsky LV, 2000, CONTRIB MINERAL PETR, V138, P68, DOI 10.1007/PL00007664; DANYUSHEVSKY LV, 1998, EOS S, V79, pS375; Eiler JM, 1996, EARTH PLANET SC LETT, V144, P453, DOI 10.1016/S0012-821X(96)00170-7; Garcia MO, 1996, J GEOPHYS RES-SOL EA, V101, P11701, DOI 10.1029/95JB03846; GURENKO AA, 1995, GEOCHIM COSMOCHIM AC, V59, P2905, DOI 10.1016/0016-7037(95)00184-0; HART SR, 1993, P NATL ACAD SCI USA, V90, P11914, DOI 10.1073/pnas.90.24.11914; Hart SR, 1999, GEOCHIM COSMOCHIM AC, V63, P4059, DOI 10.1016/S0016-7037(99)00309-9; Hauri EH, 1996, NATURE, V382, P415, DOI 10.1038/382415a0; HOFMANN AW, 1988, EARTH PLANET SC LETT, V90, P297, DOI 10.1016/0012-821X(88)90132-X; Hofmann AW, 1996, J GEOPHYS RES-SOL EA, V101, P11831, DOI 10.1029/95JB03701; HOFMANN AW, 1982, EARTH PLANET SC LETT, V57, P421, DOI 10.1016/0012-821X(82)90161-3; Kamenetsky VS, 1998, EARTH PLANET SC LETT, V160, P115, DOI 10.1016/S0012-821X(98)00090-9; Lassiter JC, 1998, EARTH PLANET SC LETT, V164, P483, DOI 10.1016/S0012-821X(98)00240-4; RHODES JM, 1988, J GEOPHYS RES-SOLID, V93, P4453, DOI 10.1029/JB093iB05p04453; RHODES JM, 1995, GEOPHYS MONOGR SER, V92, P263; ROEDDER E, 1984, REV MINERAL, V12, P1; Sharp WD, 1996, J GEOPHYS RES-SOL EA, V101, P11607, DOI 10.1029/95JB03702; Snyder GA, 1997, J PETROL, V38, P85, DOI 10.1093/petrology/38.1.85; SOBOLEV AV, 1993, NATURE, V363, P151, DOI 10.1038/363151a0; Sobolev AV, 1996, PETROLOGY+, V4, P209; Sobolev AV., 1994, PETROLOGY+, V2, P111; SOBOLEV SV, 1994, SURV GEOPHYS, V15, P515, DOI 10.1007/BF00690173; STAKES DS, 1992, J GEOPHYS RES-SOL EA, V97, P7043, DOI 10.1029/91JB02743; Stolper EM, 1996, J GEOPHYS RES-SOL EA, V101, P11593, DOI 10.1029/96JB00332; Veksler IV, 1998, J PETROL, V39, P2095, DOI 10.1093/petrology/39.11.2095; YASUDA A, 1994, J GEOPHYS RES-SOL EA, V99, P9401, DOI 10.1029/93JB03205; Yaxley GM, 1998, SCHWEIZ MINER PETROG, V78, P243; ZIMMER M, 1995, CHEM GEOL, V123, P29, DOI 10.1016/0009-2541(95)00018-H	31	281	302	3	94	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					986	990		10.1038/35010098	http://dx.doi.org/10.1038/35010098			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801125				2022-12-28	WOS:000086762000053
J	Kant, AK; Schatzkin, A; Graubard, BI; Schairer, C				Kant, AK; Schatzkin, A; Graubard, BI; Schairer, C			A prospective study of diet quality and mortality in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-HEALTH; RISK; QUESTIONNAIRE; MEN; DIVERSITY	Context Most studies of diet and health care have focused on the role of single nutrients, foods, or food groups in disease prevention or promotion. Few studies have addressed the health effects of dietary patterns, which include complex mixtures of foods containing multiple nutrients and nonnutrients. Objective To examine the association of mortality with a multifactorial diet quality index. Design and Setting Data from phase 2 (1987-1989) of a prospective cohort study of breast cancer screening, the Breast Cancer Detection Demonstration Project, with a median follow-up of 5.6 years. Participants A total of 42 254 women (mean age, 61.1 years) who completed the food frequency questionnaire portion of the survey. Main Outcome Measure All-cause mortality by quartile of Recommended Food Score (RFS; the sum of the number of foods recommended by current dietary guidelines [fruits, vegetables, whole grains, low-fat dairy, and lean meats and poultry] that were reported on the questionnaire to be consumed at least once a week, for a maximum score of 23). Results There were 2065 deaths due to all causes in the cohort. The RFS was inversely associated with all-cause mortality. Compared with those in the lowest quartile, subjects in the upper quartiles of the RFS had relative risks for all-cause mortality of 0.82 (95% confidence interval [CI], 0.73-0.92) for quartile 2, 0.71 (95% CI, 0.62-0.81) for quartile 3, and 0.69 (95% CI, 0.61-0.78) for quartile 4 adjusted for education, ethnicity, age, body mass index, smoking status, alcohol use, level of physical activity, menopausal hormone use, and history of disease (chi(1)(2) for trend = 35.64, P<.001 for trend). Conclusions These data suggest that a dietary pattern characterized by consumption of foods recommended in current dietary guidelines is associated with decreased risk of mortality in women.	NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; CUNY Queens Coll, Dept Family Nutr & Exercise Sci, Flushing, NY 11367 USA; NCI, Biostat Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; NCI, Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City University of New York (CUNY) System; Queens College NY (CUNY); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schatzkin, A (corresponding author), NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, 6120 Execut Blvd,EPS 7032, Bethesda, MD 20892 USA.			Kant, Ashima/0000-0003-4141-2063	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010118] Funding Source: NIH RePORTER	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; BINGHAM SA, 1994, AM J CLIN NUTR, V59, p227S, DOI 10.1093/ajcn/59.1.227S; BLACK AE, 1993, J AM DIET ASSOC, V93, P572, DOI 10.1016/0002-8223(93)91820-G; Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; KANT AK, 1993, AM J CLIN NUTR, V57, P434, DOI 10.1093/ajcn/57.3.434; Kant AK, 1996, J AM DIET ASSOC, V96, P785, DOI 10.1016/S0002-8223(96)00217-9; KANT AK, 1995, J AM COLL NUTR, V14, P233; Kant AK, 1997, NUTR RES, V17, P1443, DOI 10.1016/S0271-5317(97)00135-8; Kipnis V, 1999, AM J EPIDEMIOL, V150, P642, DOI 10.1093/oxfordjournals.aje.a010063; MARESPERLMAN JA, 1993, J NUTR, V123, P489, DOI 10.1093/jn/123.3.489; McCullough M, 1999, FASEB J, V13, pA932; MERTZ W, 1984, J AM DIET ASSOC, V84, P769; NUBE M, 1987, J AM DIET ASSOC, V87, P171; SEMPOS CT, 1992, AM J EPIDEMIOL, V135, P1127, DOI 10.1093/oxfordjournals.aje.a116212; SMUCKER R, 1989, AM J EPIDEMIOL, V129, P445, DOI 10.1093/oxfordjournals.aje.a115149; Yong LC, 1996, AM J EPIDEMIOL, V143, P985, DOI 10.1093/oxfordjournals.aje.a008681; [No title captured]; [No title captured]	20	401	419	0	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2109	2115		10.1001/jama.283.16.2109	http://dx.doi.org/10.1001/jama.283.16.2109			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791502	Bronze			2022-12-28	WOS:000086542800026
J	Jobe, AH				Jobe, AH			Which surfactant for treatment of respiratory-distress syndrome	LANCET			English	Editorial Material									Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Jobe, AH (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA.							Halliday HL, 1996, DRUGS, V51, P226, DOI 10.2165/00003495-199651020-00004; HORBAR JD, 1993, J PEDIATR-US, V123, P757, DOI 10.1016/S0022-3476(05)80856-X; Hudak ML, 1997, PEDIATRICS, V100, P39, DOI 10.1542/peds.100.1.39; JOBE AH, 1993, NEW ENGL J MED, V328, P861; Michna J, 1999, AM J RESP CRIT CARE, V160, P634, DOI 10.1164/ajrccm.160.2.9902016; RIDER ED, 1992, J APPL PHYSIOL, V73, P2089, DOI 10.1152/jappl.1992.73.5.2089; SOLL RF, 1999, COCHRANE LIB; SPEER CP, 1995, ARCH DIS CHILD-FETAL, V72, pF8, DOI 10.1136/fn.72.1.F8; Verder H, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.2.e24	9	15	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1380	1381		10.1016/S0140-6736(00)02130-9	http://dx.doi.org/10.1016/S0140-6736(00)02130-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791515				2022-12-28	WOS:000086829800002
J	Locke, JL				Locke, JL			Language - Movement patterns in spoken language	SCIENCE			English	Editorial Material									Univ Cambridge, Fac Social & Polit Sci, Cambridge CB2 3RQ, England; Univ Sheffield, Dept Human Commun Sci, Sheffield S10 2TN, S Yorkshire, England	University of Cambridge; University of Sheffield	Locke, JL (corresponding author), Univ Cambridge, Fac Social & Polit Sci, Free Sch Lane, Cambridge CB2 3RQ, England.							Ejiri K, 1998, PHONETICA, V55, P226, DOI 10.1159/000028434; Greenberg JosephH., 1978, UNIVERSALS HUMAN LAN, V2; LINDBLOM B, 1983, PRODUCTION SPEECH, P189; Locke J., 1983, PHONOLOGICAL ACQUISI, DOI DOI 10.2307/414500; Locke J. L., 1998, APPROACHES EVOLUTION, P190; Locke J.L., 1993, CHILDS PATH SPOKEN L; Locke JL, 1995, BRAIN LANG, V51, P498, DOI 10.1006/brln.1995.1073; Locke JL, 1999, EVOL HUM BEHAV, V20, P151, DOI 10.1016/S1090-5138(99)00003-3; MacNeilage PF, 2000, SCIENCE, V288, P527, DOI 10.1126/science.288.5465.527; Meier RP, 1997, PHONETICA, V54, P153, DOI 10.1159/000262219; OHALA, 1983, PRODUCTION SPEECH, P217; Oller D.K, 2000, EMERGENCE SPEECH CAP, DOI [10.4324/9781410602565, DOI 10.4324/9781410602565]; Oller DK, 1998, AM J MENT RETARD, V103, P249, DOI 10.1352/0895-8017(1998)103<0249:LOCBAP>2.0.CO;2; STOELGAMMON C, 1983, J CHILD LANG, V10, P455, DOI 10.1017/S0305000900007893; Studdert-Kennedy M., 1991, LANG ACQUIS, P5; Vihman M. M., 1996, PHONOLOGICAL DEV ORI	16	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					449	+		10.1126/science.288.5465.449	http://dx.doi.org/10.1126/science.288.5465.449			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10798981				2022-12-28	WOS:000086626000025
J	Macilwain, C				Macilwain, C			Critics blast US missile defence system as flawed	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					799	799		10.1038/35009217	http://dx.doi.org/10.1038/35009217			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786763	Bronze			2022-12-28	WOS:000086625000007
J	[Anonymous]				[Anonymous]			Affirmative action ignored	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	2000	404	6780					795	795						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786758				2022-12-28	WOS:000086625000001
J	Erickson, LC; Torchiana, DF; Schneider, EC; Newburger, JW; Hannan, EL				Erickson, LC; Torchiana, DF; Schneider, EC; Newburger, JW; Hannan, EL			The relationship between managed care insurance and use of lower-mortality hospitals for CABG surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOCIAL-CLASS; DISTANCE; RACE; TIME	Context Explicit information about the quality of coronary artery bypass graft (CABG) surgery has been available for nearly a decade in New York State; however, the extent to which managed care insurance plans direct enrollees to the lowest-mortality CABG surgery hospitals remains unknown. Objective To compare the proportion of patients with managed care insurance and fee-for-service (FFS) insurance who undergo CABG surgery at lower-mortality hospitals. Design A retrospective cohort study of CABG surgery discharges from 1993 to 1996, using New York Department of Health databases and multivariate analysis to estimate the use of lower-mortality hospitals by patients with different types of health Insurance. Setting Cardiac surgical centers in New York, of which 14 were classified as lower-mortality hospitals (mean rate, 2.1%) and 17 were classified as higher-mortality hospitals (mean rate, 3.2%). Patients A total of 58 902 adults older than 17 years who were hospitalized for CABG surgery. Patients were excluded if their CABG surgery was combined with any valve procedure or left ventricular aneurysm resection or if they were younger than 65 years and enrolled in Medicare FFS or Medicare managed care. Main Outcome Measure Probability of a patient receiving CABG surgery at a lower-mortality hospital. Results Compared with patients with private FFS insurance (n = 18 905), patients with private managed care insurance (n = 7169) and Medicare managed care insurance (n = 880) were less likely to receive CABG surgery at a lower-mortality hospital (relative risk [RR] of surgery at a lower-mortality hospital compared with patients with private FFS insurance, 0.77; 95% confidence interval [CI], 0.74-0.81; P<.001; and RR, 0.61;95% CI, 0.54-0.70; P<.001,respectively, after controlling for multiple potential confounding factors). Patients with Medicare FFS insurance used lower-mortality hospitals at rates more similar to those with private FFS insurance (n = 31 948; RR, 0.95; 95% CI, 0.91-0.98; P = .004), Conclusions Patients in New York State with private managed care and Medicare managed care insurance were significantly less likely to use lower-mortality hospitals for CABG surgery compared with patients with private FFS insurance.	Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat,Div Cardiovasc Surg, Boston, MA USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Cardiovasc Surg, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; SUNY Albany, Dept Hlth Policy Management & Behav, Albany, NY 12222 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Erickson, LC (corresponding author), Childrens Hosp, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA.			Schneider, Eric/0000-0002-1132-5084				Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; *BUR CENS, 1995, ZIP COD CTR LONG LAT; Escarce J, 1999, MED CARE RES REV, V56, P340, DOI 10.1177/107755879905600304; Finlayson SRG, 1999, MED CARE, V37, P204, DOI 10.1097/00005650-199902000-00010; Goodman DC, 1997, AM J PUBLIC HEALTH, V87, P1144, DOI 10.2105/AJPH.87.7.1144; Hannan EL, 1997, HEALTH SERV RES, V31, P659; Hannan EL, 1999, MED CARE RES REV, V56, P363, DOI 10.1177/107755879905600305; Iezzoni LI, 1997, ANN INTERN MED, V127, P666, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00048; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P119; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; LAVEIST TA, 1994, HEALTH SERV RES, V29, P1; LILLIEBLANTON M, 1996, ANNU REV PUBL HEALTH, V17, P441; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; MCGUIRK MA, 1984, INQUIRY-J HEALTH CAR, V21, P84; *NAT CTR HLTH STAT, 1994, HLTH US 1993; *NAT CTR HLTH STAT, 1993, TRENDS IND HLTH 1993; NICKENS HW, 1995, HEALTH SERV RES, V30, P151; *NY STAT DEP HLTH, 1998, COR ART BYP SURG NEW; *NY STAT DEP HLTH, 1997, SPARCS 1996 INP DAT; *NY STAT DEP HLTH, 1993, COR ART BYP SURG NEW; *NY STAT DEP HLTH, 1997, COR ART BYP SURG NEW; *NY STAT DEP HLTH, 1994, SPARCS 1993 INP DAT; *NY STAT DEP HLTH, 1996, COR ART BYP SURG NEW; *NY STAT DEP HLTH, 1995, COR ART BYP SURG NEW; *NY STAT DEP HLTH, 1996, SPARCS 1995 INP DAT; *NY STAT DEP HLTH, 1995, SPARCS 1994 INP DAT; Phibbs CS, 1995, MED CARE RES REV, V52, P532, DOI 10.1177/107755879505200406; POOLE C, 1994, AM J PUBLIC HEALTH, V84, P715, DOI 10.2105/AJPH.84.5.715; SCHULMAN KA, 1995, HEALTH SERV RES, V30, P179; SUSSER M, 1994, AM J PUBLIC HEALTH, V84, P825, DOI 10.2105/AJPH.84.5.825; *US BUR CENS, 1992, 1990 CENS POP HOUS; WILLIAMS AP, 1983, NEW ENGL J MED, V309, P958, DOI 10.1056/NEJM198310203091606; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	34	47	46	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2000	283	15					1976	1982		10.1001/jama.283.15.1976	http://dx.doi.org/10.1001/jama.283.15.1976			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	303RC	10789665	Bronze			2022-12-28	WOS:000086436600032
J	Perrimon, N; Bernfield, M				Perrimon, N; Bernfield, M			Specificities of heparan sulphate proteoglycans in developmental processes	NATURE			English	Article							BEHMEL OVERGROWTH SYNDROME; SULFATE PROTEOGLYCANS; FINE-STRUCTURE; CELL-DIVISION; DROSOPHILA; GENE; SYNDECAN-1; BIOSYNTHESIS; EXPRESSION; GLYPICAN	Heparan sulphate proteoglycans are abundant cell-surface molecules that consist of a protein core to which heparan sulphate glycosaminoglycan chains are attached. The functions of these molecules have remained mostly underappreciated by developmental biologists; however, the actions of important signalling molecules, for example Wnt and Hedgehog, depend on them. To understand both the mechanisms by which ligands involved in development interact with their receptors and how morphogens pattern tissues, biologists need to consider the functions of heparan sulphate proteoglycans in signalling and developmental patterning.	Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X				ALEXANDER CM, IN PRESS NATURE GENE; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Habuchi H, 1998, TRENDS GLYCOSCI GLYC, V10, P65, DOI 10.4052/tigg.10.65; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KATO M, 1994, J BIOL CHEM, V269, P18881; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1989, HEPARIN; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Veugelers M, 1998, TRENDS GLYCOSCI GLYC, V10, P145, DOI 10.4052/tigg.10.145	39	615	637	1	69	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	2000	404	6779					725	728		10.1038/35008000	http://dx.doi.org/10.1038/35008000			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783877				2022-12-28	WOS:000086523600040
J	Abbott, A				Abbott, A			German researchers seek legal backing for stem cell work	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 30	2000	404	6777					424	424		10.1038/35006702	http://dx.doi.org/10.1038/35006702			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	300MX	10787340	Bronze			2022-12-28	WOS:000086257700004
J	Spillman, BC; Lubitz, J				Spillman, BC; Lubitz, J			The effect of longevity on spending for acute and long-term care.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NURSING-HOME CARE; EXPENDITURES; PERSPECTIVE; TRENDS; AGE	Background: The proportion of the population made up of elderly persons in the United States is projected to increase from 13 percent of the population in 2000 to 20 percent by 2030. The implications for health care expenditures may be profound, because elderly persons use health care services at a greater rate than younger persons. We estimated total expenditures for acute and long-term care from the age of 65 years until death and in the last two years of life. Methods: We combined data from Medicare, the National Mortality Followback Survey, and the National Medical Expenditure Survey to estimate total national expenditures for health care according to the age at death. We also simulated expenditures with the use of projected demographic characteristics of two cohorts: people turning 65 in 2000 and those turning 65 in 2015. Results: Total expenditures (in 1996 dollars) from the age of 65 years until death increase substantially with longevity, from $31,181 for persons who die at the age of 65 years to more than $200,000 for those who die at the age of 90, in part because of steep increases in nursing home expenditures for very old persons. Spending in the last two years of life also increases with longevity, but a reduction in Medicare expenditures ($37,000 for persons who die at the age of 75 years and $21,000 for those who die at the age of 95) moderates the effect of the increase in nursing home expenditures ($6,000 for those who die at the age of 75 years and $32,000 for those who die at the age of 95). Health care spending for women is consistently higher than that for men, after adjustment for the increased longevity of women. Simulations show that increased longevity after the age of 65 years has a relatively small effect on the anticipated increase in spending, especially for services covered by Medicare, from 2000 to 2015. The effects of the larger number of people born in 1950 than in 1935 and the larger number of people surviving to the age of 65 years are much more important. Conclusions: In the United States, the effect of longevity on expenditures for acute care differs from its effect on expenditures for long-term care. Acute care expenditures, principally for hospital care and physicians' services, increase at a reduced rate as the age at death increases, whereas expenditures for long-term care increase at an accelerated rate. Increases in longevity after the age of 65 years may result in greater spending for long-term care, but the increase in the number of elderly persons has a more important effect on total spending. (N Engl J Med 2000;342:1409-15.) (C)2000, Massachusetts Medical Society.	Urban Inst, Ctr Hlth Policy, Washington, DC 20037 USA; Natl Ctr Hlth Stat, Off Anal Epidemiol & Hlth Promot, Hyattsville, MD USA; US Hlth Care Financing Adm, Off Strateg Planning, Baltimore, MD 21207 USA	Urban Institute; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Spillman, BC (corresponding author), Urban Inst, Ctr Hlth Policy, 2100 M St NW, Washington, DC 20037 USA.							Braden BR, 1998, HEALTH CARE FINANC R, V20, P83; *C BUDG OFF, 1997, LONG TERM BUDG PRESS; CARLSON BL, 1995, J ECON SOC MEAS, V21, P187; *CTR COST FIN STUD, 1998, DATA NAT MED EXP SUR; Freedman VA, 1998, AM J PUBLIC HEALTH, V88, P1457, DOI 10.2105/AJPH.88.10.1457; GORNICK M, 1993, HEALTH AFFAIR, V12, P140, DOI 10.1377/hlthaff.12.2.140; Gruenberg L, 1996, HEALTH CARE FINANC R, V17, P59; Guralnik J M, 1997, J Am Med Womens Assoc (1972), V52, P113; HELDING C, 1992, HLTH CARE FINANCE S, P23; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KEMPER P, 1991, INQUIRY-J HEALTH CAR, V28, P333; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; *OFF ACT, 1999, US LIF TABL FUNCT AC; *OFF ACT, 1999, SOC SEC AR POP 1999; Riley G F, 1989, Health Care Financ Rev, V11, P1; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; SCITOVSKY AA, 1994, MILBANK Q, V72, P561, DOI 10.2307/3350356; SCITOVSKY AA, 1988, MILBANK Q, V66, P640, DOI 10.2307/3349934; *SOC SEC ADM, 2000, 2000 ANN REP BOARD T; TEMKINGREENER H, 1992, MILBANK Q, V70, P679, DOI 10.2307/3350216; VERBRUGGE LM, 1990, WOMEN HLTH MED AM HI, P41; WAIDMANN TA, 1998, INTER EVIDENCE TREND; Waldo D R, 1989, Health Care Financ Rev, V10, P111; WEISSERT WG, 1994, J AM GERIATR SOC, V42, P348, DOI 10.1111/j.1532-5415.1994.tb01763.x	25	254	258	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	2000	342	19					1409	1415		10.1056/NEJM200005113421906	http://dx.doi.org/10.1056/NEJM200005113421906			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	312JR	10805827				2022-12-28	WOS:000086940600006
J	Buron, C; Gornitzka, H; Romanenko, V; Bertrand, G				Buron, C; Gornitzka, H; Romanenko, V; Bertrand, G			Stable versions of transient push-pull carbenes: Extending lifetimes from nanoseconds to weeks	SCIENCE			English	Article							LASER FLASH-PHOTOLYSIS; REACTIVITY; BENZENE	A (phosphanyl) (trifluoromethyl)carbene is shown to be stable for weeks in solution at temperatures up to -30 degrees C. Its chemical behavior exactly matches that of its transient congeners, even to the extent that subtle effects, such as the recently discovered weak a interaction with aromatics, are observed. The influence of substituents on the structure of push-pull carbenes is demonstrated by a single-crystal x-ray diffraction study of a (phosphanyl)[2,6-bis(trifluoromethyl)phenyl]carbene. The lifetime of these molecules makes them accessible to a wider range of standard techniques, allowing their chemical and physical behaviors to be studied in more detail than was previously possible.	Univ Toulouse 3, Lab Heterochim Fondamentale & Appl, F-31062 Toulouse 04, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Bertrand, G (corresponding author), Univ Toulouse 3, Lab Heterochim Fondamentale & Appl, 118 Route Narbonne, F-31062 Toulouse 04, France.	gbertran@ramses.ups-tise.fr		Romanenko, Vadim/0000-0001-6642-5413				Admasu A, 1998, J CHEM SOC PERK T 2, P1093, DOI 10.1039/a707586c; [Anonymous], 1994, ADV CARBENE CHEM; Arduengo AJ, 1999, ACCOUNTS CHEM RES, V32, P913, DOI 10.1021/ar980126p; BESTMANN HJ, 1982, METHODEN ORGANISCHEM, V1, P616; Bourissou D, 2000, CHEM REV, V100, P39, DOI 10.1021/cr940472u; Brahms DLS, 1996, CHEM REV, V96, P1585, DOI 10.1021/cr941141k; Brinker U. H., 1998, ADV CARBENE CHEM, V2; Buchner E., 1885, BER DTSCH CHEM GES, V8, P2377; DOERING WV, 1954, J AM CHEM SOC, V76, P6162; FISCHER EO, 1964, ANGEW CHEM INT EDIT, V3, P580, DOI 10.1002/anie.196405801; GOUMRIMAGNET S, IN PRESS J AM CHEM S; Herrmann WA, 1997, ANGEW CHEM INT EDIT, V36, P2162, DOI 10.1002/anie.199721621; Hirai K, 1999, J AM CHEM SOC, V121, P10213, DOI 10.1021/ja991387c; JOHNSON AW, YLIDES IMINES PHOSPH; Jones M., 1975, CARBENES, VII; KHAN MI, 1995, J AM CHEM SOC, V117, P6635, DOI 10.1021/ja00129a045; Kirmse W., 1971, CARBENE CHEM, V2nd; Krogh-Jespersen K, 1999, J AM CHEM SOC, V121, P6269, DOI 10.1021/ja990148m; MOSS RA, 1991, J CHEM SOC CHEM COMM, P946, DOI 10.1039/c39910000946; Moss RA, 1998, J AM CHEM SOC, V120, P1088, DOI 10.1021/ja973649l; OGARA JE, 1992, J AM CHEM SOC, V114, P3581, DOI 10.1021/ja00036a001; OGARA JE, 1992, THESIS U PENNSYLVANI; PAULING L, 1980, J CHEM SOC CHEM COMM, P688, DOI 10.1039/c39800000688; REGITZ M, 1989, CARBENE CARBENOIDE B, V19; Ruck RT, 1998, TETRAHEDRON LETT, V39, P2277, DOI 10.1016/S0040-4039(98)00291-3; Schoeller WW, 2000, EUR J INORG CHEM, P369; SHARP KG, 1976, INORG CHEM, V15, P1697, DOI 10.1021/ic50161a045; Staudinger H, 1912, BER DTSCH CHEM GES, V45, P501, DOI 10.1002/cber.19120450174; Tomioka H, 1997, ACCOUNTS CHEM RES, V30, P315, DOI 10.1021/ar9602157	29	123	123	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	2000	288	5467					834	836		10.1126/science.288.5467.834	http://dx.doi.org/10.1126/science.288.5467.834			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10796999				2022-12-28	WOS:000086869600029
J	Levine, JM				Levine, JM			Species diversity and biological invasions: Relating local process to community pattern	SCIENCE			English	Article							BIODIVERSITY; ECOSYSTEM; INVASIBILITY; RESISTANCE; GRASSLANDS; STABILITY	In a California riparian system, the most diverse natural assemblages are the most invaded by exotic plants. A direct in situ manipulation of local diversity and a seed addition experiment showed that these patterns emerge despite the intrinsic negative effects of diversity on invasions. The results suggest that species loss at small scales may reduce invasion resistance. At community-wide scales, the overwhelming effects of ecological factors spatially covarying with diversity, such as propagule supply, make the most diverse communities most likely to be invaded.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, JM (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.		Levine, Jonathan/A-7167-2014	Levine, Jonathan/0000-0003-2857-7904				CASE TJ, 1990, P NATL ACAD SCI USA, V87, P9610, DOI 10.1073/pnas.87.24.9610; Chapin FS, 1998, BIOSCIENCE, V48, P45, DOI 10.2307/1313227; DRAKE JA, 1990, J THEOR BIOL, V147, P213, DOI 10.1016/S0022-5193(05)80053-0; DUKES JS, 1999, THESIS STANFORD U; Elton C. S., 1958, ECOLOGY INVASIONS; Enserink M, 1999, SCIENCE, V285, P1834, DOI 10.1126/science.285.5435.1834; GOLDBERG DE, 1990, ECOLOGY, V71, P213, DOI 10.2307/1940261; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; Knops JMH, 1999, ECOL LETT, V2, P286, DOI 10.1046/j.1461-0248.1999.00083.x; Levine JM, 1999, OIKOS, V87, P15, DOI 10.2307/3546992; Levine JM, 1999, ECOLOGY, V80, P1762, DOI 10.2307/176566; LEVINE JM, IN PRESS ECOLOGY; Lonsdale WM, 1999, ECOLOGY, V80, P1522, DOI 10.2307/176544; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; NAEEM S, 1994, NATURE, V368, P734, DOI 10.1038/368734a0; NAEEM S, IN PRESS OIKOS; NILSSON C, 1991, CAN J BOT, V69, P2631, DOI 10.1139/b91-328; PlantyTabacchi AM, 1996, CONSERV BIOL, V10, P598, DOI 10.1046/j.1523-1739.1996.10020598.x; ROBINSON GR, 1995, ECOLOGY, V76, P786, DOI 10.2307/1939344; ROBINSON JV, 1979, J THEOR BIOL, V81, P91, DOI 10.1016/0022-5193(79)90083-3; Stachowicz JJ, 1999, SCIENCE, V286, P1577, DOI 10.1126/science.286.5444.1577; Stohlgren TJ, 1999, ECOL MONOGR, V69, P25, DOI 10.1890/0012-9615(1999)069[0025:EPSIHS]2.0.CO;2; Symstad AJ, 2000, ECOLOGY, V81, P99, DOI 10.1890/0012-9658(2000)081[0099:ATOTEO]2.0.CO;2; Tilman D, 1999, SCIENCE, V286, P1099, DOI 10.1126/science.286.5442.1099; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0; WASER NM, 1982, EVOLUTION, V36, P753, DOI 10.1111/j.1558-5646.1982.tb05441.x; Williamson M., 1996, BIOL INVASIONS; Wiser SK, 1998, ECOLOGY, V79, P2071, DOI 10.1890/0012-9658(1998)079[2071:CSAFIB]2.0.CO;2	30	757	823	11	395	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					852	854		10.1126/science.288.5467.852	http://dx.doi.org/10.1126/science.288.5467.852			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797006				2022-12-28	WOS:000086869600036
J	Nakamagoe, K; Iwamoto, Y; Yoshida, K				Nakamagoe, K; Iwamoto, Y; Yoshida, K			Evidence for brainstem structures participating in oculomotor integration	SCIENCE			English	Article							MOVEMENT-RELATED NEURONS; EYE-MOVEMENT; CEREBELLAR FLOCCULUS; INTERSTITIAL NUCLEUS; VESTIBULAR NEURONS; PARAMEDIAN TRACTS; CELL GROUPS; CAT; PREPOSITUS; SYSTEM	The cerebellar flocculus has been implicated in vestibulo-oculomotor control. One major central input to this structure originates from brainstem cells in the paramedian tract (PMT), whose function is unknown. Here it is reported that PMT cells in the pens carry vestibular and eye movement signals and their pharmacological inactivation produces a leaky integrator combined with vestibular imbalance. The results suggest that PMT cells provide the cerebellum with sensory and motor signals that are essential for velocity-to-position integration, a common premotor process that is required in all motor systems.	Univ Tsukuba, Inst Basic Med Sci, Dept Physiol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Neurol, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba	Yoshida, K (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Physiol, Tsukuba, Ibaraki 3058575, Japan.			Nakamagoe, Kiyotaka/0000-0003-4025-5780				ButtnerEnnever JA, 1996, ANN NY ACAD SCI, V781, P532, DOI 10.1111/j.1749-6632.1996.tb15726.x; BUTTNERENNEVER JA, 1989, REV NEUROL-FRANCE, V145, P533; CANNON SC, 1987, J NEUROPHYSIOL, V57, P1383, DOI 10.1152/jn.1987.57.5.1383; CHERON G, 1995, J NEUROPHYSIOL, V74, P1367, DOI 10.1152/jn.1995.74.3.1367; Chimoto S, 1999, J NEUROPHYSIOL, V81, P1199, DOI 10.1152/jn.1999.81.3.1199; CRAWFORD JD, 1991, SCIENCE, V252, P1551, DOI 10.1126/science.2047862; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; GODAUX E, 1993, J PHYSIOL-LONDON, V472, P459, DOI 10.1113/jphysiol.1993.sp019956; GRAF W, 1986, EXP BRAIN RES, V63, P35; KAMATH BY, 1976, MATH BIOSCI, V30, P341, DOI 10.1016/0025-5564(76)90073-0; MCCREA RA, 1987, J COMP NEUROL, V264, P571, DOI 10.1002/cne.902640409; METTENS P, 1994, J NEUROPHYSIOL, V72, P785, DOI 10.1152/jn.1994.72.2.785; NAKAO S, 1980, BRAIN RES, V183, P291, DOI 10.1016/0006-8993(80)90465-5; Robinson D.A., 1975, BASIC MECH OCULAR MO, P337; ROBINSON DA, 1974, BRAIN RES, V71, P195, DOI 10.1016/0006-8993(74)90961-5; SATO Y, 1990, J NEUROPHYSIOL, V64, P551, DOI 10.1152/jn.1990.64.2.551; ZEE DS, 1980, ANN NEUROL, V7, P37, DOI 10.1002/ana.410070108; ZEE DS, 1981, J NEUROPHYSIOL, V46, P878, DOI 10.1152/jn.1981.46.4.878	18	70	72	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					857	859		10.1126/science.288.5467.857	http://dx.doi.org/10.1126/science.288.5467.857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797008				2022-12-28	WOS:000086869600038
J	Moreira, D; Le Guyader, H; Philippe, H				Moreira, D; Le Guyader, H; Philippe, H			The origin of red algae and the evolution of chloroplasts	NATURE			English	Article							TREE TOPOLOGIES; SEQUENCE; DNA; ALIGNMENT; PHYLOGENY; KINGDOMS; POSITION; INTRONS; PROTEIN; GENE	Chloroplast structure and genome analyses support the hypothesis that three groups of organisms originated from the primary photosynthetic endosymbiosis between a cyanobacterium and a eukaryotic host: green plants (green algae + land plants), red algae and glaucophytes (for example, Cyanophora)(1). Although phylogenies based on several mitochondrial genes support a specific green plants/red algae relationship(2,3), the phylogenetic analysis of nucleus-encoded genes yields inconclusive, sometimes contradictory results(3,4). To address this problem, we have analysed an alternative nuclear marker, elongation factor 2, and included new red algae and protist sequences. Here we provide significant support for a sisterhood of green plants and red algae. This sisterhood is also significantly supported by a multi-gene analysis of a fusion of 13 nuclear markers (5,171 amino acids). In addition, the analysis of an alternative fusion of 6 nuclear markers (1,938 amino acids) indicates that glaucophytes may be the closest relatives to the green plants/red algae group. Thus, our study provides evidence from nuclear markers for a single primary endosymbiosis at the origin of these groups, and supports a kingdom Plantae comprising green plants, red algae and glaucophytes(5).	Univ Paris 11, Equipe Phylogenie & Evolut Mol, CNRS UPRESA 8080, F-91405 Orsay, France; Univ Miguel Hernandez, Dept Microbiol, Alicante 03550, Spain	UDICE-French Research Universities; Universite Paris Saclay; Universidad Miguel Hernandez de Elche	Moreira, D (corresponding author), Univ Paris 11, Equipe Phylogenie & Evolut Mol, CNRS UPRESA 8080, Batiment 444, F-91405 Orsay, France.		Moreira, David/F-7445-2012	Moreira, David/0000-0002-2064-5354				Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bhattacharya D, 1997, CURR GENET, V31, P439, DOI 10.1007/s002940050227; BHATTACHARYA D, 1997, ORIGINS ALGAE THEIR, P139; Burger G, 1999, PLANT CELL, V11, P1675, DOI 10.1105/tpc.11.9.1675; CAVALIERSMITH T, 1981, BIOSYSTEMS, V14, P461, DOI 10.1016/0303-2647(81)90050-2; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; Fabrizio P, 1997, EMBO J, V16, P4092, DOI 10.1093/emboj/16.13.4092; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; Kumar S, 1996, J MOL EVOL, V42, P183, DOI 10.1007/BF02198844; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; Moreira D, 1998, NUCLEIC ACIDS RES, V26, P3309, DOI 10.1093/nar/26.13.3309; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; Philippe H, 1998, CURR OPIN GENET DEV, V8, P616, DOI 10.1016/S0959-437X(98)80028-2; RAGAN MA, 1995, BOT J LINN SOC, V118, P81, DOI 10.1016/S0024-4074(95)80010-7; Stiller JW, 1997, P NATL ACAD SCI USA, V94, P4520, DOI 10.1073/pnas.94.9.4520; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Swofford David L., 1996, P407; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yamamoto A, 1997, J MOL EVOL, V44, P98, DOI 10.1007/PL00006127	26	313	333	2	101	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					69	72		10.1038/35011054	http://dx.doi.org/10.1038/35011054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811219				2022-12-28	WOS:000086901600052
J	Thier, P; Dicke, PW; Haas, R; Barash, S				Thier, P; Dicke, PW; Haas, R; Barash, S			Encoding of movement time by populations of cerebellar Purkinje cells	NATURE			English	Article							SACCADIC EYE-MOVEMENTS; FASTIGIAL NUCLEUS; OCULOMOTOR VERMIS; NEURONS; MACAQUE; PATTERNS; LESIONS; PRIMATE; MONKEY; REGION	One of the earliest computational principles attributed to the cerebellum was the measurement of time(1). This idea was originally suggested on anatomical grounds, and was taken up again to explain some of the deficits in cerebellar patients(2,3). The contribution of the cerebellum to eye movements, in contrast, has traditionally been discussed in the context of motor learning(4-7). This view has received support from the loss of saccade adaptation, one of the key examples of motor learning, following lesions of the posterior cerebellar vermis(8-11). However, the relationship between the properties of saccade-related vermal Purkinje cells and the behavioural deficits that follow lesions is unclear. Here we report results from single-unit recording experiments on monkeys that reconcile the seemingly unrelated concepts of timing and motor learning. We report that, unlike individual Purkinje cells, the population response of larger groups of Purkinje cells gives a precise temporal signature of saccade onset and offset. Thus a vermal population response may help to determine saccade duration. Modifying the time course of the population response by changing the weights of the contributing individual Purkinje cells, discharging at different times relative to the saccade, would directly translate into changes in saccade amplitude.	Univ Tubingen, Dept Cognit Neurol, D-72076 Tubingen, Germany; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Eberhard Karls University of Tubingen; Weizmann Institute of Science	Thier, P (corresponding author), Univ Tubingen, Dept Cognit Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	thier@uni-tuebingen.de		Thier, Peter/0000-0001-5909-4222				Aizenman CD, 1999, J NEUROPHYSIOL, V82, P1697, DOI 10.1152/jn.1999.82.4.1697; BAHILL AT, 1975, MATH BIOSCI, V24, P287; Barash S, 1999, J NEUROSCI, V19, P10931, DOI 10.1523/JNEUROSCI.19-24-10931.1999; BRAITENBERG V, 1961, NATURE, V190, P539, DOI 10.1038/190539b0; Desmurget M, 1998, NAT NEUROSCI, V1, P524, DOI 10.1038/2241; Fitzgibbon E. J., 1986, ADAPTIVE PROCESSES V, P329; FUCHS AF, 1993, J NEUROPHYSIOL, V70, P1723, DOI 10.1152/jn.1993.70.5.1723; Haas R., 1999, Society for Neuroscience Abstracts, V25, P1652; HANES DP, 1995, EXP BRAIN RES, V103, P85; HELMCHEN C, 1995, EXP BRAIN RES, V103, P198; ITO M, 1982, ANNU REV NEUROSCI, V5, P275, DOI 10.1146/annurev.ne.05.030182.001423; IVRY RB, 1991, J COGNITIVE NEUROSCI, V3, P355, DOI 10.1162/jocn.1991.3.4.355; IVRY RB, 1993, J COGNITIVE NEUROSCI, V1, P136; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; KASE M, 1980, J PHYSIOL-LONDON, V300, P539, DOI 10.1113/jphysiol.1980.sp013178; KAWATO M, 1992, TRENDS NEUROSCI, V15, P445, DOI 10.1016/0166-2236(92)90008-V; LLINAS R, 1988, J PHYSIOL-LONDON, V404, P241, DOI 10.1113/jphysiol.1988.sp017288; LLINAS R, 1977, EXP BRAIN RES, V29, P1; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; NODA H, 1990, J COMP NEUROL, V302, P330, DOI 10.1002/cne.903020211; OHTSUKA K, 1991, J NEUROPHYSIOL, V65, P1422, DOI 10.1152/jn.1991.65.6.1422; OPTICAN LM, 1980, J NEUROPHYSIOL, V44, P1058, DOI 10.1152/jn.1980.44.6.1058; PRESS HW, 1992, NUMERICAL RECIPES C, P650; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; SATO H, 1992, NEUROSCI RES, V12, P583, DOI 10.1016/0168-0102(92)90065-K; Scudder Charles A., 1998, Society for Neuroscience Abstracts, V24, P147; Takagi M, 1998, J NEUROPHYSIOL, V80, P1911, DOI 10.1152/jn.1998.80.4.1911; THIELERT CD, 1996, THESIS E KARLS U TUB; THIER P, 1992, EUR J NEUROSCI, V4, P539, DOI 10.1111/j.1460-9568.1992.tb00904.x	29	115	117	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	2000	405	6782					72	76		10.1038/35011062	http://dx.doi.org/10.1038/35011062			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811220				2022-12-28	WOS:000086901600053
J	Zoback, MD				Zoback, MD			Earth science - Strength of the San Andreas	NATURE			English	Editorial Material							FAULT; STRESS; STATE		Stanford Univ, Dept Geophys, Palo Alto, CA 94303 USA	Stanford University	Zoback, MD (corresponding author), Stanford Univ, Dept Geophys, Palo Alto, CA 94303 USA.			Zoback, Mark/0000-0002-8851-2099				BRACE WF, 1966, SCIENCE, V153, P990, DOI 10.1126/science.153.3739.990; BRUNE JN, 1969, J GEOPHYS RES, V74, P3821, DOI 10.1029/JB074i015p03821; BYERLEE J, 1978, PURE APPL GEOPHYS, V116, P615, DOI 10.1007/BF00876528; HARDEBECK J, 1999, SCIENCE, V278, P650; LACHENBRUCH AH, 1992, J GEOPHYS RES-SOL EA, V97, P4995, DOI 10.1029/91JB01506; Molnar P., 1992, INT GEOPHYS ACAD PRE, V51, P435; MOUNT VS, 1987, GEOLOGY, V15, P1143, DOI 10.1130/0091-7613(1987)15<1143:SOSNTS>2.0.CO;2; OPPENHEIMER DH, 1988, J GEOPHYS RES-SOLID, V93, P9007, DOI 10.1029/JB093iB08p09007; Scholz CH, 2000, GEOLOGY, V28, P163, DOI 10.1130/0091-7613(2000)28<163:EFASSA>2.0.CO;2; Townend J, 2000, GEOLOGY, V28, P399, DOI 10.1130/0091-7613(2000)28<399:HFKTCS>2.0.CO;2; *WORK GROUP CAL EA, 1999, 99517 US GEOL SURV W; ZOBACK MD, 1993, GEOLOGY, V21, P181, DOI 10.1130/0091-7613(1993)021<0181:EFNFFI>2.3.CO;2; ZOBACK MD, 1987, SCIENCE, V238, P1105, DOI 10.1126/science.238.4830.1105; Zoback ML, 1999, J GEOPHYS RES-SOL EA, V104, P10719, DOI 10.1029/1998JB900059	14	77	77	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					31	32		10.1038/35011181	http://dx.doi.org/10.1038/35011181			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811204				2022-12-28	WOS:000086901600034
J	Ayus, JC; Varon, J; Arieff, AI				Ayus, JC; Varon, J; Arieff, AI			Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	32nd Annual Meeting of the American-Society-of-Nephrology	NOV 01-08, 1999	MIAMI, FL	Amer Soc Nephrol			SYMPTOMATIC HYPONATREMIA; WATER-INTOXICATION; EXERCISE; ENCEPHALOPATHY; WOMEN	Background: Noncardiogenic pulmonary edema is often associated with increased intracranial pressure and can be the initial manifestation of hyponatremic encephalopathy. Marathon runners tend to develop conditions that lead to hyponatremia. Objective: To describe the development and treatment of noncardiogenic pulmonary edema in marathon runners that was associated with hyponatremic encephalopathy. Case series. One university hospital and two community Design: Case series. Setting: One university hospital and two community hospitals. Patients: Seven healthy marathon runners who had a history of nonsteroidal anti-inflammatory drug use. The runners collapsed after competing in a marathon and were hospitalized with pulmonary edema. Measurements: Plasma sodium levels, chest radiograph, electrocardiogram, cardiac enzyme levels, and magnetic resonance imaging or computed tomographic scans of the brain. Results: Patients had nausea, emesis, and obtundation. The mean (+/-SD) plasma sodium level was 121 +/- 3 mmol/L, and oxygen saturation was less than 70%. Electrocardiograms and echocardiograms were normal. Chest radiographs showed pulmonary edema with a normal heart. Creatine phosphokinase-MB bands, troponin levels, and pulmonary wedge pressure were not elevated. Scanning of the brain showed cerebral edema. All patients were intubated and mechanically ventilated. Treatment with intravenous NaCl, 514 mmol/L, increased plasma sodium levers by 10 mmol/L in 22 hours. Pulmonary and cerebral edema resolved as the sodium level increased. One patient had unsuspected hyponatremic encephalopathy and died of cardiopulmonary arrest ca used by brainstem herniation. All six treated patients recovered and were well after 1 year of follow-up. Conclusions: In healthy marathon runners, noncardiogenic pulmonary edema can be associated with hyponatremic encephalopathy. The condition may be fatal if undiagnosed and can be successfully treated with hypertonic NaCl.	Baylor Coll Med, Houston, TX 77024 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA USA	Baylor College of Medicine; University of California System; University of California San Francisco	Ayus, JC (corresponding author), Baylor Coll Med, 4 Brompton Court, Houston, TX 77024 USA.		Varon, Joseph/T-9481-2019; Varon, Joseph/R-5198-2019	Varon, Joseph/0000-0002-7622-9974				ARMSTRONG LE, 1993, MED SCI SPORT EXER, V25, P543; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1995, CHEST, V107, P517, DOI 10.1378/chest.107.2.517; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; Ayus JC, 1999, JAMA-J AM MED ASSOC, V281, P2299, DOI 10.1001/jama.281.24.2299; Ayus JC, 2000, TXB CRITICAL CARE, P853; Garigan TP, 1999, MIL MED, V164, P234, DOI 10.1093/milmed/164.3.234; GILBERT S, 1999, NY TIMES        1102, pF8; HOLTZHAUSEN LM, 1994, MED SCI SPORT EXER, V26, P1095; IRVING RA, 1991, J APPL PHYSIOL, V70, P342, DOI 10.1152/jappl.1991.70.1.342; MCKECHNIE JK, 1979, S AFR MED J, V56, P261; NOAKES TD, 1990, MED SCI SPORT EXER, V22, P165; NOAKES TD, 1985, MED SCI SPORT EXER, V17, P370; Speedy DB, 1999, MED SCI SPORT EXER, V31, P809, DOI 10.1097/00005768-199906000-00008; YOUNG M, 1987, AM REV RESPIR DIS, V136, P737, DOI 10.1164/ajrccm/136.3.737; Zelingher J, 1996, AM J MED SCI, V311, P86, DOI 10.1097/00000441-199602000-00007	16	229	233	1	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					711	714		10.7326/0003-4819-132-9-200005020-00005	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	308VT	10787364				2022-12-28	WOS:000086734100004
J	Lux, AL; Edwards, SW; Osborne, JP				Lux, AL; Edwards, SW; Osborne, JP			Responses of local research ethics committees to a study with approval from a multicentre research ethics committee	BRITISH MEDICAL JOURNAL			English	Article									Royal United Hosp, Childrens Ctr, Bath BA1 3NG, Avon, England		Lux, AL (corresponding author), Royal United Hosp, Childrens Ctr, Combe Pk, Bath BA1 3NG, Avon, England.							ALBERTI KGMM, 1995, BRIT MED J, V311, P639, DOI 10.1136/bmj.311.7006.639; Larcombe I, 1999, J ROY SOC MED, V92, P500, DOI 10.1177/014107689909201002; *NHS EX, 1998, INT GUID SHOULD LREC	3	50	51	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1182	1183		10.1136/bmj.320.7243.1182	http://dx.doi.org/10.1136/bmj.320.7243.1182			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784542	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000086832800019
J	Rhee, I; Jair, KW; Yen, RWC; Lengauer, C; Herman, JG; Kinzler, KW; Vogelstein, B; Baylin, SB; Schuebel, KE				Rhee, I; Jair, KW; Yen, RWC; Lengauer, C; Herman, JG; Kinzler, KW; Vogelstein, B; Baylin, SB; Schuebel, KE			CpG methylation is maintained in human cancer cells lacking DNMT1	NATURE			English	Article							DNA-CYTOSINE METHYLTRANSFERASE; DE-NOVO METHYLATION; GENETIC INSTABILITY; NEOPLASIA	Hypermethylation is associated with the silencing of tumour susceptibility genes in several forms of cancer(1,2); however, the mechanisms responsible for this aberrant methylation are poorly understood(3,4). The prototypic DNA methyltransferase, DNMT1, has been widely assumed to be responsible for most of the methylation of the human genome, including the abnormal methylation found in cancers(5,6). To test this hypothesis, we disrupted the DNMT1 gene through homologous recombination in human colorectal carcinoma cells. Here we show that cells lacking DNMT1 exhibited markedly decreased cellular DNA methyltransferase activity, but there was only a 20% decrease in overall genomic methylation. Although juxtacentromeric satellites became significantly demethylated, most of the loci that we analysed, including the tumour suppressor gene p16(INK4a), remained fully methylated and silenced. These results indicate that DNMT1 has an unsuspected degree of regional specificity in human cells and that methylating activities other than DNMT1 can maintain the methylation of most of the genome.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Program Human Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Schuebel, KE (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, 1650 Orleans St, Baltimore, MD 21231 USA.							Bachman KE, 1999, CANCER RES, V59, P798; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Eads CA, 1999, CANCER RES, V59, P2302; FEINBERG AP, 1988, CANCER RES, V48, P1159; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751; JEANPIERRE M, 1994, ANN GENET-PARIS, V37, P163; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KUO KC, 1980, NUCLEIC ACIDS RES, V8, P4763, DOI 10.1093/nar/8.20.4763; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Myohanen SK, 1998, CANCER RES, V58, P591; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; Schmutte C, 1996, CANCER RES, V56, P2375; Toyota M, 1999, CANCER RES, V59, P2307; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052	30	349	366	1	21	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					1003	1007		10.1038/35010000	http://dx.doi.org/10.1038/35010000			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801130				2022-12-28	WOS:000086762000058
J	Tefferi, A				Tefferi, A			Medical progress: Myelofibrosis with myeloid metaplasia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MARROW TRANSPLANTATION; GROWTH-FACTOR-BETA; CHRONIC MYELOPROLIFERATIVE DISORDERS; IDIOPATHIC MYELOFIBROSIS; POLYCYTHEMIA-VERA; EXTRAMEDULLARY HEMATOPOIESIS; MYELODYSPLASTIC SYNDROMES; PROGNOSTIC FACTORS; NATURAL-HISTORY; PORTAL-HYPERTENSION		Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Tefferi, A (corresponding author), Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	tefferi.ayalew@mayo.edu						Altura RA, 1999, BLOOD, V94, p114A; Anderson JE, 1999, BLOOD, V94, p396A; Barosi G, 1998, BLOOD, V91, P3630; BARTLETT RP, 1995, MAYO CLIN PROC, V70, P1161, DOI 10.4065/70.12.1161; BESA EC, 1982, CANCER, V49, P308, DOI 10.1002/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO;2-4; BUHR T, 1993, PATHOL RES PRACT, V189, P121, DOI 10.1016/S0344-0338(11)80081-6; BUSCHLE M, 1988, LEUKEMIA, V2, P658; CASTROMALASPINA H, 1982, BLOOD, V59, P1046, DOI 10.1182/blood.V59.5.1046.1046; CASTROMALASPINA H, 1981, BLOOD, V57, P781; Cervantes F, 1998, EUR J HAEMATOL, V60, P101; Cervantes F, 1998, BRIT J HAEMATOL, V102, P684, DOI 10.1046/j.1365-2141.1998.00833.x; Cervantes F, 1997, BRIT J HAEMATOL, V97, P635, DOI 10.1046/j.1365-2141.1997.782714.x; CHAITER Y, 1992, LEUKEMIA LYMPHOMA, V7, P251, DOI 10.3109/10428199209053630; Cripe LD, 1998, SEMIN HEMATOL, V35, P200; Dalley A, 1996, BRIT J HAEMATOL, V93, P856, DOI 10.1046/j.1365-2141.1996.d01-1739.x; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DEMORY JL, 1988, BLOOD, V72, P855; DIBELLA NJ, 1977, ARCH INTERN MED, V137, P380, DOI 10.1001/archinte.137.3.380; Dupriez B, 1996, BLOOD, V88, P1013; Elliott MA, 1998, BRIT J HAEMATOL, V103, P505, DOI 10.1046/j.1365-2141.1998.00998.x; ELLIS JT, 1986, SEMIN HEMATOL, V23, P144; Gilbert HS, 1998, CANCER-AM CANCER SOC, V83, P1205, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8; Guardiola P, 1999, BLOOD, V93, P2831; Guardiola P, 1997, BRIT J HAEMATOL, V98, P1004, DOI 10.1046/j.1365-2141.1997.3073124.x; HASSELBALCH HC, 1993, INT J CLIN LAB RES, V23, P124, DOI 10.1007/BF02592297; JACOBSON RJ, 1978, BLOOD, V51, P189; JAROCH MT, 1986, SURGERY, V100, P743; KATOH O, 1990, AM J HEMATOL, V35, P145, DOI 10.1002/ajh.2830350302; KIMURA A, 1989, BRIT J HAEMATOL, V72, P486, DOI 10.1111/j.1365-2141.1989.tb04310.x; KOEFFLER HP, 1979, BRIT J HAEMATOL, V43, P69, DOI 10.1111/j.1365-2141.1979.tb03721.x; Kvasnicka HM, 1997, CANCER, V80, P708, DOI 10.1002/(SICI)1097-0142(19970815)80:4<708::AID-CNCR9>3.0.CO;2-I; Levy V, 1996, AM J HEMATOL, V53, P239; LONG MW, 1995, J CLIN INVEST, V96, P2541; LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738; MARTYRE MC, 1994, BRIT J HAEMATOL, V88, P9, DOI 10.1111/j.1365-2141.1994.tb04970.x; Martyre MC, 1997, BRIT J HAEMATOL, V97, P441, DOI 10.1046/j.1365-2141.1997.292671.x; MASCHEK H, 1992, EUR J HAEMATOL, V48, P208; MASON BA, 1979, CANCER, V43, P1568, DOI 10.1002/1097-0142(197904)43:4<1568::AID-CNCR2820430452>3.0.CO;2-B; MCCARTHY DM, 1985, BRIT J HAEMATOL, V59, P1, DOI 10.1111/j.1365-2141.1985.tb02956.x; McNally RJQ, 1997, HEMATOL ONCOL, V15, P173, DOI 10.1002/(SICI)1099-1069(199711)15:4<173::AID-HON610>3.0.CO;2-K; Mesa RA, 1999, BLOOD, V94, p115A; Mesa RA, 1999, AM J HEMATOL, V61, P10, DOI 10.1002/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.3.CO;2-9; MILLER JB, 1985, CANCER, V55, P582, DOI 10.1002/1097-0142(19850201)55:3<582::AID-CNCR2820550318>3.0.CO;2-O; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; MORAN CA, 1995, MODERN PATHOL, V8, P249; NAJEAN Y, 1984, BRIT J HAEMATOL, V56, P163, DOI 10.1111/j.1365-2141.1984.tb01283.x; Neuwirtova R, 1996, LEUKEMIA RES, V20, P717, DOI 10.1016/0145-2126(96)00028-8; OKEANE JC, 1989, CANCER, V63, P1539; Raghu G, 1999, AM J RESP CRIT CARE, V159, P1061, DOI 10.1164/ajrccm.159.4.9805017; RAJANTIE J, 1986, BLOOD, V67, P1693; RAMESHWAR P, 1994, J IMMUNOL, V153, P2819; Reilly JT, 1997, BRIT J HAEMATOL, V98, P96, DOI 10.1046/j.1365-2141.1997.1722990.x; Reilly JT, 1997, BLOOD REV, V11, P233, DOI 10.1016/S0268-960X(97)90022-9; Rodriguez JN, 1998, HAEMATOLOGICA, V83, P616; ROZMAN C, 1991, CANCER, V67, P2658, DOI 10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C; RUBINS JM, 1983, CANCER, V51, P308, DOI 10.1002/1097-0142(19830115)51:2<308::AID-CNCR2820510224>3.0.CO;2-K; RUPOLI S, 1994, ANN HEMATOL, V68, P205, DOI 10.1007/BF01834368; RUUTU T, 1983, SCAND J HAEMATOL, V31, P253; Sekhar M, 1996, BRIT J HAEMATOL, V93, P394, DOI 10.1046/j.1365-2141.1996.5051046.x; Silverstein M. N., 1975, AGNOGENIC MYELOID ME; SILVERSTEIN MN, 1973, ARCH INTERN MED, V131, P532, DOI 10.1001/archinte.131.4.532; SMITH JW, 1981, CANCER-AM CANCER SOC, V48, P2198, DOI 10.1002/1097-0142(19811115)48:10<2198::AID-CNCR2820481014>3.0.CO;2-M; Solberg LA, 1997, BRIT J HAEMATOL, V99, P174, DOI 10.1046/j.1365-2141.1997.3503164.x; SOLL E, 1995, BLOOD, V86, P4667, DOI 10.1182/blood.V86.12.4667.bloodjournal86124667; TEFFERI A, 1993, J NATL CANCER I, V85, P1520, DOI 10.1093/jnci/85.18.1520; TEFFERI A, 1994, AM J HEMATOL, V46, P325, DOI 10.1002/ajh.2830460412; Tefferi A, 1997, BRIT J HAEMATOL, V99, P352, DOI 10.1046/j.1365-2141.1997.3843198.x; TEFFERI A, 1999, HEMATOLOGY 1999, P172; TEFFERI A, IN PRESS BLOOD; TERUI T, 1990, BLOOD, V75, P1540; THIELE J, 1989, ACTA HAEMATOL-BASEL, V81, P192; THIELE J, 1992, VIRCHOWS ARCH A, V421, P33, DOI 10.1007/BF01607136; THIELE J, 1994, AM J HEMATOL, V46, P36, DOI 10.1002/ajh.2830460107; Thomas DA, 1999, BLOOD, V94, p702A; TRUONG LD, 1984, MEDICINE, V63, P182, DOI 10.1097/00005792-198405000-00004; TSUKAMOTO N, 1994, BRIT J HAEMATOL, V86, P253, DOI 10.1111/j.1365-2141.1994.tb04723.x; Vallespi T, 1998, HAEMATOLOGICA, V83, P258; VANDERMOLEN L, 1985, AM J MED, V79, P297, DOI 10.1016/0002-9343(85)90307-9; VARKI A, 1983, MEDICINE, V62, P353, DOI 10.1097/00005792-198311000-00002; VERHOEF GEG, 1991, ANN HEMATOL, V63, P235, DOI 10.1007/BF01698371; Villeval JL, 1997, BLOOD, V90, P4369; VISANI G, 1990, BRIT J HAEMATOL, V75, P4, DOI 10.1111/j.1365-2141.1990.tb02609.x; WANG JC, 1992, BRIT J HAEMATOL, V80, P184, DOI 10.1111/j.1365-2141.1992.tb08898.x; WANLESS IR, 1990, HEPATOLOGY, V12, P1166, DOI 10.1002/hep.1840120515; WARD HP, 1971, MEDICINE, V50, P357, DOI 10.1097/00005792-197109000-00001; WOLF BC, 1988, AM J CLIN PATHOL, V89, P69, DOI 10.1093/ajcp/89.1.69; Yanagida M, 1997, BRIT J HAEMATOL, V99, P739, DOI 10.1046/j.1365-2141.1997.4843288.x; Yoon SY, 1999, BRIT J HAEMATOL, V106, P682, DOI 10.1046/j.1365-2141.1999.01598.x	89	576	596	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1255	1265		10.1056/NEJM200004273421706	http://dx.doi.org/10.1056/NEJM200004273421706			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10781623				2022-12-28	WOS:000086660600006
J	Wong, W; Barlow, H				Wong, W; Barlow, H			Pattern recognition - Tunes and templates	NATURE			English	Article									Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England; Physiol Lab, Cambridge CB2 3EG, England	University of Cambridge; University of Cambridge	Wong, W (corresponding author), Univ Cambridge, Cavendish Lab, Cambridge CB3 0HE, England.	hbb10@cam.ac.uk						Neri P, 1998, NATURE, V395, P894, DOI 10.1038/27661; Swets J. A., 1964, SIGNAL DETECT RECOG, P3; Tripathy SP, 1999, VISION RES, V39, P4161, DOI 10.1016/S0042-6989(99)00125-X; Warren RM, 2008, AUDITORY PERCEPTION: AN ANALYSIS AND SYNTHESIS, 3RD EDITION, P126, DOI 10.1017/CBO9780511754777.006	4	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 27	2000	404	6781					952	953		10.1038/35010196	http://dx.doi.org/10.1038/35010196			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801115				2022-12-28	WOS:000086762000043
J	Lendvai, B; Stern, EA; Chen, B; Svoboda, K				Lendvai, B; Stern, EA; Chen, B; Svoboda, K			Experience-dependent plasticity of dendritic spines in the developing rat barrel cortex in vivo	NATURE			English	Article							CORTICAL PLASTICITY; PYRAMIDAL NEURONS; VISUAL-CORTEX; FIELD CORTEX; SYNAPTOGENESIS; ORGANIZATION; FILOPODIA; SYNAPSES; DYNAMICS; CLOSURE	Do changes in neuronal structure underlie cortical plasticity(1,2)? Here we used time-lapse two-photon microscopy(3,4) of pyramidal neurons in layer 2/3 of developing rat barrel cortex(5) to image the structural dynamics of dendritic spines and filopodia. We found that these protrusions were highly motile: spines and filopodia appeared, disappeared or changed shape over tens of minutes. To test whether sensory experience drives this motility we trimmed whiskers one to three days before imaging. Sensory deprivation markedly (similar to 40%) reduced protrusive motility in deprived regions of the barrel cortex during a critical period around postnatal days (P)11-13, but had no effect in younger (P8-10) or older (P14-16) animals. Unexpectedly, whisker trimming did not change the density, length or shape of spines and filopodia. However, sensory deprivation during the critical period degraded the tuning of layer 2/3 receptive fields. Thus sensory experience drives structural plasticity in dendrites, which may underlie the reorganization of neural circuits.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Svoboda, K (corresponding author), Hungarian Acad Sci, Inst Expt Med, Szigony U43, H-1083 Budapest, Hungary.							BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Chapin J., 1990, CEREBRAL CORTEX RAT, P341; Dailey ME, 1996, J NEUROSCI, V16, P2983; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fiala JC, 1998, J NEUROSCI, V18, P8900; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Fox K, 1996, J PHYSIOLOGY-PARIS, V90, P263, DOI 10.1016/S0928-4257(97)81436-2; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; Horch HW, 1999, NEURON, V23, P353; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; MALINOW R, 1999, IMAGING LIVING CELLS; Micheva KD, 1996, J COMP NEUROL, V373, P340, DOI 10.1002/(SICI)1096-9861(19960923)373:3<340::AID-CNE3>3.0.CO;2-2; MILLER M, 1981, J COMP NEUROL, V203, P555, DOI 10.1002/cne.902030402; Moore CI, 1998, J NEUROPHYSIOL, V80, P2882, DOI 10.1152/jn.1998.80.6.2882; MOVSHON JA, 1977, J NEUROPHYSIOL, V40, P1255, DOI 10.1152/jn.1977.40.6.1255; PURPURA DP, 1975, ADV NEUROL, P91; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SIMONS DJ, 1987, NATURE, V326, P694, DOI 10.1038/326694a0; Svoboda K, 1997, NATURE, V385, P161, DOI 10.1038/385161a0; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Vees AM, 1998, J COMP NEUROL, V400, P110; Welker W. I., 1964, Behaviour, V22, P223, DOI 10.1163/156853964X00030; WINFIELD DA, 1981, BRAIN RES, V206, P166, DOI 10.1016/0006-8993(81)90110-4; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Zhu JJ, 1999, J NEUROPHYSIOL, V81, P1171, DOI 10.1152/jn.1999.81.3.1171; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	30	597	617	0	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					876	881		10.1038/35009107	http://dx.doi.org/10.1038/35009107			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786794				2022-12-28	WOS:000086625000046
J	Stroup, DF; Berlin, JA; Morton, SC; Olkin, I; Williamson, GD; Rennie, D; Moher, D; Becker, BJ; Sipe, TA; Thacker, SB				Stroup, DF; Berlin, JA; Morton, SC; Olkin, I; Williamson, GD; Rennie, D; Moher, D; Becker, BJ; Sipe, TA; Thacker, SB		MOOSE Grp	Meta-analysis of observational studies in epidemiology - A proposal for reporting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEMATIC REVIEWS; ORAL-CONTRACEPTIVES; CONTROLLED TRIALS; METAANALYSIS; QUALITY; HEALTH; HETEROGENEITY; EXPOSURE; CANCER; BIAS	Objective Because of the pressure for timely, informed decisions in public health and clinical practice and the explosion of information in the scientific literature, research results must be synthesized. Meta-analyses are increasingly used to address this problem, and they often evaluate observational studies. A workshop was held in Atlanta, Ga, in April 1997, to examine the reporting of meta-analyses of observational studies and to make recommendations to aid authors, reviewers, editors, and readers. Participants Twenty-seven participants were selected by a steering committee, based on expertise in clinical practice, trials, statistics, epidemiology, social sciences, and biomedical editing. Deliberations of the workshop were open to other interested scientists. Funding for this activity was provided by the Centers for Disease Control and Prevention. Evidence We conducted a systematic review of the published literature on the conduct and reporting of meta-analyses in observational studies using MEDLINE, Educational Research Information Center (ERIC), PsycLIT, and the Current Index to Statistics. We also examined reference lists of the 32 studies retrieved and contacted experts in the field. Participants were assigned to small-group discussions on the subjects of bias, searching and abstracting, heterogeneity, study categorization, and statistical methods. Consensus Process From the material presented at the workshop, the authors developed a checklist summarizing recommendations for reporting meta-analyses of observational studies. The checklist and supporting evidence were circulated to all conference attendees and additional experts. All suggestions for revisions were addressed. Conclusions The proposed checklist contains specifications for reporting of meta-analyses of observational studies in epidemiology, including background, search strategy, methods, results, discussion, and conclusion. Use of the checklist should improve the usefulness of meta-analyses for authors, reviewers, editors, readers, and decision makers. An evaluation plan is suggested and research areas are explored.	Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; RAND Corp, Santa Monica, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Stanford Univ, Stanford, CA 94305 USA; JAMA, Chicago, IL USA; Childrens Hosp Eastern Ontario, Res Inst, Thomas C Chalmers Ctr Systemat Rev, Ottawa, ON, Canada; Michigan State Univ, E Lansing, MI 48824 USA; Georgia State Univ, Atlanta, GA 30303 USA	Centers for Disease Control & Prevention - USA; University of Pennsylvania; RAND Corporation; University of California System; University of California San Francisco; Stanford University; University of Ottawa; Children's Hospital of Eastern Ontario; Michigan State University; University System of Georgia; Georgia State University	Stroup, DF (corresponding author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop C09, Atlanta, GA 30333 USA.	dfs2@cdc.gov	Sipe, Theresa A/C-2262-2012	Moher, David/0000-0003-2434-4206; Becker, Betsy Jane/0000-0003-3438-560X				Badgett RG, 1997, ANN INTERN MED, V126, P886, DOI 10.7326/0003-4819-126-11-199706010-00006; BERLIN JA, 1995, AM J EPIDEMIOL, V142, P383, DOI 10.1093/oxfordjournals.aje.a117645; Berlin JA, 1999, JAMA-J AM MED ASSOC, V281, P830, DOI 10.1001/jama.281.9.830; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; Berlin JA, 1999, JAMA-J AM MED ASSOC, V282, P1083, DOI 10.1001/jama.282.11.1083; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Blettner M, 1999, INT J EPIDEMIOL, V28, P1, DOI 10.1093/ije/28.1.1; Chalmers T C, 1993, Stat Methods Med Res, V2, P161; COLDITZ GA, 1995, AM J EPIDEMIOL, V142, P371, DOI 10.1093/oxfordjournals.aje.a117644; Cole MG, 1997, CAN MED ASSOC J, V157, P1055; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1998, BRIT MED J, V316, P140; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; FRANCESCHI S, 1986, TUMORI, V72, P21, DOI 10.1177/030089168607200104; FRIEDENREICH CM, 1994, EPIDEMIOLOGY, V5, P66, DOI 10.1097/00001648-199401000-00011; FRUMKIN H, 1988, AM J IND MED, V14, P79, DOI 10.1002/ajim.4700140110; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662, DOI 10.1080/10473289.1992.10467018; HEDGES LV, 1985, STAT METHODS META AN; HETHERINGTON J, 1989, PEDIATRICS, V84, P374; Huston P, 1996, CAN MED ASSOC J, V155, P1697; Huston P, 1996, CAN MED ASSOC J, V154, P1389; Ioannidis J P, 1999, Jt Comm J Qual Improv, V25, P462; Jadad A, 2000, ANN M AM AC ALL ASTH; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Kheifets LI, 1997, J OCCUP ENVIRON MED, V39, P1074, DOI 10.1097/00043764-199711000-00008; Lang T., 1997, REPORT STAT MED ANNO, DOI 10.1097/00006205-199705000-00022; Lau J, 1998, LANCET, V351, P123, DOI 10.1016/S0140-6736(97)08468-7; Lipsett M, 1999, AM J PUBLIC HEALTH, V89, P1009, DOI 10.2105/AJPH.89.7.1009; MANN CC, 1994, SCIENCE, V266, P960, DOI 10.1126/science.7973676; McManus RJ, 1998, BMJ-BRIT MED J, V317, P1562, DOI 10.1136/bmj.317.7172.1562; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; OHLSSON A, 1994, SCAND J CLIN LAB INV, V54, P25, DOI 10.3109/00365519409088573; Peipert JF, 1998, CLIN OBSTET GYNECOL, V41, P235, DOI 10.1097/00003081-199806000-00004; PETITTI D, 1994, META ANAL DECISION A; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Saag KG, 1996, ARTHRITIS RHEUM-US, V39, P1818, DOI 10.1002/art.1780391107; Schlesselman JJ, 1997, HUM REPROD, V12, P1851, DOI 10.1093/humrep/12.9.1851; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SHAPIRO S, 1994, AM J EPIDEMIOL, V140, P771, DOI 10.1093/oxfordjournals.aje.a117324; Sipe T. A., 1997, INT J EDUC RES, V25, P583, DOI [10.1016/S0883-0355(96)00021-3, DOI 10.1016/S0883-0355(96)80001-2]; Steinberg KK, 1997, AM J EPIDEMIOL, V145, P917; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; STROUP DF, 1997, INT C BIOM PEER REV; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; Vickers A, 1997, INT J TECHNOL ASSESS, V13, P111, DOI 10.1017/S0266462300010278	50	15061	15272	43	389	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2000	283	15					2008	2012		10.1001/jama.283.15.2008	http://dx.doi.org/10.1001/jama.283.15.2008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303RC	10789670				2022-12-28	WOS:000086436600037
J	Anderson, RT; Lovley, DR				Anderson, RT; Lovley, DR			Biogeochemistry - Hexadecane decay by methanogenesis	NATURE			English	Article									Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Anderson, RT (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.							Anderson RT, 1998, ENVIRON SCI TECHNOL, V32, P1222, DOI 10.1021/es9704949; LOVLEY DR, 1995, REV GEOPHYS, V33, P365, DOI 10.1029/95RG01305; Parkes J, 1999, NATURE, V401, P217, DOI 10.1038/45686; WARD DM, 1978, GEOMICROBIOL J, V1, P1, DOI 10.1080/01490457809377720; WARD DM, 1980, AMBIO, V9, P277; Zengler K, 1999, NATURE, V401, P266, DOI 10.1038/45777	6	116	140	5	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					722	723		10.1038/35008145	http://dx.doi.org/10.1038/35008145			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783875				2022-12-28	WOS:000086523600038
J	Boal, AK; Ilhan, F; DeRouchey, JE; Thurn-Albrecht, T; Russell, TP; Rotello, VM				Boal, AK; Ilhan, F; DeRouchey, JE; Thurn-Albrecht, T; Russell, TP; Rotello, VM			Self-assembly of nanoparticles into structured spherical and network aggregates	NATURE			English	Article							DNA; MOLECULES; THYMINE	Multi-scale ordering of materials is central for the application of molecular systems(1-3) in macroscopic devices(4,5). Self-assembly based on selective control of non-covalent interactions(6-8) provides a powerful tool for the creation of structured systems at a molecular level, and application of this methodology to macromolecular systems provides a means for extending such structures to macroscopic length scale(9-11). Monolayer-functionalized nanoparticles can be made with a wide variety of metallic and nonmetallic cores, providing a versatile building block for such approaches. Here we present a polymer-mediated 'bricks and mortar' strategy for the ordering of nanoparticles into structured assemblies. This methodology allows monolayer-protected gold particles to self-assemble into structured aggregates while thermally controlling their size and morphology. Using 2-nm gold particles as building blocks, we show that spherical aggregates of size 97 +/- 17 nm can be produced at 23 degrees C, and that 0.5-1 mu m spherical assemblies with (5-40) x 10(5) individual subunits form at -20 degrees C. Intriguingly, extended networks of similar to 50-nm subunits are formed at 10 degrees C, illustrating the potential of our approach for the formation of diverse structural motifs such as wires and rods. These findings demonstrate that the assembly process provides control over the resulting aggregates, while the modularity of the 'bricks and mortar' approach allows combinatorial control over the constituents, providing a versatile route to new materials systems.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Rotello, VM (corresponding author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.		DeRouchey, Jason/B-3437-2009; Russell, Thomas Paul/ADL-3689-2022; DeRouchey, Jason/C-5907-2011	Russell, Thomas Paul/0000-0001-6384-5826; DeRouchey, Jason/0000-0002-3624-4432; Thurn-Albrecht, Thomas/0000-0002-7618-0218				Alivisatos AP, 1998, ADV MATER, V10, P1297; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Andres RP, 1996, SCIENCE, V273, P1690, DOI 10.1126/science.273.5282.1690; ANELLI PL, 1991, J AM CHEM SOC, V113, P5131, DOI 10.1021/ja00013a096; Boal AK, 1999, J AM CHEM SOC, V121, P4914, DOI 10.1021/ja9905288; Breen TL, 1999, SCIENCE, V284, P948, DOI 10.1126/science.284.5416.948; BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801; de Silva AP, 1997, J AM CHEM SOC, V119, P7891, DOI 10.1021/ja9712229; Deans R, 1999, MACROMOLECULES, V32, P4956, DOI 10.1021/ma990735s; Edgecombe BD, 1998, MACROMOLECULES, V31, P1292, DOI 10.1021/ma970832q; Fyfe MCT, 1997, ACCOUNTS CHEM RES, V30, P393, DOI 10.1021/ar950199y; Ingram RS, 1997, J AM CHEM SOC, V119, P9175, DOI 10.1021/ja971734n; KOTERA M, 1994, J CHEM SOC CHEM COMM, P197, DOI 10.1039/c39940000197; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; Liu J, 1999, J AM CHEM SOC, V121, P4304, DOI 10.1021/ja990330n; Marinakos SM, 1998, CHEM MATER, V10, P1214, DOI 10.1021/cm980059t; Markovich G, 1999, ACCOUNTS CHEM RES, V32, P415, DOI 10.1021/ar980039x; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Mucic RC, 1998, J AM CHEM SOC, V120, P12674, DOI 10.1021/ja982721s; MUEHLDORF AV, 1988, J AM CHEM SOC, V110, P6561, DOI 10.1021/ja00227a045; Otsuki J, 1997, J AM CHEM SOC, V119, P7895, DOI 10.1021/ja970386m; PARK TK, 1991, J AM CHEM SOC, V113, P5125, DOI 10.1021/ja00013a093; Rebek J, 1999, ACCOUNTS CHEM RES, V32, P278, DOI 10.1021/ar970201g; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; Whetten RL, 1999, ACCOUNTS CHEM RES, V32, P397, DOI 10.1021/ar970239t	25	1040	1069	4	574	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					746	748		10.1038/35008037	http://dx.doi.org/10.1038/35008037			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783884				2022-12-28	WOS:000086523600047
J	Mant, J; Fitzmaurice, D; Murray, E; Hobbs, R				Mant, J; Fitzmaurice, D; Murray, E; Hobbs, R			Using anticoagulation or aspirin to prevent stroke - Study does not have the power to show that aspirin is as good as anticoagulation	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Mant, J (corresponding author), Univ Birmingham, Sch Med, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	J.W.Mant@bham.ac.uk		hobbs, richard/0000-0001-7976-7172				[Anonymous], 1997, ARCH INTERN MED, V157, P1237; Blackshear JL, 1996, LANCET, V348, P633; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449	5	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2000	320	7240					1009	1009						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303XP	10809556				2022-12-28	WOS:000086453100053
J	Neugebauer, R				Neugebauer, R			Research on intergenerational transmission of violence: the next generation	LANCET			English	Editorial Material							SEXUAL ABUSE; CHILDHOOD; ADJUSTMENT		New York State Psychiat Inst, Epidemiol Dev Brain Disorders Dept, New York, NY 10032 USA; Columbia Univ, Fac Med, GH Sergievsky Ctr, New York, NY USA	New York State Psychiatry Institute; Columbia University	Neugebauer, R (corresponding author), New York State Psychiat Inst, Epidemiol Dev Brain Disorders Dept, New York, NY 10032 USA.							Clarke J, 1999, ARCH INTERN MED, V159, P1920, DOI 10.1001/archinte.159.16.1920; COIE JD, 1998, HDB CHILD P0SYCHOL, V3; FARRINGTON DP, 1995, J CHILD PSYCHOL PSYC, V36, P929, DOI 10.1111/j.1469-7610.1995.tb01342.x; Fergusson DM, 1997, CHILD ABUSE NEGLECT, V21, P617, DOI 10.1016/S0145-2134(97)00021-5; FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; Johnson JG, 1999, ARCH GEN PSYCHIAT, V56, P600, DOI 10.1001/archpsyc.56.7.600; Kessler RC, 1997, PSYCHOL MED, V27, P1101, DOI 10.1017/S0033291797005588; LOEBER R, 1989, DEV PSYCHOPATHOL, V1, P39, DOI DOI 10.1017/S0954579400000237; Lynskey MT, 1997, CHILD ABUSE NEGLECT, V21, P1177, DOI 10.1016/S0145-2134(97)00093-8; Neugebauer R, 1999, JAMA-J AM MED ASSOC, V282, P455, DOI 10.1001/jama.282.5.455; PETIT MR, 1999, CHILD ABUSE NEGLECT; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; WIDOM CS, 1989, SCIENCE, V244, P160, DOI 10.1126/science.2704995; WISSOW LS, 1995, NEW ENGL J MED, V332, P1425, DOI 10.1056/NEJM199505253322107	14	16	16	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2000	355	9210					1116	1117		10.1016/S0140-6736(00)02056-0	http://dx.doi.org/10.1016/S0140-6736(00)02056-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	302TC	10791370				2022-12-28	WOS:000086380900005
J	Weatherall, DJ; Provan, AB				Weatherall, DJ; Provan, AB			Red cells I: inherited anaemias	LANCET			English	Article							HEREDITARY SPHEROCYTOSIS; DISEASE; GENETICS; ANEMIA	Examination of the genetic mechanisms underlying the thalassaemias has led to a clearer understanding of the control of eukaryotic genes in general. Inherited disorders of haemoglobin synthesis are an important cause worldwide of morbidity and mortality, and place a large burden on patients, families, and ultimately communities. The haemoglobin disorders can be controlled, by counselling and prenatal diagnosis. Treatment is usually symptomatic, though bone-marrow transplantation for beta-thalassaemia may be successful in suitable patients.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; Southampton Gen Hosp, Dept Haematol, Southampton SO9 4XY, Hants, England	University of Oxford; University of Southampton	Weatherall, DJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.							ARYA R, 1995, BLOOD REV, V9, P165, DOI 10.1016/0268-960X(95)90022-5; Bieker J J, 1998, Curr Opin Hematol, V5, P145; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; Delaunay J, 1996, ANN GENET-PARIS, V39, P209; DELAUNAY J, 1995, CRIT REV ONCOL HEMAT, V19, P79, DOI 10.1016/1040-8428(94)00139-K; DOVER GJ, 1998, HEMATOLOGY INFANCY C, P762; Gallagher P G, 1997, Curr Opin Hematol, V4, P128; Giardini C, 1997, Curr Opin Hematol, V4, P79; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; Hassoun H, 1996, BLOOD REV, V10, P129, DOI 10.1016/S0268-960X(96)90021-1; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; Hillery C A, 1998, Curr Opin Hematol, V5, P151; Maxwell P, 1998, Curr Opin Hematol, V5, P166, DOI 10.1097/00062752-199805000-00003; McMullin MF, 1999, J CLIN PATHOL, V52, P241, DOI 10.1136/jcp.52.4.241; McMullin MF, 1999, J CLIN PATHOL, V52, P245, DOI 10.1136/jcp.52.4.245; Miwa S, 1996, AM J HEMATOL, V51, P122, DOI 10.1002/(SICI)1096-8652(199602)51:2<122::AID-AJH5>3.0.CO;2-#; Okpala I, 1998, EUR J HAEMATOL, V60, P1; Olivieri N, 1998, BAILLIERE CLIN HAEM, V11, P147, DOI 10.1016/S0950-3536(98)80073-5; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Serjeant GR., 1992, SICKLE CELL DIS; Thein SL, 1998, BAILLIERE CLIN HAEM, V11, P91, DOI 10.1016/S0950-3536(98)80071-1; Weatherall DJ, 1998, BAILLIERE CLIN HAEM, V11, P127, DOI 10.1016/S0950-3536(98)80072-3; WEATHERALL DJ, 2000, IN PRESS MOL BASIS B; WEATHERALL DJ, 2000, IN PRESS METABOLIC M; WEATHERALL DJ, 1999, IN PRESS THALASSAEMI	26	31	46	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1169	1175		10.1016/S0140-6736(00)02073-0	http://dx.doi.org/10.1016/S0140-6736(00)02073-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791394				2022-12-28	WOS:000086380900038
J	Ellis, M; Manandhar, N; Manandhar, DS; Costello, AMDL				Ellis, M; Manandhar, N; Manandhar, DS; Costello, AMDL			Risk factors for neonatal encephalopathy in Kathmandu, Nepal, a developing country: unmatched case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; AUSTRALIAN CASE-CONTROL; FULL-TERM INFANTS; NEWBORN ENCEPHALOPATHY; BIRTH ASPHYXIA; INDUCTION; LABOR; MECONIUM; PREGNANCY; MAGNESIUM	Objective To determine the risk factors for neonatal encephalopathy among term infants in a developing country. Design Unmatched case-control study. Setting Principal maternity hospital of Kathmandu, Nepal. Subjects All 131 infants with neonatal encephalopathy from a population of 21 609 infants born over an 18 month period, and 635 unmatched infants systematically recruited over 12 months. Main outcome measures Adjusted odds ratio estimates for antepartum and intrapartum risk factors. Results The prevalence of neonatal encephalopathy was 6.1 per 1000 live births of which 63% were infants with moderate or severe encephalopathy. The risk of death from neonatal encephalopathy was 31%. The risk of neonatal encephalopathy increased with increasing maternal age and decreasing maternal height. Antepartum risk factors included primiparity (odds ratio 2.0) and non-attendance for antenatal care (2.1). Multiple births were at greatly increased risk (22). Intrapartum risk factors included non-cephalic presentation (3.4), prolonged rupture of membranes (3.8), and various other complications. Particulate meconium was strongly associated with encephalopathy (18). Induction of labour with oxytocin was associated with encephalopathy in 12 of 41 deliveries (5.7), Overall, 78 affected infants (60%) compared with 36 controls (6%) either had evidence of intrapartum compromise or were born after an intrapartum difficulty likely to result ill fetal compromise. A concentration of maternal haemoglobin of less than 8.0 g/dl in the puerperium was significantly associated with encephalopathy (2.5) as was a maternal thyroid stimulating hormone concentration greater than 5 mIU/l (2.1). Conclusions Intrapartum risk factors remain important for neonatal encephalopathy in developing countries. There is some evidence of a protective effect from antenatal care. The use of oxytocin in low income countries where intrapartum monitoring is suboptimal presents a major risk to the fetus. More work is required to explore the association between maternal deficiency states and neonatal encephalopathy.	UCL, Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England; Maternal & Infant Res Act, Kathmandu, Nepal	University of London; University College London	Ellis, M (corresponding author), Royal Hosp Sick Children, Inst Child Hlth, Bristol BS2 8BJ, Avon, England.	M.Ellis@bristol.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMSON SJ, 1995, BRIT MED J, V311, P598, DOI 10.1136/bmj.311.7005.598; Amiel-Tison C., 1995, P83; AMIELTISON C, 1986, DEV MED CHILD NEUROL, V28, P671; Badawi N, 1998, BMJ-BRIT MED J, V317, P1549, DOI 10.1136/bmj.317.7172.1549; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; Badawi N, 1999, BRIT MED J, V318, P1415; Bhutta ZA, 2000, IMPROVING NEWBORN INFANT HEALTH IN DEVELOPING COUNTRIES, P289, DOI 10.1142/9781848160705_0016; BOLAM A, 1997, J NEPAL MED ASS, V35, P122; *CENTR BUR STAT, 1993, AN 1991 POP CENS; CONNELL J, 1989, ARCH DIS CHILD-FETAL, V64, P452, DOI 10.1136/adc.64.4_Spec_No.452; DAGA AS, 1990, J TROP PEDIATRICS, V36, P34, DOI 10.1093/tropej/36.1.34; DIJXHOORN MJ, 1986, BRIT J OBSTET GYNAEC, V93, P217, DOI 10.1111/j.1471-0528.1986.tb07896.x; Edwards AD, 1998, BMJ-BRIT MED J, V317, P1537, DOI 10.1136/bmj.317.7172.1537; Ellis M, 2000, PAEDIATR PERINAT EP, V14, P39; Ellis M, 1999, DEV MED CHILD NEUROL, V41, P689, DOI 10.1017/S0012162299001413; ELLIS M, 1988, INDIAN PEDIATR, V35, P415; ELLIS ME, 1999, THESIS U COLLEGE LON; ESCOFFERY C, 1994, PAEDIATR PERINAT EP, V8, P119, DOI 10.1111/j.1365-3016.1994.tb00496.x; FENICHEL GM, 1983, ARCH NEUROL-CHICAGO, V40, P261, DOI 10.1001/archneur.1983.04050050029002; GAFFNEY G, 1994, BRIT MED J, V308, P743, DOI 10.1136/bmj.308.6931.743; HANNAH ME, 1992, NEW ENGL J MED, V326, P1587, DOI 10.1056/NEJM199206113262402; Harrison V, 1997, EARLY HUM DEV, V47, P287, DOI 10.1016/S0378-3782(96)01787-2; HOFMEYER GJ, 2000, COCHRANE LIBRARY; Ilves P, 1996, ACTA PAEDIATR, V85, P1348, DOI 10.1111/j.1651-2227.1996.tb13923.x; Jackson M, 1997, CLIN OBSTET GYNECOL, V40, P496, DOI 10.1097/00003081-199709000-00007; JARVELIN MR, 1993, BRIT J OBSTET GYNAEC, V100, P310, DOI 10.1111/j.1471-0528.1993.tb12971.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Laube DW, 1997, CLIN OBSTET GYNECOL, V40, P485, DOI 10.1097/00003081-199709000-00006; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; LEVENE RJ, 1995, FETAL NEONATAL NEURO, P427; LEVITON A, 1992, PEDIATR NEUROL, V8, P85, DOI 10.1016/0887-8994(92)90026-U; LOW JA, 1985, AM J OBSTET GYNECOL, V152, P256, DOI 10.1016/S0002-9378(85)80205-2; Mahomed K, 1998, BRIT J OBSTET GYNAEC, V105, P309, DOI 10.1111/j.1471-0528.1998.tb10092.x; MAHOMED K, 1998, COCHRANE LIBRARY; MAHOMED K, 1997, COCHRANE LIBRARY; MAKAREM A, 1974, CLIN CHEM, P1125; MINCHOM P, 1987, BRIT J OBSTET GYNAEC, V94, P431, DOI 10.1111/j.1471-0528.1987.tb03121.x; PARKIN JM, 1976, ARCH DIS CHILD, V51, P259, DOI 10.1136/adc.51.4.259; Reddy V., 1992, NUTR INDIA; REDLINE RW, 1995, CURR OPIN OBSTET GYN, V7, P10; WISWELL TE, 1993, PEDIATR CLIN N AM, V40, P955; *WORLD BANK, 1996, WORLD DEV REP; World Health Organization, 1996, WHOFRHMSM967; YUDKIN P, 1979, BRIT J OBSTET GYNAEC, V86, P257, DOI 10.1111/j.1471-0528.1979.tb11252.x	44	92	95	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 6	2000	320	7244					1229	1236		10.1136/bmj.320.7244.1229	http://dx.doi.org/10.1136/bmj.320.7244.1229			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797030	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000086981400015
J	Inwald, D; Jakobovits, I; Petros, A				Inwald, D; Jakobovits, I; Petros, A			Ethical debate - Brain stem death: managing care when accepted medical guidelines and religious beliefs are in conflict - Consideration and compromise are possible	BRITISH MEDICAL JOURNAL			English	Article									Inst Child Hlth, Portex Dept Anaesthesia Intens Care & Resp Med, London WC1N 1EH, England; Great Ormond St Hosp Children, Paediat Intens Care Unit, London WC1N 3JH, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Inwald, D (corresponding author), Inst Child Hlth, Portex Dept Anaesthesia Intens Care & Resp Med, 30 Guilford St, London WC1N 1EH, England.			Inwald, David/0000-0001-9518-7821				BLEICH JD, 1991, TIME DEATH JEWISH LA; PALLIS C, 1983, BRIT MED J, V286, P123, DOI 10.1136/bmj.286.6359.123; *ROYAL COLL PAED C, 1997, WITHH WITHDR LIF SAV; TENDLER M, 1991, JEWISH OBSERVER, V24, P11; *WORD GROUP C MED, 1976, LANCET, V2, P1069; WOSNER SH, 1995, PATHWAYS MED	6	16	17	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1266	1267		10.1136/bmj.320.7244.1266	http://dx.doi.org/10.1136/bmj.320.7244.1266			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797044	Green Published			2022-12-28	WOS:000086981400027
J	Skelton, JR; Edwards, SJL				Skelton, JR; Edwards, SJL			The function of the discussion section in academic medical writing	BRITISH MEDICAL JOURNAL			English	Article							SCIENCE		Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Skelton, JR (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.							Bloor David, 1976, KNOWLEDGE SCI IMAGER; CHALMERS A, 1990, SCI ITS FABRICATION; Docherty M, 1999, BRIT MED J, V318, P1224; Hopkins A., 1988, ENGL SPECIF PURP, V7, P113, DOI [10.1016/0889-4906(88)90029-4, DOI 10.1016/0889-4906(88)90029-4]; Hyland K, 1996, APPL LINGUIST, V17, P433, DOI 10.1093/applin/17.4.433; Knorr Cetina K.D., 1981, MANUFACTURE KNOWLEDG; Lakoff G, 1973, J PHILOS LOGIC, V2, P458, DOI DOI 10.1007/BF00262952; LOCK S, 1991, BRIT MED J, V302, P338; Salager-Meyer F., 1994, ENGL SPECIF PURP, V13, P149, DOI DOI 10.1016/0889-4906(94)90013-2; Skelton J, 1997, APPL LINGUIST, V18, P121, DOI 10.1093/applin/18.2.121; Skelton J, 1997, LANCET, V349, P139, DOI 10.1016/S0140-6736(05)60931-2; SKELTON J, 1994, BRIT J GEN PRACT, V44, P455; Stewart JA, 1999, BRIT MED J, V318, P967, DOI 10.1136/bmj.318.7189.967; SWALES J, 1990, GENRE ANAL ENGLISH A; THOMPSON G, 1991, APPL LINGUIST, V12, P365, DOI 10.1093/applin/12.4.365	15	28	29	1	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1269	1270		10.1136/bmj.320.7244.1269	http://dx.doi.org/10.1136/bmj.320.7244.1269			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	313CF	10797045	Green Published			2022-12-28	WOS:000086981400029
J	Walter, RC; Buffler, RT; Bruggemann, JH; Guillaume, MMM; Berhe, SM; Negassi, B; Libsekal, Y; Cheng, H; Edwards, RL; von Cosel, R; Neraudeau, D; Gagnon, M				Walter, RC; Buffler, RT; Bruggemann, JH; Guillaume, MMM; Berhe, SM; Negassi, B; Libsekal, Y; Cheng, H; Edwards, RL; von Cosel, R; Neraudeau, D; Gagnon, M			Early human occupation of the Red Sea coast of Eritrea during the last interglacial	NATURE			English	Article							DATED CORAL-REEFS; STRATIGRAPHY; SINAI	The geographical origin of modern humans is the subject of ongoing scientific debate. The 'multiregional evolution' hypothesis argues that modern humans evolved semi-independently in Europe, Asia and Africa between 100,000 and 40,000 years ago 1, whereas the 'out of Africa' hypothesis contends that modern humans evolved in Africa between 200 and 100 kyr ago, migrating to Eurasia at some later time(2). Direct palaeontological, archaeological and biological evidence is necessary to resolve this debate. Here we report the discovery of early Middle Stone Age artefacts in an emerged reef terrace on the Red Sea coast of Eritrea, which we date to the last interglacial (about 125 kyr ago) using U-Th mass spectrometry techniques on fossil corals. The geological setting of these artefacts shows that early humans occupied coastal areas and exploited near-shore marine food resources in East Africa by this time. Together with similar, tentatively dated discoveries from South Africa(3) this is the earliest well-dated evidence for human adaptation to a coastal marine environment, heralding an expansion in the range and complexity of human behaviour from one end of Africa to the other. This new, widespread adaptive strategy may, in part, signal the onset of modern human behaviour, which supports an African origin for modern humans by 125 kyr ago.	Ctr Invest Cient Educ Super Ensenada, Dept Geol, Ensenada, Baja California, Mexico; Univ Texas, Inst Geophys, Austin, TX 78712 USA; Univ Groningen, Dept Marine Biol, NL-9750 AA Haren, Netherlands; Univ Asmara, Dept Fisheries & Marine Biol, Asmera, Eritrea; Wageningen Univ Agr, Wageningen Inst Anim Sci, Expt Zool Grp, NL-6700 AH Wageningen, Netherlands; Museum Natl Hist Nat, Lab Biol Invertebres Marins & Malacol, CNRS, ESA 8044, F-75005 Paris, France; African Minerals Inc, Asmera, Eritrea; Minist Energy & Mines, Dept Mines, Asmera, Eritrea; Natl Museum Eritrea, Asmera, Eritrea; Univ Asmara, Archaeol Unit, Asmera, Eritrea; Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; Univ Rennes 1, Geosci Rennes, Lab Paleontol, F-35042 Rennes, France; Univ Toronto, Dept Anthropol, Toronto, ON M5S 3G3, Canada	CICESE - Centro de Investigacion Cientifica y de Educacion Superior de Ensenada; University of Texas System; University of Texas Austin; University of Groningen; Wageningen University & Research; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); University of Minnesota System; University of Minnesota Twin Cities; Universite de Rennes; University of Toronto	Walter, RC (corresponding author), Ctr Invest Cient Educ Super Ensenada, Dept Geol, Km 107 Carr Tijuana Ensenada, Ensenada, Baja California, Mexico.	rwalter@cicese.mx	Walter, Robert/AAD-7642-2020; Edwards, R. Lawrence/I-3124-2014	Walter, Robert/0000-0001-8761-5355; Edwards, R. Lawrence/0000-0002-7027-5881; GUILLAUME, Mireille M. M./0000-0001-7249-0131				Brink J.S., 1982, Palaeoecology of Africa and the Surrounding Islands, V15, P31; CHEN JH, 1991, GEOL SOC AM BULL, V103, P82, DOI 10.1130/0016-7606(1991)103<0082:PCOTLI>2.3.CO;2; CHENG H, IN PRESS HALF LIVES; CLARK JD, 1988, J WORLD PREHIST, V2, P235, DOI 10.1007/BF00975618; CONFORTO L, 1976, SOC IT MIN PET, V32, P153; DEACON HJ, 1989, HUMAN REVOLUTION, P547; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; El-Asmar HM, 1997, QUATERNARY SCI REV, V16, P911, DOI 10.1016/S0277-3791(96)00077-7; FAURE H, 1968, CR ACAD SCI D NAT, V267, P18; Faure H., 1980, B SOC GEOL FR, V6, P959; FREYTET P, 1993, Z GEOMORPHOL, V37, P215; GRUN R, 1991, ARCHAEOMETRY, V33, P153, DOI 10.1111/j.1475-4754.1991.tb00696.x; GVIRTZMAN G, 1992, MAR GEOL, V108, P29, DOI 10.1016/0025-3227(92)90211-Y; GVIRTZMAN G, 1977, MEMOIRES BUREAU RECH, V89, P480; Hoang CT, 1996, QUATERN INT, V31, P47, DOI 10.1016/1040-6182(95)00020-J; HOANG CT, 1991, QUATERNARY RES, V35, P264, DOI 10.1016/0033-5894(91)90072-D; HOANG CT, 1974, COL INT CNRS, V219, P103; HOROWITZ A, 1989, PALAEOGEOGR PALAEOCL, V72, P63, DOI 10.1016/0031-0182(89)90132-6; KLEIN RG, 1989, HUMAN REVOLUTION, P529; Leakey LSB., 1931, STONE AGE CULTURES K; LENEY M, 1999, DISCOV ARCHAEOL, V1, P18; Montenat C., 1986, B I FRAN ARCHEOL ORI, V86, P239; PHILIPSONDW, 1993, AFRICAN ARCHAEOLOGY; Plaziat J.-C., 1998, SEDIMENTATION TECTON, P537, DOI DOI 10.1007/978-94-011-4930-3_29; Stirling CH, 1998, EARTH PLANET SC LETT, V160, P745, DOI 10.1016/S0012-821X(98)00125-3; STRINGER CB, 1990, SCI AM           DEC, P98; Taviani M., 1998, SEDIMENTATION TECTON, P574, DOI DOI 10.1007/978-94-011-4930-3_30; Thorne Alan G., 1992, SCI AM           APR, P28; Van Peer P, 1998, CURR ANTHROPOL, V39, pS115, DOI 10.1086/204692; WALTER RC, 1997, LITHOSPHERIC STRUCTU	30	209	216	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	2000	405	6782					65	69		10.1038/35011048	http://dx.doi.org/10.1038/35011048			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811218				2022-12-28	WOS:000086901600051
J	Quinlan, KP; Brewer, RD; Sleet, DA; Dellinger, AM				Quinlan, KP; Brewer, RD; Sleet, DA; Dellinger, AM			Characteristics of child passenger deaths and injuries involving drinking drivers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies	MAY 01-04, 1999	SAN FRANCISCO, CALIFORNIA	Pediat Acad Soc			ALCOHOL; OFFENDERS; INTERVENTIONS; CRASHES	Context Motor vehicle-related injury is the leading cause of death for children and young adults aged 1 to 24 years in the United States. Approximately 24% of child traffic deaths involve alcohol. Objective To examine characteristics of crashes involving child passenger deaths and injuries associated with drinking drivers to identify opportunities for prevention. Design, Setting, and Participants Descriptive epidemiological analysis of 1985-1996 data from the Fatality Analysis Reporting System on deaths among US child passengers (aged 0-14 years) and 1988-1996 data from the General Estimates System on nonfatal injuries. Main Outcome Measures Child passenger death or injury by driver characteristics (eg, driver age, blood alcohol concentration, and driving history). Results In 1985-1996, there were 5555 child passenger deaths involving a drinking driver. Of these deaths, 3556 (64.0%) occurred while the child was riding with a drinking driver; 67.0% of these drinking drivers were old enough to be the parent or caregiver of the child, Of all drivers transporting a child who died, drinking drivers were more likely than nondrinking drivers to have had a previous license suspension (17.1% vs 7.1%) or conviction for driving while intoxicated (7.9% vs 1.2%). Child restraint use decreased as both the child's age and the blood alcohol concentration of the child's driver increased. In 1988-1996, an estimated 149 000 child passengers were nonfatally injured in crashes involving a drinking driver. Of these, 58 000 (38.9%) were riding with a drinking driver when injured in the crash. Conclusions These data indicate that the majority of drinking driver-related child passenger deaths in the United States involve a child riding unrestrained in the same vehicle with a drinking driver. Typically, the drinking driver transporting the child is old enough to be the child's parent or caregiver.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off,Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Quinlan, KP (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off,Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS K-63, Atlanta, GA 30341 USA.							BOYLE WE, 1994, PEDIATRICS, V94, P566; Brewer R D, 1995, Arch Fam Med, V4, P499, DOI 10.1001/archfami.4.6.499; BREWER RD, 1994, NEW ENGL J MED, V331, P513, DOI 10.1056/NEJM199408253310806; *CDCP, 1997, 10 LEAD CAUS DEATH 1; *CDCP, 1991, MMWR-MORBID MORTAL W, V40, P185; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1130; *CDP, 1994, MMWR-MORBID MORTAL W, V43, P759; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P178; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; FINE EW, 1976, ANN NY ACAD SCI, V273, P637, DOI 10.1111/j.1749-6632.1976.tb52938.x; FOSS RD, 1997, P 14 INT C ALC DRUGS; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; Greenberg L., 1996, DOTHS808487 NAT HIGH; HINGSON R, 1994, PUBLIC HEALTH REP, V109, P738; Howat P, 1991, Drug Alcohol Rev, V10, P151, DOI 10.1080/09595239100185211; KENNEDY J, 1997, REDBOOK          MAY, P89; KLEIN T, 1986, 807094 DOT HS; KUNEN JS, 1990, PEOPLE WEEKLY    JAN, P51; MANN RE, 1994, J STUD ALCOHOL, V55, P372, DOI 10.15288/jsa.1994.55.372; MARGOLIS LH, 1986, PEDIATRICS, V77, P870; *NAT HIGHW TRAFF S, 1998, TRAFF SAF FACTS 1997; *NAT HIGHW TRAFF S, 1999, 809008 DOT HS; *NAT HIGHW TRAFF S, 1998, CHILDR TRAFF SAF FAC; OSTROM M, 1992, ACCIDENT ANAL PREV, V24, P539, DOI 10.1016/0001-4575(92)90062-N; *US BUR CENS, 1996, US POP EST AG SEX RA; *US BUR CENS, 1993, US POP EST AG SEX RA; WELLSPARKER E, 1995, ADDICTION, V90, P907, DOI 10.1046/j.1360-0443.1995.9079074.x; ZADOR P L, 1989, Journal of Public Health Policy, V10, P467, DOI 10.2307/3342519	28	40	41	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2249	2252		10.1001/jama.283.17.2249	http://dx.doi.org/10.1001/jama.283.17.2249			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	307UB	10807383	Bronze			2022-12-28	WOS:000086671600031
J	Thompson, MM; Bell, PRF				Thompson, MM; Bell, PRF			ABC of arterial and venous disease - Arterial aneurysms	BRITISH MEDICAL JOURNAL			English	Review									Leicester Royal Infirm, Leicester, Leics, England; Univ Leicester, Leicester LE1 7RH, Leics, England	University of Leicester; University of Leicester	Thompson, MM (corresponding author), Leicester Royal Infirm, Leicester, Leics, England.							Powell JT, 1998, LANCET, V352, P1649; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821; THOMPSON MM, 1998, COMPANION SPECIALIST	3	36	39	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1193	1196		10.1136/bmj.320.7243.1193	http://dx.doi.org/10.1136/bmj.320.7243.1193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784548	Green Published			2022-12-28	WOS:000086832800023
J	Jones, DJ; Diddams, SA; Ranka, JK; Stentz, A; Windeler, RS; Hall, JL; Cundiff, ST				Jones, DJ; Diddams, SA; Ranka, JK; Stentz, A; Windeler, RS; Hall, JL; Cundiff, ST			Carrier-envelope phase control of femtosecond mode-locked lasers and direct optical frequency synthesis	SCIENCE			English	Article							PULSES; GENERATION	We stabilized the carrier-envelope phase of the pulses emitted by a femtosecond mode-locked Laser by using the powerful tools of frequency-domain laser stabilization. We confirmed control of the pulse-to-pulse carrier-envelope phase using temporal cross correlation. This phase stabilization Locks the absolute frequencies emitted by the Laser, which we used to perform absolute optical frequency measurements that were directly referenced to a stable microwave clock.	Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Natl Inst Stand & Technol, Boulder, CO 80309 USA; Bell Labs, Lucent Technol, Holmdel, NJ 07733 USA	University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA; Alcatel-Lucent; Lucent Technologies; AT&T	Cundiff, ST (corresponding author), Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA.		Cundiff, Steven T/B-4974-2009; Jones, David/F-5859-2017; Diddams, Scott A/L-2819-2013	Cundiff, Steven T/0000-0002-7119-5197; Jones, David/0000-0002-4508-5912; Diddams, Scott A/0000-0002-2144-0764				ASAKI MT, 1993, OPT LETT, V18, P977, DOI 10.1364/OL.18.000977; Diddams SA, 2000, OPT LETT, V25, P186, DOI 10.1364/OL.25.000186; DIDDAMS SA, IN PRESS PHYS REV LE; Dietrich P, 2000, OPT LETT, V25, P16, DOI 10.1364/OL.25.000016; Durfee CG, 1999, PHYS REV LETT, V83, P2187, DOI 10.1103/PhysRevLett.83.2187; FORK RL, 1984, OPT LETT, V9, P150, DOI 10.1364/OL.9.000150; Hall JL, 1999, IEEE T INSTRUM MEAS, V48, P583, DOI 10.1109/19.769663; Huber A, 1998, PHYS REV LETT, V80, P468, DOI 10.1103/PhysRevLett.80.468; Jones RJ, 2000, OPT COMMUN, V175, P409, DOI 10.1016/S0030-4018(00)00483-1; JUNGNER PA, 1995, IEEE T INSTRUM MEAS, V44, P151, DOI 10.1109/19.377796; KUROGI M, 1993, IEEE J QUANTUM ELECT, V29, P2692; Morgner U, 1999, OPT LETT, V24, P411, DOI 10.1364/OL.24.000411; PRESTAGE JD, 1995, PHYS REV LETT, V74, P3511, DOI 10.1103/PhysRevLett.74.3511; Quinn TJ, 1999, METROLOGIA, V36, P211, DOI 10.1088/0026-1394/36/3/7; Ranka JK, 2000, OPT LETT, V25, P25, DOI 10.1364/OL.25.000025; Ranka JK, 1997, OPT LETT, V22, P1344, DOI 10.1364/OL.22.001344; RELCHERT J, 1999, OPT COMMUN, V172, P59; Schnatz H, 1996, PHYS REV LETT, V76, P18, DOI 10.1103/PhysRevLett.76.18; Siegman A. E., 1986, LASER; Spielmann C, 1997, SCIENCE, V278, P661, DOI 10.1126/science.278.5338.661; Steinmeyer G, 1999, SCIENCE, V286, P1507, DOI 10.1126/science.286.5444.1507; Sutter DH, 1999, OPT LETT, V24, P631, DOI 10.1364/OL.24.000631; Telle HR, 1999, APPL PHYS B-LASERS O, V69, P327, DOI 10.1007/s003400050813; TELLE HR, 1990, OPT LETT, V15, P532, DOI 10.1364/OL.15.000532; Udem T, 1999, OPT LETT, V24, P881, DOI 10.1364/OL.24.000881; Udem T, 1999, PHYS REV LETT, V82, P3568, DOI 10.1103/PhysRevLett.82.3568; Xu L, 1996, OPT LETT, V21, P2008, DOI 10.1364/OL.21.002008	27	2044	2132	29	537	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					635	639		10.1126/science.288.5466.635	http://dx.doi.org/10.1126/science.288.5466.635			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784441	Green Published			2022-12-28	WOS:000086727100035
J	Ihde, D				Ihde, D			Putting technology in its place	NATURE			English	Editorial Material									SUNY Stony Brook, Dept Philosophy, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ihde, D (corresponding author), SUNY Stony Brook, Dept Philosophy, Stony Brook, NY 11794 USA.								0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					935	935		10.1038/35010184	http://dx.doi.org/10.1038/35010184			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801104	Bronze			2022-12-28	WOS:000086762000032
J	Petrillo, TM; Beck-Sague, CM; Songer, JG; Abramowsky, C; Fortenberry, JD; Meacham, L; Dean, AG; Lee, H; Bueschel, DM; Nesheim, SR				Petrillo, TM; Beck-Sague, CM; Songer, JG; Abramowsky, C; Fortenberry, JD; Meacham, L; Dean, AG; Lee, H; Bueschel, DM; Nesheim, SR			Enteritis necroticans (Pigbel) in a diabetic child.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; CLOSTRIDIUM-PERFRINGENS; CHITTERLINGS; MELLITUS; ANIMALS	Background: Enteritis necroticans (pigbel), an often fatal illness characterized by hemorrhagic, inflammatory, or ischemic necrosis of the jejunum, occurs in developing countries but is rare in developed countries, where its occurrence is confined to adults with chronic illnesses. The causative organism of enteritis necroticans is Clostridium perfringens type C, an anaerobic gram-positive bacillus. Methods: In December 1998, enteritis necroticans developed in a 12-year-old boy with poorly controlled diabetes mellitus after he consumed pig intestines (chitterlings). He presented with hematemesis, abdominal distention, and severe diabetic ketoacidosis with hypotension. At laparotomy, extensive jejunal necrosis required bowel resection, jejunostomy, and ileostomy. Samples were obtained for histopathological examination. Polymerase-chain-reaction (PCR) assay was performed on paraffin-embedded bowel tissue with primers specific for the cpa and cpb genes, which code for the alpha and beta toxins produced by C. perfringens. Results: Histologic examination of resected bowel tissue showed extensive mucosal necrosis, the formation of pseudomembrane, pneumatosis, and areas of epithelial regeneration that alternated with necrotic segments - findings consistent with a diagnosis of enteritis necroticans. Gram's staining showed large gram-positive bacilli whose features were consistent with those of clostridium species. Through PCR amplification, we detected products of the cpa and cpb genes, which indicated the presence of C. perfringens type C. Assay of ileal tissue obtained during surgery to restore the continuity of the patient's bowel was negative for C. perfringens. Conclusions: The preparation or consumption of chitterlings by diabetic patients and other chronically ill persons can result in potentially life-threatening infectious complications. (N Engl J Med 2000;342:1250-3.) (C) 2000, Massachusetts Medical Society.	Childrens Healthcare Atlanta Egleston, Div Crit Care Med, Atlanta, GA 30322 USA; Childrens Healthcare Atlanta Egleston, Div Endocrinol, Atlanta, GA 30322 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA USA; Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ USA; Emory Univ, Div Pediat Pathol, Atlanta, GA 30322 USA; Emory Univ, Div Surg, Atlanta, GA 30322 USA; Emory Univ, Div Infect Dis Epidemiol & Immunol, Atlanta, GA 30322 USA	Children's Healthcare of Atlanta (CHOA); Children's Healthcare of Atlanta (CHOA); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Arizona; Emory University; Emory University; Emory University	Petrillo, TM (corresponding author), Childrens Healthcare Atlanta Egleston, Div Crit Care Med, 1405 Clifton Rd NE,3rd Fl Annex, Atlanta, GA 30322 USA.	toni_petrillo@oz.ped.emory.edu		Beck-Sague, Consuelo/0000-0001-9082-0165				ALLEN SD, 1997, PATHOLOGY INFECT DIS, V1, P717; ARBONA C, 1990, MED CLIN-BARCELONA, V95, P572; Bien JP, 1998, J PEDIATR-US, V133, P712, DOI 10.1016/S0022-3476(98)70120-9; CAMILLERI M, 1984, EUR J CLIN INVEST, V14, P420, DOI 10.1111/j.1365-2362.1984.tb01206.x; CHANCUA S, 1992, J PEDIATR SURG, V27, P1236, DOI 10.1016/0022-3468(92)90798-C; Cooke R A, 1979, Perspect Pediatr Pathol, V5, P137; Cornell J, 1998, Commun Dis Public Health, V1, P28; Cucchiara S, 1998, DIABETES CARE, V21, P438, DOI 10.2337/diacare.21.3.438; Farrant JM, 1996, GUT, V39, P336, DOI 10.1136/gut.39.2.336; FICK KA, 1949, LANCET, V256, P519; JOHNSON S, 1987, LANCET, V2, P496; Johnson S, 1997, CLIN INFECT DIS, V25, pS173, DOI 10.1086/516220; LAWRENCE GW, 1990, LANCET, V336, P1165, DOI 10.1016/0140-6736(90)92776-E; LEE LA, 1990, NEW ENGL J MED, V322, P984, DOI 10.1056/NEJM199004053221407; Meer RR, 1997, AM J VET RES, V58, P702; MURRELL TGC, 1979, LANCET, V1, P279; MURRELL TGC, 1966, LANCET, V1, P217; Nicol KK, 1997, SOUTHERN MED J, V90, P83, DOI 10.1097/00007611-199701000-00021; SEVERIN WPJ, 1984, J CLIN PATHOL, V37, P942, DOI 10.1136/jcp.37.8.942; SHANN F, 1979, LANCET, V1, P1083; Songer JG, 1996, CLIN MICROBIOL REV, V9, P216, DOI 10.1128/CMR.9.2.216; Songer JG, 1996, ANAEROBE, V2, P197, DOI 10.1006/anae.1996.0027; SPENGLER U, 1989, PANCREAS, V4, P65, DOI 10.1097/00006676-198902000-00010; STERNE M, 1964, J PATHOL BACTERIOL, V88, P279, DOI 10.1002/path.1700880135; WILLIAMS MR, 1953, LANCET, V265, P1013; WRIGHT DH, 1967, J PEDIATR-US, V71, P264, DOI 10.1016/S0022-3476(67)80086-6; ZEISSLER J, 1949, BMJ-BRIT MED J, V1, P267, DOI 10.1136/bmj.1.4597.267; 1990, MMWR MORB MORTAL WKL, V39, P819	28	57	57	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1250	1253		10.1056/NEJM200004273421704	http://dx.doi.org/10.1056/NEJM200004273421704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10781621				2022-12-28	WOS:000086660600004
J	Schon, G				Schon, G			Quantum engineering - Superconducting nanowires	NATURE			English	Editorial Material							LOCALIZATION; TRANSPORT; ARRAYS		Univ Karlsruhe, Inst Theoret Festkorperphys, D-76128 Karlsruhe, Germany; Forschungszentrum Karlsruhe, Inst Nanotechnol, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology	Schon, G (corresponding author), Univ Karlsruhe, Inst Theoret Festkorperphys, Kaiserstr 12, D-76128 Karlsruhe, Germany.		Schön, Gerd/A-3582-2008					Bezryadin A, 2000, NATURE, V404, P971, DOI 10.1038/35010060; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; FAZIO R, 1991, PHYS REV B, V43, P5307, DOI 10.1103/PhysRevB.43.5307; FISHER MPA, 1989, PHYS REV B, V40, P546, DOI 10.1063/1.38820; GIORDANO N, 1988, PHYS REV LETT, V61, P2137, DOI 10.1103/PhysRevLett.61.2137; Kouwenhoven LP, 1997, NATO ADV SCI I E-APP, V345, P105; Makhlin Y, 1999, NATURE, V398, P305, DOI 10.1038/18613; MOOIJ JE, 1985, PHYS REV LETT, V55, P114, DOI 10.1103/PhysRevLett.55.114; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Penttila JS, 1999, PHYS REV LETT, V82, P1004, DOI 10.1103/PhysRevLett.82.1004; Ralph DC, 1997, PHYS REV LETT, V78, P4087, DOI 10.1103/PhysRevLett.78.4087; SCHMID A, 1983, PHYS REV LETT, V51, P1506, DOI 10.1103/PhysRevLett.51.1506; Tinkham M., 1996, INTRO SUPERCONDUCTIV, V2nd ed.; VANDERZANT HSJ, 1992, EUROPHYS LETT, V19, P541, DOI 10.1209/0295-5075/19/6/017; Zaikin AD, 1997, PHYS REV LETT, V78, P1552, DOI 10.1103/PhysRevLett.78.1552	15	16	16	1	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					948	949		10.1038/35010260	http://dx.doi.org/10.1038/35010260			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801111				2022-12-28	WOS:000086762000039
J	Schwab, K; Henriksen, EA; Worlock, JM; Roukes, ML				Schwab, K; Henriksen, EA; Worlock, JM; Roukes, ML			Measurement of the quantum of thermal conductance	NATURE			English	Article							MESOSCOPIC SYSTEMS; POINT CONTACTS; WIRES; TRANSPORT; TEMPERATURES; SCATTERING; LIMITS; FILMS; MODES	The physics of mesoscopic electronic systems has been explored for more than 15 years. Mesoscopic phenomena in transport processes occur when the wavelength or the coherence length of the carriers becomes comparable to, or larger than, the sample dimensions. One striking result in this domain is the quantization of electrical conduction, observed in a quasi-one-dimensional constriction formed between reservoirs of two-dimensional electron gas(1,2). The conductance of this system is determined by the number of participating quantum states or 'channels' within the constriction; in the ideal case, each spin-degenerate channel contributes a quantized unit of 2e(2)/h to the electrical conductance. It has been speculated that similar behaviour should be observable for thermal transport(3,4) in mesoscopic phonon systems. But experiments attempted in this regime have so far yielded inconclusive results(5-9). Here we report the observation of a quantized limiting value for the thermal conductance, G(th), in suspended insulating nanostructures at very low temperatures. The behaviour we observe is consistent with predictions(10,11) for phonon transport in a ballistic, one-dimensional channel: at low temperatures, Gth approaches a maximum value of g(0) = pi(2)k(B)(2) T=3h, the universal quantum of thermal conductance.	CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Roukes, ML (corresponding author), CALTECH, Pasadena, CA 91125 USA.		Roukes, Michael L/E-9787-2010	Henriksen, Erik/0000-0002-4978-2440				Angelescu DE, 1998, SUPERLATTICE MICROST, V23, P673, DOI 10.1006/spmi.1997.0561; Blencowe MP, 1999, PHYS REV B, V59, P4992, DOI 10.1103/PhysRevB.59.4992; CAVES CM, 1994, REV MOD PHYS, V66, P481, DOI 10.1103/RevModPhys.66.481; Holmes W, 1998, APPL PHYS LETT, V72, P2250, DOI 10.1063/1.121269; Hone J, 1999, PHYS REV B, V59, pR2514, DOI 10.1103/PhysRevB.59.R2514; KANDER I, 1990, PHYS REV B, V41, P12941, DOI 10.1103/PhysRevB.41.12941; KETCHEN MB, 1989, IEEE T MAGN, V25, P1212, DOI 10.1109/20.92513; KLITSNER T, 1988, PHYS REV B, V38, P7576, DOI 10.1103/PhysRevB.38.7576; Krive IV, 1999, PHYS REV B, V60, P1429, DOI 10.1103/PhysRevB.60.1429; KWONG YK, 1992, J LOW TEMP PHYS, V88, P261, DOI 10.1007/BF00162961; LEE KL, 1992, PHYS REV LETT, V69, P1427; Leivo MM, 1998, APPL PHYS LETT, V72, P1305, DOI 10.1063/1.120979; MAYNARD R, 1985, PHYS REV B, V32, P5440, DOI 10.1103/PhysRevB.32.5440; Mohanty P, 1997, PHYS REV LETT, V78, P3366, DOI 10.1103/PhysRevLett.78.3366; Nishiguchi N, 1997, J PHYS-CONDENS MAT, V9, P5751, DOI 10.1088/0953-8984/9/27/007; PENDRY JB, 1983, J PHYS A-MATH GEN, V16, P2161, DOI 10.1088/0305-4470/16/10/012; POTTS A, 1991, SUPERLATTICE MICROST, V9, P315, DOI 10.1016/0749-6036(91)90250-U; Rego LGC, 1999, PHYS REV B, V59, P13080, DOI 10.1103/PhysRevB.59.13080; Rego LGC, 1998, PHYS REV LETT, V81, P232, DOI 10.1103/PhysRevLett.81.232; ROUKES ML, 1985, PHYS REV LETT, V55, P422, DOI 10.1103/PhysRevLett.55.422; Roukes ML, 1999, PHYSICA B, V263, P1, DOI 10.1016/S0921-4526(98)01482-3; Roukes ML, 1984, PHYSICA B C, V126, P1177; ROUKES ML, 1985, THESIS CORNELL U; SCHWAB K, UNPUB APPL PHYS LETT; SEYLER J, 1992, PHYS REV LETT, V69, P1427, DOI 10.1103/PhysRevLett.69.1427; Tighe TS, 1997, APPL PHYS LETT, V70, P2687, DOI 10.1063/1.118994; VANWEES BJ, 1988, PHYS REV LETT, V60, P848, DOI 10.1103/PhysRevLett.60.848; YACOBY A, 1990, EUROPHYS LETT, V11, P663, DOI 10.1209/0295-5075/11/7/014; [No title captured]	30	793	803	3	194	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					974	977		10.1038/35010065	http://dx.doi.org/10.1038/35010065			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801121				2022-12-28	WOS:000086762000049
J	Rector, TS				Rector, TS			Exhaustion of drug benefits and disenrollment of medicare beneficiaries from managed care organizations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RISK	Context Many Medicare beneficiaries enroll in managed care health plans to obtain outpatient drug benefits. Increasing pharmaceutical utilization and costs and decreasing drug benefits increase the likelihood that medication use by such enrollees will exceed drug benefits, which may lead to health plan disenrollment. Objective To test the hypothesis that exhaustion of managed care drug benefits by Medicare beneficiaries is associated with disenrollment from the health plan. Design Retrospective cohort study followed up for 1 year (1998) using an enrollment/claims database. Setting Four geographically diverse network-model health plans that had annual drug benefits of $300, $500, $600, or $1000. Participants A total of 61 412 elderly Medicare beneficiaries. Main Outcome Measure Voluntary disenrollment from health plans by members who did or did not exhaust their drug benefits. Results The likelihood of exhausting 1998 drug benefits ranged from 17% to 25% across health plans (P<.001). The relative hazards of disenrollment from the 4 plans when drug benefits had been exhausted were 2.5 (95% confidence interval [CI], 2.3-2.8), 1.9 (95% CI, 1.7-2.1), 2.7 (95% CI, 2.0-3.6), and 2.1 (95% CI, 1.9-2.4). Statistical adjustments for age, sex, prior enrollment, hospital admissions, physician visits, and county of residence did not alter these estimates. Conclusions Exhaustion of drug benefits was associated with a significant increase in the likelihood of disenrollment of Medicare beneficiaries, this finding arouses concern that Medicare beneficiaries must change plans to have financial access to medications, which can lead to discontinuity in care and diversion of resources from care to administrative matters. Policymakers should strive to avoid fragmented systems of providing drug benefits.	Unitedhlth Grp, Ctr Hlth Care Policy & Evaluat, Minneapolis, MN 55440 USA		Rector, TS (corresponding author), Unitedhlth Grp, Ctr Hlth Care Policy & Evaluat, POB 1459, Minneapolis, MN 55440 USA.							ALLISON PD, 1995, SURVIVAL ANAL USING, P111; Davis M, 1999, HEALTH AFFAIR, V18, P231, DOI 10.1377/hlthaff.18.1.231; Greenwald LM, 1998, INQUIRY-J HEALTH CAR, V35, P193; HARRINGTON C, 1993, INQUIRY-J HEALTH CAR, V30, P429; JERNIGAN CL, 1999, J MANAGED CARE PHARM, V5, P44; Mueller C, 1997, AM J PUBLIC HEALTH, V87, P1626, DOI 10.2105/AJPH.87.10.1626; Newcomer R, 1996, INQUIRY-J HEALTH CAR, V33, P144; PORELL FW, 1992, FACTORS ASS DISENROL; Riley GF, 1997, HEALTH AFFAIR, V16, P117, DOI 10.1377/hlthaff.16.5.117; Schlesinger M, 1999, HEALTH SERV RES, V34, P547; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; Wilson J, 1998, CLIN THER, V20, P1263, DOI 10.1016/S0149-2918(98)80121-5	12	34	34	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	2000	283	16					2163	2167		10.1001/jama.283.16.2163	http://dx.doi.org/10.1001/jama.283.16.2163			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305MA	10791512				2022-12-28	WOS:000086542800036
J	Zuckerman, AJ				Zuckerman, AJ			Effect of hepatitis B virus mutants on efficacy of vaccination	LANCET			English	Editorial Material							SURFACE-ANTIGEN VARIANTS; MOLECULAR EPIDEMIOLOGY; MUTATIONS; CHILDREN; GENOMES		UCL Royal Free & Univ Coll Med Sch, WHO, Collaborating Ctr Reference & Res Viral Dis, London NW3 2PF, England	University of London; University College London; UCL Medical School; World Health Organization	Zuckerman, AJ (corresponding author), UCL Royal Free & Univ Coll Med Sch, WHO, Collaborating Ctr Reference & Res Viral Dis, London NW3 2PF, England.							CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; Carman WF, 1997, HEPATOLOGY, V26, P1658, DOI 10.1002/hep.510260640; CARMAN WF, 1998, VIRAL HEPATITIS, P141; Coleman PF, 1999, J MED VIROL, V59, P19, DOI 10.1002/(SICI)1096-9071(199909)59:1<19::AID-JMV4>3.0.CO;2-B; Cooreman MP, 1999, HEPATOLOGY, V30, P1287, DOI 10.1002/hep.510300508; Hsu HY, 1999, HEPATOLOGY, V30, P1312, DOI 10.1002/hep.510300511; NAINAN OV, 1997, VIRAL HEPATITIS LIVE, P132; Ogata N, 1999, HEPATOLOGY, V30, P779, DOI 10.1002/hep.510300309; OON CJ, 1995, VACCINE, V13, P699, DOI 10.1016/0264-410X(94)00080-7; Oon CJ, 1996, LANCET, V348, P1524, DOI 10.1016/S0140-6736(05)65950-8; Preikschat P, 1999, J GEN VIROL, V80, P2685, DOI 10.1099/0022-1317-80-10-2685; Seddigh-Tonekaboni S, 2000, J MED VIROL, V60, P113, DOI 10.1002/(SICI)1096-9071(200002)60:2<113::AID-JMV2>3.0.CO;2-0; Sommer G, 1997, VIROLOGY, V239, P402, DOI 10.1006/viro.1997.8898; WEINBERGER KM, 1997, VIRAL HEPATITIS LIVE, P138; Wilson JN, 1998, J VIRAL HEPATITIS, V5, P25, DOI 10.1046/j.1365-2893.1998.0050s2025.x; Zuckerman AJ, 1999, J MED VIROL, V58, P193, DOI 10.1002/(SICI)1096-9071(199907)58:3&lt;193::AID-JMV1&gt;3.0.CO;2-X	16	118	124	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1382	1384		10.1016/S0140-6736(00)02132-2	http://dx.doi.org/10.1016/S0140-6736(00)02132-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791517				2022-12-28	WOS:000086829800004
J	Niemela, JJ; Skrbek, L; Sreenivasan, KR; Donnelly, RJ				Niemela, JJ; Skrbek, L; Sreenivasan, KR; Donnelly, RJ			Turbulent convection at very high Rayleigh numbers	NATURE			English	Article							BENARD CONVECTION; THERMAL TURBULENCE; LOW-TEMPERATURE; GASEOUS HELIUM	Turbulent convection occurs when the Rayleigh number (Ra)-which quantifies the relative magnitude of thermal driving to dissipative forces in the fluid motion-becomes sufficiently high. Although many theoretical and experimental studies of turbulent convection exist, the basic properties of heat transport remain unclear. One important question concerns the existence of an asymptotic regime that is supposed to occur at very high Ra. Theory predicts that in such a state the Nusselt number (Nu), representing the global heat transport, should scale as Nu proportional to Ra-beta with beta = 1/2. Here we investigate thermal transport over eleven orders of magnitude of the Rayleigh number (10(6) less than or equal to Ra less than or equal to 10(7)), using cryogenic helium gas as the working fluid. Our data, over the entire range of Ra, can be described to the lowest order by a single power-law with scaling exponent beta close to 0.31. In particular, we rnd no evidence for a transition to the Ra-1/2 regime. We also study the variation of internal temperature fluctuations with Ra, and probe velocity statistics indirectly.	Univ Oregon, Dept Phys, Cryogen Helium Turbulence Lab, Eugene, OR 97403 USA; Yale Univ, Mason Lab, New Haven, CT 06520 USA	University of Oregon; Yale University	Donnelly, RJ (corresponding author), Univ Oregon, Dept Phys, Cryogen Helium Turbulence Lab, Eugene, OR 97403 USA.	russ@vortex.uoregon.edu	Skrbek, Ladislav/P-5146-2017	Skrbek, Ladislav/0000-0002-6016-1194				Ashkenazi S, 1999, PHYS REV LETT, V83, P3641, DOI 10.1103/PhysRevLett.83.3641; Ashkenazi S, 1999, PHYS REV LETT, V83, P4760, DOI 10.1103/PhysRevLett.83.4760; BOLGIANO R, 1959, J GEOPHYS RES, V64, P2226, DOI 10.1029/JZ064i012p02226; BUSSE FH, 1978, REP PROG PHYS, V41, P1929, DOI 10.1088/0034-4885/41/12/003; CASTAING B, 1989, J FLUID MECH, V204, P1, DOI 10.1017/S0022112089001643; Chavanne X, 1997, PHYS REV LETT, V79, P3648, DOI 10.1103/PhysRevLett.79.3648; Chavanne X, 1996, J LOW TEMP PHYS, V104, P109, DOI 10.1007/BF00754092; Cioni S, 1997, J FLUID MECH, V335, P111, DOI 10.1017/S0022112096004491; Constantin P, 1999, J STAT PHYS, V94, P159, DOI 10.1023/A:1004511312885; Glazier JA, 1999, NATURE, V398, P307, DOI 10.1038/18626; GROSSMANN S, IN PRESS J FLUID MEC; HOWARD LN, 1963, J FLUID MECH, V17, P405, DOI 10.1017/S0022112063001427; KRAICHNAN RH, 1962, PHYS FLUIDS, V5, P1374, DOI 10.1063/1.1706533; KRISHNAMURTI R, 1981, P NATL ACAD SCI USA, V78, P1981, DOI 10.1073/pnas.78.4.1981; MALKUS WVR, 1954, PROC R SOC LON SER-A, V225, P196, DOI 10.1098/rspa.1954.0197; McCarty R.D., 1972, THERMOPHYSICAL PROPE, V631; Priestley C. H. B, 1959, ADV GEOPHYS; SHE ZS, 1989, PHYS FLUIDS A-FLUID, V1, P911, DOI 10.1063/1.857401; Shen Y, 1996, PHYS REV LETT, V76, P908, DOI 10.1103/PhysRevLett.76.908; SHRAIMAN BI, 1990, PHYS REV A, V42, P3650, DOI 10.1103/PhysRevA.42.3650; SIGGIA ED, 1994, ANNU REV FLUID MECH, V26, P137, DOI 10.1146/annurev.fl.26.010194.001033; THRELFALL DC, 1975, J FLUID MECH, V67, P17, DOI 10.1017/S0022112075000158; TOOMRE J, 1977, J FLUID MECH, V79, P1, DOI 10.1017/S0022112077000019; Verzicco R, 1998, FLUID MEC A, V46, P399; WU XZ, 1992, PHYS REV A, V45, P842, DOI 10.1103/PhysRevA.45.842; WU XZ, 1991, THESIS U CHICAGO; [No title captured]	27	532	537	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	2000	404	6780					837	840		10.1038/35009036	http://dx.doi.org/10.1038/35009036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786783				2022-12-28	WOS:000086625000035
J	Le Page, F; Kwoh, EE; Avrutskaya, A; Gentil, A; Leadon, SA; Sarasin, A; Cooper, PK				Le Page, F; Kwoh, EE; Avrutskaya, A; Gentil, A; Leadon, SA; Sarasin, A; Cooper, PK			RETRACTED: Transcription-coupled repair of 8-oxoGuanine: Requirement for XPG, TFIIH, and CSB and implications for Cockayne syndrome (Retracted Article. See vol 123, pg 711, 2005)	CELL			English	Article; Retracted Publication							NUCLEOTIDE EXCISION-REPAIR; RNA-POLYMERASE-II; OXIDATIVE DNA-DAMAGE; GROUP-B CELLS; XERODERMA-PIGMENTOSUM; ESCHERICHIA-COLI; MAMMALIAN-CELLS; IN-VITRO; SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG	Analysis of transcription-coupled repair (TCR) of oxidative lesions here reveals strand-specific removal of 8-oxo-guanine (8-oxoG) and thymine glycol both in normal human cells and xeroderma pigmentosum (XP) cells defective in nucleotide excision repair. In contrast, Cockayne syndrome (CS) cells including CS-B, XP-B/CS, XP-D/CS, and XP-G/CS not only lack TCR but cannot remove 8-oxoG in a transcribed sequence, despite its proficient repair when not transcribed. The XP-G/CS defect uniquely slows lesion removal in nontranscribed sequences. Defective TCR leads to a mutation frequency at 8-oxoG of 30%-40% compared to the normal 1%-4%. Surprisingly, unrepaired 8-oxoG blocks transcription by RNA polymerase II. These data imply that TCR is required for polymerase release to allow repair and that CS results from defects in TCR of oxidative lesions.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; CNRS, UPR42, Mol Genet Lab, F-94801 Villejuif, France; Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Centre National de la Recherche Scientifique (CNRS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sarasin, A (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.	sarasin@infobiogen.fr; pkcooper@lbl.gov			NATIONAL CANCER INSTITUTE [R01CA040453, R01CA063503] Funding Source: NIH RePORTER; NCI NIH HHS [CA63503, CA40453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; BODEPUDI V, 1992, CHEM RES TOXICOL, V5, P608, DOI 10.1021/tx00029a004; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; BROUGHTON BC, 1995, AM J HUM GENET, V56, P167; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DAYAGROSJEAN L, 1987, MUTAT RES, V183, P185, DOI 10.1016/0167-8817(87)90061-7; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; Dianov GL, 1997, NUCLEIC ACIDS RES, V25, P3636, DOI 10.1093/nar/25.18.3636; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GILINGER G, 1993, J VIROL, V67, P6682, DOI 10.1128/JVI.67.11.6682-6688.1993; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Habraken Y, 1996, P NATL ACAD SCI USA, V93, P10718, DOI 10.1073/pnas.93.20.10718; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Le Page F, 1998, NUCLEIC ACIDS RES, V26, P1276, DOI 10.1093/nar/26.5.1276; Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Leadon SA, 1997, CANCER RES, V57, P3784; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEADON SA, 1988, DNA REPAIR LAB MANUA, P311; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SHIBUTANI S, 1994, CANCER LETT, V83, P315, DOI 10.1016/0304-3835(94)90335-2; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Tantin D, 1998, J BIOL CHEM, V273, P27794, DOI 10.1074/jbc.273.43.27794; Thompson LH, 1998, CONT CANC RES, P335; Tijsterman M, 1997, P NATL ACAD SCI USA, V94, P8027, DOI 10.1073/pnas.94.15.8027; Tijsterman M, 1999, J BIOL CHEM, V274, P1199, DOI 10.1074/jbc.274.3.1199; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; van Hoffen A, 1999, NUCLEIC ACIDS RES, V27, P2898, DOI 10.1093/nar/27.14.2898; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VERMEULEN W, 1993, AM J HUM GENET, V53, P185; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Wagner J, 1997, J MOL BIOL, V265, P302, DOI 10.1006/jmbi.1996.0740; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; You ZY, 1998, MOL CELL BIOL, V18, P2668, DOI 10.1128/MCB.18.5.2668	68	274	280	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 14	2000	101	2					159	171		10.1016/S0092-8674(00)80827-2	http://dx.doi.org/10.1016/S0092-8674(00)80827-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	305DP	10786832	Bronze			2022-12-28	WOS:000086524400003
J	Ohno, M; Segref, A; Bachi, A; Wilm, M; Mattaj, IW				Ohno, M; Segref, A; Bachi, A; Wilm, M; Mattaj, IW			PHAX, a mediator of U snRNA nuclear export whose activity is regulated by phosphorylation	CELL			English	Article							CAP-BINDING PROTEIN; MESSENGER-RNA; IMPORTIN-BETA; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; RECEPTOR; COMPLEX; IDENTIFICATION; REV; RAN	In metazoa, assembly of spliceosomal U snRNPs requires nuclear export of U snRNA precursors. Export depends upon the RNA cap structure, nuclear cap-binding complex (CBC), the export receptor CRM1/Xpo1, and RanGTP. These components are however insufficient to support U snRNA export. We identify PHAX (phosphorylated adaptor for RNA export) as the additional factor required for U snRNA export complex assembly in vitro. In vivo, PHAX is required for U snRNA export but not for CRM1-mediated export in general. PHAX is phosphorylated in the nucleus and then exported with RNA to the cytoplasm, where it is dephosphorylated. PHAX phosphorylation is essential for export complex assembly while its dephosphorylation causes export complex disassembly. The compartmentalized PHAX phosphorylation cycle can contribute to the directionality of export.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		bachi, angela/B-3527-2015; Segref, Alexandra/C-8325-2011	bachi, angela/0000-0003-4842-6556; Wilm, Matthias/0000-0002-5461-6834; Segref, Alexandra/0000-0001-8095-4469; Mattaj, Iain/0000-0002-5537-8284				Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; Cole CN, 1998, CURR BIOL, V8, pR368, DOI 10.1016/S0960-9822(98)70239-8; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Izaurralde E, 1995, COLD SPRING HARB SYM, V60, P669, DOI 10.1101/SQB.1995.060.01.072; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; IZAURRALDE E, 1995, NATURE, V376, P709, DOI 10.1038/376709a0; Izaurralde E, 1998, RNA, V4, P351; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; KATAOKA N, 1995, NUCLEIC ACIDS RES, V23, P3638, DOI 10.1093/nar/23.18.3638; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; Neville M, 1999, EMBO J, V18, P3746, DOI 10.1093/emboj/18.13.3746; NINKINA NN, 1994, MOL BRAIN RES, V22, P39, DOI 10.1016/0169-328X(94)90030-2; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SONTHEIMER EJ, 1994, MOL BIOL REP, V20, P35, DOI 10.1007/BF00999853; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Truant R, 1999, MOL CELL BIOL, V19, P1210; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	51	261	272	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 14	2000	101	2					187	198		10.1016/S0092-8674(00)80829-6	http://dx.doi.org/10.1016/S0092-8674(00)80829-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	305DP	10786834	Bronze			2022-12-28	WOS:000086524400005
J	Zoorob, ME; Charlton, MDB; Parker, GJ; Baumberg, JJ; Netti, MC				Zoorob, ME; Charlton, MDB; Parker, GJ; Baumberg, JJ; Netti, MC			Complete photonic bandgaps in 12-fold symmetric quasicrystals	NATURE			English	Article							NEAR-INFRARED WAVELENGTHS; QUASI-CRYSTALS; GAP STRUCTURES; LIGHT	Photonic crystals are attracting current interest for a variety of reasons, such as their ability to inhibit the spontaneous emission of light(1,2). This and related properties arise from the formation of photonic bandgaps, whereby multiple scattering of photons by lattices of periodically varying refractive indices acts to prevent the propagation of electromagnetic waves having certain wavelengths. One route to forming photonic crystals is to etch two-dimensional periodic lattices of vertical air holes into dielectric slab waveguides(3-7). Such structures can show complete photonic bandgaps(8-10), but only for large-diameter air holes in materials of high refractive index (such as gallium arsenide, n = 3.69), which unfortunately leads to significantly reduced optical transmission when combined with optical fibres of low refractive index. It has been suggested that quasicrystalline (rather than periodic) lattices can also possess photonic bandgaps(11-14). Here we demonstrate this concept experimentally and show that it enables complete photonic bandgaps-non-directional and for any polarization-to be realized with small air holes in silicon nitride (n = 2.02), and even glass (n = 1.45). These properties make photonic quasicrystals promising for application in a range of optical devices(14-18).	Univ Southampton, Dept Elect & Comp Sci, Southampton SO17 1BJ, Hants, England; Univ Southampton, Dept Phys & Astron, Southampton SO17 1BJ, Hants, England	University of Southampton; University of Southampton	Parker, GJ (corresponding author), Univ Southampton, Dept Elect & Comp Sci, Southampton SO17 1BJ, Hants, England.	gjp@ecs.soton.ac.uk	Baumberg, Jeremy J/C-1409-2009	Baumberg, Jeremy J/0000-0002-9606-9488; Charlton, Martin/0000-0003-1850-8120				Anderson CM, 1997, PHYS REV B, V56, P7313, DOI 10.1103/PhysRevB.56.7313; Atkin DM, 1996, J MOD OPTIC, V43, P1035, DOI 10.1080/09500349608233264; Barra A, 1998, APPL PHYS LETT, V72, P627, DOI 10.1063/1.120827; Cassagne D, 1996, PHYS REV B, V53, P7134, DOI 10.1103/PhysRevB.53.7134; Chan YS, 1998, PHYS REV LETT, V80, P956, DOI 10.1103/PhysRevLett.80.956; Charlton MDB, 1999, J MATER SCI-MATER EL, V10, P429, DOI 10.1023/A:1008970112219; Charlton MDB, 1997, MAT SCI ENG B-SOLID, V49, P155, DOI 10.1016/S0921-5107(97)00102-5; Cheng SSM, 1999, PHYS REV B, V59, P4091, DOI 10.1103/PhysRevB.59.4091; Feng XP, 1996, IEEE J QUANTUM ELECT, V32, P535, DOI 10.1109/3.485407; Foresi JS, 1997, NATURE, V390, P143, DOI 10.1038/36514; Gadot F, 1997, APPL PHYS LETT, V71, P1780, DOI 10.1063/1.119396; HO KM, 1994, SOLID STATE COMMUN, V89, P413, DOI 10.1016/0038-1098(94)90202-X; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; Kosaka H, 1998, PHYS REV B, V58, P10096, DOI 10.1103/PhysRevB.58.R10096; Krauss TF, 1999, PROG QUANT ELECTRON, V23, P51, DOI 10.1016/S0079-6727(99)00004-X; Krauss TF, 1996, NATURE, V383, P699, DOI 10.1038/383699a0; Labilloy D, 1997, PHYS REV LETT, V79, P4147, DOI 10.1103/PhysRevLett.79.4147; MCGURN AR, 1993, J OPT SOC AM B, V10, P539, DOI 10.1364/JOSAB.10.000539; NETTI MC, IN PRESS APPL PHYS L; Ohtera Y, 1999, ELECTRON LETT, V35, P1271, DOI 10.1049/el:19990875; PLIHAL M, 1991, PHYS REV B, V44, P8565, DOI 10.1103/PhysRevB.44.8565; Temelkuran B, 1999, APPL PHYS LETT, V74, P486, DOI 10.1063/1.123163; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YEE KS, 1966, IEEE T ANTENN PROPAG, VAP14, P302; ZOOROB ME, 1999, P I PHYS PREP 99, P161	27	460	483	4	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	2000	404	6779					740	743		10.1038/35008023	http://dx.doi.org/10.1038/35008023			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783882	Green Accepted			2022-12-28	WOS:000086523600045
J	Cotton, K				Cotton, K			Surrogacy should pay	BRITISH MEDICAL JOURNAL			English	Article									Childlessness Overcome Through Surrogacy, Sutherland IV27 4EF, Scotland		Cotton, K (corresponding author), Childlessness Overcome Through Surrogacy, Loandhu Cottage, Sutherland IV27 4EF, Scotland.								0	2	2	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 1	2000	320	7239					928	929						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	301YA	10787254				2022-12-28	WOS:000086337100034
J	van der Zee, J; Gonzalez, DG; van Rhoon, GC; van Dijk, JDP; van Putten, WLJ; Hart, AAM				van der Zee, J; Gonzalez, DG; van Rhoon, GC; van Dijk, JDP; van Putten, WLJ; Hart, AAM		Dutch Deep Hyperthermia Grp	Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial	LANCET			English	Article							TRANSITIONAL-CELL-CARCINOMA; RADIATION-THERAPY; UTERINE CERVIX; RECTAL-CANCER; SIZE; ONCOLOGY; BLADDER; FAILURE	Background Local-control rates after radiotherapy for locally advanced tumours of the bladder, cervix, and rectum are disappointing. We investigated the effect of adding hyperthermia to standard radiotherapy. Methods The study was a prospective, randomised, multicentre trial. 358 patients were enrolled from 1990 to 1996, in cancer centres in the Netherlands, who had bladder cancer stages T2, T3, or T4, N0, M0, cervical cancer stages IIB, IIIB, or IV, or rectal cancer stage M0-1 were assessed. Patients were randomly assigned radiotherapy (median total dose 65 Gy) alone (n=176) or radiotherapy plus hyperthermia (n=182). Our primary endpoints were complete response and duration of local control. We did the analysis by intention to treat. Findings Complete-response rates were 39% after radiotherapy and 55% after radiotherapy plus hyperthermia (p<0.001). The duration of local control was significantly longer with radiotherapy plus hyperthermia than with radiotherapy alone (p=0.04). Treatment effect did not differ significantly by tumour site, but the addition of hyperthermia seemed to be most important for cervical cancer, for which the complete-response rate with radiotherapy plus hyperthermia was 83% compared with 57% after radiotherapy alone (p=0.003). 3-year overall survival was 27% in the radiotherapy group and 51% in the radiotherapy plus hyperthermia group. For bladder cancer, an initial difference in local control disappeared during follow-up. Interpretation Hyperthermia in addition to standard radiotherapy may be especially useful in locally advanced cervical tumours. Studies of larger numbers of patients are needed for other pelvic tumour sites before practical recommendations can be made.	Univ Amsterdam, Acad Med Ctr, Subdiv Hyperthermia, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Radiat Oncol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Stat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van der Zee, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Subdiv Hyperthermia, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	zee@hyph.azr.nl	van Rhoon, Gerard/AAK-8286-2020	van Rhoon, Gerard/0000-0002-7365-5783				Barillot I, 1997, INT J RADIAT ONCOL, V38, P969, DOI 10.1016/S0360-3016(97)00145-4; BENTZEN SM, 1992, BRIT J CANCER, V65, P102, DOI 10.1038/bjc.1992.19; BENTZEN SM, 1984, RADIOTHER ONCOL, V2, P255, DOI 10.1016/S0167-8140(84)80066-3; BRADY LW, 1990, CANCER, V65, P610, DOI 10.1002/1097-0142(19900201)65:3+<610::AID-CNCR2820651304>3.0.CO;2-G; BRIERLEY JD, 1995, INT J RADIAT ONCOL, V31, P255, DOI 10.1016/0360-3016(94)E0102-P; BRIZEL DM, 1995, INT J RADIAT ONCOL, V32, P1121, DOI 10.1016/0360-3016(95)00106-9; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Datta N, 1987, INDIAN MED GAZETTE, V121, P68; de Wit R, 1999, BRIT J CANCER, V80, P1387, DOI 10.1038/sj.bjc.6690533; DUNCAN W, 1986, RADIOTHER ONCOL, V7, P299, DOI 10.1016/S0167-8140(86)80059-7; *EARL BREAST CANC, 1988, N ENGL J MED, V319; GIBBS FA, 1996, THERMORADIOTHERAPY T, V2, P121; GONZALEZ DG, 1996, THERMORADIOTHERAPY T, V2, P105; Gospodarowicz M K, 1991, Clin Oncol (R Coll Radiol), V3, P155, DOI 10.1016/S0936-6555(05)81190-2; Hermanek P, 1987, UICC TNM CLASSIFICAT; Hockel M, 1996, CANCER RES, V56, P4509; International Commission on Radiation Units and Measurements, 1993, PRESCR REC REP PHOT; ITO H, 1994, RADIOTHER ONCOL, V31, P240, DOI 10.1016/0167-8140(94)90429-4; Kapp KS, 1998, INT J RADIAT ONCOL, V42, P531, DOI 10.1016/S0360-3016(98)00255-7; MAGEE BJ, 1991, BRIT J RADIOL, V64, P812, DOI 10.1259/0007-1285-64-765-812; MAMEGHAN H, 1995, INT J RADIAT ONCOL, V31, P247, DOI 10.1016/0360-3016(94)E0135-7; Perez CA, 1998, INT J RADIAT ONCOL, V41, P307, DOI 10.1016/S0360-3016(98)00067-4; Raaphorst GP, 1990, INTRO PRACTICAL ASPE, P10; Rau B, 1998, ANN SURG, V227, P380, DOI 10.1097/00000658-199803000-00010; SCHNEIDER CJ, 1994, INT J HYPERTHER, V10, P733, DOI 10.3109/02656739409022451; Sharma S., 1989, ENDOCURIETHERAPY HYP, V5, P151; Thomas GM, 1999, NEW ENGL J MED, V340, P1198, DOI 10.1056/NEJM199904153401509; TREURNIETDONKER AD, 1991, CANCER-AM CANCER SOC, V67, P2042, DOI 10.1002/1097-0142(19910415)67:8<2042::AID-CNCR2820670806>3.0.CO;2-4; Van der Zee J, 1998, INT J RADIAT ONCOL, V40, P1205, DOI 10.1016/S0360-3016(98)00008-X; Van der Zee J, 1998, PROGRESS IN RADIO-ONCOLOGY VI, P137; WATSON ER, 1978, BRIT J RADIOL, V51, P879, DOI 10.1259/0007-1285-51-611-879	31	713	726	0	50	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1119	1125		10.1016/S0140-6736(00)02059-6	http://dx.doi.org/10.1016/S0140-6736(00)02059-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791373				2022-12-28	WOS:000086380900008
J	Osterhaus, ADME; Rimmelzwaan, GF; Martina, BEE; Bestebroer, TM; Fouchier, RAM				Osterhaus, ADME; Rimmelzwaan, GF; Martina, BEE; Bestebroer, TM; Fouchier, RAM			Influenza B virus in seals	SCIENCE			English	Article							MASS MORTALITY; A VIRUS; ECOLOGY	Influenza B virus is a human pathogen whose origin and possible reservoir in nature are not known. An influenza B virus was isolated from a naturally infected harbor seal (Phoca vitulina) and was found to be infectious to seal kidney cells in vitro. Sequence analyses and serology indicated that influenza virus B/Seal/Netherlands/1/99 is closely related to strains that circulated in humans 4 to 5 years earlier. Retrospective analyses of sera collected from 971 seals showed a prevalence of antibodies to influenza B virus in 2% of the animals after 1995 and in none before 1995. This animal reservoir, harboring influenza B viruses that have circulated in the past, may pose a direct threat to humans.	Erasmus Univ, Dept Virol, Natl Influenza Ctr, NL-3015 GE Rotterdam, Netherlands; Seal Rehabil & Res Ctr, NL-9968 AG Pieterburen, Netherlands	Erasmus University Rotterdam	Osterhaus, ADME (corresponding author), Erasmus Univ, Dept Virol, Natl Influenza Ctr, Doctor Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.		Fouchier, Ron A/A-1911-2014	Fouchier, Ron A/0000-0001-8095-2869	NICHD NIH HHS [HD 15527] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CALLAN RJ, 1995, J GEN VIROL, V76, P199, DOI 10.1099/0022-1317-76-1-199; CHANG C P, 1976, International Journal of Zoonoses, V3, P61; FRANK AL, 1981, J INFECT DIS, V144, P443; GERACI JR, 1982, SCIENCE, V215, P1129; HALL CB, 1979, J INFECT DIS, V140, P610, DOI 10.1093/infdis/140.4.610; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; HINSHAW VS, 1984, J VIROL, V51, P863, DOI 10.1128/JVI.51.3.863-865.1984; MURPHY BR, 1990, VIROLOGY; Osterhaus A, 1997, NATURE, V388, P838, DOI 10.1038/42163; OSTERHAUS ADM, UNPUB; OSTERHAUS ADME, 1988, NATURE, V335, P20, DOI 10.1038/335020a0; OSTERHAUS ADME, 1989, NATURE, V337, P21, DOI 10.1038/337021a0; OSTERHAUS ADME, 1985, ARCH VIROL, V86, P239, DOI 10.1007/BF01309828; PRATO CM, 1974, NATURE, V249, P255, DOI 10.1038/249255a0; Rimmelzwaan GF, 1998, J VIROL METHODS, V74, P57, DOI 10.1016/S0166-0934(98)00071-8; Roitt I.M, 1977, ESSENTIAL IMMUNOLOGY, V3rd; Shope RE, 1943, J EXP MED, V77, P111, DOI 10.1084/jem.77.2.111; SMITH AW, 1979, J AM VET MED ASSOC, V175, P918; TAKATSY G, 1967, ACTA MICROBIOL HUNG, V14, P309; Voeten JTM, 1998, J CLIN MICROBIOL, V36, P3527, DOI 10.1128/JCM.36.12.3527-3531.1998; WALLACE GW, 1977, J INFECT DIS, V135, P490, DOI 10.1093/infdis/135.3.490; WEBSTER RG, 1981, VIROLOGY, V113, P712, DOI 10.1016/0042-6822(81)90200-2; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992	23	240	275	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 12	2000	288	5468					1051	1053		10.1126/science.288.5468.1051	http://dx.doi.org/10.1126/science.288.5468.1051			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807575				2022-12-28	WOS:000086988400037
J	Hettiaratehy, S; Clarke, J; Taubel, J				Hettiaratehy, S; Clarke, J; Taubel, J			Burns after photodynamic therapy	BRITISH MEDICAL JOURNAL			English	Article							HEAD; NECK		Chelsea & Westminster Hosp, Reg Burns Ctr, London SW10 9NH, England; Charterhouse Clin Res Unit, London W6 0TN, England	Imperial College London	Hettiaratehy, S (corresponding author), Chelsea & Westminster Hosp, Reg Burns Ctr, London SW10 9NH, England.		Taubel, Jorg/I-1286-2019	Taubel, Jorg/0000-0002-0010-207X				DILKES MG, 1995, J LARYNGOL OTOL, V109, P1072, DOI 10.1017/S0022215100132050; Farber NE, 1996, ANESTHESIOLOGY, V84, P983, DOI 10.1097/00000542-199604000-00028; Kubler AC, 1999, LASER SURG MED, V25, P60, DOI 10.1002/(SICI)1096-9101(1999)25:1<60::AID-LSM8>3.0.CO;2-X; McCaughan JS, 1997, J THORAC CARDIOV SUR, V114, P940, DOI 10.1016/S0022-5223(97)70008-4	4	22	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1245	1245		10.1136/bmj.320.7244.1245	http://dx.doi.org/10.1136/bmj.320.7244.1245			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797034	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086981400020
J	Abbott, A				Abbott, A			Space-station airlock to serve as temporary lab	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					7	7		10.1038/35011222	http://dx.doi.org/10.1038/35011222			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811188	Bronze			2022-12-28	WOS:000086901600012
J	Gladwin, MT; Rodgers, GP				Gladwin, MT; Rodgers, GP			Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia	LANCET			English	Editorial Material							INHALED NITRIC-OXIDE; RISK-FACTORS; DISEASE; HYDROXYUREA; ANEMIA; TRANSFUSION; HEMOGLOBIN; BLOOD		NIDDK, Dept Crit Care Med, NIH, Bethesda, MD 20892 USA; NIDDK, Crit Hematol Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rodgers, GP (corresponding author), NIDDK, Dept Crit Care Med, NIH, Bethesda, MD 20892 USA.							Atz AM, 1997, ANESTHESIOLOGY, V87, P988, DOI 10.1097/00000542-199710000-00037; BELLET PS, 1995, NEW ENGL J MED, V333, P699, DOI 10.1056/NEJM199509143331104; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; EMRE U, 1995, J PEDIATR-US, V127, P901, DOI 10.1016/S0022-3476(95)70025-0; Gladwin MT, 1999, J CLIN INVEST, V104, P937, DOI 10.1172/JCI7637; Glover RE, 1999, MOL PHARMACOL, V55, P1006, DOI 10.1124/mol.55.6.1006; Pacelli R, 1996, LANCET, V347, P900, DOI 10.1016/S0140-6736(96)91378-1; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Saleh AW, 1999, ACTA HAEMATOL-BASEL, V102, P31, DOI 10.1159/000040964; Setty BNY, 1996, BLOOD, V88, P2311, DOI 10.1182/blood.V88.6.2311.bloodjournal8862311; Stuart MJ, 1999, BLOOD, V94, P1555, DOI 10.1182/blood.V94.5.1555.417k36_1555_1560; Styles LA, 1996, BLOOD, V87, P2573, DOI 10.1182/blood.V87.6.2573.bloodjournal8762573; Styles LA, 1997, BLOOD, V89, P2554, DOI 10.1182/blood.V89.7.2554; Sullivan KJ, 1999, CRIT CARE MED, V27, P2563, DOI 10.1097/00003246-199911000-00039; VICHINSKY E, 1994, BLOOD, V83, P3107; Vichinsky EP, 1997, BLOOD, V89, P1787, DOI 10.1182/blood.V89.5.1787.1787_1787_1792; WAYNE AS, 1993, BLOOD, V81, P1109	17	40	44	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	2000	355	9214					1476	1478		10.1016/S0140-6736(00)02157-7	http://dx.doi.org/10.1016/S0140-6736(00)02157-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LR	10801164				2022-12-28	WOS:000086830100004
J	Fey, PD; Safranek, TJ; Rupp, ME; Dunne, EF; Ribot, E; Iwen, PC; Bradford, PA; Angulo, FJ; Hinrichs, SH				Fey, PD; Safranek, TJ; Rupp, ME; Dunne, EF; Ribot, E; Iwen, PC; Bradford, PA; Angulo, FJ; Hinrichs, SH			Ceftriaxone-resistant salmonella infection acquired by a child from cattle.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIELD GEL-ELECTROPHORESIS; BETA-LACTAMASE; ESCHERICHIA-COLI; SPECTRUM CEPHALOSPORINS; KLEBSIELLA-PNEUMONIAE; UNITED-STATES; TYPHIMURIUM; OUTBREAK; GASTROENTERITIS; CEFOTAXIMASE	Background: The emergence of resistance to antimicrobial agents within the salmonellae is a worldwide problem that has been associated with the use of antibiotics in livestock. Resistance to ceftriaxone and the fluoroquinolones, which are used to treat invasive salmonella infections, is rare in the United States. We analyzed the molecular characteristics of a ceftriaxone-resistant strain of Salmonella enterica serotype typhimurium isolated from a 12-year-old boy with fever, abdominal pain, and diarrhea. Methods: We used pulsed-field gel electrophoresis and analysis of plasmids and beta-lactamases to compare the ceftriaxone-resistant S. enterica serotype typhimurium from the child with four isolates of this strain obtained from cattle during a local outbreak of salmonellosis. Results: The ceftriaxone-resistant isolate from the child was indistinguishable from one of the isolates from cattle, which was also resistant to ceftriaxone. Both ceftriaxone-resistant isolates were resistant to 13 antimicrobial agents; all but one of the resistance determinants were on a conjugative plasmid of 160 kb that encoded the functional group 1 beta-lactamase CMY-2. Both ceftriaxone- resistant isolates were closely related to the three other salmonella isolates obtained from cattle, all of which were susceptible to ceftriaxone. Conclusions: This study provides additional evidence that antibiotic-resistant strains of salmonella in the United States evolve primarily in livestock. Resistance to ceftriaxone, the drug of choice for invasive salmonella disease, is a public health concern, especially with respect to children, since fluoroquinolones, which can also be used to treat this disease, are not approved for use in children. (N Engl J Med 2000;342:1242-9.) (C) 2000, Massachusetts Medical Society.	Univ Nebraska, Med Ctr, Nebraska Med Ctr 985400, Dept Internal Med, Omaha, NE 68198 USA; Nebraska Publ Hlth Lab, Omaha, NE USA; Univ Nebraska, Med Ctr, Nebraska Med Ctr 985400, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Dept Hlth & Human Serv, Lincoln, NE USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Wyeth Ayerst Res, Pearl River, NY USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Centers for Disease Control & Prevention - USA; Pfizer	Fey, PD (corresponding author), Univ Nebraska, Med Ctr, Nebraska Med Ctr 985400, Dept Internal Med, 600 S 42nd St, Omaha, NE 68198 USA.	pfey@unmc.edu		Bradford, Patricia/0000-0002-1285-2978				Aarestrup FM, 1998, APMIS, V106, P745, DOI 10.1111/j.1699-0463.1998.tb00222.x; ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; ARCHAMBAUD M, 1991, J ANTIMICROB CHEMOTH, V27, P427, DOI 10.1093/jac/27.4.427; BACHMANN BJ, 1987, ESCHERICHIA COLI SAL, V2, P1197; Barnaud G, 1998, ANTIMICROB AGENTS CH, V42, P2352, DOI 10.1128/AAC.42.9.2352; Bauernfeind A, 1996, ANTIMICROB AGENTS CH, V40, P221, DOI 10.1128/AAC.40.1.221; BAUERNFEIND A, 1992, INFECTION, V20, P158, DOI 10.1007/BF01704610; Bradford PA, 1998, ANTIMICROB AGENTS CH, V42, P1980, DOI 10.1128/AAC.42.8.1980; Briggs CE, 1999, ANTIMICROB AGENTS CH, V43, P846, DOI 10.1128/AAC.43.4.846; BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211; COHEN ML, 1986, SCIENCE, V234, P964, DOI 10.1126/science.3535069; Gautom RK, 1997, J CLIN MICROBIOL, V35, P2977, DOI 10.1128/JCM.35.11.2977-2980.1997; HAMMAMI A, 1991, EUR J CLIN MICROBIOL, V10, P641, DOI 10.1007/BF01975816; Herikstad H, 1997, PEDIATR INFECT DIS J, V16, P904, DOI 10.1097/00006454-199709000-00015; Koeck JL, 1997, FEMS MICROBIOL LETT, V152, P255, DOI 10.1111/j.1574-6968.1997.tb10436.x; M'Zali FH, 1997, J ANTIMICROB CHEMOTH, V40, P823, DOI 10.1093/jac/40.6.823; MAIORINI E, 1993, PEDIATR INFECT DIS J, V12, P139, DOI 10.1097/00006454-199302000-00007; MARANO N, 1999, 99 GEN M AM SOC MICR, P163; MATTHEW M, 1975, J GEN MICROBIOL, V88, P169, DOI 10.1099/00221287-88-1-169; MAYER L W, 1988, Clinical Microbiology Reviews, V1, P228; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; Molbak K, 1999, NEW ENGL J MED, V341, P1420, DOI 10.1056/NEJM199911043411902; National Committee for Clinical Laboratory Standards, 1997, M2A6 NCCLS CLIN LAB, V6th; OBRIEN TF, 1982, NEW ENGL J MED, V307, P1, DOI 10.1056/NEJM198207013070101; PAVIA AT, 1990, J INFECT DIS, V161, P255, DOI 10.1093/infdis/161.2.255; Pitout JDD, 1998, ANTIMICROB AGENTS CH, V42, P1350, DOI 10.1128/AAC.42.6.1350; POUPART MC, 1991, ANTIMICROB AGENTS CH, V35, P1498, DOI 10.1128/AAC.35.7.1498; ROCHELLE PA, 1986, J GEN MICROBIOL, V132, P53; ROSSI A, 1995, J ANTIMICROB CHEMOTH, V36, P697, DOI 10.1093/jac/36.4.697; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sinnett D, 1998, BIOTECHNIQUES, V24, P752, DOI 10.2144/98245bm12; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; VAHABOGLU H, 1995, J MED MICROBIOL, V43, P294, DOI 10.1099/00222615-43-4-294; van den Bogaard AE, 1999, DRUGS, V58, P589, DOI 10.2165/00003495-199958040-00002; Vercauteren E, 1997, J CLIN MICROBIOL, V35, P2191, DOI 10.1128/JCM.35.9.2191-2197.1997; Wayne P.A, 1997, PERF VOL ANT SUSC FL, Vsixth	36	380	405	0	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	2000	342	17					1242	1249		10.1056/NEJM200004273421703	http://dx.doi.org/10.1056/NEJM200004273421703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307NZ	10781620	Green Published			2022-12-28	WOS:000086660600003
J	Gross, JA; Johnston, J; Mudri, S; Enselman, R; Dillon, SR; Madden, K; Xu, WF; Parrish-Novak, J; Foster, D; Lofton-Day, C; Moore, M; Littau, A; Grossman, A; Haugen, H; Foley, K; Blumberg, H; Harrison, K; Kindsvogel, W; Clegg, CH				Gross, JA; Johnston, J; Mudri, S; Enselman, R; Dillon, SR; Madden, K; Xu, WF; Parrish-Novak, J; Foster, D; Lofton-Day, C; Moore, M; Littau, A; Grossman, A; Haugen, H; Foley, K; Blumberg, H; Harrison, K; Kindsvogel, W; Clegg, CH			TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease	NATURE			English	Article							GENE; EXPRESSION	B cells are important in the development of autoimmune disorders by mechanisms involving disregulated polyclonal B-cell activation, production of pathogenic antibodies, and co-stimulation of autoreactive T cells. zTNF4 (BLyS, BAFF, TALL-1, THANK)(1-5) is a member of the tumour necrosis factor (TNF) ligand family that is a potent co-activator of B cells in vitro and in vivo(1,2,5). Here we identify two receptors for zTNF4 and demonstrate a relationship between zTNF4 and autoimmune disease. Transgenic animals overexpressing zTNF4 in lymphoid cells develop symptoms characteristic of systemic lupus erythaematosus (SLE) and expand a rare population of splenic B-1a lymphocytes. In addition, circulating zTNF4 is more abundant in NZBWF1 and MRL-lpr/lpr mice during the onset and progression of SLE. We have identified two TNF receptor family members, TACI(6) and BCMA(7,8), that bind zTNF4. Treatment of NZBWF1 mice with soluble TACI-Ig fusion protein inhibits the development of proteinuria and prolongs survival of the animals. These findings demonstrate the involvement of zTNF4 and its receptors in the development of SLE and identify TACI-Ig as a promising treatment of autoimmune disease in humans.	Zymogenet Inc, Dept Immunol, Seattle, WA 98102 USA; Zymogenet Inc, Dept Funct Cloning, Seattle, WA 98102 USA; Zymogenet Inc, Dept In Vivo Biol, Seattle, WA 98102 USA; Zymogenet Inc, Dept Genet, Seattle, WA 98102 USA	Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.	Gross, JA (corresponding author), Zymogenet Inc, Dept Immunol, 1201 Eastlake Ave E, Seattle, WA 98102 USA.	grossj@zgi.com	Foley, Kevin/ABC-1041-2020					BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Chan OTM, 1999, J EXP MED, V189, P1639, DOI 10.1084/jem.189.10.1639; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Foster MH, 1999, SEMIN NEPHROL, V19, P12; GRAS MP, 1995, INT IMMUNOL, V7, P1093, DOI 10.1093/intimm/7.7.1093; HARDY RR, 1994, IMMUNOL REV, V137, P91, DOI 10.1111/j.1600-065X.1994.tb00660.x; HU J, 1993, J EXP MED, V177, P1681, DOI 10.1084/jem.177.6.1681; Kotzin BL, 1996, CELL, V85, P303, DOI 10.1016/S0092-8674(00)81108-3; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; MALDRY C, 1998, INT IMMUNOL, V10, P1693; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Mukhopadhyay A, 1999, J BIOL CHEM, V274, P15978, DOI 10.1074/jbc.274.23.15978; Raymond CK, 1998, YEAST, V14, P11, DOI 10.1002/(SICI)1097-0061(19980115)14:1<11::AID-YEA196>3.0.CO;2-S; SCHEIDER P, 1999, J EXP MED, V189, P1747; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; WOFSY D, 1985, J EXP MED, V161, P378, DOI 10.1084/jem.161.2.378	21	935	1084	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 27	2000	404	6781					995	999		10.1038/35010115	http://dx.doi.org/10.1038/35010115			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801128				2022-12-28	WOS:000086762000056
J	Burri, C; Nkunhu, S; Merolle, A; Smith, T; Blum, J; Brun, R				Burri, C; Nkunhu, S; Merolle, A; Smith, T; Blum, J; Brun, R			Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial	LANCET			English	Article							HUMAN AFRICAN TRYPANOSOMIASIS; SAMPLE-SIZE FORMULAS; ENCEPHALOPATHIES; CHEMOTHERAPY; DIFFERENCE; BIOASSAY; THERAPY; RISK	Background African trypanosomiasis is a fatal disease caused by protozoan parasites of the species Trypanosoma brucei. The disease has reached epidemic dimensions in various countries of central Africa. Treatment of the second stage is long and complicated, and is hampered by severe adverse reactions to the first-line drug, melarsoprol. Despite these problems, melarsoprol is likely to remain the drug of choice for the next decade. We therefore did a randomised trial comparing the standard treatment schedule with a new, concise regimen. Methods The safety and efficacy of the new schedule were assessed in patients presenting to a hospital in Kwanza Norte, Angola with sleeping sickness. The control group followed the 26-day standard Angolan schedule of three series of four daily injections of melarsoprol at doses increasing from 1.2 to 3.6 mg/kg within each series, with a 7-day interval between series. The new treatment schedule comprised 10 daily injections of 2.2 mg/kg. Primary outcomes assessed were elimination of parasites, deaths attributed to treatment, and rate of encephalopathy. Analysis was by intention to treat. Findings Of 767 patients with second-stage disease, 500 were enrolled: 250 were assigned the standard schedule, and 250 the new schedule. 40 patients on the standard schedule and 47 on the new schedule had adverse events which resulted in treatment disruption or withdrawal. 50 patients on the standard regimen deviated or withdrew from treatment, compared with two on the new regimen. Parasitological cure 24 h after treatment was 100% in both groups; there were six deaths (all due to encephalopathy) 30 days after treatment in each group. The number of patients with encephalopathic syndromes was also the same in each group (14). Skin reactions were more common with the new treatment, but all could be resolved by additional medication or withdrawal of treatment. Interpretation Considering the economic and practical advantages of the new 10-day schedule over the standard 26-day treatment schedule, and the similarity of treatment outcome, the new schedule is a useful alternative to the present standard, especially in epidemic situations and in locations with limited resources.	Swiss Trop Inst, CH-4002 Basel, Switzerland; Norwegian Peoples Aid, Luanda, Angola	University of Basel; Swiss Tropical & Public Health Institute	Burri, C (corresponding author), Swiss Trop Inst, Socinstr 57, CH-4002 Basel, Switzerland.	Christian.Burri@unibas.ch	Smith, Thomas/B-5569-2015	Smith, Thomas/0000-0002-3650-9381; Burri, Christian/0000-0001-5418-1984				Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298; ANCELLE T, 1994, B SOC PATHOL EXOT, V87, P341; Bronner U, 1998, TROP MED INT HEALTH, V3, P913; BURRI C, 1992, TROP MED PARASITOL, V43, P223; BURRI C, 1995, ANN SOC BELG MED TR, V75, P65; BURRI C, 1994, ACTA TROP, V58, P35, DOI 10.1016/0001-706X(94)90120-1; BURRI C, 1993, CHEMOTHERAPY, V39, P225, DOI 10.1159/000239130; Croft Simon L., 1997, P245; DOUA F, 1993, ACTA TROP, V54, P163, DOI 10.1016/0001-706X(93)90090-X; DUKE BOL, 1966, T ROY SOC TROP MED H, V60, P691, DOI 10.1016/0035-9203(66)90018-6; Ekwanzala M, 1996, LANCET, V348, P1427, DOI 10.1016/S0140-6736(96)06088-6; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; Fernandes JHV, 1997, ACTA TROP, V63, P179, DOI 10.1016/S0001-706X(96)00614-6; Ferreira MS, 1997, CLIN INFECT DIS, V25, P1397, DOI 10.1086/516130; FRIEDHEIM EAH, 1949, AM J TROP MED, V29, P173; GHERARDI RK, 1990, MUSCLE NERVE, V13, P637, DOI 10.1002/mus.880130713; HUNTER CA, 1992, LANCET, V339, P956, DOI 10.1016/0140-6736(92)91531-C; JENNINGS FW, 1993, T ROY SOC TROP MED H, V87, P224, DOI 10.1016/0035-9203(93)90502-H; MAGNUS E, 1978, ANN SOC BELG MED TR, V58, P169; PEPIN J, 1994, T ROY SOC TROP MED H, V88, P447, DOI 10.1016/0035-9203(94)90430-8; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; ROEBRUCK P, 1995, STAT MED, V14, P1583, DOI 10.1002/sim.4780141409; Sjoerdsma A, 1999, LANCET, V354, P254, DOI 10.1016/S0140-6736(05)66324-6; Smith DH, 1998, BRIT MED BULL, V54, P341, DOI 10.1093/oxfordjournals.bmb.a011692; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; WHO Expert Comm, 1998, WHO TECH REP SER, V881, P1	26	129	130	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	2000	355	9213					1419	1425		10.1016/S0140-6736(00)02141-3	http://dx.doi.org/10.1016/S0140-6736(00)02141-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791526				2022-12-28	WOS:000086829800013
J	Sambrook, PN				Sambrook, PN			Inhaled corticosteroids, bone density, and risk of fracture	LANCET			English	Editorial Material							INDUCED OSTEOPOROSIS; THERAPY		Univ Sydney, Royal N Shore Hosp, Inst Bone & Joint Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney	Sambrook, PN (corresponding author), Univ Sydney, Royal N Shore Hosp, Inst Bone & Joint Res, St Leonards, NSW 2065, Australia.							Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K; Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283; HOPPER JL, 1994, NEW ENGL J MED, V330, P387, DOI 10.1056/NEJM199402103300603; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; NGUYEN T, 1993, BRIT MED J, V307, P1111, DOI 10.1136/bmj.307.6912.1111; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852	9	7	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1385	1385		10.1016/S0140-6736(00)02134-6	http://dx.doi.org/10.1016/S0140-6736(00)02134-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791519				2022-12-28	WOS:000086829800006
J	Aqvist, J; Luzhkov, V				Aqvist, J; Luzhkov, V			Ion permeation mechanism of the potassium channel	NATURE			English	Article							RANGE ELECTROSTATIC INTERACTIONS; MOLECULAR-DYNAMICS; SIMULATIONS; SELECTIVITY; CONDUCTION	Ion-selective channels enable the specific permeation of ions through cell membranes and provide the basis of several important biological functions; for example, electric signalling in the nervous system(1). Although a large amount of electrophysiological data is available(1,2), the molecular mechanisms by which these channels can mediate ion transport remain a significant unsolved problem. With the recently determined crystal structure of the representative K+ channel (KcsA) from Streptomyces lividans(3), it becomes possible to examine ion conduction pathways on a microscopic level. K+ channels utilize multi-ion conduction mechanisms(1,2,4-6), and the three-dimensional structure also shows several ions present in the channel. Here we report results from molecular dynamics free energy perturbation calculations that both establish the nature of the multiple ion conduction mechanism and yield the correct ion selectivity of the channel. By evaluating the energetics of all relevant occupancy states of the selectivity filter, we rnd that the favoured conduction pathway involves transitions only between two main states with a free difference of about 5 kcal mol(-1). Other putative permeation pathways can be excluded because they would involve states that are too high in energy.	Uppsala Univ, Biomed Ctr, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; Russian Acad Sci, Inst Chem Phys Problems, Chernogolovka 142432, Moscow Region, Russia	Uppsala University; Russian Academy of Sciences; Institute of Problems of Chemical Physics of the Russian Academy of Sciences	Aqvist, J (corresponding author), Uppsala Univ, Biomed Ctr, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.		Luzhkov, Victor/AAE-1857-2019	Luzhkov, Victor/0000-0003-2528-4567				AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; Aqvist J, 1996, J COMPUT CHEM, V17, P1587, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1587::AID-JCC1>3.0.CO;2-H; BAMBERG E, 1974, BIOCHIM BIOPHYS ACTA, V367, P127, DOI 10.1016/0005-2736(74)90037-6; BEGENISICH T, 1980, J GEN PHYSIOL, V76, P83, DOI 10.1085/jgp.76.1.83; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HLADKY SB, 1972, BIOCHIM BIOPHYS ACTA, V274, P294, DOI 10.1016/0005-2736(72)90178-2; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997; Marelius J, 1998, J MOL GRAPH MODEL, V16, P213, DOI 10.1016/S1093-3263(99)00012-1; MCCLESKEY EW, J GEN PHYSL, V13, P765; Miller C, 1999, J GEN PHYSIOL, V113, P783, DOI 10.1085/jgp.113.6.783; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; ROUX B, 1991, J PHYS CHEM-US, V95, P4856, DOI 10.1021/j100165a049; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921	23	378	383	2	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					881	884		10.1038/35009114	http://dx.doi.org/10.1038/35009114			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786795				2022-12-28	WOS:000086625000047
J	Moody, DB; Ulrichs, T; Muhlecker, W; Young, DC; Gurcha, SS; Grant, E; Rosat, JP; Brenner, MB; Costello, CE; Besra, GS; Porcelli, SA				Moody, DB; Ulrichs, T; Muhlecker, W; Young, DC; Gurcha, SS; Grant, E; Rosat, JP; Brenner, MB; Costello, CE; Besra, GS; Porcelli, SA			CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection	NATURE			English	Article							LIPOGLYCAN ANTIGENS; BIOSYNTHESIS; DOLICHOL; CD1; LIPOARABINOMANNAN; IDENTIFICATION; REQUIREMENTS; LYMPHOCYTES; METABOLISM; RESTRICTS	The discovery of the CD1 antigen presentation pathway has expanded the spectrum of T-cell antigens to include lipids(1-4), but the range of natural lipid antigens and functions of CD1-restricted T cells in vivo remain poorly understood. Here we show that the T-cell antigen receptor and the CD1c protein mediate recognition of an evolutionarily conserved family of isoprenoid glycolipids whose members include essential components of protein glycosylation and cell-wall synthesis pathways. A CD1c-restricted, mycobacteria-specific T-cell line recognized two previously unknown mycobacterial hexosyl-1-phosphoisoprenoids and structurally related mannosyl-beta 1-phosphodolichols. Responses to mannosyl-b1-phosphodolichols were common among CD1c-restricted T-cell lines and peripheral blood T lymphocytes of human subjects recently infected with M. tuberculosis, but were not seen in naive control subjects. These results define a new class of broadly distributed lipid antigens presented by the CD1 system during infection in vivo and suggest an immune mechanism for recognition of senescent or transformed cells that are known to have altered dolichol lipids.	Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Newcastle Upon Tyne, Sch Med, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University; Newcastle University - UK	Moody, DB (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.			Costello, Catherine/0000-0003-1594-5122; Besra, Gurdyal/0000-0002-5605-0395				Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; Besra GS, 1997, BIOCHEM SOC T, V25, P845, DOI 10.1042/bst0250845; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CRICK DC, 1994, J BIOL CHEM, V269, P10559; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; EDLUND C, 1992, BIOCHEM CELL BIOL, V70, P422, DOI 10.1139/o92-065; Ernst WA, 1998, IMMUNITY, V8, P331, DOI 10.1016/S1074-7613(00)80538-5; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Grant EP, 1999, J EXP MED, V189, P195, DOI 10.1084/jem.189.1.195; HENRY A, 1991, BIOCHEM J, V278, P741, DOI 10.1042/bj2780741; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; LOW P, 1991, J BIOL CHEM, V266, P19250; Moody DB, 1999, IMMUNOL REV, V172, P285, DOI 10.1111/j.1600-065X.1999.tb01373.x; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; PARODI AJ, 1993, GLYCOBIOLOGY, V3, P193, DOI 10.1093/glycob/3.3.193; PENNOCK JF, 1960, NATURE, V186, P470, DOI 10.1038/186470b0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; RIP JW, 1985, PROG LIPID RES, V24, P269, DOI 10.1016/0163-7827(85)90008-6; Rosat JP, 1999, J IMMUNOL, V162, P366; Schofield L, 1999, SCIENCE, V283, P225, DOI 10.1126/science.283.5399.225; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V316, P212, DOI 10.1016/0005-2760(73)90011-8; Wolucka BA, 1998, ANAL BIOCHEM, V255, P244, DOI 10.1006/abio.1997.2421; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	30	368	378	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					884	888		10.1038/35009119	http://dx.doi.org/10.1038/35009119			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786796				2022-12-28	WOS:000086625000048
J	Ryan, KM; Ernst, MK; Rice, NR; Vousden, KH				Ryan, KM; Ernst, MK; Rice, NR; Vousden, KH			Role of NF-kappa B in p53-mediated programmed cell death	NATURE			English	Article							RIBOSOMAL S6 KINASE; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; P53; ALPHA; INDUCTION; DEGRADATION; MUTANTS	The tumour suppressor p53 inhibits cell growth through activation of cell-cycle arrest and apoptosis(1), and most cancers have either mutation within the p53 gene or defects in the ability to induce p53. Activation or re-introduction of p53 induces apoptosis in many tumour cells and may provide effective cancer therapy 2. One of the key proteins that modulates the apoptotic response is NF-kappa B, a transcription factor that can protect or contribute to apoptosis(3). Here we show that induction of p53 causes an activation of NF-kappa B that correlates with the ability of p53 to induce apoptosis. Inhibition or loss of NF-kappa B activity abrogated p53-induced apoptosis, indicating that NF-kappa B is essential in p53-mediated cell death. Activation of NF-kappa B by p53 was distinct from that mediated by tumour-necrosis factor-alpha and involved MEK1 and the activation of pp90(rsk). Inhibition of MEK1 blocked activation of NF-kappa B by p53 and completely abrogated p53-induced cell death. We conclude that inhibition of NF-kappa B in tumours that retain wild-type p53 may diminish, rather than augment, a therapeutic response.	NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, Bldg 560,Room 22-96,W 7th St, Frederick, MD 21702 USA.			Ryan, Kevin M./0000-0002-1059-9681				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERNST MK, 1995, MOL CELL BIOL, V15, P872; Foo SY, 1999, TRENDS GENET, V15, P229; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Lane DP, 1999, BRIT J CANCER, V80, P1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; WU HY, 1994, J BIOL CHEM, V269, P20067; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w	30	641	675	2	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					892	897		10.1038/35009130	http://dx.doi.org/10.1038/35009130			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786798				2022-12-28	WOS:000086625000050
J	Gollub, JP; Cross, MC				Gollub, JP; Cross, MC			Nonlinear dynamics - Chaos in space and time	NATURE			English	Editorial Material									Haverford Coll, Dept Phys, Haverford, PA 19041 USA; CALTECH, Dept Phys, Pasadena, CA 91125 USA	Haverford College; California Institute of Technology	Gollub, JP (corresponding author), Haverford Coll, Dept Phys, Haverford, PA 19041 USA.							BOENSCHATZ E, 2000, ANNU REV FLUID MECH, V32, P709; Egolf DA, 2000, NATURE, V404, P733, DOI 10.1038/35008013; LORENZ EN, 1963, J ATMOS SCI, V20, P130, DOI 10.1175/1520-0469(1963)020<0130:DNF>2.0.CO;2; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0	4	61	61	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					710	711		10.1038/35008168	http://dx.doi.org/10.1038/35008168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783868				2022-12-28	WOS:000086523600029
J	Kilner, PJ; Yang, GZ; Wilkes, AJ; Mohiaddin, RH; Firmin, DN; Yacoub, MH				Kilner, PJ; Yang, GZ; Wilkes, AJ; Mohiaddin, RH; Firmin, DN; Yacoub, MH			Asymmetric redirection of flow through the heart	NATURE			English	Article							PATTERNS	Through cardiac looping during embryonic development(1), paths of flow through the mature heart have direction changes and asymmetries whose topology and functional significance remain relatively unexplored. Here we show, using magnetic resonance velocity mapping(2-5), the asymmetric redirection of streaming blood in atrial and ventricular cavities of the adult human heart, with sinuous, chirally asymmetric paths of flow through the whole. On the basis of mapped flow fields and drawings that illustrate spatial relations between flow paths, we propose that asymmetries and curvatures of the looped heart have potential fluidic and dynamic advantages. Patterns of atrial filling seem to be asymmetric in a manner that allows the momentum of inflowing streams to be redirected towards atrio-ventricular valves, and the change in direction at ventricular level is such that recoil away from ejected blood is in a direction that can enhance rather than inhibit ventriculo-atrial coupling(6). Chiral asymmetry might help to minimize dissipative interaction between entering, recirculating and outflowing streams(7). These factors might combine to allow a reciprocating, sling-like, 'morphodynamic' mode of action to come into effect when heart rate and output increase during exercise(6).	Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Cardiovasc Magnet Resonance Unit, London SW3 6NP, England; Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Comp, Visual Informat Proc Grp, London SW3 6NP, England; Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Dept Cardiothorac Surg, London SW3 6NP, England; Emerson Coll, Flow Design Res Grp, Forest Row RH18 5JX, E Sussex, England	Imperial College London; Royal Brompton Hospital; Imperial College London; Royal Brompton Hospital; Imperial College London; Royal Brompton Hospital	Kilner, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Cardiovasc Magnet Resonance Unit, Sydney St, London SW3 6NP, England.	p.kilner@rbh.nthames.nhs.uk	tay, wee beng/B-1095-2010	Firmin, David/0000-0003-3894-7489				BELLHOUSE BJ, 1969, NATURE, V224, P615, DOI 10.1038/224615a0; Caro CG, 1996, P ROY SOC A-MATH PHY, V452, P185, DOI 10.1098/rspa.1996.0011; DiBello V, 1996, MED SCI SPORT EXER, V28, P190, DOI 10.1097/00005768-199602000-00006; FIRMIN DN, 1990, MAGN RESON MED, V14, P230, DOI 10.1002/mrm.1910140209; FIRMIN DN, 1987, J COMPUT ASSIST TOMO, V11, P751, DOI 10.1097/00004728-198709000-00001; FRIEDMAN MH, 1993, ATHEROSCLEROSIS, V98, P193, DOI 10.1016/0021-9150(93)90128-H; Icardo JM, 1996, J EXP ZOOL, V275, P144, DOI 10.1002/(SICI)1097-010X(19960601/15)275:2/3<144::AID-JEZ7>3.3.CO;2-2; Kilner PJ, 1997, HEART VESSELS, V12, P103, DOI 10.1007/BF02767127; KILNER PJ, 1993, CIRCULATION, V88, P2235, DOI 10.1161/01.CIR.88.5.2235; KILNER PJ, 1998, THESIS U LONDON; KIM WY, 1995, J AM COLL CARDIOL, V26, P224, DOI 10.1016/0735-1097(95)00141-L; Landesberg A, 1997, ADV EXP MED BIOL, V430, P75; Liang YL, 1999, CLIN EXP PHARMACOL P, V26, P342, DOI 10.1046/j.1440-1681.1999.03039.x; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; NOBLE MIM, 1978, CLIN SCI MOL MED, V54, P1; Peskin C.S., 1996, CASE STUDIES MATH MO, P309; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Shapiro Leonard M., 1997, Cardiology Clinics, V15, P373, DOI 10.1016/S0733-8651(05)70346-5; TAYLOR DEM, 1973, CARDIOVASC RES, V7, P14, DOI 10.1093/cvr/7.1.14; TAYLOR TW, 1995, BIORHEOLOGY, V32, P61; Yacoub MH, 1999, ANN THORAC SURG, V68, pS37, DOI 10.1016/S0003-4975(99)00745-6; YANG GZ, IN PRESS INT J CARDI	22	523	551	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	2000	404	6779					759	761		10.1038/35008075	http://dx.doi.org/10.1038/35008075			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783888				2022-12-28	WOS:000086523600051
J	Troughton, RW; Frampton, CM; Yandle, TG; Espiner, EA; Nicholls, MG; Richards, AM				Troughton, RW; Frampton, CM; Yandle, TG; Espiner, EA; Nicholls, MG; Richards, AM			Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations	LANCET			English	Article							ELDERLY PATIENTS; THERAPY; NOREPINEPHRINE; PROGNOSIS; EFFICACY	Background There is currently no objective practical guide to intensity of drug treatment for individuals with heart failure. We hypothesised that pharmacotherapy guided by plasma concentrations of the cardiac peptide aminoterminal brain natriuretic peptide (N-BNP) would produce a superior outcome to empirical trial-based therapy dictated by clinical acumen. Methods 69 patients with impaired systolic function (left-ventricular ejection fraction <40%) and symptomatic heart failure (New York Heart Association class II-IV) were randomised to receive treatment guided by either plasma N-BNP concentration (BNP group) or standardised clinical assessment (clinical group). Findings During follow-up (minimum 6-months, median 9.5 months), there were fewer total cardiovascular events (death, hospital admission, or heart failure decompensation) in the BNP group than in the clinical group (19 vs 54, p=0.02). At 6 months, 27% of patients in the BNP group and 53% in the clinical group had experienced a first cardiovascular event (p=0.034). Changes in left-ventricular function, quality of life, renal function, and adverse events were similar in both groups. Interpretation N-BNP-guided treatment of heart failure reduced total cardiovascular events, and delayed time to first event compared with intensive clinically guided treatment.	Christchurch Hosp, Christchurch Cardioendocrine Res Grp, Christchurch, New Zealand; Christchurch Sch Med, Christchurch, New Zealand	Christchurch Hospital New Zealand; University of Otago	Troughton, RW (corresponding author), Christchurch Hosp, Dept Med, Riccarton Ave,POB 4345, Christchurch, New Zealand.	richard.troughton@chmeds.ac.nz		Troughton, Richard/0000-0001-7484-4036; Yandle, Timothy/0000-0002-8848-8041				Cleland JGF, 1998, LANCET, V352, P19; Cohn JN, 1997, CIRCULATION, V96, P856, DOI 10.1161/01.cir.96.3.856; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; DAVIS M, 1994, LANCET, V343, P440, DOI 10.1016/S0140-6736(94)92690-5; Domanski MJ, 1999, J AM COLL CARDIOL, V33, P598, DOI 10.1016/S0735-1097(98)00609-3; DOUGHTY R, 1995, NEW ZEAL MED J, V108, P473; FRANCIS GS, 1993, CIRCULATION, V87, P40; Hjalmarson A, 1999, LANCET, V353, P2001; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Hunt PJ, 1997, PEPTIDES, V18, P1475, DOI 10.1016/S0196-9781(97)00245-3; KINNUNEN P, 1993, ENDOCRINOLOGY, V132, P1961, DOI 10.1210/en.132.5.1961; KORNOWSKI R, 1995, AM HEART J, V129, P762, DOI 10.1016/0002-8703(95)90327-5; Lechat P, 1999, LANCET, V353, P9; Magga J, 1998, ANN MED, V30, P39; Murdoch DR, 1999, AM HEART J, V138, P1126, DOI 10.1016/S0002-8703(99)70079-7; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Reis SE, 1997, J AM COLL CARDIOL, V30, P733, DOI 10.1016/S0735-1097(97)00214-3; REMME WJ, 1994, EUR HEART J, V15, P129, DOI 10.1093/eurheartj/15.suppl_D.129; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; Richards AM, 1999, HEART, V81, P114, DOI 10.1136/hrt.81.2.114; RICHARDS AM, 1993, BRIT HEART J, V69, P414; Schrier RW, 1999, NEW ENGL J MED, V341, P577, DOI 10.1056/NEJM199908193410806; Steimle AE, 1997, CIRCULATION, V96, P1165, DOI 10.1161/01.CIR.96.4.1165; STEVENSON LW, 1989, AM J CARDIOL, V63, P461, DOI 10.1016/0002-9149(89)90320-2; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; van Veldhuisen DJ, 1999, EUR HEART J, V20, P666, DOI 10.1053/euhj.1998.1343; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	29	1054	1140	0	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	2000	355	9210					1126	1130		10.1016/S0140-6736(00)02060-2	http://dx.doi.org/10.1016/S0140-6736(00)02060-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791374				2022-12-28	WOS:000086380900009
J	Enthoven, AC				Enthoven, AC			Modernising the NHS - A promising start but fundamental reform is needed	BRITISH MEDICAL JOURNAL			English	Article								The NHS has just received its largest sustained increase in resources since the service was started in 1948. To ensure that the money is spent wisely Britain's prime minister has set about producing a national plan for health, with the help of six action teams-on prevention and inequalities, partnership, performance and productivity, the professions and the wider NHS workforce, patient care (empowerment), and patient care (speed of access). The BMJ has asked six commentators to state what their priorities would be in each of these areas, and we will be publishing these articles over the next few weeks, This week, however, we start with a commentary from Alain Enthoven, professor of public and private management at the graduate business school, Stanford University. Enthoven's ideas were a driving for ce behind the creation of the internal market in the NHS in the 1990s; he recently revisited the subject in last year's Rock Carling lecture, and Mle invited him to give his impressions on the prime minister's current plans for the NHS.	Stanford Univ, Grad Sch Business, Stanford, CA 94305 USA	Stanford University	Enthoven, AC (corresponding author), Stanford Univ, Grad Sch Business, Stanford, CA 94305 USA.							Black N, 1999, LANCET, V353, P1205, DOI 10.1016/S0140-6736(99)00108-7; CUNNINGHAM J, 1999, MODERNISING GOVT; Department of Health, 2000, NAT PLAN NAT HLTH SE; ENTHOVEN A, 1999, PURSUIT IMPROVING NA; Raftery J, 1999, J Health Serv Res Policy, V4, P63; Secretary of State for Health, 1998, 1 CLASS SERV QUAL NE	6	13	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1329	1331		10.1136/bmj.320.7245.1329	http://dx.doi.org/10.1136/bmj.320.7245.1329			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807633	Green Published			2022-12-28	WOS:000087077400032
J	Light, D				Light, D			The two tier syndrome behind waiting lists	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Penn Hlth Syst, Ctr Bioeth, Philadelphia, PA 19104 USA	University of Pennsylvania	Light, D (corresponding author), Univ Penn Hlth Syst, Ctr Bioeth, Philadelphia, PA 19104 USA.								0	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	2000	320	7245					1349	1349		10.1136/bmj.320.7245.1349	http://dx.doi.org/10.1136/bmj.320.7245.1349			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314VC	10807644	Green Published			2022-12-28	WOS:000087077400068
J	Ackerman, AS; Toon, OB; Stevens, DE; Heymsfield, AJ; Ramanathan, V; Welton, EJ				Ackerman, AS; Toon, OB; Stevens, DE; Heymsfield, AJ; Ramanathan, V; Welton, EJ			Reduction of tropical cloudiness by soot	SCIENCE			English	Article							MARINE BOUNDARY-LAYER; FRACTIONAL CLOUDINESS; INDIAN-OCEAN; CLOUDS; MODEL; STRATOCUMULUS; ALBEDO; MICROPHYSICS; SCATTERING; AEROSOLS	Measurements and models show that enhanced aerosol concentrations can augment cloud albedo not only by increasing total droplet cross-sectional area, but also by reducing precipitation and thereby increasing cloud water content and cloud coverage. Aerosol pollution is expected to exert a net cooling influence on the global climate through these conventional mechanisms. Here, we demonstrate an opposite mechanism through which aerosols can reduce cloud cover and thus significantly offset aerosol-induced radiative cooling at the top of the atmosphere on a regional scale. In model simulations, the daytime clearing of trade cumulus is hastened and intensified by solar heating in dark haze las found over much of the northern Indian Ocean during the northeast monsoon).	NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Univ Colorado, Boulder, CO 80309 USA; Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; Natl Ctr Atmospher Res, Boulder, CO 80301 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Sci Syst & Applicat, Greenbelt, MD 20771 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Colorado System; University of Colorado Boulder; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; National Center Atmospheric Research (NCAR) - USA; University of California System; University of California San Diego; Scripps Institution of Oceanography	Ackerman, AS (corresponding author), NASA, Ames Res Ctr, Moffett Field, CA 94035 USA.	ack@sky.arc.nasa.gov	Welton, Ellsworth J/A-8362-2012; Ackerman, Andrew S/D-4433-2012; Heymsfield, Andrew J/E-7340-2011	Welton, Ellsworth J/0000-0003-0208-4861; Ackerman, Andrew S/0000-0003-0254-6253; Heymsfield, Andrew J/0000-0003-4107-7533				Ackerman AS, 1996, NATURE, V380, P512, DOI 10.1038/380512a0; ACKERMAN AS, 1995, J ATMOS SCI, V52, P1204, DOI 10.1175/1520-0469(1995)052<1204:AMFPMT>2.0.CO;2; ACKERMAN AS, 1993, SCIENCE, V262, P226, DOI 10.1126/science.262.5131.226; ALBRECHT BA, 1989, SCIENCE, V245, P1227, DOI 10.1126/science.245.4923.1227; ALBRECHT BA, 1991, J ATMOS SCI, V48, P1519, DOI 10.1175/1520-0469(1991)048<1519:FCACTE>2.0.CO;2; ALBRECHT BA, 1981, J ATMOS SCI, V38, P97, DOI 10.1175/1520-0469(1981)038<0097:POTCCA>2.0.CO;2; AUGSTEIN E, 1973, MON WEATHER REV, V101, P101, DOI 10.1175/1520-0493(1973)101<0101:MAETIA>2.3.CO;2; BRILL K, 1982, MON WEATHER REV, V110, P601, DOI 10.1175/1520-0493(1982)110<0601:DVOTTW>2.0.CO;2; BUSINGER JA, 1971, J ATMOS SCI, V28, P181, DOI 10.1175/1520-0469(1971)028<0181:FPRITA>2.0.CO;2; CHYLEK P, 1984, J ATMOS SCI, V41, P3076, DOI 10.1175/1520-0469(1984)041<3076:EOGCOT>2.0.CO;2; CLOUGH SA, 1989, ATMOS RES, V23, P229, DOI [DOI 10.1016/0169-8095(89)90020-3, 10.1016/0169-8095(89)90020-3]; DEARDORFF JW, 1980, BOUND-LAY METEOROL, V18, P495, DOI 10.1007/BF00119502; Draxler R.R., 1997, DESCRIPTION HYSPLIT, P197; HANSEN J, 1983, MON WEATHER REV, V111, P609, DOI 10.1175/1520-0493(1983)111<0609:ETDGMF>2.0.CO;2; Hignett P, 1999, J GEOPHYS RES-ATMOS, V104, P2279, DOI 10.1029/98JD02021; HINDMAN EE, 1994, ATMOS ENVIRON, V28, P3393, DOI 10.1016/1352-2310(94)00171-G; HOUGHTON JT, 1996, CLIMATE CHANGE 1995, P112; Jayaraman A, 1998, J GEOPHYS RES-ATMOS, V103, P13827, DOI 10.1029/98JD00559; Kaufman YJ, 1997, SCIENCE, V277, P1636, DOI 10.1126/science.277.5332.1636; KAUFMAN YJ, 1993, J APPL METEOROL, V32, P729, DOI [10.1175/1520-0450(1993)032<0729:EOASOC>2.0.CO;2, 10.1175/1520-0450(1993)032&lt;0729:EOASOC&gt;2.0.CO;2]; LILLY DK, 1962, TELLUS, V14, P148, DOI 10.3402/tellusa.v14i2.9537; MACVEAN MK, 1990, J ATMOS SCI, V47, P1012, DOI 10.1175/1520-0469(1990)047<1012:CTEITS>2.0.CO;2; MANGHANI V, IN PRESS BOUNDARY LA; PINCUS R, 1994, NATURE, V372, P250, DOI 10.1038/372250a0; RADKE LF, 1989, SCIENCE, V246, P1146, DOI 10.1126/science.246.4934.1146; RAMANATHAN V, 1996, INDIAN OCEAN EXPT IN, P83; ROSSOW WB, 1991, B AM METEOROL SOC, V72, P2, DOI 10.1175/1520-0477(1991)072<0002:ICDP>2.0.CO;2; RUSSEL PB, 1999, J GEOPHYS RES, V104, P2279; Russell PB, 1999, J GEOPHYS RES-ATMOS, V104, P2289, DOI 10.1029/1998JD200025; Satheesh SK, 1999, J GEOPHYS RES-ATMOS, V104, P27421, DOI 10.1029/1999JD900478; Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [DOI 10.1175/1520-0493(1963)0912.3.CO;2, 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)0912.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2]; STEVENS B, 1999, 13 S BOUND LAY TURB, P269; Stevens DE, 1996, J COMPUT PHYS, V129, P284, DOI 10.1006/jcph.1996.0250; Taylor JP, 1999, Q J ROY METEOR SOC, V125, P2643, DOI 10.1002/qj.49712555915; TOON OB, 1981, APPL OPTICS, V20, P3657, DOI 10.1364/AO.20.003657; TOON OB, 1989, J GEOPHYS RES-ATMOS, V94, P16287, DOI 10.1029/JD094iD13p16287; TWOMEY S, 1974, ATMOS ENVIRON, V8, P1251, DOI 10.1016/0004-6981(74)90004-3; Webster PJ, 1996, J CLIMATE, V9, P1712, DOI 10.1175/1520-0442(1996)009<1712:CRATDC>2.0.CO;2; Welton EJ, 2000, TELLUS B, V52, P636, DOI 10.1034/j.1600-0889.2000.00025.x; Wyant MC, 1997, J ATMOS SCI, V54, P168, DOI 10.1175/1520-0469(1997)054<0168:NSAACM>2.0.CO;2	40	925	970	9	221	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	2000	288	5468					1042	1047		10.1126/science.288.5468.1042	http://dx.doi.org/10.1126/science.288.5468.1042			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	313EY	10807573	Green Submitted			2022-12-28	WOS:000086988400035
J	Tierney, S; Fennessy, F; Hayes, DB				Tierney, S; Fennessy, F; Hayes, DB			ABC of arterial and vascular disease - Secondary prevention of peripheral vascular disease	BRITISH MEDICAL JOURNAL			English	Review									Beaumont Hosp, Dublin 9, Ireland		Tierney, S (corresponding author), Beaumont Hosp, Dublin 9, Ireland.		Tierney, Sean/I-7740-2013	Tierney, Sean/0000-0002-1886-7214				*AM HEART ASS WRIT, 1994, OPT RISK FACT MAN PA; BAINTON D, 1994, BRIT HEART J, V72, P128; *COTT INT GUID NET, 1999, SIGN, P40; *DEP HLTH, 1997, STAND MED ADV STAT U; LENG GC, 1999, COCHRANE LIBRARY; O'Brien E, 1998, LANCET, V352, P1700, DOI 10.1016/S0140-6736(97)09026-0; Tribble DL, 1999, CIRCULATION, V99, P591, DOI 10.1161/01.CIR.99.4.591	7	35	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1262	1265		10.1136/bmj.320.7244.1262	http://dx.doi.org/10.1136/bmj.320.7244.1262			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797042	Green Published			2022-12-28	WOS:000086981400026
J	Lang, EV; Benotsch, EG; Fick, LJ; Lutgendorf, S; Berbaum, ML; Berbaum, KS; Logan, H; Spiegel, D				Lang, EV; Benotsch, EG; Fick, LJ; Lutgendorf, S; Berbaum, ML; Berbaum, KS; Logan, H; Spiegel, D			Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial	LANCET			English	Article							INTERVENTIONAL RADIOLOGICAL PROCEDURES; CONSCIOUS SEDATION; PAIN INTENSITY; DRUG-USE; HYPNOSIS; SURGERY; MODELS	Background Non-pharmacological behavioural adjuncts have been suggested as efficient safe means in reducing discomfort and adverse effects during medical procedures. We tested this assumption for patients undergoing percutaneous vascular and renal procedures in a prospective, randomised, single-centre study. Methods 241 patients were randomised to receive intraoperatively standard care (n=79), structured attention (n=80), or self-hypnotic relaxation (n=82). All had access to patient-controlled intravenous analgesia with fentanyl and midazolam. Patients rated their pain and anxiety on 0-10 scares before, every 15 min during and after the procedures. Findings Pain increased linearly with procedure time in the standard group (slope 0.09 in pain score/15 min, p<0.0001), and the attention group (slope 0.04/15 min; p=0.0425), but remained fiat in the hypnosis group. Anxiety decreased over time in all three groups with slopes of -0.04 (standard), -0.07 (attention), and -0.11 (hypnosis). Drug use in the standard group (1.9 units) was significantly higher than in the attention and hypnosis groups (0.8 and 0.9 units, respectively). One hypnosis patient became haemodynamically unstable compared with ten attention patients (p=0.0041), and 12 standard patients (p=0.0009). Procedure times were significantly shorter in the hypnosis group (61 min) than in the standard group (78 min, p=0.0016) with procedure duration of the attention group in between (67 min). Interpretation Structured attention and self-hypnotic relaxation proved beneficial during invasive medical procedures. Hypnosis had more pronounced effects on pain and anxiety reduction, and is superior, in that it also improves haemodynamic stability.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiol, Boston, MA 02215 USA; Univ Iowa, Iowa City, IA USA; Univ Florida, Dept Radiol, Gainesville, FL 32610 USA; Univ Florida, Dept Psychol, Div Publ Hlth Serv & Res, Gainesville, FL 32610 USA; Univ Alabama, Social Sci Res Inst, Tuscaloosa, AL USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Iowa; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Alabama System; University of Alabama Tuscaloosa; Stanford University	Lang, EV (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiol, W Campus CC308,330 Brookline Ave, Boston, MA 02215 USA.		Benotsch, Eric/AAG-7466-2020	Spiegel, David/0000-0002-9476-9173; Berbaum, Kevin/0000-0003-0489-2360	NCCIH NIH HHS [R01 AT000002] Funding Source: Medline; NIMH NIH HHS [R01-MH56274] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056274] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*AC PAIN MAN GUID, 1992, AHCPR PUB US DEP HHS; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; BARBER TX, 1963, PSYCHOSOM MED, V25, P303, DOI 10.1097/00006842-196307000-00001; Bayer TL, 1998, PAIN, V74, P327, DOI 10.1016/S0304-3959(97)00196-6; BENOTSCH EG, 1998, ANN BEHAV MED, V20, P138; Dixon WJ, 1992, BMDP STAT SOFTWARE M, V2, P1311; Duggleby W, 1992, Clin Nurs Res, V1, P107, DOI 10.1177/105477389200100111; FAYMONVILLE ME, 1995, REGION ANESTH, V20, P145; Faymonville ME, 1997, PAIN, V73, P361, DOI 10.1016/S0304-3959(97)00122-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HORNE DJD, 1994, BEHAV MED, V20, P5; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; JOHN ME, 1983, AM J OPHTHALMOL, V96, P540, DOI 10.1016/S0002-9394(14)77919-X; KAZDIN AE, 1995, METHODS PSYCHOTHERAP; KIRK RE, 1995, PACIFIC GROVE, P72; Lang EV, 1998, J VASC INTERV RADIOL, V9, P407, DOI 10.1016/S1051-0443(98)70291-X; Lang EV, 1996, INT J CLIN EXP HYP, V44, P106, DOI 10.1080/00207149608416074; Lang EV, 1999, SEMIN INTERVENT RAD, V16, P113, DOI 10.1055/s-0028-1082196; LUDWICKROSENTHAL R, 1988, PSYCHOL BULL, V104, P326, DOI 10.1037/0033-2909.104.3.326; MONCHER FJ, 1991, CLIN PSYCHOL REV, V11, P247, DOI 10.1016/0272-7358(91)90103-2; Murphy DF, 1987, CLIN J PAIN, V3, P197, DOI [DOI 10.1097/00002508-198712000-00003, 10.1097/00002508-198712000-00003]; Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002; PATTERSON DR, 1992, J CONSULT CLIN PSYCH, V60, P713, DOI 10.1037/0022-006X.60.5.713; Schelling G, 1996, J UROLOGY, V155, P43, DOI 10.1016/S0022-5347(01)66534-0; SCHUTZ SM, 1994, AM J GASTROENTEROL, V89, P1476; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Siegel S, 1988, NONPARAMETRIC STAT B, P103; Smith JT, 1996, J COUNS PSYCHOL, V43, P187, DOI 10.1037/0022-0167.43.2.187; WALTZ J, 1993, J CONSULT CLIN PSYCH, V61, P620, DOI 10.1037/0022-006X.61.4.620; WEINSTEIN EJ, 1991, AM J CLIN HYPN, V34, P29, DOI 10.1080/00029157.1991.10402957	32	304	309	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 29	2000	355	9214					1486	1490		10.1016/S0140-6736(00)02162-0	http://dx.doi.org/10.1016/S0140-6736(00)02162-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	310LR	10801169				2022-12-28	WOS:000086830100009
J	Nguyen, TQ; Wu, JJ; Doan, V; Schwartz, BJ; Tolbert, SH				Nguyen, TQ; Wu, JJ; Doan, V; Schwartz, BJ; Tolbert, SH			Control of energy transfer in oriented conjugated polymer-mesoporous silica composites	SCIENCE			English	Article							EXCITON DYNAMICS; FEMTOSECOND; POLY(P-PHENYLENEVINYLENE); PHOTOLUMINESCENCE; LUMINESCENCE; RELAXATION; SPECTRA; FILMS; CHAIN	Nanoscale architecture was used to control energy transfer in semiconducting polymers embedded in the channels of oriented, hexagonal nanoporous silica. Polarized femtosecond spectroscopies show that excitations migrate unidirectionally from aggregated, randomly oriented polymer segments outside the pores to isolated, aligned polymer chains within the pores. Energy migration along the conjugated polymer backbone occurred more slowly than Forster energy transfer between polymer chains. The different intrachain and interchain energy transfer time scales explain the behavior of conjugated polymers in a range of solution environments. The results provide insights for optimizing nanostructured materials for use in optoelectronic devices.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Schwartz, BJ (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.		Tolbert, Sarah H./L-2321-2016	Schwartz, Benjamin/0000-0003-3257-9152				BECK JS, 1992, J AM CHEM SOC, V114, P10834, DOI 10.1021/ja00053a020; BOLIVAR PH, 1995, CHEM PHYS LETT, V245, P534, DOI 10.1016/0009-2614(95)01057-G; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P474; Cerullo G, 1999, SYNTHETIC MET, V101, P306, DOI 10.1016/S0379-6779(98)00838-8; Dogariu A, 1999, SYNTHETIC MET, V100, P95, DOI 10.1016/S0379-6779(98)00168-4; Firouzi A, 1997, J AM CHEM SOC, V119, P9466, DOI 10.1021/ja971267+; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Fox MA, 1999, ACCOUNTS CHEM RES, V32, P201, DOI 10.1021/ar9600953; Friend RH, 1999, NATURE, V397, P121, DOI 10.1038/16393; Harrison NT, 1996, PHYS REV LETT, V77, P1881, DOI 10.1103/PhysRevLett.77.1881; HAYES GR, 1995, PHYS REV B, V52, P11569, DOI 10.1103/PhysRevB.52.R11569; Hayes GR, 1997, PHYS REV B, V56, P3838, DOI 10.1103/PhysRevB.56.3838; Hoofman RJOM, 1998, NATURE, V392, P54, DOI 10.1038/32118; Kageyama K, 1999, SCIENCE, V285, P2113, DOI 10.1126/science.285.5436.2113; Kaschak DM, 1999, J AM CHEM SOC, V121, P3435, DOI 10.1021/ja982985e; Kaschak DM, 1996, J AM CHEM SOC, V118, P4222, DOI 10.1021/ja960384m; Kersting R, 1997, J LUMIN, V72-4, P936, DOI 10.1016/S0022-2313(97)00035-5; Kersting R, 1997, J CHEM PHYS, V106, P2850, DOI 10.1063/1.473094; KERSTING R, 1993, PHYS REV LETT, V70, P3820, DOI 10.1103/PhysRevLett.70.3820; Klimov VI, 1997, CHEM PHYS LETT, V277, P109, DOI 10.1016/S0009-2614(97)00923-8; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; LEMMER U, 1993, CHEM PHYS LETT, V209, P243, DOI 10.1016/0009-2614(93)80101-T; Moller K, 1999, CHEM MATER, V11, P665, DOI 10.1021/cm9805368; Nguyen TQ, 2000, J PHYS CHEM B, V104, P237, DOI 10.1021/jp993190c; Nguyen TQ, 1999, J CHEM PHYS, V110, P4068, DOI 10.1063/1.478288; Orrit M, 1999, SCIENCE, V285, P349, DOI 10.1126/science.285.5426.349; Rothberg LJ, 1996, J MATER RES, V11, P3174, DOI 10.1557/JMR.1996.0403; Ruseckas A, 1998, J LUMIN, V76-7, P474, DOI 10.1016/S0022-2313(97)00238-X; Tolbert SH, 1997, SCIENCE, V278, P264, DOI 10.1126/science.278.5336.264; Warmuth C, 1998, J LUMIN, V76-7, P498, DOI 10.1016/S0022-2313(97)00243-3; Watanabe A, 1997, CHEM PHYS LETT, V273, P227, DOI 10.1016/S0009-2614(97)00533-2; Weder C, 1997, ADV MATER, V9, P1035, DOI 10.1002/adma.19970091308; Wohlgenannt M, 1998, CHEM PHYS, V227, P99, DOI 10.1016/S0301-0104(97)00281-4; WU CG, 1994, SCIENCE, V266, P1013, DOI 10.1126/science.266.5187.1013; WU CG, 1994, SCIENCE, V264, P1757, DOI 10.1126/science.264.5166.1757; Wu JJ, 1999, J PHYS CHEM B, V103, P2374, DOI 10.1021/jp984070s; YAN M, 1995, PHYS REV LETT, V75, P1992, DOI 10.1103/PhysRevLett.75.1992; Zhang JZ, 1997, J CHEM PHYS, V106, P3710, DOI 10.1063/1.473423	38	628	649	4	177	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					652	656		10.1126/science.288.5466.652	http://dx.doi.org/10.1126/science.288.5466.652			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784444				2022-12-28	WOS:000086727100038
J	Sharples, JM; Meharg, AA; Chambers, SM; Cairney, JWG				Sharples, JM; Meharg, AA; Chambers, SM; Cairney, JWG			Evolution - Symbiotic solution to arsenic contamination	NATURE			English	Article							PHOSPHATE-UPTAKE SYSTEM; RESISTANCE; TOLERANCE; PLANTS		Univ Western Sydney, Sch Sci, Mycorrhiza Res Grp, Kingswood, NSW 2747, Australia; Inst Terr Ecol, Huntingdon PE17 2LS, England	Western Sydney University; UK Centre for Ecology & Hydrology (UKCEH)	Sharples, JM (corresponding author), Univ Western Sydney, Sch Sci, Mycorrhiza Res Grp, POB 10, Kingswood, NSW 2747, Australia.		Meharg, Andrew Alexander/F-8182-2014	Meharg, Andrew Alexander/0000-0003-2019-0449				BRADLEY R, 1981, NATURE, V292, P335, DOI 10.1038/292335a0; Cairney JWG, 1999, ENVIRON POLLUT, V106, P169, DOI 10.1016/S0269-7491(99)00081-0; LEE RB, 1982, ANN BOT-LONDON, V50, P429, DOI 10.1093/oxfordjournals.aob.a086383; MACNAIR MR, 1993, NEW PHYTOL, V124, P541, DOI 10.1111/j.1469-8137.1993.tb03846.x; MEHARG AA, 1992, J EXP BOT, V43, P519, DOI 10.1093/jxb/43.4.519; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; Smith SE., 1996, MYCORRHIZAL SYMBIOSI; STRAKER CJ, 1987, NEW PHYTOL, V106, P129, DOI 10.1111/j.1469-8137.1987.tb04796.x	8	104	128	3	50	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					951	952		10.1038/35010193	http://dx.doi.org/10.1038/35010193			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801114				2022-12-28	WOS:000086762000042
J	Keohane, C				Keohane, C			Pulvinar sign on MRI images in variant Creutzfeldt-Jakob disease	LANCET			English	Editorial Material									Cork Univ Hosp, Dept Histopathol, Cork, Ireland	University College Cork	Keohane, C (corresponding author), Cork Univ Hosp, Dept Histopathol, Cork, Ireland.							*ADV COMM DANG PAT, 1998, TRANSM SPONG ENC AG; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; Ironside JW, 1997, BRAIN PATHOL, V7, P1243; McLean CA, 1998, BRAIN PATHOL, V8, P429	5	1	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1384	1384		10.1016/S0140-6736(00)02133-4	http://dx.doi.org/10.1016/S0140-6736(00)02133-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791518				2022-12-28	WOS:000086829800005
J	Look, KY				Look, KY			Who benefits from radiotherapy in treatment of endometrial cancer and at what price?	LANCET			English	Editorial Material							STAGE-I; CARCINOMA; ADENOCARCINOMA; PATTERNS; IMPACT		Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Look, KY (corresponding author), Indiana Univ, Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.							AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Barnes MN, 1999, GYNECOL ONCOL, V74, P443, DOI 10.1006/gyno.1999.5480; DISAIA PJ, 1985, AM J OBSTET GYNECOL, V151, P1009, DOI 10.1016/0002-9378(85)90371-0; Gretz HF, 1996, GYNECOL ONCOL, V61, P409, DOI 10.1006/gyno.1996.0165; LEWANDOWSKI G, 1990, GYNECOL ONCOL, V36, P401, DOI 10.1016/0090-8258(90)90151-A; Lybeert MLM, 1998, EUR J CANCER, V34, P586, DOI 10.1016/S0959-8049(97)10087-9; MEERWALDT JH, 1990, INT J RADIAT ONCOL, V18, P299, DOI 10.1016/0360-3016(90)90093-Y; Naumann RW, 1999, GYNECOL ONCOL, V75, P4, DOI 10.1006/gyno.1999.5548; Orr JW, 1997, AM J OBSTET GYNECOL, V176, P777, DOI 10.1016/S0002-9378(97)70601-X; POTISH RA, 1990, INT J RADIAT ONCOL, V18, P1005, DOI 10.1016/0360-3016(90)90434-L; Roberts James Allan, 1998, Gynecologic Oncology, V68, P135	11	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1381	1382		10.1016/S0140-6736(00)02131-0	http://dx.doi.org/10.1016/S0140-6736(00)02131-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791516				2022-12-28	WOS:000086829800003
J	Barbour, V				Barbour, V			Haematology for non-haematologists	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Barbour, V (corresponding author), Lancet, London WC1X 8RR, England.			Barbour, Virginia/0000-0002-2358-2440					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2000	355	9210					1118	1118		10.1016/S0140-6736(00)02058-4	http://dx.doi.org/10.1016/S0140-6736(00)02058-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791372				2022-12-28	WOS:000086380900007
J	Kalra, L; Yu, G; Perez, I; Lakhani, A; Donaldson, N				Kalra, L; Yu, G; Perez, I; Lakhani, A; Donaldson, N			Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WARFARIN; ASPIRIN	Objective To determine whether trial efficacy of prophylaxis with warfarin for patients with atrial fibrillation at high risk of stroke translates into effectiveness in clinical practice. Design Two year prospective cohort study. Setting District general hospital. Participants 167 patients with atrial fibrillation and at high stroke risk who were eligible for anticoagulation. Interventions Long term anticoagulation with warfarin at adjusted doses to maintain an international normalised ratio of 2.0-3.0. Main outcome measures Comparison of patient characteristics, comorbidity, anticoagulation control, stroke rate, and haemorrhagic complications with pooled data from five randomised controlled trials. Results Patients in the study group were seven years older (95% confidence interval 4 to 10) and comprised 33%, more women than patients in the pooled trials. The inter national normalised ratio was in the target range for 61% of the time (range 37%-85%), below for 26% of the time (range 8%-32%), and above for 13% of the time (range 6%-26%). The time that patients in the study group spent in the target range was significantly less than in the pooled analysis. The incidence of stroke in the study group (2.0% per rear, 0.7% to 4.4%) was comparable to that of patients receiving warfarin in pooled studies (1.4%, 0.8% to 2.3%). Per year the incidence of major (1.7% v 1.6%) and minor (5.4% v 9.2%) bleeding complications was also similar. Conclusion Rates of stroke and major haemorrhage after anticoagulation in clinical practice were comparable to those obtained from pooled data from randomised controlled studies for patients with atrial fibrillation at high risk of stroke.	Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England; Orpington Hosp, Bromley Hosp NHS Trust, Dept Med Elderly, Kent BR6 9JU, England; Farnborough Hosp, Bromley Hosp NHS Trust, Dept Haematol, Orpington BR6 8ND, Kent, England; Kings Coll Hosp London, Dept Res & Dev, Biostat Unit, London SE5 9RS, England	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital	Kalra, L (corresponding author), Guys Kings & St Thomass Sch Med, Dept Med, London SE5 9PJ, England.	lalit.kalra@kcl.ac.uk						Albers GW, 1996, ARCH INTERN MED, V156, P2311, DOI 10.1001/archinte.156.20.2311; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; Aronow WS, 1999, J AM GERIATR SOC, V47, P366, DOI 10.1111/j.1532-5415.1999.tb03004.x; Blackshear JL, 1996, LANCET, V348, P633; Brass LM, 1997, STROKE, V28, P2382, DOI 10.1161/01.STR.28.12.2382; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Feinberg WM, 1998, NEUROLOGY, V51, pS20, DOI 10.1212/WNL.51.3_Suppl_3.S20; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; Green CJ, 1997, CAN J CARDIOL, V13, P811; GULLOW AL, 1998, ARCH INTERN MED, V158, P1487; Hellemons BSP, 1999, BMJ-BRIT MED J, V319, P958, DOI 10.1136/bmj.319.7215.958; Kalra L, 1999, STROKE, V30, P1218, DOI 10.1161/01.STR.30.6.1218; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1995, CHEST S, V108, P352; Lip GYH, 1996, BRIT MED J, V312, P45, DOI 10.1136/bmj.312.7022.45; MATCHAR DB, 1994, ANN INTERN MED, V121, P54; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PETERSEN P, 1989, LANCET, V1, P175; SANDERCOCK PAG, 1991, Q J MED, V286, P101; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; WHITTLE J, 1997, ARCH INTERN MED, V157, P451	24	121	128	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 6	2000	320	7244					1236	1239		10.1136/bmj.320.7244.1236	http://dx.doi.org/10.1136/bmj.320.7244.1236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797031	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000086981400016
J	Kim, C; Burrows, PE; Forrest, SR				Kim, C; Burrows, PE; Forrest, SR			Micropatterning of organic electronic devices by cold-welding	SCIENCE			English	Article							LIGHT-EMITTING DEVICES; ADHESION; ELECTROLUMINESCENCE; CONTACT; FILMS	A simple and general postdeposition electrode patterning technique for active organic electronic devices is demonstrated and is applied to patterning the metal cathodes of organic light-emitting devices. Selective lift-off of the metal cathode layer is achieved by pressing a prepatterned, metal-coated silicon stamp on the unpatterned device layers. Under pressure, the metal coating on the stamp cold-welds to the metal cathode coating the underlying organic films. Subsequent separation of the stamp from the substrate results in removal of the cathode metal in the regions contacted by the stamp, resulting in submicrometer feature definition. A 17x17 passive matrix display, with a pixel size of 440 micrometers by 320 micrometers, was fabricated with this process. Cold-welding followed by lift-off of the cathode metal allows simple, cost-effective, and high-throughput large-area fabrication of organic electronic devices.	Princeton Univ, Dept Elect Engn, Ctr Photon & Optoelect Mat, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA	Princeton University; Princeton University	Forrest, SR (corresponding author), Princeton Univ, Dept Elect Engn, Ctr Photon & Optoelect Mat, Princeton, NJ 08544 USA.							Bansal N. P., 1986, HDB GLASS PROPERTIES; Bharathan J, 1998, APPL PHYS LETT, V72, P2660, DOI 10.1063/1.121090; Bolz R. E, 1973, HDB TABLES APPL ENG; BOWDEN FP, 1964, FRICTION LUBRICATI 2; Burrows PE, 1996, J APPL PHYS, V79, P7991, DOI 10.1063/1.362350; Chang SC, 1999, ADV MATER, V11, P734, DOI 10.1002/(SICI)1521-4095(199906)11:9<734::AID-ADMA734>3.0.CO;2-D; Duffy DC, 1999, ADV MATER, V11, P546, DOI 10.1002/(SICI)1521-4095(199905)11:7<546::AID-ADMA546>3.0.CO;2-E; FERGUSON GS, 1991, SCIENCE, V253, P776, DOI 10.1126/science.253.5021.776; Gu G, 1999, J APPL PHYS, V86, P4067, DOI 10.1063/1.371331; Hebner TR, 1998, APPL PHYS LETT, V72, P519, DOI 10.1063/1.120807; LIEDENBAUM CTH, 1999, 2 INT C EL MOL MAT R; MACHLIN ES, 1954, J APPL PHYS, V25, P576, DOI 10.1063/1.1721691; MIYAGUCHI S, 1998, P 9 INT WORKSH IN OR, P137; Noach S, 1996, APPL PHYS LETT, V69, P3650, DOI 10.1063/1.117012; SMITH JR, 1989, PHYS REV LETT, V63, P1269, DOI 10.1103/PhysRevLett.63.1269; SPENCE DA, 1973, P CAMB PHILOS SOC, V73, P249; TANG CW, 1989, J APPL PHYS, V65, P3610, DOI 10.1063/1.343409; TAYLOR PA, 1991, PHYS REV B, V44, P5834, DOI 10.1103/PhysRevB.44.5834; Tian PF, 1997, APPL PHYS LETT, V71, P3197, DOI 10.1063/1.120288	19	205	220	5	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					831	833		10.1126/science.288.5467.831	http://dx.doi.org/10.1126/science.288.5467.831			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10796998				2022-12-28	WOS:000086869600028
J	Wedekind, C; Milinski, M				Wedekind, C; Milinski, M			Cooperation through image scoring in humans	SCIENCE			English	Article							INDIRECT RECIPROCITY; PRISONERS-DILEMMA; EVOLUTION	The "tragedy of the commons," that is, the selfish exploitation of resources in the public domain, is a reason for many of our everyday social conflicts. However, humans are often more helpful to others than evolutionary theory would predict, unless indirect reciprocity takes place and is based on image scoring (which reflects the way an individual is viewed by a group), as recently shown by game theorists. We tested this idea under conditions that control for confounding factors. Donations were more frequent to receivers who had been generous to others in earlier interactions. This shows that image scoring promotes cooperative behavior in situations where direct reciprocity is unlikely.	Univ Bern, Inst Zool, Abt Verhaltensokol, CH-3032 Hinterkappelen, Switzerland; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	University of Bern; Utah System of Higher Education; University of Utah	Wedekind, C (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		Wedekind, Claus/S-3353-2016	Wedekind, Claus/0000-0001-6143-4716				Alexander R., 1987, BIOL MORAL SYSTEMS; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Ferriere R, 1998, NATURE, V393, P517, DOI 10.1038/31102; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Lotem A, 1999, NATURE, V400, P226, DOI 10.1038/22247; Milinski M, 1998, P NATL ACAD SCI USA, V95, P13755, DOI 10.1073/pnas.95.23.13755; Nowak MA, 1998, J THEOR BIOL, V194, P561, DOI 10.1006/jtbi.1998.0775; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; NOWAK MA, 1995, SCI AM, V272, P50; Ostrom E, 1999, SCIENCE, V284, P278, DOI 10.1126/science.284.5412.278; Roberts G, 1998, NATURE, V394, P175, DOI 10.1038/28160; Wedekind C, 1996, P NATL ACAD SCI USA, V93, P2686, DOI 10.1073/pnas.93.7.2686; Zahavi A., 1991, COOPERATIVE BREEDING, P105	14	555	580	2	163	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					850	852		10.1126/science.288.5467.850	http://dx.doi.org/10.1126/science.288.5467.850			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797005				2022-12-28	WOS:000086869600035
J	Fan, HY; Lu, YF; Stump, A; Reed, ST; Baer, T; Schunk, R; Perez-Luna, V; Lopez, GP; Brinker, CJ				Fan, HY; Lu, YF; Stump, A; Reed, ST; Baer, T; Schunk, R; Perez-Luna, V; Lopez, GP; Brinker, CJ			Rapid prototyping of patterned functional nanostructures	NATURE			English	Article							MESOPOROUS MOLECULAR-SIEVES; SELF-ASSEMBLED MONOLAYERS; SILICA; FILMS; MICROFABRICATION; SURFACE; GOLD	Living systems exhibit form and function on multiple length scales and at multiple locations. In order to mimic such natural structures, it is necessary to develop efficient strategies for assembling hierarchical materials. Conventional photolithography, although ubiquitous in the fabrication of microelectronics and microelectromechanical systems, is impractical for defining feature sizes below 0.1 micrometres and poorly suited to pattern chemical functionality. Recently, so-called 'soft' lithographic approaches(1) have been combined with surfactant(2,3) and particulate(4) templating procedures to create materials with multiple levels of structural order. But the materials thus formed have been limited primarily to oxides with no specific functionality, and the associated processing times have ranged from hours to days. Here, using a self-assembling 'ink', we combine silica-surfactant self-assembly with three rapid printing procedures-pen lithography, ink-jet printing, and dip-coating of patterned self-assembled monolayers-to form functional, hierarchically organized structures in seconds. The rapid-prototyping procedures we describe are simple, employ readily available equipment, and provide a link between computer-aided design and self-assembled nanostructures. We expect that the ability to form arbitrary functional designs on arbitrary surfaces will be of practical importance for directly writing sensor arrays and fluidic or photonic systems.	Sandia Natl Labs, Albuquerque, NM 87185 USA; Univ New Mexico, Ctr Microengineered Mat, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Chem & Nucl Engn, Albuquerque, NM 87131 USA	United States Department of Energy (DOE); Sandia National Laboratories; University of New Mexico; University of New Mexico	Brinker, CJ (corresponding author), Sandia Natl Labs, POB 5800, Albuquerque, NM 87185 USA.	cjbrink@sandia.gov						Asefa T, 1999, NATURE, V402, P867, DOI 10.1038/47229; BAER TA, IN PRESS INT J NUMER; BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; Brinker CJ, 1999, ADV MATER, V11, P579, DOI 10.1002/(SICI)1521-4095(199905)11:7<579::AID-ADMA579>3.0.CO;2-R; Burkett SL, 1996, CHEM COMMUN, P1367, DOI 10.1039/cc9960001367; CAIRNCROSS RA, IN PRESS INT J NUMER; Chang SC, 1999, ADV MATER, V11, P734, DOI 10.1002/(SICI)1521-4095(199906)11:9<734::AID-ADMA734>3.0.CO;2-D; Fowler CE, 1997, CHEM COMMUN, P1769, DOI 10.1039/a704644h; Frink LJD, 1999, J CHEM PHYS, V110, P5969, DOI 10.1063/1.478497; Frye G. C., 1988, Better Ceramics Through Chemistry III. Symposium, P349; Inagaki S, 1999, J AM CHEM SOC, V121, P9611, DOI 10.1021/ja9916658; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Lebeau B, 1999, J MATER CHEM, V9, P2279, DOI 10.1039/a905155d; Lim MH, 1997, J AM CHEM SOC, V119, P4090, DOI 10.1021/ja9638824; Liu J, 1998, ADV MATER, V10, P161, DOI 10.1002/(SICI)1521-4095(199801)10:2<161::AID-ADMA161>3.3.CO;2-H; Lu YF, 1999, NATURE, V398, P223, DOI 10.1038/18410; Lu YF, 1997, NATURE, V389, P364, DOI 10.1038/38699; Melde BJ, 1999, CHEM MATER, V11, P3302, DOI 10.1021/cm9903935; Pede D, 1998, MAT SCI ENG C-BIOMIM, V5, P289, DOI 10.1016/S0928-4931(97)00056-8; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; PRAKASH SS, 1995, NATURE, V374, P439, DOI 10.1038/374439a0; Sellinger A, 1998, NATURE, V394, P256, DOI 10.1038/28354; TANEV PT, 1995, SCIENCE, V267, P865, DOI 10.1126/science.267.5199.865; Tender LM, 1996, LANGMUIR, V12, P5515, DOI 10.1021/la960627o; Trau M, 1997, NATURE, V390, P674, DOI 10.1038/37764; Wilbur JL, 1996, NANOTECHNOLOGY, V7, P452, DOI 10.1088/0957-4484/7/4/028; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Yang H, 1997, ADV MATER, V9, P811, DOI 10.1002/adma.19970091010; Yang H, 1996, NATURE, V381, P589, DOI 10.1038/381589a0; Yang P, 1999, MATER RES SOC SYMP P, V542, P159; Yang PD, 2000, SCIENCE, V287, P465, DOI 10.1126/science.287.5452.465; Yang PD, 1998, SCIENCE, V282, P2244, DOI 10.1126/science.282.5397.2244	32	360	401	1	215	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	2000	405	6782					56	60		10.1038/35011026	http://dx.doi.org/10.1038/35011026			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811215	Green Submitted			2022-12-28	WOS:000086901600048
J	Tully, J; Ninis, N; Booy, R; Viner, R				Tully, J; Ninis, N; Booy, R; Viner, R			The new system of review by multicentre research ethics committees: prospective study	BRITISH MEDICAL JOURNAL			English	Article							SOUTH THAMES REGION	Objective To assess the function of the ne iv system of review by multicentre research ethics committees and to highlight areas where improvement is still needed. Design Prospectively collected data from a multicentre study was examined with respect to the ethics review process. Administrative, financial, and time elements of the review process were audited. Setting A single multicentre research ethics committee and 125 local ethics committees front six regions of England, Main outcome measures Time to reply, time to approval, and number of non-local changes to the application requested. Results Only 40% of local ethics committees considered our study in the manner specified in the 1998 directive. Less than a third of committees replied within the 21 day period stipulated, although committees acting by executive subcommittee replied more quickly than those not acting by executive subcommittee, There was a tendency for executive subcommittees to approve studies in a shorter time. Local ethics committees asked for a large number of non-local changes to the application. The financial cost of applying to multiple ethics committees remains high, mainly because multiple copies of research applications are being requested. Conclusions The new system of approval by multicentre research ethics committee for multicentre studies was introduced to reduce administrative costs, speed up the process of reviews by multiple research ethics committees, and standardise the conclusions of the local research ethics committees. Since its introduction an improvement has been seen, but the system is not yet universally functioning as intended. Ethics review still remains a hindrance to the financial resources and commencement of national studies. We strongly support the structure of review by multicentre research ethics committees but suggest that the system has vet to achieve its aims.	Inst Child Hlth, Dept Epidemiol, London WC1N 1EH, England; Royal London Hosp, Dept Child Hlth, London E1 1BB, England; Royal Coll Paediat & Child Hlth, London W1N 6DE, England; Middlesex Hosp, Middlesex Adolescent Unit, London W1N 8AA, England	University of London; University College London; Barts Health NHS Trust; Royal London Hospital; University of London; University College London	Tully, J (corresponding author), Inst Child Hlth, Dept Epidemiol, 30 Guilford St, London WC1N 1EH, England.		Viner, Russell M/A-1441-2009	Viner, Russell M/0000-0003-3047-2247; Tully, Joanna/0000-0002-3918-6063	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Busby A, 1998, J ROY COLL PHYS LOND, V32, P142; Foster C, 1998, J ROY COLL PHYS LOND, V32, P242; HARRIES UJ, 1994, J ROY COLL PHYS LOND, V28, P150; Holley S, 1998, J ROY COLL PHYS LOND, V32, P238; Stacey TE, 1998, J ROY COLL PHYS LOND, V32, P190; STACEY TE, 1998, SHOULD LREC HANDLE M, P1; WHILE AE, 1995, BRIT MED J, V311, P661, DOI 10.1136/bmj.311.7006.661	7	78	78	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1179	1182		10.1136/bmj.320.7243.1179	http://dx.doi.org/10.1136/bmj.320.7243.1179			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784541	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000086832800018
J	Blanchoin, L; Amann, KJ; Higgs, HN; Marchand, JB; Kaiser, DA; Pollard, TD				Blanchoin, L; Amann, KJ; Higgs, HN; Marchand, JB; Kaiser, DA; Pollard, TD			Direct observation of dendritic actin filament networks nucleated by Arp2/3 complex and WASP/Scar proteins	NATURE			English	Article							CAPPING PROTEIN; ACANTHAMOEBA-CASTELLANII; F-ACTIN; POLYMERIZATION; PROFILIN; PURIFICATION; PHOSPHATE; MECHANISM; DYNAMICS; AGAROSE	Most nucleated cells crawl about by extending a pseudopod that is driven by the polymerization of actin filaments in the cytoplasm behind the leading edge of the plasma membrane(1,2). These actin filaments are linked into a network by Y-branches, with the pointed end of each filament attached to the side of another filament and the rapidly growing barbed end facing forward(3). Because Arp2/3 complex nucleates actin polymerization and links the pointed end to the side of another filament in vitro, a dendritic nucleation model has been proposed 4 in which Arp2/3 complex initiates filaments from the sides of older filaments. Here we report, by using a light microscopy assay, many new features of the mechanism. Branching occurs during, rather than after, nucleation by Arp2/3 complex activated by the Wiskott-Aldrich syndrome protein (WASP) or Scar protein; capping protein and profilin act synergistically with Arp2/3 complex to favour branched nucleation; phosphate release from aged actin filaments favours dissociation of Arp2/3 complex from the pointed ends of filaments; and branches created by Arp2/3 complex are relatively rigid. These properties result in the automatic assembly of the branched actin network after activation by proteins of the WASP/ Scar family and favour the selective disassembly of proximal regions of the network.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Pollard, TD (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Higgs, Henry/0000-0002-2917-9644				ALMO SC, 1994, J MOL BIOL, V236, P950, DOI 10.1006/jmbi.1994.1200; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; DANCKER P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P197, DOI 10.1016/0304-4165(90)90116-E; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MOGILNER A, 1996, BIOPHYS J, V71, P303; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; POLLARD TD, 1999, GUIDEBOOK CYTOSKELET, P3; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; Xu JY, 1999, CELL MOTIL CYTOSKEL, V42, P73, DOI 10.1002/(SICI)1097-0169(1999)42:1<73::AID-CM7>3.0.CO;2-Z	28	409	421	4	37	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					1007	1011		10.1038/35010008	http://dx.doi.org/10.1038/35010008			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801131				2022-12-28	WOS:000086762000059
J	Reichhardt, T				Reichhardt, T			NASA's new environmental satellite shows its sensitive side	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					913	913		10.1038/35010229	http://dx.doi.org/10.1038/35010229			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801093	Bronze			2022-12-28	WOS:000086762000010
J	Stephen, LJ; Brodie, MJ				Stephen, LJ; Brodie, MJ			Epilepsy in elderly people	LANCET			English	Review							DRUG-INDUCED SEIZURES; ANTIEPILEPTIC DRUGS; STATUS EPILEPTICUS; DOUBLE-BLIND; ACUTE STROKE; ETIOLOGY; MANAGEMENT; THERAPY; AGE; GABAPENTIN	The prevalence and incidence of epilepsy are highest in later life with around 25% of new cases occurring in elderly people, many of whom will have concomitant neurodegenerative, cerebrovascular, or neoplastic disease. Difficulties accepting the diagnosis are frequently compounded by its unpredictable nature. Those affected commonly lose confidence and independence. Seizures in older people can result in physical injury, adding to low morale. Complete control is achievable in around 70% of patients with antiepileptic drug treatment. Optimum management requires rapid investigation, accurate diagnosis, effective treatment, sympathetic education, and assured support. The emergence of seizure disorders in old age places an increasing burden on health-care facilities and costs. A coordinated programme among health-care workers is advised to maintain the independence and improve the quality of life of this vulnerable patient population.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Brodie, MJ (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland.							ADAMS RD, 1997, PRINCIPLES NEUROLOGY, P367; Asconape J J, 1991, Clin Geriatr Med, V7, P483; Brodie MJ, 1999, EPILEPSY RES, V37, P81, DOI 10.1016/S0920-1211(99)00039-X; Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; BRODIE MJ, 1992, EPILEPSIA S1, V33, P13; CAMERON H, 1995, EPILEPSY RES, V21, P149, DOI 10.1016/0920-1211(95)00016-4; CELESIA GG, 1988, ARCH NEUROL-CHICAGO, V45, P781, DOI 10.1001/archneur.1988.00520310099023; COCITO L, 1982, STROKE, V13, P189, DOI 10.1161/01.STR.13.2.189; CRAIG I, 1994, EPILEPSIA, V35, P381, DOI 10.1111/j.1528-1157.1994.tb02448.x; Craig I, 1991, CARE ELDERLY, V3, P69; DAM AM, 1985, EPILEPSIA, V26, P227, DOI 10.1111/j.1528-1157.1985.tb05410.x; delaCourt A, 1996, EPILEPSIA, V37, P141; DEREUCK J, 1980, J NEUROL, V224, P101; Dichter MA, 1996, NEW ENGL J MED, V334, P1583, DOI 10.1056/NEJM199606133342407; Drury I, 1998, ARCH INTERN MED, V158, P99, DOI 10.1001/archinte.158.1.99; FRANSON KL, 1995, DRUG AGING, V7, P38, DOI 10.2165/00002512-199507010-00005; GIROUD M, 1994, EPILEPSIA, V35, P959, DOI 10.1111/j.1528-1157.1994.tb02540.x; GODFREY JBW, 1989, AGE AGEING, V18, P17, DOI 10.1093/ageing/18.1.17; HAUSER A, 1988, EPIDEPSIA S2, V29, P66; HAUSER WA, 1992, EPILEPSIA S4, V33, P6, DOI DOI 10.1111/J.1528-1157.1992.TB06222.X; HOLMES GL, 1980, CLIN ELECTROENCEPHAL, V11, P83, DOI 10.1177/155005948001100207; HOPKINS A, 1988, LANCET, V1, P721; Jallon P, 1999, LANCET, V353, P1496, DOI 10.1016/S0140-6736(99)00583-8; KILPATRICK CJ, 1992, ARCH NEUROL-CHICAGO, V49, P509, DOI 10.1001/archneur.1992.00530290097017; Lackner TE, 1998, EPILEPSIA, V39, P1083, DOI 10.1111/j.1528-1157.1998.tb01294.x; Lambrakis CC, 1998, J EPILEPSY, V11, P233, DOI 10.1016/S0896-6974(98)00029-2; Leach JP, 1997, J NEUROL NEUROSUR PS, V62, P372, DOI 10.1136/jnnp.62.4.372; LEE H, 1990, NEUROLOGY, V40, P165, DOI 10.1212/WNL.40.1.165; LUHDORF K, 1986, EPILEPSIA, V27, P458, DOI 10.1111/j.1528-1157.1986.tb03567.x; MCAREAVEY MJ, 1992, EPILEPSIA, V33, P657, DOI 10.1111/j.1528-1157.1992.tb02343.x; MESSING RO, 1984, NEUROLOGY, V34, P1582, DOI 10.1212/WNL.34.12.1582; OMAHONY MS, 1994, PHARMACOL THERAPEUT, V61, P279, DOI 10.1016/0163-7258(94)90066-3; Read CL, 1998, SEIZURE-EUR J EPILEP, V7, P159, DOI 10.1016/S1059-1311(98)80073-3; ROBERTS MA, 1982, AGE AGEING, V11, P24, DOI 10.1093/ageing/11.1.24; ROMANELLI MF, 1990, ARCH NEUROL-CHICAGO, V47, P847, DOI 10.1001/archneur.1990.00530080029006; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; SCHEUER ML, 1993, NEUROL CLIN, V11, P787, DOI 10.1016/S0733-8619(18)30124-5; SCHOTT GD, 1977, BRIT MED J, V1, P1454, DOI 10.1136/bmj.1.6074.1454; SMITH DF, 1991, J NEUROL NEUROSUR PS, V54, P915, DOI 10.1136/jnnp.54.10.915; SO E, 1996, NEUROLOGY, V8, P417; Stephen L.J., 1998, PRESCRIBERS J, V38, P98; Stephen LJ, 1999, SEIZURE-EUR J EPILEP, V8, P339, DOI 10.1053/seiz.1999.0301; Stolarek IH, 1995, J ROY SOC MED, V88, P686; SUNDARAM MBM, 1989, NEUROEPIDEMIOLOGY, V8, P234, DOI 10.1159/000110188; SUNG CY, 1989, ACTA NEUROL SCAND, V80, P51, DOI 10.1111/j.1600-0404.1989.tb03842.x; TALLIS R, 1990, LANCET, V336, P295, DOI 10.1016/0140-6736(90)91816-S; Thomas RJ, 1997, ARCH INTERN MED, V157, P605, DOI 10.1001/archinte.157.6.605; Wilson EA, 1998, EPILEPSY RES, V29, P161, DOI 10.1016/S0920-1211(97)00078-8; WILSON EA, 1996, BAILLIERE CLIN NEUR, P694; YOUNG GB, 1985, CAN J NEUROL SCI, V12, P317, DOI 10.1017/S0317167100035411	50	166	172	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1441	1446		10.1016/S0140-6736(00)02149-8	http://dx.doi.org/10.1016/S0140-6736(00)02149-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791538				2022-12-28	WOS:000086829800039
J	Giardina, CP; Ryan, MG				Giardina, CP; Ryan, MG			Evidence that decomposition rates of organic carbon in mineral soil do not vary with temperature	NATURE			English	Article							NATURAL C-13 ABUNDANCE; 5 HAWAIIAN SOILS; MATTER DYNAMICS; MICROBIAL RESPIRATION; FOREST; TURNOVER; STORAGE; FLUXES; CO2; SENSITIVITY	It has been suggested that increases in temperature can accelerate the decomposition of organic carbon contained in forest mineral soil (C-s), and, therefore, that global warming should increase the release of soil organic carbon to the atmosphere(1-6). These predictions assume, however, that decay constants can be accurately derived from short-term laboratory incubations of soil or that in situ incubations of fresh litter accurately represent the temperature sensitivity of C-s decomposition. But our limited understanding of the biophysical factors that control C-s decomposition rates, and observations of only minor increases in C-s decomposition rate with temperature in longer-term forest soil heating experiments(7-12) and in latitudinal comparisons of C-s decomposition rates(13-15) bring these predictions into question. Here we have compiled C-s decomposition data from 82 sites on five continents. We found that C-s decomposition rates were remarkably constant across a global-scale gradient in mean annual temperature. These data suggest that C-s decomposition rates for forest soils are not controlled by temperature limitations to microbial activity, and that increased temperature alone will not stimulate the decomposition of forest-derived carbon in mineral soil.	Univ Hawaii Manoa, Dept Nat Resources & Environm Management, Honolulu, HI 96822 USA; US Forest Serv, USDA, Rocky Mt Res Stn, Ft Collins, CO 80526 USA; Colorado State Univ, Grad Degree Program Ecol, Ft Collins, CO 80523 USA	University of Hawaii System; University of Hawaii Manoa; United States Department of Agriculture (USDA); United States Forest Service; Colorado State University	Giardina, CP (corresponding author), Univ Hawaii Manoa, Dept Nat Resources & Environm Management, 1910 East West Rd, Honolulu, HI 96822 USA.		Ryan, Michael G/A-9805-2008; Giardina, Christian P/C-3120-2011	Ryan, Michael G/0000-0002-2500-6738; Giardina, Christian P/0000-0002-3431-5073				[Anonymous], 1996, SOIL MICROBIOLOGY BI; BALESDENT J, 1987, SOIL BIOL BIOCHEM, V19, P25, DOI 10.1016/0038-0717(87)90120-9; Bashkin MA, 1998, ECOLOGY, V79, P828, DOI 10.1890/0012-9658(1998)079[0828:CISCFA]2.0.CO;2; Binkley D, 1999, SOIL SCI SOC AM J, V63, P222, DOI 10.2136/sssaj1999.03615995006300010032x; BONDE TA, 1992, SOIL BIOL BIOCHEM, V24, P275, DOI 10.1016/0038-0717(92)90230-U; Cao MK, 1998, NATURE, V393, P249, DOI 10.1038/30460; Cheng WX, 1996, SOIL BIOL BIOCHEM, V28, P1283, DOI 10.1016/S0038-0717(96)00138-1; Feller C, 1997, GEODERMA, V79, P69, DOI 10.1016/S0016-7061(97)00039-6; Goulden ML, 1998, SCIENCE, V279, P214, DOI 10.1126/science.279.5348.214; GREGORICH EG, 1995, CAN J SOIL SCI, V75, P161, DOI 10.4141/cjss95-023; HART SC, 1994, ECOLOGY, V75, P880, DOI 10.2307/1939413; HOLLAND EA, 1995, GLOB CHANGE BIOL, V1, P115, DOI 10.1111/j.1365-2486.1995.tb00011.x; JENKINSON DS, 1991, NATURE, V351, P304, DOI 10.1038/351304a0; KIRSCHBAUM MUF, 1995, SOIL BIOL BIOCHEM, V27, P753, DOI 10.1016/0038-0717(94)00242-S; Liski J, 1999, AMBIO, V28, P171; Mahieu N, 1999, SOIL SCI SOC AM J, V63, P307, DOI 10.2136/sssaj1999.03615995006300020008x; MELILLO JM, 1995, GLOBAL BIOGEOCHEM CY, V9, P407; MOTAVALLI PP, 1994, SOIL BIOL BIOCHEM, V26, P935, DOI 10.1016/0038-0717(94)90106-6; NADELHOFFER KJ, 1991, ECOLOGY, V72, P242, DOI 10.2307/1938918; PETERJOHN WT, 1993, OECOLOGIA, V93, P18, DOI 10.1007/BF00321185; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; SCHIMEL DS, 1994, GLOBAL BIOGEOCHEM CY, V8, P279, DOI 10.1029/94GB00993; SORENSEN L H, 1981, Soil Biology and Biochemistry, V13, P313, DOI 10.1016/0038-0717(81)90068-7; Townsend AR, 1997, BIOGEOCHEMISTRY, V38, P1, DOI 10.1023/A:1017942918708; TOWNSEND AR, 1995, ECOLOGY, V76, P721, DOI 10.2307/1939339; Trumbore SE, 1996, SCIENCE, V272, P393, DOI 10.1126/science.272.5260.393; TRUMBORE SE, 1995, GLOBAL BIOGEOCHEM CY, V9, P515, DOI 10.1029/95GB02148; UPDEGRAFF K, 1995, ECOL APPL, V5, P151, DOI 10.2307/1942060; VELDKAMP E, 1994, SOIL SCI SOC AM J, V58, P175, DOI 10.2136/sssaj1994.03615995005800010025x; Winkler JP, 1996, SOIL BIOL BIOCHEM, V28, P1067, DOI 10.1016/0038-0717(96)00076-4	30	710	835	16	387	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					858	861		10.1038/35009076	http://dx.doi.org/10.1038/35009076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786789				2022-12-28	WOS:000086625000041
J	Goodenough, JB				Goodenough, JB			Ceramic technology - Oxide-ion conductors by design	NATURE			English	Editorial Material							DOPED LAGAO3		Univ Texas, Texas Mat Inst, Austin, TX 78713 USA	University of Texas System; University of Texas Austin	Goodenough, JB (corresponding author), Univ Texas, Texas Mat Inst, ETC 9-102, Austin, TX 78713 USA.		Biradar, Nirmala/AAY-2295-2020	Goodenough, John Bannister/0000-0001-9350-3034				ABRAHAM F, 1990, SOLID STATE IONICS, V40-1, P934, DOI 10.1016/0167-2738(90)90157-M; ABRAHAM F, 1988, SOLID STATE IONICS, V28, P529, DOI 10.1016/S0167-2738(88)80096-1; Boivin JC, 1998, CHEM MATER, V10, P2870, DOI 10.1021/cm980236q; GOODENOUGH JB, 1990, SOLID STATE IONICS, V44, P21, DOI 10.1016/0167-2738(90)90039-T; Huang KQ, 1998, J AM CERAM SOC, V81, P2565, DOI 10.1111/j.1151-2916.1998.tb02662.x; ISHIHARA T, 1994, J AM CHEM SOC, V116, P3801, DOI 10.1021/ja00088a016; Lacorre P, 2000, NATURE, V404, P856, DOI 10.1038/35009069; SCHULZ H, 1979, ACTA CRYSTALLOGR A, V35, P309, DOI 10.1107/S0567739479000632	8	215	222	7	101	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 20	2000	404	6780					821	823		10.1038/35009177	http://dx.doi.org/10.1038/35009177			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786774				2022-12-28	WOS:000086625000026
J	Slovis, BS; Plitman, JD; Haas, DW				Slovis, BS; Plitman, JD; Haas, DW			The case against anergy testing as a routine adjunct to tuberculin skin testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; DELAYED-TYPE HYPERSENSITIVITY; CELL-MEDIATED-IMMUNITY; INTRAVENOUS-DRUG-USERS; PULMONARY TUBERCULOSIS; ACTIVE TUBERCULOSIS; NURSING-HOME; MILIARY TUBERCULOSIS; HIGH-RISK; MULTITEST	Although anergy testing is commonly used to help interpret negative tuberculin skin test results, the validity of this approach haj not been demonstrated. Specific issues include lack of a standardized protocol for antigen selection, number needed to reliably evaluate inability to respond, and uniform criteria for defining cutaneous reactivity, as well as regional variation in skin test reactivity. Tuberculin skin testing is used to screen for latent infection and to evaluate the need for isoniazid prophylaxis. The presence or absence of reactivity to control antigens does not affect this decision. The results of anergy testing also do not predict the risk for progression to active disease in either HIV-negative or HIV-positive patients. In HIV-negative patients with active tuberculosis, 10% to 20% have negative tuberculin test results, and 5% to 10% have a negative tuberculin result but have a positive reaction to another antigen. A negative tuberculin skin test result does not exclude either latent infection or active disease, even in the presence of a reaction to other antigens, Neither anergy testing nor tuberculin testing obviates the need for microbiologic evaluation when there is suspicion for active tuberculosis infection. Therefore, anergy testing is not useful in screening for asymptomatic tuberculous infection or for diagnosing active tuberculosis.	Vanderbilt Univ, Med Ctr, Div Infect Dis, Dept Med, Nashville, TN 37221 USA; High Point Gastroenterol Associates, High Point, NC USA	Vanderbilt University	Haas, DW (corresponding author), Vanderbilt Univ, Med Ctr, Div Infect Dis, Dept Med, 1211 21st Ave S,Suite 539, Nashville, TN 37221 USA.	david.haas@mcmail.vanderbilt.edu			NHLBI NIH HHS [HL 07123] Funding Source: Medline; NIAID NIH HHS [U01-92-AI-14] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; ALVAREZ S, 1984, MEDICINE, V63, P25, DOI 10.1097/00005792-198401000-00003; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; BASS JB, 1985, AM REV RESPIR DIS, V132, P379; BATES SE, 1979, CANCER, V43, P2306, DOI 10.1002/1097-0142(197906)43:6<2306::AID-CNCR2820430621>3.0.CO;2-K; BEER DJ, 1987, CRC CR REV IMMUNOL, V7, P55; BROCKMEYER NH, 1988, CLIN IMMUNOL IMMUNOP, V48, P50, DOI 10.1016/0090-1229(88)90156-0; Buckley C E 3rd, 1977, Monogr Allergy, V11, P97; CAINZOS M, 1993, JPEN-PARENTER ENTER, V17, P454, DOI 10.1177/0148607193017005454; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; Chin DP, 1998, AM J RESP CRIT CARE, V158, P1797, DOI 10.1164/ajrccm.158.6.9804029; COHN JR, 1983, J AM GERIATR SOC, V31, P261, DOI 10.1111/j.1532-5415.1983.tb04867.x; CREDITOR MC, 1988, J GERONTOL, V43, pM97, DOI 10.1093/geronj/43.4.M97; DANIEL TM, 1981, AM REV RESPIR DIS, V123, P556; DELAFUENTE JC, 1988, J AM GERIATR SOC, V36, P733, DOI 10.1111/j.1532-5415.1988.tb07176.x; DORKEN E, 1987, CHEST, V92, P237, DOI 10.1378/chest.92.2.237; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; ELLNER JJ, 1978, ANN INTERN MED, V89, P932, DOI 10.7326/0003-4819-89-6-932; ELLNER JJ, 1978, J IMMUNOL, V121, P2573; Ellner JJ, 1996, INFECT AGENT DIS, V5, P62; FAIST E, 1990, J TRAUMA, V30, P8, DOI 10.1097/00005373-199001000-00002; FRAZER IH, 1985, CLIN IMMUNOL IMMUNOP, V35, P182, DOI 10.1016/0090-1229(85)90064-9; Furcolow Michael L., 1942, AMER REV TUBERC, V45, P504; GANTZ NM, 1986, HOSP PRACT, V21, P25; GOLDBERG N M, 1968, Rocky Mountain Medical Journal, V65, P66; Gordin FM, 1997, NEW ENGL J MED, V337, P315, DOI 10.1056/NEJM199707313370505; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; HARRISON BD, 1975, LANCET, V1, P421; HOLDEN M, 1971, NEW ENGL J MED, V285, P1506, DOI 10.1056/NEJM197112302852704; HUEBNER RE, 1994, CLIN INFECT DIS, V19, P26, DOI 10.1093/clinids/19.1.26; HYDE L, 1972, AM REV RESPIR DIS, V105, P453; JENSEN B, 1977, CLIN EXP IMMUNOL, V27, P303; Kendig EL, 1998, CHEST, V113, P1175, DOI 10.1378/chest.113.5.1175; KENT DC, 1967, AM J MED SCI, V254, P866, DOI 10.1097/00000441-196712000-00016; KHAN MA, 1977, AM J MED, V62, P31, DOI 10.1016/0002-9343(77)90346-1; KIM JH, 1990, REV INFECT DIS, V12, P583; KLEINHENZ ME, 1981, J CLIN INVEST, V68, P153, DOI 10.1172/JCI110231; KNIKER WT, 1984, ANN ALLERGY, V52, P75; Koch R., 1890, DEUT MED WOCHENSCHR, V16, P1029, DOI [10.1055/s-0029-1207546, DOI 10.1055/S-0029-1207546]; MAARTENS G, 1990, AM J MED, V89, P291, DOI 10.1016/0002-9343(90)90340-J; MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002; Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005; MARRIE TJ, 1988, J ALLERGY CLIN IMMUN, V81, P836, DOI 10.1016/0091-6749(88)90939-6; MCFADDEN J, 1992, J INVEST DERMATOL, V99, P784, DOI 10.1111/1523-1747.ep12614744; MCMURRAY DN, 1978, AM REV RESPIR DIS, V118, P827; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; Murray J F, 1991, Bull Int Union Tuberc Lung Dis, V66, P21; NASH DR, 1980, CHEST, V77, P32, DOI 10.1378/chest.77.1.32; Pouchot J, 1997, ANN INTERN MED, V126, P210, DOI 10.7326/0003-4819-126-3-199702010-00005; Reichman LB, 1998, CHEST, V113, P1153, DOI 10.1378/chest.113.5.1153; REUBEN JM, 1984, ANN ALLERGY, V53, P390; ROOK GAW, 1976, CLIN EXP IMMUNOL, V26, P129; ROONEY JJ, 1976, AM J MED, V60, P517, DOI 10.1016/0002-9343(76)90718-X; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; STIMPSON PG, 1976, SOUTHERN MED J, V69, P424, DOI 10.1097/00007611-197604000-00013; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; WADEE AA, 1980, J IMMUNOL, V125, P1380; WEBSTER CT, 1995, AM J RESP CRIT CARE, V151, P805, DOI 10.1164/ajrccm/151.3_Pt_1.805; WIECZOREK Z, 1977, ARCH IMMUNOL THER EX, V25, P63; WINKELSTEIN W, 1992, EPIDEMIOL REV, V14, P1; 1991, MMWR MORB MORTAL WKL, V40, P27; 1993, MMWR MORB MORTAL WKL, V42, P961; [No title captured]; 1997, MMWR MORB MORTAL WKL, V46, P880; 1999, WKLY EPIDEMIOL REC, V74, P401	69	35	35	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2000	283	15					2003	2007		10.1001/jama.283.15.2003	http://dx.doi.org/10.1001/jama.283.15.2003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303RC	10789669				2022-12-28	WOS:000086436600036
J	Wiedemann, HP; Komara, J; Welsh, C; Fulkerson, WJ; MacIntyre, N; Mallatratt, L; Sebastian, M; Thompson, D; Govert, JA; Brower, RG; Morris, AH; Clemmer, T; Davis, R; Orme, J; Young, M; Gooder, V; Jesberger, S; Gottlieb, J; Elmer, M; Matthay, MA; Daniel, B; Kallet, R; Luce, JM; Abraham, E; Glodowski, J; Lockrem, J; McIntyre, R; Parsons, P; Reid, K; Stevens, C; Silverman, HJ; Corral, W; Toews, GB; Arnoldi, D; Bartlett, RH; Dechert, R; Watts, C; Lanken, PN; Anderson, H; Finkel, B; Hanson, CW; Barton, R; Mone, M; Hudson, LD; Davis, D; Maier, RV; Steinberg, KP; Wheeler, AP; Bernard, G; Stroud, M; Swindell, B; Thompson, BT; Anckiewicz, M; Hayden, D; Molay, F; Bernard, GR; Gail, DB; Bosken, CH; Randall, P; Waclawiw, M; Steinberg, KP; Maier, RV; Schoenfeld, D; Thompson, BT				Wiedemann, HP; Komara, J; Welsh, C; Fulkerson, WJ; MacIntyre, N; Mallatratt, L; Sebastian, M; Thompson, D; Govert, JA; Brower, RG; Morris, AH; Clemmer, T; Davis, R; Orme, J; Young, M; Gooder, V; Jesberger, S; Gottlieb, J; Elmer, M; Matthay, MA; Daniel, B; Kallet, R; Luce, JM; Abraham, E; Glodowski, J; Lockrem, J; McIntyre, R; Parsons, P; Reid, K; Stevens, C; Silverman, HJ; Corral, W; Toews, GB; Arnoldi, D; Bartlett, RH; Dechert, R; Watts, C; Lanken, PN; Anderson, H; Finkel, B; Hanson, CW; Barton, R; Mone, M; Hudson, LD; Davis, D; Maier, RV; Steinberg, KP; Wheeler, AP; Bernard, G; Stroud, M; Swindell, B; Thompson, BT; Anckiewicz, M; Hayden, D; Molay, F; Bernard, GR; Gail, DB; Bosken, CH; Randall, P; Waclawiw, M; Steinberg, KP; Maier, RV; Schoenfeld, D; Thompson, BT		ARDS Network	Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHARMACOKINETICS; INHIBITION; ENDOTOXIN; ARDS	Context Three clinical studies have suggested that ketoconazole, a synthetic imidazole with anti-inflammatory activity, may prevent the development of acute respiratory distress syndrome (ARDS) in critically ill patients. However, the use of ketoconazole as treatment for acute lung injury (ALI) and ARDS has not been previously studied. Objective To test the efficacy of ketoconazole in reducing mortality and morbidity in patients with ALI or ARDS. Design Randomized, double-blind, placebo-controlled trial conducted from March 1996 to January 1997. Setting Twenty-four hospitals associated with 10 network centers in the United States, constituting the ARDS Network. Patients A total of 234 patients with ALI or ARDS. Intervention Patients were randomly assigned to receive ketoconazole, 400 mg/d (n=117),or placebo (n=117), initiated within 36 hours of fulfilling study entry criteria and given enterally for up to 21 days. Main Outcome Measures Primary outcome measures were the proportion of patients alive with unassisted breathing at hospital discharge and the number of days of unassisted breathing (ventilator-free days) during 28 days of follow-up. Secondary outcome measures included the proportion of patients achieving unassisted breathing for 48 hours or more, the number of organ failure-free days, and changes in plasma interleukin 6 (IL-6) and urinary thromboxane A(2) metabolites (thromboxane B-2 [TXB2] and 11-dehydro-TXB2). Results In-hospital mortality (SE) was 34.1 % (4.3 %) for the placebo group and 35.2 % (4.3 %) for the ketoconazole group (P=.85). The median number of ventilator-free days within 28 days of randomization was 9 in the placebo group and 10 in the ketoconazole group (P=.89). There were no statistically significant differences in the n umber of organ failure-free days, pulmonary physiology, or adverse events between treatment groups. The median serum ketoconazole level was 1.25 mu g/mL and serum levels greater than 0.5 mu g/mL were detected in 96% of patients assayed. Plasma IL-6, urinary TXB2, and 11-dehydro-TXB2 levels were unaffected by ketoconazole. Conclusions In these patients with ALI or ARDS, ketoconazole was safe and bioavailable but did not reduce mortality or duration of mechanical ventilation or improve lung function. These data do not support the use of ketoconazole,for the early treatment of ALI or ARDS.	Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Thompson, BT (corresponding author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, 55 Fruit St, Boston, MA 02114 USA.	tthompson1@partners.org	Mone, Mary/F-1971-2019	Mone, Mary/0000-0001-7176-2860	NHLBI NIH HHS [N01-HR46054-64] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR046054] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AC RESP DISTR SYN, 2000, NEW ENGLAND J M 0310; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BODET CA, 1985, J CLIN MICROBIOL, V22, P157, DOI 10.1128/JCM.22.2.157-160.1985; Bonten MJM, 1997, AM J RESP CRIT CARE, V156, P1105, DOI 10.1164/ajrccm.156.4.9610002; CATELLA F, 1987, THROMB RES, V47, P647, DOI 10.1016/0049-3848(87)90103-4; CHIN TW, 1993, ANTIMICROB AGENTS A, V1436, P382; DANESHMEND TK, 1988, CLIN PHARMACOKINET, V14, P13, DOI 10.2165/00003088-198814010-00002; DONNELLY TJ, 1994, CRIT CARE MED, V22, P768, DOI 10.1097/00003246-199405000-00010; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; HUDSON LD, 1995, AM J RESP CRIT CARE, V151, P293, DOI 10.1164/ajrccm.151.2.7842182; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOLLEF MH, 1995, NEW ENGL J MED, V332, P27, DOI 10.1056/NEJM199501053320106; LELCUK S, 1984, J TRAUMA, V24, P393, DOI 10.1097/00005373-198405000-00004; LYBERG T, 1990, EUR RESPIR J, V3, P61; MILBERG JA, 1995, JAMA-J AM MED ASSOC, V273, P306, DOI 10.1001/jama.273.4.306; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PISCITELLI SC, 1991, ANTIMICROB AGENTS CH, V35, P1765, DOI 10.1128/AAC.35.9.1765; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; REPINE JE, 1991, AM REV RESPIR DIS, V144, P251, DOI 10.1164/ajrccm/144.2.251; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; Sinuff T, 1999, J CRIT CARE, V14, P1, DOI 10.1016/S0883-9441(99)90001-1; SLOTMAN GJ, 1988, J TRAUMA, V28, P648, DOI 10.1097/00005373-198805000-00015; SUGAR EF, 1992, AIDS, V6, P1221, DOI 10.1097/00002030-199210000-00030; TOMASHEFSKI JF, 1990, CLIN CHEST MED, V11, P593; VANTYLE JH, 1984, PHARMACOTHERAPY, V4, P343; WEKSLER BB, 1983, NEW ENGL J MED, V308, P800, DOI 10.1056/NEJM198304073081402; WILLIAMS JG, 1992, SURGERY, V112, P270; WINN R, 1983, J CLIN INVEST, V72, P911, DOI 10.1172/JCI111062; YU MH, 1993, CRIT CARE MED, V21, P1635, DOI 10.1097/00003246-199311000-00010; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	31	205	212	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 19	2000	283	15					1995	2002						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	303RC	10789668				2022-12-28	WOS:000086436600035
J	Egolf, DA; Melnikov, IV; Pesch, W; Ecke, RE				Egolf, DA; Melnikov, IV; Pesch, W; Ecke, RE			Mechanisms of extensive spatiotemporal chaos in Rayleigh-Bernard convection	NATURE			English	Article							SPIRAL-DEFECT CHAOS; BENARD CONVECTION; PRANDTL NUMBER; DYNAMICS; TRANSITION; ATTRACTORS; DIMENSION; FLUID	Spatially extended dynamical systems exhibit complex behaviour in both space and time-spatiotemporal chaos(1,2). Analysis of dynamical quantities (such as fractal dimensions and Lyapunov exponents(3)) has provided insights into low-dimensional systems; but it has proven more difficult to understand spatiotemporal chaos in high-dimensional systems, despite abundant data describing its statistical properties(1,4,5). Initial attempts have been made to extend the dynamical approach to higher-dimensional systems, demonstrating numerically that the spatiotemporal chaos in several simple models is extensive(6-8) (the number of dynamical degrees of freedom scales with the system volume). Here we report a computational investigation of a phenomenon found in nature, 'spiral defect' chaos(5,9) in Rayleigh-Benard convection, in which we rnd that the spatiotemporal chaos in this state is extensive and characterized by about a hundred dynamical degrees of freedom. By studying the detailed space-time evolution of the dynamical degrees of freedom, we rnd that the mechanism for the generation of chaotic disorder is spatially and temporally localized to events associated with the creation and annihilation of defects.	Univ Calif Los Alamos Natl Lab, Ctr Nonlinear Studies, Div Theoret, Los Alamos, NM 87545 USA; Univ Bayreuth, Inst Phys, D-95440 Bayreuth, Germany	United States Department of Energy (DOE); Los Alamos National Laboratory; University of Bayreuth	Egolf, DA (corresponding author), Univ Calif Los Alamos Natl Lab, Ctr Nonlinear Studies, Div Theoret, Los Alamos, NM 87545 USA.			Ecke, Robert/0000-0001-7772-5876				ASSENHEIMER M, 1994, NATURE, V367, P345, DOI 10.1038/367345a0; Bodenschatz E, 2000, ANNU REV FLUID MECH, V32, P709, DOI 10.1146/annurev.fluid.32.1.709; BUSSE FH, 1979, J FLUID MECH, V91, P319, DOI 10.1017/S002211207900015X; Cakmur RV, 1997, PHYS REV LETT, V79, P1853, DOI 10.1103/PhysRevLett.79.1853; CHATE H, 1993, EUROPHYS LETT, V21, P419, DOI 10.1209/0295-5075/21/4/007; CROSS MC, 1993, REV MOD PHYS, V65, P851, DOI 10.1103/RevModPhys.65.851; CROSS MC, 1995, PHYS REV LETT, V75, P834, DOI 10.1103/PhysRevLett.75.834; CROSS MC, 1994, SCIENCE, V263, P1569, DOI 10.1126/science.263.5153.1569; deBruyn JR, 1996, REV SCI INSTRUM, V67, P2043, DOI 10.1063/1.1147511; DECKER W, 1994, PHYS REV LETT, V73, P648, DOI 10.1103/PhysRevLett.73.648; ECKE RE, 1995, SCIENCE, V269, P1704, DOI 10.1126/science.269.5231.1704; ECKMANN JP, 1985, REV MOD PHYS, V57, P617, DOI 10.1103/RevModPhys.57.617; Egolf DA, 1998, PHYS REV LETT, V81, P4120, DOI 10.1103/PhysRevLett.81.4120; Egolf DA, 1998, PHYS REV LETT, V80, P3228, DOI 10.1103/PhysRevLett.80.3228; EGOLF DA, 1994, NATURE, V369, P129, DOI 10.1038/369129a0; GOLLUB JP, 1995, P NATL ACAD SCI USA, V92, P6705, DOI 10.1073/pnas.92.15.6705; HU YC, 1995, PHYS REV E, V51, P3263, DOI 10.1103/PhysRevE.51.3263; HU YC, 1995, PHYS REV LETT, V74, P391, DOI 10.1103/PhysRevLett.74.391; Manneville P., 1994, LECT NOTE PHYS, V280, P319; MORRIS SW, 1993, PHYS REV LETT, V71, P2026, DOI 10.1103/PhysRevLett.71.2026; Morris SW, 1996, PHYSICA D, V97, P164, DOI 10.1016/0167-2789(96)00096-6; Plapp BB, 1998, PHYS REV LETT, V81, P5334, DOI 10.1103/PhysRevLett.81.5334; RUELLE D, 1982, COMMUN MATH PHYS, V87, P287, DOI 10.1007/BF01218566; ZOLDI SM, 1998, PHYS REV E, V58, P6903	24	111	114	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					733	736		10.1038/35008013	http://dx.doi.org/10.1038/35008013			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783880				2022-12-28	WOS:000086523600043
J	Medema, RH; Kops, GJPL; Bos, JL; Burgering, BMT				Medema, RH; Kops, GJPL; Bos, JL; Burgering, BMT			AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27(kip1)	NATURE			English	Article							CAENORHABDITIS-ELEGANS; RETINOBLASTOMA PROTEIN; KINASE; DAF-16; SIGNALS	The Forkhead transcription factors AFX, FKHR and FKHR-L1 are orthologues of DAF-16, a Forkhead factor that regulates longevity in Caenorhabditis elegans(1-3). Here we show that overexpression of these Forkhead transcription factors causes growth suppression in a variety of cell lines, including a Ras-transformed cell line and a cell line lacking the tumour suppressor PTEN. Expression of AFX blocks cell-cycle progression at phase G(1), independent of functional retinoblastoma protein (pRb) but dependent on the cell-cycle inhibitor p27(kip1). Indeed, AFX transcriptionally activates p27(kip1), resulting in increased protein levels. We conclude that AFX-like proteins are involved in cell-cycle regulation and that inactivation of these proteins is an important step in oncogenic transformation.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Hematol, Jordan Lab G03647, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Burgering, BMT (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands.			Kops, Geert/0000-0003-3555-5295; Medema, Rene/0000-0002-6754-0381				Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Furnari FB, 1998, CANCER RES, V58, P5002; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741	22	1188	1223	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					782	787		10.1038/35008115	http://dx.doi.org/10.1038/35008115			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783894				2022-12-28	WOS:000086523600057
J	Zaanen, J				Zaanen, J			High-temperature superconductivity - Stripes defeat the Fermi liquid	NATURE			English	Editorial Material									Leiden Univ, Inst Lorentz Theoret Phys, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Zaanen, J (corresponding author), Leiden Univ, Inst Lorentz Theoret Phys, POB 9506, NL-2300 RA Leiden, Netherlands.	jan@lorentz.leidenuniv.nl						Aeppli G, 1997, SCIENCE, V278, P1432, DOI 10.1126/science.278.5342.1432; ANDERSON PW, 1999, THEORY SUPERCONDUCTI, V286, P251; EMERY VJ, 1994, PHYSICA C, V235, P189, DOI 10.1016/0921-4534(94)91345-5; Mook HA, 2000, NATURE, V404, P729, DOI 10.1038/35008005; Sachdev S, 1999, PHYS WORLD, V12, P33; Sharma RP, 2000, NATURE, V404, P736, DOI 10.1038/35008018; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; Zaanen J, 1999, SCIENCE, V286, P251, DOI 10.1126/science.286.5438.251; Zaanen J, 2000, PHYS REV LETT, V84, P753, DOI 10.1103/PhysRevLett.84.753; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391	10	56	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	2000	404	6779					714	715		10.1038/35008176	http://dx.doi.org/10.1038/35008176			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783870				2022-12-28	WOS:000086523600031
J	Brodsky, MH; Nordstrom, W; Tsang, G; Kwan, E; Rubin, GM; Abrams, JM				Brodsky, MH; Nordstrom, W; Tsang, G; Kwan, E; Rubin, GM; Abrams, JM			Drosophila p53 binds a damage response element at the reaper locus	CELL			English	Article							PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; GENE-EXPRESSION; WILD-TYPE; PROTEIN; DOMAIN; MUTATIONS; APOPTOSIS; OLIGOMERIZATION	The tumor suppressor gene p53 regulates multiple cellular responses to DNA damage, but the transcriptional targets that specify these responses are incompletely understood. We describe a Drosophila p53 homolog and demonstrate that it can activate transcription from a promoter containing binding sites for human p53. Dominant-negative forms of Drosophila p53 inhibit both transactivation in cultured cells and radiation-induced apoptosis in developing tissues. The cis-regulatory region of the proapoptotic gene reaper contains a radiation-inducible enhancer that includes a consensus p53 binding site. Drosophila p53 can activate transcription from this site in yeast and a multimer of this site is sufficient for radiation induction in vivo. These results indicate that reaper is a direct transcriptional target of Drosophila p53 following DNA damage.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rubin, GM (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.			Rubin, Gerald/0000-0001-8762-8703	NIA NIH HHS [R01 AG12466] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012466] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; ABRAMS JM, 1996, APOPTOSIS NORMAL DEV, P171; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brodsky MH, 2000, GENE DEV, V14, P666; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; IWABUCHI K, 1993, ONCOGENE, V8, P1693; James P, 1996, GENETICS, V144, P1425; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kitazono A, 1998, BIOESSAYS, V20, P391, DOI 10.1002/(SICI)1521-1878(199805)20:5<391::AID-BIES6>3.0.CO;2-R; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Luo Y, 1996, BIOTECHNIQUES, V20, P564; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; TEPASS U, 1990, ROUX ARCH DEV BIOL, V199, P189, DOI 10.1007/BF01682078; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8	63	381	388	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 31	2000	101	1					103	113		10.1016/S0092-8674(00)80627-3	http://dx.doi.org/10.1016/S0092-8674(00)80627-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	300JM	10778860	Bronze			2022-12-28	WOS:000086249900012
J	Holmes, MC; Tjian, R				Holmes, MC; Tjian, R			Promoter-selective properties of the TBP-Related factor TRF1	SCIENCE			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTION; DROSOPHILA; COMPLEX; ACTIVATION; DOMAINS; DNA	The TATA-binding protein (TBP)-related factor 1 (TRF1) is expressed in a tissue-restricted fashion during Drosophila embryogenesis and may serve as a promoter-specific recognition factor that can replace TBP in regulating transcription. However, bona fide target promoters that would preferentially respond to TRF1 have remained elusive. Polytene chromosome staining, chromatin immunoprecipitation, direct messenger RNA analysis, and transient cotransfection assays identified the Drosophila gene tudor as containing a TRF1-responsive promoter. Reconstituted in vitro transcription reactions and deoxyribonuclease I footprinting assays confirmed the ability of TRF1 to bind preferentially and direct transcription of the tudor gene from an alternate promoter. Thug, metazoans appear to have evolved gene-selective and tissue-specific components of the core transcription machinery to regulate gene expression.	Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Tjian, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Howard Hughes Med Inst, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R01CA025417, R37CA025417] Funding Source: NIH RePORTER; NCI NIH HHS [CA25417] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CROWLEY TE, 1993, NATURE, V361, P557, DOI 10.1038/361557a0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; ENGLAND BP, 1990, J BIOL CHEM, V265, P5086; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Holmes M. J., UNPUB; Maldonado E, 1999, J BIOL CHEM, V274, P12963, DOI 10.1074/jbc.274.19.12963; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Margolis P, 1991, CURR OPIN GENET DEV, V1, P330, DOI 10.1016/S0959-437X(05)80296-5; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Ohbayashi T, 1999, NUCLEIC ACIDS RES, V27, P750, DOI 10.1093/nar/27.3.750; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; TAKADA S, UNPUB; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313	23	87	89	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 5	2000	288	5467					867	870		10.1126/science.288.5467.867	http://dx.doi.org/10.1126/science.288.5467.867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311DN	10797011				2022-12-28	WOS:000086869600041
J	Reiffel, L				Reiffel, L			Sagan breached security by revealing US work on a lunar bomb project	NATURE			English	Letter									Exelar Corp, Chicago, IL 60614 USA		Reiffel, L (corresponding author), Exelar Corp, 602 Deming Pl, Chicago, IL 60614 USA.							POUNDSTONE W, 1999, NATURE, V401, P857	1	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					13	13		10.1038/35011148	http://dx.doi.org/10.1038/35011148			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811192	Bronze			2022-12-28	WOS:000086901600015
J	Satheesh, SK; Ramanathan, V				Satheesh, SK; Ramanathan, V			Large differences in tropical aerosol forcing at the top of the atmosphere and Earth's surface	NATURE			English	Article							RAINFALL MEASURING MISSION; PRE-INDOEX CRUISE; INDIAN-OCEAN; ANTHROPOGENIC AEROSOLS; TROPOSPHERIC AEROSOL; RADIATION BUDGET; CLIMATE; IMPACT; MODEL; DUST	The effect of radiative forcing by anthropogenic aerosols is one of the largest sources of uncertainty in climate predictions(1-6). Direct observations of the forcing are therefore needed, particularly for the poorly understood tropical aerosols. Here we present an observational method for quantifying aerosol forcing to within +/-5 per cent. We use calibrated satellite radiation measurements and five independent surface radiometers to quantify the aerosol forcing simultaneously at the Earth's surface and the top of the atmosphere over the tropical northern Indian Ocean. In winter, this region is covered by anthropogenic aerosols of sulphate, nitrate, organics, soot and fly ash from the south Asian continent(7,8). Accordingly, mean clear-sky solar radiative heating for the winters of 1998 and 1999 decreased at the ocean surface by 12 to 30 W m(-2), but only by 4 to 10 W m(-2) at the top of the atmosphere. This threefold difference (due largely to solar absorption by soot) and the large magnitude of the observed surface forcing both imply that tropical aerosols might slow down the hydrological cycle.	Univ Calif San Diego, Scripps Inst Oceanog, Ctr Clouds Chem & Climate, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Ramanathan, V (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Ctr Clouds Chem & Climate, La Jolla, CA 92093 USA.		Keyes, Dennis/AAZ-9285-2021					ACKERMAN AS, IN PRESS SCIENCE; Bates TS, 1998, J GEOPHYS RES-ATMOS, V103, P16297, DOI 10.1029/97JD03741; BREIGLEB BP, 1986, J CLIM APPL METEOROL, V25, P214; BUSH BC, IN PRESS J ATMOS OCE; CESS RD, 1985, J GEOPHYS RES-ATMOS, V90, P2937, DOI 10.1029/JD090iD07p12937; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; COAKLEY JA, 1985, J ATMOS SCI, V42, P1677, DOI 10.1175/1520-0469(1985)042<1677:ROTNCC>2.0.CO;2; Cooke WF, 1999, J GEOPHYS RES-ATMOS, V104, P22137, DOI 10.1029/1999JD900187; Hansen JE, 1998, P NATL ACAD SCI USA, V95, P12753, DOI 10.1073/pnas.95.22.12753; HARTMAN DL, 1994, GLOBAL PHYSICAL CLIM; Haywood JM, 1999, SCIENCE, V283, P1299, DOI 10.1126/science.283.5406.1299; Houghton JT., 1995, CLIMATE CHANGE 1994; Jayaraman A, 1998, J GEOPHYS RES-ATMOS, V103, P13827, DOI 10.1029/98JD00559; Kaufman YJ, 1998, J GEOPHYS RES-ATMOS, V103, P31783, DOI 10.1029/98JD02281; Krishnamurti TN, 1998, TELLUS B, V50, P521, DOI 10.1034/j.1600-0889.1998.00009.x; Lavanchy VMH, 1999, J GEOPHYS RES-ATMOS, V104, P21227, DOI 10.1029/1999JD900408; Lee RB, 1998, IEEE T GEOSCI REMOTE, V36, P1173, DOI 10.1109/36.701024; Meywerk J, 1999, J GEOPHYS RES-ATMOS, V104, P24359, DOI 10.1029/1999JD900502; PENNER JE, 1992, SCIENCE, V256, P1432, DOI 10.1126/science.256.5062.1432; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; Rajeev K, 2000, J GEOPHYS RES-ATMOS, V105, P2029, DOI 10.1029/1999JD900414; RAMANATHAN V, 1996, C4 PUBLICATION SCRIP, V162; Russell PB, 1999, J GEOPHYS RES-ATMOS, V104, P2289, DOI 10.1029/1998JD200025; Satheesh SK, 1999, J GEOPHYS RES-ATMOS, V104, P27421, DOI 10.1029/1999JD900478; Tegen I, 1996, NATURE, V380, P419, DOI 10.1038/380419a0; THEON JS, 1993, ADV SPACE RES, V14, P159; [No title captured]	28	466	478	3	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					60	63		10.1038/35011039	http://dx.doi.org/10.1038/35011039			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811216				2022-12-28	WOS:000086901600049
J	Greene, WL; Concato, J; Feinstein, AR				Greene, WL; Concato, J; Feinstein, AR			Claims of equivalence in medical research: Are they supported by the evidence?	ANNALS OF INTERNAL MEDICINE			English	Article							SAMPLE-SIZE; GENERAL-PRACTICE; BRAND-NAME; THERAPY; TRIAL; BIOAVAILABILITY; BIOEQUIVALENCY; EXPERIENCE; EFFICACY; POTENCY	Background: Most clinical studies are done to show comparative superiority, but many reports now claim equivalence between the investigated entities. These assertions may not always be supported by the methods used and the results obtained. Purpose: To assess the justification and support for claims of clinical or therapeutic equivalence in medical journals. Data Sources: A search of MEDLINE for articles published from 1992 through 1996. Study Selection: From 1209 citations that contained the word equivalence in the title or abstract or contained the Medical Subject Heading therapeutic equivalency, we excluded 1121 studies reporting nonoriginal research, purely laboratory or other nonhuman research, and studies in which equivalence was not the main claim. The remaining 88 eligible papers were evaluated for five methodologic attributes. Data Synthesis: Only 45 (51%) of the 88 reports were specifically aimed at studying equivalence; the others either tried to show superiority or did not state a research aim. The quantitative distinctions regarded as "equivalent" ranged from 0% to 21% for direct increments and from 0% to 76% for proportionate differences. An equivalence boundary was set and confirmed with an appropriate statistical test in only 23% of reports. In 67% of reports, equivalence was declared after a failed test for comparative superiority, and in 10%, the claim of equivalence was not statistically evaluated. The sample size needed to confirm results had been calculated in advance for only 33% of reports. Sample size was 20 patients per group or fewer in 25% of reports. Conclusions: Many studies of clinical equivalence do not set boundaries for equivalence. Claims of "difference" or "similarity" are often made not by thoughtful examination of the data but by tests of statistical significance that are often misapplied or accompanied by inadequate sample sizes. These methodologic flaws can lead to false claims, inconsistencies, and harm to patients.	Yale Univ, Sch Med, New Haven, CT USA; Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Greene, WL (corresponding author), Genentech Inc, Med Affairs Dept, Mailstop 84,1 DNA Way, San Francisco, CA 94080 USA.	wgreene@gene.com						ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; [Anonymous], 1995, Lancet, V346, P329; Babul N, 1998, J CLIN PHARMACOL, V38, P74, DOI 10.1002/j.1552-4604.1998.tb04380.x; BARCKOW D, 1993, J ANTIMICROB CHEMOTH, V32, P187, DOI 10.1093/jac/32.suppl_B.187; BOISSEL JP, 1995, J HYPERTENS, V13, P1059, DOI 10.1097/00004872-199509000-00018; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; DIMUNNO O, 1995, J RHEUMATOL, V22, P1492; Dong BJ, 1997, JAMA-J AM MED ASSOC, V277, P1205, DOI 10.1001/jama.277.15.1205; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; EDGAR PP, 1992, MOL PHARMACOL, V41, P1124; Feinstein AR, 1998, J CLIN EPIDEMIOL, V51, P527; FEINSTEIN AR, 1975, CLIN PHARMACOL THER, V18, P491; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; FULLER RW, 1995, RESP MED, V89, P525, DOI 10.1016/0954-6111(95)90152-3; GROOTHUIS JR, 1995, ANTIMICROB AGENTS CH, V39, P668, DOI 10.1128/AAC.39.3.668; Harenberg J, 1996, HAEMOSTASIS, V26, P127; Hatala R, 1996, ANN INTERN MED, V124, P717, DOI 10.7326/0003-4819-124-8-199604150-00003; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KRAGHSORENSEN P, 1995, J CLIN PSYCHOPHARM, V15, pS24, DOI 10.1097/00004714-199508001-00005; KRON IL, 1992, ANN THORAC SURG, V54, P617, DOI 10.1016/0003-4975(92)91003-R; LECOUTRE B, 1995, STAT MED, V14, P1057, DOI 10.1002/sim.4780140924; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; MASON KA, 1994, INT J RADIAT ONCOL, V28, P667, DOI 10.1016/0360-3016(94)90192-9; *NAT LIB MED, 1997, ABR IND MED, V28; OBERLIN O, 1992, J CLIN ONCOL, V10, P1602, DOI 10.1200/JCO.1992.10.10.1602; OLES KS, 1992, NEUROLOGY, V42, P1147, DOI 10.1212/WNL.42.6.1147; OQUIGLEY J, 1988, STATISTICIAN, V37, P51, DOI 10.2307/2348378; PALAZZINI E, 1992, INT J CLIN PHARM RES, V12, P179; RAMMELOO RHU, 1992, RESPIRATION, V59, P322; SCHUIRMANN DJ, 1987, J PHARMACOKINET BIOP, V15, P657, DOI 10.1007/BF01068419; SPRIET A, 1979, BRIT J CLIN PHARMACO, V7, P623, DOI 10.1111/j.1365-2125.1979.tb04653.x; STOCK AJ, 1994, AM J HOSP PHARM, V51, P2279, DOI 10.1093/ajhp/51.18.2279; TAGGART SCO, 1995, BRIT MED J, V310, P1639, DOI 10.1136/bmj.310.6995.1639a; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VandeWerf F, 1997, NEW ENGL J MED, V337, P1124; Verster GC, 1998, S AFR MED J, V88, P260; Ware JH, 1997, NEW ENGL J MED, V337, P1159, DOI 10.1056/NEJM199710163371610; 1999, N ENGL J MED, V354, P716	41	123	125	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					715	722		10.7326/0003-4819-132-9-200005020-00006	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308VT	10787365				2022-12-28	WOS:000086734100005
J	Nicholl, J				Nicholl, J			The ethics of research ethics committees	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Sheffield, Med Care Res Unit, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Nicholl, J (corresponding author), Univ Sheffield, Med Care Res Unit, Sheffield S10 2TN, S Yorkshire, England.		Nicholl, Jon/B-8257-2008						0	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 29	2000	320	7243					1217	1217		10.1136/bmj.320.7243.1217	http://dx.doi.org/10.1136/bmj.320.7243.1217			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310MW	10784570	Green Published			2022-12-28	WOS:000086832800051
J	Lanza, RP; Cibelli, JB; Blackwell, C; Cristofalo, VJ; Francis, MK; Baerlocher, GM; Mak, J; Schertzer, M; Chavez, EA; Sawyer, N; Lansdorp, PM; West, MD				Lanza, RP; Cibelli, JB; Blackwell, C; Cristofalo, VJ; Francis, MK; Baerlocher, GM; Mak, J; Schertzer, M; Chavez, EA; Sawyer, N; Lansdorp, PM; West, MD			Extension of cell life-span and telomere length in animals cloned from senescent somatic cells	SCIENCE			English	Article							HUMAN DIPLOID CELLS; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; G(0) STATE; CULTURE; ARREST; FETAL; ADULT	The potential of cloning depends in part on whether the procedure can reverse cellular aging and restore somatic cells to a phenotypically youthful state. Here, we report the birth of six healthy cloned calves derived from populations of senescent donor somatic cells. Nuclear transfer extended the replicative lifespan of senescent cells (zero to four population doublings remaining) to greater than 90 population doublings. Early population doubling level complementary DNA-1 (EPC-1, an age-dependent gene) expression in cells from the cloned animals was 3.5- to 5-fold higher than that in cells from age-matched (5 to 10 months old) controls. Southern blot and flow cytometric analyses indicated that the telomeres were also extended beyond those of newborn (<2 weeks old) and age-matched control animals. The ability to regenerate animals and cells may have important implications for medicine and the study of mammalian aging.	Adv Cell Technol, Worcester, MA 01605 USA; Lankenau Inst Med Res, Wynnewood, PA 19096 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19104 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada	Lankenau Medical Center; Lankenau Institute for Medical Research; Jefferson University; British Columbia Cancer Agency; University of British Columbia	Lanza, RP (corresponding author), Adv Cell Technol, 1 Innovat Dr, Worcester, MA 01605 USA.	rlanza@advancedcell.com		West, Michael/0000-0002-4842-5468; Lansdorp, Peter/0000-0001-7435-1071; Cibelli, Jose/0000-0002-2176-3854	NIAID NIH HHS [AI29524] Funding Source: Medline; NIA NIH HHS [AG00378] Funding Source: Medline; NIGMS NIH HHS [GM56162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI029524, R01AI029524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; CRISTOFALO VJ, 1993, PHYSIOL REV, V73, P617, DOI 10.1152/physrev.1993.73.3.617; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; Cristofalo VJ, 1996, EXP GERONTOL, V31, P111, DOI 10.1016/0531-5565(95)02018-7; CRISTOFALO VJ, 1992, ANN NY ACAD SCI, V663, P187, DOI 10.1111/j.1749-6632.1992.tb38662.x; de Lange T, 1999, SCIENCE, V283, P947, DOI 10.1126/science.283.5404.947; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Galli C, 1999, Cloning, V1, P161, DOI 10.1089/15204559950019924; GORMAN SD, 1986, EXP CELL RES, V167, P87, DOI 10.1016/0014-4827(86)90206-5; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; Lanza RP, 1999, NAT BIOTECHNOL, V17, P1171, DOI 10.1038/70709; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LIPETZ J, 1972, J ULTRA MOL STRUCT R, V39, P43, DOI 10.1016/S0022-5320(72)80005-4; Meng L, 1997, BIOL REPROD, V57, P454, DOI 10.1095/biolreprod57.2.454; PHINNEY DG, 1994, ONCOGENE, V9, P2353; Pignolo RJ, 1998, EXP GERONTOL, V33, P67, DOI 10.1016/S0531-5565(97)00090-9; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; WEST MD, 1989, EXP CELL RES, V184, P138, DOI 10.1016/0014-4827(89)90372-8; WEST MD, 1994, ARCH DERMATOL, V130, P87, DOI 10.1001/archderm.130.1.87; West MD, 1996, EXP GERONTOL, V31, P175, DOI 10.1016/0531-5565(95)02013-6; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	41	325	374	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					665	669		10.1126/science.288.5466.665	http://dx.doi.org/10.1126/science.288.5466.665			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784448				2022-12-28	WOS:000086727100042
J	Zars, T; Fischer, M; Schulz, R; Heisenberg, M				Zars, T; Fischer, M; Schulz, R; Heisenberg, M			Localization of a short-term memory in Drosophila	SCIENCE			English	Article							I ADENYLYL-CYCLASE; MUSHROOM BODIES; SYNAPTIC PLASTICITY; BEHAVIORAL SENSITIZATION; PREFERENTIAL EXPRESSION; NERVOUS-SYSTEM; SPATIAL MEMORY; MUTANT MICE; CYCLIC-AMP; MELANOGASTER	Memories are thought to be due to lasting synaptic modifications in the brain. The search for memory traces has relied predominantly on determining regions that are necessary for the process. However, a more informative approach is to define the smallest sufficient set of brain structures. The rutabaga adenylyl cyclase, an enzyme that is ubiquitously expressed in the Drosophila brain and that mediates synaptic plasticity, is needed exclusively in the Kenyon cells of the mushroom bodies for a component of olfactory short-term memory. This demonstrates that synaptic plasticity in a small brain region can be sufficient for memory formation.	Theodor Boveri Inst Biowissensch, Lehrstuhl Genet, Biozentrum, D-97074 Wurzburg, Germany; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Wurzburg; University of Texas System; UTMD Anderson Cancer Center	Zars, T (corresponding author), Theodor Boveri Inst Biowissensch, Lehrstuhl Genet, Biozentrum, D-97074 Wurzburg, Germany.	zars@biozentrum.uni-wuerzburg.de		Zars, Troy/0000-0003-4114-9322				ACEVESPINA EO, 1983, COLD SPRING HARB SYM, V48, P831, DOI 10.1101/SQB.1983.048.01.086; Armstrong JD, 1998, LEARN MEMORY, V5, P102; BALLING A, 1987, J NEUROGENET, V4, P65, DOI 10.3109/01677068709102334; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNELLI M, 1976, SCIENCE, V194, P1178, DOI 10.1126/science.186870; Chen C, 1997, ANNU REV NEUROSCI, V20, P157, DOI 10.1146/annurev.neuro.20.1.157; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; Crittenden JR, 1998, LEARN MEMORY, V5, P38; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; ERBER J, 1980, PHYSIOL ENTOMOL, V5, P343, DOI 10.1111/j.1365-3032.1980.tb00244.x; Faber T, 1999, NAT NEUROSCI, V2, P74, DOI 10.1038/4576; FOLKERS E, 1982, J INSECT PHYSIOL, V28, P535, DOI 10.1016/0022-1910(82)90034-8; GAILEY DA, 1984, GENETICS, V106, P613; HAMMER M, 1995, J NEUROSCI, V15, P1617, DOI 10.1523/JNEUROSCI.15-03-01617.1995; Hammer M, 1998, LEARN MEMORY, V5, P146; Han KA, 1998, J NEUROSCI, V18, P3650; Han KA, 1996, NEURON, V16, P1127, DOI 10.1016/S0896-6273(00)80139-7; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HANSE E, 1992, EUR J NEUROSCI, V4, P1191, DOI 10.1111/j.1460-9568.1992.tb00144.x; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; Ito K, 1998, LEARN MEMORY, V5, P52; Ito K, 1997, CELL TISSUE RES, V290, P1, DOI 10.1007/s004410050901; Joiner MLA, 1999, LEARN MEMORY, V6, P177; KLEIN M, 1980, P NATL ACAD SCI-BIOL, V77, P6912, DOI 10.1073/pnas.77.11.6912; Lashley KS., 1929, BRAIN MECH INTELLIGE; Lechner HA, 1998, NEURON, V20, P355, DOI 10.1016/S0896-6273(00)80977-0; Lee T, 1999, DEVELOPMENT, V126, P4065; Liu L, 1999, NATURE, V400, P753, DOI 10.1038/23456; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Martin JR, 1998, LEARN MEMORY, V5, P179; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NASSEL DR, 1992, CELL TISSUE RES, V267, P147, DOI 10.1007/BF00318701; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SCHACHER S, 1993, NEURON, V10, P1079, DOI 10.1016/0896-6273(93)90056-W; Schulz RA, 1996, ONCOGENE, V12, P1827; Strausfeld NJ., 1976, ATLAS INSECT BRAIN, DOI 10.1007/978-3-642-66179-2; TECHNAU G, 1982, NATURE, V295, P405, DOI 10.1038/295405a0; Tettamanti M, 1997, DEV GENES EVOL, V207, P242, DOI 10.1007/s004270050112; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; Villacres EC, 1998, J NEUROSCI, V18, P3186; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; Wolf R, 1998, LEARN MEMORY, V5, P166; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; Wustmann G, 1996, J COMP PHYSIOL A, V179, P429, DOI 10.1007/BF00194996; Wustmann G, 1997, LEARN MEMORY, V4, P328, DOI 10.1101/lm.4.4.328; YANG MY, 1995, NEURON, V15, P45; YAO KM, 1994, J NEUROCHEM, V63, P41; Zars T, 2000, LEARN MEMORY, V7, P18, DOI 10.1101/lm.7.1.18; ZARS T, UNPUB; ZHONG Y, 1991, SCIENCE, V251, P198, DOI 10.1126/science.1670967	55	412	416	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2000	288	5466					672	675		10.1126/science.288.5466.672	http://dx.doi.org/10.1126/science.288.5466.672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784450				2022-12-28	WOS:000086727100044
J	Frassoni, F; Labopin, M; Powles, R; Mary, JY; Arcese, W; Bacigalupo, A; Bunjes, D; Gluckman, E; Ruutu, T; Schaefer, UW; Sierra, J; Vernant, JP; Willemze, R; de Witte, T; Gorin, NC				Frassoni, F; Labopin, M; Powles, R; Mary, JY; Arcese, W; Bacigalupo, A; Bunjes, D; Gluckman, E; Ruutu, T; Schaefer, UW; Sierra, J; Vernant, JP; Willemze, R; de Witte, T; Gorin, NC		Acute Leukaemia Working Pary Europ	Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia	LANCET			English	Article							FIRST REMISSION; ACUTE-LEUKEMIA; CHEMOTHERAPY; SURVIVAL; VOLUME; ASSOCIATION	Background There is increasing pressure for the recognition and replication of good clinical practice. We undertook a study to assess the variability in outcome of allogeneic bone-marrow transplantation among major European centres. Methods We studied 13 centres, including 522 patients (aged 16-55 years), which had undertaken more than 30 bone-marrow transplantations between Jan 1, 1987, and Dec 31, 1995, for acute myeloid leukaemia in first complete remission. We undertook a (global) multivariate analysis of all factors known previously to influence outcome and a stratified analysis that initially defined, by multivariate analysis, significant variables in this study and then used a proportional-hazard model including centres. Findings The overall results at 3 years were 57% (95% CI 53-61) for leukaemia-free survival (LFS), 23% (19-27) for relapse incidence (RI), and 26% (22-30) for treatment-related mortality (TRM) with a range for centres of 36-75%, 10-37%, and 8-54%, respectively. Both methods of analysis showed the centre effect to be highly significant for LFS and TRM, but not for RI. Variables associated with a significantly poor outcome were age over 43 years (p=0.01), time from diagnosis to first complete remission longer than 65 days (p=0.02), and centre (p=0.013) for LFS, and age over 43 years (p=0.023), time from first complete remission to transplantation of longer than 93 days (p=0.03), and centre (p=0.001) for TRM. Moreover, different centres had different prognostic criteria for good-risk or bad-risk patients indicating that risk factors do not have the same impact in each individual centre. Interpretation The outcome of bone-marrow transplantation for acute myeloid leukaemia in first complete remission is influenced by the centre in which the procedure is done, even with adjustment for known prognostic risk factors. Significant prognostic factors vary among centres, which means that the relative risk is not the same in each individual centre. However, centres may treat populations with different risks of as yet unidentified prognostic factors. Experience may partly account for the difference in outcome among centres.	Osped San Martino Genova, Div Ematol 2, I-16132 Genoa, Italy; AP HP, Hop St Antoine, Paris, France; AP HP, Ctr Int Greffes, Paris, France; Royal Marsden Hosp, London SW3 6JJ, England; Univ Paris 07, INSERM, U444, Biostat Team, F-75221 Paris, France; Ist Ematol, Rome, Italy; Bone Marrow Transplant Unit, Ulm, Germany; Hop St Louis, Paris, France; Univ Helsinki, Cent Hosp, Helsinki, Finland; Klin & Poliklin Knochenmartransplantat, Essen, Germany; Hosp San Pau, Barcelona, Spain; Pitie Salpetriere, Paris, France; Univ Leiden Hosp, NL-2300 RC Leiden, Netherlands; Univ Nijmegen Hosp, NL-6500 HB Nijmegen, Netherlands	University of Genoa; IRCCS AOU San Martino IST; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Royal Marsden NHS Foundation Trust; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Helsinki; Helsinki University Central Hospital; University of Duisburg Essen; Leiden University; Leiden University Medical Center (LUMC); Radboud University Nijmegen	Frassoni, F (corresponding author), Osped San Martino Genova, Div Ematol 2, I-16132 Genoa, Italy.		de Witte, T.J.M./L-4762-2015; Frassoni, Francesco/K-3971-2018	Frassoni, Francesco/0000-0003-1262-0648; ARCESE, WILLIAM/0000-0001-5697-366X				BLOOMFIELD CD, 1994, BLOOD, V84, pA111; Burnett A. K., 1996, British Journal of Haematology, V93, P313; Burnett AK, 1998, LANCET, V351, P700, DOI 10.1016/S0140-6736(97)09214-3; Byar DP., 1988, CANC CLIN TRIALS MET, P423; Cassileth PA, 1998, NEW ENGL J MED, V339, P1649, DOI 10.1056/NEJM199812033392301; COX DR, 1972, J R STAT SOC B, V34, P187; Frassoni F, 1996, BONE MARROW TRANSPL, V17, P13; FRASSONI F, 1994, LEUKEMIA, V8, P924; HANNAN EL, 1990, NEW ENGL J MED, V340, P12677; HOROWITZ MM, 1992, BLOOD, V79, P2771; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAMER S, 1984, J CLIN ONCOL, V2, P917, DOI 10.1200/JCO.1984.2.8.917; LOWENBERG B, 1995, NEW ENGL J MED, V332, P260, DOI 10.1056/NEJM199501263320411; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; PETERS W, 1999, J CLIN ONCOL, V18, pA1; SAINSBURY JRC, 1995, BRIT J CANCER, V71, P1275; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; SOWDEN AJ, 1995, BMJ-BRIT MED J, V311, P151, DOI 10.1136/bmj.311.6998.151; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P223	22	85	86	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1393	1398		10.1016/S0140-6736(00)02137-1	http://dx.doi.org/10.1016/S0140-6736(00)02137-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310LN	10791522				2022-12-28	WOS:000086829800009
J	Kaprio, J				Kaprio, J			Science, medicine, and the future - Genetic epidemiology	BRITISH MEDICAL JOURNAL			English	Review							CANCER; DISEASE; BREAST; HEALTH; BRCA1		Univ Oulu, Dept Publ Hlth & Gen Practice, FIN-90220 Oulu, Finland	University of Oulu	Kaprio, J (corresponding author), Univ Oulu, Dept Publ Hlth & Gen Practice, Aapistie 1, FIN-90220 Oulu, Finland.		Kaprio, Jaakko/A-1820-2008	Kaprio, Jaakko/0000-0002-3716-2455				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Brunet JS, 1998, J NATL CANCER I, V90, P761, DOI 10.1093/jnci/90.10.761; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Creinin MD, 1999, FERTIL STERIL, V72, P646, DOI 10.1016/S0015-0282(99)00318-0; FORD D, 1995, AM J HUM GENET, V57, P1457; Geddes DM, 1999, THORAX, V54, P1052, DOI 10.1136/thx.54.12.1052; Gulcher J, 1999, NAT BIOTECHNOL, V17, P620, DOI 10.1038/10796; Heath AC, 1995, BEHAV GENETIC APPROA, P45; Keavney B, 2000, LANCET, V355, P434; Kervinen K, 1996, GASTROENTEROLOGY, V110, P1785, DOI 10.1053/gast.1996.v110.pm8964404; KIRK KM, 1999, TWIN RES, V2, P59; Koppelman GH, 1999, EUR RESPIR J, V13, P2, DOI 10.1183/09031936.99.13100299; Luft FC, 1998, J HYPERTENS, V16, P1871, DOI 10.1097/00004872-199816121-00004; MEYER JM, 1995, BEHAV GENETIC APPROA, P145; Morton N. E., 1982, OUTLINE GENETIC EPID; *NAT CTR BIOT INF, 2000, HUM GEN SEQ; O'Donnell HC, 2000, NEW ENGL J MED, V342, P240, DOI 10.1056/NEJM200001273420403; OLESEN J, 2000, GENETICS HEADCHE DIS; Rosendaal FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0; SING CF, 1996, VARIATION HUMAN GENO, P211; Smith KR, 1999, EPIDEMIOLOGY, V10, P573, DOI 10.1097/00001648-199909000-00027; SPECTOR TD, 2000, ADV TWIN SIB PAIR AN; Terwilliger JD, 2000, HUM BIOL, V72, P63; Terwilliger JD, 1998, CURR OPIN BIOTECH, V9, P578, DOI 10.1016/S0958-1669(98)80135-3; THOMAS D, 1999, GENET EPIDEMIOL, V17, P228; Tobin SL, 1999, GENET TEST, V3, P37, DOI 10.1089/gte.1999.3.37	26	33	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	2000	320	7244					1257	1259		10.1136/bmj.320.7244.1257	http://dx.doi.org/10.1136/bmj.320.7244.1257			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	313CF	10797040	Bronze, Green Published			2022-12-28	WOS:000086981400024
J	Diehn, M; Alizadeh, AA; Brown, PO				Diehn, M; Alizadeh, AA; Brown, PO			Examining the living genome in health and disease with DNA microarrays	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review									Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University	Diehn, M (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.		Alizadeh, Ash A/C-5594-2009	Alizadeh, Ash A/0000-0002-5153-5625				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hacia JG, 1999, NAT GENET, V21, P42, DOI 10.1038/4469; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; Yates JR, 2000, TRENDS GENET, V16, P5, DOI 10.1016/S0168-9525(99)01879-X	11	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	2000	283	17					2298	2299		10.1001/jama.283.17.2298	http://dx.doi.org/10.1001/jama.283.17.2298			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	307UB	10807394	hybrid			2022-12-28	WOS:000086671600042
J	Anderson, WF				Anderson, WF			Gene therapy - The best of times, the worst of times	SCIENCE			English	Editorial Material							ADENOSINE-DEAMINASE DEFICIENCY; BONE-MARROW; LYMPHOCYTES; CELLS		Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California	Anderson, WF (corresponding author), Univ So Calif, Keck Sch Med, Norris Canc Ctr, Room 6316,1441 Eastlake Ave, Los Angeles, CA 90033 USA.	sdiaz@genome2.hsc.usc.edu						ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Hoogerbrugge PM, 1996, GENE THER, V3, P179; Isner JM, 1999, J CLIN INVEST, V103, P1231, DOI 10.1172/JCI6889; Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Mullen CA, 1996, HUM GENE THER, V7, P1123, DOI 10.1089/hum.1996.7.9-1123; Onodera M, 1998, BLOOD, V91, P30, DOI 10.1182/blood.V91.1.30.30_30_36	11	47	56	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	2000	288	5466					627	+		10.1126/science.288.5466.627	http://dx.doi.org/10.1126/science.288.5466.627			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10799000				2022-12-28	WOS:000086727100031
J	Brzustowicz, LM; Hodgkinson, KA; Chow, EWC; Honer, WG; Bassett, AS				Brzustowicz, LM; Hodgkinson, KA; Chow, EWC; Honer, WG; Bassett, AS			Location of a major susceptibility locus for familiar schizophrenia on chromosome 1q21-q22	SCIENCE			English	Article							GENOME-WIDE SEARCH; DUFFY BLOOD-GROUP; LINKAGE ANALYSIS; MILLENNIUM-CONSORTIUM; COMPLEX TRAITS; GENES; SCAN; INHERITANCE; PEDIGREES; SYMPTOMS	Schizophrenia is a complex disorder, and there is substantial evidence supporting a genetic etiology. Despite this, prior attempts to localize susceptibility loci have produced predominantly suggestive findings, A genome-wide scan for schizophrenia susceptibility loci in 22 extended families with high rates of schizophrenia provided highly significant evidence of linkage to chromosome 1 (1q21-q22), with a maximum heterogeneity Logarithm of the likelihood of linkage (lod) score of 6.50. This linkage result should provide sufficient power to allow the positional cloning of the underlying susceptibility gene.	Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA; Univ Toronto, Dept Psychiat, Toronto, ON M6J 1H4, Canada; Univ Toronto, Ctr Addict & Mental Hlth, Schizophrenia Res Program, Genet Sect, Toronto, ON M6J 1H4, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC V6H 3Z6, Canada	Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of British Columbia	Brzustowicz, LM (corresponding author), Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [N01HG065403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001392] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [53216] Funding Source: Medline; NHGRI NIH HHS [N01HG65403] Funding Source: Medline; NIMH NIH HHS [K08 MH01392] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abreu PC, 1999, AM J HUM GENET, V65, P847, DOI 10.1086/302536; BASSETT AS, 1993, SCHIZOPHR RES, V11, P9, DOI 10.1016/0920-9964(93)90033-F; BASSETT AS, 1994, AM J HUM GENET, V54, P864; Blouin JL, 1998, NAT GENET, V20, P70, DOI 10.1038/1734; Brzustowicz LM, 1999, AM J HUM GENET, V65, P1096, DOI 10.1086/302579; Brzustowicz LM, 1997, AM J HUM GENET, V61, P1388, DOI 10.1086/301623; Cloninger CR, 1998, AM J MED GENET, V81, P275, DOI 10.1002/(SICI)1096-8628(19980710)81:4<275::AID-AJMG1>3.3.CO;2-U; COON H, 1994, AM J MED GENET, V54, P59, DOI 10.1002/ajmg.1320540111; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Detera-Wadleigh SD, 1999, P NATL ACAD SCI USA, V96, P5604, DOI 10.1073/pnas.96.10.5604; Dror V, 1999, MOL PSYCHIATR, V4, P254, DOI 10.1038/sj.mp.4000508; Durner M, 1999, AM J HUM GENET, V64, P281, DOI 10.1086/302181; Fananas L, 1997, AM J PSYCHIAT, V154, P716; Faraone SV, 1998, AM J MED GENET, V81, P290, DOI 10.1002/(SICI)1096-8628(19980710)81:4<290::AID-AJMG3>3.0.CO;2-Y; Greenberg DA, 1998, AM J HUM GENET, V63, P870, DOI 10.1086/301997; Gurling HMD, 1999, MOL PSYCHIATR, V4, pS4; Hovatta I, 1999, AM J HUM GENET, V65, P1114, DOI 10.1086/302567; Kaufmann CA, 1998, AM J MED GENET, V81, P282, DOI 10.1002/(SICI)1096-8628(19980710)81:4<282::AID-AJMG2>3.0.CO;2-W; KOSOWER NS, 1995, AM J MED GENET, V60, P133, DOI 10.1002/ajmg.1320600209; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Levinson DF, 1998, AM J PSYCHIAT, V155, P741; MCGUFFIN P, 1994, BRIT J PSYCHIAT, V164, P593, DOI 10.1192/bjp.164.5.593; MOISES HW, 1995, NAT GENET, V11, P321, DOI 10.1038/ng1195-321; Morton NE, 1998, AM J HUM GENET, V62, P690, DOI 10.1086/301741; OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; Ott J., 1999, ANAL HUMAN GENETIC L; Rees MI, 1999, MOL PSYCHIATR, V4, P353, DOI 10.1038/sj.mp.4000521; RISCH N, 1992, HUM HERED, V42, P77, DOI 10.1159/000154047; Risch N, 1996, NAT GENET, V12, P351, DOI 10.1038/ng0496-351; RISCH N, 1990, AM J HUM GENET, V46, P222; SAHA N, 1990, GENET EPIDEMIOL, V7, P303, DOI 10.1002/gepi.1370070408; Shaw SH, 1998, AM J MED GENET, V81, P364, DOI 10.1002/(SICI)1096-8628(19980907)81:5<364::AID-AJMG4>3.0.CO;2-T; Straub RE, 1997, MOL PSYCHIATR, V2, P148, DOI 10.1038/sj.mp.4000258; TERWILLIGER JD, 1993, GENET EPIDEMIOL, V10, P217, DOI 10.1002/gepi.1370100402; VIELAND VJ, 1993, HUM HERED, V43, P329, DOI 10.1159/000154155; WEEKS DE, 1990, AM J HUM GENET S, V47, pA204; Williams NM, 1999, HUM MOL GENET, V8, P1729, DOI 10.1093/hmg/8.9.1729	38	396	429	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 28	2000	288	5466					678	682		10.1126/science.288.5466.678	http://dx.doi.org/10.1126/science.288.5466.678			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	308RR	10784452	Green Accepted			2022-12-28	WOS:000086727100046
J	Jansen, M; Letschert, HP				Jansen, M; Letschert, HP			Inorganic yellow-red pigments without toxic metals	NATURE			English	Article							OXYNITRIDES	Inorganic pigments have been utilized by mankind since ancient times(1), and are still widely used to colour materials exposed to elevated temperatures during processing or application(2). Indeed, in the case of glasses, glazes and ceramics, there is no alternative to inorganic pigments for colouring. However, most inorganic pigments contain heavy metals or transition metals that can adversely effect the environment and human health if critical levels are exceeded. Cadmium-based pigments in particular are a cause of concern(3) : although the pigments are not toxic due to their very low solubility in water and dilute mineral acids, cadmium itself is toxic and can enter the environment in a bioavailable form through waste-disposal sites and incineration plants(4). This has led to regulations, based on the precautionary principle, that strongly restrict the use of cadmium pigments(5). And even though recent assessments(20,21) have concluded that the risk to humans or the environment might be not as significant as originally feared, a strong demand for inherently safer substitutes remains. Here we demonstrate that solid solutions of the perovskites CaTaO2N and LaTaON2 constitute promising candidates for such substitutes: their brilliance, tinting strength, opacity, dispersability, light-fastness and heat stability rival that of the cadmium pigments, while their colour can be tuned through the desired range, from yellow through orange to deep red, by simple composition adjustments. Because all the constituent elements are harmless, this perovskite-based inorganic pigment system seems a promising replacement that could eliminate one of the sources for cadmium emissions to the environment and some of the remaining concerns about pigment safety.	Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; Degussa Met Catalysts Cerdec, Dmc2, D-60039 Frankfurt, Germany	Max Planck Society; Evonik Industries	Jansen, M (corresponding author), Max Planck Inst Festkorperforsch, Heisenbergstr 1, D-70569 Stuttgart, Germany.							BEYER HH, 1972, Patent No. 2312535; BEYER HH, 1977, CHEM ZEITUNG, V101, P319; BUXBAUM G, 1993, IND INORGANIC PIGMEN; *EUR EC COMM, 1991, 91338EWG EUR EC COMM; GRINS J, 1994, MATER RES BULL, V29, P801, DOI 10.1016/0025-5408(94)90206-2; GUNTHER E, IN PRESS Z ANORG ALL; *ISO, 1988, 747 ISO; *ISO, 1986, 787 ISO 24; JANSEN M, 1995, Patent No. 0697373; JANSEN M, 1992, Patent No. 0627382; Jorgensen C. K, 1969, OXIDATION NUMBERS OX; Knorn D., 1983, METALL, V37, P633; MARCHAND R, 1986, REV INT HAUTES TEMP, V23, P11; MARCHAND R, 1991, ANN CHIM-SCI MAT, V16, P553; Marchand R., 1991, Journal of the European Ceramic Society, V8, P197, DOI 10.1016/0955-2219(91)90096-I; Noll W., 1975, ANGEW CHEM-GER EDIT, V87, P639, DOI [10.1002/ange.19750871803, DOI 10.1002/ANGE.19750871803]; Phillips JC., 1973, BONDS BANDS SEMICOND; PORS F, 1988, MATER RES BULL, V23, P1447, DOI 10.1016/0025-5408(88)90270-X; STRAHLE J, 1973, Z ANORG ALLG CHEM, V402, P47, DOI 10.1002/zaac.19734020107; VANVECHT.JA, 1970, PHYS REV B, V2, P2160, DOI 10.1103/PhysRevB.2.2160; WIRTH W, 1981, TOXIKOLOGIE; *WS ATK INT, 1998, ASS RISKS HLTH ENV C	22	568	592	9	303	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 27	2000	404	6781					980	982		10.1038/35010082	http://dx.doi.org/10.1038/35010082			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	309HG	10801123				2022-12-28	WOS:000086762000051
J	Goldfrad, C; Rowan, K				Goldfrad, C; Rowan, K			Consequences of discharges from intensive care at night	LANCET			English	Article							HIGH-DEPENDENCY UNIT; SOCIETY APACHE-II; CASE-MIX; SET-UP; BRITAIN; IMPACT; SHORTAGES; ADMISSION; PROVISION; REGISTER	Background It is generally believed that pressure for beds on intensive-care units (ICUs) has increased in the UK. This study used discharge at night as a proxy measure to investigate pressure. Methods Night was defined in two ways: "out of office hours' from 2200 to 0659 h and "the early hours of the morning" from 0000 to 0459 h. The rate of discharge at night was compared for 21 295 adult admissions to 62 ICUs covering the period 1995-98 with 10 806 admissions to 26 ICUs covering the period 1988-90. With data solely from 1995-98, the consequences of discharge at night and premature discharge were investigated. Findings Overall, 2269 (21.0%) admissions did not survive the ICU in 1988-90 compared with 4487 (21.1%) in 1995-98. Of ICU survivors, 2.7% were discharged at night (2200-0659 h) in 1988-90 compared with 6.0% in 1995-98. In 1995-98, night discharges (2200-0659 h) had a higher crude (odds ratio 1.46, 95% CI 1.18-1.80) and case-mix adjusted (1.33, 1.06-1.65) ultimate hospital mortality. Higher odds ratios were observed when the definition of night was 0000-0459 h. Premature discharge was commoner at night, 42.6% vs 5.0% and its importance was apparent when incorporated into the logistic-regression model (premature discharge 1.35, 1.10-1.65; night discharge 1.17, 0.92-1.49). Interpretation Night discharges from ICU are increasing in the UK. This practice is of concern because patients discharged at night fare significantly worse than those discharged during the day. Night discharges are more likely to be "premature" in the view of the clinicians involved. The implication of these results is that many hospitals have insufficient intensive-care beds. In deciding whether or not to invest more resources in intensive care we must, however, consider the cost-utility of this particular service compared with other ways that additional resources could be used.	Intens Care Natl Audit & Res Ctr, London WC1H 9HR, England	Intensive Care National Audit & Research Centre	Rowan, K (corresponding author), Intens Care Natl Audit & Res Ctr, Tavistock House,Tavistock Sq, London WC1H 9HR, England.							BION J, 1995, BMJ-BRIT MED J, V310, P682, DOI 10.1136/bmj.310.6981.682; Black N, 1996, HEART, V76, P1, DOI 10.1136/hrt.76.4_Suppl_4.1; BULL AR, 1995, BRIT MED J, V310, P1010, DOI 10.1136/bmj.310.6985.1010b; CHADDA D, 1995, HLTH SERV J     0720, P4; DYER O, 1995, BRIT MED J, V310, P688, DOI 10.1136/bmj.310.6981.688a; Gunning K, 1999, BRIT MED J, V319, P241, DOI 10.1136/bmj.319.7204.241; KILPATRICK A, 1994, ANAESTHESIA, V49, P666, DOI 10.1111/j.1365-2044.1994.tb04393.x; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; METCALFE A, 1995, STUDY PROVISION INTE; Metcalfe MA, 1997, LANCET, V350, P7, DOI 10.1016/S0140-6736(96)10018-0; MITCHELL I, 1995, LANCET, V345, P652, DOI 10.1016/S0140-6736(95)90554-5; PEACOCK JE, 1995, BRIT MED J, V310, P1413, DOI 10.1136/bmj.310.6991.1413; Rowan K, 1996, BRIT MED J, V313, P1007; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; Rowan KM., 1992, THESIS U OXFORD; RYAN DW, 1995, BRIT MED J, V310, P1010, DOI 10.1136/bmj.310.6985.1010c; Ryan DW, 1997, ANAESTHESIA, V52, P265, DOI 10.1111/j.1365-2044.1997.068-az0055.x; SMITH GB, 1995, BRIT MED J, V310, P1412, DOI 10.1136/bmj.310.6991.1412b; Wallace PGM, 1997, BRIT MED J, V314, P369, DOI 10.1136/bmj.314.7077.369; Warden J, 1996, BRIT MED J, V313, P575; *WORK PART, 1994, REV INT CAR SERV W M; 1995, HLTH SERV J     0126, P6; [No title captured]	24	220	222	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 1	2000	355	9210					1138	1142		10.1016/S0140-6736(00)02062-6	http://dx.doi.org/10.1016/S0140-6736(00)02062-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302TC	10791376				2022-12-28	WOS:000086380900011
J	Sacker, A; Firth, D; Fitzpatrick, R; Lynch, K; Bartley, M				Sacker, A; Firth, D; Fitzpatrick, R; Lynch, K; Bartley, M			Comparing health inequality in men and women: prospective study of mortality 1986-96	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CAMBRIDGE-SCALE; SMALLER; GENDER	Objectives To study prospectively the differences in health inequality in men and women from 1986-96 using the Office for National Statistics' longitudinal study and new socioeconomic classification. To assess the relative importance of social class (based on employment characteristics) and social position according to the general social advantage of the household to mortality risk in men and women. Design Prospective study. Setting England and Wales. Subjects Men and women of working age at the time of the 1981 census, with a recorded occupation. Main outcome measures Mortality. Results In men, social class based on employment relations, measured according to the Office for National Statistics' socioeconomic classification, was the most important influence on mortality. In women, social class based on individual employment relations and conditions showed only a weak gradient Large differences in risk of mortality in women were found, however; when social position was measured according to the general social advantage in the household, Conclusions Comparisons of the extent of health inequality in men and women are affected by the measures of social inequality used. For women, even those in paid work, classifications based on characteristics of the employment situation may give a considerable underestimate. The Office for National Statistics' new measure of socioeconomic position is useful for assessing health inequality in men, but in women a more important predictor of mortality is inequality in general social advantage of the household.	Inst Educ, Ctr Longitudinal, London WC1H 0AL, England; UCL Royal Free & UCL Med Sch, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; Univ Oxford Nuffield Coll, Oxford OX1 1NF, England; Univ Oxford, Inst Hlth Sci, Oxford OX3 7LF, England	University of London; University College London; University of London; University College London; University of Oxford; University of Oxford	Bartley, M (corresponding author), UCL Royal Free & UCL Med Sch, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England.	mel@public-health.ucl.ac.uk	Firth, David/A-8207-2011	Firth, David/0000-0003-0302-2312; Sacker, Amanda/0000-0001-8796-5398				Arber S, 1997, SOC SCI MED, V44, P773, DOI 10.1016/S0277-9536(96)00185-2; ARBER S, 1997, CONSTRUCTING CLASSES, P78; Bartley M, 1999, SOC SCI MED, V49, P831, DOI 10.1016/S0277-9536(99)00192-6; BLACKBURN RM, 1991, BRIT J SOCIOL, V42, P507, DOI 10.2307/591445; Chandola T, 1998, SOC SCI MED, V47, P525, DOI 10.1016/S0277-9536(98)00141-5; DAHL E, 1991, SOCIOLOGY HLTH ILLNE, V13, P491; DOLLAMORE G, 1999, HLTH STAT Q, V2, P33; FITZPATRICK R, 1997, CONSTRUCTING CLASSES, P93; Hattersley L, 1995, LONGITUDINAL STUDY 1; KOSKINEN S, 1994, SOC SCI MED, V38, P1385, DOI 10.1016/0277-9536(94)90276-3; LEON D, 1992, AM J IND MED, V22, P141, DOI 10.1002/ajim.4700220115; Macintyre S, 1997, J Health Psychol, V2, P315, DOI 10.1177/135910539700200304; MACRAN S, 1994, SOCIOL HEALTH ILL, V16, P182, DOI 10.1111/1467-9566.ep11347322; MARSH C, 1992, CONSUMPTION AND CLASS, P184; MARSHALL G, 1995, EUR SOCIOL REV, V11, P1; MOSER KA, 1988, BRIT MED J, V296, P1221, DOI 10.1136/bmj.296.6631.1221; Prandy K, 1999, SOCIOL HEALTH ILL, V21, P466, DOI 10.1111/1467-9566.00167; PRANDY K, 1990, SOCIOLOGY, V24, P629, DOI 10.1177/0038038590024004005; PRANDY K, 1990, 18 CAMBR U SOC POL S; Raleigh VS, 1997, J EPIDEMIOL COMMUN H, V51, P649, DOI 10.1136/jech.51.6.649; ROSE D, 1997, CONSTRUCTING CLASSES; ROSE O, 1998, FINAL REPORT ESRC RE; Stewart A., 1980, SOCIAL STRATIFICATIO; STRONKS K, 1995, INT J EPIDEMIOL, V24, P559, DOI 10.1093/ije/24.3.559	24	114	115	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2000	320	7245					1303	1307		10.1136/bmj.320.7245.1303	http://dx.doi.org/10.1136/bmj.320.7245.1303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	314VC	10807620	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000087077400021
J	Heisenberg, CP; Tada, M; Rauch, GJ; Saude, L; Concha, ML; Geisler, R; Stemple, DL; Smith, JC; Wilson, SW				Heisenberg, CP; Tada, M; Rauch, GJ; Saude, L; Concha, ML; Geisler, R; Stemple, DL; Smith, JC; Wilson, SW			Silberblick/Wnt11 mediates convergent extension movements during zebrafish gastrulation	NATURE			English	Article							DANIO-RERIO; SIGNALING PATHWAYS; XENOPUS EMBRYOS; BETA-CATENIN; CELL; MORPHOGENESIS; EXPRESSION; FOREBRAIN; WNT; OVEREXPRESSION	Vertebrate gastrulation involves the specification and coordinated movement of large populations of cells that give rise to the ectodermal, mesodermal and endodermal germ layers. Although many of the genes involved in the specification of cell identity during this process have been identified, little is known of the genes that coordinate cell movement. Here we show that the zebrafish silberblick (slb) locus(1) encodes Wnt11 and that Slb/Wnt11 activity is required for cells to undergo correct convergent extension movements during gastrulation. In the absence of Slb/Wnt11 function, abnormal extension of axial tissue results in cyclopia and other midline defects in the head(2). The requirement for Slb/Wnt11 is cell non-autonomous, and our results indicate that the correct extension of axial tissue is at least partly dependent on medio-lateral cell intercalation in paraxial tissue. We also show that the slb phenotype is rescued by a truncated form of Dishevelled that does not signal through the canonical Wnt pathway(3), suggesting that, as in flies(4), Wnt signalling might mediate morphogenetic events through a divergent signal transduction cascade. Our results provide genetic and experimental evidence that Wnt activity in lateral tissues has a crucial role in driving the convergent extension movements underlying vertebrate gastrulation.	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; Natl Inst Med Res, Div Dev Biol, London NW7 1AA, England; Max Planck Inst Entwicklungsbiol, Genet Abt, D-72076 Tubingen, Germany	University of London; University College London; MRC National Institute for Medical Research; Max Planck Society	Heisenberg, CP (corresponding author), UCL, Dept Anat & Dev Biol, Gower St, London WC1E 6BT, England.	c.heisenberg@ucl.ac.uk; mtada@nimr.mrc.ac.uk	Saúde, Leonor/D-2720-2012; Tada, Masazumi/A-1431-2009; Wilson, Stephen W/B-9404-2008; Geisler, Robert/K-6201-2013; Concha, Miguel/I-2551-2013; Zebrafish, UCL/A-3125-2009	Saúde, Leonor/0000-0001-5933-8872; Wilson, Stephen W/0000-0002-8557-5940; Geisler, Robert/0000-0002-3909-8311; Concha, Miguel/0000-0003-3353-9398; Heisenberg, Carl-Philipp/0000-0002-0912-4566				Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; BARTH KA, 1995, DEVELOPMENT, V121, P1755; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Concha ML, 1998, DEVELOPMENT, V125, P983; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Elul T, 1997, DEV BIOL, V191, P243, DOI 10.1006/dbio.1997.8711; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Heisenberg CP, 1996, DEVELOPMENT, V123, P191; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; KELLER R, 1992, DEVELOPMENT, P81; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; Knapik EW, 1996, DEVELOPMENT, V123, P451; Kobayashi M, 1998, DEVELOPMENT, V125, P2973; Makita R, 1998, MECH DEVELOP, V71, P165, DOI 10.1016/S0925-4773(98)00013-6; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOON RT, 1993, DEVELOPMENT, V119, P97; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Pai LM, 1997, DEVELOPMENT, V124, P2255; Pelegri F, 1998, MECH DEVELOP, V77, P63, DOI 10.1016/S0925-4773(98)00132-4; RAUCH GJ, 1997, POLYMORPHIC ZEBRAFIS; SAUDE L, UNPUB DEVELOPMENT; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; TADA M, IN PRESS DEVELOPMENT; UNGAR AR, 1995, MECH DEVELOP, V52, P153, DOI 10.1016/0925-4773(95)00386-F; WARGA RM, 1990, DEVELOPMENT, V108, P569; WILSON PA, 1989, DEVELOPMENT, V105, P155; Yamamoto A, 1998, DEVELOPMENT, V125, P3389	30	802	817	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	2000	405	6782					76	81		10.1038/35011068	http://dx.doi.org/10.1038/35011068			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	311TK	10811221				2022-12-28	WOS:000086901600054
J	Bates, DW; Gawande, AA				Bates, DW; Gawande, AA			Error in medicine: What have we learned?	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; INTERVENTION; PREVENTION; COMMUNITY; CARE		Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.							Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; Bogner MS, 1994, HUMAN ERROR MED; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Cook RI, 1994, HUMAN ERROR MED, P255; CORRIGAN J, 2000, ERR HUMAN BUILDING S; GABA DM, 1994, HUMAN ERROR MED, P197; Helmreich RL., 1994, HUMAN ERROR MED, P225; Honigman B, 1998, J AM MED INFORM ASSN, P1018; Jha AK, 1998, J AM MED INFORM ASSN, V5, P305, DOI 10.1136/jamia.1998.0050305; KOCH KE, 1990, AM J HOSP PHARM, V47, P1314, DOI 10.1093/ajhp/47.6.1314; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Leape LL, 1994, HUMAN ERROR MED, P13; LEAPE LL, 1998, REDUCING ADVERSE DRU; *MED PAYM ADV COMM, 1999, REP C; Millenson ML., 1997, DEMANDING MED EXCELL; Paget M. A., 1988, UNITY MISTAKES; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Reason JT, 1994, HUMAN ERROR MED, pvii; Rizzo JA, 1996, MED CARE, V34, P954, DOI 10.1097/00005650-199609000-00007; SIMBORG DW, 1975, ANN INTERN MED, V83, P342, DOI 10.7326/0003-4819-83-3-342; TEICH JM, 1996, COST EFFECTIVE QUALI, P3; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301	27	61	64	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					763	767		10.7326/0003-4819-132-9-200005020-00025	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00025			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308VT	10787381				2022-12-28	WOS:000086734100023
J	Young, MW				Young, MW			Circadian rhythms - Marking time for a kingdom	SCIENCE			English	Editorial Material							DROSOPHILA CLOCK GENE; MUTATION; HAMSTERS		Rockefeller Univ, Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Natl Sci Fdn, Ctr Biol Timing, New York, NY 10021 USA	Rockefeller University; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University	Young, MW (corresponding author), Rockefeller Univ, Genet Lab, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020					Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Loudon ASI, 1998, P ROY SOC B-BIOL SCI, V265, P517, DOI 10.1098/rspb.1998.0325; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Okamura H, 1999, SCIENCE, V286, P2531, DOI 10.1126/science.286.5449.2531; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; Scully AL, 2000, CELL, V100, P297, DOI 10.1016/S0092-8674(00)80665-0; Silver R, 1996, NATURE, V382, P810, DOI 10.1038/382810a0; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; VIELHABER E, IN PRESS MOL CELL BI; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114	15	25	35	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	2000	288	5465					451	453		10.1126/science.288.5465.451	http://dx.doi.org/10.1126/science.288.5465.451			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306YJ	10798982				2022-12-28	WOS:000086626000026
J	Valentini, R; Matteucci, G; Dolman, AJ; Schulze, ED; Rebmann, C; Moors, EJ; Granier, A; Gross, P; Jensen, NO; Pilegaard, K; Lindroth, A; Grelle, A; Bernhofer, C; Grunwald, T; Aubinet, M; Ceulemans, R; Kowalski, AS; Vesala, T; Rannik, U; Berbigier, P; Loustau, D; Guomundsson, J; Thorgeirsson, H; Ibrom, A; Morgenstern, K; Clement, R; Moncrieff, J; Montagnani, L; Minerbi, S; Jarvis, PG				Valentini, R; Matteucci, G; Dolman, AJ; Schulze, ED; Rebmann, C; Moors, EJ; Granier, A; Gross, P; Jensen, NO; Pilegaard, K; Lindroth, A; Grelle, A; Bernhofer, C; Grunwald, T; Aubinet, M; Ceulemans, R; Kowalski, AS; Vesala, T; Rannik, U; Berbigier, P; Loustau, D; Guomundsson, J; Thorgeirsson, H; Ibrom, A; Morgenstern, K; Clement, R; Moncrieff, J; Montagnani, L; Minerbi, S; Jarvis, PG			Respiration as the main determinant of carbon balance in European forests	NATURE			English	Article							LONG-TERM MEASUREMENTS; ATMOSPHERIC CO2; HIGH-LATITUDES; TEMPERATURE; ECOSYSTEMS; DIOXIDE; SINK; SENSITIVITY; FLUXES; WATER	Carbon exchange between the terrestrial biosphere and the atmosphere is one of the key processes that need to be assessed in the context of the Kyoto Protocol(1). Several studies suggest that the terrestrial biosphere is gaining carbon(2-8), but these estimates are obtained primarily by indirect methods, and the factors that control terrestrial carbon exchange, its magnitude and primary locations, are under debate. Here we present data of net ecosystem carbon exchange, collected between 1996 and 1998 from 15 European forests, which confirm that many European forest ecosystems act as carbon sinks. The annual carbon balances range from an uptake of 6.6 tonnes of carbon per hectare per year to a release of nearly 1 t C ha(-1) yr(-1), with a large variability between forests. The data show a significant increase of carbon uptake with decreasing latitude, whereas the gross primary production seems to be largely independent of latitude. Our observations indicate that, in general, ecosystem respiration determines net ecosystem carbon exchange. Also, for an accurate assessment of the carbon balance in a particular forest ecosystem, remote sensing of the normalized difference vegetation index or estimates based on forest inventories may not be sufficient.	Univ Tuscia, Dept Forest Environm & Resources, I-01100 Viterbo, Italy; Alterra, NL-6700 AA Wageningen, Netherlands; Max Planck Inst Biogeochem, D-07745 Jena, Germany; Univ Bayreuth, Lehrstuhl Pflanzenokol, D-95440 Bayreuth, Germany; Ctr Rech Nancy, Unite Ecophysiol Forestiere, Equipe Bioclimatol, F-54280 Champenoux, France; Riso Natl Lab, DK-4000 Roskilde, Denmark; Lund Univ, Dept Phys Geog, SE-22100 Lund, Sweden; SLU, Dept Prod Ecol, Fac Forestry, S-7042 Uppsala, Sweden; Tech Univ Dresden, Inst Hydrol & Meteorol, D-01737 Tharandt, Germany; Fac Univ Sci Agron Gembloux, Unite Phys, B-5030 Gembloux, Belgium; Univ Instelling Antwerp, Dept Biol, B-2610 Antwerp, Belgium; Univ Helsinki, Dept Phys, FIN-00014 Helsinki, Finland; INRA Bordeaux, Unite Bioclimatol, F-33883 Villenave Dornon, France; INRA Bordeaux, Unite Rech Forestieres, F-33611 Gazinet, France; Agr Res Inst, Dept Environm Res, IS-112 Reykjavik, Iceland; Univ Gottingen, Inst Bioklimatol, D-37077 Gottingen, Germany; Univ Edinburgh, Inst Ecol & Resource Management, Edinburgh EH9 3JU, Midlothian, Scotland; Univ Padua, Dept Land & Agroforestry Syst, I-35020 Padua, Italy; Autonomous Prov Bolzano Forest Serv, I-39100 Bolzano, Italy	Tuscia University; Wageningen University & Research; Max Planck Society; University of Bayreuth; Technical University of Denmark; Lund University; Swedish University of Agricultural Sciences; Technische Universitat Dresden; University of Liege; University of Antwerp; University of Helsinki; INRAE; INRAE; University of Gottingen; University of Edinburgh; University of Padua	Valentini, R (corresponding author), Univ Tuscia, Dept Forest Environm & Resources, I-01100 Viterbo, Italy.	rik@unitus.it	Kowalski, Andrew S./A-7515-2008; Pilegaard, Kim/H-9026-2019; Rebmann, Corinna/R-2359-2019; Schulze, Ernst-Detlef/K-9627-2014; Ceulemans, Reinhart J M/F-2109-2016; Vesala, Timo/C-3795-2017; Montagnani, Leonardo/F-1837-2016; Ibrom, Andreas/A-9850-2011; Moors, Eddy/J-5165-2012; Matteucci, Giorgio/AAB-7022-2021; Gudmundsson, Jon/AAD-1659-2021; Valentini, Riccardo/D-1226-2010; Matteucci, Giorgio/N-3526-2015; Rebmann, Corinna/E-5666-2011; Pilegaard, Kim/I-7137-2013; Lindroth, Anders/N-4697-2014; Gudmundsson, Jon/A-7112-2013	Kowalski, Andrew S./0000-0001-9777-9708; Pilegaard, Kim/0000-0002-5169-5717; Rebmann, Corinna/0000-0002-8665-0375; Ceulemans, Reinhart J M/0000-0003-4773-9358; Vesala, Timo/0000-0002-4852-7464; Montagnani, Leonardo/0000-0003-2957-9071; Moors, Eddy/0000-0003-2309-2887; Gudmundsson, Jon/0000-0002-1703-8916; Valentini, Riccardo/0000-0002-6756-5634; Matteucci, Giorgio/0000-0002-4790-9540; Pilegaard, Kim/0000-0002-5169-5717; Lindroth, Anders/0000-0002-7669-784X; Gudmundsson, Jon/0000-0002-1703-8916; Loustau, Denis/0000-0003-3990-400X; Dolman, A.J./0000-0003-0099-0457; Ibrom, Andreas/0000-0002-1341-921X				ANDERSON JM, 1992, ADV ECOL RES, V22, P163, DOI 10.1016/S0065-2504(08)60136-1; Aubinet M, 2000, ADV ECOL RES, V30, P113, DOI 10.1016/S0065-2504(08)60018-5; Baldocchi D, 1996, GLOBAL CHANGE BIOL, V2, P159, DOI 10.1111/j.1365-2486.1996.tb00069.x; BALDOCCHI DD, 1988, ECOLOGY, V69, P1331, DOI 10.2307/1941631; Burton AJ, 1998, ECOL APPL, V8, P771, DOI 10.1890/1051-0761(1998)008[0771:DRRRIS]2.0.CO;2; CHAPMAN WL, 1993, B AM METEOROL SOC, V74, P33, DOI 10.1175/1520-0477(1993)074<0033:RVOSIA>2.0.CO;2; Chen WJ, 1999, GLOBAL CHANGE BIOL, V5, P41, DOI 10.1046/j.1365-2486.1998.00201.x; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; DENNING AS, 1995, NATURE, V376, P240, DOI 10.1038/376240a0; DIXON RK, 1994, SCIENCE, V263, P185, DOI 10.1126/science.263.5144.185; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; Goulden ML, 1996, GLOBAL CHANGE BIOL, V2, P169, DOI 10.1111/j.1365-2486.1996.tb00070.x; Goulden ML, 1998, SCIENCE, V279, P214, DOI 10.1126/science.279.5348.214; HANSON PJ, 1993, TREE PHYSIOL, V13, P1, DOI 10.1093/treephys/13.1.1; KAUPPI PE, 1992, SCIENCE, V256, P70, DOI 10.1126/science.256.5053.70; KIRSCHBAUM MUF, 1995, SOIL BIOL BIOCHEM, V27, P753, DOI 10.1016/0038-0717(94)00242-S; Lindroth A, 1998, GLOBAL CHANGE BIOL, V4, P443, DOI 10.1046/j.1365-2486.1998.00165.x; Moncrieff JB, 1996, GLOB CHANGE BIOL, V2, P231, DOI 10.1111/j.1365-2486.1996.tb00075.x; Myneni RB, 1997, NATURE, V386, P698, DOI 10.1038/386698a0; Nabuurs GJ, 1997, BIOMASS BIOENERG, V13, P345, DOI 10.1016/S0961-9534(97)00036-6; OECHEL WC, 1993, NATURE, V361, P520, DOI 10.1038/361520a0; Running S. W., 1998, EARTH OBS, V10, P8; SAS, 1989, SAS STATR US GUID VE, V2; SCHLENTNER RE, 1985, CAN J FOREST RES, V15, P97, DOI 10.1139/x85-018; Schlesinger W. H., 1997, BIOGEOCHEMISTRY ANAL, P161; Schulze E.D., 1998, IGBP SERIES, P145; Steffen W, 1998, SCIENCE, V280, P1393; Vogt K., 1995, ADV SOIL SCI SOIL MA, P159	28	1171	1334	19	544	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	2000	404	6780					861	865		10.1038/35009084	http://dx.doi.org/10.1038/35009084			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	306XY	10786790				2022-12-28	WOS:000086625000042
J	Narlikar, JV				Narlikar, JV			Venture funding for new ideas - Explanations for anomalies should be sought with an open mind.	NATURE			English	Editorial Material									Interuniv Ctr Astron & Astrophys, Pune 411007, Maharashtra, India	Inter-University Centre for Astronomy & Astrophysics	Narlikar, JV (corresponding author), Interuniv Ctr Astron & Astrophys, Pune 411007, Maharashtra, India.								0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					707	707		10.1038/35008158	http://dx.doi.org/10.1038/35008158			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783865	Bronze			2022-12-28	WOS:000086523600026
J	Quinn, H				Quinn, H			No conflict between SLAC and Japan's KEK	NATURE			English	Letter									Stanford Linear Accelerator Ctr, Stanford, CA 94309 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Quinn, H (corresponding author), Stanford Linear Accelerator Ctr, MS 81,POB 4349, Stanford, CA 94309 USA.								0	1	1	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					701	701		10.1038/35008256	http://dx.doi.org/10.1038/35008256			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783864	Bronze			2022-12-28	WOS:000086523600019
J	Dickson, D				Dickson, D			Affymetrix loses first round of patent battle	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					697	697		10.1038/35008240	http://dx.doi.org/10.1038/35008240			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783861	Bronze			2022-12-28	WOS:000086523600015
J	Williams, JW; Mulrow, CD; Chiquette, E; Noel, PH; Aguilar, C; Cornell, J				Williams, JW; Mulrow, CD; Chiquette, E; Noel, PH; Aguilar, C; Cornell, J			A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary	ANNALS OF INTERNAL MEDICINE			English	Review							SEROTONIN REUPTAKE INHIBITORS; NATIONAL-COMORBIDITY-SURVEY; RANDOMIZED CLINICAL-TRIALS; LONG-TERM TREATMENT; ST-JOHNS WORT; PRIMARY-CARE; DOUBLE-BLIND; MAJOR DEPRESSION; TRICYCLIC ANTIDEPRESSANTS; DISCONTINUATION RATES	Background: Depressive disorders are persistent, recurring illnesses that cause great suffering for patients and their families. Purpose: To evaluate the benefits and adverse effects of newer pharmacotherapies and herbal treatments for depressive disorders in adults and adolescents. Data Sources: English-language and non-English-language literature from 1980 to January 1998 was identified from a specialized registry of controlled trials, meta-analyses, and experts. Study Selection: Randomized trials evaluating newer antidepressants (such as serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and St. John's wort) that reported clinical outcomes were selected. Data Extraction: Two persons independently abstracted data that were then synthesized descriptively; some data were pooled by using a random-effects model. Data Synthesis: Of 315 eligible trials, most evaluated antidepressants in adults with major depression, were conducted among outpatients, and examined acute-phase treatment. Newer antidepressants were more effective than placebo for major depression (relative benefit, 1.6 [95% CI, 1.5 to 1.7]) and dysthymia (relative benefit, 1.7 [CI, 1.3 to 2.3]). They were effective among older adults and primary care patients. Efficacy did not differ among newer agents or between newer and older agents. Hypericum (St. John's wort) was more effective than placebo for mild to moderate depression (risk ratio, 1.9 [Cl, 1.2 to 2.8]), but publication bias may have inflated the estimate of benefit. Newer and older antidepressants did not differ for overall discontinuation rates, but side effect profiles varied significantly. Data were insufficient for determining the efficacy of newer antidepressants for subsyndromal depression, depression with coexisting medical or psychiatric illness, or depression in adolescents. Conclusions: Newer antidepressants are clearly effective in treating depressive disorders in diverse settings. Because of similar efficacy, both newer and older antidepressants should be considered when making treatment decisions. Better information is urgently needed on the efficacy of newer antidepressants in patients with nonmajor depression and in special populations, including adolescents.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio Evidence Based Practice Ctr, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie Murphy Div, Kerrville, TX USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Williams, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio Evidence Based Practice Ctr, 7703 Floyd Curl Dr,Mail Code 7879, San Antonio, TX 78229 USA.		Williams, John W/A-3696-2008; Williams, John/AAM-4572-2020	Williams, John W/0000-0002-5267-5558; Williams, John/0000-0002-5267-5558; Noel, Polly/0000-0002-1519-7489	PHS HHS [290-97-0012] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; ANGST J, 1995, J CLIN PSYCHOPHARM, V15, pS16, DOI 10.1097/00004714-199508001-00004; ANTON SF, 1994, PSYCHOPHARMACOL BULL, V30, P165; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BEASLEY CM, 1992, INT CLIN PSYCHOPHARM, V6, P35, DOI 10.1097/00004850-199206006-00006; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERGMANN R, 1993, TW NEUROLOGIE PSYCHI, P7235; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Boyer P, 1996, EUR PSYCHIAT, V11, pS135, DOI 10.1016/0924-9338(96)85188-1; BREMNER JD, 1995, J CLIN PSYCHIAT, V56, P519; Brown C, 1995, GEN HOSP PSYCHIAT, V17, P414, DOI 10.1016/0163-8343(95)00072-0; BYRNE MM, 1989, ACTA PSYCHIAT SCAND, V80, P138, DOI 10.1111/j.1600-0447.1989.tb07194.x; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; CHURCHILL R, 1998, SYSTEMATIC REV META, P2; CLAGHORN JL, 1992, J CLIN PSYCHIAT, V53, P434; CONTE HR, 1986, ARCH GEN PSYCHIAT, V43, P471; COYNE JC, 1994, GEN HOSP PSYCHIAT, V16, P267, DOI 10.1016/0163-8343(94)90006-X; Cucherat M, 1996, ENCEPHALE, V22, P378; DELINISTULA A, 1995, J AFFECT DISORDERS, V35, P21, DOI 10.1016/0165-0327(95)00034-K; Devane CL, 1996, J CLIN PSYCHIAT, V57, P55; DITZLER K, 1994, COMPLEMENT THER MED, V2, P5; Donoghue J, 1996, BRIT MED J, V313, P861; DUNBAR GC, 1993, ACTA PSYCHIAT SCAND, V87, P302, DOI 10.1111/j.1600-0447.1993.tb03376.x; DUNBAR GC, 1995, PHARMACOLOGY, V51, P137, DOI 10.1159/000139327; EGGER M, 1997, BRIT MED J, V314, P629; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; Entsuah AR, 1995, PSYCHOPHARMACOL BULL, V31, P759; FAWCETT J, 1995, J CLIN PSYCHIAT, V56, P37; FRANCHINI L, 1994, J AFFECT DISORDERS, V32, P225, DOI 10.1016/0165-0327(94)90085-X; Franchini L, 1997, J CLIN PSYCHIAT, V58, P104, DOI 10.4088/JCP.v58n0303; FREEMANTLE N, 1993, EFFECTIVE HLTH CARE, P5; FREEMANTLE N, 1998, SELECTIVE SEROTONIN, P2; GOLDSTEIN DJ, 1993, CLIN PHARMACOL THER, V54, P245, DOI 10.1038/clpt.1993.144; GOODNICK PJ, 1995, J CLIN PSYCHIAT, V56, P128; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P419; GREENBERG RP, 1992, J CONSULT CLIN PSYCH, V60, P664, DOI 10.1037/0022-006X.60.5.664; GREENBERG RP, 1994, J NERV MENT DIS, V182, P547, DOI 10.1097/00005053-199410000-00003; HELLERSTEIN DJ, 1993, AM J PSYCHIAT, V150, P1169; HENRY JA, 1995, BRIT MED J, V310, P221, DOI 10.1136/bmj.310.6974.221; Hoffmann J, 1979, ZFA (Stuttgart), V55, P776; HORNIG M, 1998, ALTERNATIVE MED ALER, V1, P4; Hotopf M, 1997, J EPIDEMIOL COMMUN H, V51, P354, DOI 10.1136/jech.51.4.354; Hotopf M, 1996, BRIT J PSYCHIAT, V168, P404, DOI 10.1192/bjp.168.4.404; Hotopf M, 1997, BRIT J PSYCHIAT, V170, P120, DOI 10.1192/bjp.170.2.120; HOTOPF M, 1998, SYSTEMATIC REV TREAT, P2; Hunkeler E, 1998, INT J PSYCHIAT MED, V28, P389; IBOR JJL, 1993, EUR PSYCHIAT, V8, pS17; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; Kasper S, 1996, INT CLIN PSYCHOPHARM, V11, P35, DOI 10.1097/00004850-199609004-00005; Kasper S, 1995, INT CLIN PSYCHOPHARM, V10, P25, DOI 10.1097/00004850-199512004-00005; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katzelnick D, 1998, INT J PSYCHIAT MED, V28, P391; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KNIEBEL R, 1988, Z ALLG MED, V64, P689; LIMA MS, 1998, COMP DRUGS VERSUS PL, P2; LIN EHB, 1995, MED CARE, V33, P67, DOI 10.1097/00005650-199501000-00006; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; LINDE K, 1998, ST JOHNS WORT DEPRES, P2; Mandoki MW, 1997, PSYCHOPHARMACOL BULL, V33, P149; McCusker J, 1998, ARCH INTERN MED, V158, P705, DOI 10.1001/archinte.158.7.705; MONTGOMERY DE, 1995, MODAL ANAL, V10, P1; MONTGOMERY SA, 1995, INT CLIN PSYCHOPHARM, V9, P33, DOI 10.1097/00004850-199501004-00005; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P35, DOI 10.1097/00004850-199403001-00006; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199400910-00008; MONTGOMERY SA, 1993, INT CLIN PSYCHOPHARM, V8, P189, DOI 10.1097/00004850-199300830-00009; Mulrow CD, 1998, PSYCHOPHARMACOL BULL, V34, P409; MULROW CD, 1999, AHCPR PUBLICATION; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; *N ENGL EV BAS GUI, 1998, CHOIC ANT DEPR PRIM; PARNETTI L, 1993, DRUG INVEST, V6, P181, DOI 10.1007/BF03259242; PEDEN JG, 1995, TREATMENTS PSYCHIAT, P1330; PERSAD E, 1990, CAN J PSYCHIAT, V35, P175, DOI 10.1177/070674379003500214; Persons JB, 1996, ARCH GEN PSYCHIAT, V53, P283; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Puech A, 1997, INT CLIN PSYCHOPHARM, V12, P99, DOI 10.1097/00004850-199703000-00005; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REH C, 1992, THERAPIEWOCHE, V42, P1576; Rost K, 1998, INT J PSYCHIAT MED, V28, P398; SALZMANN E, 1995, NEUROPSYCHOBIOLOGY, V31, P68, DOI 10.1159/000119175; Schmidt U, 1993, Fortschr Med, V111, P339; SIMEON JG, 1990, PROG NEURO-PSYCHOPH, V14, P791, DOI 10.1016/0278-5846(90)90050-Q; SIMON GE, 1993, GEN HOSP PSYCHIAT, V15, P399, DOI 10.1016/0163-8343(93)90009-D; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; Smeraldi E, 1998, J AFFECT DISORDERS, V48, P47, DOI 10.1016/S0165-0327(97)00139-0; Sobin C, 1996, BRIT J PSYCHIAT, V169, P322, DOI 10.1192/bjp.169.3.322; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; Stahl S, 1997, ACTA PSYCHIAT SCAND, V96, P22, DOI 10.1111/j.1600-0447.1997.tb05955.x; Stassen HH, 1996, PHARMACOPSYCHIATRY, V29, P87, DOI 10.1055/s-2007-979551; Steffens D C, 1997, Depress Anxiety, V6, P10, DOI 10.1002/(SICI)1520-6394(1997)6:1<10::AID-DA2>3.0.CO;2-9; STEGER W, 1985, Z ALLG MED, V61, P914; Szegedi A, 1997, PHARMACOPSYCHIATRY, V30, P97, DOI 10.1055/s-2007-979490; TAYLOR D, 1995, BRIT J PSYCHIAT, V167, P575, DOI 10.1192/bjp.167.5.575; Thase ME, 1996, ARCH GEN PSYCHIAT, V53, P777; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; TOLLEFSON GD, 1994, J CLIN PSYCHOPHARM, V14, P163; TRINIDADE E, 1997, 19973E19974E CCOHTA; *US DEP HHS, 1993, AHCPR PUBL; Vanelle JM, 1997, BRIT J PSYCHIAT, V170, P345, DOI 10.1192/bjp.170.4.345; VANMOFFAERT M, 1989, NEW TRENDS EXPT CLIN, V5, P167; Vorbach EU, 1997, PHARMACOPSYCHIATRY, V30, P81, DOI 10.1055/s-2007-979524; VORBACH EU, 1994, J GERIATR PSYCHIA S1, V7, P519; Wagner W, 1992, Drugs, V43 Suppl 2, P48; Warshaw MG, 1996, J CLIN PSYCHIAT, V57, P158; WERNICKE JF, 1985, J CLIN PSYCHIAT, V46, P59; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; WILLIAMS JW, 1995, J GEN INTERN MED, V10, P7, DOI 10.1007/BF02599568; Williams JW, 1999, ARCH FAM MED, V8, P58, DOI 10.1001/archfami.8.1.58; WILSON K, 1998, REV ANTIDEPRESSANT D, P2; Witte B, 1995, Fortschr Med, V113, P404; 1993, AM J PSYCHIAT S4, V150, pR3	114	275	283	0	36	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					743	756		10.7326/0003-4819-132-9-200005020-00011	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00011			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	308VT	10787370				2022-12-28	WOS:000086734100010
J	Dickson, D				Dickson, D			UK ethicists back use of stem cells	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 13	2000	404	6779					697	697		10.1038/35008240	http://dx.doi.org/10.1038/35008240			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	305DF	10783861	Bronze			2022-12-28	WOS:000086523600016
